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CHAPTER 1 
GENERAl INTRODUCTION 
Immune recognition plays a central role in our understanding of the function of the immune 
system. The ability to specifically recognize foreign antigens allows selective but efficient actions 
of the immune system against all kinds of pathogens. This is mediated by antigen-specific 
receptors on B and T lymphocytes. Immunoglobulin (lg) molecules represent the antigen-
specific receptors of B lymphocytes, while the T cell receptor (TeA) has this function in T 
lymphocytes (1). Although these two types of antigen receptors have remarkable similarities in 
protein structure and their encoding genes, they differ significantly in their ability to interact with 
antigens (1). Via their surface membrane lg (Smlg) molecules, B lymphocytes are able to 
recognize antigens in their native configuration either free in solution, on surfaces or on cell 
membranes (1). TeA molecules ofT lymphocytes can only recognize processed or degraded 
antigens which are physically associated with major histocompatibility complex (MHC) 
molecules (2,3). This TeA-mediated recognition is therefore called MHC-restricted antigen 
recognition (2,3). 
Expression of Smlg or TcA molecules by lymphocytes is acquired during lymphoid 
differentiation via several rearrangement processes in the lg or TcR genes (3-7). B 
lymphopoiesis mainly occurs in the bone marrow (8), while the thymus is thought to represent 
the main tissue compartment for T lymphopoiesis (9-11 ). During T cell differentiation in the 
thymus the T lymphocytes are "educated" for their future functions, i.e. T cells which recognize 
self antigens are eliminated (negative selection), while positive selection occurs for T cells 
which recognize foreign (non-self) antigens in association with self-MHC molecules (12-14). 
Upon recognition of a TeA-compatible antigen, T lymphocytes are activated, start to proliferate 
and exhibit their regulatory or cytotoxic functions (2). These T cell functions play a central role 
in the regulation of the immune system. The T lymphocytes probably coordinate immune 
processes via cellular interactions and lymphokines and in this way adjust and harmonize the 
actions of the immune system. 
The TeA consists of two chains, which are closely associated with the CD3 protein complex 
(TcA-CD3). The CD3 chains probably play an important role in signal transduction from the TeA 
to the cytoplasm (15). Two main types of TcA have been identified: the classical TcA-a.B and 
the alternative TcR-rcS (2,3,7). Data about the structure and rearrangement of the four TcR 
genes have become available during the last six years. The majority of these data are derived 
from in vivo and in vitro studies in mice (7,9). Experimental data on human T cell differentiation 
and human T cell function are mainly restricted to studies on thymocytes and T cell 
malignancies (10, 11, 16). 
We have used freshly obtained cell samples from healthy individuals as well as cell samples 
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from leukemia patients and immunodeficiency patients to study human T cells and human T 
cell differentiation. Although most of these studies have a descriptive and inventory character, 
they reveal important information on the differentiation of T cells including the rearrangement 
and expression of TcR genes during their differentiation. Our studies also demonstrate that 
such basic information can be used for the development of new diagnostic tools. Optimal 
results in such studies can only be obtained, if a close collaboration is established between the 
clinical scientists and the laboratory scientists. Such a collaboration enables integration of the 
obtained results and evaluation of the sensitivity and specificity of newly developed diagnostic 
assays. 
The following Chapters of this thesis describe the applied techniques (Chapters 2 and 3), 
the experimental work on human T cells and T cell differentiation (Chapter 4) and the 
application of the obtained information and techniques for diagnostic purposes (Chapters 5 and 
6). 
Chapter 2 summarizes the immunologic markers, which are generally used for im-
munophenotyping of leukocytes. The microscopic techniques to detect the expression of these 
markers are discussed. Especially the application of immunofluorescence labeling techniques 
are described, because they can easily be used for double or even triple labelings, which allow 
detailed analysis of specific cell populations as well as the detection of small cell populations 
with a specific immunophenotype. 
Chapter 3 describes the genetic basis of the diversity of the antigen-specific receptors of 
lymphocytes, the lg and TcR molecules. Also the differences between lg and TcR molecules 
are discussed. Subsequently the Southern blot techniques for analysis of lg and TcR genes are 
described. The pitfalls and limitations of these Southern blot analyses are indicated. The various 
aspects of these analyses are illustrated with a series of figures and special attention is paid 
to the germline configuration of the lg and TcR genes. 
Chapter 4 is a compilation of a series of studies concerning the heterogeneity of human T cells 
and human T cell differentiation. These studies concern the immunophenotype ofT cells during 
T cell development and the hierarchic order of TcR gene rearrangements during T cell 
differentiation as studied in T cell leukemias. Also the expression of TcR-a,B and TcR--yo 
molecules in healthy individuals and children with hypoplasia or aplasia of the thymus is 
described. Based on these data the various processes during T cell differentiation and their 
thymus dependency are discussed. 
Chapter 5 summarizes the application of immunologic marker analysis of leukocytes for 
diagnostic purposes. This Chapter focusses on applications for diagnosing leukemias and 
malignant lymphomas. The major achievements are the detailed and reproducible immunologic 
classification of the hematopoietic malignancies, the development of new immunologic markers 
such as the cytoplasmic expression of CD3 molecules (CyCD3) as marker for immature T cell 
leukemias and, most importantly, the detection of minimal residual disease. Extremely low 
detection limits for identification of malignant cells could be achieved in patients with a terminal 
deoxynucleotidyl transferase positive (TdT+) T cell malignancy. Furthermore, early detection 
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of central nervous system leukemia has proven to be possible in patients with a TdT+ 
malignancy. 
Chapter 6 describes the occurrence of lg and TcR gene rearrangements in lymphoid leukemias 
and malignant lymphomas. Analysis of lg and TcR genes can be used for diagnostic purposes 
in patients with lymphoproliferative diseases. This is based on the fact that the far majority of 
malignant lymphoproliferations have clonally rearranged lg andjor TcR genes, which can be 
detected by Southern blot analysis. It is emphasized that clonal lg and TcR gene rearrange-
ments may also occur in clinically benign lymphoproliferations, which implies that clonality per 
se is not equivalent to malignancy. A series of clinical cases is presented to illustrate diagnostic 
applications of lg and TcR gene analysis. 
Chapter 7 discusses the significance of the presented experimental data and their clinical 
application. In addition, some new developments are discussed, such as the application of the 
polymerase chain reaction (PCR) analysis of TcR--y and TcR-o genes for the detection of 
minimal residual disease in patients with acute lymphoblastic leukemia. 
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INTRODUCTION 
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Leukocytes and their malignant counterparts can be recognized on the basis of 
morphological and cytochemical characteristics (1-4). A more detailed characterization of 
leukocytes can be obtained by immunologic marker analysis (5,6). Immunologic markers are 
proteins or glycoproteins, which are located on the cell membrane or intracellularly; their 
expression is detectable by use of conventional antisera or monoclonal antibodies (McAb). 
Several techniques can be used to determine the reactivity of antibodies against leukocyte 
antigens: resetting techniques and immunofluorescence, immunogold and immunoenzyme 
labeling techniques (Table 1). 
TECHNIQUES FOR THE DETECTION OF IMMUNOLOGIC MARKERS 
In resetting techniques the relevant antibodies or second step reagents are bound to 
erythrocytes, latex beads or magnetic beads (7-9). Furthermore, sheep red blood cells (SRBC) 
can directly bind to human T cells via the CD2 antigen (SRBC receptor), which results in the 
formation of so-called E rosettes (10, 11). A sub population of human 8 lymphocytes can form 
rosettes with mouse erythrocytes (12,13). Resetting techniques are generally not used for 
routine immunophenotyping, but represent easy techniques for cell separation (9, 10, 14-16). 
In immunoenzyme techniques the antibodies are labeled with an enzyme, such as 
peroxidase (PO), alkaline phosphatase (AP) or ,8-galactosidase (17-19). These techniques are 
generally used for immunologic marker analysis of cells in tissue sections. Many of the available 
anti-leukocyte McAb can be used on acetone fixed frozen sections, but only a few of them are 
suitable for application on formaldehyde-fixed paraffin-embedded tissue sections (20). 
lmmunogold techniques in which antibodies are labeled with small colloidal gold particles 
were first used in electron microscopy, because of the high electron density of the gold 
particles (21). However, immunogold labeling can also be visualized in light microscopy by use 
of the same epi-illumination system as in fluorescence microscopy (see below) (21 ). The immu-
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TABLE 1. Microscopic techniques for the detection of immunologic markers. 
1. Rosette techniques 
e.g. - E rosette (binding of SRBC to C02 molecules on T cells) 
- M rosette (binding of mouse erythrocytes to particular receptors on a subpopulation of B 
lymphocytes) 
- erythrocytes or beads coated with McAb (e.g. magnetic beads for cell separation) 
2. Immunofluorescence techniques 
fluorochromes: - fluorescein isothiocyanate (FITC) 
- tetramethylrhodamine isothiocyanate (TRITC) 
- Texas red (TX) 
3. lmmunogold techniques 
with or without silver enhancement 
4. lmmunoenzyme techniques 
enzymes, e.g.: - peroxidase (PO) 
- alkaline phosphatase (AP) 
- ,8-galactosidase 
nogold signal can be improved by the so-called silver enhancement (22). Interestingly, this 
immunogold-silver-staining (IGSS) technique can be combined with routine morphological or 
cytochemical stainings, because the silver enhancement procedure can be followed by 
morphological stainings such as May-Grunwald Giemsa or cytochemical stainings such as 
acid phosphatase or a-naphtylesterase (22,23). 
Immunofluorescence (IF) techniques are widely used for immunophenotyping, because 
they can easily be applicated for both single and double stainings (24). Even triple immunologic 
stainings can be performed (25-28). The first or second step reagents are conjugated with a 
fluorochrome as label. In fluorescence microscopy generally fluorescein isothiocyanate (FITC) 
and tetramethylrhodamine isothiocyanate (fRITC) or Texas red (fX) are used, whereas FITC 
and phycoerythrin are used in fluorescence activated flowcytometry (27). For triple immunologic 
stainings immunogold can be used as third label in fluorescence microscopy (25,26) and 
allophycocyanin (APC) as third label in flowcytometry (27,28). The possibilities and limitations 
of flowcytometric analysis of the expression of leukocyte antigens is extensively discussed in 
several recent publications (29-31). Therefore this Chapter will focus on fluorescence 
microscopy. Special attention will be paid to detection of intracellular markers and the use of 
double IF stainings. 
IMMUNOFLUORESCENCE MICROSCOPY 
For evaluation of immunofluorescence stainings we routinely use Zeiss Standard 16 
microscopes (Carl Zeiss, Oberkochen, FRG), equipped with phase contrast facilities and a IV 
FL Fluoreszenz-Auflichtkondensor (epi-illumination condenser) with a 50 Watt HBO mercury 
lamp (Osram, Berlin, FRG). These microscopes contain at least two Zeiss immersion-oil objec-
phase-contrast 
objectives 
phase-contrast ......___ 
condenser 
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epiillumination 
Figure 1. Fluorescence microscope equipped with epiillumination system, phase contrast condenser and phase-
contrast objectives. 
tives with phase contrast rings: a neofluar 63/1.25 Oel Ph3 for evaluation of the majority of 
membrane stainings and intracellular stainings and a Planapo 40/1.0 Oel Ph3 for evaluation 
of strong fluorescence staining patterns such as cytoplasmic immunoglobulin (Cylg) staining 
in plasma cells. These objectives are used in combination with Zeiss wide-field oculars Kpi-W 
10x/18 (Figure 1). 
The filter combinations in the epi-illumination system consist of excitation filters, emission 
filters and a dichroic mirror, which reflects the excitation light but allows the emission light to 
pass (24). Two filter combinations are used in our fluorescence microscopes: Zeiss filter 
combination 19 (BP 485/20; FT510; LP515) combined with KP560 filters for the evaluation of 
FITC labeling and Zeiss filter combination 14 (BP510-560; FT580; LP590) for the evaluation of 
TRITC labeling (Figure 2). 
From our experience phase contrast facilities are essential for optimal evaluation of 
immunofluorescence stainings, since they provide valuable information about the morphology 
of the cells and the precise location of the fluorescence labeling. The latter is especially 
important in case of intracellular markers, since they generally exhibit specific staining patterns, 
which are dependent on the subcellular location of those markers. An example is given in 
Figure 3, which illustrates the typical cytoplasmic CD3 (CyCD3) staining in immature T cells 
(32,33). Detailed information concerning CyCD3 expression is given in Chapter 3.2. 
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FILTERCOMBINATION FOR FITC 
emission filters 
(LP 515 and KP 560) 
dichroic mirror 
(FT 510) 
excitation filter 
(BP 485/20) 
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FILTERCOMBINATION FOR TRITC 
dichroic mirror 
(FT 580) 
excitation filters 
(LP 51 0 and KP 560) 
Figure 2. Filter combinations for the visualization of labelings with the fluorochromes FITC and TRITC. 
SURFACE MEMBRANE AND INTRACELLULAR IMMUNOLOGIC MARKERS 
The majority of the regularly used immunologic markers are surface membrane proteins, 
which are easily detectable by immunofluorescence labeling of viable cells in suspension and 
subsequent analysis with a flowcytometer or a fluorescence microscope. Flowcytometric 
analysis of such immunofluorescence stainings allows the screening of many cells in a short 
time period (500-5000 per sec) as well as a precise determination of the fluorescence intensity 
of each cell, which is a measure for the antigen density on the cell surface. Restricted 
information about size and morphology of the cells can be obtained via forward light scatter 
(FLS) and perpendicular light scatter (PLS). Also the computerized data analysis and data 
storage is an advantage of flowcytometry. In fluorescence microscopy only limited numbers of 
cells can be evaluated per time span and the quantification of fluorescence intensity is a 
subjective determination. However, detailed information about staining patterns and morphology 
can easily be obtained via the phase contrast facilities of a fluorescence microscope. The high 
specificity of the fluorescence microscope allows the detection of a small cell population ( < 
0.1 %) within a large heterogeneous cell sample. Despite these differences, the results of 
flowcytometric and microscopic analyses of membrane bound immunologic markers are 
comparable. 
However, some important immunologic markers for leukocyte typing are localized 
intracellularly. Permeabilization of the cell membrane is needed to permit detection of these 
markers by use of antibodies and information about the precise intracellular localization of the 
staining is important for correct interpretation. It is obvious that such information can only be 
obtained by use of a fluorescence microscope and not by use of the current generation of 
flowcytometers. 
Microscopic detection of intracellular markers can be achieved by making cytocentrifuge 
preparations of the cells under study. These cytocentrifuge preparations are air-dried, fixed with 
an appropriate fixative (acetone, formol-acetone, acidic ethanol or methanol, depending on the 
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TABLE 2. Detection of intracellular immunologic markers. 
Immunologic Expression pattern Fixation AntiserajMcAb 
marker (hematopoietic malignancies) procedure (isotype) 
TdT - immature lymphoid cells methanol rabbit anti-TdT antiseraa / 
(virtually all ALL and most (30 min, 4 o C) McAb: HTdT-1 (71 )a, 
lymphoblastic lymphomas) HTdT -3{-y2a)a, HTdT -4('}'2a)a 
- small subpopulation of immature 
myeloid cells (part of AML) 
CyCD3 all immature T cells (all SmCD3- acetone (1 0 min, 4 o C) Leu-4 (71)b, UCHT1 (11)c 
T-ALL and most SmCD3+ T-ALL) or acidic ethanol 
(15 min, -20°C) 
CyCD22 immature and mature B cells acetone (1 0 min, 4 o C) Leu-14 (-y2b)b, RFB4 ('Y)d, 
(majority of precursor-B-ALL) HD39 (71)d 
weak Cyp. pre-S-cells (pre-B-ALL) acidic ethanol selected anti-p. antisera 
(15 min, -20°C) 
Cylg plasma cells and their precursors acidic ethanol anti-1 g antisera 
(plasmacytoma, immunocytoma, (15 min, -20 o C) 
some immunoblastic lymphomas) 
MPO immature and mature myeloid cells acetone (10 min, 4°C) MP0-7(11 )c,CLB-MP0-1 (72a)e 
(majority of AML) 
Ki67 antigen all proliferating cells in late G1, S, methanol (30 min, 4 o C) Ki67(71)c 
G2 and M phases of cell cycle 
BrdU incor- proliferating cells in S phase methanol (30 min, 4 o C) anti-BrdU(-y2a) + nucleaseg 
porationf of cell cycle 
a. Supertechs, Bethesda, MD. 
b. Becton Dickinson, San Jose, CA. 
c. DAKOPATTS, Glostrup, Denmark. 
d. Sera Lab, Crawley Down, UK. 
e. Central Laboratory of the Blood Transfusion Service, Amsterdam, The Netherlands. 
f. The BrdU incorporation assay can only be performed on freshly isolated cells by preincubation with 100 llM BrdU (Sigma, St. Louis, 
MO) at 37"C for one hour. 
g. For optimal delectability of the incorporated BrdU the cytocentrifuge preparations are incubated with a mixture of anti-BrdU McAb and 
nuclease (Amersham, Amersham, UK) for one hour. 
type of immunologic marker), rehydrated by washing in phosphate buffered saline and 
subsequently incubated with the relevant antibodies. Several important intracellular markers, the 
appropriate fixation procedures and the relevant antibodies are summarized in Table 2. 
The enzyme terminal deoxynucleotidyl transferase (fdT) is expressed in the nucleus of 
immature lymphoid cells, i.e. precursor B cells in bone marrow and cortical thymocytes (34-
36). Also a small subpopulation of immature myeloid cells may express TdT (37). 
CyCD3 is found in all immature T cells: in more than 95% of thymocytes and all immature 
24 CHAPTER 2.1 
Figure 3. CyCD3 staining on the T cell line Molt4. A: phase contrast morphology. B: CyCD3 + cells (FITC labeling). 
This figure illustrates the typical cytoplasmic staining for CD3. The cytoplasmic location of the staining is especially 
prominent in the mitotic cell. 
T cell acute lymphoblastic leukemias (T-ALL) which do not express CD3 on their surface 
membrane (SmCD3)(32,33). 
The expression of the CD22 antigen on the cell membrane of immature B cells is often 
weak and it may be difficult to detect by CD22 antibodies in fluorescence microscopy. In 
cytocentrifuge preparations CD22 expression by precursor B cells is better detectable, which 
has led to the suggestion that the expression of CD22 antigens in precursor B cells is mainly 
localized in the cytoplasm (CyCD22) (38). However the CyCD22 staining pattern is not 
comparable to other typical cytoplasmic staining patterns, but resembles membrane stainings. 
Evidence for the membrane localization of the CD22 antigen in most precursor B cells has also 
been found by flowcytometry (39). The improved detectability of CD22 antigens in 
cytocentrifuge preparations is probably due to a better availability of the antigenic epitopes in 
fixed cells on cytocentrifuge preparations as compared to viable cells in suspension. 
A subset of precursor B cells in bone marrow weakly expresses cytoplasmic f.L heavy chains 
(weak Cyf.L), without expression of lg light chains. These cells have been defined as pre-B cells 
(40). Strong Cylg expression of both lg heavy and lg light chains is found in plasma cells and 
their precursors (41). 
Myeloperoxidase (MPO) is localized in the azurophilic granules of myeloid cells (42). 
Synthesis of MPO already occurs in early stages of myeloid differentiation (43,44). Most 
probably MPO is only expressed in myeloid cells and their malignant counterparts, the acute 
myeloid leukemias (AML) (45). Therefore MPO is an excellent marker for immature myeloid cells 
and AML (45). 
Proliferative activity of cells can be studied by analyzing cycle-associated features such as 
Ki67 expression (46,47) and 5-bromo-2' -deoxyuridine (BrdU) incorporation (47,48). The nuclear 
protein Ki67 is expressed during late G1, S, G2 and M phases of the cell cycle and is detectable 
by use of an antibody (26,46). The incorporation of BrdU in DNA can be detected by use of 
anti-BrdU antibodies and gives an indication of the percentage of cells in S phase of the cell 
cycle (26,47,48). 
Because of the advantages of speed and quantifiability of fluorescence intensity in case of 
flowcytometry, several investigators have tried to develop fixation and labeling techniques for 
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the detection of intracellular markers in cell suspensions (49-51). So far, intracellular 
background staining and fixation-associated changes in cell size and morphology hamper the 
flowcytometric detection of intracellular markers. In addition, the flowcytometer cannot provide 
information about staining patterns and the subcellular location of the staining. 
APPLICATION OF DOUBLE IMMUNOFLUORESCENCE STAINING TECHNIQUES 
IF techniques are optimally suitable for the simultaneous detection of two different 
molecules or epitopes. Detailed technical information about the double IF stainings needed for 
this purpose is given in Chapter 2.3. Double IF stainings are important for both diagnostic and 
research purposes (fable 3). 
Applications of double IF staining techniques in the immunodiagnosis of hematopoietic 
malignancies are the following: detection of small populations of malignant B cells ( > 2%) based 
TABLE 3. Applications of double IF staining techniques. 
A. lmmunodiagnosis of hematopoietic malignancies 
1. Detection of small populations of malignant lg+ 8 cells (>2%) 
e.g. - careful determination of K/A ratio by use of K/A double IF stainings or by use of K/B cell marker 
and >..;s cell marker double IF stainings 
2. Characterization of small malignant cell populations 
e.g. - analysis of TdT+ cell populations(> 1%) in blood or lymph nodes 
3. Detection of subpopulations within a malignancy 
e.g. - AML 
- chronic myeloid leukemia in blast crisis 
4. Characterization of two hematopoietic malignancies in one patient 
5. Detection of minimal residual disease in patients with acute leukemia 
e.g. - TdT+ T cell malignancies 
- TdT+ AML 
B. Applications in research 
1. Determination of the specificity of antibodies 
e.g. - cocapping experiments to study whether particular antibodies recognize the same molecule. 
2. Studies on the reactivity patterns of antibodies in normal heterogeneous cell populations 
3. Detailed characterization of a particular cell population 
e.g. - analysis of TdT+ cells in bone marrow 
- analysis of TcR--yo+ cells in blood or thymus 
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Figure 4. Cocapping experiment using the 8 cell-specific antibody L26 in conjunction with the CD20 antibody 81 
on the 8 cell line ROS-17. Viable cells were first incubated with the 81 antibody and a TRITC-conjugated second 
step reagent. These incubations were performed for more than 1 hour at 37 o C to enable capping. Cytocentrifuge 
preparations of the labeled cells were air dried, fixed in acetone {1 0 min; 4 o C) and incubated with biotinylated L26 
and FITC-conjugated streptavidin. A: phase contrast morphology of the labeled cells; B: the same cells showing 
that CD20 antigen is present in a capped dot-like distribution, often localized at one pole of the cell (TRITC 
labeling); C: L26 staining {FITC labeling) is completely identical in distribution to the CD20 antigen. This figure 
illustrates that l26 most probably recognizes the CD20 antigen. 
on lg light chain restriction (52,53), immunophenotypic analysis of a small malignant cell 
population, detection of subpopulations within a malignancy (37,54), and the characterizationof 
two different hematopoietic malignancies in one patient (55). In our department we especially 
use double IF staining techniques for detection of minimal residual disease in patients with a 
TdT+ T cell malignancy or a TdT+ AML by use ofT cell markerjTdT or myeloid marker/TdT 
double IF stainings, respectively (56,57). The detection limit of these double staining techniques 
is extremely low (0.01 - 0.001 %), and therefore allows a careful evaluation of the efficacy of the 
treatment during follow-up of the leukemia patients as well as an early detection of a possible 
relapse (56). More details about the detection of minimal residual disease by immunologic 
marker analysis are given in Chapter 5.3 and 5.4. 
In research, double IF stainings are useful for studying the specificity of antibodies and for 
evaluation of their reactivity patterns in normal heterogeneous cell populations. An elegant 
example is the application of cocapping experiments to determine whether different McAb 
recognize the same molecule. Using this approach we were able to demonstrate that the B 
cell specific antibody L26 recognizes an intracellular domain of the CD20 molecule (Figure 4) 
(58). Finally, double IF stainings are necessary for detailed characterization of small cell 
populations, such as TdT+ cells in bone marrow (35-37) or T cell receptor--yo (fcR--yli)+ cells 
in blood or thymus (59,60). 
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CONCLUSION 
Immunofluorescence stainings are important for immunophenotyping of hematopoietic cells 
and their malignant counterparts as well as for research topics. Especially the easy workability 
of double IF stainings makes this technique valuable. 
Flowcytometric analysis of fluorescence stainings has the advantages of speed and 
quantifiability of fluorescence intensity. Fluorescence microscopy, on the other hand, has the 
advantages of high specificity and high sensitivity, especially in case of intracellular immunologic 
markers. 
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For the detection of immunologic markers on hematopoietic cells generally monoclonal 
antibodies (McAb) are used. During the last ten years many McAb against immunologic 
markers of leukocytes have become available. To create clearness and order within the large 
panels of McAb an international nomenclature has been designed (1-4). 
During four Leucocyte Typing Conferences (Paris, 1982; Boston, 1984; Oxford, 1986; 
Vienna, 1989) a large part of the McAb against leukocyte antigens have been grouped into 
antibody clusters based on their reactivity with identical antigens (fable 1). Each cluster has 
its own code, the so-called CD ("cluster of differentiation" or "cluster designation") code (1-4). 
In this way McAb against e.g. the T cell markers T6 and T11 have received the codes CD1 
and C02, respectively, while the CD3 code is assigned to McAb against the T cell receptor 
(feR) associated CD3 chains. 
CD NOMENCLATURE 
In principle CD codes are only assigned, if three or more McAb from different laboratories 
recognize the same antigen, of which the molecular (mol.) mass as well as the expression 
pattern has been determined. However, in a few clusters only two antibodies are present; in 
some other clusters antibodies of only two laboratories are available and sometimes information 
about the recognized immunologic marker is lacking (e.g. the mol. mass). In such cases the 
CD code is supplied with the letter "w" (workshop), which indicates that it concerns a 
preliminary clustering. 
The name of the McAb, which has been used to detect a specific CD molecule, can be 
placed in parentheses behind the CD code. In this way, code CD3 can be extended to 
CD3(0KT3), CD3(Leu-4), CD3(VIT-3) or CD3(UCHT1), depending on the antibody used. Such 
a supplementation is important for optimal comparison of data from different laboratories, since 
McAb of the same cluster may slightly differ in their reaction pattern. For instance, the majority 
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TABLE 1. CD codes as established during the four Leucocyte Typing Conferences. 
Leucocyte Typing Number of submitted Number of established 
Conference monoclonal antibodies CD codes 
Paris, 1982 
-
150 CD1 - CDw15 
II Boston, 1984 - 350 CD16- CDw26 
Ill Oxford, 1986 
- 900 CD27- CD45 
IV Vienna, 1989 - 1100 CD46- CDw78 
of CD3 antibodies are able to recognize CD3-c: chains at the cell surface of viable cells (5), 
but cytoplasmic CD3 chains (CyCD3) in fixed cytocentrifuge preparations or frozen sections 
can be recognized by only a few CD3 antibodies (6). Apparently not all epitopes on the CD3-c: 
chain are resistant to denaturation by acetone or ethanol fixation of cyto-centrifuge preparations 
or frozen sections. 
So far 78 CD codes have been assigned. A condensed summary of these clusters, the 
antigen recognized and the reactivity pattern of the clustered antibodies is given in Table 2. 
Several clusters are subdivided with letter codes, because the antibodies of these clusters 
recognize antigens which are homologous, but not identical (e.g. CD1 and CD11 antigens) 
(7-10). The genes which code for these molecules belong to the same gene family (7-10). In 
other clusters the subdivision is based on reactivity of the antibodies with different isoforms 
of a CD molecule, which represent different splicing products from the same gene complex 
(e.g. CD45 molecules) (11, 12). However, antibodies against complement receptor type 2 
(CR2), complement receptor type 1 (CR1) and the decay-accelerating factor were grouped 
into different clusters (CD21, CD35 and CD55, respectively), although they belong to the same 
gene cluster of regulators of complement activation (13). 
A detailed summary of all CD clusters is given in the Appendix of this Chapter. This 
Appendix summarizes relevant information about the various McAb (isotype, origin, reactivity 
pattern with hematopoietic cells) as well as the recognized immunologic markers (alternative 
name, known function, mol. mass, etc.). Most antibodies mentioned in the Appendix are 
commercially available (see footnotes of the Appendix). 
FUNCTIONS OF CD MOLECULES 
During the first three Leucocyte Typing Conference only limited information about functions 
of CD molecules was available. However, during the fourth conference in Vienna in 1989 more 
functional data were presented. Several CD molecules appear to play a role in signal 
transduction and activation of B lymphocytes (e.g. CD19, CD20 and CD22 molecules) or T 
lymphocytes (e.g. CD2, CD3 and CD5 molecules)(4), while other CD molecules exhibit receptor 
functions (1-4, 14, 15), are involved in cell-cell interactions (10, 16-18) or represent homing 
receptors (19-22). 
TABLE 2. CD nomenclature as established during the four Leucocyte Typing Conferences. 
CD code CD antigen Reactivity CD code CD antigen Reactivity CD code CD antigen Reactivity 
CD1 T6 antigen Thy, sub-8, DC CD28 Tp44 antigen sub-T CD51 VNR-a chain Pit 
C02 T2 antigen, LFA-2 pan-T CD29 integrin /31 chain broad CDw52 Campath-1 broad 
CD3 T3 antigen T CD30 Ki-1 antigen act-T, act-8, RS CD 53 gp32-40 antigen leukocytes 
CD4 T4 antigen sub-T CD31 platelet GPIIa' Pit, Mo, G, sub-T CD 54 ICAM-1 broad 
CD5 T1 antigen T CDw32 FcrRII Mo,G, B, Eo CD 55 OAF broad 
CD6 T12 antigen T CD33 gp67 antigen My,Mo CD 56 NCAM sub-T, NK 
CD? Tp41 antigen pan-T CD34 gp115 antigen prog-leukocytes CD 57 HNK1 sub-T, sub-NK 
CDS TB antigen sub-T CD35 CR1 B,G,Mo CD58 LFA-3 broad 
CD9 p24 antigen sub-S, Pit CD36 platelet GPIV Pit, prog-Ery, Mo CD 59 Ly-6 antigen broad 
CD10 CALLA prog-B CD37 B cell antigen B CDw60 NeuAc-NeuAc-Gal sub-T, Pit 
CD11a LFA-1 Ly, My, Mo CD38 T10 antigen prog-Ly, act-T, PC CD61 integrin /33 chain Pit 
CD11b MAC-1, CR3 My, Mo CD39 gpBO antigen B CD62 GMP 140 act-Pit 
CD11c p150,95 My, Mo, sub-S CD40 gp50 antigen sub-S, DC CD63 GP-53 act-Pit, Mo, G 
CDw12 myeloid antigen My, Mo, Pit CD41 platelet GPIIb-llla Pit CD64 Fc-yRI Mo 8 CD13 aminopeptidase N My,Mo CD42a platelet GPIX Pit CDw65 fucoganglioside My, Mo :;:, 
CD14 gp55 antigen Mo CD42b platelet GPib Pit CD66 gp180-200 antigen G 0 3 CD15 X hapten, FAL My, G CD43 leukosialin broad CD67 p100 antigen G ~ CD16 FerRill NK,G CD44 Pgp-1, homing-A broad CD68 macrophage antigen Mc;h () 
CDw17 lactosylceramide Mo, G, Pit CD45 LCA leukocytes CD69 AIM act-T, act-S ii> ~ CD18 integrin /32 chain Ly, My, Mo CD45RO restricted LCA sub-T, G, Mo CDw?O Ki-24 antigen act-T, act-B, RS s; 
CD19 gp90 antigen pan-S CD45RA restricted LCA sub-T, B, G, Mo CD71 transferrin receptor act-leukocytes 
CD20 p35 antigen B CD45RB restricted LCA sub-T, B, G, Mo CD72 gp43/39 antigen pan-S 
CD21 CR2, EBV-R sub-S CD46 MCP broad CD73 ecto-5'-NT B, sub-T 
CD22 gp135 antigen pan-S CD47 gp47-52 antigen broad CD74 invariant chain B, sub-Mo 
CD23 FcfRII B, Mo, Eo CD48 gp41 antigen leukocytes CDw75 B cell antigen sub-S, sub-T 
CD24 BA-1 antigen sub-B, G CDw49b VLA-a2 Pit, act-T CD76 gp85/87 antigen sub-B, sub-T 
CD25 IL-2 receptor act-T, act-B, act-Mc;h CDw49d VLA-a4 B, T,Mo CD?? Gb3 antigen act-S 
CD26 DPPIV act-T, act-S, Mc;h CDw49f VLA-a6 Pit, sub-T CDw78 B cell antigen B, sub-Mc;h 
CD27 p110 antigen sub-T, act-T, sub-S CDw50 gp148/108 antigen leukocytes 
Abbreviations used: act = activated, AIM = activation inducer molecule, B = B cells, broad = broad tissue distribution, CALLA = common ALL antigen, CD 
= cluster of differentiation/cluster designation, CR = complement receptor, DAF = decay accelerating factor, DC = dendritic cells, DPP IV= dipeptidylpeptidase 
IV, EBV = Epstein-Barr virus, Eo = eosinophils, ery = erythrocytes, FAL = fucosyi-N-acetyl-lactosamin, FaR = Fe receptor for lgE, FcyR = Fe receptor for 
lgG, G = granulocytes, GMP = granule membrane protein, GP = glycoprotein, HNK = human natural killer cells, ICAM = intercellular adhesion molecule, IL-
2 = interleukin 2, LCA = leukocyte common antigen, LFA = leukocyte function antigen, Ly = lymphocytes, MCP = membrane cofactor proteins, Mc;h = 
macrophages, Mo = monocytes, My = myeloid cells, NCAM = neural cell adhesion molecule, NeuAc-NeuAc-Gal = disialosyl group, NK = natural killer cells, 
5 ·-NT = 5 '-nucleotidase, PC = plasma cells, Pit = platelets, prog = progenitor, R = receptor, RS = Reed Sternberg cells, sub = sub population, T = T cells, 
w Thy = thymocytes, VLA = very late activation, VNR = vitronectin receptor. w 
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Antibodies against the three types of Fe receptors for lgG, Fc-yRI, Fc-yRII and Fc-yRIII, have 
received the codes CD64, CDw32 and CD16, respectively (4, 14). Antibodies against the three 
complement receptors, CR1, CR2 and CR3, are grouped into the clusters CD35, CD21 and 
CD11 b/CD18, respectively (2-4). 
During the last three years a new group of intercellular adhesion molecules has been 
recognized, the so-called integrins (10,17). This family of cell surface receptors consists of at 
least six subfamilies, based on the use of common f3 chains, which differ between the 
subfamilies but have a high degree of homology (1 0, 17). Antibodies against members of three 
integrin subfamilies have received CD codes. The very late activation (VLA) antigen subfamily 
consists of at least six different a chains (CDw49 antigens) and one common ,81 integrin chain 
(CD29 antigen) (1 0, 17, 18). The leukocyte adhesion molecule (Leu CAM) family consists of three 
different a chains (CD11 antigens) and a common ,82 integrin chain (CD18 antigen)(10), while 
the cytoadhesin family consists of at least two a chains (GPIIb of the CD41 molecule and 
CD51) and one common integrin {33 chain (CD61 antigen) (10,17). 
Some CD molecules represent homing receptors. CD44 molecules are homing receptors 
on the cell surface of lymphocytes, allowing selective binding of the lymphocytes to the 
endothelium of high endothelial venules (HEV) (19-21). The CDw49d/CD29 molecule probably 
represents one of the homing receptors for Peyer's patches (22). 
Interestingly, several CD molecules appear to represent membrane bound enzymes, such 
as CD10 (neutral endopeptidase), CD13 (aminopeptidase N), CD26 (dipeptidylpeptidase IV) and 
CD73 (ecto-5'-nucleotidase)(4). The precise role of these membrane bound enzymes in 
differentiation, activation or other cell functions has still to be determined. 
The available data concerning functions of CD molecules indicate that most cell surface 
molecules are involved in complex cellular interactions or represent receptors for signals which 
induce activation or proliferation of the cell or lead to changes in the differentiation status of 
the cell. Future Leucocyte Typing Conferences will probably not only establish new antibody 
clusters, but will also contribute more information on functions of CD molecules. This will further 
enhance the progress in our understanding of differentiation, migration, cell-cell interaction, 
activation and proliferation of both immune and non-immune cells. 
REACTIVITY OF ClUSTERED McAb WITH VIABLE AND FIXED CEllS 
The majority of clustered McAb can be used for the detection of immunologic markers on 
the cell surface of viable cells in suspension. Several of these antibodies can also be used on 
acetone-fixed or ethanol-fixed cytocentrifuge preparations or frozen sections. However, the 
reactivity with formalin-fixed paraffin-embedded tissue sections is restricted to a small number 
of clustered McAb (4,23-26). 
In most laboratories for Clinical Pathology the majority of tissue samples are routinely 
processed by formalin fixation and paraffin embedding. Therefore, it is important that these 
laboratories have access to antibodies which can react with routinely processed tissue sections. 
Preferably, clustered antibodies should be used, so that immunophenotyping results from routi-
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TABLE 3. Clustered McAb that can be used on formaldehyde-fixed, paraffin-embedded tissue sections. 
CD code 
CD3 
CD15 
CD20 
CD30 
CD35 
CD43 
CD45RO 
CD45RA 
CD45RB 
CD61 
CD68 
CD71 
CD74 
CDw75 
CD76 
only polyclonal rabbit 
antiserum availableb 
l26('}'2a)b 
Ber-H2('Y1 )b 
7E11 ('Y1)e 
DFT-1 ('Y1)b, Leu-22('Y1)c 
UCHL1 (-y2a)b 
4KB5('Y1)b, MB1 ('Y1)d, MT2('Y1)d 
PD7 /26('}'1 )b 
Y2/51 ('Y1 )b 
KP1 ('Y1)b 
Ber-T9(-y1 )b 
HD66(J.L/, CRIS-4(/.L)g 
Reactivity with hematopoietic cells 
immature T cells (cytoplasmic expression; CyCD3) and mature 
T cells (membrane expression; SmCD3) 
myeloid cells, granulocytes 
B cells, follicular dendritic reticulum cells 
subpopulation of activated lymphocytes, Reed-Sternberg cells 
B cells, granulocytes, monocytes, dendritic reticulum cells 
T cells, monocytes, granulocytes (broad tissue distribution) 
thymocytes, activated T cells, memory T cells 
virgin T cells, B cells, granulocytes, monocytes 
B cells, subpopulation of T cells, monocytes, macrophages, 
granulocytes 
megakaryocytes, platelets 
macrophages (especially cytoplasmic expression) 
proliferating cells, activated cells 
subpopulation of precursor B cells, B cells, subpopulation of 
monocytes 
subpopulation of mature B cells (especially germinal center 
B cells), subpopulation ofT cells (weak) 
subpopulation of mature B cells (especially mantle zone 
B cells), subpopulation ofT cells 
a. Detailed information on these McAb can be found in references 4, 23-26. 
b. DAKOPATTS, Glostrup, Denmark. 
c. Becton Dickinson, San Jose, CA. 
d. Biotest, Dreieich, FAG. 
e. Dr. N.M. Hogg, London, UK. 
f. Dr. G. Moldenhauser, Heidelberg, FAG. 
g. Dr. A. Vilella, Barcelona, Spain. 
nely processed tissue sections can be compared with results from immunophenotyping on 
frozen sections or cell suspensions. Therefore, we have summarized all available clustered 
McAb which can be used on formalin-fixed paraffin-embedded tissue sections (Table 3)(4,23-
26). 
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CONCLUSION 
The international CD nomenclature has created order and clearness in the abundance of 
available McAb against leukocyte antigens. This CD nomenclature enables the composition of 
representative antibody panels, which allow comparison of immunophenotyping results from 
different laboratories. This is important for designing internationally accepted immuno-
phenotyping protocols for diagnostic purposes. 
Not all detailed information concerning the CD nomenclature is easily accessible. For 
instance, it is not always clear which antibodies have officially been clustered and whether the 
relevant antibodies are commercially available. In the Appendix of this Chapter, we therefore 
summarize all relevant information about clustered McAb and several non-clustered antibodies, 
which are important for immunophenotyping of hematopoietic cells. 
ACKNOWLEDGMENTS. We gratefully thank Professor Dr. R. Benner for his continuous support and Mrs. W.M. 
Comans-Bitter for critically reading the manuscript and the Appendix. 
REFERENCES 
1. Bernard A, Boumsell L, Dausset J, Milstein C, Schlossman SF, eds. Leucocyte Typing. Human leucocyte 
differentiation antigens detected by monoclonal antibodies. Berlin: Springer-Verlag, 1984. 
2. Reinherz EL, Haynes BF, Nadler LM, Bernstein 10, eds. Leucocyte Typing II. Volume 1: Human T lymphocytes; 
Volume 2: Human B lymphocytes; Volume 3: Human myeloid and hematopoietic cells. Berlin: Springer-Verlag, 
1986. 
3. McMichael AJ, Beverley PCL, Gilks W, Horton M, Mason DY, Cobbold S, Gotch FM, Ling N, Milstein C, 
Waldmann H, Crumpton MJ, Hogg N, Maclennan ICM, Spiegelhalter D, eds. Leucocyte Typing Ill: White cell 
differentiation antigens. Oxford: Oxford University Press, 1987. 
4. Knapp W, Dorken B, Rieber EP, Stein H, Gilks WR, Schmidt RE, Von dem Borne AEGKr, eds. Leucocyte 
Typing IV: White cell differentiation antigens. Oxford: Oxford University Press, 1989. 
5. Transy C, Moingeon PE, Marshall B, Stebbins C, Reinherz EL Most anti-human CD3 monoclonal antibodies 
are directed to the CD3 € subunit. Eur J lmmunol1989;19:947-50. 
6. Van Dongen JJM, Krissansen GW, Wolvers-Tettero ILM, Comans-BitterWM, Adriaansen HJ, Hooijkaas H, Van 
Wering ER, Terhorst C. Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-
een malignancies. Blood 1988;71 :603-12. 
7. Martin LH, Calabi F, Lefebvre F-A, Bilsland CAG, Milstein C. Structure and expression of the human thymocyte 
antigens CD1a, CD1b,.and CD1c. Proc Nat! Acad Sci USA 1987;84:9189-93. 
8. Calabi F, Jarvis JM, Martin L, Milstein C. Two classes of CD1 genes. Eur J lmmunol1989;19:285-92. 
9. Corbi AL, Larson RS, Kishimoto TK, Springer TA, Morton CC. Chromosomal location of the genes encoding 
the leukocyte adhesion receptors LFA-1, Mac-1 and p150,95. J Exp Med 1988;167:1597-607. 
10. Arnaout MA. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 1990;75:1037-
50. 
11. Streuli M, Hall LR, Saga Y, Schlossman SF, Saito H. Differential usage of three exons generates at least five 
different mRNAs encoding human leukocyte common antigens. J Exp Med 1987;166:1548-66. 
12. Streuli M, Morimoto C, Schrieber M, Schlossman SF, Saito H. Characterization of CD45 and CD45R 
monoclonal antibodies using transfected mouse cell lines that express individual human leukocyte common 
antigens. J lmmunol1988;141 :3910-4. 
13. Rey-Campos J, Rubinstein P, Rodriguez de CordobaS. A physical map of the human regulator of complement 
activation gene cluster linking the complement genes CR1, CR2, OAF and C4BP. J Exp Med 1988;167:664-
CD nomenclatuur 37 
9. 
14. Hogg N. The structure and function of Fe receptors. lmmunol Today 1988;9:185-7. 
15. Fanger MW, Shen L, Graziano RF, Guyre PM. Cytotoxicity mediated by human Fe receptors for lgG. lmmunol 
Today 1989;10:92-9. 
16. SpringerTA, Dustin ML, Kishimoto TK, Marlin SD. The lymphocyte function-associated LFA-1, CD2, and LFA-
3 molecules: cell adhesion receptors of the immune system. Ann Rev lmmunol1987;5:223-52. 
17. Hynes RO. lntegrins: a family of cell surface receptors. Cell1987;48:549-54. 
18. Hemler ME. Adhesive protein receptors on hematopoietic cells. lmmunol Today 1988;9:109-13. 
19. Steelman LM. Adhesion molecules controlling lymphocyte migration. Cell 1989;56:907-10. 
20. Pals ST, Hogervorst F, Keizer GD, Thepen T, Horst E, Figdor CC. Identification of a widely distributed 90-kDa 
glycoprotein that is homologous to the hermes-1 human lymphocyte homing receptor. J lmmunol 
1989;143:851-7. 
21. De los Toyos J, Jalkanen S, Butcher EC. Flow cytometric analysis of the Hermes homing-associated antigen 
on human lymphocyte subsets. Blood 1989;74:751-60. 
22. Holzmann B, Weissman IL. Peyer's patch-specific lymphocyte homing receptors consist of a VLA-4-Iike a 
chain associated with either of two integrin {3 chains, one of which is novel. EMBO J 1989;8:1735-41. 
23. Poppema S, Hollema H, Visser L, Vas H. Monoclonal antibodies (MT1, MT2, MB1, MB2, MB3) reactive with 
leukocyte subsets in paraffin-embedded tissue sections. Am J Pathol 1987;127:418-29. 
24. Norton AJ, Isaacson PG. Lymphoma phenotyping in formalin-fixed and paraffin wax-embedded tissue: I. 
Range of antibodies and staining patterns. Histopathol1989;14:437-46. 
25. Norton AJ, Isaacson PG. Lymphoma phenotyping in formalin-fixed and paraffin wax-embedded tissues: II. 
Profiles or reactivity in the various tumour types. Histopathol1989;14:557-79. 
26. Mason DY, Comans-Bitter WM, Cordell JL, Verhoeven M-AJ, Van Dongen JJM. Antibody L26 recognizes an 
intracellular epitope on the B cell associated CD20 antigen. Am J Pathol1990, in press. 
38 CHAPTER 2.2 
APPENDIX. Summary of clustered and non-clustered immunologic markers. 
CD no. a Name(s)/function mol. mass McAb (mouse isotype) Reactivity with hematopoietic cells 
CD1 TS antigen; common CD1a:gp49 Leu-6{12b)b, OKT6(71)0 •d, T6(71)•, • cortical thymocytes (strong), Langerhans 
thymocyte antigen j NA1/S4(12a)f,g, VIT-6(72a)h cells, subpopulation of dendritic cells, 
MHC-Iike protein; can subpopulation of B cells 
associate with {32- CD1b:gp45 7C4/160/4G9 (11)i -cortical thymocytes (moderate), Langer-
microglobulin hans cells, subpopulation of dendritic 
CD1c:gp4S 7C6/162/SB10{!L)i 
cells, subpopulation of B cells 
-cortical thymocytes (weak), subpopula-
tion of B cells, Langerhans cells, 
subpopulation of dendritic cells 
CD2 T11 antigen; SRBC receptor gpSO Leu-Sb(72a)b, OKT11(72a)0 'd, all T cells, most NK cells; three different ( = E rosette receptor); LFA-2/ T11(71)0 , CLB·T11/1(71)k, antigenic epitopes are known, of which 
receptor for T cell activation; TM1(JL)d, MT910(71)f, one is the SRBC binding site 
ligand for CD58 (LFA-S) MT1110(71)h 
CD2R CD2 epitope restricted to gpSO VIT-1S(JL)i activated T lymphocytes 
activated T lymphocytes 
CD3 T3 antigen (associated gp16-25 Leu-4/SK7(11)b, OKTS(12a)0 • d, immature T cells (cytoplasmic expression; 
with TcR)jsignal trans- T3(71)•, T3-4B5(71)f, SL5(73)8 , CyCDS) and mature functional T cells 
duction from TcR to BW242/55(7S)h, VIT-3(1L)i, (membrane expression); the CD3 antigen 
cytoplasm CLB-TS/2(72a)k, UCHT1 (71)f,l consists of at least five protein chains; 
(most CDS MoAb recognize the NK cells only express CDS-I chains 
CDS-€ chain) 
CD3-7: gp25 only polyclonal antisera these antibodies can detect 
CD3-o: gp20 SP-64(71)m, SP-7S(11)m intracellular CD3 chains 
CDS-€: p20 Leu-4/SK7(71)b, VIT-3b(71)i, 
UCHT1(71)f,l, SP-6(71)m 
CD3-I:gp16/16 TIA-2(71)n 
CD4 T4 antigen/involved in gp60 Leu-3a(11)b, OKT4(72b) 0 'd, subpopulation of cortical thymocytes, 
MHC-class-11-restricted T4A(71)•, T3-10(71)f, BT5.9(7S)s, helper /inducer T cells, subpopulation 
antigen recognition; BW264/123{!L)h, CLB-T4f1{12a)k, of monocytes and macrophages 
HIV receptor TI4(12a) 0 , T151 {12a)P 
CDS T1 antigen/function in gp67 Leu-1{12a)b, OKCLL(72a)0 , thymocytes and mature T lymphocytes, 
T cell proliferation OKT1(71)d, T1B(72a)0 , MIDS(JL)S, subpopulation of B cells (e.g. B-CLL) 
CLB-T1/1 (71)k, DK23(72a)f 
CDS T12 antigen; pan-T cell gp120 OKT17(72)0 , T12(1L)•, ST23(72a)f, thymocytes and mature T lymphocytes, 
antigen Tp120(72a)8 , VIT-12(71)i, subpopulation of B cells (e.g. B-CLL) 
TG33(72a) 0 , T411 (71)P 
CD? Tp41 antigen/Fc re- gp41 Leu-9(72a)b, OKT16(72)0 , 3A1 (71)d, almost all T cells, NK cells, subpopulation 
captor for lgM (FciLR) DK24(12b)f, PAN-L7D{12a)8, of immature myeloid cells (e.g. some 
HD49(71)h, CLB-3A1(12a)k, WT1(72a)q AML) 
CDS TS antigen; the CDS molecule gpS2 Leu-2a(71)b, OKT8(72a) 0 • d, subpopulation of cortical thymocytes, 
consists of two disulfide TSA(11)•, CLB-TS/1 (71)k, cytotoxic/suppressor T cells, 
linked chains: a-a homodimer DK25(71)f, MID4{!L)8, T811 (7)g,p subpopulation of NK cells 
or a-{3 heterodimer /involved BW1S5/S0(72a)h, TG102(71) 0 
in MHC-class-1-restricted 
antigen recognition cos-a most CDS antibodies 
CD8-{3 
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CD no. a Name(s)jfunction mol. mass McAb (mouse isotype) Reactivity with hematopoietic cells 
CD9 p24 antigen/induction p24 BA-2{73)r, CLB-thrombj8{72a)k, subpopulation of precursor B cells, sub-
of aggregation of FMC8(72a)g population of B cells (follicular center 
platelets cells), monocytes, megakaryocytes, 
platelets, eosinophils, basophils 
CD10 common ALL antigen gp100 J5(72a) 0 , VIL-A1 (JL)h, i, BA·3(72b)r, subpopulation of precursor B cells, sub· 
(CALLA)jneutral OKBCalla(72a) 0 , W8E7(72a)b, population of B cells (follicular cen-
endopeptidase (enke· SS-2/36(71)f, CALLA·LC3M(71)s, ter cells), subpopulation of cortical 
phalinase) CLB-CALLA/1 (72a)k, UL96(1')0 thymocytes, granulocytes 
CD11a LFA-1 antigen (aL chain); gp180 MHM24(71)f, CLB-LFA·1/2(72a)k majority of lymphoid and myeloid cells; 
associated with CD18 anti- no membrane expression in LAD patients 
genjadhesion molecule; binds 
to CD54 antigen (ICAM-1) 
CD11b MAC·1 antigen (aM chain); gp155 Leu-15/D12(72a)b, Ki-M5(71)h monocytes, macrophages, granulocytes, 
associated with CD18 anti- Mo1(JL) 0 , CL8-mon-gran/1(1')k, NK cells; no membrane expression in 
genjadhesion molecule; 2LPM19c(71)f, OKM1 (72b) 0 • d LAD patients 
CR3 (C3bi receptor) 
CD11c p150,95 antigen (aX chain); gp150 Leu-M5/SHCL3(72b)b, KB90(71)f, monocytes, macrophages, granulocytes, 
associated with CD18 FD11(71)g subpopulations of lymphocytes (e.g. HCL-
antigenjadhesion molecule like cells in the spleen and NK cells); 
no membrane expression in LAD patients 
CDw12 myeloid antigen p90·120? M67(71)5 monocytes, granulocytes, platelets 
CD13 pan-myeloid antigen; gp150 My7{71) 0 , CLB·mon-gran/2(72a)k, almost all myeloid cells, dendritic 
aminopeptidase N MCS2(7)t cells in the skin 
CD14 monocytic antigen; gp55 Leu-M3{72b)b, 63D3{71)d, monocytic cells, macrophages, follicular 
PI-linked protein My4{71) 0 , Mo2(1') 0 , FMC17{72b)s, dendritic reticulum cells; absent in 
UCHM1{72a)S, VIM-13(JL)i, patients with PNH 
CLB-Monj1 {72a)k 
CD15 X hapten; FAL {fucosyl- variety VIM-D5(JL)i, Leu-M1 (g)b, cells of the granulocytic lineage, weak 
N-acetyl-lactosamine) of gp's CLB-granj2(tL)k, C3D-1 (JL)f, expression by monocytes, Reed 
FMC13{1L)s, VIM-C6(JL)h, Tu9(g) 0 , Sternberg cells 
MCS1{72a)\ 1G10{1L)u 
CD16 Fc7RIII {low affinity Fe gp50.£5 Leu-11b(l')b, OKNK(JL) 0 , neutrophil granulocytes, macrophages, 
receptor for lgG); PI-linked VEP-13{1')h, CLB-FcR-gr/1 {72a)k, NK cells; absent on granulocytes in 
protein on granulocytes GRM1{72a) 0 patients with PNH 
CDw17 lactosylceramide glycolipid T5A7{1')u granulocytes, monocytes, platelets 
CD18 integrin {32 chain/ gp95 MHM23{71)f, CLB-LFA-1/1{71)k majority of lymphoid and myeloid cells 
associated with CD11 (see CD11); absent or defect in LAD 
chains (a chains) patients 
CD19 pan-B cell antigenjfunction gp90 Leu-12{71)b, 84{71) 0 , CLB-B4{71)k, precursor B cells and 8 cells 
in B cell activation HD37{71)5 •f,h,p, F97-4A2(JL)s, 
B-ly-3{1L)0 
CD20 B cell antigen/function p35 Leu-16{71)b, 81 {72a) 0 , L26(12a)f, subpopulation of precursor B cells, all 
in B cell activation B-ly-1 (71) 0 , G28-2(73)v B cells, follicular dendritic reticulum 
cells; L26 recognizes an intracellular 
epitope of the CD20 molecule 
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CD no. a Name(s)/function mol. mass McAb (mouse isotype) Reactivity with hematopoietic cells 
CD21 B cell antigen/CR2 (C3d gp140 B2(1L)0 , OKB1 (72a) 0 , HB-5(72a)b, subpopulations of B cells (e.g. follicular 
receptor); EBV receptor RFB6(7)w, F97-6B3(71)s, B-ly-4(71)0 mantle cells), follicular dendritic 
reticulum cells 
CD22 B cell antigen/function in gp135 Leu-14/SHCL-1 (72b)b, HD6(71)g,h,p, precursor B cells and mature B cells 
B cell activation; related 4KB128(71)f, RFB4(7)g, w, To15(72b)f, 
to NCAM (CD56) HD39(71)g,h,P, CLB-B-Jyf1(71)k 
CD23 B cell antigenjFc<RII (low gp45 Leu-20jEBVCS-5(71)b, Tu1(71)0 , Fc<RIIa is expressed by a subpopulation 
affinity Fe receptor for JgE); MHM6(7l)f of B cells (e.g. follicular mantle cells) and 
two types of Fc<RII exist, which B-CLL cells; Fc<RIIb is expressed by 
differ in their cytoplasmic do- monocytes and eosinophils 
main (Fc<RIIa and Fe< RUb) 
CD24 B cell-granulocytic antigen; gp42 BA-1 (IL)r, CLB-gran·B:lyf1(71)k, subpopulation of (precursor) B cells, 
PI-linked protein on granu- OKB2(71)0 , VIB-E3(1L),, VJB-CS(IL)i granulocytes; absent on granulocytes in 
Jocytes patients with PNH 
CD25 Tac antigenf.B chain of gp55 2A3(71)b, OKT26A(72)0 , activated T cells, activated B cells 
the IL-2 receptor (low IL-2R1(72a)0 , ACT-1(71)f, (e.g. HCL), activated macrophages 
affinity IL·2R) CLB-IL-2R/1 (72b)k, Tu69(71)0 
CD26 dipeptidylpeptidase IV gp120 134-2C2(1L)x activated T cells, activated B cells, 
(DPP IV) macrop hages 
CD27 T cell antigen (homo· p110 OKT1BA(72) 0 , VIT-14(72b)i, mature T cells, activated T cells, sub-
dimer) (55/55) CLB-9F4(72a)k population of B cells (e.g. cytoplasmic 
expression in plasma cells) 
CD28 Tp44 antigen(homodimer)/ gp90 Kolt2(7t)t subpopulation of T cells (especially 
function in T cell prolifer- (44/44) cytotoxicjsuppressor T cells) 
ation 
CD29 integrin .81 chain 0/LA·.B gp130 484(71)0 subpopulation of T cells (especially CD4 
chain; platelet GPIIa)jasso- positive T cells), subpopulations of other 
ciated with CDw49 molecules leukocytes, megakaryocytes, platelets 
0/LA-a chains) (broad tissue distribution) 
CD30 activation antigen gp105 Ki-1 (73)f, Ber-H2i71lf subpopulation of activated lymphoid 
cells, Reed-Sternberg cells 
CD31 myeloid antigen; gp140 SG134(71)y monocytes, granulocytes, platelets, 
platelet GPJJa' subpopulation of T cells 
CDw32 Fc7RII Ontermediate af. gp40 C1 KM5(71)z, IV.3(72b)aa monocytes, subpopulation of macro-
finity Fe receptor for JgG) phages, B cells, granulocytes, eosine-
phils 
CD33 pan-myeloid antigen gp67 Leu-M9(71)b, My9(72b)0 ,WM-54(71)f, majority of myeloid and monocytic cells 
L4F3(1L)u (except for granulocytes) 
CD34 precursor antigen gp115 My10(71)b, BI-3C5(71)s, precursors of lymphoid cells, precursors 
JCH3(72a)bb of myeloid cells 
CD35 CRt (C3b receptor); four gp160-250 44D(71)b, To5(71)f, Z£11111lzz B cells, granulocytes, monocytes, 
different allotypes erythrocytes, dendritic reticulum cells 
CD36 monocytic-thrombocytic gp90 OKM5(71) 0 , ESIVC7(71)k, 5F1(~)u, monocytes, macrophages, early ery· 
antigenjthrombospondin CJMeg1 (71)z throid cells, megakaryocytes, platelets 
receptor (platelet GPIV) 
CD nomenc/atuur 41 
CD no. a Name(s)/function mol. mass McAb {mouse lsotype) Reactivity with hematopoietic cells 
CD37 B cell antigen gp40-52 RFB7(1L)g'w, Y29/55(72a) 00, B cells; weak expression on T cells, 
HD28{72a)g'p, G28-1 (11r monocytes and granulocytes 
CD38 T10 antigen gp45 Leu-17{71)b, OKT10{71)0 •d activated T and B cells, precursor cells 
A10{72a)g (e.g. thymocytes), subpopulations of 
B cells (e.g. follicular center cells), 
plasma cells 
CD39 B cell antigen gp80 OKT28{71) 0 , G28-8(71t, G28-10{71)v, large part of mature B cells 
CD40 B cell antigenjfunction gp50 G28-5{71t subpopulation of B cells, interdigitating 
in B cell activation reticulum cells 
CD41 platelet GPIIb-GPIIIa gp145/115 J15{72a)f, CLB-thrombo/7{71)k, megakaryocytes, platelets; absent or 
complex; platelet GPIIb HPL1{71)g, V1-P11{71)' reduced in patients with Glanzmann's 
consists of a large " sub- thrombasthenia 
unit and a small {3 subunit 
{disulfide linked) and is 
associated with platelet 
GPIIIa (CD61 antigen)/ 
fibrinogen receptor 
CD42a platelet GPIX; associated gp20 FMC25{71)dd megakaryocytes, platelets; absent 
with CD42b antigen {platelet or reduced in patients with Bernard-
GPib)/receptor for von Soulier syndrome 
Willebrand factor 
CD42b platelet GPib consists of a gp170 AN51 {72a)f, HPL 11 (71)5, megakaryocytes, platelets; absent 
large " subunit and a small {143/22) or reduced in patients with Bernard· 
{3 subunit; associated with Soulier syndrome 
CD42a antigen {platelet 
GPIX)freceptor for von 
Willebrand factor 
CD43 leukosialin (sialophorin; gp95 Leu-2201\b, DFT-101\f, T cells, monocytes, granulocytes 
leukocyte sialoglycoprotein) .MI.!.W.t, G1Q.2{71)v, G19-1{71)v (broad tissue distribution); absent in 
some patients with Wiskott-A!drich 
syndrome 
CD44 Pgp-1 /lymphocyte gpS0-95 Hermes-3{72a)00, BRIC35{71)ff, leukocytes, e.g. T cells, granulocytes and 
homing receptor NKI-P1 {71)gg erythrocytes {broad tissue distribution) 
CD45 LCA {leukocyte common gp180·220 anti-leukocyte {Hle·1){71)b, T200{71)h all leukocytes 
antigen), T200 antigen CLB·T200{71)k, PD7 /26{71)!, 
CD45RO restricted LCA gp180 UCHL1b2a)f thymocytes, activated T cells, memory 
T cells; weak expression on monocytes 
and granulocytes 
CD45RA restricted LCA gp220 2H4{71) 0 , 4KB501lf, MT2b1)0 , virgin T cells, B cells, granulocytes, 
MB1(J1) 0 , G1-15{71)v monocytes 
CD45RB restricted LCA gp220 PD7 /26171\f B cells, subpopulation of T cells, 
205,190 monocytes, macrophages, granulocytes 
CD46 non-lineage antigen/ gp66/56 J48(71)hh leukocytes (broad tissue distribution) 
membrane cofactor 
protein (MCP) 
CD47 non-lineage antigen gp47-52 CIKM1(71)z leukocytes (broad tissue distribution) 
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CD no. a Name(s)jfunction mol. mass McAb (mouse isotype) Reactivity with hematopoietic cells 
CD48 non-lineage antigen; gp41? Tii145(1<)0 , J4-57(11)hh leukocytes; absent in patients with PNH 
PI-linked protein 
CDw49b VLA-a2 chain (platelet gp170 CLB-thrombo/4(11)k platelets, activated T cells, cultured 
GPia); associated with Tcells 
CD29jreceptor for collagen 
CDw49d VLA-a4 chain; associated gp150 HP2/1(11)ii, HP1/3(13)ii thymocytes, T cells, B cells, monocytes 
with CD29 jfibronectin 
receptor; homing receptor 
for Peyer's patches 
CDw49f VLA-a6 chain (platelet GPic); gp150 GoH3(rat 12a)kk platelets, subpopulation of T cells 
consists of a large a subunit (120/30) 
and a small f3 subunit; asso-
ciated with CD29flaminin 
receptor 
COw 50 non-lineage antigen gp148/108? leukocytes 
CD51 aV chain of the vitro- gp140 NKI·M7(11) ff platelets 
nectin receptor (VNR-a); (125/25) 
associated with CD61 
(platelet GPIIIa) 
COw 52 Campath-1 antigen gp21-28? YTH66.9(1<)nm, YTH34.5(12b)rnm leukocytes (broad tissue distribution) 
CD53 MEM-53 antigen gp32·40 MEM·53(11)nn, HD77{1<) 00 leukocytes 
CD54 intracellular adhesion gp90 OKT27(12)c, My13(11)PP monocytes, lymphocytes (broad tissue 
molecule-1 (ICAM-1)/ distribution); increased expression upon 
ligand for CD11a-CD18 activation 
molecule (LFA-1) 
CD 55 decay accelarating factor gp70 BRIC110(11)ff, BRIC128(1')ff leukocytes, platelets, erythrocytes 
(OAF); PI-linked protein (broad tissue distribution); absent in 
patients with PNH 
CD 56 neural cell adhesion gp135-220 Leu-19/NKH-1 (11)b NK cells, some T cells (neuroectodermal 
molecule (NCAM); PI linked cells) 
and transmembrane forms 
CD 57 human natural killer cell gp110 Leu-7 JHNK-1 (l<)b' d subpopulation of NK cells, subpopulation 
antigen of T cells, some B cells 
CD58 LFA-3; ligand for CD2 (LFA-2); gp4Q-65 G26(1<)h, BRIC5(12a/f leukocytes, erythrocytes (broad tissue 
PI-linked and transmembrane distribution) 
forms 
CD59 Ly-6 antigen; gp18-20 MEM·43(12a),nn leukocytes, platelets, erythrocytes (broad 
PI-linked protein YTH53.1(72b)mm tissue distribution); absent in patients with 
PNH 
CDw60 NeuAc-NeuAc-Gal; expressed glycolipid M-T121 (1') 5 , M-T32(1')5 subpopulation of T cells, platelets 
by various gangliosides 
CD61 integrin /33 chain (platelet gp115 Y2/5101)f, VIP-L2(11)i megakaryocytes, platelets 
GPIIIa; VNR-/3 chain)fassoci- CLB-thrombo/1 (C17)(11)k 
ated with platelet GPIIb 
(see CD41) or CD51(VNR-a) 
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CD no. a Name(s)jfunction mol. mass McAb (mouse isotype) Reactivity with hematopoietic cells 
CD62 granule membrane protein gp140 CLB-thrombo/5 (C8)(11),k megakaryocytes, platelets; increased 
(GMP-140); platelet GPIIa" CLB-thrombo/6 (C2) (71)k expression upon activation 
CD63 GP-53 antigen gp53 CLB-gran/12 (71)k activated platelets, monocytes, 
lymphocytes (weak), granulocytes (weak) 
CD64 Fc7RI (high affinity Fe gp75 32.2 (71)aa monocytes 
receptor for lgG) 
CDw65 myelomonocytic antigen glycolipid VIM-2(JL)h,i, VIM-S(JL)i majority of myeloid and monocytic cells 
(fucoganglioside; ceramide- and a part of their precursors 
dodecasaccharide 40) 
CD66 granulocytic antigen gp180-200 CLB-granj10(71)k granulocytes; increased expression 
(phosphoprotein) upon activation 
CD67 granulocytic antigen; p100 B13.9(71)k granulocytes; increased expression upon 
PI-linked protein activation; absent in patients with PNH 
CD68 macrophage antigen gp110 EBM11 (71)f, !SEl.bJ/, macrophages (mainly cytoplasmic 
Ki-M6(71)h, Ki-M7(71)h expression) 
CD69 activation inducer gp60 Leu-23/L78(71)b early activated B and T cells, which do 
molecule (AIM); early (28/34) not yet proliferate 
activation antigen 
CDw70 activation antigen ? Ki-24qq subpopulation of activated B and 
and T cells, Reed-Sternberg cells 
CD71 T9 antigen(homodimer)/ gp190 OKT9(71)0 , T9(72a) 9 , proliferating cells (e.g. thymocytes), 
transferrin receptor (95/95) Ber-T901)f, VIP-1 (71)h,i activated cells, macrophages 
CD72 B cell antigen gp43/39 J3-109(71)hh, BU-40(72a)rr precursor B cells and mature B cells 
CD73 ecto-5'-nucleotidase (5'-NT); gp69 AD-2 {71) 55, most B cells, subpopulation of T cells; 
PI-linked protein 7G2.2.11 (72a) tt absent in some types of SCID 
CD74 MHC-class-11-associated gp41/35/33 BU-43(1')rr, BU-45(71)rr, subpopulation of precursor B cells, 
invariant chain LN201) 0 B cells, subpopulation of rnonocytes 
CDw75 B cell antigen p53? OKB4(JL)0 , LN1 (til0 subpopulation of mature B cells (mainly 
germinal center B cells), subpopulation of 
T cells (weak) 
CD76 B cell antigen p85/07? HD66(/!l00 , CRIS-41ti{ subpopulation of mature B cells (mainly 
mantle zone B cells), subpopulation of 
Tcells 
CD77 B cell antigen (globe- glycolipid 424/4A11(JL)uu germinal center B cells, activated B cells; 
triaosylceramide; Gb3) Burkitt lymphoma cells, CC and CB-CC 
lymphoma cells 
CDw78 pan-B cell antigen gpsn Leu-21(JL)b subpopulation of precursor B cells, 
resting B cells, subpopulation of 
macro phages 
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CD no. a Name(s)/functlon mol. mass McAb (mouse lsotype) 
TdT /function in lg and 
TcR gene rearrangement 
(Insertion of nucleotides 
at junction sites) 
B cell antigen 
HCLantigen 
p58 conventional antisera vv and 
McAb (HTdT-1(71)vv, HTdT-3(72a)vv, 
HTdT -4(72a)vv) 
gp105 FMC7(!l)5 •dd 
gp144 B-ly-7(71)-
mol. mass conventional antisera and McAb Smlg (surface membrane 
immunoglobulin); lgM, 
lgD, lgG, lgA, lgE 
is dependent 
on lg class 
mol. mass conventional antisera and McAb Cylg (cytoplasmic 
immunoglobulin) is dependent 
on lg class 
weak Cyp. (weak cytoplas-
mic expression of p. chain) 
TcR-a.B (classical TcR; 
TCR2) 
TcR-75 (alternative TcR; 
TCR1) 
MPO (myeloperoxidase); 
MPO consists of two subunits 
monocytic antigen 
macrophage antigen 
GpA (glycophorin A) 
H antigen; backbone of ABO 
variable blood group proteins 
HLA-A, B, C, shared deter-
minantjheavy chain of MHC-
class I molecule 
,82-microglobulinjlight 
chain of MHC-class I 
molecule 
HLA-DR, non-polymorphic 
antigen /MHC-class II 
molecule 
nuclear antigen in pro-
!iterating cells 
gp70 selected anti-p. antisera 
gp80 WT31 (71)b and BMA031 (72b)h 
(44/40) probably recognize non-polymorphic 
epitopes of T cR-a.B 
gp75 anti-TcR-7/5-1 (71)b and TCR51 (71)xx 
(44/42 or recognize non-polymorphic epitopes 
55/42) of TcR--y5 
gp60/12 MP0-7(71)!, CLB-MP0-1 (72a)k 
gp75 Monocyte-2j61D3(71)YY 
gp25 RFD9(71)w 
gp41 VIE-G4(!l)h•i, CLB-eryj1(71)k 
variable CLB-eryH/1 (!l)k 
gp43 W6/32(72a)d,f,g 
gp12 L368(71 )b, FMC16(72a)B 
gp29/34 L243(72a)b,d, OKDr(72a) 0 , 
DK22(72a)f, RF-B-HLA-DR(p.)5 , 
LN3b2a)0 
? Ki-67(71)! 
Reactivity with hematopoietic cells 
immature lymphoid cells, small part of 
precursors of myeloid cells, virtually 
all ALL and some AML 
mature B cells 
small subpopulation of B cells 
("HCL-specific") 
Smlg positive cells; each B cell clone ex-
presses only one type of lg light chain 
(lc or ~). but may express multiple lg 
heavy chains 
Cylg positive cells (immunoblasts, 
immunocytes and plasma cells) 
pre-B cells; only p. heavy chains are 
weakly expressed in the cytoplasm 
(no lg light chains) 
TcR-a.B is expressed by the majority of 
mature CD3+ T cells 
TcR-78 is expressed by a minority 
of mature CD3+ T cells 
majority of cells of the myeloid lineage 
(granulocytic and monocytic cells) 
monocytic cells 
macrophages 
erythroid cells 
erythroid cells 
all nucleated cells 
all nucleated cells 
hematopoietic precursor cells, B cells, 
activated T cells, monocytic cells and 
macrophages 
proliferating cells during late G1, S, 
G2 and M phases of the cell cycle 
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Footnotes belonging to the Appendix (Summary of clustered and non-clustered immunologic markers) 
a. CD = cluster of differentiation, as defined during the 
Leukocyte Typing Conferences (Paris, 1982; Boston, 1984; 
Oxford, 1986; Vienna, 1989). 
b. Becton Dickinson, San Jose, CA. 
c. Ortho Diagnostic Systems, Raritan, NJ. 
d. American Type Culture Collection, Rockville, MD. 
e. Coulter Clone, Hialeah,FL. 
f. DAKOPATIS, Glostrup, Denmark. 
g. Seralab, Crawley Down, UK. 
h. Behring, Marburg, FRG. 
Dr. W. Knapp and Dr. 0. Majdic, Vienna, Austria. 
k. Central Laboratory of the Blood Transfusion Service, 
Amsterdam, The Netherlands; in other countries: Janssen 
Biochimica, Beerse, Belgium. 
Dr. P.C.L. Beverly, London, UK. 
m. Dr. C. Terhorst, Boston, MA. 
n. Dr. P. Anderson, Boston, MA. 
o. Biotest, Dreieich, FRG. 
p. Boehringer Mannheim, Mannheim, FRG. 
q. Dr. W. Tax, Nijmegen, The Netherlands. 
r. Hybritech, San Diego, CA. 
s. Dr. P. Rieber, Munich, FRG. 
t. Nichirei Co., Tokyo, Japan. 
u. Dr. I. Bernstein, Washington, DC. 
v. Dr. J.A. Ledbetter, Oncogen Corporation, Seattle, WA. 
w. Royal Free Hospital, London, UK. 
x. Dr. R. Vilella, Barcelona, Spain. 
y. Dr. S.M. Goyert, Tei-Hashomer, Israel. 
z. Dr. G.R. Pilkington, Melbourne, Australia. 
Abbreviations used in the Appendix: 
AIM 
ALL 
AML 
CALLA 
CB-CC 
cc 
Cylg 
CLL 
CR 
OAF 
DPPIV 
EBV 
FAL 
Fc1R 
FcER 
FcllR 
GMP 
GP 
gp 
GpA 
HIV 
HCL 
I CAM 
= activation inducer molecule 
= acute lymphoblastic leukemia 
= acute myeloid leukemia 
= common ALL antigen 
= centroblastic-centrocytic lymphoma 
= centrocytic lymphoma 
= cytoplasmic lg 
= chronic lymphocytic leukemia 
= complement receptor 
= decay accelerating factor 
= dipeptidylpeptidase IV 
= Epstein Barr virus 
= fucosyi-N-acetyllactosamine 
= Fe receptor for lgG 
= Fe receptor for lg E 
= Fe receptor for lg M 
= granule membrane protein 
= glycoprotein 
= glycoprotein 
= glycophorin A 
= human immunodeficiency virus 
= hairy cell leukemia 
= intercellular adhesion molecule 
Rotterdam, March 1990 
aa. Medarex Inc., West Lebanon, NH. 
bb. Dr. R.J. Levinsky, London, UK. 
cc. Dr. H.K. Forster, Helfman-La Roche, Basel, Switzerland. 
dd. Dr. H. Zola, Bedford Park, Australia. 
ee. Dr. E.C. Butcher, Stanford, CA. 
If. Dr. D. Anstee, Bristol, UK. 
gg. Dr. C.G. Rgdor, Amsterdam, The Netherlands. 
hh. Dr. J.M. Pesando, Seattle, WA. 
ii. Dr. F. Sanchez, Madrid, Spain. 
kk. Dr. A. Sonnenberg, Amsterdam, The Netherlands. 
II. Dr. F. Hogervorst, Amsterdam, The Netherlands. 
mm. Dr. H. Waldmann, Cambridge, UK. 
nn. Dr. V. Horejsi, Prague, Czechoslovakia. 
oo. Dr. G. Moldenhauser, Heidelberg, FRG. 
pp. Dr. C.l. Civin, Baltimore, MD. 
qq. Dr. H. Stein, Berlin, FRG. 
rr. Dr. D.L. Hardie, Birmingham, UK. 
ss. Dr. M. Cooper, Birmingham, AL. 
tt. Dr. L. Thompson, La Jolla, CA. 
uu. Dr. Brodin, Lund, Sweden. 
w. Supertechs, Bethesda, MD. 
ww. Dr. S. Poppema, Edmonton, Canada. 
xx. T Cell Sciences, Cambridge, MA. 
yy. Bethesda Research Laboratories, Gaithersburg, MD. 
zz. Dr. N.M. Hogg, London, UK. 
Underlined McAb work on paraffin sections. 
lg 
IL-2 
kDa 
LAD 
LCA 
LFA 
McAb 
MCP 
MHC 
MPO 
mol. mass 
NCAM 
NKcell 
5'-NT 
p 
PI 
PNH 
SCID 
Smlg 
SRBC 
TcR 
TdT 
VLA 
VNR 
= immunoglobulin 
= interleukin 2 
= kilo Dalton 
= leukocyte adhesion deficiency 
= leukocyte common antigen 
= leukocyte function antigen 
= monoclonal antibody ;antibodies 
= membrane cofactor protein 
= major histocompatibility complex 
= myeloperoxidase 
= molecular mass in kDa 
= neural cell adhesion molecule 
= natural killer cell 
= 5' -nucleotidase 
= protein 
= phosphatidyl-inositol glycan 
= paroxysmal nocturnal hemoglobinuria 
= severe combined immunodeficiency 
= surface membrane lg 
= sheep red blood cells 
= T cell receptor 
= terminal deoxynucleotidyl transferase 
= very late antigen 
= vitronectin receptor 
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The characterization of cells in the various hematopoietic differentiation stages can be 
performed morphologically (1-5). Additional characterization is obtained by immunologic marker 
analysis (6-12). The expression of a particular set of immunologic markers designates a cell to 
a particular differentiation stage. The various markers are detectable by means of antibodies 
or by rosette techniques (13-18). 
Leukemias and non-Hodgkin lymphomas (NHL) can be regarded as malignant counterparts 
of cells in the various hematopoietic differentiation stages (6-12, 19-24). Hematopoietic 
differentiation schemes as presented in Figure 1, are based upon knowledge concerning 
normal hematopoiesis as well as leukemias and NHL (1-12, 19-24). Such differentiation schemes 
are hypothetical and cannot be complete. In addition, it should be realized that differentiation 
is a gradual procession of events and that differentiation stages are not as finite as suggested 
in the figure. However, such differentiation schemes provide an indication as to where the 
various leukemias and NHL can be located according to their maturation arrest (Rgure 2). It 
is noteworthy that a maturation arrest is not always restricted to one differentiation stage, but 
that several differentiation stages can occur within one malignancy. 
It will be discussed which cells express the various immunologic markers, how the 
expression of these markers can be detected and how immunologic markers can be used for 
the characterization of normal hematopoietic cells as well as leukemic and NHL cells. 
HEMATOPOIETIC DIFFERENTIATION STAGES AND IMMUNOLOGIC MARKERS 
Hematopoietic differentiation can be divided into a lymphoid and a myeloid lineage. The 
*Published in: Ruiter DJ, Fleuren GJ, Warnaar SO, eds. Application of monoclonal antibodies in tumor pathology. 
Dordrecht: Martin us Nijhoff Publishers, 1987:87-116. Updated for CD codes and several new immunologic markers. 
48 CHAPTER 2.3 
BONE MARROW •• ~ PERIPHERAL BLOOD 
o-o- ----o----o- --@-w-@ 
/-pre-8 celt pre-8 cell early /8 fell Intermediate mature 8 cell lmmunoblast lmmunocyte plasma cell 
0 6. THYMUS OBcelll- 1--IOJ--~ /lymph~ ~ ~stem ~~0 ~ 0 0_.......- maMe helpec/l"d"cec activated __ __ thymocyte T-lymphocyte helper/Inducer -...........__ T-lymphocyte prothymocyte Immature common ---............0 0 ~ l thymocyte thymocyte )- r.-1 )--~ mature suppressor/ activated thymocyte cytotoxic suppressor/cytotoxic 0 '-----0-~---_-_---®----_-_--~ :5t~ r-~·::@ 
stem cell\ /Q<oo"obl"'t pco©m'".ocyte m@o~". ocy.te maccophage 
onocytlc --- o~----- . .. : 
em celt 
myeloblast promyelocyte granulocyte 
CJ~~o @~ ________ ®@ 
myeloid ~ C:::l 
stem cell pcoecythcoblast ecythcoblast ecyth~ocyte 
0------~----- -[}~~<o 
megakaryoblast megakaryocyte platelets 
LYMPHOID TISSUE 
Figure 1. Hypothetical scheme of hematopoiesis. The different compartments, where cells in the various 
differentiation stages are located, are indicated. 
lymphoid differentiation consists of the B cell and T cell lineages. The B cell differentiation 
occurs partly in the bone marrow (BM) and partly in the lymphoid tissues, finally resulting in 
antibody secreting plasma cells. The major part of the T cell differentiation probably occurs in 
the thymus, finally resulting in the mature helper /inducer T lymphocytes and suppressor I 
cytotoxic T lymphocytes, which are present in the peripheral blood (PB) and lymphoid tissues. 
The precise origin of the natural killer (NK) cell is not yet known (not included in Figure 1). The 
myeloid differentiation, consisting of the monocytic, granulocytic, erythroid, and thrombocytic 
lineages mainly takes place in the BM (Figure 1). 
Most hematopoietic differentiation stages can be characterized by the use of immunologic 
markers (6-12, 19-24). Although immunologic markers represent differentiation antigens, they 
usually are not specific for one differentiation stage, but are expressed in several stages. How-
ever, a certain combination of markers can be specific for a particular differentiation stage. The 
expression of the various immunologic markers per differentiation stage is summarized in the 
Figures 3 and 4. As is illustrated by these figures, markers for the lymphoid differentiation 
lineage are more discriminating and more numerous than those for the myeloid lineage. 
Therefore, in particular, cells in the various lymphoid differentiation stages and their malignant 
counterparts can be characterized precisely. Detailed information about the markers presented 
in the Figures 3 and 4 is summarized in Table 1. In this table the markers are divided into 
groups according to their specificity: 1, lymphoid markers (B cell markers, T cell markers) and 
NK cell markers; 2, myeloid markers (pan-myeloid markers, myeloid-granulocytic markers, 
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T lymphoblastic lymphoma (e.g. convoluted T cell 
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Figure 2. Hypothetical scheme of hematopoiesis. The numbers indicate as to where the various leukemias and 
NHL can be located according to their maturation arrest (see insert). The nomenclature of the NHL, Indicated by 
numbers 12 to 20 is derived from the Kiel classification of NHL (4). The numbers 22 to 28 represent the various 
AML types according to the FAB classification (1-3). 
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monocyte-macrophage markers, erythroid markers and thrombocytic markers); 3, markers 
which are expressed by cells of several differentiation lineages. 
International nomenclature and classification of immunologic markers 
In order to classify the large number of monoclonal antibodies (McAb) against immunologic 
markers, an international nomenclature has been developed analogous to nomenclatures such 
as those for classifying HLA antigens and blood group antigens (15-18). The various McAb 
(and the recognized immunologic markers) are classified in clusters of differentiation (CD). 
McAb against most lymphoid and myeloid markers have received a CD code (Table 1; Figures 
3 and 4). Detailed information about the international CD nomenclature is summarized in 
Chapter 2.2 and an extensive list of all CD codes (CD1-CDw78) is given in the Appendix of 
Chapter 2.2. In the following sections the various McAb and the recognized markers will be 
indicated by their CD codes. When specific immunologic stainings are discussed, the names 
of the used McAb will be placed in parentheses behind the CD codes. 
Lymphoid markers 
The enzyme terminal deoxynucleotidyl transferase (TdT) is present in the nucleus of 
immature lymphoid cells, but is absent in more mature differentiation stages (6,7,25,26). Early 
in B cell differentiation, in the pre-B cell stage, weak cytoplasmic expression of fl. 
immunoglobulin heavy chains (weak CyJJ.) occurs (27-30), while more mature B cells express 
both immunoglobulin heavy and light chains on their cell surface membrane (Smlg) (31 ,32). 
Finally, the plasma cell strongly expresses cytoplasmic immunoglobulin (Cylg) heavy and light 
chains (33). Additional characterization of the various B cell differentiation stages can be 
performed by the use of other B cell markers such as the pan-B cell markers CD19 and CD22 
(34-36), the common acute lymphoblastic leukemia antigen (CALLA; CD10 antigen) and the B 
cell markers CD9, CD20, CD21, CD24, CD37, FMC7 and B-ly-7 (39-50). The expression of the 
markers CD9 and CD24 is not restricted to the B cell lineage, but is also found in other 
differentiation lineages (17, 18). The plasma cell is negative for the mentioned B cell markers, 
but expresses the CD38 antigen (Figure 3) (41). 
During T cell differentiation, several T cell markers appear on the cell surface membrane, 
resulting in the expression of many T cell antigens by functional T lymphocytes (7,8,51 ,52). The 
putative prothymocyte only expresses the C02 and CD7 antigens (53-58). The C02 antigen 
represents the sheep red blood cell (SRBC) receptor (56,57,59). Another valuable marker for 
immature T cells is the cytoplasmic expression of the CD3 antigen (CyCD3) (60,61). During 
further differentiation also the CD5 antigen as well as the CD4 and CDS molecules are 
expressed and finally the CD3 antigen appears on the cell surface membrane (51,52,62-66). 
The CD6 antigen is generally co-expressed with the CD5 antigen (67), while the CD1 antigen 
or so-called "common thymocyte antigen" is only temporarily expressed in the thymus (Figure 
3) (51 ,52,68). 
It is noteworthy that the mature T cell antigen CD3 is closely associated with the T cell 
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receptor (feR) (69-71), which represents an antigen-specific receptor, comparable to Smlg, the 
antigen-specific receptor of the B cell (72-74). Within the protein complex formed by TcR and 
CD3(fcR-CD3 complex), the CD3 antigen probably plays an important role in the anchorage 
of TcR as well as in the transduction of signals from TcR to intracellular components (71, 75). 
Two types of TcR exist: the "classical" TcR-a.B and the "alternative" TcR-ro (76,77). TcR-a.B is 
expressed on the majority ofT lymphocytes, while TcR-ro is found on a minority of the CD3+ 
T cells (78-81). 
NK cells generally express the CD16 antigen (low affinity Fe receptor for lgG; FerRill) and 
the CD56 antigen (neural cell adhesion molecule; NCAM) (82). A subpopulation ofthe NK cells 
also expresses the CDS molecule and the CD57 molecule (83). The CD16, CD56 and CD57 
molecules may also be expressed by a subpopulation of CD3+ T lymphocytes. The CD16 
antigen is also expressed by granulocytes (84). 
Myeloid markers 
Analogous to the lymphoid markers, also during myeloid differentiation more or less 
characteristic markers appear on the cell surface membrane, while other markers disappear. 
Virtually all myelo-monocytic cells (immature and mature) are positive for the CD13 and CD33 
molecules (9, 11 ,85,86). Also CDw65 and myeloperoxidase (MPO) are expressed by most 
myelo-monocytic cells (87,88). Cells of the monocytic lineage express CD14 (85,86,89-91) and 
more mature monocytes are positive for Monocyte-2 (91 ,92), while macro phages may express 
the markers CD68 and RFD9 (93,94). The myeloid-granulocytic cells are positive for CD15 
(95,96), while more mature granulocytic cells also express CD16, CD66 and CD67 (Figure 4) 
(17, 18). The H antigen, which represents the backbone of the ABO blood group proteins, and 
glycophorin A (GpA) can be used as markers for cells of the erythroid lineage (Figure 4) (97-
100). Cells of the megakaryocytic-platelet lineage can be recognized by use of McAb against 
the platelet-specific glycoproteins (GP), such as the whole Gpllb-GPIIIa complex (CD41 
molecule), GPIX chain (CD42a molecule), GPib (CD42b molecule) and GPIIIa chain (CD61 
molecule) (fable 1 and Figure 4) (101-104). 
Markers which are not or partly restricted to one differentiation lineage 
Several markers are not restricted to one differentiation lineage, but are expressed by cells 
of several differentiation lineages. The HLA-DR antigen is expressed by cells in immature 
hematopoietic differentiation stages, but also by B cells, monocytic cells and activated T 
lymphocytes (Figures 3 and 4) (105-108). The interleukin 2 (IL-2) receptor (CD25 antigen) is 
expressed by activated T cells and activated B cells, while the CD38 antigen and the transferrin 
receptor (CD71 antigen) are expressed by virtually all proliferating and activated cells 
(17,18,108-110). The precursor antigen CD34 is found on most immature cells of both the 
lymphoid and myeloid differentiation lineages (Figures 3 and 4) (111). 
The CD16 antigen (FerRill) is not only expressed on NK cells (82,83), but is also found on 
mature granulocytes (Figures 3 and 4) (84,112). The CD11/CD18 antigens represent a family 
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Figure 3. Hypothetical scheme of lymphoid differentiation. The expression of the various immunologic markers by cells in the different stages of lymphoid 
differentiation are indicated. The markers in parentheses are not always expressed. 
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Figure 4. Hypothetical scheme of myeloid differentiation. The expression of the various immunologic markers by cells in the different stages of myeloid 
differentiation are indicated. The markers in parentheses are not always expressed. 
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TABLE 1. Immunologic markers, which can be used for the characterization of cells in the various 
hematopoietic differentiation stages and their malignant counterparts. 
coa,b 
code 
Antlbodiesb f 
techniques 
1. LYMPHOID MARKERS 
Immature lymphoid marker 
anti-TdT0 
antiserum 
B cell markers 
CD10 VIL·A1d,e, J5f, 
BA-35 
CD19 84f, Leu-12h 
CD20 81 f, Leu-1sh 
CD21 B2f, HB-5h 
CD22 Leu-14h, HD39d,i,k, 
RFB4i,o 
CD37 Y29j55l. 
FMC7i,m 
B-ly-7n 
M rosette 
weak Gyp. 
(pre-B) 
Smlg (lc,:>.,p.,S,1,a,€) 
Cylg (K,A,fJ.,o,1,a,€) 
Kj:>. ratio 
T cell markers 
CD1 
C02 
Leu-sh, 6611C7P, 
OKT6q,r 
E rosette 
T11 f, Leu-5bh, 
OKT11q,r 
Antigen 
recognized 
terminal deoxynu-
cleotidyl transferase 
common ALL antigen 
(CALLA) (gp100) 
pan-8 cell antigen 
(gp90) 
B cell antigen (p35) 
B cell antigen; complement 
(C3d) receptor (CR2) (gp140) 
pan-8 cell antigen 
(gp135) 
B cell antigen (gp40-52) 
B cell antigen (gp105) 
hairy cell antigen (gp144) 
mouse red blood cell 
(MRBC) receptor 
weak cytoplasmic 
expression of fl. heavy chain 
surface membrane 
immunoglobulin 
cytoplasmic immunoglobulin 
T6 antigen (common 
thymocyte antigen) 
(gp43, gp45, gp49)· 
sheep red blood cell 
(SRBC) receptor 
Reactivity with 
hematopoietic cells 
immature lymphoid cells (Figure 3), a small 
subpopulation of immature myeloid cells 
(Figure 4) 
pre-pre-8 cells, pre-8 cells, subpopulation of 
cortical thymocytes (Figure 3), granulocytes 
all (precursor) B cells (Figure 3) 
all B cells (Figure 3) 
subpopulations of B cells (Figure 3) 
all (precursor) B cells (Figure 3) 
Smlg + B cells (Figure 3) 
subpopulations of Smlg + B cells (Figure 3) 
small subpopulation of normal B cells; HCL 
subpopulation of B cells ("resting B cells"), 
8-CLL 
pre-8 cells (Figure 3) 
Smlg + B cells (each 8 cell expresses only 
one lg light chain isotype: K or A, but can 
express multiple lg heavy chain isotypes) 
immunoblasts, immunocytes, plasma cells 
the normal Kj:>. ratio ranges from 0,8 to 
2,0 (mean: 1 ,4) 
cortical thymocytes (Figure 3), Langerhans 
cells, subpopulation of dendritic cells 
(Figure 4), subpopulation of B cells 
all T cells,most NK cells 
T11 antigen; SRBC receptor all T cells, most NK cells (Figure 3) 
(gp50) 
References 
6,7,25,26 
6,37-41,122,123 
34,40,41 
35,40,41,44,45 
35,40,41 ,46 
35,36,41 
35,41,47 
40,41 ,48,49 
50 
118,121 
27-30 
31,32 
33 
31 
51 ,52,68, 115 
56,57,59 
51 ,52,56,57 
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coa,b Antibodiesb f Antigen Reactivity with References 
code techniques recognized hematopoietic cells 
CD3 VIT-3°, leu-4h, T3 antigen (gp16-25) immature T cells (cytoplasmic expression) and 51,52,60,61 
OKT3q,r, UCHT1 5 ' t mature T cells (membrane expression (Rgure 3) 
CyCD3 Leu-4h, UCHT1 5 • t cytoplasmic CD3 antigen cytoplasmic expression of the CD3 antigen in 60,61 
immature T cells (Rgure 3) 
CD4 T4Af, Leu-3ah, T4 antigen (gp60) subpopulation of thymocytes, helper/inducer 51,52,64 
OKT4q,r T cells (Rgure 3) 
CDS T1Bf, Leu-1h, OKT1r T1 antigen (gp67) thymocytes and mature T cells, subpopulation 51,52,62,63 
of B cells (Rgure 3), B-CLL 117-119 
CDS OKT17q T12 antigen (gp120) thymocytes and mature T cells, subpopulation 67,120 
of B cells (B-CLL) 
CD7 Leu-9h, 3A1r, WT1u Tp41 antigen (gp41) virtually all T cells, NK cells (Rgure 3), 53-55 
subpopulation of immature myeloid cells 
(Rgure 4), -5% of AML 
CDS T8Af, Leu-2ah, TS antigen (gp32) subpopulation of cortical thymocytes, 51,52,64,65 
OKT8q,r cytotoxic/suppressor T cells, subpopulation 
of NK cells (Rgure 3) 
BMA031d, WT31h TcR-a/l (gp80) majority (85-98%) of mature CD3+ T cells 78,79 
anti-TCR-7 j o -1 TcR-78 (gp75) minority (2-15%) of mature CD3+ T cells 80,81 
(11F2)h, TCRo1v 
NK cell markers 
CD56 Leu-19(My31)h neural cell adhesion mole- NK cells, some T cells (Rgure 3) 82 
cule (NCAM) (gp135-220) 
CD 57 Leu-7(HNK-1)h' r human NK cell subpopulation of NK cells, subpopulation of 83 
antigen (gp110) T cells (Rgure 3) 
2. MYELOID MARKERS 
Pan-myeloid markers 
CD13 My7f, MCS2w, pan-myeloid antigen almost all myeloid cells (Rgure 4) 9,11,85,86 
CLB-mon-granj2x (gp150) 
CD33 My9f, Leu-M9h pan-myeloid majority of myeloid and 11 
antigen (gp67) monocytic cells, except 
for granulocytes (Rgure 4) 
CDw65 VIM-2d,e myelomonocytic majority of myeloid and 87 
antigen monocytic cells 
MP0-75 , CLB-MP0-1x myeloperoxidase (MPO) majority of myeloid and monocytic cells 88 
(gp60/12) (Figure 4) 
Monocyte-macrophage markers 
CD14 My4 f, Mo2f, Leu-M3h, monocytic antigen (gp55) monocytic cells, macrophages (Rgure 4) 9,11,85,86, 
FMC17\ UCHM1i 89-91 
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CDa,b Antlbodiesb f Antigen Reactivity with References 
code techniques recognized hematopoietic cells 
CD68 Ki-M6d, Ki-M7d macrophage antigen (gp110) macrophages (Rgure 4) 93 
Monocyte-2/61D3Y monocytic antigen (gp75) monocytic cells 91,92 
RFD9° macrophage antigen (gp25) macrophages (Rgure 4) 94 
Myeloid-granulocytic markers 
CD15 VIM-05°, Leu-M1h X hapten cells of the granulocytic lineage (Rgure 4) 95,96 
CD66 CLB-granj1o" granulocytic antigen granulocytes 18 
(gp180-200) 
CD67 813.9" granulocytic antigen (p100) granulocytes (Rgure 4) 18 
Erythroid markers 
CLB-eryHx H antigen (backbone of erythroid cells (Rgure 4) 97 
ABO proteins) 
VIE-G4d, 0 ,CLB-eryf1x GpA (glycophorin A) (gp41) erythroid cells (Rgure 4) 97-100 
Megakaryocyte-platelet markers 
CD41 J155 , CLB-thrombo/T GPIIb-GPIIIa complex (Glanz- megakaryocytes, platelets (Rgure 4) 101-104 
mann antigen) (gp145/115) 
CD42a FMC25m platelet GPIX (gp20) megakaryocytes, platelets (Rgure 4) 101-103 
CD42b AN51 5 platelet GPib (gp170) megakaryocytes, platelets (Rgure 4) 102,10 
CD61 CLB-thrombo/1 (C17)x, platelet GPIIIa (gp115); megakaryocytes, platelets (Figure 4) 101-104 
Y2/51 5 associated with GPIIb (see 
CD41) 
3. MARKERS WHICH ARE NOT RESTRICTED TO ONE DIFFERENTIATION LINEAGE 
CD9 BA-2g, CLB-thrombo/8x p24 antigens subpopulation of precursor B cells, 39-43,101 
subpopulation of B cells (Rgure 3), 
megakaryocytes, platelets (Rgure 4) 
CD11a CLB-LFA-1/2" LFA-1 antigen (gp180) majority of lymphoid and myeloid cells 113,114 
CD11b Mo1f, OKM1q,r MAC-1 antigen, complement monocytes, macrophages, granulocytes 113,114 
(C3bi) receptor (CR3) (Rgure 4), NK cells 
CD11c Leu-M5/SHCL3h p 150,95 antigen monocytes, macrophages, granulocytes, 113,114 
subpopulation of lymphocytes (Rgure 3) 
CD16 Leu-11bh, low affinity Fe receptor NK cells, subpopulation ofT cells (Figure 3), 82-84,112 
CLB-FcR-grx for lgG (FC1RIII) neutrophil granulocytes (Rgure 4) 
CD18 CLB-LFA-1/1x ~ chain of CD11 majority of lymphoid 
molecules and myeloid cells 
CD24 BA-1g B cell-granulocytic subpopulations of (precursor) B cells, 39-41,124 
antigens (gp42) granulocytes 
Immunofluorescence staining techniques 57 
coa,b Antlbodiesb f Antigen 
code techniques recognized 
CD25 mh fJ chain of interleukin 2 
receptor {IL-2R) 
CD34 My1d', BI-3C5i precursor antigen (gp115) 
CD38 Leu-17\ OKT10q,r T1 0 antigen (gp45) 
CD71 T9f, OKT9q transferrin receptor 
(gp190) 
L243h,r, OKiaq HLA-DR, non-polymorphic 
antigen (gp29/34) 
a. CD = cluster of differentiation, as defined during the 
Leukocyte Typing Conferences (Paris, 1982; Boston, 1984; 
Oxford, 1986; Vienna, 1989). 
b. Detailed information about all CD codes, additional clustered 
McAb and isotypes of McAb is given in the Appendix of 
Chapter 2.2. In this table we only included McAb, which are 
routinely used in the immunodiagnostic laboratory of the 
Department of Immunology, University Hospital Dijkzigt, 
Rotterdam, The Netherlands. 
c. Supertechs, Bethesda, MD. 
d. Behring, Marburg, FAG. 
e. Dr. W. Knapp and Dr. 0. Majdic, Vienna, Austria. 
f. Coulter Clone, Hialeah,FL 
g. Hybritech, San Diego, CA. 
h. Becton Dickinson, San Jose, CA. 
i. Seralab, Crawley Down, UK. 
k. Boehringer Mannheim, Mannheim, FAG. 
Reactivity with References 
hematopoietic cells 
activated T cells, activated B cells 17,18 
(e.g. HCL) (Rgure 3) 
precursors of lymphoid and myeloid cells 17,18,111 
cells (Rgures 3 and 4) 
activated T and B cells precursor cells, 17,18,41,108 
subpopulations of B cells, plasma cells 
proliferating cells, activated cells 108-110 
hematopoietic precursor cells, B cells, acti- 105-108 
vated T cells, monocytic cells (Rgures 3 and 4) 
I. Dr. H.K. Forster, Hottman-La Roche, Basel, Switzerland. 
m. Dr. H. Zola, Bedford Park, Australia. 
n. Dr. S. Poppema, Edmonton, Canada. 
o. Royal Free Hospital, London, UK. 
p. MonosanjSanbio, Nistelrode, The Netherlands 
q. Ortho Diagnostic Systems, Raritan, NJ. 
r. American Type Culture Collection, Rockville, MD. 
s. DAKOPATTS, Glostrup, Denmark. 
t. Dr. P.C.L Beverly, London, UK. 
u. Dr. W. Tax, Nijmegen, The Netherlands. 
v. T Cell Sciences, Cambridge, MA. 
w. Nichirei Co., Tokyo, Japan. 
x. Central Laboratory of the Blood Transfusion Service, 
Amsterdam, The Netherlands; in other countries: Janssen 
Biochimica, Beerse, Belgium. 
y. Bethesda Research Laboratories, Gaithersburg, MD. 
of adhesion molecules, in which the a chains (CD11 a, CD11 b and CD11 c antigens) are 
associated with one common f3 chain (CD18 antigen) (113,114). CD11a/CD18 molecule 
represents leukocyte function antigen-1 (LFA-1), CD11b/CD18 represents the complement 
(C3bi) receptor type 3 (CR3), while the last member of this adhesion molecule family 
(CD11cjCD18) also binds complement (C3bi) (113, 114). The expression patterns of the 
CD11/CD18 molecules are summarized in Table 1 and partly indicated in Figures 3 and 4 
(113, 114). 
Some markers, which initially seemed to be restricted to one differentiation lineage, later 
appeared to be expressed by cells of other lineages as well. This is especially the case for 
several T cell markers. The CD1 antigen is not only expressed by thymocytes, but also by 
Langerhans cells in the skin (115). The CD4 molecule is also found on a subpopulation of 
monocytes and macrophages (116). The CD5 and CDS antigens appear to be expressed by 
a subpopulation of B cells (117-120), which also express the mouse red blood cell (MRBC) 
receptor (118, 121). Finally, the CD? antigen is expressed by a small subpopulation of immature 
myeloid cells (54). Also some B cell markers are not totally lineage-restricted. For example, the 
CD9 antigen is also expressed by cells of the megakaryocytic-platelet lineage (101), CD10 
molecules are found to be present on many cortical thymocytes (122) and on granulocytes 
(123) and also the CD24 antigen is found on granulocytes (124). 
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DETECTION Of IMMUNOLOGIC MARKERS Of CELLS IN SUSPENSION AND CELLS 
IN TISSUE SECTIONS 
In recent years McAb have increasingly been used for the detection of immunologic 
markers in addition to conventional antisera (14-18). In order to visualize the reactivity of the 
antibodies, fluorochromes or enzymes are generally used as labels (125, 126). Sometimes 
rosette techniques using erythrocytes are applied, e.g. for the detection of the T cell specific 
SRBC receptor (E rosette) (59) and the MRBC receptor (M rosette), which is expressed by a 
subpopulation of B cells (118, 121 ). The staining techniques mentioned can be used for the 
detection of immunologic markers on hematopoietic cells in suspension (Figures 5-12) as well 
as on cells in tissue sections. 
Immunologic marker analysis of cells in suspension 
Cells in suspension can be obtained from BM, PB, cerebrospinal fluid (CSF), broncho-
alveolar lavage (BAL) fluid, pleural exudate, ascites, synovial fluid, etc. Generally, the granulo-
cytes and erythrocytes are removed from the BM and PB samples by ficoll density centri-
fugation, which purification facilitates the analysis of the remaining mononuclear cells (MNC) 
(127). 
For the detection of markers on the cell surface membrane the cells are incubated with 
the relevant antibodies in suspension, while for the detection of cytoplasmic or nuclear markers, 
cytocentrifuge preparations are made, which are subsequently incubated with the relevant anti-
A 
Figure 5. Double immunologic staining for CD1 o and TdT on MNC of PB from a patient in early relapse of an ALL 
A: phase contrast picture; B: CD10 positive cells (TRITC labeled); C: TdT positive cells (FITC labeled). All TdT 
positive cells in the PB sample appeared to express CD10, indicating that it concerned a CD10 positive ALL 
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Figure 6. Immunologic staining for cytoplasmic J1. lg heavy chain on MNC of BM from an ALL patient at diagnosis. 
A: phase contrast picture; B: weak CyJI. positive cells (FITC labeled). Most MNC of BM appeared to be weakly 
positive for CyJI., indicating that it concerned a pre-B-ALL 
bodies. In our laboratory we mainly use direct and indirect fluorescence methods for the 
visualization of the reactivity of the antibodies (Figures 5-7 and 9-12). It is one of the 
advantages of a fluorochrome as label, that double stainings can be easily performed and 
evaluated (Figures 5,7,9 and 10) (6-8,58). In these double stainings we use fluorescein 
isothiocyanate (FITC) and tetramethylrhodamine isothiocyanate (TRITC) as labels. TRITC can 
be replaced by texas red (TX) or phycoerythrin (1 28,1 29). Although phycoerythrin has 
advantages for fluorescence activated cell sorting procedures, we prefer to use TRITC in 
fluorescence microscopy, because phycoerythrin fades very quickly. If necessary, even a triple 
immunologic staining can be performed using colloidal gold particles as the third label next to 
FITC and TRITC (Figure 12) (125). Such double and triple immunologic stainings allow the 
evaluation of two or three different markers at the single cell level. This is important for 
determining whether the markers are expressed by the same cell or by different cells (1 25,1 30). 
Detailed information concerning methods for immunologic marker analysis of cells in 
suspension is described below. 
In our opinion it is necessary to use phase contrast facilities on a fluorescence microscope, 
since phase contrast morphology gives valuable information about the cells evaluated and 
allows the precise localization of the labels, which is important when intracellular antigens are 
stained such as TdT (Figures 5,9 and 12). In addition, this equipment allows optimal 
discrimination between labeled cells and contaminating auto-fluorescent particles (for details, 
see Chapter 2. 1). 
Immunologic marker analysis of cells in tissue sections 
Cells in tissues such as obtained by biopsies from lymph nodes, tonsils, liver and spleen, 
can be characterized immunologically by the use of tissue sections. The tissue sections, usually 
frozen sections, are incubated with the relevant antibodies. The reactivity of the antibodies is 
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visualized by the use of direct or indirect staining methods using an enzyme as label, such as 
peroxidase (PO) or alkaline phosphatase (AP) (20, 131). Such enzymes transform a substrate 
into a colored precipitate. Double immunologic stainings, using enzymes as labels (e.g. PO and 
AP) are possible if the detected antigens are expressed by different cells (126, 130-132). 
Expression of two antigens by the same cell is difficult to prove by use of enzymes as labels 
(130), unless the antigens are expressed very strongly (133, 134). Detailed information 
concerning methods for immunologic marker analysis of cells in tissue sections are extensively 
described in several reviews (135-137). 
The advantage of the use of tissue sections is that histologic information can be combined 
with information about the expression of immunologic markers (20). Nevertheless it may be 
necessary that a cell suspension is made from a tissue biopsy in order to perform immunolo-
gic marker analysis, especially if a part of the cell suspension is used for cytogenetic analysis. 
METHODS FOR IMMUNOLOGIC MARKER ANALYSIS OF CELLS IN SUSPENSION 
Preparation of cell suspensions 
MNC from BM and PB are isolated by ficoll density centrifugation (Ficoll Paque; density 
1.077 gjml; Pharmacia, Uppsala, Sweden) for 15 min at room temperature (RT) with a 
centrifugal force of 1000 g. All standard washings of cells in suspension derived from BM, PB, 
CSF, pleural exudate, ascites, etc., are performed with phosphate-buffered saline (PBS) (300 
mosmol; pH 7.8), supplemented with 0.5% bovine serum albumin (BSA; Organon Teknika, Oss, 
Figure 7. Double immunologic staining for Cy"' and Cy).. on BM cells from a patient with a plasmacytoma. A: phase 
contrast picture; 8: Cy"' positive cells (TRITC labeled); C: Cy).. positive cell (FITC labeled). The majority of the Cylg 
positive cells appeared to be positive for Cy"'; only a few Cy).. positive cells were detectable in the cytocentrifuge 
preparation. This indicates that the plasmacytoma cells were Cy"' positive. 
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The Netherlands) and 0.05% sodium azide. Washing centrifugations are performed for 5 min 
at 4 o c with a force of 400 g. If the cells are incubated in suspension for the detection of surface 
membrane markers by use of antibodies, the cell concentration is adjusted to 107 cells per mi. 
Cytocentrifuge preparations are made using cell suspensions with a concentration of 0.5 to 2 
x 106 cells per ml, depending on the size of the cells; in the case of a BM or PB cell sample 
a concentration of 2 x 106 cells per ml is generally used. if the cell suspension is used for 
rosette techniques, the cell concentration is also adjusted to 2 x 106 cells per mi. 
General remarks concerning immunologic stainings 
Most immunologic markers are detected by the use of antibodies. Commercially available 
McAb generally can be diluted 1 :50 to 1 :200, while commercially available conventional antisera 
can be diluted 1 :20 to 1 :80. However, each batch of antibodies has to be optimally titrated for 
the different applications. The labeled cells or cytocentrifuge preparations are mounted in 
glycerol/PBS (9:1), containing 1 mg p-phenylenediamine per ml (BDH Chemicals, Poole, UK) 
to prevent fading of fluorochromes (138). Coverslips are sealed with paraffin wax with ceresin 
(BDH Chemicals). Some immunologic markers are detected by rosette techniques. Such 
rosette tests generally are evaluated by the use of a counting chamber. 
We will describe several single, double and triple immunofluorescence staining methods 
as well as the microscopes, which we use for the evaluation of the immunofluorescence 
stainings. 
Single immunologic stainings 
In single staining methods using antibodies, we generally use FITC as fluorochrome. 
Several single staining methods using antibodies or rosette techniques are described below. 
Detection of cell surface membrane markers by the use of antibodies. 
In case of a direct immunologic staining (e.g. using FITC-conjugated anti-human-lg antisera) 
50 p.l of a cell suspension (107 cells per ml) is incubated for 30 min at 4°C with 50 p.l of the 
relevant, optimally titrated, FITC-conjugated antibody. After this incubation the cells are washed 
twice. In the case of an indirect immunologic staining (e.g. using mouse McAb), the cells 
undergo an additional incubation (30 min, 4 ° C) with the relevant FITC-conjugated second step 
antiserum (a FITC-conjugated goat anti-mouse-lg antiserum, if mouse McAb are used). After 
the second incubation, the cells are washed twice and the cell pellet is mounted in glycerol. 
Detection of Cylg. 
Fifty p.l of a cell suspension (2 x 106 cells per ml) is centrifuged on slides in a cyto-
centrifuge (Nordic Immunological Laboratories, Tilburg, The Netherlands). The cytocentrifuge 
preparations are air-dried for at least 15 min and the location of the cells is marked by 
encircling with a glass pencil. The preparations are fixed in acid ethanol (ethanol with 5% acetic 
acid) for 15 min at -20°C. The preparations are then washed in PBS (pH 7.8) for 15 min, dried, 
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and incubated with 15 tLI of a FITC-conjugated anti-human-lg heavy or light chain antiserum 
(fable 1) in a moist chamber (30 min, room temperature (RT)) (33). Subsequently the slides 
are washed again in PBS (15 min), mounted in glycerol, covered with a coverslip and sealed 
(Figures 6, 7 and 10). 
Detection of TdT. 
Cytocentrifuge preparations are made, air dried, fixed in methanol (30 min, 4°C) and 
washed in PBS. The preparations are incubated with 15 tLI of optimally titrated rabbit anti-TdT 
antiserum (fable 1) in a moist chamber (30 min, RT) and washed in PBS. Subsequently, the 
preparations are incubated with 15 tLI of a FITC-conjugated goat anti-rabbit-lg antiserum and 
washed again (26,58). Afterwards the preparations are mounted in glycerol, covered with a 
coverslip and sealed (Figures 5, 9 and 12). 
E rosette test. 
SRBC are washed five times with PBS; washing centrifugations are performed for 10 min 
at RT with a centrifugal force of 1500 g. Subsequently, the SRBC are incubated with 2-amino-
ethylisothiouronium bromide (AET) (40 mg per ml; pH 9.0) for 15 min at 3rC. Afterwards these 
AET-treated SRBC are washed several times with PBS and finally are resuspended in PBS, 
supplemented with 10% fetal calf serum (FCS) (59). 
One hundred tLI of the cell suspension (2 x 106 cells per ml) is mixed with 100 tLI 
AET-treated SRBC (2 x 108 SRBC per ml), and centrifuged for 5 min at 4°C with a centrifugal 
force of 300 g. The pellet is incubated for at least 15 min at 4 ° C. After this incubation the pellet 
is very carefully resuspended in the supernatant. Fifty tLI of acridine orange (5 tLg per ml) is 
added to stain the DNA of the nucleated cells. The cell suspension is carefully mounted into a 
Figure 8. E rosette test on MNC of PB from a healthy adult. The nucleated cells were stained with acridine orange 
and evaluated by combining epi-illumination (using a FITC filter combination) with trans-illumination. Eight cells in 
the presented field form rosettes, while six cells do not. 
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counting chamber and evaluated by combining epi-illumination (using the FITC filter 
combination) with trans-illumination (Figure 8). A nucleated cell is regarded as positive, if three 
or more erythrocytes are attached to the cell (Figure 8). 
M rosette test. 
Freshly collected MRBC are washed five times with PBS. Fifty J.LI of the cell suspension (2 
x 106 cells per ml), 50 J.LI of the MRBC suspension (1 x 108 MRBC per ml) and 100 J.LI FCS are 
mixed. This mixture is incubated for 15 min at 3rC and subsequently centrifuged for 5 min 
at 4 ° C with a centrifugal force of 300 g. The pellet is incubated at 4 o C for 18 hours without 
being disturbed (118, 121 ). After this incubation 100 J.LI of the supernatant is removed and the 
pellet is very carefully resuspended. Acridine orange is added to the cell suspension and the 
percentage M rosette forming cells is determined in a counting chamber (see E rosette test). 
Double immunologic stainings 
All of the various single immunologic stainings, described above, can be combined. When 
antibodies are used in double immunologic stainings, we use FITC and TRITC as labels. In our 
laboratory the double stainings with antibodies are performed in four different ways: 
1. Combination of two fluorochrome-conjugated antibodies. 
The advantage of fluorochrome-conjugated antibodies is that these antibodies can be 
mixed and that therefore only one incubation step is needed for the double staining. 
However, weakly expressed antigens might be insufficiently stained in a direct staining 
method, so that positivity is not always detectable. 
Figure 9. Double immunologic staining for the CD15 antigen and TdT on MNC of BM from a CML patient in early 
lymphoid BC. A: phase contrast picture; B: CD15 (VIM-05) positive cells (TRITC labeled); C: TdT positive cells 
(FITC labeled). The three TdT positive cells do not express the myeloid marker CD15 (VIM-05). 
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2. Combination of a fluorochrome-conjugated mouse McAb and an unconjugated mouse 
McAb. 
In such combinations, the cell suspension is first incubated with the unconjugated McAb, 
followed by an incubation with a fluorochrome-conjugated anti-mouse-lg antiserum. 
Subsequently, the cells are incubated with normal mouse serum to block free antigen 
binding sites of the anti-mouse-lg antiserum. Finally, the cells are incubated with the 
fluorochrome-conjugated McAb. 
3. Combination of two unconjugated mouse McAb of different isotypes. 
Indirect staining methods using McAb can be performed by selecting pairs of mouse 
McAb on the basis of their different isotypes (e.g. lgM and lgG or lgG1 and lgG2). The 
isotypes of many clustered and non-clustered McAb are given in the Appendix of 
Chapter 2.2. The application of this double staining method is restricted by the availability 
of FITC- and TRITC-conjugated anti-mouse-lg-(sub)class specific antisera (excellent 
antisera can be purchased from Nordic Immunological Laboratories). 
4. Combination of antibodies from different species. 
Antibodies, raised in different species, can be combined very easily. E.g. a rabbit 
antiserum can be combined with a mouse McAb, using a FITC-conjugated goat 
anti-rabbit-lg antiserum and a TRITC-conjugated goat anti-mouse-lg antiserum, 
respectively. 
By the use of these four possibilities or their combinations, many different double im-
munofluorescence stainings can be performed. Additional possibilities for double immunologic 
stainings can be obtained by using biotin-conjugated or arsanilic-acid-conjugated McAb; the 
reactivity of such McAb is visualized by the use of fluorochrome-conjugated avidin molecules 
or fluorochrome-conjugated anti-arsanilic-acid antisera, respectively (139, 140).1n the combined 
detection of a cell surface membrane antigen and a cytoplasmic antigen, we prefer to use FITC 
as label for the detection of the cytoplasmic antigen and TRITC as label for the detection of the 
cell surface membrane antigen. In our experience the use of TRITC for the labeling of 
cytoplasmic antigens generally results in a higher background staining as compared with FITC. 
In addition to double stainings with antibodies, an antibody staining can be combined with a 
rosette technique. Several double immunologic stainings will be described. 
Double immunofluorescence staining for Sm~t and Sm'A. 
The cell suspension is incubated with a mixture of a TRITC-conjugated anti-human-~t 
antiserum and a FITC"conjugated anti-human->.. antiserum (Table 1) (30 min at 4 ·c). After the 
incubation the cells are washed and a suspension preparation is made. 
Double immunofluorescence staining for Cy~t and Cy>... 
A cytocentrifuge preparation is made, fixed in acid ethanol and subsequently incubated 
with 15 JLI of a mixture of a TRITC-conjugated anti-human-~t antiserum and a FITC-conjugated 
anti-human->.. antiserum (30 min, RT) (Figure 7). 
Double immunofluorescence staining for a cell surface membrane antigen and TdT. 
Fifty JLI of the cell suspension is incubated with the relevant antibody, which is directly or 
indirectly labeled with TRITC. After the incubation and washings, 200 J.Li of PBS/0.5% BSA is 
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Figure 10. Double immunologic staining for HLA-DR and Cyp. on cells of a Burkitt lymphoma derived cell line. A: 
phase contrast picture; B: HLA-DR positive cells (TRITC labeled); C: Cyp. positive cells (FITC labeled). The HLA-
DR positive cells did not express Cyp.. 
added to the cell pellet. Subsequently cytocentrifuge preparations are made (50 p.l of the cell 
suspension per preparation), which are fixed in methanol (30 min, 4°C). The cytocentrifuge 
preparations are subjected to the indirect TdT staining with a rabbit anti-TdT antiserum and a 
FITC-conjugated goat anti-rabbit-lg antiserum (Figures 5 and 9). 
Double immunofluorescence staining for a cell surface membrane antigen and Cylg. 
The cell suspension is incubated with the relevant antibody, which is directly or indirectly 
labeled with TRITC. Subsequently cytocentrifuge preparations are made. The cytocentrifuge 
preparations are fixed in acid ethanol (15 min, -20°C) and subjected to a direct Cylg staining, 
using a FITC-conjugated anti-human-lg antiserum (Figure 10). 
Double immunologic staining for Sm!g and the MRBC receptor. 
Fifty p.l of the cell suspension is incubated with a FITC-conjugated anti-human-lg antiserum. 
After the incubation and washings, the cell suspension is subjected to the M rosette test (see 
above). Subsequently the concentration of the cell suspension (MRBC plus nucleated cells) is 
adjusted to 2 x 106 cells per ml and cytocentrifuge preparations are made (50 p.l of the cell 
suspension per preparation). The cytocentrifuge preparations are fixed in methanol (5 min, 
4°C), mounted in glycerol, covered with a coverslip and sealed (Figure 11). 
Triple immunologic staining 
In the triple immunologic staining we use colloidal gold particles of 30 nm as the third label 
next to FITC and TRITC (125). Colloidal gold can be visualized in the same epi-illumination sys-
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Figure 11. Double immunologic staining for Sm.A and M rosette on MNC of PB from a CLL patient. A and C: phase 
contrast pictures; B and D: Sm.A positive cells (FITC labeled). A and B represent the same field and C and D 
represent the same field. The M rosette forming cells also weakly expressed Sm.A, while the Sm.A negative cells 
did not form M rosettes. 
tern, which is used for the evaluation of fluorescence (see Chapter 2.1). Although colloidal 
gold particles of 30 nm can easily be used as label for the detection of cytoplasmic markers 
of cells in tissue sections (141), this is more difficult when cytocentrifuge preparations are used. 
Therefore we use the colloidal gold technique for staining cell surface membrane markers. One 
example of a triple immunologic staining will be described. 
Triple immunologic staining tor the CD3 antigen, HLA-DR and TdT. 
Fifty JLI of the cell suspension is incubated with the CD3 McAb Leu-4 (Table 1), washed 
and subsequently incubated with 50 JLI of an undiluted goat anti-mouse-lg antiserum, 
conjugated with colloidal gold particles of 30 nm (GAM-G30; Janssen Pharmaceutica, Beerse, 
Belgium). Afterwards the cells are incubated with normal mouse serum (diluted 1 in 100) to 
block free antigen binding sites of the goat anti-mouse-lg antiserum. Subsequently the cells are 
incubated with a TRITC-conjugated anti-HLA-DR McAb (Becton Dickinson). After the incubation 
and washings, 200 JLI of PBS/0.5% BSA is added to the cell pellet. Finally, cytocentrifuge 
preparations are made, which are subjected to the indirect TdT staining using FITC as label 
(Figure 12). 
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Figure 12. Triple immunologic staining for the CD3 antigen, HLA-DR and TdT on MNC of BM from a child with ALL 
in complete remission under maintenance treatment. A: phase contrast picture; B: CD3 (Leu-4) positive cells 
(colloidal gold labeled); C: HLA-DR positive cells (rRITC labeled); D: TdT positive cells (FITC labeled). The three 
TdT positive cells are also positive for HLA-DR, but negative for the CD3 (Leu-4) antigen. The former cells probably 
represent precursor B cells, while the CD3 positive cells represent mature T lymphocytes. 
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Microscopes 
Evaluation of single and double immunologic stainings, using fluorochromes. 
For the evaluation of fluorescence (FITC, TRITC and acridine orange), we use Zeiss 
Standard 16 microscopes (Carl Zeiss, Oberkochen, FRG), equipped with a IV FL Fluor-
eszenz-Auflichtkondensor (epi-illumination condenser) and phase contrast facilities. The 
epi-illumination system contains two filter combinations: Zeiss filter combination 14 (BP 51 0-560; 
FT 580; LP 590) for the evaluation ofTRITC labelling and Zeiss filtercombination 19 (BP 485/20; 
FT 510; LP 515) combined with a KP 560 filter for the evaluation of FITC labeling and acridine 
orange staining. The microscopes are equipped with at least three Zeiss objectives : a neofluar 
63/1.25 Oel Ph3 for evaluation of surface membrane staining, TdT staining, etc.; a plan-
apochromat40/1.0 Oel Ph3 for evaluation of strong expression of Cylg and a neofluar 16/0.40 
Ph2 for evaluation of the rosette tests. These objectives are used in combination with the Zeiss 
wide-field oculars Kpi-W10x/18. 
Evaluation of the triple immunologic staining, using colloidal gold as the third label. 
We use two different microscopes for the evaluation of colloidal gold in combination with 
FITC and TRITC: a Zeiss Universal II (Carl Zeiss) and a Leitz Orthoplan (Ernst Leitz, Wetzlar, 
FRG). The Zeiss Universal II is equipped with a Ill RS Fluoreszenz- Auflichtkondensor, phase 
contrast facilities and the same filtercombinations, objectives and oculars as described for the 
Zeiss Standard 16 microscopes (see above). The Leitz Orthoplan is equipped with a Ploemopak 
2 epi-illumination system, phase contrast facilities and the following two filtercombinations: Leitz 
filtercombination 12 (BP 450-490; RKP 510; LP 515) for the evaluation of FITC and Leitz filter 
combination N2 (BP 530-560; RKP 580; LP 580) for the evaluation of TRITC. The most 
frequently used objective of the Leitz microscope is the PL APO 63/1.40 Oel PHACO 4 in 
combination with the wide-field oculars Periplan GW 10xM. 
For the evaluation of colloidal gold, we use a polarization filter combination in both 
microscopes, consisting of a polarizer for the excitation light, a beam-splitter and an analyzer, 
which extinguishes the reflected light that has the same polarization as the excitation beam. The 
objectives which are used for evaluation of colloidal gold should not contain phase contrast 
rings. According to our experience the best objective is the Zeiss Antiflex-Neofluar 63/1.25 Oel, 
which contains a rotatable quarter-wave plate (125). 
IMMUNOLOGIC PHENOTYPES OF lEUKEMIAS AND NHl 
Immunologic marker analysis can be applied not only to the characterization of normal 
hematopoietic cells, but also to the characterization of leukemias and NHL (Figure 2). 
The maturation-arrest of the acute leukemias is localized in the immature differentiation 
stages (e.g. acute lymphoblastic leukemias (ALL) and acute myeloid leukemias (AML)). Chronic 
leukemias are the malignant counterparts of cells in more mature differentiation stages (e.g. 
chronic lymphocytic leukemias (CLL) and chronic myeloid leukemias (CML)). Generally, NHL 
have a mature immunologic phenotype. 
Several differentiation stages may occur within one malignancy. This indicates that malig-
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TABLE 2. Immunologic phenotypes of All. 
TdT HLA-DR CD19 and/ CD10 weak Gyp. Smlg pan-T cell 
or CD22 (CALLA) markers 
(CD2,CyCD3,CD7) 
null ALL + + + 
common ALL + + + + 
pre-B-ALL + + + + + 
B-ALL + + (+)a + 
T-ALLb + _c -/+ + 
a. Not always expressed. 
b. Several subtypes of T-ALL can be recognized, based on their positivity for the various T cell markers (see ref. 22 and 143). 
c. A few T-ALL may be HLA-DR positive (see ref. 58). 
nant cells are capable of further maturation and that their maturation-arrest is not restricted to 
a single differentiation stage. This especially occurs in AML and NHL. 
Lymphoid malignancies 
ALL can be divided into at least five different types according to their immunologic 
phenotype : null ALL, common ALL, pre-B-ALL, B-ALL and T-ALL (6,7, 19,22,23, 142). These 
immunologic phenotypes are summarized in Table 2. T-ALL can be subdivided into several 
immature and more mature subtypes, as is indicated in Figures 2 and 3 (7, 19,22,23,52, 143). 
The morphological 'French American British' (FAB) classification of ALL recognizes three ALL 
types: L 1, L2 and L3 (1 ,3). This FAB classification does not correlate well with the immunologic 
classification. L 1 and L2 morphology can be found in most immunologic ALL types ; only L3 
morphology seems to be restricted to the rarely occurring B-ALL 
Normally about 60% of the B cells express K light chain, while about 30% express>. light 
chain; the normal Kj>. ratio varies from 0.8 to 2.0 (31). Since a B cell malignancy represents the 
clonal expansion of a single B cell, only one type of lg light chain (either K or>.) is expressed. 
Therefore, the K.j>. ratio is used for the detection of a B cell malignancy and may give an 
impression of the number of malignant cells (31, 144). Several B cell malignancies can be 
distinguished by the use of additional B cell markers. B cell CLL (B-CLL) can be discriminated 
from other B cell malignancies by their weak expression of Smlg and positivity for the CD5 and 
CD6 antigen (117,118,120). On the other hand, the B cell prolymphocytic leukemia (B-PLL) 
strongly expresses Smlg and is generally negative for the CD5 and CD6 antigens (19,22). Hairy 
cell leukemia (HCL) is a B cell malignancy which expresses the "HCL-specific" B-ly-7 antigen 
as well as the CD11 c and CD25 antigens (50, 145, 146), which are generally absent on 8-CLL 
and B-PLL cells (147). The detailed immunologic phenotypes of 8-CLL, HCL and 8-PLL are 
summarized in Table 3. 
Immunologic marker analysis of NHL does not result in a classification comparable to the 
detailed morphological classifications such as the Kiel classification (4, 148). However, 
immunologic marker analysis is still valuable in the diagnosis of NHL (148). It is possible to 
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TABLE 3. Immunologic phenotypes of chronic B cell leukemias. 
CD5 CD6 CD11c CD20 CD22 CD25 CD37 FMC7 Smlg B-ly-7 
8-CLL + + ± ± + -I± ± 
HCL + + + + + + + + 
B-PLL + + + + ++ 
Used symbols: -, no expression; ±, weak expression; +, normal expression; + +, strong expression. 
determine whether a B cell or T cell malignancy is involved and to prove, in the case of a B cell 
malignancy, the clonality of the tumor by means of the,./>.. ratio (Figure 7) (31, 144). In addition, 
more immunologic markers (especially B cell markers) have become available, which enable 
a better immunologic classification of NHL (17, 18). 
Myeloid malignancies 
The various myeloid markers can be used for the classification of the myeloid malignancies, 
although they are not as discriminating as the lymphoid markers (Figures 2 and 4). 
The morphological FAB classification of AML and the immunologic classification of AML are 
both based on differentiation characteristics (1-3,9, 11 ,85,86). Although Figures 2 and 4 suggest 
that the FAB classification and immunologic classification of AML are similar, this is only true 
in the case of more mature AML (i.e. acute monocytic leukemia and acute promyelocytic 
leukemia) (11 ,24). AML often appear to consist of several subpopulations, which hampers the 
immunologic marker analysis of AML (24). Only double immunofluorescence stainings for the 
various myeloid markers allow the immunologic marker analysis of these subpopulations. CML 
cells express granulocytic markers such as CD15 and CD67 (Figure 4). When a CML 
transforms into a blastic crisis (BC), immunologic marker analysis can reveal whether it 
concerns a myeloid or lymphoid BC (Figure 9). The immunologic phenotypes of a myeloid BC 
are comparable to those of the various AML, while the phenotype of a lymphoid BC is generally 
similar to the phenotype of a common ALL or pre-B-ALL (22, 149). 
The true histiocytic NHL is very rare. By use of the various monocytic-macrophage markers 
(indicated in Figure 4 and Table 1) it is possible to characterize these NHL. 
APPLICATION OF IMMUNOLOGIC MARKER ANALYSIS 
Immunologic marker analysis of cells in normal hematopoietic differentiation stages 
Immunologic marker analysis can be used for the characterization of hematopoietic cell 
populations, such as in patients with primary immunodeficiencies (150). It can also provide 
information concerning diseases, where the balance between various (sub)populations is dis-
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TABLE 4. Application of immunologic marker analysis. 
A. Immunologic marker analysis of cells in normal hematopoietic differentiation stages is important for: 
- determination of percentages ofT lymphocytes and CD4 /CDS ratios in cell samples from patients with diseases 
such as sarcoidosis, AIDS, etc. 
- analysis of cell populations in BM, PB and lymphoid tissues from patients with (primary) immunodeficiencies. 
- analysis of cultured cells, e.g. in the case of lymphocyte proliferation tests. 
B. Immunologic marker analysis of leukemias and NHL is important for: 
- classification of leukemias and NHL. 
- recognition of subtypes of leukemias and NHL, which differ in clinical behaviour and therapy resistance. 
- recognition of association between immunologic phenotypes of leukemias and NHL and chromosomal 
aberrations. 
- detection of two malignancies in one patient. 
- characterization of subpopulations within one malignancy. 
- detection of low numbers of malignant cells. 
- staging of NHL, especially TdT+ T-NHL. 
turbed (151, 152). In patients with acquired immunodeficiency syndrome (AIDS) the CD4/CD8 
ratio in PB becomes extremely low (153, 154). In patients with active sarcoidosis the percentage 
T lymphocytes in BAL fluid is about 22% and sometimes up to 80% with high CD4/CD8 ratios, 
while in BAL fluid from normal controls, low percentages T lymphocytes are detected (155, 156). 
The monitoring of percentages ofT lymphocytes and CD4/CD8 ratios may be useful during 
follow-up of patients, who have undergone an organ transplantation (e.g. during anti-thymocyte 
globulin (ATG) treatment) (157, 158) (Table 4). 
In addition, immunologic marker analysis is used to determine the nature of cells in culture, 
such as in lymphocyte proliferation tests. 
Immunologic marker analysis of leukemias and NHL 
Immunologic marker analysis of leukemias and NHL enables a reproducible classification 
of these malignancies. By means of clinical trials it may be possible to recognize immunologic 
subtypes of leukemias and NHL, which differ in clinical behavior and therapy sensitivity (159). 
Therefore it is necessary to characterize these malignancies according to clinical, morphological 
and immunologic criteria, allowing adaptation of treatment protocols. Furthermore, immunologic 
marker analysis is important for the detection of associations between immunologic phenotypes 
and chromosome aberrations, to gain more insight in oncogenesis (160, 161). In addition 
immunologic marker analysis allows the detection of two malignancies in one patient (162) and 
the characterization of subpopulations within one malignancy (163) (Table 4). 
During maintenance therapy and even after termination of therapy it remains uncertain 
whether malignant cells are still present. The application of immunologic marker analysis can 
be used for the detection of low numbers of malignant cells, but is hampered by the presence 
of their normal counterparts (164). Therefore, cells positive for a certain marker or marker 
combination can only be regarded as malignant if these positive cells are present in higher 
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frequencies than normal or if they are detected outside their normal sites of occurrence. Since 
TdT positive cells are normally not detectable in CSF and since most ALL are positive for TdT, 
the TdT determination is valuable for the early detection of central nervous system leukemia 
(165). Another example of immunologic detection of low numbers of malignant cells is the 
double immunofluorescence staining for aT cell marker and TdT on cell samples from patients 
suffering from a TdT positive T cell malignancy (166-168). This approach is based on the fact 
that CD1+ /TdT+, cos+ /TdT+, and cos+ /TdT+ cells normally occur in the thymus only 
(58, 166, 167). The application of these double stainings for analysis of BM and PB samples of 
T-ALL patients allows early detection of relapse (164, 168) (for details see Chapters 5.3 and 5.4). 
CONCLUSION 
Immunologic marker analysis of normal hematopoietic cells and their malignant counterparts 
is an important tool for diagnostic use. It allows a precise analysis of leukocyte subpopulations 
in various diseases, such as immunodeficiencies. Moreover, it results in a reproducible 
classification of leukemias and NHL and allows, in several types of ALL and NHL, the detection 
of low numbers of malignant cells. Finally, it may be used not only for diagnostic purposes, but 
also for clinical research. 
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CHAPTER 2.4 
TRIPLE IMMUNOLOGIC STAINING WITH COLLOIDAL GOLD, 
FLUORESCEIN AND RHODAMINE LABELS * 
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Colloidal gold particles are detectable by light microscopy with polarized light in the same 
epi-illumination system as for fluorescence microscopy. Colloidal gold particles can thus be 
used in combination with a fluorochrome for the combined immunologic detection of surface 
membrane and cytoplasmic markers. We analyzed human bone marrow cells by a triple 
immunologic staining for 3 different markers, using colloidal gold, fluorescein and rhodamine 
as labels. Our results demonstrate that such a triple immunologic staining provides a powerful 
tool for study of the heterogeneity of small cell populations. 
INTRODUCTION 
In microscopy, immunologic staining techniques are widely used for both research and 
diagnostic purposes, especially for the detection of surface membrane and cytoplasmic 
markers. The antibodies used can be conjugated with fluorochromes such as fluorescein 
isothiocyanate (FITC) or tetramethylrhodamine isothiocyanate (TRITC), or with enzymes such 
as peroxidase (PO) or alkaline phosphatase(AP). For simultaneous detection of different 
markers, a double staining technique can be used, e.g. FITC in combination with TRITC (1) 
or PO in combination with AP (2,3). 
Double staining techniques provide additional information about marker distribution within 
a cell population that cannot be obtained by 2 separate stainings of individual samples. For 
instance, the combined detection of kappa and lambda immunoglobulin (lg) light chains on 
different cells proves the 8 cell character of these cells, while their presence on the same cell 
indicates Fe receptor binding of autologous lg, e.g. by monocytes (4). Another example of the 
useful application of double staining is the simultaneous detection of a T cell marker and the 
• Published in: J lmmunol Methods 1985;80:1-6. Updated for CD codes. 
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nuclear enzyme terminal deoxynucleotidyl transferase (fdT) on single cells. Since T cell 
marker+ jTdT+ cells normally occur only in the thymus, the presence of cells with the T cell 
marker+ /TdT+ phenotype in extra-thymic locations for indicative ofT cell acute lymphoblastic 
leukemia (f-ALL) or TdT-positive T cell non-Hodgkin lymphoma (5,6). 
For the identification of small cell populations, it may be mandatory to use a triple staining 
technique for detection of 3 different markers at the single cell level. In microscopy it is difficult 
to combine FITC and TRITC with a third fluorochrome, e.g. 4-acetamido-4 'isothiocyanato 
stilbene-2,2 '-disulphonic acid (SITS) (7), Texas Red (8) or phycoerythrin (9), because of 
marked fading or a considerable overlap in excitation and emission spectra (10). 
Recently a technique was described which allows the detection of colloidal gold particles 
in light microscopy by epi-illumination with polarized light (1 1 ). In theory, colloidal gold particles 
are a suitable label for combining with fluorochromes. We adapted this technique for triple 
staining with colloidal gold, FITC and TRITC. 
MATERIALS AND METHODS 
Preparation of cell suspension 
Bone marrow (BM) cells from children treated for non-T-ALL and from healthy adult volunteers were obtained 
by needle aspiration. Mononuclear cells (MNC) were isolated by Ficoii-Paque (density 1.077 gjml; Pharmacia, 
Uppsala) density centrifugation (12). The MNC were washed twice. These and all subsequent washings of cell 
suspensions were performed with phosphate-buffered saline (PBS) (300 mosmol; pH 7.8), supplemented with 1% 
bovine serum albumin (BSA; Organon Teknika, Oss) and 0.05% sodium azide. The cell concentration was adjusted 
to 107 cells per mi. 
Triple staining technique 
We performed triple staining for the detection of the T cell marker CD7 (13), a non-polymorphic HLA-DR 
antigen (14) and the nuclear enzyme TdT. Fifty microliters of the cell suspension were incubated with 50 p,l of the 
optimally titrated monoclonal antibody (McAb) CD7 (3A 1) (American Type Culture Collection, Rockville, MD) at room 
temperature (RT). After 30 min the cells were washed twice and incubated (30 min, RT) with 50 p,l undiluted goat 
anti-mouse lg antiserum, conjugated with colloidal gold particles of 30 nm (G30; Janssen Pharmaceutica, Beerse). 
The cells were washed twice and subsequently incubated (30 min, RT) with normal mouse serum (diluted 1 in 100 
in PBS) to block free antigen binding sites of the goat anti-mouse lg serum. The cells were washed twice and 
incubated (30 min, RT) with a TRITC-conjugated anti-HLA-DR McAb (Becton Dickinson, Sunnyvale, CA). After 2 
washings the cell suspension was adjusted to 2 x 106 cells per mi. Fifty microliters of this cell suspension were 
centrifuged on slides in a cytocentrifuge (Nordic Immunological Laboratories, Tilburg, The Netherlands). The 
cytocentrifuge preparations were air dried during 15 min and the location of the cells was marked by encircling 
with a glass pencil. The preparations were fixed in methanol (30 min, 4 • C) and washed in PBS for 15 min. The 
slides were dried and incubated with 15 p,l of a rabbit anti-TdT antiserum (Bethesda Research Laboratory, 
Gaithersburg, MD) in a moist chamber (30 min, RT). The slides were then washed in PBS for 15 min, dried and 
incubated with 15 P,l FITC-conjugated goat anti-rabbit lg antiserum (Bethesda Research Laboratory) in a moist 
chamber (30 min, RT). The slides were washed again in PBS (15 min). dried and mounted in glycerol/PBS (9:1) 
containing 1 mg phenylenediaminejml to prevent fading of the fluorochromes (15). A coverslip was sealed to the 
slide with paraffin wax with ceresin (BDH Chemicals, Poole, UK). 
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Microscopes 
For evaluation of immunofluorescence and immunogold staining Zeiss and Leitz fluorescence microscopes 
were used. Both were equipped with phase contrast facilities and an adjustable aperture diaphragm in the epi-
illumination system. The Zeiss microscope (Carl Zeiss, Oberkochen, FRG) was a Zeiss Universal II, equipped with 
a Ill RS Fluoreszenz-Auflicht condenser and a 50 W HBO mercury lamp (Osram, Berlin, FRG) and two 63x 
objectives (Carl Zeiss): neofluar 63/1.25 Oel Ph 3 and neofluar63/1.25 Oel. Filter combination 19 (Carl Zeiss) was 
used for the evaluation of FITC and filter combination 14 (Carl Zeiss) for TRITC. The Leitz microscope (Ernst Leitz 
Wetzlar, Wetzlar, FRG) was a Leitz Orthoplan, equipped with a Leitz Ploemopak 2 illumination, a 100 W HBO 
mercury lamp (Osram), a Leitz Vario Orthomat camera and two 63x objectives (Leitz): PL APO 63/1.40 Oel Phaco 
4 and 63/1.30 Oel Fluoreszenz. Filter combination 12 (Leitz) was used for evaluation of FITC and filter combination 
N2 (Leitz) for TRITC. For evaluation of colloidal gold, we used in both microscopes a polarization filter combination, 
consisting of a polarizer for the excitation light, a beamsplitter and an analyzer that extinguished reflected light by 
having the same polarization as the excitation light (11 ). 
RESULTS 
Microscopes 
63x objectives with phase rings can be used for visualization of FITC and TRITC, but not 
for colloidal gold because of high background, probably due to reflection and depolarization 
of the polarized light by the phase rings. Visualization of the colloidal gold was made possible 
by the use of 63x objectives without phase rings and by closing the aperture diaphragm of the 
epi-illumination system. The best results were obtained by use of the Zeiss objective Antiflex-
Neofluar 63/1.25 Oel which contains a rotatable quarter-wave plate. With the phase contrast 
dia-illumination system, the gold particles were not detectable, but by epi-illumination with 
polarized light the gold-yellow scattered light was clearly visible. For routine evaluation of triple 
staining the Zeiss microscope was used. 
Triple immunologic staining 
In the BM samples tested the percentage TdT positive cells ranged from 0.5 to 10%. The 
triple staining revealed that the majority (more than 70%) of the TdT positive cells was positive 
for HLA-DR, but negative for the T cell antigen CD? (Figure 1). A minority (0.1-8%) of the TdT 
positive cells was positive for both HLA-DR and CD?. Detailed studies of these cell populations 
will be published elsewhere. 
DISCUSSION 
Colloidal gold particles are microscopically detectable by polarized light used in the same 
epi-illumination system as for fluorescence. Our results demonstrate that in triple immunologic 
staining, colloidal gold particles can be used as a third label in combination with the 
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Figure 1. Triple immunologic staining of BM cells forCD7 (3A1), HLA-DR and TdT. A: phase contrast; B: CD7 (3A1) 
positive cells (colloidal gold labeled); C: HLA-DR positive cells (TRITC labeled); D: TdT positive cells (FITC labeled). 
The 2 TdT positive cells are also positive for HLA-DR, but not for the T cell marker CD7; they probably represent 
precursor B cells. Three cells are positive for CD7 and not for HLA-DR and TdT, probably representing normal T 
lymphocytes. 
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fluorochromes FITC and TRITC. The triple staining of BM cells for CD?, HLA-DR and TdT 
revealed that within the small TdT positive cell population subpopulations are present, e.g. a 
CDT/HLA-DR+ jTdT+ subpopulation, and also a very small one of CD?+ /HLA-DR+ /TdT+ 
phenotype. Thus triple immunologic staining can be a powerful tool in analyzing the 
heterogeneity of small cell populations in cell differentiation studies. 
Since we used 2 mouse McAb and a rabbit antiserum in the triple staining, it was sufficient 
to use only 1 conjugated McAb. However, where combination of 3 mouse McAb is required, 
it has hitherto been necessary to use at least 2 conjugated McAb or McAb differing in lg 
(sub)class in combination with differently conjugated anti-mouse lg (sub)class antisera. A more 
elegant and less time-consuming solution is to use 3 differently conjugated McAb. Therefore 
it would be convenient if the McAb of the required specificities were not only available as FITC 
or TRITC conjugates, but also as colloidal gold conjugates. 
ACKNOWLEDGMENTS. We gratefully acknowledge Prof.Dr. R. Benner's support, and thank Mrs. E.G.M. Cristen, 
A.A. van der Linde-Preesman and I.L.M. Tettero for their excellent technical assistance, Dr. J. De Mey from Janssen 
Pharmaceutica and Dr. J.H. W. Leuvering from Organon International B. V. and Dr. M. De Waele for their advice, Mr. 
C. G. Enkelaar from Zeiss Nederland for his technical support, Mr. J. Fengler for his photographic assistance, and 
Mrs. C.J.M. Meijerink-Cierkx for typing this manuscript. 
REFERENCES 
1. Ploem JS. The use of a vertical illuminator with interchangeable dichroic mirrors for fluorescence microscopy 
with incident light. Z Wiss Mikr 1967;68:129-42. 
2. Feller AC, Parwaresch MR. Simultaneous enzyme-immunocytochemical detection of antigens in monocellular 
specimens with monoclonal antibodies. J lmmunol Methods 1983;63:273-9. 
3. Moir DJ, Ghosh AK, Abdulaziz Z, Knight PM, Mason DY. lmmunoenzymatic staining of haematological samples 
with monoclonal antibodies. Br J Haematol1983;55:395-410. 
4. Schuit HRE, Hijmans W. Identification of mononuclear cells in human blood. II. Evaluation of morphological 
and immunologic aspects of native and formaldehyde-fixed cell populations. Clin Exp lmmunol1980;41:567-
74. 
5. Bradstock KF, Janossy G, Tidman N, Papageorgiou ES, Prentice HG, Willoughby M, Hoffbrand AV. 
Immunologic monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. Leuk Res 
1981 ;5:301-9. 
6. Van Dongen JJM, Hooijkaas H, Hahlen K, Benne K, Bitter WM, Vander Linde-Preesman AA, Tettero ILM, Van 
de Rijn M, Hilgers J, Van Zanen GE, Hagemeijer A. Detection of minimal residual disease in TdT positive T cell 
malignancies by double immunofluorescence staining. In: Lowenberg B, Hagenbeek A, eds. Minimal residual 
disease in acute leukemia. Dordrecht: Martinus Nijhoff Publishers, 1984:67-81. 
7. Rothbarth Ph H, Tanke HJ, Mul NAJ, Ploem JS, Vliegenthart JFG, Ballieux RE. Immunofluorescence studies 
with 4-acetamido-4'-isothiocyanato stilbene-2,2'-disulphonic acid (SITS). J lmmunol Methods 1978;19:101-9. 
8. Titus JA, Haugland R, Sharrow SO, Segal DM. Texas red a hydrophilic, red-emitting fluorophore for use with 
fluorescein in dual parameter flow microfluorometric and fluorescence microscopic studies. J lmmunol 
Methods 1982;50:193-204. 
9. Oi VT, Glazer AN, Stryer L. Fluorescent phycobiliprotein conjugates for analyses of cells and molecules. J Cell 
Bioi 1982;93:981-6. 
10. Shapiro HM. Multistation multiparameter flow cytometry: a critical review and rationale. Cytometry 1 983;3:227-
43. 
11. De Mey J. Colloidal gold probes in immunocytochemistry. In: Polak JM, Van Noorden S, eds. Im-
munocytochemistry, Practical application in pathology and biology. Bristol: Wright PSG, 1983:82-112. 
86 CHAPTER 2.4 
12. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 
1968;21 :77-89. 
13. Haynes BF, Mann DL, Hemler ME, Schroer JA, Shelhamer JH, Eisenbarth GS, Strominger JL, Thomas CA, 
Mostowski HS, Fauci AS. Characterization of a monoclonal antibody that defines an immunoregulatory T cell 
subset for immunoglobulin synthesis in humans. Proc Natl Acad Sci USA 1980;77:2914-8. 
14. Lampson LA, Levy R. Two populations of !a-like molecules on a human B cell line. J lmmunol1980;125:293-
9. 
15. Johnson GO, DeC Nogueira Araujo GM. A simple method of reducing the fading of immunofluorescence 
during microscopy. J lmmunol Methods 1981;43:349-50. 
87 
CHAPTER 3 
ANALYSIS OF IMMUNOGLOBULIN AND T CEll RECEPTOR GENES 
3.1 Introduction: Analysis of immunoglobulin and T cell receptor genes. 89 
3.2 Antigen-specific receptors of lymphocytes. 93 
3.3 Southern blot analysis of immunoglobulin genes and T cell receptor genes. 137 

CHAPTER 3.1 
INTRODUCTION: ANALYSIS OF IMMUNOGLOBULIN 
AND T CELL RECEPTOR GENES 
J.J.M. van Dongen and I.L.M. Wolvers-Tettero 
Department of Immunology, Erasmus University/ 
University Hospital Dijkzigt, Rotterdam, The Netherlands. 
89 
The surface membrane bound immunoglobulin (lg) molecules and the T cell receptor (TcR) 
molecules represent the antigen-specific receptors of B and T lymphocytes, respectively (1-5). 
The diversity of these receptors is based on the fact that the variable parts of the lg and TcR 
chains are encoded by combinations of gene segments, which differ in each lymphocyte 
(clone) (1-5). These different combinations of gene segments are obtained via processes of 
gene rearrangement, which start early during lymphoid differentiation (1-5). 
The various types of lymphoid malignancies are generally regarded as clonal malignant 
counterparts of cells in the various stages of lymphoid differentiation (6-10). Because of their 
clonality and their availability in high cell numbers, these malignancies have been used to study 
the hierarchic order of lg and TcR gene rearrangements during human lymphoid differentiation 
(11-24). Especially acute lymphoblastic leukemias (ALL) have been used for this purpose, 
because ALL represent the counterparts of normal precursor B cells and thymocytes (11-13, 16-
24). The use of T-ALL cell samples for studying human T cell differentiation will be discussed 
extensively in Chapter 4. 
The detection of clonally rearranged lg and/or TcR genes can be used for diagnostic 
purposes in patients with lymphoproliferative diseases, since clonality is equivalent to 
malignancy in the majority of cases. This is important when morphologic techniques and 
immunologic marker analysis cannot discriminate between a malignant and a reactive process 
(26-30). 
In Chapter 3.2 we shall consider the structure of the antigen-specific receptors as well as 
the genetic basis of their diversity, i.e. the configuration of the lg and TcR genes and their 
rearrangement during lymphoid differentiation. Several similarities and differences between lg 
and TcR genes/molecules will be discussed. In Chapter 3.3 the methods for the analysis of lg 
and TcR gene rearrangements as well as their pitfalls will be described. In addition, the 
diagnostic applications of such analyses will be indicated briefly. A more extensive description 
of the possibilities and limitations of lg and TcR gene analysis for the diagnosis and 
management of lymphoproliferative diseases will be given in Chapter 6. 
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* 
The ability of the immune system to recognize specifically multiple antigens or antigenic 
epitopes is based on the enormous diversity (at least 107 to 109) of antigen-specific receptors, 
namely surface membrane bound immunoglobulin (Smlg) on B lymphocytes and T cell receptor 
(TcR) molecules on T lymphocytes (1-4). When the lg or TcR molecules of a particular B or T 
lymphocyte recognize the antigen against which the receptor is directed, lymphocyte activation 
and proliferation will follow. All cells derived from one lymphocyte have identical antigen-specific 
receptors and together they form a clone. The B lymphocytes derived from this process can 
mature to plasma cells which secrete antigen-specific antibodies (lg molecules), while activated 
T lymphocytes can exhibit their specific regulatory and cytotoxic functions (2-4). 
lg molecules are composed of two lg heavy (lgH) chains and two lg light (lgl) chains, held 
together by disulfide bonds (Figure 1)(5). The lgl chains of a B lymphocyte or B cell clone 
are of the same type: lgx; or lg.A. The TcR is composed of two chains, which are generally also 
linked by a disulfide bond (6, 7). On the cell surface the TcR is closely associated with CD3 
molecules and together they form the TcR-CD3 complex (Figure 1)(6-9). The CD3 structure 
consists of at least five protein chains and is probably involved in signal transduction from the 
TcR into the cytoplasm (10-12). Each of the lg chains and TcR chains consists of a constant 
(C) region as well as a variable M region which is involved in antigen recognition (Figure 1). 
If the entire repertoire of the human lg and TcR chains would be encoded by separate 
genes, they would occupy a large part of the human genome. Instead, a limited number of 
gene segments is able to code for the receptor diversity due to the fact that the V regions of 
the lg and TcR chains are encoded by combinations of gene segments, which are different for 
each lymphocyte or lymphocyte clone (13-15). The joining of these gene segments is obtained 
via a process of gene rearrangement (13-15). In 1987 the Nobel prize was awarded to Dr. Susumu 
Tonegawa for his contribution to the unraveling of the genetic mechanisms, which allow the 
encoding of so many different antigen-specific receptors by a relatively small number of gene 
segments (14,16,17). 
*This manuscript will be published as part of a review in Clin Chim Acta. 
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TcR-a TcR-{:l 
Figure 1. Schematic diagram of an lg molecule and a TcR-CD3 complex on the cell membrane of a B lymphocyte 
and aT lymphocyte, respectively. VH: variable domain of lgH chains; VL: variable domain of lgl chain; CH constant 
domain of lgH chain; CL: constant domain of lgl chain; h: hinge region; Va: variable domain of TcR-a chain; V/3: 
variable domain of V/3 chain; Ca: constant domain ofT eR-a chain; C/3: constant domain of TcR-/3 domain; CD3-)', 
o and E: protein chains of the CD3 molecule. 
IMMUNOGLOBULIN GENES AND T CELL RECEPTOR GENES 
Immunoglobulin molecules and their encoding genes 
Five different classes of human lg molecules are known (lgM, I gO, lgG, lgA and lgE). Within 
the classes of lgG and lgA molecules several subclasses can be recognized: lgG1, lgG2, lgG3 
and lgG4 as well as lgA1 and lgA2. The class or subclass 0sotype) of an lg molecule is determined 
by the constant region of the lgH chain expressed (J.£, o, -y1, -y2, -y3, -y4, a1, a2, or E), independent 
of the type of lgl chain (5). The constant region of the lgH chains are responsible for effector 
functions such as transmembrane signalling, complement activation and binding to Fe receptors 
(5). A B lymphocyte will irreversibly express only one type of lgl chain (~~:or).), whereas different 
lgH chains can be expressed: i.e. different lgH constant regions, linked to the same variable 
region (18, 19). The majority of B lymphocytes in peripheral blood express lgM and lgD on the 
cell membrane, whereas a minority express lgG or lgA. In lymph nodes and other lymphoid tissues 
higher frequencies of lgG and lgA bearing lymphocytes are present. 
The lgH and lgl chains are composed of several domains, which consist of roughly 110 
amino acids (Figure 1)(5). The variable regions of lg chains consist of one domain. Also the 
lgL constant region consists of a single domain (CL), but most lgH constant regions are 
composed of three domains (CH1, CH2 and CH3) and a hinge region (h), which is located 
between CH1 and CH2 (Figure 1)(5). The hinge region creates a high flexibility within the lg 
molecule, which allows bivalent recognition of variably spaced antigenic determinants. The 
lgH genes 
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Figure 2. Schematic diagram of the human lg genes. The lgH genes consist of many V genes, at least ten D genes, about six J genes, and C genes for the various 
lgH classes and subclasses (20-24). Most C genes are preceded by a switch gene (s), which plays a role in lgH (sub)class switch (19,38-41). The lg/1: gene complex 
consists of a series of V genes, about five J genes and one C gene (42,43), while the I g). gene complex consists of V genes and six C genes, all of which are preceded 
by a J gene (44-46). Pseudo genes (1/1) are indicated with open symbols. 
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Figure 3. Schematic diagram of the organization of the human lgH constant genes on chromosome 14 based on data from the literature (c. f. references 24-35). The 
various exons which code for the C domains and the hinge regions (h) as well as the switch sequences (s) are indicated. In case of the Ca genes, the hinge region 
sequences are Included in the second C exon (32). The distances between the C region genes are given (see references 24,25,28-30,50-52), but the diagram is not 
on scale. The complete locus of lgH-C genes is located within a region of 300-320 kb (51 ,52). In addition to the functional cr genes one pseudo r gene (ifry) without 
preceding switch sequences is located between Ga1 and Cy2 (30,50). Also two pseudo c genes (1/lc1 and 1/lc2) are known (33-37). The decapitated 1/lc1 gene is 
located between Cy1 and Ga1 on chromosome 14 (24,35), while the 1/lc2 gene (consisting of one large exon without intervening sequences) is located outside the 
lgH gene locus, i.e. on chromosome 9 (36). CD CJl 
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flexibility is very high in lgG3 molecules due to an extended hinge region (5). In case of lgM and 
lgE molecules the hinge region is replaced by a constant domain; the p. and E chains therefore 
have four CH domains (5). 
Uke many genes in eukaryotic cells, the lg genes consist of encoding gene segments (exons), 
separated by intervening non-coding gene segments (introns). Each domain of an lg chain is 
encoded by a separate ex on. The variable region domain of the lg chains is encoded by an exon, 
which consists of a combination of a V (variable), aD (diversity) and a J Gaining) gene segment 
in case of the lgH chain or a combination of a V and a J gene segment in case of the lgl chain 
(13, 14). During B cell differentiation these V, (D,) and J gene segments are joined through a 
process of gene rearrangement (13, 14). The constant domains of the lg chains are encoded 
by a C (constant) gene. 
The lgH gene locus contains a large number of V gene segments (20), at least ten D genes 
(21-23) and about six functional J genes (21). For each lgH isotype a separate CH gene exists 
(24). Each CH gene consists of several exons: one exon for each CH domain and one or more 
exons for most hinge regions (25-37). The lgH-C genes, except for the Co gene, are preceded 
by a switch gene (S), which is necessary for isotype switching (see below)(18,19,25,38-41). 
The lg~~; gene locus consists of a series ofV~~; genes, five J~~; genes and only one C~~; gene (42,43). 
Finally, the lg>. gene locus contains several V>. genes and six virtually identical C>. genes, which 
each are preceded by one J>. gene segment (44,45). Two of these C>. genes are non-functional 
genes (pseudogenes)(46). In about 25% of individuals even more than six C>. genes are present 
on one or both alleles (47). Recently, new lg>. genes have been identified, which are located 
outside the "classical" lg>. gene locus (48,49). 
The germline (non-rearranged) configuration of the lgH, lg~~; and lg>. genes is illustrated in 
Figure 2, while the separate exons for the constant domains and the hinge regions of the lgH 
chains are presented in Figure 3 (25-37). Figures 2 and 3 illustrate that during evolution a 
duplication of lgH-C genes has probably occurred, involving the C-y, CE and Ca genes (24,30,32, 
35,50). The complete cluster of functional CH genes is located within 300-320 kilobases (kb) 
(51 ,52). Within the lg>. gene locus a multiplication of J>.-C>. gene segments has occurred during 
evolution (44,47). 
T cell receptor molecules and their encoding genes 
Two different types afTeR have been recognized: the classical TcR, which consists of a TcR-a 
chain and a TcR-.B chain (TcR-a,B) (3,4,6) and the "alternative" TcR, which is composed of a TcR--y 
and a TcR-o chain (TcR--yo)(53-55). The majority of mature T lymphocytes (85 to 98%) in peripheral 
blood and most lymphoid tissues express TcR-a,B, while a minority (2 to 15%) expresses TcR--yo 
(56,57).lnterestingly, intraepitheliallymphocytes in the murine intestine mainly representTcR--yo + 
T lymphocytes (58,59). This epithelial tropism afTeR--yo+ cells has not been found in man (60,61 ). 
In contrast to the various isotypes of lgH and lgl chains, the four different TcR chains do 
not randomly pair with each other. For instance, no TcR-a-y or TcR-,8-y have been identified so 
far. Even cell lines which produce complete TcR-,8, TcR--y and TcR-o chains only express TcR--yo 
(62,63) and transfection of functional TcR-a and/or TcR-.B gene sequences into TcR--yo+ cells 
did not result in the expression of aberrant TcR, although some of the transfectants expressed 
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Figure 4. Schematic diagram of the human TcR genes. The TcR-a genes consist of many V genes, a remarkably 
long stretch of J genes and one C gene (66-72). The TcR-.8 gene complex consists of a series of V genes and two 
C genes, both of which are preceded by one D gene and six or seven J genes (73-76). The TcR-r genes consist 
of a restricted number of V genes (eight functional V-y genes and seven pseudo genes) and two C genes, each 
of which are preceded by two or three J genes (77-82). Interestingly, the TcR-o genes are located between the Va 
and Ja genes and probably consist of a few V genes, three D genes, three J genes and one C gene (83-87). 
both TcR-a.B and TcR-ro (63,64). Nevertheless the human T cell line DND4i was proven to express 
a .Bo receptor (65), which has not been found on normal T lymphocytes so far. 
The TcR chains are composed of two domains: a variable domain and a constant domain 
(Figure 1). Analogous to the lg chains, the variable domains of the TcR chains are encoded by 
a combination of a V and a J gene in case of the TcR-a and the TcR-r chain or by a combina-
tion ofV, D and J genes in case of the TcR-.8 and the TeR-eS chain (66-87). The constant domains 
of the TcR-chains are encoded by C genes. One C gene codes for the constant domain of the 
TcR-a chain and one for the TeR-eS chain, while two C genes are available for the constant domains 
of the TcR-.8 and TcR-r chains (66-87). 
The germ line configuration of the four TcR genes is presented in Figure 4. The TcR-a genes 
consist of many Va genes, a remarkably long stretch of Ja genes (about 85 kb) and one Ca 
gene (66-72). Interestingly, the TeR-eS gene locus is located within the TcR-a gene complex between 
the Va genes and the long stretch of Ja genes (69-72,84). The TeR-eS genes consist of a few 
Vo genes, three Do genes, three Jo genes and one Co gene (69-72,83-87). Figure 4 illustrates 
that both C.B gene segments are preceded by a D.B gene and six or seven J.B genes (73-76) and 
that both Cr genes are preceded by two or three Jr genes (77,78,80). 
Analysis of the nucleotide sequence of the two C.B genes revealed that they are highly 
homologous (76,88). High levels of homology were also found between the two Jr-Cr gene 
segments (77,80,89). This suggests that during evolution a duplication has occurred within the 
TcR-.8 gene locus as well as within the TcR-r gene locus. Nevertheless, several differences exist 
between the duplicated gene segments. This is clearly illustrated by a difference between the 
two Cr gene segments (89-91). 
A TcR-ro, in which the TcR-r chain is derived from Cr1 genes has an interchain disulfide 
bond, comparable to the disulfide bond between the protein chains of TcR-a.B (Figure ; ) (92-94). 
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Figure 5. Schematic diagram of the two main types ofT cR--yo receptors. The protein chains of the TcR--y1o receptor 
are disulfide linked, while this interchain disulfide bond is lacking in TcR--y2o receptors (92-94}. 
However, if the TcR--y chain is derived from C-y2 genes, the interchain disulfide bond is lacking 
(Figure 5)(92-94). Disulfide bonds are formed between cysteine residues. The cysteine residue 
which is responsible for the interchain disulfide bond is coded by a TGT codon in the second 
exon of the C-y1 gene (89,90,92). Although the second exon in the C-y2 gene is duplicated (or 
even triplicated in one third of individuals), no cysteine codon is present (89-92). The far majority 
of the TcR--yo + T lymphocytes in peripheral blood appear to express the disulfide linked receptor 
(54,55,95). It is not clear whether C-y1 and C-y2 encoded TcR--yo define functionally distinct lineages. 
It has been suggested that TcR--y18 T lymphocytes exhibit a higher degree of cytotoxicity than 
the TcR--y28 T lymphocytes (96). Also differences in morphology, cytoskeletal organization and 
growth characteristics have been found (97). 
Chromosomal localization and orientation of the lg and TcR genes 
Human-rodent somatic cell hybrids, which segregate human chromosomes, have proven 
to be useful for gene localization studies (98,99). Correlations between human protein expression 
by hybrid cells and the presence of specific human chromosomes or fragments of these 
chromosomes allow the assignment of the encoding genes to the correct chromosome or 
chromosome fragment (98,99). If DNA sequences of the involved gene are available, DNA 
extraction from hybrid cells with a known human chromosome content and its subsequent analysis 
for the presence of the encoding gene can be used for gene mapping (100). The availability 
of the appropriate DNA sequences also allows the application of a completely different approach 
in which somatic cell hybrids are not needed: in situ hybridization of labeled DNA sequences 
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Figure 6. Location and orientation of the three lg genes and the four TcR genes on chromosomes 2, 7, 14 and 
22 {103-127). The orientation of the lg~~:, lg.A, TcR-.8 and TcR-ajo gene complexes is such that the V regions are 
located at the centromeric side and the C regions at the telomeric side {120-127). In case of the lgH genes, the 
V segments are telomeric and the C genes centromeric {119). The orientation of the TcR-r genes on chromosome 
7 is not yet known. 
to fixed human metaphase chromosomes (1 01,1 02). The lattertechnique enables a more precise 
regional localization of genes (1 01,1 02). 
All three techniques have been used for mapping of the lg and TcR genes. The lgH genes 
were assigned to chromosome 14 (band q32)(103, 104), the lg~~: genes to chromosome 2 (band 
p12)(105, 106) and the lg.A genes to chromosome 22 (band q11)(105, 107, 108). The TcR-agenes 
as well as the TeR-eS genes appear to be located on chromosome 14 (band q11)(84, 109-113), 
the TcR-.8 genes on chromosome 7 (band q35)(113-117) and the TcR-r genes also on chromo-
some 7 (bands p14-15)(113, 118). 
Lymphoid malignancies with chromosomal aberrations involving the lg and TcR gene loci, 
can be used for both fine mapping of the genes as well as for determining the orientation of 
the genes on the chromosomes. In this way the orientation of alllg and TcR genes, except for 
the TcR-r gene, has been established (Figure 6)(72,84,119-127). 
Breakpoints in chromosome bands containing the lg and TcR genes are not only frequently 
found in translocations in lymphoid malignancies (128-131), but also in the recurrent chromosomal 
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Figure 7. Schematic diagram of the three Burkitt translocations. In t(8;14) (q24;q32) the c-myc oncogene is translocated 
from chromosome 8 to the lgH genes in band 14q32 (147,148), while in the two variant Burkitt translocations 
t(2;8)(p12;q24) and t(8;22}(q24;q11) the telomeric parts ofthe I gil: and lg.A genes are translocated to the c-myc gene 
in band 8q24 (147,148). 
aberrations in the lymphoid cells of patients with ataxia telangiectasia (132-137); such 
chromosomal aberrations are occasionally found in lymphocytes from normal individuals 
(132, 134, 138-143). Ataxia telangiectasia (AT) is a rare complex multisystemic disease (including 
immunological defects) and is characterized by chromosomal instability, a DNA repair /processing 
defect and a high tendency to develop leukemia or non-Hodgkin lymphoma (NHL)(144). These 
data indicate that the lg and TcR genes are highly vulnerable to breakage and that such breaking 
points may play a role in the oncogenic events which lead to the development of a lymphoid 
malignancy. This is illustrated by the so-called Burkitt translocations t(8;14)(q24;q32), t(2;8)-
(p12;q24) and t(8;22)(q24;q11) in which one of the lg genes and the c-myc oncogene (located 
in band 8q24) are involved (119-121,145-148)(Figure 7). 
DIVERSITY Of THE ANTIGEN-SPECIFIC RECEPTORS 
As mentioned above, the enormous diversity of antigen-specific receptors of lymphocytes 
is based on the rearrangement of gene segments which code for the variable domains of the 
lg and TcR molecules (13-15). The extent of the whole repertoire of lg and TcR molecules is 
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mediated by : 1, the diversity of the germline genome (i.e. the number of V, D and J segments); 
2, the combinatorial diversity (i.e. the number of possible V-(D-)J combinations); and 3, the 
junctional diversity 0.e. diversity due to the imprecise joining of the V, D and J seg-
ments)(13-15, 149). After the standard V-(D-)J rearrangements secondary rearrangements may 
occur, which represent replacements of previously rearranged gene segments (149). All the 
genomic rearrangement events together generate the primary repertoire of the antigen receptors, 
i.e. the variable domains of the lg and TcR chains (13-15, 149). 
Within the variable domain of each lg chain the antigen binding site is composed of three 
hypervariable regions, the so-called complementarity determining regions (CDR) (150-154). 
Two of these CDR are encoded by germline sequences of the V gene, while the third CDR 
(CDR3) is encoded by the junctional region of the V-(D-)J segments (150-154). Therefore this 
junctional region directly influences the antigen binding of the lg molecules. In analogy to the 
lg molecules also the variable domains of TcR chains contain CDR-equivalent regions in their 
variable domains (155-157). Also here the CDR3-equivalent region probably corresponds to the 
junctional region (156, 157). 
The primary antibody repertoire of lg molecules can be enhanced via antigen-induced somatic 
mutations in the V gene segments of lg genes (158, 159). So far, somatic mutations in V genes 
have not been reported for TcR genes. The secondary antigen-dependent mutation processes 
in lg-V genes will be discussed in one of the next sections. 
Several aspects of the gene rearrangement processes as well as the various mechanisms 
for the development of the primary (antigen-independent) repertoire of lg and TcR molecules 
will be discussed below. 
Gene rearrangement: V-(D-)J joining 
During 8 and T cell differentiation the germline V, (D,) and J segments rearrange and each 
lymphocyte thereby obtains its own specific combination ofV-(D-)J segments (13-15). An example 
of an lgH gene rearrangement is illustrated in Figure 8: first one of the J gene segments is joined 
to one of the D gene segments and subsequently a V to D-J joining occurs, thereby deleting 
all intervening sequences. After the process of rearrangement the gene is transcribed into a 
precursor mRNA, which becomes a mature mRNA after splicing and eliminating all non-coding 
intervening sequences (Rgure 8)(13). Virtual identical rearrangement and transcription processes 
occur in the other lg and TcR genes (13-15). 
The gene rearrangement processes are mediated by an, as yet, unidentified recombinase 
enzyme system, which recognizes specific joining sequences. These joining sequences consist 
of a palindromic heptamer and nonamer, separated by spacer regions of 12 or 23 base pairs 
(14, 160, 161). A complete joining sequence, starting with the heptamer, borders the 3' side of 
each V and D segment and the 5' side of each D and J segment (13,14,160,161). A gene 
rearrangement first involves a back-to-back fusion of the heptamer-nonamer sequences. This 
is followed by deletion of these joining sequences as well as the sequences between them in 
the form of a circle and by subsequent joining ofthe two gene segments (Figure 9) (13, 14 ). Indeed 
circular TcR gene excision products could be isolated from thymocytes. Gene segments of all 
four TcR genes have been identified in such circular DNA products (162-165). 
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Figure 8. Schematic diagram of rearrangement and transcription of lgH genes. First D to J joining occurs, followed 
by V to D-J joining. The rearranged genes can be transcribed into a precursor lgH mRNA, which becomes a mature 
lgH mRNA after splicing all non-coding intervening sequences (13,149). 
The heptamer-nonamer recognition sequences of the lg and TcR genes are well conserved 
during evolution ("166,"167). This is illustrated by the high homology of the heptamer-nonamer 
sequences, which flank the V, (D,) and J segments of the lg and TcR genes ("166, "167). Further-
more, several experiments have demonstrated that the artificial introduction of lg or TcR gene 
sequences (containing heptamer-nonamer sequences) into immature B cells results in site-specific 
joining events of the introduced lg or TcR genes ("167-"170). These data suggest that BandT 
cells use a common recombinase for their receptor gene rearrangements ("167-"170). 
Junction of two gene segments can not only be obtained via deletion of the intervening 
sequences (Figure 9), but also via inversion without deletion of gene segments ("149, "166). The 
latter process of inversion joining has occasionally been found in lgH genes ("17"1, "172), TcR-.8 
genes ("173, "174) and TcR-o genes (87, "175) and seems to occur more frequently in murine lg~~: 
genes ("176,"177). 
Secondary gene rearrangements 
lg and TcR gene rearrangements are complex processes in which the joinings of the gene 
segments are imprecise (i 4, "149, "17"1). Because of the triplet reading frame of DNA sequences, 
approximately two out of three joinings will be aberrant, i.e. a mRNA is produced which cannot 
be transcribed into a complete protein. The high frequency of aberrant rearrangements explains 
why most B cells have rearranged both lgH gene alleles and why most T cells have biallelic 
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Figure 9. Schematic diagram of the function of joining sequences during gene rearrangement. The 3' DH3 and 
5' JH4 heptamer-nonamer sequences fuse back to back. This is followed by a DH3 - JH4 joining and the deletion 
of a circular excision product (162-165). The given heptamer-nonamer sequences are not the exact 3' DH3 and 
5' JH4 joining sequences, but represent the consensus heptamer-nonamer sequences which are well conserved 
in lg as well as TcR genes (166,167). 
rearrangements of their TcR-.8 and TcR--y genes ("178-"183). 
In addition to the biallelic rearrangements, secondary gene rearrangements appear to occur 
in order to rescue precursor 8 and T cells with two non-productive lg or TcR genes ("184-"186). 
In 8 cells two types of secondary rearrangements have been described: D-JH replacements and 
Vto VDJH rearrangements ("184-"186). In T cells replacements of preexisting V-J rearrangements 
have been reported to occur in TcR-a genes ("1 64, "1 87-"1 89) and V gene replacements may probably 
occur in TcR-.8 genes ("190,"19"1). 
The secondary D-JH rearrangements in 8 cells replace the whole preexisting out-frame DJH 
complex by joining an upstream DH gene to a downstream JH gene. Due to the multiple element 
organization of the DH and JH gene clusters, D-J replacements may occur repeatedly on the 
same chromosome as long as it carries unrearranged DH and JH elements ("184). Similar 
replacement processes may also occur in lg~~: and I g). genes, in which V-J complexes can poten-
tially be replaced ("184). Indeed multiple rearrangements on the same allele have been observed 
in the murine lg~~: locus ("176, "1 77). 
The other type of secondary rearrangement in 8 cells is the V to V-D-JH rearrangement in 
which the 'old' VH gene is replaced by a new upstream VH gene (185,186). The joining in this 
rearrangement is mediated by a heptamer joining sequence found in the 3' region of most VH 
genes (Figure "10)("185, "186). Interestingly, VH gene replacements do not only occur in 8 cells 
with two aberrant V-D-J rearrangements ("185), but may also occur in productive VDJH alleles, 
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Figure 10. Schematic diagram of V to V-0-JH rearrangement. In this example the VH4 gene segment is replaced 
by the VH3 gene segment via a rearrangement process in which heptamer (indicated as: 7) joining sequences 
are involved (185,186). 
resulting in a new productive rearrangement (186). 
Internal V heptamer joining sequences, which allow the V to V-D-JH rearrangements in lgH 
genes, are not present in the V segments of Igl and TcR loci, except for the TcR-Vr genes (185). 
Nevertheless changes in antigen specificity of cytotoxic T lymphocytes were attributed to V gene 
replacements in functionally rearranged TcR-.8 genes (190, 191). 
In recent studies it was demonstrated that the protein chemical differences between TcR-o:.B 
molecules of subclones and their parental T cell line were due to Vo:-Jo: replacements (187, 189). 
In these secondary rearrangements preexisting productive and non-productive Vo:-Jo: complexes 
were replaced by joining an upstream Vo: segment to a downstream Jo: gene. The occurrence 
of Vo:-Jo: replacements was confirmed by the presence of rearranged Vo:-Jo: gene segments in 
circular excision products, isolated from thymocytes (164, 188). It was suggested that these Vo:-Jo: 
replacements may play a role in the thymic selection of the T cell repertoire (187). 
Germline diversity and combinatorial diversity 
Based on the above described gene rearrangements many different combinations of V-D-J 
complexes can be obtained, depending on the number of V, D and J gene segments within the 
gene locus. 
The lgH gene locus probably contains 100 to 200 VH genes, which are grouped into six 
families based on homology (20, 192-195). In addition, at least ten DH genes and about six 
functional JH genes exist (21 ,22). Thus, assuming a random paring of the gene segments during 
the rearrangement processes, at least 6000 different V-D-JH complexes can be made (fable 
1). For the lg~~: genes (40-80 V~~: genes and about 5 J~~: genes) about 400 combinations can be 
made (42,43, 196-198), while for the lg.X genes (over 40 V.X genes and at least 4 functional J.X 
genes) at least 160 combinations are available (45,46, 198-200). Since an lg molecule consists 
of lgH and lgl chains, the pairing of an lgH chain with an lg~~: or an lg.X chain will result in at least 
2-4 million combinatorial possibilities (fable 1). 
Also for the TcR-a.B and TcR-ro receptors calculations for combinatorial diversity can be made. 
The TcR-o: genes do not have D segments, but contain more than 50 Vo: genes and a remarkably 
long stretch of about 55 Jo: genes (67,70,201-204). Together with the various V-D-J.B combinations 
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TABLE 1. Estimation of the potential primary repertoire of human lg and TcR molecules. 
lg molecules TeA-ajl molecules TeA-7& molecules 
lgH lglt lg>. TeA-a TeA-.8 TeA-7 TeA-& 
Germline diversity; 
number of genes 
5' • V genes 100-200 4Q.8() >40 >50 >70 ~6 
(families)a (6) (4) (7) (19) (20) (4) (6) 
- D genes >10 2 3c 
. J genes 6 5 >4 about 55 13 5 3 
Combinatorial diversity 
-per chain 6000-12,000 200-400 >160 >2750 >1820 40 >75 
• per complete molecule >2-4x 106 >5x1o6 >3000 
Junctional diversity 
- number of joining sites 2 2 1-4c 
- N region insertion ++ + ++ ++ ++++ 
• estimated degree of 
increase in diversity x104 x102 x104 x103 x109 
Estimation of total primary 
receptor repertoire >1010 >1012 >1015 
a. The various V genes are grouped into families based on homology (references 79,81,82,175,192·208). The number of V gene families 
is given in parentheses. 
b. In addition to the eight functional V7 genes seven pseudogenes have been described (references 79,81 ,82, 175). 
c. The variable domain of the TcR-S chain may not only be encoded by V-D-J complexes, but also by a V-J complex or even by V-0-D-J 
or V-D-D-0-J complexes (references 70,87,211,213). 
at least five million different TcR-et,B receptors can be produced (Table 1)(203-206). 
The combinatorial diversity of the TcR-rcS receptors appears to be limited, because only 
eight functional Vr genes and five Jr genes are available in addition to at least six VcS genes, 
three Do genes and three JcS genes (Table 1)(79-82,86,97, 175,207,208). Since the TcR-cS genes 
are located between the Vet and Jet gene segments, the TcR-cS and TcR-et chains can potentially 
share the very same pool of V genes (69-71). The usage of a V gene from the Vet6 gene family 
by a TcR-cS chain has been demonstrated in a T cell clone obtained from a patient with an 
immunodeficiency (201 ,209). Similarly, in the mouse some V segments rearranged to TcR-cS 
gene segments appeared to be virtually identical to V segments used in TcR-et gene 
rearrangements, while another VcS gene showed more than 90% homology with a Vet gene 
segment (164,210,211). This raises the possibility that TcR-cS chains can draw their V genes 
from a much larger V gene pool. Another curious phenomenon concerning the TcR-cS chain is 
that the variable part of the TcR-cS chain may not only be encoded by V-D-JcS complexes 
(83,212), but also by V-JcS complexes, V-D-D-JcS complexes, and even V-D-D-D-JcS complexes 
(70,87,211 ,213). Both phenomena increase the combinatorial diversity of the TcR-rcS receptors 
to at least 3 x 103 (Table 1). 
The above described calculations of the combinatorial diversity are based on the 
assumption that the various V, D and J gene segments are used at random. However, this 
seems not always to be the case (149). For instance, fetal B cells seem to use a restricted set 
of VH segments, related to JH proximity (149, 194,214). Also preferential use of DH and JH 
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segments has been described (149, 194,215). In addition, preferential use of the J,B2.5 gene 
segment in certain TcR-a,B+ cells has been described (216) and TcR-ro+ lymphocytes in blood 
appear to use a restricted number of the available V"f and Vo genes (217-220). On the other 
hand, it may well be that the whole possible combinatorial repertoire is present, but that certain 
receptor specificities dominate due to clonal selection/expansion. 
Junctional diversity (N region diversity) 
As indicated above the joining of the V, (D,) and J segments is imprecise (14, 171). This im-
precision is manifested by loss of original nucleotides as well as by de novo insertion of 
nucleotides between the joined gene segments (14, 171 ,221). This insertion of nucleotides (N 
region insertion) at the junction sites is most probably mediated by the enzyme terminal deoxy-
nucleotidyl transferase (TdT)(171,221), which is present in the nucleus of all immature Band 
T cells (222,223). TdT is able to add nucleotides to 3' ends of DNA breakpoints without need 
for a template (222). The strong link between TdT and N region insertion has been further 
established by experiments in which Tdl transformed cells appeared to produce N regions 
at junction sites upon artificial introduction of active TdT genes via retroviral expression vectors 
(224). 
Insertion of N regions at joining sites can increase the diversity of antigen receptors. This 
N region diversity occurs in rearranged lgH genes, but is limited or absent in rearranged lgl 
genes (171 ,221 ,224). The junctional diversity has also been found in rearranged TcR genes 
(87,201-204,211,225-230). Especially in TcR-r genes and TcR-o genes large N regions have 
been identified (Table 1)(87,211-213,228-230). As expected, no N region diversity could be 
demonstrated in the rearranged TcR-o genes of Tdl murine fetal thymocytes (211). 
The size of the N region can vary from a few nucleotides up to nine or more (171 ,211 ,221, 
225,230). If one assumes a random use of the four different nucleotides, then the diversity per 
junction site in case of insertion of one to six nucleotides is : 46 + 45 + 44 + 43 + 42 + 41 = 
5460 (211). Of course such calculations should be corrected for the probability that the triplet 
reading frame of the junctional sequences is maintained (one third of the insertions). Further 
correction should include the chance of termination codons (1 0% of the in-frame joins) as well 
as the chance of triplets that code for identical amino acids (about one third of the codons) 
(211 ). Still the potential diversity of N regions is very high and can therefore dramatically 
increase the combinatorial diversity (155,211). 
Rough estimations suggest that the N region diversity can increase the repertoire of lg 
molecules at least 104 fold to more than 1010. The TcR-a,B repertoire may in this way increase 
106 fold to > 1012. TheN region diversity of TcR-o is extremely high(> 109 fold increase) due 
to the relatively high number of inserted nucleotides per junction site and to the variable number 
of junction sites in the TcR-o genes (155,211 ). Therefore it seems that a major part of the 
variability of the TcR-o chain and the other TcR chains is concentrated in the V(-D)-J junctional 
region. This has important implications for our understanding of antigen recognition, since this 
junctional region of TcR molecules corresponds to the CDR3 of lg molecules and probably 
directly interacts with the antigen (155-157). 
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REARRANGEMENT OF IMMUNOGLOBULIN GENES AND T CEll RECEPTOR GENES 
DURING LYMPHOID DIFFERENTIATION 
Studies in mouse and man have demonstrated that the processes of lg and TcR gene 
rearrangement occur in an ordered manner during differentiation. 
Immunoglobulin gene rearrangement during B cell differentiation 
Studies on transformed murine precursor B cells (231 ,232) and human precursor-B-cell 
acute lymphoblastic leukemia (precursor-B-ALL) as malignant counterparts of normal precursor 
B cells (178-180,233-237) have demonstrated that the lgH genes rearrange early during B cell 
differentiation and prior to lgL gene rearrangement. First D to JH rearrangement occurs, 
followed by V to D-JH rearrangement (232). Subsequently the lgK: genes rearrange as 
demonstrated by studies on precursor-B-ALL, B cell chronic lymphocytic leukemias (B-CLL) 
and other mature B cell malignancies (178, 179,233-235,238-241). Functional rearrangement and 
transcription of lgH and lgK: genes will result in expression of lgH/K: molecules at the cell surface 
(238-242). 
If the lgK: gene rearrangement is not functional on any of the two alleles, the lg.A genes will 
rearrange (238-242). Transcription of functionally rearranged lg.A genes in the presence of 
functionallgH gene transcripts will result in surface membrane expression of lgH/.A molecules. 
Interestingly, in the majority of lg.A expressing B cells the CK: genes and in a part of them also 
the JK: genes are deleted on both alleles (238,239,241 ,242). This deletion is mediated via a 
rearrangement process in which a K: deleting element (Kde) replaces the CK: gene (60% of 
cases) or the whole JK:-CK: gene segment (40% of cases)(243,244). Like in V(-D)-J rearrange-
ments, also in this rearrangement heptamer-nonamer sequences are involved (244,245). The 
deletion of K: genes in lg.A expressing B cells may serve as a protective mechanism to eliminate 
aberrant transcripts and protein fragments that might interfere with the synthesis and assembly 
of effective lg molecules (243,244). · 
A second type of rearrangement in the lgH genes is the class switch process, in which 
one of the switch sequences in front of the CH genes rearrange to the switch sequences in 
front of the CJL-Co gene segment (18,25,39). The various lg gene rearrangements are 
summarized in Figure 11 (246). 
T cell receptor gene rearrangement during T cell differentiation 
Studies on murine fetal thymocytes and hybrids derived from murine fetal thymocytes 
indicate that during T cell ontogeny the TcR-o genes rearrange at day 14 of gestation (247,248), 
followed by rearrangement of the TcR--y and TcR-,8 genes during day 14 to 17 (248-250). Fully 
rearranged TcR-.8 genes are present from day 16 on, when probably also TcR-a genes start to 
rearrange (249). This hierarchy of TcR gene rearrangements is supported by RNA studies, 
which indicate that high levels of TcR--y gene transcripts and probably also TcR-o gene 
transcripts are present at day 14 and day 15, but subsequently decline (247,251 ,252). Mature 
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Figure 11. Hypothetical scheme of lymphoid differentiation, summarizing the available data about the ordered 
rearrangement of the lg and TcR genes, as well as the expression of TdT, lg molecules and TcR molecules. The 
horizontal bars represent the rearrangement of the lg genes {lgH, lg~~: and lgA) and TcR genes (TcR-a, TcR-,8, 
TcR-'Y and TcR-o). The expression of TdT, weak CyJ.l., Smlg, Cylg, CyCD3 and the TcR-CD3 complex (TcR-a,B or 
TcR-')'o) is given in italics (c.f. ref. 246). 
TcR-,8 gene transcripts are present from day 16 on and TcR-a gene transcripts can be detected 
from day 17 on (251,252). These data are in line with the appearance of TcR--yo expressing 
thymocytes as early as day 15, while TcR-a,B expressing cells are present in increasing numbers 
from day 17 on (253-255). 
The murine ontogenic data (247-255) seem to reflect normal T cell differentiation as studied 
by analysis of human T cell malignancies and T cell clones (180-183,213,256-264). Especially 
immature T cell acute lymphoblastic leukemias (T-ALL) without expression of a TcR-CD3 
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complex at the cell surface appeared to be informative (180-183,213,256-264). The majority of 
these immature CDT T-ALL had rearranged TcR--y and TcR-.8 genes (180-183 ,213,256-261 ) as 
well as rearranged TcR-o genes (213,262-264). A few CD3- T-ALL had germ line -y and .B genes 
(182,213,256,257,259-261) and recently some immature T-ALL with rearranged TcR-o genes 
but germline -y and .B genes have been found (213,263). This suggests that TcR-o gene 
rearrangement occurs before rearrangement of the TcR--y and TcR-.8 genes. CD3- T-ALL and 
CD3- T-NHL with rearranged TcR--y genes but germline TcR-.8 genes are rare (257,265,266). 
This suggests that TcR--y and TcR-.B genes rearrange at virtually the same early T cell 
differentiation stage. It also explains why most mature TcR--yo expressing cells have rearranged 
TcR-.8 genes (94,264,267). Interestingly, TcR-ro + cells which use r1 genes often have germline 
TcR-.8 genes or incompletely rearranged TcR-.B genes, while TcR--yo+ cells which use -y2 genes 
generally have completely rearranged TcR-.8 genes (94,264,267). Most CD3- and CD3+ T cell 
malignancies have rearranged their TcR--y2 genes and have consequently deleted their TcR--y1 
genes (180,256,259,260,264,268,269). The majority of CD3+ T cell malignancies probably 
express TcR-a.B as determined by the presence of TcR-a gene rearrangements andjor TcR-a 
mRNA (181-183,259, 260) or by reactivity with an anti-TcR-a.B antibody (260,264). Most of the 
TcR-a.B+ malignancies have deleted both TcR-o gene alleles, since the TcR-o genes are located 
between the Va and Ja gene segments (Figure 4)(70,83,212,213,262-264). In a part of the T 
cells one TcR-o gene allele is deleted, while the other allele is still present (70,213,247,262--
264). 
All these data are compatible with a model ofT cell differentiation in which the TcR-o genes 
rearrange first, immediately followed by rearrangement of the TcR--y genes and in most cells 
also rearrangement of the TcR-.8 genes. Probably the TcR--y gene rearrangement first involves 
the -y1 locus and if this rearrangement is non-functional, rearrangement to the -y2 locus occurs 
(94,267). Transcription of functional TcR--y and TcR-o genes results in TcR--yo expressing cells. 
If the TcR--y andjor TcR-o gene rearrangements are not functional or incomplete, the involved 
T cells remain TcR-CD3- and will probably be eliminated. On the other hand, these T cells or 
newly formed precursor T cells may delete one or both TcR-o genes and rearrange their TcR-.B 
and TcR-a genes. There is evidence that a specific deletion of the D, J and C segments of the 
TcR-o genes occurs before rearrangement of the TcR-a genes (213,270-272). These two 
separate consecutive steps are therefore comparable to the deletion of lgx; gene segments in 
B cells, which rearrange their lg>.. genes (238,242). Functional rearrangement of the TcR-a and 
TcR-.8 genes results in TcR-a.B expressing cells. Non-functional rearrangements will probably 
lead to the cell death. 
It is not yet clear whether the TcR--yo differentiation pathway is separate from the TcR-a.B 
pathway or whether the TcR--yo+ cells develop prior to the TcR-a.B+ cells in the same linear 
differentiation pathway. The presence of TcR-.8 gene rearrangements in TcR--yo+ cells 
(94,264,267) and the presence of TcR--y gene rearrangements (generally in the -y2 locus) in 
TcR-a.B+ cells (180,256,259,260,264,268,269) are in favor of a linear differentiation pathway 
(94,267). However, a functional rearrangement of the TcR-o genes on the one hand and the 
specific deletion of the Do-Jo-Co gene segment on the other hand may represent regulation 
events, which separate the TcR--yo pathway from the TcR-a.B pathway (213,271). The recent 
detection of circular excision products with germline Do, Jo and Co gene segments in the 
thymus supports this hypothesis (273). This would imply that the rearrangement/deletion 
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processes in the TcR-o genes play a crucial role in the separation of the -yo and a.B pathways. 
In this case the occurrence of TcR--y gene rearrangements in TcR-a.B+ cells and TcR-.B gene 
rearrangements in TcR--yo+ cells may be explained by activity of a "common TcR gene 
recombinase". The various processes in the hierarchy afTeR gene rearrangements are summa-
rized in Figure 11. Additional aspects concerning the divergence of the -yo and a.B pathways are 
discussed in Chapter 4.1. 
The unique structure of the TcR-a/o locus may not only ensure a controlled hierarchy of 
gene rearrangements, but may also ensure the mutually exclusive expression of TcR-a and 
TcR-o genes to avoid dual receptor expression (70,264). In addition, the deletion of the 
Do-Jo-Co segment before the rearrangement of the TcR-a genes prevents that Do and Jo gene 
segments, which provide the major source ofTcR-o gene diversity, are used in conjunction with 
TcR-a (271). 
It is not yet known to what extent all TcR gene rearrangements are thymus dependent. 
Interestingly, in nude mice as well as in athymic man, i.e. patients with a complete DiGeorge 
syndrome or a classical type of severe combined immunodeficiency, TcR--yo + cells are present, 
while TcR-a.B+ cells are virtually absent (274-276). This suggests that TcR--yo+ cells are still able 
to develop in athymic species, while the development of TcR-a.B+ cells is highly thymus 
dependent (276). 
Natural killer cells (NK cells) are generally considered as a subpopulation of T cells since 
most of them express the pan-T cell markers CD2 and CD? in addition to the CD16 antigen 
(Fe receptor for lgG) and the CD56 antigen (Leu-19 antigen)(277-280). However, several 
reports indicate that functional NK cells do not express a TcR-CD3 complex at the cell surface 
(277-280) and have all TcR genes tested in germline configuration (281-286). Therefore NK cells 
are probably derived from precursor T cells, which did not (yet) rearrange their TcR genes 
(Figure 11). 
Relationship between protein expression and gene rearrangement 
During B cell differentiation the results of functional lgH gene rearrangement can be seen 
at the pre-B cell stage, i.e. weak cytoplasmic expression of the lgH chain p, (weak Cyp,)(287). 
Smlg expression does not occur until functional rearrangement of both lgH and lgL genes 
has occurred (Figure 11 ). To a certain extent this relationship between lg protein chain expres-
sion and lg gene rearrangement is illustrated by the phenotypic and genotypic characteristics 
of precursor-B-ALL (178-180,233-237). While virtually all precursor-B-ALL (null ALL, common 
ALL and pre-B-ALL) have rearranged lgH genes, the lgL gene rearrangements are found in only 
a part of the common ALL (pre-pre-B cell) and pre-B-ALL (pre-B cell)(178-180,233-237). 
Analogous to Smlg expression during B cell differentiation, the expression of the TcR-CD3 
complex at the cell surface ofT cells only occurs after functional rearrangement of TcR--y and 
TcR-o genes or functional rearrangement of TcR-a and TcR-.B genes. Expression of the 
TcR-CD3 complex at the cell surface is preceded by cytoplasmic expression of the CD3 protein 
chains (CyCD3) during the early stages of T cell differentiation (Figure 11) (181 ,288-290). 
Therefore CyCD3 staining can be used as a diagnostic marker for immature CD3- T cell 
malignancies (181 ,290-294). Immature normal CDTT cells as well as CDTT cell malignancies 
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may also be positive for cytoplasmic TcR-.8 chains (295-297). It should be remarked that such 
expression does not prove that these cells are precursors ofTcR-a,B+ cells, since also TcR--yo+ 
cells may contain functional TcR-.8 gene transcripts (63,64,94,264) and TcR-.8 protein chains 
(62). 
The nuclear enzyme TdT is expressed by all immature lymphoid cells, but is absent in 
mature B and T lymphocytes (222,223). This suggests that TdT expression disappears after 
functional rearrangement of lg and TcR genes, which is in agreement with the postulate that 
TdT mediates the insertion of N regions at the joining sites during gene rearrangement 
(171 ,221 ,224). Although during T cell differentiation coexpression of TdT and the TcR-CD3 
complex at the cell surface is found in the thymus, such coexpression of Smlg and TdT during 
normal B cell differentiation is not found (298-300). Along with these findings, only a few 
TdT+ /Smlg+ B-ALL have been reported (300-302), while large series of TdT+ /CD3+ T-ALL 
have been described (181-183,259). This discrepancy may be related to the virtual absence of 
N regions in rearranged lgL genes (171 ,221 ,224), while N region diversity is present in all 
rearranged TcR genes (201-204,225-230). It suggests that during B cell differentiation TdT 
activity decreases as soon as lgH gene rearrangement is completed, resulting in the absence 
of TdT when Smlg is started to be expressed. 
DIFFERENCES BETWEEN IMMUNOGLOBULIN AND T CEll RECEPTOR GENES AND 
THEIR PROTEIN PRODUCTS 
The genes which code for the various lg and TcR chains have similar germline organiza-
tions and undergo similar gene rearrangement processes (Figures 2 and 4)(13-15). This is 
reflected at the protein level where the primary, secondary and tertiary structure of the protein 
chains have a high degree of homology (Figure !)(reviewed in ref. 303 and 304). Despite these 
similarities several major differences exist between the lg and TcR molecules and their function 
(Table 2). 
We shall first discuss the relatedness between lg and TcR molecules. Subsequently we shall 
consider several differences between lg and TcR genes and molecules. 
Immunoglobulin gene superfamily 
The structure of the lg and TcR molecules are related to each other as well as to other 
molecules which are involved in specific immune recognition, such as the major histocom-
patibility complex (MHC) molecules of class I and class II and the T cell accessory molecules 
CD4 and CDS (Figure 12) (303-306). These similarities are not restricted to the protein structure, 
but are also present at the level of gene organization, suggesting that the encoding genes have 
a common evolutionary origin (306). These closely related genes belong to the so-called lg 
gene superfamily (305, 306). 
Hood et al. defined the lg gene superfamily as a set of multigene families and single-copy 
genes related by sequence (implying common ancestry), but not necessarily related in function 
(306). Members of this superfamily code for protein chains with domains which are homolo-
112 CHAPTER3.2 
TABLE 2. Differences between the antigen specific receptors of B and T lymphocytes. 
Basic structure of the receptor 
- number of protein chains per molecule 
- number of constant domains per chain 
- number of antigen binding/recognition 
sites per molecule 
- close association with other molecules 
Antigen recognition/binding 
- HLA-restricted antigen recognition 
- antigen-induced somatic mutations 
- affinity of the receptor 
Changes of the receptor during maturation 
- secretion of receptor molecules 
- isotype switching 
B lymphocytes T lymphocytes 
4 2 
1-4a 
2 
+ 
(CD3 molecules) 
+b 
+ 
high (108-10 13) low (<106) 
+ 
+ 
a. The lgl chains contain one constant domain, while the lgH chain contains three constant domains (8, 1 and a) or four constant domains 
(JL and €) (Figure 3). 
b. The antigen recognition is MHC-class I restricted in case of TcR-a.B+/CDS+ cells and HLA-class II restricted in case of TcR-a.B+/CD4+ 
cells. TcR-78+ T lymphocytes probably also recognize antigen in association with MHC or MHC-Iike molecules. 
gous to the lg chain domains. These so-called lg homology units are composed of 100 to 110 
amino acids and have a centrally placed disulfide bridge, which spans about 65 amino acids 
and stabilizes the secondary and tertiary structure of the homology unit (303-306). Two main 
types of homology units can be recognized: the V and C homology units, named after the 
respective domains of the lg molecules (c.f. Figure 12)(303-306). The degree of amino acid 
sequence similarities between homology units of distinct families varies from about 15 to 40% 
(306), whilethe degree of homology within a family is much higher (303). At the DNA level each 
homology unit is usually encoded by a separate exon (306). This demonstrates the striking 
correlation between the distinct structural features of these proteins and the exon-intron 
organization of their encoding genes (306). 
Homology to lg units is also found in molecules which are not directly involved in the 
immune system. Som£;J of these molecules have no known function (Thy-1, MRC OX-2, 
a1 B-glycoprotein), while others interact with homologous molecules either within the immune 
system (e.g. the CD58 molecule (LFA-3) and Fe receptors) or in different systems (e.g. the 
CD56 molecule (NCAM) and MAG/Hcp3)(303-308). 
Nine multigene families and at least twenty-five single-gene families have been included in 
the lg gene superfamily so far. The multigene families are the lg genes, the TcR genes and the 
MHC-class I and class II genes. The single-gene families include the genes for the CD1 
molecules, the T cell antigens (C02, CD3, CD4, CD?, CDS and CD28), the hematopoi-
etic-endothelium antigens (CD58 molecule and MRC OX-45), the brain-lymphoid antigens 
(Thy-1 and MRC OX-2), Fe receptors, neural molecules (e.g. CD56 molecule and MAG/Hcp3), 
growth factor receptors (PDGF receptor and CSF1 receptor) and non-cell surface molecules 
(e.g. a1 B-glycoprotein)(303-308). 
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Figure 12. Schematic diagram of several members ofthe lg gene superfamily i.e. lgM molecule, TcR-a,B molecule, 
HLA-class I molecule, HLA-class II molecule, CD4 molecule and CDS molecule. V: variable domain, C: constant 
domain, ,82m: ,82-microglobulin, 'V': V-like domain. 
Thus the members of the lg gene superfamily extend beyond the immune system. This 
suggests that the lg homology unit has played a central role in cell-cell interaction during 
evolution (307). Therefore investigation of structure and function of related systems in lower 
organisms may provide clues about the primordial function of the members of the lg gene 
superfamily (303). 
Major histocompatibility complex-restricted antigen recognition 
One of the major differences between lg and TcR molecules is that the TcR of most T 
lymphocytes is able to recognize the corresponding antigen only if this is associated with an 
MHC molecule on the surface membrane of another cell (309-3"12). In contrast, lg molecules 
can bind to both free and membrane-bound antigens. After recognition of the antigen-MHC 
complex T lymphocytes will be activated and will exhibit their specific regulatory or cytotoxic 
functions. This phenomenon is called MHC-restricted antigen recognition and has been 
demonstrated to occur in case of TcR-a.B+ T lymphocytes (309-3"12). TcR--yo+ T lymphocytes 
probably also recognize antigen in association with MHC or MHC-Iike molecules (3"13-3"15). 
The mature TcR-a,B+ T lymphocytes express either CD4 or CDS molecules. The majority 
of the CD4 + T lymphocytes exhibit helper /inducer functions, while most CDS+ T lymphocytes 
exhibit cytotoxicjsuppressor functions (3"16,3"17). However, a subset of CD4 + T lymphocytes 
can also display cytolytic activity (3"1S,3"19). There appears to exist a strong correlation between 
CD4 expression and MHC-class If-restricted antigen recognition and between CDS expression 
and MHC-class !-restricted antigen recognition (309-3"12,3"16,3"17). This implies that CD4+ T 
lymphocytes can only be activated if the relevant antigen is presented by MHC-class II 
expressing cells, such as B lymphocytes, monocytes and most macrophages. It is assumed 
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Figure 13. Hypothetical schemes of MHC-restricted antigen recognition byT lymphocytes. A: CD4 + T lymphocytes 
recognize antigens presented by HLA-class II molecules. B: cos+ T lymphocytes recognize antigens presented 
by HLA-class I molecules. In these figures the junctional regions (CDR3-equivalent region) of the TcR-et,B molecules 
contact the antigen (Ag), while the distal parts of the V domains (containing the CDR1 and CDR2-equivalent 
regions) contact the polymorphic domains of the MHC molecules (155, 157,332). The binding of the CD4 and CDS 
molecules to the HLA-class II and HLA-class I molecules, respectively, is depicted as occurring in basically the 
same way as suggested for the TcR-et,B molecules (155,311). The latter probably implies that TcR and CD4 or CDS 
interact with separate MHC molecules. 
that CDS+ T lymphocytes can be activated by each nucleated cell, since they all express 
MHC-class I molecules. 
Several reports indicate that the antigen recognized by the TcR-a.B+ T lymphocytes is a 
peptide fragment of the antigen (presumably derived from intracellular processing), which is 
bound to a specific site of the MHC molecule (320-322). The recent description of the crystal 
structure of a human MHC-class I molecule has demonstrated that the binding site for the 
peptide fragment is a cleft on the outer surface of the MHC molecule, located between two 
polymorphic domains (323,324). The structurally related MHC-class II molecules are predicted 
to contain a similar peptide binding site (325). 
It has been suggested that the Va domains of the TcR are associated with recognition of 
the antigenic peptide fragment, while the use of specific V.B domains correlates with the 
recognition of the polymorphic part of certain MHC molecules (326-329). However, such a 
correlation between V gene usage and antigen or MHC recognition has not been found in all 
studies (330-332). Alternatively it has been suggested that the CDR3-equivalent regions of both 
V domains contact the antigen fragment, while the distal parts of the V domains (containing 
CDR I and CDR2-equivalent regions) contact the polymorphic domains of the MHC molecules 
(Figure 13) (155, 157,332). 
The T cell accessory molecules CD4 and CDS probably play a role in the interaction 
between the T lymphocyte and the antigen-presenting cell or target cell (311 ,317,333-335). It 
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has been suggested that the CD4 and CDS molecules in fact are receptors for MHC-class II 
and MHC-class I molecules, respectively, and that these T cell accessory molecules enhance 
in this way the contact between the TcR and the antigen-presenting MHC molecules (333-343). 
It is not fully understood how the CD4 and CDS molecules interact with the MHC molecules. 
There is some evidence that CD4 and CDS molecules are physically associated with the 
TcR-CD3 complex and therefore probably interact with the constant (non-polymorphic) domain 
of the same MHC molecule which presents antigen to the TcR (344-346). On the other hand, 
it might well be that the accessory molecules and the TcR interact with separate MHC 
molecules, which allows interaction of the V-like domains of the CD4 and CDS molecules with 
(non-polymorphic epitopes of) the polymorphic domains of the MHC molecules (Figure 
13)(1 55,31 1). Future studies will elucidate the precise nature of these interactions. 
Somatic mutation, antibody diversity and antibody affinity 
The antibody repertoire of virgin B cells is based on the combinatorial and junctional 
repertoire of the lg genes, acquired during the antigen-independent stages of B cell 
differentiation (1 3-15,1 49). During the immune response B cells can change the antigen-binding 
properties of the antibodies, resulting in the production of antibodies with higher affinities 
(14,347,34S). Several studies on the development of the immune response against simple 
antigens (e.g. oxazolone, p-azophenylarsonate and hydroxy-nitro-phenylacetyl) have 
demonstrated that these changes are caused by molecular events in the V regions, so-called 
somatic mutations (349-352). Somatic mutations are point mutations in the nucleotide sequence 
of V regions, preferentially in the CDR1 and CDR2 encoding sequences (14,348,349). The 
mutations do not only occur in VH genes, but also in VL genes (14,348-352). The frequency of 
somatic mutation in the V gene segments during the immune response is estimated to be about 
·10-3 /base pair /cell division (353-356), more than a thousand times higher than the mutation 
frequency in other genes (353). 
Somatic mutations do not occur in virgin B cells, as shown in non-immune mice, but arise 
only after antigenic stimulation (351,357-359). Some reports indicate that the mutation 
mechanism is not continuously active during the immune response, but seems to concentrate 
in the mid to late phase of the primary response (356,359). It has been postulated that the 
mutations especially occur in B cells of the memory pathway (359). Reexposure to the antigen 
leads to activation of only those memory B cells, which carry advantageous antibody mutants, 
i.e. antibodies with a higher affinity (348,359). It was demonstrated that the intraclonal antibody 
affinity can increase more than 15 fold (360). Increase in antibody affinity could also be 
obtained via specific V region mutations by use of oligonucleotide-directed mutagenesis (361). 
The somatic mutation-mediated maturation and clonal expansion of the immune response 
is antigen driven (348-360) and cannot be mimicked in vitro with polyclonal mitogens (362). 
Interestingly, anti-idiotype (ld) antibodies can select for B cells which changed their ld via 
somatic mutation. This became evident in clinical studies concerning the in vivo treatment of 
B-NHL with anti-ld antibodies (363,364). Several B-NHL patients only had a partial response to 
the antibody therapy due to a strong selection and growth of ld- B-NHL cells (363,364). In 
some follicular lymphomas ld variants could already be detected at diagnosis (365). In an 
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Figure 14. Schematic diagram of RNA splicing processes for the production of membrane bound lg molecules or 
secretory lg molecules. Membrane bound lg molecules and secretory lg molecules differ in their carboxy-terminal 
part, which is encoded by secretion sequences or membrane sequences. The terminal secretion sequences (*) 
are generally contiguous with the final lgH-C region exon, while the membrane sequences ( •) are located in one 
or more exons downstream of the last CH exon. Mature forms of secretion mRNA and membrane mRNA are 
produced via a process of RNA splicing (c.f. ref. 371-374). 
extensive study on one patient it was proven that many point mutations had occurred in the 
various VH gene segments of the lymphoma cells (366). 
So far, no evidence has been produced indicating somatic mutation in the V segments of 
the TcR-a and TcR-.8 genes (201,367-370). 
Surface membrane bound lg molecules and secreted lg molecules 
The lg molecules on the cell membrane (Smlg) are the antigen-specific receptors of B 
lymphocytes, while the soluble lg molecules in serum, tissue fluids and mucosal layers are the 
antibodies which play an important role in the neutralization and opsonization of micro-
organisms and other antigens. The serum antibodies (lgM, lgG and lgA) are mainly secreted 
by plasma cells in the bone marrow, while the antibodies in the mucosal layers (especially lgA) 
are produced locally. In plasma cells high amounts of lg molecules are synthesized and 
accumulated intracellularly. These are detectable as 'cytoplasmic lg molecules' (Cylg). 
The difference between the two forms of lg molecules is located in the carboxy-terminal 
part of the lgH chain. The genetic basis for this difference resides in the exon organization of 
the CH gene segments. The terminal secretion sequences are generally contiguous with the 
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Figure 15. Schematic diagram of the production of mature mRNA for the lgH chain of lgD molecules. Mature 
mRNA for the lgH chain of lgM or lgD is produced via alternative processing of precursor mRNA, resulting in 
splicing of the V-0-J segment to Cp, gene segments or to Co gene segments (377,378). 
final lgH-C region exon, while the surface membrane binding sequences are located in one or 
more exons downstream of the last CH exon (371 ,372). Regulation of the production of Smlg 
versus secretory Cylg most probably occurs at the mRNA level via a process of RNA splicing 
(Figure 14)(371-374). 
So far, there are no reports on the occurrence of secreted forms of TcR. Also at the DNA 
level no evidence has been found for the existence of secretory forms of TcR molecules. 
lgH class switching 
Most B lymphocytes in the peripheral blood express lgM and lgD on their cell surface, 
while a smaller part expresses lgG or lgA. In lymph nodes and spleen a higher frequency of 
lgG and lgA bearing lymphocytes is found. Coexpression of multiple lgH classes may occur 
in B lymphocytes (375), but plasma cells produce only one lgH chain of only one (sub)class 
(376). 
Coexpression of lgM and lgD molecules on the cell surface of B lymphocytes can be 
mediated by alternative RNA processing (377,378). This results in splicing of the VDJ gene 
segment to the Cp, gene segments or to the Co gene segments (Figure 15). 
Early studies have indicated that JgH class switching from lgM and lgD to lgG or lgA can 
be mediated via a second type of lg gene rearrangement, which replaces the Cp, gene by the 
appropriate CH gene, thereby deleting all intervening sequences (379,380). The recombination 
sites of this rearrangement appeared to contain repetitive sequences, the so-called switch (S) 
regions, which are located at the 5' side of each CH gene except for the Co gene (Figures 
15 and 16)(38,39,381,382). TheseS regions are probably directly or indirectly involved in the 
lgH class switch rearrangement, which is therefore called S-S recombination (39). Although the 
precise mechanism of the S-S recombination is unknown, recent studies indicate that the 
process may occur by looping-out and deletion (Figure 16)(383). 
Several studies indicate that lgH class switch or coexpression of lgM and lgG or lgM and 
lgA may occur without any detectable S-S recombination (384-386). It was concluded that this 
type of lgH isotype expression is accomplished by alternative RNA processing of large (up to 
180 kb) transcripts that span the lgH-C region locus (384-386). 
The combined data have led to the hypothesis that lgH class switching may be a two-step 
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process. First formation of large transcripts and expression of the various lgH isotypes occurs 
by differential RNA splicing. Later, during the course of B cell activation and maturation, S-S 
recombination represents the final step of lgH class switching (387,388). Recent evidence 
indicates that this two-step lgH class switch process can be regulated by interleukins such as 
-y-interferon, interleukin-4 and interleukin-5 (389-391). Interestingly there appears to be no 
correlation between the lgH class switching on the productive lgH gene allele and the class 
switching on the non-productive allele (392-394). Therefore, it has to be concluded that 
interleukins only regulate the class switching of the productive lgH gene allele. 
While lgH class switching is a frequent event in B lymphocytes, no evidence has been 
found for switching from one type of TcR to another type of TcR in T lymphocytes. Although 
it has been found that TcR--yo+ cells develop earlier than TcR-a.B+ cells during murine T cell 
ontogeny (247-255), there is no indication that TcR--yo+ cells can develop into TcR-a,B+ cells 
or that TcR--y1 s+ cells can develop into TcR--y25+ cells. 
CONClUSION 
B and T lymphocytes play a central role in the immune system due to their ability to 
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specifically recognize antigens via their Smlg and TcR molecules, respectively. The structure 
of the lg and TcR genes, the gene rearrangement processes and the insertion of nucleotides 
in the junctional regions form the basis of the diversity of these antigen-specific receptors of 
lymphocytes. Despite the similarities between lg and TcR genes/molecules, several major 
differences exist between BandT lymphocytes, such as the MHC-restricted antigen recognition 
of T lymphocytes and the somatic mutations and lg class switch of B lymphocytes. These 
differences makes B and T lymphocytes to different, but complementary immune cells. 
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During rearrangements of lg and TcR genes certain DNA segments are deleted, while other 
segments are relocated. These processes also change the distances between the specific 
cut-sites of restriction endonucleases. These are enzymes which reproducibly cut DNA only at 
sites where they recognize a specific sequence of base pairs; e.g. the restriction endonuclease 
EcoRI recognizes the sequence GAA TIC. In the Southern blot analysis the DNA fragments (re-
striction fragments) produced are size-separated by agarose gel electrophoresis and subse-
quently transferred (blotted) onto a nitrocellulose or nylon membrane. The membrane is then 
incubated with a radiolabeled DNA probe, which hybridizes to complementary sequences of 
lg or TcR genes. Unbound probe is washed away and the location of the probe and thereby 
the recognized restriction fragment is visualized by autoradiography. If the appropriate 
restriction enzymes and DNA probes are used, the detected restriction fragments of rearranged 
lg or TcR genes will differ from those of germline genes. 
The cells of most malignancies have a common clonal origin. Therefore, the cells of a 
lymphoid malignancy will have rearranged their lg or TcR genes identically, while in reactive 
polyclonallymphoid cell proliferations many different rearrangements of lg and TcR genes are 
present. The latter rearrangements will not be detectable by Southern blot analysis, because 
the autoradiographic.signal of each individual restriction fragment is too weak to be clearly 
visible within the smear of the other restriction fragments. In contrast, when a clonal cell 
population is studied, many identical restriction fragments will co-migrate in the agarose gel 
rendering their signals visible as one or more rearranged bands. Therefore Southern blot 
analysis of lg and TcR genes allows discrimination between clonal rearrangements and 
polyclonal rearrangements (Figure 1 and Table 1). 
In this chapter we shall describe the various aspects of Southern blot analysis: DNA sampl-
ing, Southern blotting itself and the various lg and TcR gene probes. Subsequently we shall 
discuss several limitations of Southern blot analysis of lg and TcR genes, such as some 
*This manuscript will be published as part of a review in Clin Chim Acta. 
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complicating pitfalls and the detection limit of the technique. Finally, we shall briefly indicate 
several diagnostic applications of Southern blot analysis of lg and TcR genes. 
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TABLE 1. Cell populations in the lymph nodes from patients A, 
B and C (in Figure 1) as estimated by immunologic 
marker analysis. 
Monoclonal 
B lymphocytes 
Polyclonal 
B lymphocytes 
Reactive 
T lymphocytes 
Monocytesj 
macrophages 
Patient A 
lymph 
node 1 
O%a 
30%a 
60% 
10% 
Patient A 
lymph 
node 2 
O%a 
50% a 
45% 
5% 
Patient B 
lymph 
node 
10%a 
25%a 
50% 
15% 
Patient C 
lymph 
node 
20%b 
25%b 
45% 
10% 
a. The K/>- ratios in the lymph node cell samples from patients A and B were within 
the normal range. Nevertheless in case of patient B a small subpopulation of 
SmK + large B lymphocytes could be detected. 
b. In case of patient C the K/A ratio was slightly elevated (4.5). 
Figure 1. Discrimination between a polyclonal B cell proliferation and 
a monoclonal B cell population by lgH gene analysis. DNA samples 
from two lymph node biopsies of patient A with an unexplained 
lymphadenopathy as well ?S DNA samples from lymph node biopsies 
Bg/11, JH probe of patient Band patient C were digested with the restriction enzyme 
Bg/11. The Southern blot filter was hybridized with a radiolabeled JH 
probe. The approximate size of the germline band (G) and rearranged bands are indicated in kilobases (kb). In 
the two lymph node samples from patient A no indication for the presence of a clonal B cell population was found. 
The background of the multiple faint non-germline bands in lymph node 1 and lymph node 2 are probably due to 
the presence of the reactive (polyclonal) B cells (c.f. Table 1). In case of patient Band patient C, two rearranged 
bands are visible in addition to the germline band. This indicates that a clonal B cell population is present in both 
lymph nodes. Morphological reevaluation and careful immunophenotyping revealed that 15 to 20% of the lymph 
node cells r!'presented B-oon-Hodgkin lymphoma (B-NHL) cells (c.f. Table 1). 
DNA SAMPLING 
Southern blot analysis of lg and TcR genes to identify clonal lymphoid populations is 
generally performed on DNA extracted from fresh or frozen cell samples (1 ). In addition, several 
reports have described the extraction of DNA from formaldehyde-fixed and paraffin embedded 
tissue (2-5). Also extraction of DNA from air dried or fixed cell smears appears to be possible 
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(6). DNA extraction from unfixed and fixed cell samples as well as the storage of DNA samples 
will be discussed. 
Preparation of DNA from fresh or frozen cell samples 
In many cases it is possible to prepare the DNA from freshly obtained cells or frozen cells, isolated from 
peripheral blood (PB) or bone marrow (BM) by ficoll density centrifugation or isolated from other body fluids, such 
as pleural exudate and ascites. DNA is also easily extractable from freshly obtained or snap-frozen tissue samples 
after homogenization with a tissue grinder (e.g. from Tamson, Zoetermeer, The Netherlands; or from Kontess, 
Fineland, NJ). Cell pellets or homogenized tissue samples are lysed and dissolved in TNE buffer (10 mM Tris-HCI 
pH 7.5; 100 mM NaCI; 10 mM EDTA) at an estimated concentration of about 5 x 106 cells per mi. Subsequently 
EDTA (10 mM final concentration), Proteinase K (50 JLgjml final concentration; Merck, Darmstadt, FRG) and SDS 
(1% wjvfinal concentration) is added. This viscous mixture is incubated for at least 2 hours (or overnight) at 37•c. 
After this incubation DNA is extracted with an equal volume of phenol extraction buffer (50% high quality phenol; 
49% chloroform; 1% isoamylalcohol) by gently mixing until a homogeneous solution is obtained. After centrifugation 
(5 min at 2000 g) the water phase, containing the DNA, is removed without disturbing the interphase. If admixture 
with interphase material occurs the extraction procedure should be repeated once or twice. To this 0.1 voiurne of 
2M NaAc (pH 5.6) is added, mixed and subsequently 2 volumes of cold (-2o•q ethanol (96%) are added. This 
is mixed until the DNA is precipitated. The precipitated DNA is removed with a small glass rod, washed in ethanol 
(70%) and subsequently dissolved in TE buffer (1 0 mM Tris-HCI, pH 7.5; 1 mM EDTA) at 4 • C; the volume of TE 
buffer is about 0.5 ml/5 x 106 cells. 
When the DNA is dissolved completely, DNase-free RNase (Boehringer Mannheim, Mannheim, FRG) is added 
to a final concentration of 20 JLgjml and incubated for at least 1 hour at 37•c. Subsequently, Proteinase K (final 
concentration of 25 JLgjml) and SDS (0.1% w jv final concentration) are added and incubated for at least 2 hours 
at 37•c. This is followed by phenol extraction, precipitation of the DNA in NaAc and ethanol, and washing of the 
precipitated DNA in 70% ethanol as before. Then the DNA is dissolved in 0.1 volume TE buffer and 0.9 volume 
water (0.5-5 ml, depending on the amount of extracted DNA). This dissolving of the DNA generally takes 24-48 
hours. Finally, the optical density of the preparations is measured with a spectrophotometer at 260 and 280 nm 
in order to calculate the DNA concentration and to estimate the degree of protein contamination of the sample (1 ). 
Extraction of DNA from formalin-fixed, paraffin-embedded tissue samples 
The reliance on unfixed cell samples for the isolation of DNA for Southern blot analysis limits retrospective 
studies, because often only fixed tissues are stored. Therefore, several investigators have developed techniques 
for the extraction of high molecular weight DNA from formalin-fixed, paraffin-embedded tissues (2-5). 
The quality of the formalin-fixed paraffin-embedded tissues and the location of the relevant tissue areas has 
to be determined by means of histological sections. The paraffin blocks should not be used if the tissue appears 
to be fixed inadequately or if autolysis or tissue necrosis is evident, because these are important causes of failure 
to recover intact high-molecular mass DNA (3-5). The selected blocks of paraffin-embedded tissue are trimmed 
with a scalpel blade for removal of excess of paraffin wax, stromal tissue or other unwanted material (3-5). The 
trimmed tissue samples are diced with a scalpel or sliced with a microtome (5-JLm-thick slices). The tissue slices 
or dices are deparaffinized and rehydrated by resuspension in xylene and subsequent resuspension and washing 
in xylene (once or twice), absolute ethanol (once or twice) and water (once)(see references 3 and 5). Afterwards 
the tissue fragments are directly transferred to 2 - 5 ml of Proteinase K digestion solution (see above) for a 
prolonged digestion, lasting 2- 4 days; fresh Proteinase K (100 JLgjml final concentration) is added at 24 hours 
intervals (5). During this digestion the tissue fragments form a loose gelatinous lump, which disperses into fine 
fragments in an increasingly viscous solution. After the Proteinase K digestion, DNA is extracted with phenol ex-
traction buffer. The subsequent steps are identical to those described above. 
The rate of DNA release during the Proteinase K digestion varies in different types of tissue and depends on 
the density and abundance of extracellular stroma (3). In case of highly cellular tissue, such as lymphoid tissues, 
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most DNA is released within 1 - 2 days (3). To remove low-molecular mass DNA unsuitable for Southern blot 
analysis, Dubeau and colleagues (3) used a two-step Proteinase K digestion. In this method, after the first in-
cubation (3 hours in case of lymphoid tissues) the supernatant, presumably containing only degraded DNA, is 
discarded. Only the supernatant obtained after the second incubation is used for DNA extraction (3). Nevertheless 
in all DNA samples some degraded DNA will be present. 
The quality of the extracted DNA decreases progressively when the formalin fixation has lasted longer than 
one day (3-5). Although it has been reported that the electrophoretic mobility of restriction-enzyme-digested DNA 
obtained from formalin fixed tissues is decreased when compared to DNA from fresh or frozen tissues (2-5), the 
Southern blotting banding pattern (e.g. position of the germline bands) appears to be the same (3). Thus it can 
be concluded that Southern blots of DNA obtained from optimally fixed tissues (neutral buffered formalin fixation 
for less than 24 hours) are comparable to blots of DNA from unfixed material (3-5). 
Extraction of DNA from cells of stored bone marrow or blood smears 
If no fresh or frozen blood or bone marrow samples from a leukemia patient are available, the extraction of 
DNA from stored slides may be attempted (6). The smears are scraped off the glass slides with a scalpel blade 
and the resulting powdered material is transferred into an eppendorf tube. The cell material is lysed for 10 min in 
1.2 ml of distilled water and 400 JLI of the detergent Nonidet P40 (0.1% solution) (6). After centrifugation the nuclear 
pellet is incubated with the above described Proteinase K buffer. All subsequent procedures for DNA extraction 
are as described above. 
The yield of DNA per slide is dependent on the cellularity of the cell smear: an average quantity of 16 JLg DNA 
(range: 1-50 JLg) can be obtained per bone marrow slide (6). Neither fixation nor staining of the slides seems to 
influence the quality of the DNA, because DNA from unfixed, methanol-fixed, and stained slides appeared to give 
comparable results in Southern blot analysis (6). 
Generally, the DNA extracted from slides is partially degraded, and it should be emphasized that the quality 
of the analysis is unlikely to be optimal (6). Especially large restriction fragments (> 10 kb) may appear to be 
absent. 
Control DNA samples 
For optimal Southern blot analysis of lg and TcR genes control DNA samples are needed to determine the 
exact position of the germline bands. In principle DNA from any cell sample with germline lg and TcR genes can 
be used for this purpose. Frequently used sources for such germline DNA are non-hematopoietic cells, such as 
placenta, fibroblasts, liver cells, carcinomas and cell lines (7-10). Also DNA from malignant T cells with germline 
lg genes or DNA from malignant B cells with germline TcR genes can be used as controls for the analysis of lg 
genes and T cR genes, respectively. 
More or less extensive polymorphisms occur in many genes. Some of them involve the target sequences of 
restriction enzymes, which results in restriction fragment length polymorphisms (RFLP). A second type of DNA 
polymorphism, designated hypervariable (or length) polymorphism (HVP), results from insertion or deletion of DNA 
segments (11). Also polymorphic amplification of genes or gene segments may occur {12,13). Although only a 
few RFLP, HVP and polymorphic gene amplifications occurring in lg genes (11,12,14-17) and TcR genes (13,18-
24) have been reported, it may be important to obtain both the tumor DNA and the control DNA from the same 
patient. In retrospective studies it will often be difficult to collect control DNA from the same patient as the tumor 
DNA. On the other hand, in prospective studies one should try to obtain granulocytes or fibroblasts from each 
patient. 
Granulocytes represent an easily-accessible source of control DNA. The nuclei of purified granulocytes can 
be obtained after ficoll density centrifugation of peripheral blood by lysis of the erythrocyte/granulocyte pellet with 
a detergent such as Zaponin (Coulter Electronics, Luton, UK) and subsequent washing with phosphate buffered 
saline. Cultured fibroblasts from a skin biopsy may also serve as a source of control DNA, but usually several 
weeks of culture are required to obtain sufficient numbers of cells. 
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Storage of DNA samples 
DNA samples are often stored at a concentration of 100-400 JLgjml in an eppendorf tube or in a larger 
well-sealed tube at 4 •c. This is suitable for short-term storage, but long-term storage(> 1 year) at 4 •c results in 
a progressive degradation of the DNA and, sometimes, infection may develop. Therefore in our laboratory long-term 
storage of DNA samples is performed in eppendorf tubes at -70 • C. This prevents degradation of the DNA as well 
as growth of microorganisms. The aliquots of DNA per tube should not exceed 200-400 JLg, since repeated freezing 
and thawing will lead to progressive shearing of the DNA. 
SOUTHERN BLOT ANALYSIS 
In this section we shall describe the digestion of DNA by use of restriction enzymes, the 
agarose gel electrophoresis of the restriction fragments, the blotting of the fragments onto a 
membrane, hybridization with radiolabeled DNA probes and the autoradiography (i ,25). Several 
aspects of these procedures are illustrated in Figure 2. 
Restriction enzyme digestion 
Approximately 15 JLg of DNA is digested with 100 units of the appropriate enzyme (Pharmacia, Uppsala, 
Sweden; Boehringer Mannheim, Mannheim, FRG; New England Biolabs, Beverly, MA; Amersham, Amersham, UK; 
Promega, Madison, WI). The most suitable type of digestion buffer (low, medium, or high ionic strength) depends 
on the type of restriction enzyme used and should be prepared according to the manufacturers guidelines. The 
complete digestion mixture contains 15 JLg of DNA, 100 units restriction enzyme, 20 JLI of 1 Ox concentrated 
digestion buffer, 1 JLI of 20% BSA (special quality for molecular biology; Boehringer Mannheim) and 8 JLI of 100 mM 
Spermidine (Sigma, St. Louis, MO) in case of high ionic digestion buffer; this mixture is supplemented with distilled 
water to a final volume of 200 JLI. The digestion mixture is incubated at 37•c for 6 hours (or overnight) in an 
eppendorf tube while shaking slowly. 
Two controls are performed per digestion in order to assess its completeness. These include 10 JLI of the 
digestion mixture supplemented with 16 JLg of bacteriophage A DNA as first control and 10 JLI digestion mixture 
supplemented with 16 JLg of plasmid DNA containing an insert with many different restriction enzyme sites as 
second control. These control digests are incubated overnight at 37 • C in eppendorf tubes together with the sam pie 
digests. After the incubation the control digests are evaluated for completeness of digestion as follows. One 
volume of TES buffer (10 mM Tris-HCI, pH 7.5; 5 mM EDTA; 0.1% SDS) is added to both control tubes. 
Subsequently two volumes of phenol extraction buffer are added. After mixing and centrifugation (3 min at 15,000 
gin a high-speed microcentrifuge; Centra-M, International Equipment Company, Needham, MA) the water phases, 
completed with 5 JLI of loading buffer with Orange Gas tracking dye (20% ficoll; 10 mM Tris-HCI, pH 7.5; 0,1% 
Orange G), are run in a 0.7% agarose gel in TAE buffer (40 mM Tris; 10 mM EDTA; adjusted to pH 8.2 with glacial 
acetic acid), containing ethidium bromide (0.5 JLgjml; Serva Fein Biochimica, Heidelberg, FRG) to stain the DNA. 
After running the gel at 80-100 V for 1-2 hours, the resulting banding pattern is visualized with UV light ( -300 
nm) (Figures 2A and 2B). If the banding pattern indicates that the digestion is complete, it is assumed that also the 
digestion of the human DNA sample is complete. If the digestion of the A DNA andjor plasmid DNA appears to 
be incomplete, additionally 100 units of restriction enzyme are added to the human DNA digestion mixture, followed 
by a second incubation for a few hours or overnight (depending on the degree of incompleteness of digestion). 
Also this second digestion is checked by parallel incubations with A DNA and plasmid DNA. 
When the digestion of the human DNA sample is assumed to be complete, a phenol extraction is performed 
by adding SDS (0.1% final concentration), EDTA (5 mM final concentration) and an equal volume of phenol 
extraction buffer to the eppendorf tube. After centrifugation (3 min at 15,000 g) the water phase is isolated and the 
DNA is precipitated by adding 0.1 volume of 2 M NaAc (pH 5.6) and 2 volumes of ethanol (96%)(precipitation 
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Figure 2. Southern blot analysis of the lgH genes of a control DNA sample (r cell leukemia) and four different B 
cell chronic lymphocytic leukemia (B-CLL) samples by use of the restriction enzyme Bg/11 and the JH probe_ A:Bg/11 
control digests supplemented with A-DNA. B: Bg/11 control digests supplemented with plasmid DNA. C: 
Ethidiumbromide stained agarose gel with size-separated Bg/11 restriction fragments of the control DNA sample and 
the four B-CLL samples. The two outer lanes contain size markers: Left: Hindlll digested A-DNA; Right: EcoRI/ 
Hind ill digested A-DNA. D: Photograph of the X-ray film after exposure to the Bg/11 filter, which was hybridized with 
a radiolabeled JH probe. The approximate sizes of the germline band (G) and the rearranged bands are indicated 
in kilobases (kb). 
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overnight at -2o•c or for 30 min at -7o•c). After centrifugation (15 min at 15,000 g) the pellet is washed in ethanol 
(70%), centrifuged again and subsequently air-dried to evaporate all ethanol. The pellet is then dissolved in 20 JI.I 
Hp and 5 JI.I loading buffer with Orange G as tracking dye. 
Agarose gel electrophoresis 
The agarose used for the electrophoretic separation of DNA restriction fragments should be of high quality 
(FMC Rockland, ME; Sigma). The concentration of the agarose depends on the expected sizes of the restriction 
fragments. Generally 0.7% agarose gels are used when one expects relatively small restriction fragments (1-15 kb), 
while 0.5-0.6% agarose gels are used when one expects larger restriction fragments (15-25 kb). If possible, the 
analysis of restriction fragments of > 20 kb should be avoided, because of the difficulty in separating such large 
fragments in conventional gel electrophoresis. For this purpose pulsed field gradient gel electrophoresis is 
recommended (26-29); this technique will not be discussed here. 
Several types of well designed plexiglas electrophoresis equipment are commercially available (e.g. from 
DanKar Corporation, Reading, MA; or from Pharmacia). These usually consist of an electrophoresis tank with an 
accompanying gel tray and several types of slotformers. The gel tray can be used for both pouring as well as 
running the gel, and allows a precise and reproducible placing of the slot formers. The top and the bottom side 
walls of the gel tray are carefully sealed and the slot former is placed at the appropriate position. 
The agar is dissolved in TAE electrophoresis buffer, containing ethidium bromide (0.5 JI.g/ml), by bringing it 
to boil in a microwave oven. The agarose is then cooled to approximately 5o•c before pouring the gel in order 
to prevent the opening of the seams of the plexiglas gel tray. It is important that the gel tray is placed at a precisely 
horizontal position during pouring and congealing of the gel. After the gel is completely set (30-45 min at room 
temperature) the slot formers and the tray seals are carefully removed. The gel tray is submerged in the electro-
phoresis tank; the TEA electrophoresis buffer should be sufficient to cover the gel with a fluid layer of 3-5 mm. 
The digested DNA samples can now be loaded into the slots of the gel; the two outer slots are used to load 
A-DNA restriction fragments as size markers. If the expected sizes of the restriction fragments are between 1 and 
15 kb, one should use Hindiii-EcoRI digested A-DNA and Hindlll digested A-DNA as size markers (Figures 2C and 
3). If the expected restriction fragments are between 15 and 25 kb, also other A-DNA restriction fragments should 
be used, e.g. Stul, Xhol, XholjNael or XholjKpnl digested A-DNA (Figure 3). 
Electrophoresis is performed at 30-40 V overnight (about 15 hours) with a precisely horizontal position of the 
tank. When the Orange G tracking dye has run for 18-20 em, the electrophoresis is stopped and the gel is in-
spected by use of transillumination with UV light of -300 nm (TM20 UV-transilluminator; UVP, San Gabriel, CA). 
Photographs of the gel can be made with a polaroid camera (Polaroid MP-4 Land-Camera; Polaroid, Cambridge, 
MA) or a reflex camera with macro-objective (Nikon FM2 camera with an E2 focusing screen and a 55 mm 
micro-Nikkor 2.8 objective; Nikon, Tokyo, Japan) using Polaroid 667 film for the polaroid camera or IIford PAN F 
50 ASA film for the reflex camera (1). During photography a UV ruler (Diversific Biotech, Newton Centre, MA) is 
placed along the gel for future estimation of the sizes of rearranged and germline bands (Figure 2C). 
Blotting of the restriction fragments to a membrane 
After size fractionation, the restriction fragments are blotted onto a nitrocellulose membrane or a nylon 
membrane (1 ,25). We prefer nylon membranes because of their high mechanical strength and chemical resistance, 
which permit both the use of highly stringent assay conditions and repeated hybridizations. Several types of nylon 
membranes are commercially available (e.g. Nytran 13N membranes from Schleicher and Schuell, Dassel, FRG; 
Gene Screen nylon membranes from New England Nuclear, Boston, MA; Biodyne nylon membranes from Pall 
Ultrafine Filtration Corporation, Glen Core, NY). The nylon membrane is wetted thoroughly in distilled water and 
subsequently soaked in transfer buffer until use. 
In order to achieve an even transfer of small and large restriction fragments, the DNA is fragmentated before 
blotting by an acid and a subsequent alkaline treatment of the gel (1 ,25). First, the gel is immersed in 0.25 M HCI 
for 10 min at room temperature, while shaking gently. Second, the gel is soaked twice in the alkaline solution (1.0 
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Figure 3. Size markers for agarose gel electrophoresis of restriction fragments. HindllljEcoRI (H/E) digested 
A-DNA and Hindlll (H) digested A-DNA can be used as size-markers for calculation of the sizes of restriction 
fragments between 1 and 15 kb. Stul (S) digested A-DNA, Xhol (X) digested A-DNA, XholjNael (X/N) digested 
A-DNA, and XholjKpnl (X/K) digested A-DNA can be used as size markers for calculation of the sizes of restriction 
fragments between 15 and 25 kb. 
M NaCI; 0.5 M NaOH) for 15 min at room temperature while shaking gently. The alkaline solution also denatures 
the DNA, which is necessary for the subsequent hybridization procedure. After the alkaline treatment the gel is 
neutralized by soaking in neutralization buffer (0.5 M Tris, pH 7.4; 1.5 M NaCI) for 2 x 20 min while shaking gently. 
Finally the gel is soaked for 15 min in transfer buffer (10 x SSC: 1.5 M NaCI; 150 mM C6H5Na30 7, pH 7.0). 
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The fragmentated DNA is transferred to the nylon membrane by the capillary blotting method via the mass 
flow of transfer buffer through the agarose gel to the absorbent layer of paper on the top of the gel (1 ,25). For 
this purpose a piece of GB004 blot paper (Schleicher and Schuell) is placed on a glass plate, the sides of the blot 
paper being draped into the transfer buffer reservoir. The gel is placed on the blot paper, followed by the prepared 
nylon membrane and eight layers of 3 mm Chr Whatmann paper (Whatmann, Maidstone, UK), which are cut to 
fit the gel and soaked in the transfer buffer. A 5-1 0 em stack of paper towels is placed on top, followed by a glass 
plate and a weight of 1/2 - 1 kg to secure the blot. During the set-up of the blot all air-bubbles should be carefully 
removed from each layer by rolling a glass rod over the surface. 
The blotting requires 2-4 hours at room temperature, but is generally carried out overnight. After the blotting 
the nylon membrane is washed in 10 x SSC, air dried for 2 hours and baked in an oven at 80°C for 2 hours. 
Hybridization with 32P-Iabeled DNA probes 
Hybridization of the membrane-bound DNA involves three essential steps: A, prehybridization to block 
non-specific hybridization of the probe to the membrane; B, hybridization with the 32P-labeled probe; C, stringent 
washes to eliminate non-specific binding of the probe (1 ,30). 
The nylon membrane is first thoroughly wetted in 0.5 M NaHPO 4. Prehybridization with 50 ml hybridization 
mixture is carried out in a plastic box with a lid at 65 o C for 1/2 to 1 hour. The hybridization mixture consists of: 
0.5 M NaHP04 pH 7.2, 1% BSA Fraction V (Boehringer Mannheim), 1 mM EDTA, 3% SDS and 200 tLgfml sheared 
salmon sperm DNA. 
Subsequently, the 32P-labeled genomic lg orTcR probe (see next section) is added to the mixture. The probe 
has to be denatured before use by boiling in TES buffer for 3 min and immediate cooling down on ice. The 
hybridization is performed overnight at 65°C, while shaking gently. During the prehybridization and the hy-
bridization, the membrane(s) should be submerged completely and no air-bubbles should be present under or 
between the membrane(s). 
After hybridization the membrane is washed once in wash buffer 1 (40 mM NaHP04, pH 7.2; 2% SDS; 1 mM 
EDTA; 0.5% BSA) for 5 min at 60-65°C, followed by eight washes in wash buffer 2 (40 mM NaHP04, pH 7.2; 1% 
SDS; 1 mM EDTA) for 3-5 min at 60-65 o C. Subsequently the membrane is rinsed with 100 mM NaHPO 4 (pH 7.2) 
and the excess of buffer is removed by briefly placing the membrane between two paper layers. Finally the 
membrane is sealed in a plastic bag, ready for X-ray film exposure. 
Film exposure 
The sealed membrane is placed in a cassette with an X-ray film and an intensifying screen. For this purpose 
we generally use Fuji NIF-RX films (Fuji Photo Film Co., Japan) or the more sensitive Kodak X-Omat AR films 
(Eastman Kodak Company, Rochester, NY). The exposure is performed at -70°C for 1 - 4 days. The optimal 
exposure time depends on the type of DNA probe and the quality of the 32P-labeling, and should be determined 
empirically. 
Probe removal for rehybridization 
Hybridized DNA probes can be removed easily from nylon membranes without loss of the transferred DNA 
fragments. This enables repeated hybridizations of a single membrane with different DNA probes (30). This may 
be important when only a restricted quantity of DNA is available. 
The membrane is washed in 50% formam ide and 6 X SSC for 30 min at 65 o C, rinsed in 3 X SSC, soaked in 
0.1 M NaHPO 4, dried and sealed in a plastic bag for storage or directly used for rehybridization. In the latter case 
an X-ray exposure may be performed in order to exclude the presence of residual 32P-Iabeling on the membrane. 
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ISOLATION AND RADIOLABEUNG OF PROBES 
The DNA probes used for Southern blot analysis of the lg and TcR genes are genomic 
sequences, complementary to segments directly involved in the rearrangements of these 
genes. The majority of the probes are available as inserts in plasmids. 
Plasmids are extrachromosomal, circular, double-stranded DNA molecules, which can be 
artificially transferred into bacteria. This process is called transformation. The various types of 
laboratory plasmids contain genes coding for selection markers, such as resistance to 
antibiotics (e.g. ampicillin and tetracycline) as well as a DNA segment with several closely 
spaced restriction sites (the so-called polylinker) into which foreign DNA (e.g. lg or TcR probes) 
can be inserted (1). 
Plasmid-transformed bacteria allow a large scale growth of the plasmids, which can 
subsequently be isolated. The inserts are cut out, purified, radiolabeled and used as probe for 
Southern blot analysis. Several aspects of the isolation of probes will be described. 
Transformation of bacteria with plasmids 
Plasmid transformation of Escherichia coli (E. coli) can be performed in the presence of divalent cations (e.g. 
CaC12) at low temperatures (31). A variety of factors may improve the transformation frequency obtained with 
divalent cations alone, e.g. brief exposure of the bacteria-plasmid mixture at 42 o C (32). 
Freshly isolated E. coli colonies grown with MgCI2 are dissolved in 150 J.LI of 1 00 mM CaCI2 at 4 o C for 2 hours 
in an eppendorf tube. Subsequently 50 J.LI of 100 mM CaCI2 with 20-50 ng of plasmid (containing the appropriate 
insert) are added to the bacteria. This mixture is first incubated for 30 min at 4 o C, then for 1 /2 to 1 min at 42 o C 
and finally for 2 min at 4 o C. Next, 800 J.LI of SOC-medium are added, followed by an incubation for 45 min at 
37°C. SOC-medium consists of 2% (wjv) Bacto-tryptone (Difco, Detroit, Ml), 0.5% (wjv) Bacto-yeast extract 
(Difco), 10 mM NaCI, 2.5 mM KCI, 10 mM MgCI2, 10 mM MgS04 and 20 mM glucose. The mixture is then 
centrifuged (30 seconds at 15,000 g), the supernatant is decanted and the bacteria pellet is resuspended in the 
remaining medium. The bacteria are plated and cultured overnight on L-Broth agar, supplemented with antibiotics 
(e.g. ampicillin or tetracycline, depending on the resistance of the plasmid). L-Broth agar consists of 1% 
Bacto-tryptone, 0.5% Bacto-yeast extract, 0.5% NaCI and 1.5% Bacto-agar (Difco), adjusted to pH 7.2 with NaOH. 
If the transformation is successful, colonies will be visible after an overnight culture at 37° C. 
Evaluation of plasmid transformation 
To evaluate whether the growing colonies have been transformed correctly, six colonies are picked and grown 
in 5 ml L-Broth medium (same composition as L-Broth agar, but without agarose) at 37°C overnight. A part of 
each culture {450 J.LI) is supplemented with 50 J.LI of 10 x Hogness (36 mM K2HP04; 13 mM KH2P04; 20 mM 
C6H5Na30 7; 10 mM MgS04; 44% glycerol) and stored at -70°C. 
The remaining of each culture is tested for the presence of the plasmid with insert as follows. After 
centrifugation (5 min, 2000 g) bacteria are lysed in 200 J.LI Maxiprep (50 mM glucose; 25 mM Tris-HCI, pH 7.5; 10 
mM EDTA), completed with 400 J.LI of 0.2 M NaOH and 1% SDS. Subsequently, 200 p,l of 3M NaAc (pH 4.8) is 
added in order to precipitate the bacterial DNA. After centrifugation (3 min, 15,000 g) the supernatants with the 
plasmid DNA are collected and 0.5 ml of isopropanol is added to precipitate the plasmid DNA. The tubes are 
centrifuged again {3 min, 15,000 g), the supernatants are discarded and the pellets are washed in ethanol (70%), 
air-dried and dissolved in 200 p,l distilled water. Subsequently RNase is added to a final concentration of 200 J.Lgjml, 
followed by an incubation at 37°C for 30 min. Then EDTA (5 mM final concentration) and SDS (0.1% final 
concentration) are added to each tube and a phenol extraction is performed (see above). The water phases are 
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isolated and a NaAcjethanol precipitation is performed by adding 0.1 volume of NaAc (2 M, pH 5.6) and 2 volumes 
of cold (-20 o C) ethanol (96%). After centrifugation the pellets are washed in ethanol (70%), air-dried and dissolved 
in 1 00 p.l distilled water. 
About 20 p.l of each isolate is mixed with 0.1 volume of 10 x digestion buffer (the type of digestion buffer 
depends on the type of restriction enzyme; see above) and 10 units of the appropriate restriction enzyme is added 
to cut out the inserts from the plasmids. After an incubation of 2-4 hours at 37° C, EDTA (5 mM final concentration) 
and SDS (0.1% final concentration) are added, followed by a phenol extraction. The water phases of the six tubes 
are mixed with 5 p.lloading buffer with Orange Gas tracking dye and run on a 0.7% agarose gel, containing 0.5 
p.gjml ethidium bromide. Hindiii-EcoRI digested >..-DNA is used as size marker. After running the gel at 80- 100 
V for 1-2 hours the gel is inspected by use of transillumination with UV light (300 nm). If the transformation is 
successful and if the plasmid isolation as well as the restriction enzyme digestion have been performed properly, 
in most cases two bands will be visible: a plasmid band and an insert band. 
Large scale growth of plasmids 
A culture of the plasmid-transformed bacteria colony is started in 5 ml of L-Broth medium, supplemented with 
antibiotics (selected as the basis of the resistance of the plasmid) and incubated at 37°C for 3-4 hours while 
shaking. This culture is transferred to one liter of L-Broth medium with antibiotics and incubated overnight at 37° C 
while shaking (1). 
Nine ml of the large scale culture are mixed with 1 ml of 10 x Hogness and stored at -70°C in 1 ml vials for 
future cultures. The remaining of the culture is centrifuged (1 0 min, 5000 g). The bacteria-pellet is lysed in a mixture 
of 40 ml Maxiprep (50 mM glucose; 25 mM Tris-HCI, pH 7.5; 10 mM EDTA) and 80 ml of 0.2 M NaOH and 1% 
SDS. After mixing gently, the bacterial DNA is precipitated by adding 40 ml of 3 M NaAc (pH 4.8). After centrifuga-
tion (10 min at 5000 g) the supernatant is mixed with 0.6 volume of isopropanol to precipitate the plasmid DNA. 
The precipitated plasmid DNA is centrifuged (1 0 min, 5000 g) in a Sorvall centrifuge (Sorvall RC5C with GSA 
rotor; Du Pont Co., Wilmington, DE). The pellet is air-dried and dissolved in 9 ml of 10 x TE buffer (100 mM 
Tris-HCI, pH 7.5; 10 mM EDTA). Subsequently 10.2 g of cesium chloride and 1 ml of ethidium bromide (5 mgjml) 
is added. This mixture is transferred to a special ultracentrifuge tube (e.g. 11.5 ml Ultracrimp sealable tube; Du 
Pont) for overnight centrifugation in a Sorvall OTD75B Ultracentrifuge with a T1270 rotor (DuPont) at 20°C and 
a rotor speed of 50,000 rpm. After centrifugation the top of the tube is performed to admit the entrance of air. 
Subsequently, the lower band, containing the circular plasmid DNA, is collected by puncturing the side of the tube 
just below the plasmid band by use of a 21-gauge needle; contamination of the plasmid DNA with material from 
other bands should be avoided. One volume of distilled water and two volumes of ethanol (96%) are added to 
precipitate the plasmid DNA (during 15 - 30 min). After centrifugation (10 min; 2000 g), the pellet is washed in 
ethanol (70%), air-dried and dissolved in 500 p.l distilled water containing EDTA (5 mM final concentration) and 
SDS (0.1% final concentration), followed by a phenol extraction. The water phase is transferred to an eppendorf 
tube and a NaAc-ethanol precipitation is performed by adding 0.1 volume 2 M NaAc (pH 5.6) and 2 volumes of 
cold (-20°C) ethanol {96%). After centrifugation (5 min at 15,000 g) the pellet is washed in ethanol (70%), air-dried 
and dissolved in 500 p.l distilled water. Then RNase is added to a final concentration of 200 p.gjml, followed by 
an incubation of 30 min at 37°C. Afterwards EDTA (5 mM final concentration) and SDS (0.1% final concentration) 
are added, followed by a phenol extraction. The plasmid DNA in the water phase is precipitated by use of 0.1 
volume of 2M NaAc (pH 5.6) and 2volumes of cold (-20°C) ethanol (96%). After centrifugation the pellet is washed 
in ethanol (70%), air-dried and dissolved in 100-400 p.l TE buffer (10 mM Tris-HCI, pH 7.5; 1 mM EDTA). 
Isolation of inserts from plasmids 
Approximately 50 p.g of plasmid DNA (with the appropriate lg or TcR probe as insert) is mixed with 0.1 volume 
of 10 x digestion buffer (selected according to the type of enzyme) and 50 to 1 oo units of the appropriate 
restriction enzyme to cut out the insert from the plasmid. The final volume is usually -100 p.l. This mixture is 
incubated at 37 o C for 3-4 hours or overnight. 
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Figure 4. Isolation ofthe human JH probe. After digestion with the restriction enzymes EcoRI and Bg/11 the plasmid 
(pBR328) and insert fragments (including the JH probe) are separated in an 0.7% agarose gel. A: Ethidium bromide 
stained agarose gel of size-separated plasmid and insert fragments. B: The band containing the JH probe (2.5 kb) 
is cut out of the gel. 
In order to evaluate the degree of restriction enzyme digestion, 2 f.J,g of plasmid is taken from the incubation 
mixture and added to 16 fJI of TES buffer (1 0 mM Tris-HCI, pH 7.5; 5 mM EDTA; 0.1% SDS) and 20 f.Ll of phenol 
extraction buffer. After the phenol extraction, the water phase is mixed with 5 J.LIIoading buffer (containing Orange 
G) and loaded in a 0.7% agarose gel (containing 0.5 J.Lg/ml ethidium bromide to stain the DNA). After running the 
gel for 1-2 hours at 80 - 100 V the banding pattern is evaluated by use of UV light. If the digestion appears to be 
incomplete, additional restriction enzyme is added to the incubation mixture and the incubation is prolonged for 
several hours (depending on the degree of incompleteness of digestion) as already discussed. 
If the digestion is complete, EDTA (5 mM final concentration) and SDS (0.1% final concentration) are added 
to the digestion mixture and a phenol extraction is performed. The water phase (-100 fJI) is mixed with 25 J.LI 
loading buffer (containing Orange G) and loaded into a broad slot (about 3-5 em) of a 0.7% agarose gel. Both the 
gel and the electrophoresis buffer contain 0.5 f.J,gjml ethidium bromide. Electrophoresis is performed at 80 - 100 
V until the plasmid band and the insert band are sufficiently separated to cut out the latter band with a sterile 
scalpel blade (Figure 4). The probe is electrophoretically recovered from the agarose gel fragment by using a se-
paration chamber specially designed for this purpose (Biotrap; Schleicher and Schuell) at 100 V overnight. The 
concentration of the probe is estimated with ethidium bromide staining by comparing it to standard DNA concen-
trations using UV light. 
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Radiolabeling of DNA probes 
DNA probes are usually radiolabeled by either nick-translation (33,34) or the Klenow-oligo-
nucleotide method (35). 
In the nick-translation method E. coli DNA polymerase I is used to replace preexisting 
nucleotides with radioactive nucleotides (33,34). E. coli DNA polymerase I, by virtue of its 5' 
to 3' polymerase activity, adds nucleotides to the 3' hydroxyl terminus that is created when 
one strand of a double-stranded DNA molecule is nicked (e.g. with DNase 1). E. coli DNA poly-
merase I can also remove nucleotides from the 5' side of the nick, due to its 5' to 3' 
exonucleolytic activity. The elimination of nucleotides from the 5' side and the sequential 
addition of nucleotides to the 3' side results in the movement of the nick along the DNA (nick 
translation). It is therefore possible to prepare radiolabeled probes by replacing the preexist-
ing nucleotides with 32P-Iabeled nucleotides. 
The Klenow-oligonuc/eotide method is based on the fact that oligonucleotides can serve 
as primers for copying single stranded templates in the presence of DNA polymerase (35). In 
the large fragment of E. coli DNA polymerase I (the Klenow fragment) the 5' to 3' polymerase 
activity is preserved, while the 5' to 3' exonucleolytic activity is lost, preventing the degrada-
tion of oligonucleotides. Therefore, in the presence of oligonucleotides (e.g. hexadeoxyribonu-
cleotides) Klenow fragments allow the copying of DNA probes, after they have been denatured 
(e.g. by boiling). If 32P-Iabeled nucleotides are added during the process, all copies of the 
probe will be radiolabeled. 
In our laboratory, we prefer to use the Klenow-oligonucleotide method for 32P-Iabeling of 
DNA probes, because even one or two 32P-Iabeled deoxynucleotidetriphosphates (dNTP) are 
sufficient to obtain highly labeled DNA probes. In contrast all four types of dNTP have to be 
32P-Iabeled when using the nick-translation method. An additional advantage of the 
Klenow-oligonucleotide method is that over 70% of the 32P-dNTP will be routinely incorporated 
into the probe (35). 
The Klenow-oligonucleotide method is performed as follows. Eleven p.l of distilled water containing about 
50-100 ng of DNA probe are boiled for 3 min to denature the probe and cooled down on ice. Subsequently 4 p.l 
of oligo-labeling-buffer (OLB). which contains unlabeled dGTP and dTTP as well as oligonucleotides (see reference 
35 for a detailed description of the composition of OLB), is added together with 0.8 p.l of 20% BSA (Boehringer 
Mannheim), 2 p.l of (o:32P)-dATP, 2 p.l of (o:32P)-dCTP (Amersham) and 2-4 units of Klenow (Promega). This mixture 
is incubated for 3-5 hours at room temperature. The reaction is stopped by adding 80 p.l of TES buffer (10 mM 
Tris-HCI, pH 7.5; 5 mM EDTA; 0.1% SDS). 
The radiolabeled probe is separated from the unincorporated dNTP on a small Sephadex G-50 column (1). 
For this purpose the bottom of a 1 ml disposable syringe is plugged with a small amount of sterile glass wool and 
subsequently 0.9 ml of Sephadex G-50 (Pharmacia) equilibrated in water is added. The needle of the syringe is 
pricked through the cap of an eppendorf tube (the cap should have additional perforations to let out air during cen-
trifugation). The total column is placed in a glass tube (Corex tube, Du Pont) and centrifuged for 1 min at 500 g. 
This removes the excess of water and packs the Sephadex. Extra Sephadex is added, followed by centrifugation, 
until the packed column reaches the 0.9 ml mark. After replacing the eppendorf tube the reaction mixture is loaded 
onto the column and centrifuged (1 min at 600 g). Additional 100 p.l of TES buffer might be loaded and centri-
fuged for further probe recovery. 
The 32P-Iabeled DNA probe in the eppendorf tube is boiled for 3 minutes and subsequently cooled down on 
ice. Now the probe is ready for hybridization. 
150 CHAPTER3.3 
IMMUNOGLOBUliN PROBES AND T CEll RECEPTOR PROBES 
Since J gene segments are usually involved in the rearrangements of lg and TcR genes, 
these can be detected by using probes complementary to the 3' side of the J regions. The use 
of C region probes can also be informative, when the recognized sequences reside on the 
same restriction fragment as the J gene segments (see below). C region probes may also give 
valuable information about changes in C regions, such as lgH class switch rearrangements or 
deletions. 
When lg or TcR gene analysis is performed for diagnostic purposes, the investigation of lgH 
andjor TcR-.8 genes is usually sufficient. In more complicated cases the analysis of the lgl 
genes andjor TcR--y and TcR-o genes may be necessary. The analysis of the TcR-a gene 
complex is difficult, because more than ten Ja probes may be needed to analyse the complete 
Ja region (36,37), which consists of a long stretch (> 80 kb) of about 55 Ja gene segments 
(38-40). The availability of detailed information about the germline configuration of the genes 
and the position of the restriction sites is a prerequisite for an accurate study. In addition the 
appropriate probes must be available. We shall summarize this information for the lgH, lglb 
and lg). genes (Figures 5-11 and Tables 2 and 3) as well as for the TcR-.8, TcR--y and TcR-o 
genes (Figures 12-15 and Table 4). 
IMMUNOGLOBULIN PROBES 
lgH genes 
Rearrangements of the lgH genes are detectable with a JH probe (Figure 5) after digestion 
with the restriction enzyme Bglll, BamHI or the combination of BamHI and Hindlll. The 
interpretation of results obtained with the enzymes Hind Ill or EcoRI might be difficult, because 
a hypervariable polymorphic (HVP) region is located between the JH region and the first Hind Ill 
and EcoRI sites at the 5' side of the JH region (see below; 11). Data about the germline con-
JH Cf.L 
5' Sf1. 3' ojJ12ojJ345ojJ6 1 2 3 4 
< HVP region DIIDIIIU ~ ,.,.1 I I ~ I I 
------1 I II E H 8 Bg BgH E E E BH 
-2 kb JH probe Cf1. probe 
Figure 5. Organization of the J and Cp, regions of the human lgH genes (references 11,41-44). The locations of 
the relevant EcoRI (E), Hindlll (H), Bam HI (B) and Bg/11 (Bg) restriction sites are indicated. Also the location of the 
hypervariable polymorphism (HVP) region at the 5 'side of the JH region as well as the Cp, switch region (SJJ.) are 
indicated (references 11 and 42). The solid bars represent the JH probe (ref. 41) and the Cp, probe (ref. 43). 
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Figure 6. Organization of the CH regions of the human lgH genes (50-63). The locations of the relevant EcoRI (E), Hindlll (H) and BamHI (B) restriction sites are 
indicated. The polymorphic Hindlll and EcoRI sites in the Ca2 gene, which are associated with the A2m(2) allotype, are indicated with an asterisk (16). Also the 
polymorphic EcoRI site in the C"(4 gene is marked (17). The polymorphic BamHI sites in the C"(2, C"(4 and 1/J'Y genes are not given in this figure, but are described 
by Bech-Hansen and colleagues (14,15,17). The pseudo 'Y (1/J'Y) gene and pseudo £1 (l/Jt:1) gene are indicated as open boxes. The shaded areas indicate the 
approximate position of the CH switch regions (s) (16,42,54,60). The solid bars represent the CJ.I probe (43), the C"f probe (53), the Ca probe (56,60) and the Ct: probe 
(60). 
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TABLE 2. Genomic probes for the detection of rearrangements and deletions in lgH genes. 
DNA probe8 size of insert restriction enzymes approximate size of germline restric-
(code name) in kb (restric- used for digestion tion fragments in kb (exon content 
tion enzymes) of genomic DNA of restriction fragment) 
JH probe 2.5 Bg/11 3.9 
(subclone of H24)b (EcoRI-Bg/11) BamHijHindlll 6.0 
Hindlll0 9.5° 
EcoRI0 16.0° 
Bam HI 16.5 
Cp. probe 1.2 Bam HI 16.5 
(subclone of .\C75)d (EcoRI-EcoRI) Hind ill 11.5 
C-y probe 3.1 Bam HI 12.5 (C-y1) 
(subclone of ,\HG4.1)d (Hindiii-EcoRI) 13.5 or 25e (C12) 
11.8 (C"f3) 
9.0 or 9.4e (C-y4) 
8.8 or 10.0e (1/J-y) 
EcoRI 26.5 (C11) 
23.5 (C12) 
21.0 (C13) 
20.0 (or 11.0 and 9.0)e (C14) 
17.0 (1/J-y) 
Hind ill 7.8 (C-y1, C-y3 and 1/J-y) 
6.3 (C14) 
6.0 (C-y2) 
Ca probe 4.3 Bam HI 17.0 (Ca1) 
(subclone of Hua1)1 (Xhoi-BamHI) 16.0 (Ca2) 
EcoRI 25 (Ca1) 
30 (or 8.0)9 (Ca2) 
Hind Ill 18.3 (Ca1) 
18.7 (or 8.0)9 (Ca2) 
Pstlh 1.2 (Ca1) 
2.0 (Ca2) 
CE probe 2.6 Bam HI 2.6 (CE) 
(subclone of 38A)1 (BamHI-BamHI) 6.0 (1/J€1) 
9.0 (1/J€2) 
EcoRI 30 (or 22)9 (CE) 
25 (1/J£1) 
(1/J€2) 
Hind Ill 18.7 (or 10.7)9 (CE) 
18.3 (1/J€1) 
8.5 (1/J€2) 
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a. The various probes are presented in Figure 5 (JH and Cp. probes) and Figure 6 (CH probes). 
b. Dr. T. Honjo (Kyoto Japan) kindly provided the JH probe (ref. 41}. 
c. The Hind ill and £coR! germline restriction fragments of the JH region may vary in size due to the presence of a hypervariable polymorphic 
region at the 5' side of the JH region (ref. 11). 
d. Dr. T.H. Rabbitts (Cambridge, UK) kindly provided the Cp. probe (ref. 43} and the C7 probe (ref. 53). 
e. BamHI and £coR! restriction fragment polymorphisms as described by Bech Hansen and colleagues (ref. 14,15 and 17}. 
f. Dr.Ph.Leder (Boston,MA) kindly provided theCa probe (ref. 56 and 60} and the C€ probe (ref. 60). 
g. £coR! and Hindlli restriction fragment polymorphisms; the presence of these restriction sites is associated with the A2m(2) allotype of 
the Ca2 gene (ref. 16}. 
h. The Psti restriction sites are not indicated in Figure 6, but can be found in ref. 16. 
figuration of the JH and Cfl- gene region, the JH probe and the sizes of the germline restriction 
fragments are summarized in Figure 5 and Table 2 (II ,41-44). 
lgH class switches and the accompanying CH gene deletions can be studied with CH region 
probes (45-48). Although a Oy3 specific probe, recognizing the Oy3 hinge region, has been 
isolated (49), all other available C1, Co: and Cc probes cross-hybridize to CH region (pseudo) 
genes of the same lgH class (50-62). Particularly in case of C1 probes this results in multiple 
bands, of which the germ line patterns are complex due to various polymorphisms (see below 
and Table 2)(14-17). The investigation of lgH class switches has an additional complication, 
because an lgH class switch also occurs in the allelically excluded lgH gene in 75% of the lgG 
and lgA expressing B cell tumors (47). Such class switches are variable: i.e. 5' of or 3' of the 
CH region of the productive lgH gene allele (47). Nevertheless in many B cell malignancies it 
will be possible to study lgH class switches by the combined use of a JH probe and a CH probe 
(47,48). In case of restriction fragment polymorphisms, this study is facilitated by the availability 
of germline DNA from the same individual. 
Germline Bam HI restriction fragments, which contain the complete JH region, span the Cfl-
gene and its switch region. No BamHI restriction sites are located between the other CH 
regions and their accompanying switch regions (Figure 6)(42,43,50-63). Therefore JH gene 
segments and a switched CH gene are located on the same rearranged BamHI restriction 
fragment. This can be demonstrated by sequential hybridization of the same Bam HI filter with 
the JH and the appropriate CH probe (47,48). Similarly, in EcoRI digests the JH gene segments 
and the switched CH genes are located on the same restriction fragment. However, most 
germline and rearranged CH gene containing EcoRI fragments are large (generally > 20 bands, 
of which the germline patterns are complex due to various polymorphisms (see below and 
Table 2) (14-17). The investigation of lgH class switches has an additional complication, because 
an lgH class switch also occurs in the allelically excluded lgH gene in 75% of the lgG and lgA 
expressing B cell tumors (47). Such class switches are variable: i.e. 5' of, equal to, or 3' of the 
CH region of the productive lgH gene allele (47). Nevertheless in many B cell malignancies it 
will be possible to study lgH class switches by the combined use of a JH probe and CH probe 
( 4 7 ,48). In case of restriction fragment polymorph isms, this study is facilitated by the availability 
of germline DNA from the same individual. 
Germline Bam HI restriction fragments, which contain the complete JH region, span the Cfl-
gene and its switch region. No BamHI restriction sites are located between the other CH 
regions and their accompanying switch regions (Figure 6)(42,43,50-63). Therefore JH gene 
segments and a switched CH gene are located on the same rearranged BamHI restriction 
fragment. This can be demonstrated by sequential hybridization of the same Bam HI filter with 
the JH and the appropriate CH probe (47,48). Similarly in EcoRI digests the JH gene segments 
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Figure 7. Inherited CH gene deletions. A: Germline organization of the human CH gene regions. B: Nine different 
types of inherited CH gene deletions, which all occur in the C-y3-Ca2 gene cluster: C-y1-C-y4 deletion (64,65), 
C-y1-C-y2 deletion (66), C-y1 deletion (66), "¢t:1-C-y4 deletion (67,68), "¢E1-"¢-y deletion (65), Ca1-CE deletion (67), 
"¢1-Ca2 deletion (70,71), C-y2 deletion (70,71) and C-y4 deletion (71). 
and the switched CH genes are located on the same restriction fragment. However, most 
germline and rearranged CH gene containing EcoRI fragments are large (generally > 20 
kb)(Table 2)(50,53,54,59,60). 
Deletions of CH genes are detectable in Bam HI and EcoRI digests, and also Hindlll and Pstl 
digests can give additional information (Figure 6 and Table 2). 
It must be emphasized that deletions of one or more lgH-C genes may sometimes occur 
as an inherited aberration. So far, nine different types of inherited lgH-C gene deletions have 
been discovered: all these occur in the C-y3-Ca2 gene cluster and do not involve the Cp,-Co 
gene segment (Figure 7) (64-71 ). It has been estimated that about 3% of individuals is heterozy-
gous for these inherited lgH-C gene deletions (67,71). 
lg~~; genes 
Rearrangements in the lg~~; genes are detectable in BamHI digests with a c,. probe andjor 
a J~~; probe and in Sacl, Hindlll and EcoRI digests with the J~~; probe (Figure 8; Table 3)(72,73). 
In most lg:A + B cells or precursor B cells with rearranged lg:A genes the C~~; gene region or the 
whole J~~;-C~~; gene region is deleted on both alleles (74,75). These deletions are detectable with 
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Figure 8. Organization of the J and C regions as well as the K. deleting element (Kde) region of the human lgK. 
genes (72,73,77,78). The location of the EcoRI (E), BamHI (B), Hindlll (H) and Sacl (S) restriction sites are 
indicated. The shaded area represents the Kde region. The solid bars represent the JK. and CK. probes (72,73) and 
the Kde probe (76,77). 
the Kde probe, which recognizes a gene region (K deleting element; Kde) that rearranges 
during the deletion process (76-78). The Kde probe may be important in cases where additional 
investigations must be performed on samples containing a small malignant SmA + B cell popu-
lation amongst normal cells with germline lgK genes. In such cases, deletions in the lgK. genes 
are likely to be detectable with the Kde probe, while the JK andjor CK. probes may be insuf-
ficient, due to the presence of germline bands from the "contaminating" normal cells. 
lgA genes 
Six CA genes, each preceded by a J gene segment, are located on a 40 kb DNA segment 
(79,80). Two of these CA genes are pseudogenes (~A4 and ~A5), while four are functional (81). 
In addition to this well-established lg>- gene locus several other >- genes have been reported, 
including two pseudogenes and two potentially functional A genes (82-84; Dr. B. Blomberg, 
personal communication). 
In most studies possible rearrangements in the classical lgA gene locus are investigated in 
EcoRI digests with a CA probe (Figure 9). In germline lgA genes without polymorphic 
amplification of the A genes, this results in three bands: 8.3 kb (CA2 and CA3), 14.0 kb (CA 1) 
and 17.0 kb (~A4, ~A5 and CA6){Figure 9 and Table 3). In case of polymorphic amplifications 
of the CA2-CA3 gene segment, other bands will be detectable (Figures 9 and 10 and Table 
3)(12). For a correct interpretation of the banding pattern, it is important to know whether a 
particular band is due to the well-established A polymorphism or to rearrangement. For this 
purpose a probe which detects the polymorphic A bands (A-IVS probe) and, if available, control 
DNA from the same individual should be used (Figure 10)(12). In EcoRI/Hindlll digests the 
occurrence of polymorphic amplification of the CA2-CA3 gene segment is detected as a 5.4 kb 
band, irrespective of the type of polymorphism (Figure 11)(12). This can facilitate the analysis 
of lg>. genes, as demonstrated in 22 lg>.-expressing B cell leukemias. EcoRI digests in 
combination with the CA probe detected rearrangements in 20 of the 22 leukemias, while 
EcoRI/Hindlll double digests allowed detection of lgA gene rearrangements in all 22 lgA + 
leukemias (W.M. Comans-Bitter, unpublished results). 
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Figure 9. Organization of the J and C regions of the human lg.A genes (12,79-81). The EcoRI (E), Bg/11 (Bg) and Hindlll (H) restriction sites are indicated. The l{JA4 
and l{J.A5 genes are presented as open boxes and the shaded areas indicate the approximate positions of the J.A4 and J.A5 genes (81 ). The polymorphic amplifications 
of the C.A2-C.A3 gene segments are presented in the lower part of the figure (12). The solid bars represent the C.A probe (79) and .A-IVS probe (12). 
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TABLE 3. Genomic probes for the detection of rearrangements and deletions in lgL genes. 
DNA probe8 size of insert restriction enzymes approximate size of germline restriction 
(code name) in kb (restric- used for digestion fragments in kb (exon content of rectric-
tion enzymes) of genomic DNA tion fragment) 
lgK genes 
JK probe 1.8 Sac I 1.8 
(from HuK)b (Saci-Sacl) Hind III 5.4 
EcoRI 8.7 
Bam HI 12.0 
CK. probe 2.5 Bam HI 12.0 
{from HuK)b (EcoRI-EcoRI) 
Kde probe 2.5 Bam HI 14.0 (and 2.5)d 
(Kde-Nalm-11.5)c (Hindiii-BamHI) 
lg>. genes 
c>. probe 0.8 kb EcoRI 14.0 (CA1) 
(from Hu>. C2, C3)b (Bg/11-EcoRI) 8.3 (C>-2 and C>.3) 
17.0 (1/J>-4, 1/J>-5 and CA6) 
(13. 7, 19.1 or 24.5 in case 
of c>. polymorphisms)e 
Hindiii/EcoRI 2.7 (C>.1) 
3.7 (C>-2) 
4.6 (CA3) 
5.4 (1/J>-4) 
10.5 (1/J>-5 and CA6) 
(5.4 in case of c>. polymorphisms)e 
A-IVS probe 2.1 EcoRI 8.3 (13.7,19.1 or 24.5 in case 
(from Hu>. C2,C3)b (Hindiii-BamHI) of c>. polymorphisms)e 
Hindiii/EcoRI 3.7 (>-2-IVS) 
4.6 (A3-IVS) 
(5.4 in case of c>. polymorphisms)e 
a. The various probes are presented in Rgure 8 (JK, CK and Kde probes) and Rgure 9 (C.l. and .l.-IVS probe). 
b. Dr. Ph. Leder (Boston, MA) kindly provided the JK probe and CK probe (ref. 72,73) as well as the C.l. probe (ref. 79) and the .l.-IVS probe 
(ref. 12). 
c. Dr. S. Korsmeyer (Saint Louis, MO) kindly provided the Kde probe (ref. 76,77). 
d. The 2.5 kb Hindiii-BamHI Kde probe not only recognizes the K deleting element which rearranges in order to delete CK or JK-CK, but 
also dross-hybridizes to sequences on the long arm of chromosome 2 (2q11). In a BamHI digest these crosshybridizing sequences are 
located on a 2.5 kb fragment (76,77). 
e. Wrthin the lg.l. gene locus a variable amplification of the C.l.2-C.l.3 gene segment may occur. This genetic polymorphism results in 13.7 kb, 
19.1 kb or 24.5 kb bands in case of EcoRI digests as detected by a C.l. probe or .l.-IVS probe (Rgure 1 0) or in a 5.4 kb band in case of 
HindllljEcoRI digests as detected by a C.l. probe or .l.-IVS probe (Rgure 11). 
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Figure 10. Polymorphic amplification of the CA2-C).3 gene segment as detected in EcoRI digests. A: EcoRI 
digested DNA samples with germline I g). genes from different individuals were size fractionated, blotted to a nylon 
membrane and hybridized with a 32P-Iabeled C). probe. In case of germline lg). genes without polymorphic 
amplification of the C;\.2-C;\.3 gene segment, three germline bands are present: 8.3 kb (CA2-CA3), 14.0 kb (C;\.1) 
and 17.0 kb (l/JA4-1/!A5-CA6). If the polymorphic amplification is present, also other bands are detected (13.7 kb, 
19.1 kb and/or 24.5 kb), while the 8.3 kb band is reduced in intensity (polymorphism of one allele) or absent 
(polymorphism of both alleles). B: The EcoRI filter is now hybridized with the A-IVS probe, which detects the 
C;\.2-C;\.3 gene segment. In case of the polymorphic amplification one or two large bands are detectable, while in 
absence of the polymorphism only the 8.3 kb band is detected. C: Schematic diagram of the polymorphic 
amplification of the C;\.2-C;\.3 gene segment. The EcoRI restriction sites and the relevant restriction fragments as 
well as the C). probe and the A-IVS probe are indicated (c.f. reference 12). 
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Figure 11. Polymorphic amplification of the CA2-CA3 gene segment as detected in EcoRijHindlll digests. A: DNA 
samples with germline lgA genes from three different individuals were digested with a combination of EcoRI and 
Hind Ill, size fractionated, blotted to a nylon membrane and hybridized with a 32P-Iabeled CA probe. TheCA 1, CA2, 
CA3,1/JA4 and l/JA5-CA6 gene segments are located on separate restriction fragments of 2.7, 3.7, 4.6, 5.4 and 10.5 
kb, respectively. In case of polymorphic amplification of the CA2-CA3 gene segment (lane 1), the 5.4 kb band is 
stronger than in absence of the polymorphism (lanes 2 and 3). The 2.2, 14.1 and 16.1 kb bands contain CA genes, 
which are located outside the "classical" lgA gene locus (82-84; Dr. B. Blomberg, personal communication). B: 
When the EcoRIJHindlll filter is hybridized with the A-IVS probe, the strong 5.4 kb band only remains in case of 
the polymorphism (lane 1 ). In EcoRI/Hindlll digests all different types of polymorphic amplifications of the CA2-CA3 
gene segment result in the same 5.4 kb band (c.f. Figure 9). 
In both EcoRI and EcoRI/Hindlll digests faint germline bands are detectable with a c;. 
probe. Several of these bands have been demonstrated to represent new A (pseudo) genes 
(82-84; Dr. B. Blomberg, personal communication). 
Despite the complexity of the lg). genes, it will generally be possible to detect their rear-
rangements in large malignant lgA + B cell populations. However, if the clonal lg). + B cell 
population is small, the rearranged lg;. gene bands may be difficult to detect. In such case, the 
Kde probe can be useful for the detection of deletions in lg~~: genes, which occur in most lg;. + 
cells (see above). 
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TABLE 4. Genomic probes for the detection of rearrangements and deletions in the TcR-~, TcR-')' and TeR-eS 
genes. 
DNA probea size of insert restriction enzymes approximate size of germline 
(code name) in kb (restric- used for digestion restriction fragments in kb 
tion enzymes) of genomic DNA (exon content of restriction 
fragment) 
TcR-~ genes 
J~1 probe 4.0 EcoRI 10.5 (J~1 and C~1) (J~1 subclone of C~50)b (Hindlll-Hindlll) Hindlll 4.0 (J~1) 
J~2 probe 1.9 EcoRI 4.1 (7.9)0 (J~2) 
(J/32 subclone of C~47)b (Pvull-Pvull) Hind Ill 7.5 (J~2 and C~2) 
c~ probe 1.1 Bam HI 22.5 (~1 and ~2 genes) (5'C~2 subclone of C~47)b (EcoRl-Hindlll) 
EcoRI 10.5 (J~1 and C~1) 
3.8 (7.9)0 (C~2) 
Hindlll 3.5 (C~1) 
7.5 (J~2 and C~2) 
TcR-')' genes 
J')'2.1 probe 0.2 EcoRI 2.3 (J')'1.1) 
(subclone of p')'C1 C2)d (Hindlll-EcoRl) 1.2 (J')'2.1) 
J')'1.2 probe 1.2 EcoRI 2.5 (J')'1.2) 
(subclone of .A33)d (Hindlll-EcoRl) 
J')'1.3 probe 0.8 EcoRI 1.8 (J')'1.3) 
(subclone of .A33)d (Hindlll-EcoRl) 3.3 (or 1.8)e (J')'2.3) 
Kpnl1 9.0 (all J')'1 genes)1 
16.0 (all J')'2 genes) 1 
C-y probe 0.4 EcoRI9 5.0 (C/'1) 
(C/'1 clone)b (BamHI-BamHI) 6.8 (C/'2) 
Bam HI 20.0 (1'1 genes) 
12.5 (')'2 genes) 
TeR-eS genes 
JcS1 probe 1.5 EcoRI 6.0 and 5.0 (JcS1) 
(pJcSS16)h (Saci-Sacl) Hind Ill 6.0 (JcS1) 
Kpnl 16.0 (JcS1) 
Bam HI 17.5 (JcS1 and JcS2) 
Jc52 pro~e 2.3 EcoRI 5.7 (Jo2) 
(R21XH) (EcoRl-Hindlll) Hind Ill 3.5 (Jo2) 
KpnljBamHl 6.4 (JcS2) 
Bam HI 17.5 (JcS1 and JcS2) 
Kpnl 17.0 (Jo2-Vo3) 
CcS probe . 0.7i BamHljSacl 8.0 (JcS3 and CcS) 
(pCTCRcS2c)' (EcoRI-EcoRI) Bam HI 14.0 (JcS3-VcS3) 
Kpnl 17.0 (Jo2-Vo3) 
Bg/ll 4.5 and 3.1 (CcS and VcS3) 
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a. The various probes are presented in Figure 12 (TcR-.8 probes), Figure 13 (TcR-7 probes) and Figure 15 (TcR-o probes). 
b. Dr. J. Seidman (Boston, MA) kindly provided the J.B1 probe (ref. 86,89), the J.B2 probe (ref. 86,89), the C.B probe (ref. 86) and the C7 
probe (ref. 92,95). 
c. The EcoRI site between the J.B2 gene and C.B2 gene is sometimes partly resistant to digestion. This results in a 7.9 kb band which 
hybridizes to both the J.B2 probe and the C.B probe. 
d. Dr. T. Quertermous (Boston, MA) kindly provided the J72.1 probe, J71.2 probe and the J71.3 probe (ref. 92,95). 
e. In some individuals a polymorphic EcoRI site is present at the 5' side of the J72.3 gene segment, which results in a J72.3 restriction 
fragment of 1.8 kb (Figure 14)(20). 
f. Each rearrangement to any of the J11 or J12 gene segments can be identified with the J11.3 probe, when the DNA is digested with Kpnl 
(ref. 93). 
g. Hybridization of the C7 probe to EcoRI digested DNA is useful for the detection of C71 gene deletions. 
h. Dr. T.H. Rabbitts (Cambridge, UK) kindly provided the Jot probe and the Jo2 probe (ref. 36,104). 
i. Dr. P. van den Elsen (Leiden, The Netherlands) kindly provided the Co probe. This is a eDNA probe, which only contains human Co 
sequences (101). 
T CELL RECEPTOR PROBES 
TcR-,8 genes 
Rearrangements in the TcR-,8 genes are generally detectable by the combined use of a J,B2 
probe and a C,B probe in EcoRI and Bam HI digests. Also the J,81 probe and Hindi II digests can 
give additional information (Figure 12 and Table 4)(85-89). 
The C,B probe recognizes both C,81 and C,82 sequences (90), while J,B probes do not 
cross-hybridize. Rearrangements to the J,81 region are detectable with the C,B probe in EcoRI 
digests or with the J,B1 probe in Hindlll digests. Rearrangements to the J,B2 region can be 
detected with the J,82 probe in EcoRI digests or with the C,B probe in Hindlll digests. 
Importantly, the EcoRI and Hindlll restriction sites in the C,B2 region may be partly resistant 
to digestion (91). Such an underdigestion leads to an extra germline band, not to be mistaken 
for a rearranged one (Figure 12 and Table 4). 
TcR-r probes 
All rearrangements in the TcR-r genes are detectable with the Cr probe in BamHI digests 
(19,92) or with the Jr1.3 probe in Kpnl digests (93). This is based on the capacity of the Cr 
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Figure 12. Organization of the D,B, J,B and C,B regions of the human TcR-,8 genes (85-89). The locations of the 
relevant EcoRI (E), Hind Ill (H) and BamHI (B) restriction sites are indicated. The partly resistant EcoRI and Hindlll 
sites in the C,82 region are indicated with an asterisk (91). The solid bars represent the J,81 probe, J,82 probe and 
C,B probe (86,89). 
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Figure 15. Organization of the D, J and C regions of the human TcR-o genes (24,36,101,104-107). The locations of the relevant Kpnl (K), Hindlll (H), EcoRI (E) and 
BamHI (B) restriction sites are indicated. Only one Sacl (S) site is given; further information on the location of Sacl sites is given in reference 36. The Vo3 gene 
segment is located within 3 kb at the 3 'side of the Co region (1 07). The solid bars represent the Jo1 probe (36, 1 04), the Jo2 probe (36) and the Co probe (1 01). The 
latter probe is a eDNA probe, which only contains Co sequences. 
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Figure 14. Southern blot analysis of 
the TcR-r genes, illustrating the poly-
morphic presence of an EcoRI restric-
tion site at the 5' side of the Jr2.3 
gene segment (20). EcoRI digested 
DNA samples with germline TcR-r 
genes from different individuals were 
size fractionated, blotted to a nylon 
membrane and hybridized to the Jr1.3 
probe (Figure 13). In most individuals 
the Jr1.3 and Jr2.3 gene segments 
reside on restriction fragments with a 
different size {1.8 kb and 3.3 kb, re-
spectively). In some individuals a poly-
morphic EcoRI site is present at the 5' 
side of the Jr2.3 gene segment, which 
results in Jr1.3 and Jr2.3 restriction 
fragments of identical size {20). 
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probe to hybridize to both Cr1 and Cr2 sequences and of the Jr1.3 probe to recognize both 
Jr1.3 gene and Jr2.3 gene segments (92). A detailed analysis of the TcR-r gene rearrange 
ments can be performed with the Jr2.1, Jr1.2, and Jr1.3 probes in EcoRI digests (92). 
Like the Jr1.3 probe, the Jr2.1 probe cross-hybridizes to its equivalent in the TcRr1 locus, 
i.e. the Jr1.1 gene segment (92). Detailed information about the configuration of the TcR-r 
genes and the various TcR-r probes is summarized in Figure 13 and Table 4 (13, 19,21 ,92-96). 
Rearrangements to the Jr2 gene segments will delete the TcR-r1 gene locus. This deletion is 
easily detectable with the Cr probe and the Jr1.3 probe in EcoRI digests, the Cr probe in 
BamHI digests and the Jr1.3 probe in Kpnl digests (Figure 13). 
Two types of polymorphisms in the TcR-r genes have been described. One concerns the 
occurrence of a polymorphic EcoRI site at the 5' side of the Jr2.3 gene segment (Figure 
13)(20). In most individuals this site is absent, which results in a germline Jr2.3 restriction 
fragment of 3.3 kb. If this site is present, the size of the EcoRI restriction fragments of both the 
Jr1.3 and the Jr2.3 gene segments is 1.8 kb (Figures 13 and 14). Therefore, the presence of 
the polymorphic EcoRI site should not be misinterpreted as a deletion of the Jr2.3 gene 
164 CHAPTER 3.3 
segment (Figure 14). The second type of polymorphism concerns the second exon of the C-y2 
gene region, which is duplicated in two-third of alleles and triplicated in one-third of alleles 
(13,21 ,97). However, this polymorphism does not influence the sizes of the germline and 
rearranged restriction fragments in the above described combinations of probes and restriction 
enzymes (Figure 13 and Table 4). 
TcR-o probes 
Most rearrangements in the TcR-o genes involve Jo gene segments (98-101), although V-D 
and D-D joining with germ line Jo genes has been described as well (1 02,1 03). For the detection 
of each rearrangement in the Jo gene region, several combinations of probes and restriction 
enzymes should be used (Figure 15 and Table 4)(24,36, 101, 104-107). 
Rearrangements to the Jo1 gene segment are detectable with the Jo1 probe in EcoRI, 
Hindlll, Kpnl or Bam HI digests. Rearrangements to the Jo2 gene segment can be detected with 
the Jo2 probe in EcoRI and Hindlll digests and, if necessary, they can be confirmed in 
Kpnl/BamHl double digests. The Jo2 probe in a BamHI digest cannot discriminate between 
a rearrangement to the Jo1 or to the Jo2 segment (Figure 15). By using the Co probe in 
BamHI/Sacl double digests it is possible to detect rearrangements to the Jo3 gene segment 
(101). The use of KpnljBamHl and BamHI/Sacl double digests for the detection of rearrange-
ments to the Jo2 and Jo3 gene segments, respectively, prevents that Vo3 gene rearrangements 
are mistaken for Jo2 or Jo3 rearrangements. The Vo3 gene is located on the same germline 
Kpnl fragment as Jo2 and Jo3 and on the same germline BamHI fragment as Jo3 (Figure 15). 
Deletion of TcR-o genes can be detected with the Co probe in any digest. TcR-o gene 
segments can be deleted without rearrangement of the TcR-a genes (98, 108). Such an 
intermediate stage of rearrangement in the TcR-a/o gene cluster can be determined by the 
recently described oRec and lfJJa probes (98, 1 08). 
LIMITATIONS AND PITFALLS OF SOUTHERN BLOT ANALYSIS OF lg AND TcR GENES 
Since Southern blot analysis of lg and TcR genes, has several limitations and pitfalls (Table 
5) the results should always be interpreted with utmost caution. 
Polymorphisms of lg and TcR genes 
Several polymorphisms have been shown to occur in the lg and TcR genes. Some of these 
involve the target sequences of restriction enzymes, resulting in restriction fragment length 
polymorphisms (RFLP). Examples are: 
-Polymorphic Bam HI restriction sites around the lgH-C-y gene regions (14, 15, 17). 
-Polymorphic EcoRI site in the lgH-C-y4 gene segment (Figure 6)(17). 
-Polymorphic Hindlll and EcoRI sites in the Ca2 gene region. The presence of these 
restriction sites is associated with the A2m(2) allotype, which occurs at a low frequency 
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in Caucasians (1-2%), and at a higher frequency in Africans and Asians (50-80%)(16). 
-Polymorphic Bg/11 site at the 5' side of the TcR-C.B2 gene exons (18). 
-Polymorphic EcoRI and Hindlll sites at the 5' side of the TcR-J-y2.3 gene segment (Figures 
13 and 14)(19,20,94). 
A second type of polymorphism results from insertion or deletion of non-coding DNA 
segments and is designated hypervariable (or length) polymorphism (HVP). Such a HVP is 
found at the 5' side of the lgH-J gene region (Figure 5)(11). 
Finally, polymorphic amplifications or deletions of genes or gene segments are reported. 
These are: 
- Inherited deletion of one or more lgH constant genes, which all occur in the C-y3-Ca2 gene 
cluster (Figure 7)(64-71). About 1 - 3% of individuals is heterozygous for such a deletion 
(67,71). 
- Polymorphic duplication of the lgH-C-y2 gene. The frequency of this haplotype is estimated 
to be 0.043 (17). 
-Polymorphic amplification of the C>-2-C>-3 gene segment in the lg>- genes (Figures 9-11). 
The frequencies of allelic duplication, triplication and quadruplication of this gene segment 
are estimated to be 0.05, 0.19 and 0.01, respectively (12). 
- Polymorphic amplification of the second exon of the C-y2 gene segment of the TcR--y 
genes. In two-third of the TcR--y gene alleles this second exon is duplicated, while in the 
remaining one-third this exon is triplicated (Figure 13)(13,19,21). 
The above polymorphisms are the most frequently described, but as yet unreported 
polymorphisms may be found during diagnostic analysis of the lg and TcR genes. It is therefore 
advisable to use germline control DNA and tumor DNA from the same patient. 
TABLE 5. Limitations and pitfalls of the Southern blot analysis of lg and TcR gene rearrangements. 
1. Polymorphisms in lg and TcR genes: 
- restriction site polymorphism (RFLP) 
- hypervariable (or length) polymorphism 
(HVP) 
- polymorphic amplification of genes or 
gene segments 
2. Underdigestion of DNA. 
3. Co-migration of a rearranged band with a 
germline band. 
Underdigestion of DNA 
4. Limited combinatorial diversity of the TcR-"Y 
and TcR-o genes. 
5. Multiple rearranged bands: 
- oligoclonality 
- chromosomal aberrations 
6. Detection limit of the Southern blot technique 
(1-5%). 
Restriction enzyme digestions should always be checked for completeness by running 
parallel incubations with >--DNA and/or plasmid-DNA (see above). Despite these controls, some 
digestions may still be incomplete. Especially the EcoRI site between the J{32 and C/32 gene 
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Figure 16. The £coR! site between the J/32 and C/32 gene segments of the TcR-{3 genes is partly resistant to 
digestion (91, 1 09). A: A germline control DNA sample, a DNA sample from a reactive lymph node as well as DNA 
samples from two lymph nodes with aT cell non-Hodgkin lymphoma (T-NHL) were digested with EcoRI, size 
separated and blotted to a nylon membrane. The membrane was hybridized with the 32P-Iabeled C/3 probe. In the 
lanes of the reactive lymph node as well as in the lane of T-NHL-1 a 7.9 kb band was visible, while in the lane of 
T-NHL-2 a slightly larger band (- 8.2 kb) was detected. B: The EcoRI membrane was also hybridized with the 
32P-Iabeled J/32 probe. Then the 7.9 kb was only present in the lane of the reactive lymph node, while in the two 
T-NHL lanes two rearranged bands were found. This illustrates that on the one hand a 7.9 kb band in an EcoRI 
digest using the C/3 probe may be caused by underdigestion (91), but that on the other hand such a 7.9 kb band 
may be caused by a rearrangement. C: Schematic diagram of the TcR-{3 genes. The locations of the EcoRI sites 
(E) as well as the J/32 probe and the C/3 probe are given. Also the position of the partly resistant EcoRI site and 
the sizes of the various germline bands are indicated. 
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segments of the TcR-.B genes may appear to be partly resistant to digestion (Figure 12)(91, 109). 
This leads to an additional "germline" band of 7.9 kb, which contains both J,B2 and C,B2 gene 
sequences. In completely digested DNA these gene segments are located on separate fcoRI 
fragments of 4.1 kb and 3.8 kb, respectively. The 7.9 kb band may be mistaken for a rear-
ranged band or a polymorphism (11 0-115). Such a misinterpretation can be prevented by 
sequential hybridizations of the EcoRI membranes with the J,B2 probe and C,B probe (91). Both 
probes will hybridize to the 7.9 kb band, if this band is indeed due to underdigestion of the 
DNA. The importance of this approach is illustrated in Figure 16. 
Also the Hindlll site in the C,B2 region of the TcR-.B genes has been reported to be 
sometimes partly resistant to digestion (91). 
Co-migration of a rearranged band with a germline band 
In Southern blot analysis, discrimination between the presence of germline and rearranged 
lg or TcR genes is based upon differences in size of the germline and rearranged bands. 
However, sometimes a rearranged band and a germline band may appear to have similar sizes, 
resulting in co-migration of the bands (Figures 16 and 17). There is little chance of co-migration, 
when the germ line and rearranged bands are small ( < 10 kb), but the likelihood of this event 
increases progressively with the size of the bands. For instance TcR-.B gene rearrangements 
are often difficult to evaluate when studied in Bam HI digests using a C,B probe. 
The risk of misinterpretations due to co-migration of rearranged and germline bands can 
be eliminated, when at least two or even three different restriction enzyme digests are used for 
each probe. In addition, restriction enzymes which do not produce large germline bands should 
be preferred. 
In our laboratory we generally use the JH probe in combination with a Bg/11 digest and a 
BamHI/Hindlll digest for lgH gene analysis; if necessary, also BamHI or EcoRI are used. The 
J,B2 and C,B probe in combination with EcoRI digests and BamHI digests are used for studying 
TcR-.B genes; if necessary, also the J,B1 probe in combination with Hindlll digests is used. 
limited combinatorial diversity of TcR-r and TcR-o genes 
Discrimination between polyclonal and monoclonal lymphoid cell populations is possible 
because in a polyclonallymphoproliferation many different lg or TcR gene rearrangements are 
present, while the lg or TcR gene rearrangements of a monoclonal lymphoproliferation are 
identical (Figure 1). This is the case for lgH, lgx: and lg.A genes as well as for TcR-a and TcR-.B 
genes. However, the combinatorial repertoire of the TcR-r genes and TcR-o genes is limited, 
implying that polyclonal rearrangements of these genes will result in a restricted number of 
rearranged bands (20,92,93,95,96, 101,106,107, 116-120). 
The combinatorial repertoire of the TcR-r genes is determined by fifteen Vr genes (eight 
functional V genes and seven pseudo V genes) and five Jr genes (20,92,95,96, 118). The TcR-o 
genes consist of at least six Vo genes, three Do genes and three Jo genes (106, 107,119, 120). 
Since a large part of the TcR-ro + blood T lymphocytes use Vr9 and Jr1.2 in combination with 
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Figure 17. Southern blot analysis of the lgH genes of a B cell chronic lymphocytic leukemia (B-CLL). DNA from 
a control cell sample and DNA from a B-CLL sample were digested with Bglll (A) and BamHl/Hindlll (B), size-sepa-
rated and blotted to a nylon membrane, which was hybridized with the 32P-Iabeled JH probe. Although two 
rearranged bands were detectable in the BamHljHindlll digest, only one rearranged band was present in the Bg/11 
digest. This suggests that one rearranged band comigrated with the germline band. This interpretation was 
supported by the finding that also in an EcoRI digest (C) two rearranged bands were seen. 
Vo2 and Jo1 (121, 122), it can be assumed that the available TcR--y and TcR-o gene segments 
are not used randomly in normal TcR--yo+ cells. However, TcR--y gene rearrangements in 
normal TcR-a.B+ T lymphocytes as well as most T cell malignancies usually include a random 
use of one of the eight functional V-y genes together with the J-y2.3 or the J-y1.3 gene segment 
(1 01,109, 123-126). This results in a restricted number of rearranged bands as illustrated in 
Table 6 and Figure 18 (93,95, 116, 117). The background of rearranged TcR--y gene bands from 
normal blood T lymphocytes hampers the detection of a clonal T cell population. From Figure 
18 it can be concluded that a clonal T cell population should take up at least 45% of the cell 
sample analyzed to be detectable by TcR--y gene analysis. 
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Figure 18. Analysis of the TcR-r genes of E rosette-separated normal mononuclear blood cells (E+ and E-cells), 
T-ALL cells and a series of artificial mixtures of T-ALL cells and normal blood cells (dilution experiment). The DNA 
samples were digested with EcoRI, size-separated and blotted to a nylon membrane, which was hybridized with 
a 32P-Iabeled Jr1.3 probe. In the E- cells (non-T cells) only the two germline bands were found, while in the e 
cells (T cells) several rearranged bands occurred. In each T-ALL lane two rearranged bands are present. These 
bands have the same size as the rearranged bands in the T cell fraction of PB. In the artificial mixtures of the 
dilution experiment the "background" of rearranged bands of the normal T cells hampers the detection of the 
rearranged bands of the leukemic cells. 
In most TcR-a.B+ cells both alleles of the TcR-5 genes are deleted (36,98-101) and the 
frequency of TcR-r5+ cells in blood is relatively low (127, 128). This would imply that the back-
ground of rearranged TcR-5 gene bands from normal blood T lymphocytes is low. However, 
it has still to be demonstrated to what extent Southern blot analysis of the TcR-5 genes is useful 
for the detection of a small population of malignant cells with clonally rearranged TcR-5 genes. 
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TABLE 6. Reported sized (in kb) of EcoRI and Kpnl restriction fragments of germ line and rearranged TcR--y 
genes, as detected by the J-y1.3 probe. 
Rearranged J-y segments 
V-y gene segments 
J-y1.1 J-y1.2 J-y1.3a J-y2.1 J-y2.3a 
EcoRI digests 
germline NDb ND 1.8 ND 3.3 
V-y2 ND ND 0.9 ND 0.9 
V-y3 ND ND 5.4 ND 5.4 
V-y4 ND ND 0.9 ND 0.9 
V-y5 ND ND 2.2 ND 2.2 
1/JV-y? ND ND 3.1 ND 3.1 
V-y8 ND ND 4.2 ND 4.2 
V-y9 ND ND 2.4 ND 2.4 
V-y10 ND ND 0.65 ND 0.65 
V-y11 ND ND 9.5 ND 9.5 
Kpnl digests 
germline 9.0 9.0 9.0 16.0 16.0 
V-y9 14.5 12.0 7.5 10.7 7.5 
V-y11 12.7 10.0 6.0 9.0 6.0 
all other V-y's 8.5 5.9 1.8 4.7 1.8 
a. Rearrangements to J11.3 and J12.3 result in bands with identical size. Nevertheless it is possible to discriminate between these 
rearrangements, because rearrangements to J12 segments will delete the TcR-11 locus. This deletion can easily be detected with the 
C1 probe in £coRI digests, but also the use of the J11.3 probe in £coRI digests or Kpnl digests will generally be informative. 
b. ND, not detectable. Rearrangements to J11.1, J11.2 or J12.1 gene segments are not detectable with the J11.3 probe in £coRI digests. 
In diagnosis of lymphoproliferative diseases it is usually not necessary to investigate TcR-r 
and TeR-eS genes. One can confine the analyses to the TcR-,8 genes, because they are 
rearranged in all TcR-a,B+ T cell malignancies as well as in the majority TcR--ycS+ and CD3-T 
cell malignancies (101,124,129,130). 
Multiple rearranged bands 
The analysis of lg and TcR genes of lymphoid malignancies occasionally reveals the 
presence of more than two rearranged bands (131, 132). This is frequently found in lgH gene 
analysis of acute lymphoblastic leukemias (All) of B cell lineage (133-137). 
If more than two rearranged bands are detected, the possibility that they are due to 
underdigestion or polymorphisms must be excluded. Therefore, the investigation should be 
repeated and an additional restriction enzyme should be used, to study whether the multiple 
bands remain. For instance, if multiple rearranged lgH gene bands are detectable in EcoRI 
digests or Hindlll digests, while only two bands are detected in Bam HI digests (133, 134), this 
may be due to the presence of the HVP region at the 5' side of the JH gene segments (Figure 
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5)(11). Therefore, also germline control DNA from the same patient should be used in the 
analyses, if available. 
The presence of multiple rearranged bands may be due to chromosome aberrations 
(hyperdiploidy or translocations) or to the presence of subclones with differently rearranged lg 
or TcR genes (131-137). Obvious differences in intensity between pairs of rearranged bands 
suggest oligoclonality, while the presence of three or more bands of comparable intensity may 
be due to hyperdiploidy. Optimal discrimination between these two causes is only possible, if 
also cytogenetic analysis is performed. 
Detection limit of the Southern blot technique 
Several studies indicate that the limit for the detection of clonal lg or TcR gene rearrange-
ments is about 5 to 10% (138-140), while others have reported the detection of 1% of clonal 
cells (8,141-143). One report even suggests that as low as 0.2% of malignant cells are 
detectable (144). 
In most studies the detection limit was determined by mixing of DNA samples (8, 140,141, 
143, 144). The objection against such mixing experiments is, that it is difficult to make accurate 
mixtures of high molecular weight DNA samples. This probably explains the discrepancies 
between the reported detection limits. Therefore we performed several dilution experiments, in 
which we did not mix DNA samples, but viable cells. 
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Figure 19. Dilution experiments to determine the detection limit of the Southern blot technique. The B cell line 
ROS-17 and the T cell line Molt-4 were mixed in various proportion. The mixtures were checked by immunologic 
marker analysis (CD19 as marker for ROS-17 cells and CyCD3 as marker for Molt-4 cells). DNA from each mixture 
was subjected to lgH gene analysis (JH probe in Bglll digests) for the detection of ROS-17 cells and to TcR-.8 gene 
analysis (J,82 probe in EcoRI digests) for the detection of Molt-4 cells. These experiments showed that the detection 
limit of the Southern blot technique generally is 4-5%, but that it is possible to detect 1-2% of clonal cells if the 
exact position of the rearranged band(s) is known. 
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The B cell line ROS-"17 and the T cell line Molt-4 were mixed in various proportions. The 
mixtures were checked with immunologic marker analysis: cytoplasmic CD3 (CyCD3) staining 
was used as marker for Molt-4 cells, while CD"19 was used as marker for ROS-"17 cells. DNA 
was extracted from each mixture and subjected to lgH gene analysis for the detection of 
ROS-"17 cells as well as to TcR-,8 gene analysis for the detection of Molt-4 cells. The results of 
one of these experiments are summarized in Figure "19. 
From the dilution experiments as well as from our experience with clinical cell samples we 
conclude that the detection limit of the Southern blot technique generally is 4-5%. However, if 
one knows the exact position of the rearranged bands, it is often possible to detect "1-2% of 
clonal cells (Figure "19). The latter may be important for staging of NHL at diagnosis (e.g. de-
tection of lymphoma cells in blood and bone marrow) and for the detection of minimal residual 
disease during or after treatment ("145-"147). 
DIAGNOSTIC APPLICATIONS Of lg AND TcR GENE ANALYSIS 
The various lymphoid malignancies can be regarded as the malignant counterparts of cells 
in the various stages of lymphoid differentiation ("148-"152). The ALL represent malignant 
counterparts of immature lymphoid cells, while the chronic lymphocytic leukemias (CLL) and 
the NHl represent malignant counterparts of more mature lymphoid cells ("150-"152). This 
implies that malignant lymphoid cells have virtually the same characteristics as normal lymphoid 
cells. Since lg and TcR gene rearrangement occurs early during lymphoid differentiation, almost 
all lymphoid malignancies have rearranged lg or TcR genes. 
Generally routine morphologic techniques and immunologic marker analysis are sufficient 
to demonstrate the presence of a lymphoid malignancy ("150-"152). However, sometimes 
diagnostic problems arise, especially if the lymphoproliferation contains a small subpopulation 
of suspected B cells or if the proliferation concerns mature T lymphocytes. Although Southern 
blot analysis is time consuming and expensive, in selected cases analysis of lg and TcR genes 
may be important to prove or exclude the clonal character of the lymphoproliferation (7, i 53-
"155). 
Based on data from the literature and our own experiences during the last five years, we 
conclude that analysis of lg and TcR genes can be used for several diagnostic purposes, which 
will be indicated below. These diagnostic applications will be discussed more extensively in 
Chapter 6. 
Discrimination between reactive polyclonallymphoid cell populations and a monoclonal 
lymphoid cell population 
Using morphologic techniques or immunologic marker analysis, it may be difficult to 
determine whether a T cell population in a lymph node or T cell infiltrate in the skin represents 
normal T cells or malignant T cells. Generally, analysis of TcR-,8 genes allows discrimination 
between the presence of a polyclonal T cell population and a monoclonal T cell population 
("158-"160). 
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Caution: Clonality is not always equivalent to malignancy 
Clinically benign lymphoproliferation may consist of clonal cell populations, as found in 
benign monoclonal gammapathies (161), lymphomatoid papulosis (113) and CD8/T--y 
lymphocytosis (162). Also dysregulation of the immune system, such as in patients with primary 
or secondary immunodeficiencies, may result in the development of monoclonal or oligoclonal 
B or T cell populations without evidence of malignant behavior (161, 163, 164). The monoclonal 
or oligoclonal B cell proliferation in immunodeficiency patients are generally associated with 
Epstein-Barr virus (EBV) (165-168). In some patients these proliferations may proceed and 
transform into B cell malignancies via a multistep process (169), but also regression of such 
proliferations has been observed in transplant patients, after withdrawal of immunosuppressive 
treatment (170). This indicates that clonallymphoproliferations in immunodeficiency patients are 
not necessarily malignancies (161,163,164,"170), although such patients have a high tendency 
to develop a malignancy ("171). 
Detection of two or more clones in a malignancy 
Several studies indicate that subclones occur in 15-30% of precursor B-ALL as detected by 
lgH gene analysis in multiple restriction enzyme digests (132, 134,137, "172, "173). Since glucose-
6-phosphate dehydrogenase (G6PD) isotype analysis as well as cytogenetic analysis indicate 
that precursor B-ALL have a clonal origin (174-176), it has been concluded that subclone 
formation in these leukemias is due to secondary lg gene rearrangements (135), such as D-
JH replacements (177) or V to V-D-JH rearrangements (178). 
Also in a part of germinal-center-cell-derived lymphomas and immunocytomas subclones 
are detectable upon lgH gene analysis (179-181). The lgH gene rearrangement patterns of the 
subclones in these lymphomas differ from the parental clone in some but not all restriction 
enzyme digests (180). Therefore, it is assumed that they are due to somatic mutations 
(180,181), which also occur in normal germinal-center cells (182). 
Finally, biclonal and oligoclonal B cell malignancies have been found in immunodeficiency 
patients (166, 167). As indicated above, these are probably derived from EBV-induced 
lymphoproliferations, which are transformed into B cell malignancies (169). Therefore, these 
patients probably suffer from multiple lymphomas, i.e. lymphomas that do not have a common 
clonal origin, but are caused by the same multistep transforming process. 
Analysis of lymphoid malignancies at relapse and comparison with initial diagnosis 
lg and TcR gene analysis of cell samples at diagnosis and subsequent relapse(s) can prove 
that the reoccurrence of a lymphoid malignancy indeed represents a relapse of the same 
tumor. Sometimes the histomorphological characteristics of a B cell lymphoma are changed 
at relapse, while the lgH and lgL gene rearrangement patterns remain identical (131). 
However, it is obvious that changes in lgH gene rearrangement patterns can occur at 
relapse in precursor B-ALL, germinal-center-cell-derived lymphomas and immunocytomas, 
because subclone formation frequently occurs in these malignancies (136,147,181). 
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Proof or exclusion of the common clonal origin of two malignant lymphoid cell 
populations 
In some patients with a B cell malignancy a second B cell malignancy may develop or 
sometimes two B cell malignancies occur simultaneously in the same patient. Southern blot 
analysis of lg genes can indicate whether such malignancies have a common clonal origin 
(131, 180,181, 183-185) or represent two independent malignancies (186-191 ). Since subclones 
can develop in some B cell lymphomas (179-181), extensive analysis of both lgH and lgLgenes 
(using multiple restriction enzyme digests) are necessary to exclude a possible common clonal 
origin (180, 181). Even lymphomas with bitypic lgL chain expression may be derived from the 
same clone (181), which supports the hypothesis that an oncogenic event may have taken 
place early during B cell differentiation (184), before lgL gene rearrangements. 
Determination of the differentiation lineage of a malignancy 
In some cases it is not possible, using immunologic marker analysis, to determine whether 
the malignant cells belong to the B cell lineage or the T cell lineage, or whether it concerns a 
non-lymphoid malignancy. Although lg and TcR gene rearrangements will generally only be 
functional in B cells and T cells, respectively, such rearrangements have been described to 
occur occasionally in cells from other differentiation lineages, such as lg gene rearrangements 
in T-ALL and acute myeloid leukemias (AML) and TcR gene rearrangements in precursor-B-
ALL (192,193). 
Due to such "lineage infidelities", the detection of lg or TcR gene rearrangements in 
malignant cells does not provide definitive proof of the differentiation lineage to which the 
malignancy belongs. However, the presence of germline lg and TcR gene strongly supports 
the non-lymphoid character of a malignancy (194, 195). 
Detection of low numbers of malignant cells 
As discussed above, the detection limit of routinely performed Southern blot analysis is 1 
to 5% (138-143). For many lymphoid malignancies, such detection limits can also be reached 
by use of morphologic techniques or immunologic marker analysis (196). Southern blot analysis 
of lg or TcR genes may, however, be valuable for the detection of minimal residual disease in 
some cases (137, 147). 
CONCLUSION 
The Southern blot technique allows a detailed analysis of the lgH and lgL genes as well as 
the TcR-,8, TcR--y and TcR-o genes. However, one should be aware of the limitations and pitfalls 
of these analyses, especially the occurrence of genetic polymorphisms and the limited 
combinatorial repertoire of TcR--y and TcR-o genes. 
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In some patients morphologic techniques and immunologic marker analysis are not 
sufficient for diagnosing a lymphoid malignancy. In these cases, analysis of lg and TcR genes 
may be of high diagnostic value, because Southern blotting is a powerful technique for 
determining clonality and for proving or excluding the clonal origin of two malignant lymphoid 
cell populations. 
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INTRODUCTION: DEVELOPMENT OF HUMAN T lYMPHOCYTES 
AND THEIR THYMUS-DEPENDENCY* 
Jacques J.M. van Dongen \ W. Marieke Comans-Bitter1•2, 
Ingrid l.M. Wolvers-Tettero 1 and Jannie Borst3 
187 
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INTRODUCTION 
It is generally assumed that the earliest precursors of T lymphocytes are generated in the 
bone marrow (1-4). Thymus repopulation experiments in mice have demonstrated that these 
precursor T cells, the prothymocytes, are able to migrate to the thymus where they can develop 
into mature T lymphocytes (1-4). 
Most data on human T cell differentiation are derived from studies on normal bone marrow 
(BM), thymus and blood samples as well as from analysis of T cell acute lymphoblastic 
leukemias (f-ALL). T-ALL can be regarded as malignant clonal expansions of cells at the 
various stages of T cell differentiation and thus represent a convenient tool for studying the 
phenotypic and genotypic changes during T cell development (5-7). 
One of the most important events during T cell development is the rearrangement of the 
genes encoding the T cell receptor (fcR)(8,9). The TcR consists of two chains, closely 
associated with the CD3 protein complex (fcR-CD3) (8-1 0). Two main types of TcR have been 
recognized: the "classical" TcR-o:.B (8,9) and the "alternative" TcR-ro (11, 12). The majority of 
mature T lymphocytes in blood and lymphoid tissues express TcR-o:,B, a minority TcR-ro (13, 14). 
Another important process during T Cell differentiation is the elimination of T cells 
recognizing self antigens (negative selection) and the positive selection ofT cells for recognition 
of antigens in de context of self major histocompatibility complex (MHC) molecules (9). This 
selection occurs in the thymus and at least concerns TcR-o:,B+ cells (9, 15). The Tcell accessory 
molecules CD4 and CDS play a supportive role in this MHC-restricted antigen recognition 
(16, 17). TcR-ro+ T lymphocytes probably also recognize antigen in association with MHC or 
MHC-Iike molecules (18-20), but it is unclear to what extent intrathymic differentiation and 
thymic selection of TcR-ro+ cells occurs (21). 
In this review we shall summarize our data concerning the immunophenotype of normal 
cells and leukemic cells (7, 14,22-28), TcR gene rearrangements in T-ALL (26,29-32), TcR-o:,B 
* Published in: Thymus 1990, in press. 
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and TcR--yS expression in healthy children and children with hypoplasia or aplasia of the thymus 
(DiGeorge anomaly)(33), and the repertoire of normal TcR--ys+ T lymphocytes (28,33). Based 
on these data and those from the literature, we shall discuss the immunophenotype of T cells 
during T cell differentiation, the hierarchic order of TcR gene rearrangement and the thymus-
dependency of TcR--yS+ cell development. 
IMMUNOPHENOTVPE OF T CEllS DURING DIFFERENTIATION 
Based on immunologic marker analysis of T-All cell samples a hypothetical scheme ofT 
cell differentiation has been designed, as illustrated in Figure 1 (22,26,27,29,34). The enzyme 
terminal deoxynucleotidyl transferase (TdT) is present in the nucleus of immature lymphoid cells 
(35). Virtually all T-ALL and their assumed normal counterparts, i.e. cortical thymocytes, express 
TdT, while mature T lymphocytes are negative for this enzyme (5-7). This expression pattern 
is related to the presumed function of TdT to insert nucleotides at the joining sites of gene 
segments during TcR gene rearrangements (36-38). 
common 
thymocyte 
HLA·DR HLA·DR CD? 
CD34 CD34 C02 
CD? CDS common 
(C02) CD1 thymocytes 
1 (CD4 and/or COB) CD? 
I gg~ 
mature 
thymocyte 
CD? 
C02 
CDS 
CD4 
TcR·CD3 
helper/inducer 
T lymphocyte 
CD? 
C02 
CDS 
CD4 
TcR·CD3 
activated 
helper/inducer 
T lymphocyte 
CD? 
C02 
CDS 
CD4 
TcR·CD3 
HLA·DR 
J CD 1 mature cytotoxic/ activated 
I (CD4 and/or CDS) thymocyte suppressor cytotoxic/ TcR·CD3 T lymphocyte suppressor I CD? T lymphocyte 
C02 I CDS gg~ gg~ 
I CDS CDS CDS TcR·CD3 I CDS CDS 
I I TcR·CD3 TcR·CD3 
HLA·DR -----~----------------~---------
Figure 1. Hypothetical scheme of human T cell differentiation based on immunophenotypic analysis ofT -ALL and 
infant thymocytes. The immunophenotype of cells in the various stages of T cell differentiation are indicated 
(22,26,27,34). Immunologic markers in parentheses are not always expressed. The dotted lines represent the tissue 
compartments where the various cell types are found. 
T cell development 1S9 
The majority of lymphoid precursor cells in bone marrow express both HLA-DR and the 
precursor antigen CD34, markers also expressed by "prothymocytic" T-ALL This type of T-
ALL was first recognized as an ALL, which expressed HLA-DR and the pan-T cell antigens CD? 
and C02, but appeared to be negative for all other BandT cell antigens tested (22,24). Double 
and triple immunofluorescence (IF} stainings revealed that normal counterparts of this immature 
T-ALL occur in low frequencies in BM and thymus (23,24}. 
The pan-T cell markers CD? and C02 are expressed by virtually all T cells throughout 
development, the CDS antigen is present on most cortical thymocytes and mature T 
lymphocytes, while the expression of the CD1 antigen is restricted to the "common thymocytes" 
in the thymic cortex (34). A large part of cortical thymocytes express CD4 and/or CDS, while 
the majority of peripheral T lymphocytes express CD4 or CDS in a mutually exclusive fashion 
(22,26,34). 
The CD3 protein complex consists of at least five chains: the three structurally related 
CD3-r, CD3-o, CD3-E chains and two disulfide-linked CD3-r chains, which probably play an 
important role in signal transduction from the TcR to the cytoplasm (Figure 2)(10). Northern blot 
studies on T-ALL cell samples revealed that CD3-o and CD3-E mRNA was not only detectable 
in CD3+ T-ALL, but also in all CD3- T-ALL tested (29,39).This was in line with the presence of 
CD3-o and CD3-€ proteins in the cytoplasm (CyCD3) of all CD3- T-ALL (including weak 
expression in the prothymocytic T-ALL) and the majority of CD3 + T-ALL, as detected by mono-
clonal antibodies (McAb)(27). Apparently CyCD3 is already expressed in immature T cells, 
which do not yet bear a TcR-CD3 complex at the cell surface. Identical results were obtained 
in studies on normal thymocytes (27,40,41). Therefore CyCD3 is an excellent marker for 
immature normal T cells and their malignant counterparts (Figure 1)(27,41). The completely 
assembled TcR-CD3 complex is found at the cell surface of mature thymocytes and peripheral 
T lymphocytes only (27). 
The TcR-CD3 complex is expressed by 60-65% of normal thymocytes (42), while only 30-
35% of the T-ALL express CD3 on their membrane (Table 1}. This discrepancy might be 
explained by the fact that a total thymocyte suspension includes TdT+ cortical cells as well as 
mature CD3+ medullary cells, while T-ALL only represent the TdT+ T cell population. Since 
more than 95% of cells in a thymocyte suspension express pan-T cell markers while only 70 
to SO% of them express TdT, it can be assumed that 20-30% of the thymocytes probably 
represent TcR-CD3+ medullary T lymphocytes. This was proven by double immunofluor-
escence staining, which showed that only 45% of the TdT+ thymocytes express a TcR-CD3 
complex on their cell membrane. This frequency is comparable to the frequency of CD3+ T-
ALL (Table 1). 
The majority of blood T lymphocytes (S5-9S%) express TcR-a.B and a minority (2-15%) 
express TcR-ro (13, 14,33}. The frequency of normal TcR-ro+ cells in the thymus is even lower 
(0.2-1.0%)(14,43 and Table 1). The frequency of TcR-ro expression by TdT+ thymocytes is 
extremely low(< 0.1%) when compared to TcR-a.B expression (43 and Table 1). This is in line 
with the finding that TcR-ro+ cells occur more frequently in the medulla than in the cortex of 
the thymus (44,45}. These data suggest that the development of TcR-r.s+ cells represents a 
minor differentiation pathway in the human thymus. However, a relatively large proportion of 
T-ALL express TcR-ro (12%)(46,47 and Table 1). This discrepancy between the frequency of 
normal TcR-ro+ /TdT+ thymocytes and their presumed malignant counterparts in a random 
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TABLE 1. Expression of the TcR-CD3 complex by normal infant thymocytes and T-ALL 
CD3 negative CD3 positive 
TcR-a.B TcR-"(o 
Infant thymocytes 
(n=6) 
TdT+ thymocytesa 
(n=3) 
T-ALLd 
-Campana et al.6 
- Loiseau et al. f 
-Van Dongen et al.g 
Total (percentage) 
39±9% 
56±16%b 
26/37 
20/33 
22/31 
68/101 (67%) 
60±9% 
9/37 
6/33 
6/31 
21/101 (21%) 
a. The percentage of TdT+ thymocytes within an infant thymus cell sample is 78±13% (n = 11). 
0.4±0.2% 
<0.1%b,c 
2/37 
7/33 
3/31 
12/101 (12%) 
b. Data obtained by double immunofluorescence stainings for surface membrane expression of TcR-CD3 molecules and nuclear expression 
ofTdT. 
c. Double IF stainings revealed that < 3% of the TcR-18+ thymocytes expressed TdT. 
d. The here presented series otT-ALL are claimed to be random. Therefore it is remarkable that the frequency of TcR-18+ T-ALL in the series 
of Loiseau et al. is more than twice as high than in the series of Campana et al. and Van Dongen et al. However, in a recent report on 
ToR expression by CD3+ T-ALLcells, it was found that 10 out of 15 T-ALLexpressed TcR-18, whereas only 5 out of 15 expressed TcR-afi 
(reference 48). 
e. Data from reference 48. 
f. The expression of TcR-a,B and TcR-18 in the T-ALL series of Loiseau et al. is deduced from their Southern blot data and data concerning 
the reactivity of antibodies against ToR molecules (47). 
g. Unpublished results. 
series of T-ALL may be explained in two ways: either TcR--yc5+ /TdT+ thymocytes are more 
prone to malignant transformation or a major proportion of TcR--yc5 + cells develops outside the 
thymus. 
In a recent study differences between T-ALL and T cell lymphoblastic lymphomas (f-LBL), 
it was found that the majority of CD3+ T-ALL express TcR--yc5 (10 out of 15), while the majority 
of CD3+ T-LBL express TcR-a.B (13 out of 15)(48). Based on clinical similarities, T-LBL are 
generally regarded as lymphomatous variants of T-ALL However, T-LBL patients have 
mediastinal tumors (thymic location), pleural effusions and/or lymph node involvement with no 
or minimal BM involvement, whereas patients with T-ALL present with massive BM and blood 
invasion (48). This would imply that T-LBL represent more precise malignant counterparts of 
TdT+ cortical thymocytes than T-ALL and that T-ALL also include malignant counterparts of 
extrathymic immature T cells. 
HUMAN TcR GENES AND THEIR REARRANGEMENT DURING T CElL DIFFERENTIATION 
The TcR protein chains consist of a variable M domain and a constant (C) domain (Figure 
2), which are encoded by separate exons. A functional V domain exon arises during a process 
of gene rearrangement, which mediates the joining of a particular combination of V, diversity 
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TcR-a TcR-{3 TcR-o TcR-y1 TcR-8 TcR-y2 
Figure 2. Schematic diagram of the various types of human TcR-CD3 complexes. The TcR molecules consist of 
two chains, each of which contain a V domain and C domain. In TcR-a,B and TcR-r1 o molecules the two chains 
are linked via a disulfide bond. This interchain disulfide bond is lacking in TcR-ro molecules, in which the TcR-r 
chain is derived from the Cr21ocus {31,66,67). 
(D) and joining (J) gene segments in case of the TcR-,8 and TcR-o genes or V and J gene 
segments in case of the TcR-a and TcR-r genes. The enormous diversity of TcR molecules, 
needed to recognize a wide variety of antigens, is generated via these gene rearrangement 
processes. 
During the last five years detailed information has become available about the configuration 
and rearrangement of the four human TcR genes. The germ line configuration ofthe human TcR 
genes is given in Figure 3. The TcR-a locus contains many different V gene segments, a long 
stretch of J gene segments and one C gene segment (49,50). The TcR-,8 locus consists of 
many different V and two C gene segments, both of which are preceded by one D and six or 
seven J gene segments (51-53). The TcR-r locus consists of a restricted number of V gene 
segments (eight functional and seven pseudo genes) and two C segments (r1 and r2), each 
of which are preceded by two or three J gene segments (30,54-56). Curiously, the TcR-o locus 
is situated in between the Va and Ja gene segments (57-59) and probably consists of only a 
few V, three D, three J and one C gene segment (60-63). Due to their localization within the 
TcR-a gene locus, the TcR-o genes can theoretically draw their V gene segments from the 
much larger pool of Va gene segments. 
It is obvious that many different Va-Ja and V.B-D/3-J/3 combinations can be obtained, while 
the combinatorial repertoire of the TcR-r and TcR-o genes is restricted due to the limited 
number of available V, (D) and J gene segments (19). However, the TcR-r and particularly the 
TcR-o genes have an enormous junctional repertoire, i.e. diversity due to insertion of 
nucleotides (N regions) at the joining sites of the gene segments (15,64,65). 
In all TcR-a/3 molecules and TcR-r1 o molecules the two protein chains are linked by a 
disulfide bond (Figure 2). This interchain disulfide bond is lacking in TcR-ro molecules, in which 
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TcR-a and TcR-8 genes 
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Figure 3. Schematic diagram of the germline configuration of the four human TcR genes. The TcR-a genes consist 
of many Va gene segments, a remarkably long stretch of Ja gene segments and one CO! gene segment. The TcR-o 
locus is located within the TcR-a gene complex between the Va and the Ja gene segments and consists of a 
few Vo, three Do, three Jo and one Co gene segments. The TcR-,8 genes contain many V,B and two C,B gene 
segments, which are preceded by a 0,8 and six or seven J,B gene segments. The TcR-1' genes consist of two C-y 
gene segments, preceded by two or three J-y gene segments and a restricted number of V-y gene segments: eight 
functional genes and seven pseudo-genes (1/J; open boxes). The functional V-y genes are grouped in four families 
{V-yl, V-yll, V-ylll and V-yiV) based on degrees of sequence homology. 
the TcR--y chain is derived from C-y2 genes (31 ,66,67). This is due to the absence of a cysteine 
residue in the second exon of C-y2 (66-68). It is not clear whether C-y1 and C-y2 encoded TcR--yo 
define functionally distinct lineages. It has been suggested that TcR--y1 OT lymphocytes exhibit 
a higher degree of non-MHC-restricted cytotoxicity than the TcR--y2o T lymphocytes (69). Also 
differences in morphology, cytoskeletal organization and growth characteristics have been 
found (70). 
Hierarchic order of rearrangement and transcription of TcR genes studied in T-ALL 
Initial studies concerning TcR-,8 and TcR--y in T-ALL revealed that a large part of the CD3-
T-ALL (83-90%) have rearranged TcR-,8 and TcR--y genes, suggesting that both genes 
rearrange early during T cell differentiation (29,39,71-79). Probably the TcR--y genes are 
rearranged and transcribed prior to the TcR-,8 genes, since a few CD3- T-ALL with rearranged 
TcR--y genes but germline TcR-,8 genes have been reported (46,47,72 and Table 2). 
The TcR-a gene configuration is difficult to analyze because of the long stretch of Ja gene 
segments (49,50). So far only one detailed report on the configuration of TcR-a genes in T-
ALL has been published (79), but several papers describe the transcription of rearranged TcR-a 
genes in T-ALL (29,39, 72,7 4, 75, 79). These reports indicate that most CDTT-ALL have germline 
TcR-a genes and that rearrangement and transcription of TcR-a genes is mainly found in CD3 + 
T-ALL. This suggests that the TcR-a genes rearrange late during T cell development. 
During the last two years also data concerning the TcR-o genes have become available 
(32,46,47,80-83). A few CD3- T-ALL have germ line TcR-,8, TcR--y and TcR-o genes, but the ma-
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TABLE 2. TcR gene rearrangements in CD3- and CD3+ T-ALL 
CD3-T-ALLa 
Hara et al. {79,80) 
Hockett et al. {81) 
Foroni et al. {82) 
Loiseau et al. {47) 
Van Dongen et al. {32)b 
Campana et al. {46) 
Total (percentage) 
CD3+ T-ALLa 
Hara et al. {79,80) 
Hockett et al. {81) 
Foroni et al. {82) 
Loiseau et al. {47) 
Van Dongen et al. {32)b 
Campana et al. {46) 
Total (percentage) 
TcR-.8 genes 
rearranged 
7/7 
1/2 
0/2 
15/16 
5/6 
11/14 
39/47 {83%) 
12/12 
7/8c 
3/3 
7/9c 
11/11 
9/9 
49/52 {94%) 
TcR-'Y genes 
rearranged 
7/7 
1/2 
0/2 
20/20 
5/6 
13/14 
46/51 {90%) 
12/12 
8/8 
2/2 
13/13 
11/11 
9/9 
55/55 {100%) 
19S 
TcR-o genes 
rearranged 
(R/G or R/R 
orR/D) 
deleted 
(D/G or D/D) 
6/7 
2/2 
2/2 
17/20 
5/6 
12/14 
1/7 
0/2 
0/2 
3/20 
0/6 
0/14 
44/51 {86%) 4/51 {8%) 
48/51 {94%) 
7/12 5/12 
3/8 5/8 
2/3 1/3 
8/13 5/13 
7/11 4/11 
4/9 5/9 
31/56 {55%) 25/56 {45%) 
56/56 {100%) 
a. The here presented series of COS- T·ALL and COS+ T-ALL may not be representative for all T-ALL. 
b. The data of this series of T-ALL were partly published in reference S2. 
c. The three COS+ T-ALL with germline TcR·Jl genes appeared to express TcR-76 (47,81). 
jority of the cos- T-ALL ( -95%) have rearranged one or both TcR-o alleles, while some have 
deleted one or both alleles (S2,46,47,80-82). Also several cos- T-ALL with germline TcR-.8 
and/or TcR--y genes appeared to have rearranged TcR-o genes (Table 2) (81,82). These data 
indicate that TcR-o genes rearrange early during T cell differentiation, probably prior to other 
TcR genes. cos- T-ALL with rearranged TcR-o genes generally only contain immature TcR-o 
transcripts (i.e. "truncated" transcripts, lacking V gene sequences) (S2,80,81), whereas mature 
TcR-o transcripts are found in TcR--ys+ T-ALL (S2,81). 
In all cos+ T-ALL rearrangements andjor deletions of the TcR-o gene locus were found 
(Table 2). Deletion of one or both TcR-o alleles is associated with rearrangement of the TcR-a 
genes (80). This is in line with the location of the TcR-o genes within the TcR-a locus in between 
the Va and Ja gene segments (57-59). 
As expected, all TcR--ys+ T-ALL have rearranged at least one TcR--y allele and at least one 
TcR-o allele. In one TcR--ys+ T-ALL we found one rearranged and one deleted TcR-o allele, 
suggesting that a TcR-a gene rearrangement had occurred on one allele (TableS). A large part 
of the TcR--yo+ T-ALL ( -80%) also have rearranged TcR-.8 genes (TableS). Detailed analyses 
of the TcR--y and TcR-.8 genes in TcR--ys+ T-ALL and TcR--yc5+ T cell clones have revealed that 
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TABLE 3. TcR gene rearrangements in TcR-a.B+ and TcR--yo+ T-ALL. 
TcR-.8 genes TcR-'Y genes TcR-o genes 
rearranged rearranged 
R/G or R/R R/D D/G or D/D 
TcR-ar T-ALL 
Hockett et al. (81) 7/7 7/7 0/7 2/7 5/7 
Loiseau et al. (47)a 5/5 6/6 0/6 1/6 5/6 
Van Dongen et al. (32)b 4/4 4/4 0/4 0/4 4/4 
Campana et al. (46) 7/7 7/7 0/7 2/7 5/7 
Total 23/23 24/24 0/24 5/24 19/24 
(percentage) (100%) (100%) (0%) (21%) (79%) 
TcR--yo+ T-ALL 
Hockett et al. (81) 0/1 1/1 1/1 0/1 0/1 
Loiseau et al. (47)a 2/4 7/7 7/7 0/7 0/7 
Van Dongen et al. (32)b 7/7 7/7 6/7 1/7 0/7 
Campana et al. {46) 2/2 2/2 2/2 0/2 0/2 
Total 11/14 17/17 16/17 1/17 0/17 
(percentage) (79%) (100%) (94%) (6%) (0%) 
a. The expression of TcR-a.B and TcR-1o in the T-ALL series of Loiseau et al. is deduced from their Southern blot data and data concerning 
the reactivity of antibodies against TcR molecules {47). 
b. The data of this series of T-ALL were partly published in reference 32. 
TcR--yiS+ T cells generally have germline TcR-.8 genes or incomplete (D.B-J.B) rearrangements, 
whereas TcR--y2s+ T cells generally have incomplete (O-J) or complete (V-0-J) TcR-.8 gene 
rearrangements (31 ,84). Transcripts of these rearranged TcR-.8 genes are often found in 
TcR--yo+ cells (31 ,32,84) and even TcR-.8 proteins may be present in the cytoplasm (85). 
All TcR-a.B+ T-ALL have rearranged one or both TcR-.8 genes. In -80% of them both 
TcR-Sgene alleles are deleted and in -20% one TcR-o allele is deleted, which is in line with 
rearrangements of the TcR-a genes (Table 3) (32,46,47,81). The TcR--y genes are rearranged 
in all TcR-a.B+ T-ALL (Table 3) and in a few of them also low amounts of TcR--y transcripts are 
found (32,81). 
Apparently TcR gene rearrangements and even TcR gene expression overlap in -yo and a.B 
cells without leading to aberrant TcR protein expression. There obviously exist exclusion 
mechanisms to avoid dual receptor expression. Deletion of TcR-o genes in TcR-a.B+ cells 
represents one of such mechanisms (see below). 
Based on the combined T-ALL data we have previously postulated a linear T cell differentia-
tion scheme (Figure 4). The TcR-o genes rearrange first. Subsequently, the TcR--y genes rear-
range to the C-y1 locus prior to or coinciding with O-J joining of the TcR-.8 genes, potentially 
followed by rearrangement to the C-y2 locus and V-0-J joining of the TcR-.8 genes (31). If the 
TcR--y and TcR-o gene rearrangements are functional, TcR--yiS+ T cells or TcR--y28+ T cells 
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Figure 4. Hypothetical scheme of human T cell differentiation with a linear sequentially ordered rearrangement of 
TcR genes {31). The horizontal bars summarize the hierarchic order of TcR gene rearrangement as deduced from 
studies on T-ALL and human TcR--yc5+ T cell clones. The dotted lines mark the tissue compartments, where the 
cells in the various T cell differentiation stages are found. 
may develop. If one of the rearrangements is not functional, the T cell may complete the TcR-.B 
gene rearrangement together with deletion of the TcR-c5 genes and rear-rangement of the TcR-a 
genes. If these rearrangements are functional, TcR-a.B+ T cells may develop. This linear T cell 
differentiation pathway is supported by the presence of rearranged TcR--y gene (generally to 
the -y21ocus) in all CD3+ T-ALL (32,46,71 ,74,75,78), of which a large part probably expresses 
TcR-a.B. Most of the TcR--y gene transcripts in TcR-a.B+ cells are nonfunctional (87-89). 
The linear sequentially ordered rearrangement of TcR genes is also in line with data 
concerning murine T cell ontogeny, which indicate that rearrangement of the TcR-c5 genes 
occurs at least as early as day 14 in fetal thymocytes (90-92), at the same time or before 
rearrangement and transcription of the TcR--y genes (91 ,93-95). TcR-.B genes start to rearrange 
from day 14 on, resulting in fully rearranged genes and mature 1.3 kb transcripts two days later 
(93-97). Rearrangement and transcription of the TcR-a genes occurs from day 17 on (94,95). 
TcR--yc5 is indeed expressed by day-14 and day-15 fetal thymocytes, whereas the first TcR-a.B+ 
thymocytes can be detected two days later (98-101). 
New hypothetical scheme of T cell differentiation 
Although most if not all T-ALL fit in the postulated linear T cell differentiation scheme (Figure 
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4), recent findings suggest that the 10 and a/3 differentiation pathways are separated in an early 
stage and that cells in the a/3 pathway are not necessarily derived from cells with unsuccessful 
rearrangement oftheir TcR-1 and/or TcR-o genes. This early divergence ofa/3 and 10 pathways 
is probably regulated via a combination of silencers of the TcR-a gene enhancer and rearrange-
ment/deletion mechanisms in the TcR-a/o gene locus. We will present a new hypothetical 
differentiation scheme based on new data in the literature as well as our own T-ALL data. 
1. TEA-Ca transcripts. 
In immature T cells a curious 2.0 kilobase (kb) mRNA with Ca sequences was found, which 
did not contain a Va gene segment but a tandemly repetitive motif called "T early a" (TEA) 
(102). The TEA-Ca transcripts are sterile, i.e. not translatable into protein (102). The TEA gene 
segment is located in between the TcR-o genes ( -10 kb 3' of Co) and the Ja genes ( -75 kb 
5' of Ca) and is not rearranged in the immature T cells which express the TEA-Ca transcripts 
(Figure 5)(81, 1 02). This implies that the 2.0 kb TEA-Ca transcript is a splicing product of a long 
(75-80 kb) precursor mRNA. The TEA-Ca transcript has been found in immature CD3- T-ALL 
(81) and human fetal thymocytes (102), but also in a TcR-"(o+ T-ALL (74,81, 102). The TEA gene 
segment remains in germline configuration in immature T cells as well as in TcR-1o+ T cells, 
but is deleted in TcR-a/3+ cells, in line with its genomic location (102). It has been suggested 
that TEA-Ca transcription may play a regulatory role in opening the Ja locus to obtain TcR-o 
deletion and subsequent Va-Ja rearrangement (81). 
2. TcR-o deleting elements. 
The human TcR-o locus is flanked by o deleting elements that undergo preferential 
rearrangement in the thymus, resulting in deletion of internal TcR-o gene segments (1 03,1 04). 
One deleting element is located -12 kb 3' of Co, just 3' of the TEA gene segment and just 
5' of the Ja gene segments (Figure 5). This deleting element is called lfJJa, because of its high 
homology to Ja gene segments and a heptamer-nonamer sequence at the 5' side, which 
represents a specific joining sequence for gene rearrangement (103). It is likely to be a 
pseudogene since the Ja consensus sequence is incomplete (103). The second deleting 
element is called oREC and is located 5' of the TcR-o locus, but 3' of the Vo1 gene; its precise 
position is not yet known (103). In the murine TcR-o locus at least three OREC gene segments 
are present (104,105), which may also be the case in man. The known human oREC gene 
segment is flanked by a consensus heptamer-nonamer sequence at its 3' side, which permits 
rearrangement to lfJJa with concomitant deletion of the TcR-o locus. The oREC-lfJJa rearrange-
ment occurs at high frequency in the developing thymus (1 03,1 04) and has been found in an 
immature T-ALL (106) as well as some T cell lines (103). The TcR-o deleting rearrangement 
event probably represents an important mechanism in separating the af3 and 10 lineages, 
because cells undergoing oREC-1/JJa rearrangement on both alleles will not be able to express 
TcR-"(o. However, certain functional Vo-Do rearrangements on both alleles will delete the oREC 
gene segment which may hamper differentiation along the a/3 pathway. 
3. Circular excision products. 
The joining of gene segments during rearrangement probably occurs via a process of 
looping-out and excision of the intervening sequences (107, 108). It is generally assumed that 
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Figure 5. Schematic diagram of the human TcR-ajcS locus. The various gene segments are presented: TeR-eS 
deleting elements (cSREC and 1/JJcr), 'T early ci' (TEA) gene segment, TeR-eS gene enhancer (cS enh.) and the TcR-a 
gene enhancer (cr enh.) with its flanking silencer sequences (cr sil.). The possible gene rearrangements and the 
TEA-Ccr transcription are indicated (see text). 
such gene rearrangements start with the back-to-back fusion of the heptamer-nonamer 
joining sequences, which flank the involved gene segments (i.e. the 3' joining sequences of 
the upstream gene segment and the 5' joining sequences of the downstream gene 
segment)(107). With joining of two TcR gene segments a circular excision product is formed, 
which contains a head-to-head structure of the two heptamer-nonamer sequences as well as 
all intervening TcR gene sequences (107,108). Such excised circles could indeed be isolated 
from murine thymocytes and sequences of all four murine TcR genes have been identified in 
these small circular excision products (105,109-113). 
Detailed studies on the occurrence ofTcR-cr and TeR-eS gene sequences in circular excision 
products have proven that at least the following types of rearrangement events can occur in 
the TcR-cr/cS locus: 
- Dc51-Dc52 joining (105); 
-incomplete TeR-eS gene rearrangements (V-DcS joining) can be replaced by VcS-JcS 
rearrangements ( 112); 
-non-functional complete TeR-eS gene rearrangements (V-0-D-J) can be deleted (105); 
- germline TeR-eS sequences (DcS-JcS region) can be deleted (113); 
- cSREC-1/JJcr rearrangements can be followed by Vcr-Jcr rearrangements (105, 111); 
- Vcr-Jcr rearrangements can be followed by new Vcr-Jcr rearrangements of an upstream 
Vcr and a downstream Jcr gene segment (111, 112); 
-the head to head joints of the heptamer-nonamer joining sequences (reciprocal joints) 
in circular excision products of rearranged TeR-eS genes are often imprecise with 
insertion or deletion of several bases (1 05), while virtually all excision products of TcR-o: 
gene rearrangements contain precisely fused heptamer sequences (1 09,111, 112). 
These combined data indicate that progressive rearrangements can occur in the TcR-crjcS 
locus on the same chromosome. This includes the deletion of germline TeR-eS genes or non-
functionally rearranged TeR-eS genes, followed by TcR-cr gene rearrangements. 
4. Silencer of the TcR-cr gene enhancer. 
The enhancer for transcription of the murine TcR-cr gene is located -3 kb downstream of 
the Ccr gene segment; it is assumed that the location in the human genome is comparable 
(Figure 5)(114). The unique structure of the TcR-cr locus suggests that the enhancer can act 
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over -70 kb, up to the most 5' located Ja gene segment. Transfection experiments have 
demonstrated that the TcR-a enhancer is indeed very powerful and that its activity is T cell 
specific (114). This lineage specificity of the TcR-a enhancer is achieved through the activation 
of multiple negative cis-acting elements, which silence the enhancer in non-T cells as well as 
in TcR--y.s+ cells, but not in TcR-a,B+ cells (115). These silencers are located in between theCa 
gene segment and the a enhancer (115). Since germline transcription is generally thought to 
precede rearrangement, the silencing of the TcR-a locus in cells of the -yeS lineage would explain 
why the Ja genes are not targets of rearrangements in TcR--ycS+ cells. 
5. TeR-eS enhancer elements. 
Two transcription enhancing elements have been identified in the human TeR-eS gene locus 
in between the Jc53 and CcS gene segments (Figure 5) (116). This localization implies that the 
enhancer remains undeleted during all types of TeR-eS gene rearrangements. Transfection 
experiments with one of the TeR-eS gene enhancers demonstrated activity in both TcR--ycS + cells 
and TcR-a,B+ cells, but not in B cells or fibroblasts (116). This indicates that this enhancer is T 
cell specific, but not restricted to cells of the -yeS pathway. 
6. TcR--y gene silencer. 
Recent studies in transgenic mice suggest that transcription of functionally rearranged 
TcR--y genes in TcR-a,B+ cells is repressed via silencer sequences (101, 117, 118). In transgenic 
mice constructed with a "short" TcR--y gene clone the transgene transcripts accumulate 
abundantly, which is associated with a severe blockage in the generation of TcR-a,B+ cells, 
while TcR--ycS cells are present in relatively high frequencies (21, 117). However, in transgenic 
mice constructed with a "long" TcR--y gene clone no accumulation of transgene transcripts 
occurs, which is accompanied with an apparently normal generation of TcR-a,B+ T cells. This 
data suggests that the TcR--y gene flanking sequences (1 01, 118) contain cis-acting silencer 
elements, which are absent in the "short", but present in the "long" TcR--y transgenes 
(101,117,118). 
The investigators hypothesized that T cell precursors can be committed to generating 
TcR-a,B+ cells, independently of the rearrangement status of their TcR--y genes and that this 
commitment involves repression of TcR--y gene transcription through interaction with a 
cis-regulatory DNA element (a silencer)(101,117). They further suggested that this -y-silencer 
model applies to the separation of a,B and -yeS cell lineages {101, 117). However, the data cannot 
indicate whether this separation occurs in an early or late stage of T cell differentiation. 
Furthermore, the repression of TcR--y gene transcription in cells of the a,B lineage is only 
necessary, if the TcR--y genes are rearranged functionally. Although virtually all TcR-a,B+ cells 
have rearranged TcR--y genes, in most cases these rearrangements appear to be non functional 
(87-89) 
Based on the above data, we have postulated a newT cell differentiation scheme in which 
an early separation of the a,B pathway and -yeS pathway is depicted (Figure 6). The complex 
organization of the TcR-a/ c5 locus necessitates differential accessibility of this gene locus in the 
two different pathways (Figure 5). Therefore it is suggested that the activity of the silencer of 
the TcR-a genes is one of the main regulatory mechanisms in the new hypothetical 
differentiation scheme. 
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TcR-y gene silencer active (if necessary) 
TcR-yo+ 
T lymphocytes 
Figure 6. Hypothetical scheme of human T cell differentiation with separated a[3 and rS pathways. The dotted bars 
summarize the hierarchic order of TcR gene rearrangements for each pathway. The shaded bars represent the 
activity of the TcR-a gene silencer in the rs pathway and the TcR-r gene silencer in the a[3 pathway. It is assumed 
that the TcR-a gene silencer plays a central role in the early separation of the a[3 pathway and rs pathway (115). 
As long as the TcR-a silencer remains active, the rearrangements in the TcR-ajS locus are restricted to the TcR-S 
genes. If the a silencer is inactivated, rearrangements in the TcR-a locus will occur (see text). The TcR-r silencer 
is necessary to repress transcription of possibly functionally rearranged TcR-r genes in TcR-a/3+ cells. 
One of the earliest events during T cell differentiation probably is the T cell specific 
activation of the TcR-S enhancer elements, resulting in transcription-mediated opening of the 
TcR-S locus in all immature T cells ("1 "16). If the a silencer remains active, only rearrangements 
in the TcR-S genes can occur ("1 "15), immediately followed by TcR-r gene rearrangements. In 
many cells of the rs pathway also rearrangements in the TcR-[3 genes will occur. If the 
rearrangements of the TcR-S and TcR-r genes are functional, this may result in TcR-rs+ cells. 
The TcR-a genes in TcR-rs+ cells remain in germline configuration due to the continuous 
activity of the a silencer ("1 "15). 
If the a-silencer becomes inactivated, the TcR-a enhancer can induce transcription-mediated 
opening of the TcR-a locus ("1 "15), e.g. via TEA-Ca transcription (8"1). This transcription opens 
the l{JJa gene segment, while the structure of the SREC gene segment was already opened via 
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the early activation of the TeR-eS gene enhancer (116). Subsequently cSREC-ljiJa rearrangement 
may occur (103,104), resulting in the deletion of germline TeR-eS gene sequences (113) or 
incompletely rearranged TeR-eS gene sequences. Even completely rearranged TeR-eS genes can 
be deleted (105). As a consequence of such deletions the Va gene segments are positioned 
in closer proximity to the TcR-a enhancer, which may facilitate the subsequent Va-Ja 
rearrangements (105, 111). In the mean time also the TcR--y and TcR-.8 genes are rearranged. 
Functional TcR-a and TcR-.8 gene rearrangements may result in TcR-a.B+ cells in which an 
activated -y-silencer represses transcription of a possibly functionally rearranged TcR--y gene 
(101,117,118). 
The hierarchic order of TcR gene rearrangements does not essentially differ between the 
linear differentiation scheme (Figure 4) and the differentiation scheme with separate a.B and -yeS 
pathways (Figure 6). The main difference between the two schemes is the postulated differential 
accessibility of the complex TcR-ajcS locus (Figure 5), which is easy to fit into a two-lineage 
scheme, but difficult into a linear scheme. This emphasizes the central role of the TcR-a/cS locus 
in T cell differentiation. 
The T-ALL data fit into the proposed two-lineage T cell differentiation scheme. In most 
TcR-a.B+ T-ALL ( -80%) both TeR-eS gene alleles are deleted, but in some of them one 
rearranged TeR-eS gene allele is present (Table 3). Whether such a rearranged TeR-eS gene is 
transcribed in a TcR-a.B+ cell, has not been reported. Virtually all TcR-a.B+ cells have rearranged 
TcR--y genes (Table 3). However, TcR--y gene transcripts are generally absent or occur in low 
amounts in TcR-a.B+ cells (32,81), which is in line with the activation of a -y-silencer in cells of 
the a.B lineage (101,117,118). 
In virtually all TcR--ycS+ cells both TeR-eS gene alleles are rearranged (32,46,47,81). Therefore 
they lack rearrangement and transcription of TcR-a genes, which is in line with an activated 
silencer of the TcR-a enhancer in TcR--ycS+ cells (115). Expression of rearranged TcR-.8 genes 
in TcR--ycS+ cells appears to be possible (31,32,84,85). Apparently no TcR-.8 gene silencer 
exists. This may sometimes lead to aberrant TcR expression such as the recently described 
expression of TcR-.Bo by the DND41 T cell line (119). However, in most T cells such aberrant 
TcR expression will not occur. Even transfection of functional TcR-a gene sequences in 
TcR--ycS+ T cells with functional TcR-.8 genes resulted in the expression ofTcR-a.B andjorTcR--ycS 
molecules, but no aberrant TcR molecules were formed (120, 121). This indicates that a 
preferential association of TcR-a and .B chains and TcR--y and 5 chains occurs. 
THYMUS DEPENDENCY OF THE DEVELOPMENT OF TcR--yo+ CELLS 
The far majority of mature TcR-a.B+ cells express CD4 or CD8 molecules, which play a 
supportive role in MHC restricted antigen recognition (9, 15). In the interaction between TcR-a.B+ 
T lymphocytes and antigen presenting cells, the CD4 and CD8 molecules associate with MHC-
class II and class I molecules, respectively. It is generally assumed that TcR-a.B+ cells are 
positively selected for the capability to interact with self MHC molecules in the thymus and that 
the CD4 and CD8 molecules are involved in this process (9, 15, 122). 
Therefore it is intriguing that most TcR--ycS + cells do not express CD4 or CD8 molecules (11-
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14,33). This may suggest that TcR--yo + cells are not subject to such thymic selection. It should 
however be emphasized that in peripheral blood 0,5-2% of TcR--yo+ cells express the CD4 
molecule (14) and 5-10% the CDS molecule (Table 4). Perhaps these TcR--yo+ lymphocytes 
have undergone thymic selection, while the CD4-;cos- -yo cells may be derived from an 
extrathymic differentiation pathway or exported from the thymus before thymus selection. 
As indicated in one of the previous sections, there is evidence that at least a part of 
theTcR--yo+ cells may develop along an extrathymic pathway. First, the frequency of TcR--yo+ 
cells in the thymus is low (Table 1). Second, virtually no TdT+ -yo cells are detectable in the 
thymus, while a large part of the TdT+ thymocytes express TcR-a.B (Table 1). One could argue 
that TcR--ycS+ cells do not need TdT activity during their development, but the contrary is 
probably true, because the TdT-mediated junctional diversity (36-3S) is more extensive in 
TcR--yo+ cells than in TcR-a.B+ cells (15,64,65). Third, the frequency of TcR--ycS+ cells in the 
medulla is higher than in the cortex of the thymus (44,45). Fourth, the frequency of TcR--ycS 
expression by T-LBL is much lower than by T-ALL, although T-LBL represent more precise 
malignant counterparts of cortical thymocytes (4S). 
Evidence for extrathymic development of TcR--ycS+ cells originally came from studies on 
TcR--y and TeR-eS gene transcripts in athymic (nude) mice (123, 124). However, recent studies 
in normal mice indicate that the TcR--yo+ cells in murine epidermis and epithelia of reproductive 
organs have emerged from the fetal thymus in spatially distinct waves (100, 101, 125-129). 
TcR--yo+ cells are indeed absent at these epithelial sites in nude mice (101, 130), but present 
in spleen (123, 124, 131), lymph nodes (1S), and intestine (101). Also in man no predominance 
of TcR--yo+ cells in epidermis and epithelia of reproductive organs has been found (44,45, 132). 
Therefore, the various TcR--ycS+ cell lineages in mice may have different environmental 
requirements for development (101, 131), whereas in man there is no evidence yet for direct 
TABLE 4. Expression of CD4 and CDS molecules by TcR-a.B+ and TcR--yo+ T lymphocytes in blood from 
healthy individuals 
TcR-a.B+T lymphocytesa TcR--yo+ T Jymphocytesb 
CD4+ cos+ C04+ cos+ 
Children: 0-2 y 65-85% 15-35% 1±1% 10±7% 
(n=35) (n=16) 
Children: 2-16 y 50-70% 30-50% 0.5±0.5% 5±4% 
(n=62) (n=17) 
Adults 50-75% 25-50% 2±5% 9±7% 
(n= 16) (n=16) 
a. Normal values for expression of CD4 and CDS molecules by TcR-a,B+ T lymphocytes, as determined in the immunodiagnostic laboratory 
of the Department of Immunology, University Hospital Dijkzigt/ Erasmus University, Rotterdam. The numbers of healthy individuals tested 
per age group are given in parentheses. 
b. Expression of CD4 and CDS molecules by TcR-76+ T lymphocytes as determined by double immunofluorescence stainings (25,33). The 
numbers of healthy individuals tested per age group are given in parentheses. 
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involvement of the thymus in differentiation of TcR--yo cells. 
To study the situation in man, we have enumerated TcR-a.B+ and TcR--yo+ T lymphocytes 
in blood samples from eight infants with DiGeorge anomaly (DGA) (33). DGA is characterized 
by facial, cardiac, parathyroid and thymic defects, due to malformations or disruptions of the 
pharyngeal arches and pouches from which these organs develop (133-136). The degree of 
thymus hypoplasia or aplasia in DGA is assumed to determine the degree of T cell immuno-
deficiency (i.e. from partial to complete) (134, 136). The eight patients represented the broad 
spectrum from partial to complete DGA with respect to their T cell immunodeficiency. Seven 
patients had partial DGA with variable degrees of T cell deficiency and one patient had 
complete DGA with extremely low numbers of blood T lymphocytes. To obtain normal values 
for the expression of TcR-a.B and TcR--yo by peripheral T lymphocytes, we collected blood 
samples from hundred-eleven healthy children in different age groups. 
In the healthy children the majority of the CD3+ T lymphocytes expressed TcR-a,B, while a 
minority expressed TcR--yo (Figure 7). in the seven infants with partial DGA the decrease in T 
lymphocytes mainly involved the TcR-a.B+ cells, while the absolute numbers of TcR--yo+ cells 
were much less affected. In the one patient with complete DGA the great majority of the few 
remaining CD3+ T lymphocytes expressed TcR--yo, while virtually no TcR-a.B+ T lymphocytes 
were found (Figure 7). Interestingly, the absolute number of TcR--yo+ cells in the blood of this 
complete DGA patient was just below the normal range for age (33). These data indicate that 
the T cell deficiency in DGA patients is mainly restricted to the TcR-a.B+ T lymphocytes. 
It is generally assumed that the variable degree of T cell immunodeficiency in DGA is 
directly related to the degree of thymus hypoplasia or aplasia, since the thymic defect in DGA 
involves thymic mass rather than a dysplastic process, i.e. a quantitative instead of a qualitative 
defect (134, 136). Our data indicate that the development of TcR-a,B + cells is severely hampered 
by decrease in thymic epithelium, while the TcR--yo lineage is significantly less affected. This 
suggests that TcR--yo+ T lymphocytes in man can develop via an extrathymic differentiation 
pathway. 
It is remarkable that in healthy children the absolute numbers of T lymphocytes gradually 
decrease from approximately 4 x 109 /I in early infancy to approximately 1.5 x 109 /I in 
adolescence. This decrease only concerns TcR-a.B+ cells, since the absolute numbers of 
TcR--yo+ cells remain stable (Figure 7). During aging from infancy to adolescence also a 
prominent involution of the thymus occurs (137, 138). This coincidence of thymic involution and 
selective decrease of TcR-a.B+ cells during aging of children is in line with the relationship 
between thymic mass and the absolute numbers of TcR-a.B+ cells, as found in DGA patients. 
All data together indicate that at least a part of the human TcR--yo+ cells are derived from 
an extrathymic differentiation pathway. Given that human TcR--yo + cells isolated from peripheral 
blood display extensive diversity in the junctional region of their TcR-o genes (61-63, 139), this 
would imply that TdT is probably also active during development of TcR--yo+ cells outside the 
thymus. Except for low frequencies of CD2+ /TdT+ cells and CD7+ /TdT+ cells, no TdT+ T cells 
(e.g. CD3+ /TdT+ cells) have been identified outside the thymus so far (24, 140-142). However, 
the putative extrathymic development of TcR--yo+ cells may occur at specific (as yet 
undiscovered) locations. 
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Figure 7. Expression of TcR.a,B and TcR--yo by CD3+ T lymphocytes in neonatal cord blood, blood from healthy 
children (five different age groups) and the patient with complete DGA (see reference 33). The analyses were 
performed by use of TcR/CD3 double immunofluorescence stainings as described (25,33). A: absolute numbers 
ofTcR.a,a+ and TcR--ycS+ T lymphocytes. 8: relative distribution ofTcR.a,B and TcR-ycS expression within the CD3+ 
T lymphocyte population. The vertical lines in the bars represent the SD values. 
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CONClUSION AND SPECUlATIONS 
Our T-ALL studies indicate that during T cell differentiation a hierarchic order of TcR gene 
rearrangements exists. Based on these data as well as recent data from the literature we have 
adapted our linear T cell differentiation scheme to a scheme with an early divergence of the a.f3 
and rs pathway. This early divergence is probably mediated via rearrangement/deletion 
processes in the TcR-a./Siocus, which are dependent on the activity of the silencer of the TcR-a. 
gene enhancer (Figures 5 and 6). 
While the a.f3 pathway is assumed to be strictly thymus-dependent, we have strong evidence 
that at least a part of the rs pathway is not. This is based on our immunophenotypic studies 
of normal thymus and blood samples (Table 1 and Figure 7) as well as on analyses of blood 
samples from athymic patients, i.e. children with DGA (Figure 7). 
Mechanisms of thymic negative and positive selection play a crucial role in the generation 
of TcR-a.{3 cell repertoire and influence the subsequent expression of CD4 and CDS molecules 
(143, 144). It is not known whether similar thymic selection processes also influence the 
repertoire of TcR-rs+ cells. Concerning the thymus-dependency ofT cell differentiation we 
would like to speculate that in man migration of prothymocytes into the thymus and interaction 
with thymic epithelial cells will switch off the silencer of the TcR-a. gene enhancer. In this way 
the majority of the thymic T cells are induced to develop along the a.f3 pathway, whereas only 
a minority escape the down regulation of the silencer and thereby develop along the rs 
pathway. This hypothesis would also explain why extrathymic T cell development (as in DGA 
patients) mainly results in TcR-rs+ cells and not in TcR-a.f3+ cells, if one assumes that 
extrathymic decrease of the activity of the a silencer is an inefficient process. The relatively high 
frequency of TcR-rs+ cells in the thymus during early murine ontogeny (98-101) may be 
explained by immaturity of the thymic epithelium. 
ACKNOWLEDGMENTS. We thank Professor Dr. R. Benner, Dr. H. Hooijkaas and Dr. H.J. Adriaansen for their 
continuous support, Mr. T.M. van Os (Department of Immunology, Erasmus University, Rotterdam) and Mr. C. van 
Dijk (lnterpoint, Hapert) for preparation of the figures and Ms. H.J. de Jager for typing the manuscript. 
REFERENCES 
1. Basch RS, Kadish JL Hematopoietic thymocyte precursors II: properties of precursors. J Exp Med 1977; 
145:405-19. 
2. Lepault F, Weissman IL. An in vivo assay for thymus-homing bone marrow cells. Nature 1981 ;293:151-4. 
3. Boersma W, Betel I, Daculsi R, Vander Westen G. Post-irradiation thymocyte regeneration after bone marrow 
transplantation 1: regeneration and quantification of thymocyte progenitor cells in the bone marrow. Cell 
Tissue Kinet 1981;14:179-96. 
4. Ezine S, Weissman IL, Rouse RV. Bone marrow cells give rise to distinct cell clones within the thymus. Nature 
1984;309:629-31. 
5. Janossy G, Bellum FJ, Bradstock KF, Ashley J. Cellular phenotypes of normal and leukemic hemopoietic 
cells determined by analysis with selected antibody combinations. Blood 1980;56:430-41. 
6. Foon KA, Todd Ill RF. Immunologic classification of leukemia and lymphoma. Blood 1986;68:1-31. 
7. Van Dongen JJM, Adriaansen HJ, Hooijkaas H. lmmunophenotyping of leukemias and non-Hodgkin 
lymphomas: immunological markers and their CD codes. Neth J Med 1988;33:298-314. 
T cell development 205 
s. Royer HD, Reinherz EL. T lymphocytes: ontogeny, function, and relevance to clinical disorders. N Engl J 
Med 19S7;317:1136-42. 
9. Marrack P, Kappler J. The T cell receptor. Science 19S7;23S:1073-9. 
1 0. Clevers H, Alarcon B, Wileman T, Terhorst C. The T cell receptor jCD3 complex: a dynamic protein ensemble. 
Annu Rev lmmunol1988;6:629-62. 
11. Brenner MB, Mclean J, Dialynas DP, Strominger JL, Smith JA, Owen FL, Seidman JG, lp S, Rosen F, Krangel 
MS. Identification of a putative second T-cell receptor. Nature 19S6;322:145-9. 
12. Borst J, Van de Griend RJ, Van Oostveen JW, Ang S-L, Melief CJ, Seidman JG, Bolhuis RLH. AT-cell 
receptor 1 jCD3 complex found on cloned functional lymphocytes. Nature 19S7;325:683-S. 
13. Lanier LL, Weiss A. Presence of Ti (WT31) negative T lymphocytes in normal blood and thymus. Nature 
19S6;324:26S-70. 
14. Borst J, Van Dongen JJM, Bolhuis RLH, Peters PJ, Hatler DA, De Vries E, Van de Griend RJ. Distinct 
molecular forms of human T cell receptor 11 o detected on viable T cells by a monoclonal antibody. J Exp 
Med 1988;167:1625-44. 
15. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988;334:395-402 and 
corrigenda 1988;335:744. 
16. Littman DR. The structure of the CD4 and CDS genes. Annu Rev lmmunol 19S7;5:561-84. 
17. Parnes JR. Molecular biology and function of CD4 and CDS. Adv lmmunoi19S9;44:265-311. 
1S. Matis LA, Cron R, Bluestone JA. Major histocompatibility complex-linked specificity of -yo receptor-bearing 
T lymphocytes. Nature 19S7;330:262-4. 
19. Strominger JL. The -yo T cell receptor and class lb MHC-related proteins: enigmatic molecules of immune 
recognition. Cell 19S9;57:S95-8. 
20. Bonneville M, Ito K, Krecko EG, ltohara S, Kappes D, Ishida I, Kanagawa 0, Janeway CA jr, Murphy DB, 
Tonegawa S. Recognition of a self major histocompatibility complex TL region product by 1 o T -cell receptors. 
Proc Natl Acad Sci USA 19S9;S6:592S-32. 
21. DentAL, Matis LA, Hooshmand F, Widacki SM, Bluestone JA, Hedrick SM. Self-reactive -yo T cells are 
eliminated in the thymus. Nature 1990;343:714-9. 
22. Van Dongen JJM, Hooijkaas H, Hahlen K, Van Zanen GE. The small subpopulation ofT cell marker+ jTdT+ 
cells in the human bone marrow may represent prothymocytes. Adv Exp Med Biol1985;186:889-99. 
23. Van Dongen JJM, Hooijkaas H, Comans-Bitter WM, Benne K, Van Os TM, De Josselin de Jong J. Triple 
immunological staining using colloidal gold, fluorescein and rhodamine as labels. J lmmunol Methods 
19S5;S0:1-6. 
24. Van Dongen JJM, Hooijkaas H, Comans-Bitter WM, Hahlen K, De Klein A, Van Zanen GE, Van 't Veer MB, 
Abels J, Benner R. Human bone marrow cells positive for terminal deoxynucleotidyl transferase (TdT), 
HLA-DR, and aT cell marker may represent prothymocytes. J lmmunol1985;135:3144-50. 
25. Van Dongen JJM, Adriaansen HJ, Hooijkaas H. Immunological marker analysis of cells in the various hemato-
poietic differentiation stages and their malignant counterparts. In: Ruiter DJ, Fleuren GJ, Warnaar SO, eds. 
Application of monoclonal antibodies in tumor pathology. Dordrecht: Martinus Nijhoff Publishers, 19S7:S7-
116. 
26. Van Dongen JJM, Comans-Bitter WM. Phenotypic and genotypic characteristics of the human prothymocyte. 
lmmunol Res 19S7;6:250-62. 
27. Van Dongen JJM, Krissansen GW, Wolvers-Tettero ILM, Comans-Bitter WM, Adriaansen HJ, Hooijkaas H, 
Van Wering ER, Terhorst C. Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature 
T-cell malignancies. Blood 19SS;71 :603-12. 
2S. Borst J, Wicherink A, Van Dongen JJM, De Vries E, Comans-Bitter WM, Wassenaar F, Van den Elsen P. 
Non-random expression ofT cell receptor 1 and o variable gene segments in functional T lymphocyte clones 
from human peripheral blood. Eur J lmmunoi19S9;19:1559-68. 
29. Van DongenJJM, QuertermousT, Bartram CR, Gold DP, Wolvers-Tettero ILM, Comans-BitterWM, Hooijkaas 
H, Adriaansen HJ, De Klein A, Raghavachar A, Ganser A, Duby AD, Seidman JG, Van den Elsen P, Terhorst 
C. T cell receptor-CD3 complex during early T cell differentiation: analysis of immature T cell acute 
lymphoblastic leukemias (T-ALL) at DNA, RNA, and cell membrane level. J lmmunol 19S7;13S:1260-9. 
30. Quertermous T, Strauss WM, Van Dongen JJM, Seidman JG. Human T cell'"( chain joining regions and T 
cell development. J lmmunol 19S7;13S:2687-90. 
206 CHAPTER4.1 
31. Van Dongen JJM, Wolvers-Tettero ILM, Seidman JG, Ang S-L, Van de Griend RJ, De Vries EFR, Borst J. Two 
types of gamma T cell receptors expressed by T cell acute lymphoblastic leukemias. Eur J lmmunol 
1987;17:1719-28. 
32. Van Dongen JJM, Wolvers-Tettero ILM, Wassenaar F, Borst J, Van den Elsen P. Rearrangement and 
expression ofT cell receptor delta genes in T cell acute lymphoblastic leukemias. Blood 1989;74:334-42. 
33. Van Dongen JJM, Comans-Bitter WM, Friedrich W, Neijens HJ, Belohradsky BH, Kohn Th, Hagemeijer A, 
Borst J. Analysis of patients with DiGeorge anomaly provides evidence for extrathymic development of 
TcR--y5+ lymphocytes in man. Submitted for publication. 
34. Reinherz EL, Kung PC, Goldstein G, Levey RH, Schlossman SF. Discrete stages of human intrathymic 
differentiation: analysis of normal thymocytes and leukemic lymphoblasts ofT-cell lineage. Proc Natl Acad 
Sci USA 1980;77:1588-92. 
35. Bellum FJ. Terminal deoxynucleotidyl transferase as a hematopoietic cell marker. Blood 1979;54:1203-15. 
36. Alt FW, Baltimore D. Joining of immunoglobulin heavy chain gene segments: implications from a 
chromosome with evidence of three D-JH fusions. Proc Natl Acad Sci USA 1982;79:4118-22. 
37. Desiderio SV, Yancopoulos GD, Paskind M, Thomas E, Boss MA, Landau N, Alt FW, Baltimore D. Insertion 
of N regions into heavy-chain genes is correlated with expression of terminal deoxytransferase in B cells. 
Nature 1984;311 :752-5. 
38. Landau NR, Schatz DG, Rosa M, Baltimore D. Increased frequency of N-region insertion in a murine pre-B-cell 
line infected with a terminal d~oxynucleotidyl transferase retroviral expression vector. Mol Cell Bioi 
1987;7:3237 -43. 
39. Furley AJ, Mizutani S, Weilbaecher K, Dhaliwal HS, Ford AM, Chan LC, Melgaard HV, Toyonaga B, Mak T, 
Van den Elsen P, Gold D, Terhorst C, Greaves MF. Developmentally regulated rearrangement and expression 
of genes encoding the T cell receptor-T3 complex. Cell 1986;46:75-87. 
40. Link MP, Stewart SJ, Warnke RA, Levy R. Discordance between surface and cytoplasmic expression of the 
Leu-4 (T3) antigen in thymocytes and in blast cells from childhood T lymphoblastic malignancies. J Clin 
Invest 1985;76:248-53. 
41. Campana D, Thompson JS, Amiot P, BrownS, Janossy G. The cytoplasmic expression of CD3 antigens in 
normal and malignant cells of the T lymphoid lineage. J lmmunol 1987;138:648-55. 
42. Lanier LL, Allison JP, Phillips JH. Correlation of cell surface antigen expression on human thymocytes by 
multi-color flow cytometric analysis: implications for differentiation. J lmmunol1986;137:2501-7. 
43. Campana D, Janossy G, Coustan-Smith E, Amiot PL, Tian W-T, lp S, Wong L. The expression of T cell 
receptor-associated proteins during T cell ontogeny in man. J lmmunol1989;142:57-66. 
44. Groh V, Porcelli S, Fabbi M, Lanier LL, Picker LJ, Anderson T, Warnke RA, Bhan AK, Strominger JL, Brenner 
MB. Human lymphocytes bearing T cell receptor 1 I 5 are phenotypically diverse and evenly distributed 
throughout the lymphoid system. J Exp Med 1989;169:1277-94. 
45. Falini B, Flenghi L, Pileri S, Pelicci P, Fagioli M, Martelli MF, Maretta L, Ciccone E. Distribution ofT cells 
bearing different forms of the T cell receptor -y I 5 in normal and pathological human tissues. J lmmunol 
1989;143:2480-8. 
46. Campana D, Van Dongen JJM, Mehta A, Coustan-Smith E, Wolvers-Tettero ILM, Ganeshaguru K, Janossy 
G. The stages of T cell receptor protein expression in T cell acute lymphoblastic leukemia. Manuscript 
submitted. 
47. Loiseau P, Guglielmi P, Le Paslier D, Macintyre E, Gessain A, Bories J-C, Flandrin G, Chen Z, Sigaux F. 
Rearrangements of the T cell receptor 5 gene in T acute lymphoblastic leukemia cells are distinct from those 
occurring in B lineage acute lymphoblastic leukemia and preferentially involve one V5 gene segment. J 
lmmunol1989;142:3305-11. 
48. Gouttefangeas C, Bensussan A, Boumsell L. Study of the CD3-associated T-cell receptors reveals further 
differences between T-cell acute lymphoblastic lymphoma and leukemia. Blood 1990;75:931-4. 
49. Hayday AC, Diamond DJ, Tanigawa G, Heilig JS, Folsom V, Saito H, Tonegawa S. Unusual organization and 
diversity ofT-cell receptor a-chain genes. Nature 1985;316:828-32. 
50. Yoshikai Y, Clark SP, TaylorS, Sohn U, Wilson Bl, Minden MD, Mak TW. Organization and sequences of the 
variable, joining and constant region genes of the human T-cell receptor a-chain. Nature 1985;316:837-40. 
51. Sims JE, Tunnacliffe A, Smith WJ, Rabbitts TH. Complexity of human T-cell antigen receptor ,8-chain constant-
and variable-region genes. Nature 1984;312:541-5. 
T cell development 207 
52. Toyonaga B, Yorshikai Y, Vadasz V, Chin B, Mak TW. Organization and sequences of the diversity, joining, 
and constant region genes of the human T-cell receptor f3 chain. Proc Nat! Acad Sci USA 1985;82:8624-8. 
53. Duby AD, Seidman JG. Abnormal recombination products result from aberrant DNA rearrangement of the 
human T-cell antigen receptor {3-chain gene. Proc Nat! Acad Sci USA 1986;83:4890-4. 
54. lefranc M-P, Rabbitts TH. Two tandemly organized human genes encoding the T-cell "Y constant-region 
sequences show multiple rearrangement in different T-cell types. Nature 1985;316:464-6. 
55. lefranc M-P, Forster A, Baer R, Stinson MA, Rabbitts TH. Diversity and rearrangement of the human T cell 
rearranging -y genes: nine germ-line variable genes belonging to two subgroups. Cell1986;45:237-46. 
56. lefranc M-P, Rabbitts TH. The human T -cell receptor"'{ (TRG) genes. Trends Biochem Sciences 1989;14:214-
8 
57. Baer R, Boehm T, Yssel H, Spits H, Rabbitts TH. Complex rearrangements within the human Jo-CojJc:t-Cc:t 
locus and aberrant recombination between Jc:t segments. EMBO J 1988;7:1661-8. 
58. lsobe M, Russo G, Haluska FG, Croce CM. Cloning of the gene encoding the c5 subunit of the human T-cell 
receptor reveals its physical organization within the a-subunit locus and its involvement in chromosome 
translocations in T-cell malignancy. Proc Nat! Acad Sci USA 1988;85:3933-7. 
59. Satyanarayana K, Hata S, Devlin P, Grazia Roncarolo M, De Vries JE, Spits H, Strominger Jl, Krangel MS. 
Genomic organization of the human T-cell antigen-receptor aj c5 locus. Proc Natl Acad Sci USA 1988;85:8166-
70. 
60. Takihara Y, Tkachuk D, Michalopoulos E, Champagne E, Reimann J, Minden M, Mak TW. Sequence and 
organization of the diversity, joining, and constant region genes of the human T-cell o-chain locus. Proc Nat! 
Acad Sci USA 1988;85:6097-101. 
61. loh EY, Cwirla S, Serafini AT, Phillips JH, Lanier ll. The human T-cell receptor delta chain: genomic 
organization, diversity, and expression in populations of cells. Proc Natl Acad Sci USA 1988;85:9714-8. 
62. Hata S, Clabby M, Devlin P, Spits H, De Vries JE, Krangel MS. Diversity and organization of human T cell 
receptor c5 variable gene segments. J Exp Med 1989;169:41-57. 
63. Takihara Y, Reimann J, Michalopoulos E, Ciccone E, Maretta l, Mak TW. Diversity and structure of human 
T cell receptor c5 chain genes in peripheral blood-y jo-bearing T lymphocytes. J Exp Med 1989;169:393-405. 
64. Quertermous T, Strauss W, Murre C, Dialynas DP, StromingerJl, Seidman JG. Human T-cell -y genes contain 
N segments and have marked junctional variability. Nature 1986;322:184-7. 
65. Hata S, Satyanarayane K, Devlin P, Band H, Mclean J, Strominger Jl, Brenner MB, Krangel MS. Extensive 
junctional diversity of rearranged human T cell receptor c5 genes. Science 1988;240:1541-4. 
66. Littman DR, Newton M, Crommie D, Ang S-l, Seidman JG, Gettner SN, Weiss A. Characterization of an 
expressed CD3-associated Ti "'{-chain reveals C-y domain polymorphism. Nature 1987;326:85-8. 
67. Krangel MS, Band H, Hata S, Mclean J, Brenner MB. Structurally divergent human T cell receptor -y proteins 
encoded by distinct C-y genes. Science 1987;237:64-7. 
68. lefranc M-P, Forster A, Rabbitts TH. Genetic polymorphism and exon changes of the constant regions of 
the human T-cell rearranging gene"'{. Proc Natl Acad Sci USA 1986;83:9596-600. 
69. Christmas SE. Most human CD3+WT31- clones with T cell receptor C-y1 rearrangements show strong non-
MHC-restricted cytotoxic activity in contrast to those with C-y2 rearrangements. Eur J lmmunol 1989; 19:7 41-
6. 
70. Grossi CE, Ciccone E, Migone N, Bottino C, Zarcone D, Mingari MC, Ferrini S, Tambussi G, Viale 0, Casorati 
G, Millo R, Maretta l, Maretta A. Human T cells expressing the-y joT-cell receptor (TcR-1): C-y1-and C-y2-
encoded forms of the receptor correlate with distinctive morphology, cytoskeletal organization, and growth 
characteristics. Proc Nat! Acad Sci USA 1989;86:1619-23. 
71. Greenberg JM, Quertermous T, Seidman JG, Kersey JH. Human T cell "'{-chain gene rearrangements in acute 
lymphoid and nonlymphoid leukemia: comparison with the T cell receptor {3-chain gene. J lmmunol 
1986; 137:2043-9. 
72. Davey MP, Bongiovanni KF, Kaulfersch W, Quertermous T, Seidman JG, Hershfield MS, Kurtzberg J, Haynes 
BF, Davis MM, Waldmann TA. Immunoglobulin and T-cell receptor gene rearrangement and expression in 
human lymphoid leukemia cells at different stages of maturation. Proc Nat! Acad Sci USA 1986;83:8759-63. 
73. Goorha R, Bunin N, Mirra J, Murphy SB, Cross AH, Behm FG, Quertermous T, Seidman J, Kitchingman GR. 
Provocative pattern of rearrangements of the genes for the -y and f3 chains of the T-cell receptor in human 
leukemias. Proc Natl Acad Sci USA 1987;84:4547-51. 
208 CHAPTER4.1 
74. Felix CA, Wright JJ, Poplack DG, Reaman GH, Cole D, Goldman P, Korsmeyer SJ. T cell receptor a-, {3-, 
and r-genes in T cell and pre-B cell acute lymphoblastic leukemia. J Clin Invest 1987;80:545-56. 
75. Le Paslier D, Chen Z, Loiseau P, Cohen D, Sigaux F. T cell rearranging gene r: diversity and mRNA 
expression in fresh cells from T cell acute lymphoblastic leukemia. Blood 1987;70:637-46. 
76. Foroni L, Foldi J, Matutes E, Catovsky D, O'Connor NJ, Baer R, Forster A, Rabbitts TH, Luzzatto L. a, {3 and 
r T-cell receptor genes: rearrangements correlate with haematological phenotype in T cell leukaemias. Br 
J Haematol1987;67:307-18. 
77. Miwa H, Konishi H, Kobayashi N, Kita K, Shirakawa S, Shimizu A, Honjo T, Hatanaka M. The T-cell receptor 
gene rearrangements in T-lineage tumors without OKT-3,4,6,8 markers. J Mol Celllmmunol1987;3:37-42. 
78. Tawa A, Benedict SH, Hara J, Hozumi N, Gelfand EW. Rearrangement of the T cell receptor r-chain gene 
in childhood acute lymphoblastic leukemia. Blood 1987;70:1933-9. 
79. Hara J, Benedict SH, Champagne E, Mak TW, Minden M, Gelfand EW. Comparison ofT cell receptor a, {3, 
and r gene rearrangement and expression in T cell acute lymphoblastic leukemia. J Clin Invest 1988;81 :989-
96. 
80. Hara J, Benedict SH, Champagne E, Takihara Y, Mak TW, Minden M, Gelfand EW. T cell receptor o gene 
rearrangements in acute lymphoblastic leukemia. J Clin Invest 1988;82:1974-82. 
81. Hockett RD, De Villartay J-P, Pollock K, Poplack DG, Cohen 01, Korsmeyer SJ. Human T-cell antigen receptor 
(fCR) o-chain locus and elements responsible for its deletion are within the TCR a-chain locus. Proc Nat! 
Acad Sci USA 1988;85:9694-8. 
82. Foroni L, Laffan M, Boehm T, Rabbitts TH, Catovsky D, Luzzatto L. Rearrangement of the T-cell receptor o 
genes in human T-cellleukemias. Blood 1989;73:559-65. 
83. Asou N, Hattori T, Matsuoka M, Kawano F, Takatsuki K. Rearrangements ofT-cell antigen receptor o chain 
gene in hematologic neoplasms. Blood 1989;74:2707-12. 
84. Triebel F, Lefranc M-P, Hercend T. Further evidence for a sequentially ordered activation ofT cell rearranging 
gamma genes during T lymphocyte differentiation. Eur J lmmunol1988;18:789-94. 
85. Koning F, Maloy WL, Cohen D, Coligan JE. Independent association ofT cell receptor {3 and r chains with 
CD3 in the same ceiL J Exp Med 1987;166:595-600. 
86. Boehm TW, Werle A, Ganser A, Kornhuber B, Drahovsky D. T cell receptor r chain variable gene 
rearrangements in acute lymphoblastic leukemias ofT and B lineage. Eur J lmmunol1987;17:1593-7. 
87. Rupp F, Frech G, Hengartner H, Zinkernagel RM, Joho R. No functional r-chain transcripts detected in an 
alloreactive cytotoxic T-cell clone. Nature 1986;321:876-8. 
88. Reilly EB, Kranz OM, Tonegawa S, Eisen HN. A functional 'Y gene formed from known r-gene segments is 
not necessary for antigen-specific responses of murine cytotoxic T lymphocytes. Nature 1986;321 :878-80. 
89. Yoshikai Y, Toyonaga B, Koga Y, Kimura N, Griesser H, Mak TW. Repertoire of the human T cell gamma 
genes: high frequency of nonfunctional transcripts in thymus and mature T cells. Eur J lmmunol1987;17:119-
26. 
90. Chien Y, lwashima M, Kaplan KB, Elliott JF, Davis MM. A newT-cell receptor gene located within the alpha 
locus and expressed early in T-cell differentiation. Nature 1987;327:677-82. 
91. Chien Y, lwashima M, Wettstein DA, Kaplan KB, Elliott JF, Born W, Davis MM. T-cell receptor o gene 
rearrangements in early thymocytes. Nature 1987;330:722-7. 
92. Lindsten T, Fowlkes BJ, Samelson LE, Davis MM, Chien Y-H. Transient rearrangements of the T cell antigen 
receptor a locus in early thymocytes. J Exp Med 1987;166:761-5. 
93. Born W, Rathbun G, Tucker P, Marrack P, Kappler J. Synchronized rearrangement ofT-cell rand {3 chain 
genes in fetal thymocyte development. Science 1986;234:479-82. 
94. Raulet DH, Garman RD, Saito H, Tonegawa S. Developmental regulation ofT-cell receptor gene expression. 
Nature 1985;314:103-7. 
95. Snodgrass HR, Dembic Z, Steinmetz M, Von Boehmer H. Expression ofT-cell antigen receptor genes during 
fetal development in the thymus. Nature 1985;315:232-3. 
96. Snodgrass HR, Kisielow P, Kiefer M, Steinmetz M, Von Boehmer H. Ontogeny of the T-cell antigen receptor 
within the thymus. Nature 1985;313:592-5. 
97. Born W, Yague J, Palmer E, Kappler J, Marrack P. Rearrangement ofT-cell receptor /3-chain genes during 
T-cell development. Proc Nat! Acad Sci USA 1985;82:2925-9. 
98. Pardoll OM, Fowlkes BJ, Bluestone JA, Kruisbeek A, Maloy WL, Coligan JE, Schwartz RH. Differential 
T cell development 209 
expression of two distinct T-cell receptors during thymocyte development. Nature 1987;326:79-81. 
99. Bluestone JA, Pardoll D, Sharrow SO, Fowlkes BJ. Characterization of murine thymocytes with 
CD3-associated T-cell receptor structures. Nature 1987;326:82-4. 
100. Havran WL, Allison JP. Developmentally ordered appearance ofthymocytes expressing differentT-cell antigen 
receptors. Nature 1988;335:443-5. 
101. Tonegawa S, Berns A, Bonneville M, Farr AG, Ishida I, Ito K, ltohara S, Janeway CAjr, Kanagawa 0, Katsuiki 
M, Kubo R, L.afaille JJ, Mombaerts P, Murphy DB, Nakanishi N, Takagaki Y, Van Kaer L, Verbeek S. Diversity, 
development, ligands and probable functions of -yo T cells. Progr lmmunol 1989;7:243-57. 
102. De Villartay J-P, Lewis D, Hockett R, Waldmann TA, Korsmeyer SJ, Cohen Dl. Deletional rearrangement in 
the human T-cell receptor a-chain locus. Proc Natl Acad Sci USA 1987;84:8608-12. 
103. De VillartayJ-P, Hockett RD, Coran D, KorsmeyerSJ, Cohen Dl. Deletion of the humanT-cell receptor o-gene 
by a site-specific recombination. Nature 1988;335:170-4. 
104. Hockett RD, Nunez G, Korsmeyer SJ. Evolutionary comparison of murine and human o T-cell receptor 
deleting elements. New Biologist 1989;1 :266-74. 
105. Takeshita S, Toda M, Yamagishi H. Excision products of the T cell receptor gene support a progressive 
rearrangement model of the ajo locus. EMBO J 1989;8:3261-70. 
106. Begley CG, Aplan PD, Davey MP, De Villertay J-P, Cohen Dl, Waldmann TA, Kirsch IR. Demonstration of 
orec-pseudo Ja rearrangement with deletion of the o locus in a human stem-cell leukemia. J Exp Med 
1989;170:339-42. 
107. Tonegawa S. Somatic generation of antibody diversity. Nature 1983;302:575-81. 
108. Kronenberg M, Siu G, Hood LE, Shastri N. The molecular genetics of the T-cell antigen receptor and T-cell 
antigen recognition. Annu Rev lmmunol1986;4:529-91. 
109. Fujimoto S, Yamagishi H. Isolation of an excision product ofT-cell receptor a-chain gene rearrangements. 
Nature 1987;327:242-3. 
110. Okazaki K, Davis DD, Sakano H. T cell receptor f3 gene sequences in the circular DNA of thymocyte nuclei: 
direct evidence for intramolecular DNA deletion in V-D-J joining. Cell1987;49:477-85. 
111. Toda M, Fujimoto S, lwasato T, Takeshita S, Tezuka K, Ohbayashi T, Yamagishi H. Structure of extra-
chromosomal circular DNAs excised from T-cell antigen receptor alpha and delta-chain loci. J Mol Bioi 
1988;202:219-31. 
112. Okazaki K, Sakano H. Thymocyte circular DNA excised from T cell receptor a-o gene complex. EMBO J 
1988;7:1669-74. 
113. Winoto A, Baltimore D. Separate lineages of T cells expressing the a/3 and -yo receptors. Nature 
1989;338:430-2. 
114. Winoto A, Baltimore D. A novel, inducible and T cell-specific enhancer located at the 3' end of the T cell 
receptor a locus. EMBO J 1989;8:729-33. 
115. Winoto A, Baltimore D. af3 lineage-specific expression of the aT cell receptor gene by nearby silencers. Cell 
1989;59:649-55. 
116. Bories JC, Loiseau P, d' Auriol L, Gontier C, Bensussan A, Degos L, Sigaux F. Regulation of transcription of 
the human T cell antigen receptor o chain gene: aT lineage-specific enhancer element is located in the Jo3-
Co intron. J Exp Med 1990;171 :75-83. 
117. Bonneville M, Ishida I, Mombaerts P, Katsuki M, Verbeek S, Berns A, Tonegawa S. Blockage of a/3 T-cell 
development by TcR -yo transgenes. Nature 1989;342:931-4. 
118. Ishida I, Verbeek S, Bonneville M, Berns A, Tonegawa S. T cell receptor -yo transgenic mice suggest a role 
of a 'Y gene silencer in the generation of a/3 T cells. Proc Natl Acad Sci USA, in press. 
119. Hochstenbach F, Brenner MB. T-cell receptor o-chain can substitute for a to form a {3o heterodimer. Nature 
1989;340:562-5. 
120. Saito T, Hochstenbach F, Marusic-Galesic S, Kruisbeek AM, Brenner M, Germain RN. Surface expression of 
only -yo andjor a/3 T cell receptor heterodimers by cells with four (a, {3, 'Y. o) functional receptor chains. J 
Exp Med 1988;168:1003-20. 
121. De Waal Malefyt R, Alarcon B, Yssel H, Sancho J, Miyajima A, Terhorst CP, Spits H, De Vries JE. Introduction 
ofT cell receptor (TcR)-a eDNA has differential effects on TcR--yojCD3 expression by peer and lyon-1 cells. 
J lmmunol 1989;142:3634-42. 
122. Strominger JL. Developmental biology ofT cell receptors. Science 1989;244:943-50. 
210 CHAPTER 4.1 
123. Yoshikai Y, Reis MD, Mak TW. Athymic mice express a high level of functional'}'-chain but greatly reduced 
levels of a- and ,8-chain T cell receptor messages. Nature 1986;324:482-5. 
124. Yoshikai Y, Matsuzaki G, Takeda Y, Ohga S, Kishihara K, Yuuki H, Nomoto K. Functional T cell recptor o 
chain gene messages in athymic nude mice. Eur J lmmunol1988;18:103943. 
125. Havran WL, Grell S, Duwe G, Kimura J, Wilson A, Kruisbeek AM, O'Brien RL, Born W, Tigelaar RE, Allison 
JP. Limited diversity ofT-cell receptor '}'-chain expression of murine Thy-1 + dendritic epidermal cells revealed 
by V-y3-specific monoclonal antibody. Proc Natl Acad Sci USA 1989;86:4185-9. 
126. Lafaille JJ, DeCioux A, Bonneville M, Takagaki Y, Tonegawa S. Junctional sequences ofT cell receptor -yo 
genes: implications for -yo T cell lineages and for a novel intermediate of V-(D)-J joining. Cell1989;59:859-
70. 
127. Ito K, Bonneville M, Takagaki Y, Nakanishi N, Kanagawa 0, Krecko EG, Tonegawa S. Different -yo T-cell 
receptors are expressed on thymocytes at different stages of development. Proc Natl Acad Sci USA 
1989;86:631-5. 
128. ltohara S, Nakanishi N, Kanagawa 0, Kubo R, Tonegawa S. Monoclonal antibodies specific to native murine 
T-cell receptor -yO: analysis of -yo T cells during thymic ontogeny and in peripheral lymphoid organs. Proc 
Natl Acad Sci USA 1989;86:5094-8. 
129. Asarnow DM, Goodman T, LeFrancois L, Allison JP. Distinct antigen receptor repertoires of two classes of 
murine epithelium-associated T cells. Nature 1989;341 :60-2. 
130. Nixon-Fulton JL, Kuziel WA, Santerse B, Bergstresser PR, Tucker PW, Tigelaar RE. Thy-1 + epidermal cells 
in nude mice are distinct from their counterparts in thymus-bearing mice: a study of morphology, function, 
and T cell receptor expression. J lmmunol 1988;141:1897-903. 
131. Pardoll DM, Fowlkes BJ, Lew AM, MaloyWL, Weston MA, Bluestone JA, Schwartz RH, Coligan JE, Kruisbeek 
AM. Thymus-dependent and thymus-independent developmental pathways for peripheral T cell receptor-
-yo-bearing lymphocytes. J lmmunol1988;140:4091-6. 
132. Vroom TM, Bos JD, Borst J. Scientific correspondence. Nature 1989;341 :114. 
133. DiGeorge AM. Congenital absence of the thymus and its immunologic consequences: concurrence with 
congenital hypoparathyroidism. Birth Defects 1968;4(1):116-21. 
134. Belohradsky BH. Thymusaplasie und -hypoplasia mit Hypoparathyreoidismus, Herz- und GefaBmiBbildungen 
(Di-George-Syndrom). Ergebnisse der lnneren Medizin und Kinderheilkunde 1985;54:35-105. 
135. Lammer EJ, Opitz JM. The DiGeorge anomaly as a developmental field defect. Am J Med Genet 1986;2S:113-
27. 
136. Bastian J, LawS, Vogler L, Lawton A, Herrod H, Anderson S, Horowitz S,Hong R. Prediction of persistent 
immunodeficiency in the DiGeorge anomaly. J Pediatr 1989;115:391-6. 
137. Steinmann GG, Klaus B, MOIIer-Hermelink H-K. The involution of the ageing human thymic epithelium is 
independent of puberty. Scand J lmmunol1985;22:563-75. 
138. Steinmann GG. Changes in the human thymus during aging. Current Topics Pathol1986;75:43-88. 
139. Koning F, Knot M, Wassenaar F, Van den Elsen P. Phenotypical heterogeneity among human T cell receptor 
1 I o-expressing clones derived from peripheral blood. Eur J lmmunol 1989;19:2099-1 05. 
140. Janossy G, Tid man N, Papageorgiou ES, Kung PC, Goldstein G. Distribution ofT lymfocyte subsets in the 
human bone marrow. and thymus: an analysis with monoclonal antibodies. J lmmunol1981;126:1608-13. 
141. Neudorf SML, Le Bien TW, Bollum F, Kersey JH. Double fluorochrome analysis of human bone marrow 
lymphoid cells: studies with terminal transferase and anti-T-cell monoclonal antibodies. Exp Hematol 
1984;12:69-73. 
142. Van Dongen JJM, Hooijkaas H, Adriaansen HJ, Hahlen K, Van Zanen GE. Detection of minimal residual acute 
lymphoblastic leukemia by immunological marker analysis: possibilities and limitations. In: Hagenbeek A, 
Lowenberg B, eds. Minimal rsidual disease in acute leukemia. Dordrecht: M Nijhoff Publishers, 1986:113-
33. 
143. Von Boehmer H, Kisielow P, Kishi H, Scott B, Borgulya P, Teh HS. The expression of CD4 and CDS 
accessory molecules on mature T cells is not random but correlates with the specificity of the a.B receptor 
for antigen. lmmunol Rev 1989;109:143-51. 
144. Van Ewijk W, Kisielow P, Von Boehmer H. Immunohistology of T cell differentiation in the thymus of 
H-Y-specific T cell receptor aj,B transgenic mice. Eur J lmmunol 1990;20:129-37. 
211 
CHAPTER 4.2 
HUMAN BONE MARROW CEllS POSITIVE FOR TERMINAl 
DEOXYNUClEOTIDYl TRANSFERASE (TdT), HlA-DR, AND A T CEll 
MARKER MAY REPRESENT PROTHYMOCYTES * 
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SUMMARY 
Recent evidence suggests that prothymocytes, which occur in a low frequency in murine 
bone marrow (BM), are already committed to thymocyte differentiation and discrete from 
precursor B cells as well as pluripotent hematopoietic stem cells. Furthermore, it was suggested 
that, in rodents, prothymocytes are positive for the nuclear enzyme terminal deoxynucleotidyl 
transferase (TdT) and a T cell surface antigen. The human prothymocyte has not been 
identified as yet. We analyzed human BM cells by double immunofluorescence staining for TdT 
and the T cell surface antigens CD1, C02, CDS and CD?. In the BM samples tested, neither 
CD1 + jTdT+ nor cos+ /TdT+ cells were detected, but C02+ /TdT+ and CD?+ jTdT+ cells were 
present in low frequencies. In childhood BM, the frequency was about two to five in 10,000, 
whereas in adult BM and regenerating BM, these cells were not always detectable, but if 
detected, their frequency was five- to 10-fold lower. In a triple staining, using fluorescein, 
rhodamine, and colloidal gold particles as labels, it appeared that all CD?+ /TdT+ cells were 
also positive for HLA-DR. These CD?+ /HLA-DR+ /TdT+ cells were also detectable in low 
frequencies in the thymus, and occasionally C02+ /TdT+ and CD?+ /TdT+ cells were detected 
in the peripheral blood (PB), suggesting a migration from the BM to the thymus via the PB. The 
malignant counterpart of the CD?+ /HLA-DR+ /TdT+ cell was detected in a patient with acute 
lymphoblastic leukemia with the C02+ /CD?+ /HLA-DR+ /TdT+ /CD1-/CDS- phenotype and 
germline immunoglobulin heavy chain genes. We postulate that the C02+ /CD?+ /HLA-
DR + /TdT+ /CD1-;cos- cell represents a human prothymocyte. 
* Published in: J lmmunol 1985;135:3144-50. Updated for CD codes. 
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INTRODUCTION 
Bone marrow (BM) and thymus are the breeding sites of B and T lymphocytes, respectively 
(1). Pre-B cells have been identified in the BM and fetal liver as large lymphoid cells with a small 
amount of cytoplasmic immunoglobulin {lg) and without surface lg (2). The precursors of the 
T lymphocytes, the so-called "prothymocytes", are also generated in the hematopoietic organs 
(3,4). Recent evidence suggests that prothymocytes, which occur in low frequencies in murine 
BM (0.015 to 0.03%) (5-7), are already committed to thymocyte differentiation and discrete from 
precursor B cells as well as pluripotent hematopoietic stem cells {8-1 0). Although the phenotype 
of the thymocyte is well described (1 ,4, 11-13), the phenotype of the prothymocyte is not well 
known. 
Several investigators suggest that rodent prothymocytes may be positive for the nuclear 
enzyme terminal deoxynucleotidyl transferase (TdT) and aT cell surface antigen (10,14-19). 
Jannossy and colleagues (20,21) have suggested that the human prothymocyte belongs 
to the pool of 0.3 to 10% TdT+ cells in normal BM. However, cells positive for both aT cell 
marker and TdT have never been demonstrated in extrathymic locations such as BM, except 
in patients with T cell acute lymphoblastic leukemia (T-ALL) (13,20-23). Because thymus 
repopulation experiments in mouse and rat have demonstrated that the prothymocytes are 
extremely rare in the BM (5-7, 17), we have standardized a method for identifying rare immature 
lymphoid cells by simultaneous detection of two or three markers {24,25). By using TdT, HLA-
DR, and T cell surface antigens as markers, we analyzed BM, peripheral blood (PB), and 
thymus samples from children, BM samples from adults, and liver and BM samples from 
fetuses to determine whether immature T cells are detectable in these cell samples. In addition, 
the BM cells from a patient suffering from an ALL with a rare immunologic phenotype were 
studied. 
MATERIALS AND METHODS 
Cell samples 
1. BM and PB samples from children and adults. 
Thirty-nine BM samples were obtained from 34 children and five adults, and 10 PB samples were obtained 
from 10 children. The childhood BM samples were obtained from 12 children with precursor B-ALL (common ALL 
or pre-B-ALL) in complete remission under maintenance therapy, from four children with T-ALL under maintenance 
therapy (who were at least 6 mo in remission since the BM sampling), and from seven children with precursor 
B-ALL in complete remission, 6 wk after termination of maintenance therapy. In addition, BM samples wera 
obtained from 11 children suffering from non-lymphoid malignancies with normal BM morphology, who did not 
receive any prior chemotherapy. The adult BM samples were obtained from five healthy volunteers {21 to 28 y 
old). The childhood PB samples were obtained from 10 children with precursor B-ALL in complete remission under 
maintenance therapy. 
2. Thymus samples. 
Four thymus samples were obtained from four children ( <2 y old) undergoing cardiac surgery. These samples 
were minced with scissors in RPMI1640 medium containing 10% fetal calf serum (FCS) and were flushed through 
a nylon gauze filter with 100-JLm openings (Stokvis and Smits Textielmij, Haarlem, The Netherlands). 
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3. Fetal liver and BM samples. 
Eight human fetuses of 14 to 19 wk gestational age were obtained by interruption of pregnancy on nonmedical 
indications. Fetal liver samples were minced with scissors in RPM I 1640 medium containing 1 O% FCS and were 
flushed through 100-JLm nylon gauze. Fetal BM cells were sampled by flushing the long bones with a 10% FCS-
RPMI solution; afterwards, the BM cells were flushed through 100-JLm nylon gauze. 
4. BM sample from ALL patient at diagnosis. 
A BM sample was obtained from a 34-y-old man suffering from an acute leukemia. According to conventional 
morphology and cytochemistry, this leukemia appeared to be an ALL. The laboratory values at diagnosis revealed 
a hemoglobin of 5.4 mmol jl, platelets 90 x 1 o9 jl, and white blood cells 2.4 x 1 09 jl, of which 71% were 
lymphoblasts. In the BM, all cells appeared to be lymphoblasts. Physical examination revealed discrete 
lymphadenopathy, no hepatosplenomegaly, and no mediastinal mass. The patient responded to daunorubicin-
vincristine-cytarabine-prednisone therapy and remained in remission for 14 mo. 
Immunologic characterization of cell samples 
Mononuclear cells (MNC) from BM, PB, and fetal liver were isolated by Ficoii-Paque (density: 1.077 gjml; 
Pharmacia, Uppsala, Sweden) density centrifugation. All washings were performed in phosphate-buffered saline 
(PBS) containing 1% bovine serum albumin (BSA), pH 7.8. For the immunologic characterization of the cell 
samples, we used an anti-TdT antiserum (26), an anti-HLA-DR monoclonal antibody (McAb) (27), the McAb WT1 
(22,28) and 3A1 (29), both recognizing different epitopes of the same (41kDa) T cell antigen CD? (30), the McAb 
OKT11 (31), and Leu-5 (32), both of which recognize the C02 antigen (the sheep red blood cell receptor), the 
CD5 McAb Leu-1 (33), and the CD1 McAb 66111E5 (34). For additional characterization of the BM cells from the 
ALL patient, the following McAb were used: the T cell-specific McAb Leu-3a (35), Leu-2a (35), and Leu-4 (36), 
recognizing the CD4, CDS and CD3 antigens respectively; the McAb VIL-A1 (37), which recognizes the CD10 
antigen; the McAb BA-1 (38), BA-2 (39), B1 (40), and B2 (41), which recognize the B cell antigens CD24, CD9, 
CD20 and CD21 respectively; and the McAb VIM-05 (42), My4 (43), My8 (43), My906 (44), and FMC17 (45), which 
recognize myelomonocytic antigens. (Further information about the various McAb used is given in Table 4) The 
McAb CD10 (VIL-A1) and CD24 (BA-1) were also used for additional characterization of the fetal liver and BM cells 
and the BM cells from the children with precursor B-ALL in complete remission, 6 wk after termination of 
maintenance therapy. 
The cells were incubated with the relevant McAb, were washed, and were subsequently incubated with a 
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse lg antiserum. 
Double immunofluorescence (IF) staining 
Double IF stainings were performed for aT orB cell antigen and TdT. The CD1jTdT, CD2jTdT, CD5jTdT, 
and CD? jTdT double IF stainings were performed on the childhood BM and PB samples, the adult BM samples, 
and the fetal liver and BM samples. The HLA-DRjTdT, CD10jTdT, and CD24jTdT double IF stainings were 
performed on the fetal liver and BM samples and several infant BM samples, especially those from children with 
precursor B-ALL in complete remission, 6 wk after termination of maintenance therapy. The MNC were successively 
incubated with one of the optimally titrated anti-T cell or anti-B cell McAb and a tetramethylrhodamine 
isothiocyanate (fRITC)-conjugated goat anti-mouse lg antiserum (Nordic Immunological Laboratories, Til burg, The 
Netherlands) (24). Subsequently, cytocentrifuge preparations of these labeled cells were subjected to indirect IF 
staining with a rabbit anti-TdT antiserum and a FITC-conjugated goat anti-rabbit lg antiserum (Bethesda Research 
Laboratory, Gaithersburg, MD). The slides were mounted in glycerol/PBS (9:1) containing 1 mg phenylenediamine 
per milliliter to prevent fading of the fluorescence (46). For the detection of the CD? antigen in the CD? jTdT double 
IF stainings, the McAb WT1 as well as 3A 1 were used; the McAb OKT11 and Leu-5 were used for the detection of 
the C02 antigen in the CD2jTdT double IF stainings. In recent studies, we demonstrated in dilution experiments 
that it is possible to detect one double-positive cell in 10,000 or even 100,000 MNC (24). 
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Triple immunologic staining 
For the CD7 /HLA-DR(fdT triple immunologic staining the MNC were successively incubated with the McAb 
3A1 and a goat anti-mouse lg antiserum, conjugated with colloidal gold particles of about 30 nm (Janssen 
Pharmaceutica, Beerse, Belgium). Subsequently, the cells were incubated with normal mouse serum (diluted 1 
in 100) to block free antigen-binding sites of the goat anti-mouse lg antiserum. Finally, the cells were incubated 
with a TRITC-conjugated anti-HLA-DR McAb (Becton Dickinson, Sunnyvale, CA) (25). The cells were centrifuged 
on slides and were subjected to the indirect IF staining with the rabbit anti-TdT antiserum and the FITC-conjugated 
goat anti-rabbit lg antiserum (25). 
Microscopes 
Zeiss (Carl Zeiss, Oberkochen, FRG) and Leitz (Ernst Leitz Wetzlar, Wetzlar, FRG) microscopes were used 
for the evaluation of the immunofluorescence and the immunogold staining. The microscopes were equipped with 
HBO mercury lamps (Osram, Berlin, FRG), phase-contrast facilities, and filter combinations for the selective 
visualization of FITC and TRITC. The immunogold staining was evaluated by epi-illumination with polarized light 
(25). 
Evaluation of cytocentrifuge preparations 
In the double- as well as the triple-labeling experiments, at least two cytocentrifuge preparations were made, 
each containing at least 25,000 cells. The percentages of double- or triple-positive cells were calculated by 
determining the fraction of TdT+ cells per MNC, followed by counting the TdT+ cells which were also positive for 
the second marker in case of double staining or for the two additional markers in case of triple staining. At least 
1000 TdT+ cells were evaluated for each double staining. This condition could generally be met when counting 
two cytocentrifuge preparations. However, for the detection of CD7+ (fdT+ cells, two CD7 (3A1)(fdT as well as 
two CD7 (WT1)(fdT preparations were used. For the detection of the CD2 antigen, two C02 (OKT11)(fdTas well 
as two C02 (Leu-5)(fdT preparations were counted. 
DNA analysis 
DNA was prepared (47) from human placenta, BM cells from the described ALL patient, BM cells from a 
patient with a precursor B-ALL, and PB cells from a patient with chronic myeloid leukemia (CML). The DNA was 
digested with the restriction enzymes Hindlll, Pvull, and Bg/11, was electrophoresed on a 0.7% agarose gel, and 
was blotted to nitrocellulose. Hindlll- and EcoRI-Hindlll-digested A-DNA preparations were included as mol. mass 
markers. The filters were hybridized to a 3.5 kilobase (kb) EcoRl-Hindlll fragment containing the human J segment 
of the J.L-heavy chain clone H24 (48). Hybridization and washing procedures were carried out according to 
described methods (49). Recombinant plasmids were handled under PZEK 1 containments according to the 
National Institutes of Health Guidelines for Research Involving Recombinant DNA molecules. 
RESULTS 
Double IF staining for TdT and a T cell marker on BM cells from children and adults 
In the BM from children under ALL maintenance therapy and in normal childhood BM, the 
percentages of TdT+ cells were about 2 to 4%, whereas in the BM from children 6 wk after 
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TABLE 1. Analysis of human BM cells by double IF staining for aT cell marker and TdT. 
% Positive cells per MNC 
BM samples % TdT+ % CD2+ jTdT+ % CD7+ jTdT+ % CD1+ jTdT+ %cos+ fTdT+ 
cells cells cells cells cells 
BM from children with pre- 2.2 ± 2.8a 0.05 ± 0.08 0.04 ± 0.04 c 
cursor B-ALL in complete (0.2-10.5) (0-0.3) (0.005-0.12) 
remission under maintenance 
therapy (n; 12) 
BM from children with T-ALL 2.4 ± 0.9 NTb 0.02 ± 0.02 
under maintenance therapy (1.4-3.6) (0.001-0.05) 
and at least 6 mo in remission 
after the BM sampling (n;4) 
BM from children with nor- 3.9 ± 3.1 0.03 ± 0.03 0.02 ± 0.01 
mal BM morphology (n;11) (1.1-10.8) (0.004-0.11) (0.001-0.04) 
BM from children with pre- 6.5 ± 2.3 0.009 ± 0.006 0.007 ± 0.006 
cursor B-ALL in complete (4.1-10.2) (0.005-0.02) (0-0.015) 
remission, 6 wk after ter-
mination of maintenance 
therapy (n;7) 
BM from healthy adult 1.1 ± 0.4 0.004 ± 0.004 0.002 ± 0.002 
volunteers (21 to 28 y old) (0.7-1.7) (0-0.009) (0-0.005) 
(n;5) 
a. Mean ± SO. The figures in parentheses represent the ranges of the percentages of positive cells. 
b. NT, not tested. 
c. No double-positive cells detectable in at least 50,000 cells analyzed. 
termination of maint~nance therapy (i.e. regenerating BM), the percentages of TdT+ cells 
werehigher: about 6.5%. In normal adult BM, about '1% of the MNC were TdT+. Cells positive 
for both the CDI antigen and TdT or the CD5 antigen and TdT could not be detected in any 
of the BM samples tested. However, cells positive for both the C02 antigen and TdT and the 
CD? antigen and TdT were detected in almost all childhood and adult BM samples (Table '1). 
The frequency of the C02+ /TdT+ and CD?+ /TdT+ cells in BM from children under ALL 
maintenance therapy and in normal childhood BM is about two to five in '10,000 (Table '1). 
However, in regenerating childhood BM and in normal adult BM, C02+ /TdT+ and CD?+ /TdT+ 
cells were not always detectable, and if detected, their frequency was about five-to 1 0-fold lower 
than in normal childhood BM and childhood BM under ALL maintenance therapy (Table 1). 
Such low frequencies are around the detection limit of the double IF staining (24). 
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TABLE 2. Analysis of fetal liver and fetal BM cells by single and double IF staining. 
Fetal %TdT+ % HLA-DR+ % CD10+ % CD24+ % CD10+ % CD24+ 
cell cells per cells per cells per cells per cells per cells per 
samples MNC TdT+ cells TdT+ cells TdT+ cells MNC MNC 
Fetal liver 4.1 ± 1.6a 97 ± 2.5 94.4 ± 2.5 99.9 ± 0.2 13.1 ±7.9 18.4 ± 7.4 
(2.5-6.6) (92.5-99.5) (90-97.5) (99.5-100) (5.2-28.5) (9.0-32.5) 
Fetal BM 13.9 ± 6.2 97.6 ± 2.2 91.7 ± 4.6 99.1 ± 1.2 27.1 ± 14.9 31.9 ± 13.5 
(3.4-24) (94.5-99.5) (85.5-97.5) (97.5-100) (6.6-46.2) (14.5-47.5) 
a. Mean ± SD. The figures in parentheses represent the ranges of the percentages of positive cells. 
Double IF staining for TdT and a T cell marker on PB cells from children 
In the 10 PB samples from children with precursor B-ALL under maintenance therapy, the 
percentages of TdT+ cells ranged from 0.01 to 0.2%. Only occasionally could CD2+ /TdT+ 
and CD?+ /TdT+ cells be detected. CD1 + /TdT+ and cos+ /TdT+ cells were never detected 
in PB samples tested. 
Double IF staining for TdT and aT cell marker, TdT and a B cell marker, or TdT and 
HLA-DR on fetal liver and fetal BM cells 
In the fetal liver, about 4% of the MNC was TdT+, whereas in the fetal BM, about 14% 
TdT+ MNC were found. Neither in the fetal liver cell samples nor in the fetal BM cell samples 
could T cell marker+ /TdT+ cells be detected in at least 1000 TdT+ cells. Double staining for 
TdTand HLA-DR, CD10, or CD24 revealed that almost all (>92%) TdT+ cells were also positive 
for the HLA-DR and CD24 antigen, whereas more than 85% of the TdT+ cells were also positive 
for the CD1 0 antigen (fable 2). Furthermore, many Tdl cells were also positive for the CD1 0 
and CD24 antigen (fable 2). These data indicate that almost all TdT+ cells are precursor B 
cells. 
Double IF staining for TdT and the CD10 antigen on infant BM cells 
In BM samples from children 6 wk after termination of the ALL maintenance therapy, about 
6.5% of the MNC were positive for TdT, and more than 85% of these TdT+ cells were also 
positive for the CD10 antigen. Many Tdl cells were also positive for the CD10 antigen (up to 
40% of the MNC). Furthermore, a high percentage of CD24 + cells (>30%) was detected. 
In BM samples from children under maintenance therapy and normal infant BM samples, 
the percentages of TdT+ cells were lower (2 to 4%), and a smaller part of the TdT+ cells was 
also positive for the CD1 0 antigen. Almost all CD1 0 + cells were also positive for TdT, and only 
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Figure 1. Analysis of mononuclear BM cells from a child with precursor B-ALL in complete remission under 
maintenance therapy, by a triple staining for CD7, HLA-DR, and TdT, using FITC, TRITC, and colloidal gold particles 
as labels. A: Phase-contrast picture of the BM cells; B: CD7+ cells (labeled with colloidal gold particles); C: HLA-
DR+ cells (TRITC-Iabeled); 0: TdT+ cells (FITC-Iabeled). A, B, C, and D represent the same field. One cell (1) is 
positive for TdT, HLA-DR, and CD7 and another cell (2) is positive for TdT and HLA-DR but negative for CD7. The 
latter might be a precursor B cell (c.f. references 20 and 51), and the former might be a prothymocyte. 
a small percentage of CD24+ cells (<10%) was detected in these BM samples. 
These data indicate that almost all TdT+ cells in regenerating BM are precursor B cells, 
whereas in normal infant BM and BM from children under maintenance therapy, a smaller part 
of the TdT+ cells are precursor B cells. 
Triple immunologic staining tor the CD7 antigen, HlA-DR, and TdT 
Because most TdT+ cells in BM are also positive for HLA-DR (20), we investigated whether 
the CD?+ /TdT+ cells are also positive for HLA-DR. In the four BM samples from children under 
ALL maintenance therapy and in the two normal adult BM samples tested, all CD?+ /TdT+ cells 
appeared to be also positive for HLA-DR (Figure 1; Table 3). In addition, we investigated 
whether CD?+ jHLA-DR+ /TdT+ cells occur in the thymus as well. The triple-staining method 
revealed that large blasts with the CD?+ /HLA-DR+ /TdT+ phenotype were detectable in a 
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TABLE 3. Analysis of BM and thymus samples by triple immunologic staining for CD7, HLA-DR, and TdT. 
BM from children with BM from Thymus from 
precursor B-ALL in healthy children 
Triple complete remission adult undergoing 
immunologic under maintenance volunteers cardiac surgery 
staining therapy (n=4) (n=2) (n=4) 
% CD7+ /HLA-DR+ I 0.05 ± 0.03a 0.003 ± 0.003 0.02 ± 0.01 
TdT+ cells per MNC (0.01-0.07) (0.001-0.006) (0.009-0.03) 
a. Mean ± SO. The figures in parentheses represent the ranges of the percentages of positive cells. 
frequency of 0.009 to 0.03% (Table 3). This special population represented 0. '1 to 0.4% of the 
large CD7+ /TdT+ blasts. 
Immunologic marker analysis and lg heavy chain gene analysis of the BM cells from the 
All patient at diagnosis 
The immunologic marker analysis of the BM cells from the ALL patient revealed that most 
cells were positive for TdT, HLA-DR, the CD2 antigen, and the CD7 antigen, but negative for 
all other T cell markers and negative for all B cell and myelomonocytic markers tested (Table 
4}. 
Southern blot analysis of the lg heavy chain genes revealed that the BM cells from the 
ALL patient had germline lg heavy chain genes. The DNA from human placenta and from the 
PB from a CML patient had germline lg heavy chain genes, whereas the DNA from the BM 
cells from a common ALL patient had rearranged lg heavy chain genes (Figure 2). 
DISCUSSION 
The phenotype of the human prothymocyte is not known, although it was suggested that 
this cell may be positive for TdT (2'1). Until now, however, cells positive for both aT cell marker 
and TdT have never been demonstrated in extrathymic locations such as BM ('13,20-23). 
By use of double IF stainings, we could detect CD2+ /TdT+ and CD7+ /TdT+ cells in very 
low frequencies in almost all childhood and adult BM samples tested. The frequency of the 
CD2+ /TdT+ and CD7+ /TdT+ cells in normal childhood BM and BM from children under ALL 
maintenance therapy was about two to five in '10,000 MNC. In adult BM and regenerating 
childhood BM, these cells were not always detectable, but if detected, their frequency was five-
to '10-fold lower. Occasionally, the CD2+ /TdT+ and CD7+ /TdT+ cells could be detected in 
childhood PB. CD'1 + /TdT+ or cos+ /TdT+ cells were never detected in any of the BM and 
PB samples tested. NoT cell marker+ jTdT+ cells could be detected in the liver and BM 
samples from fetuses of '14 to '19 wk gestational age. Almost all TdT+ cells in regenerating 
childhood BM and fetal liver and BM appeared to be precursor B cells. 
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TABLE 4. Immunologic marker analyse of the BM cells from the ALL patient. 
Cluster of Antigen 
differentiation a Antibodies % Positive cells recognized References 
anti-TdTb 92 TdT 26 
anti-HLA-DR0 74 HLA-DR, nonpoly- 27 
morphic antigen 
CD7 WT1d 78 Tp41 antigen 22,28,30 
CD? 3A1e 92 Tp41 antigen 29,30 
CD2 OKT11f 94 T11 antigen 31 
CD2 Leu-5° 90 T11 antigen 32 
CDS Leu-1° 2 T1 antigen 33 
CD1 66111E5g 0 T6 antigen 34 
CD4 Leu-3a0 0.5 T4 antigen 35 
CDS Leu-2a0 1.5 T8 antigen 35 
CD3 Leu-4° 1.5 T3 antigen 36 
CD10 VIL-A1h 0 common ALL antigen 37 
CD24 BA-1i 0.5 B cell antigen 38 
CD9 BA-2i 0 B cell antigen 39 
CD20 B1i 0 B cell antigen 40 
CD21 Bzi 0 B cell antigen 41 
CD15 VIM-D5h 1 myeloid antigen 42 
CD14 My4k 2 monocytic antigen 43,44 
CD11 My8k 0 myelomonocytic antigen 43,44 
CD33 My906k 0.5 myelomonocytic antigen 44 
CD14 FMCJ?' 1.5 monocytic antigen 45 
a. Cluster of differentiation, as established during the Leucocyte g. Dr. J.M. van de Rijn, Amsterdam, The Netherlands. 
Typing Conferences (Paris, 1982; Boston, 1984: Oxford, 1986). h. Dr. W. Knapp, Vienna, Austria. 
b. Bethesda Research Laboratory, Gaithersburg, MD. i. Hybritech, San Diego, CA. 
c. Becton Dickinson, Sunnyvale, CA. j. Coulter Clone, Hialeah, FL. 
d. Dr. W. Tax, Nijmegen, The Netherlands. k. Dr. J.D. Griffin, Boston, MA. 
e. American Type Culture Collection, Rockville, MD. I. Sera Laboratories, Crawly Down, UK. 
f. Ortho Diagnostic Systems, Raritan, NJ. 
The C02 and CD7 antigens are the most consisted T cell markers, and therefore 
C02+ /TdT+ and CD7+ /TdT+ cells may represent precursor T cells. Because human 
hematopoietic progenitors are positive for HLA-DR {50), we investigated whether the CD7+ 
cells in the BM belong to the HLA-DR+ /TdT+ or the smaller HLA-DR-/TdT+ cell population 
(21). A triple staining for CD7, HLA-DR, and TdTwas performed, using fluorescein, rhodamine, 
and colloidal gold particles as labels {25). All CD7+ /TdT+ cells in the BM proved to be positive 
for HLA-DR as well. To investigate whether similar CD7+ /HLA-DR+ /TdT+ cells also occur in 
the normal thymus, we analyzed thymus samples from four children. Previous studies have 
already shown that large CD7+ blasts, which constitute 5% of all thymocytes strongly express 
TdT in the infant thymus {21 ), but it was still unknown whether a subset of these cells also 
express HLA-DR. Our triple-staining method revealed that large blasts of the CD7+ /HLA-
DR+ /TdT+ cell phenotype were found in a frequency of 0.009 to 0.03% {Table 3). 
Finally, we studied leukemic BM cells from a 34-y-old man which proved to have the 
C02+ /CD7+ /HLA-DR+ /TdT+ jCD1-/COo phenotype. This patient had an ALL according to 
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Figure 2. Southern blot analysis of lg heavy chain genes. Hindlll-
digested DNA was prepared from human placenta (lane A), from BM 
cells from the described patient with the ALL of the CD2+ /CD7+ I 
HLA-DR+ fTdT+ /CD1-;cos- phenotype (lane B), from BM cells from 
a patient with precursor B-ALL (lane C), and from PB cells from a 
patient with CML (lane D). The sizes of the germline bands (8 kb; 
lanes A,B, and D) and rearranged bands (7 and 5 kb; lane C) are 
indicated. 
conventional morphology and cytochemistry, which responded to ALL therapy. DNA analysis 
revealed that the leukemic cells of this patient had germline lg heavy chain genes. To our 
knowledge, no other HLA-DR+ ALL without lg gene rearrangements has been reported. This 
corresponds to the absence of lg gene rearrangements in T cell leukemias (51 ,52), and 
indicates that the described HLA-DR+ ALL is not a precursor B-ALL These data suggest that 
the CD2+ /CD?+ /HLA-DR+ /TdT+ /CD1-/CD5- leukemia originated from a precursor T cell, 
probably a prothymocyte. T cell marker+ /HLA-DR+ /TdT+ leukemias are rare (53), because 
only three other cases have been reported without, however, describing the lg genes 
(24,54,55). 
It must be mentioned that some papers describe CD2- precursor T cell leukemias (22,53). 
More mature CD5 + T cell leukemias that are negative for the CD2 antigen have also been 
described (54). Furthermore, several sheep red blood cell receptor-negative T cell leukemias 
proved to be positive for the CD2 antigen, as detected by the McAb OKT11 (54). These 
discrepancies might be due to the weak expression of the CD2 antigen on immature T cell 
leukemias. 
The phenotype of the putative prothymocytic leukemia corresponds to that of the normal 
CD?+ /HLA-DR+ /TdT+ cell in human BM and thymus, which cells consequently may represent 
a normal prothymocyte. The frequencies of the CD?+ /HLA-DR+ /TdT+ and CD2+ /TdT+ cells 
in normal childhood infant BM and BM from children under maintenance therapy (Tables 1 and 
3) are consistent with the frequency of the prothymocyte in murine BM (5- to 6-wk-old mice), 
as found by Kadish and Basch (0.015 to 0.02%) (5), Lepault and Weissman ( <0.1%) (6), and 
Boersma et al. (0.03%)(7). Furthermore, it has been described that the frequency of the murine 
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prothymocyte is strongly reduced in regenerating BM (5,7). Boersma et al. (7) demonstrated 
that after 8 wk of BM regeneration, the frequency of the murine prothymocyte in the BM was 
about "16% of the normal frequency. This corresponds to five- to "10-fold lower frequencies of 
the C02+ /TdT+ and CD?+ /TdT+ cells in the regenerating BM of children 6 wk after termination 
of maintenance therapy, as compared to normal childhood BM or BM from children under 
maintenance therapy. Boersma (56) also demonstrated that the frequency of the prothymocyte 
in the murine fetal liver is about "1 0% of the frequency of the prothymocyte in the BM of 6-wk-
old mice. This low frequency might explain that noT cell marker+ /TdT+ cells could be detected 
in human fetal liver. The latter finding corresponds to the data of Badger et al. (57) that TdT+ 
cells are detectable only in thymuses from human fetuses older than 20 wk gestational age. 
On the basis of these data, we postulate that the human prothymocyte has the C02+ j 
CD?+ jHLA-DR+ /TdT+ ;cor;co5- phenotype. Furthermore, the presence of co2+ /TdT+ 1 
HLA-DR+ /TdT+ cells in the BM and the thymus, and the occasional detection of C02+ /TdT+ 
and CD?+ /TdT+ cells in the PB, is consistent with the hypothesis that prothymocytes migrate 
from the BM via the PB to the thymus. 
The difference between our human data and the rodent data is that no functional data are 
available about human precursor T cells, whereas all knowledge concerning the rodent 
prothymocyte is based on functional tests, but without further establishment of the precise 
phenotype. Nevertheless, our observations are very suggestive, especially due to the fact that 
amalignantcounterpartoftheCD2+ /CD?+ /HLA-DR+ /TdT+ /CD"1-/CD5-prothymocyteexists. 
The establishment of the phenotype of the human prothymocyte may provide more insight 
into human T lymphocyte differentiation. The triple-staining method will be useful for studying 
the differentiation ofT cells and other cell lineages in vitro, e.g. in cell clusters derived from T 
cell colony-forming cells. Also, the migration pattern of the prothymocyte in rodents can be 
studied by using the two- or threefold staining technique. Furthermore, it should be possible 
to purify murine prothymocytes by fluorescence-activated cell sorting with the use of markers 
analogous to the ones applied in the present study, and to conduct thymus repopulation 
experiments (5-7) with these cells. 
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SUMMARY 
T cell acute lymphoblastic leukemias (T-ALL) can be regarded as the malignant counter-
parts of cells in various T cell differentiation stages. To study the expression of the human T 
cell receptor (TcR)-CD3 complex during the early stages of T cell differentiation, we have 
analyzed 22 T-ALL at the cell membrane level and the DNA level and 12 of them at the RNA 
level. According to their immunologic phenotype, the T-ALL could be divided into three main 
groups: I 0 immature T-ALL (CD I-/CD3l, 7 common thymocytic T-ALL (CD I+ jCD3- or +)and 
five mature T-ALL (CDr /CD3 +). Among the ten immature T-ALL three appeared to express 
the immunologic phenotype of the putative prothymocyte (TdT+ /HLA-DR+ jCD2+ /CD?+ j 
CDr /CDT/CD5l, whereas the other seven T-ALL appeared to be immature thymocytic 
(TdT+ /HLA-DR-/CD7+ /C02+ /CD5+ /CDI-/CD3l. 
Transcripts of the CD3-o and CD3-c genes were present in all COT and CD3 + T-ALL 
tested, including prothymocytic T-ALL. However, the prothymocytic T-ALL had germline TcR-,8 
genes and were not rearranged to the characterized TcR-r joining regions. The presence of 
CD3 transcripts and absence of TcR gene rearrangements in prothymocytic T-ALL supports 
*Published in: J lmmunol 1987;138:1260-9. 
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their immature T cell character. Two immature thymocytic T-ALL also had germline TcR--y genes 
and one ofthem had germ line TcR-.8 genes. In all other T-ALL the TcR--y and TcR-.8 genes were 
rearranged. The presumptive functional 1.3-kb TcR-.8 transcripts were detected in the majority 
of T-ALL with rearranged TcR-.8 genes. Distinct levels of TcR--y transcripts appeared to be 
present only in some thymocytic T-ALL, i.e. some immature thymocytic T-ALL and common 
thymocytic T-ALL. TcR-a mRNA could only be detected in CD3 + mature T-ALL, but was absent 
in all CD3+ common thymocytic T-ALL tested. 
Our data indicate that CD3 gene transcription is one of the earliest events during T cell 
differentiation and already occurs in prothymocytes. The TcR--y and TcR-.8 genes rearrange 
early during thymocytic differentiation and can subsequently be transcribed. High levels of 
TcR--y gene transcription may only occur in a part of the T cells during thymic differentiation, 
while TcR-.8 gene transcription continues during further differentiation. TcR-a gene transcription 
may be the final step in the production of the complete set of TcR and CD3 proteins, resulting 
in the expression of the TcR-a.B-CD3 complex at the cell surface of mature T cells. Our data 
point to a predetermined order of rearrangement and expression of the TcR and CD3 genes 
during early stages of human T cell differentiation. 
In the CD3+ common thymocytic T-ALL tested no TcR-a transcripts could be detected, 
while TcR-.8 transcripts were present in all three T-ALL and TcR-1 transcripts in two of them. 
Since the expression of CD3 on the cell surface seems to be dependent on the presence of 
the TcR chains, these data suggest that in these T-ALL the TcR may be formed by a TcR-1 and 
a TcR-.8 chain, or that an alternate or aberrant TcR was present in these T-ALL. 
INTRODUCTION 
Recently much information has become available about the mouse and human antigen-
specific T cell receptor (TcR)(1-3). The TcR, expressed on the cell surface of most mature T 
lymphocytes, consists of two glycoprotein chains, the TcR-a-chain (49 kDa) and TcR-.B-chain 
(43 kDa)(4,5). Analogous to immunoglobulins, the diversity of the TcR-a- and -.B-chains is based 
on the use of different variable, diversity and joining regions, which become linked by gene 
rearrangement (6-12). It is postulated that the rearrangement of the TcR-a and -.B genes takes 
place during the differentiation/maturation process in the thymus (13-15). Similar to the lg gene 
rearrangement during B cell differentiation (16), ordered rearrangement and transcription of the 
TcR genes seems to exist, i.e. the TcR-.8 genes rearrange and are transcribed prior to the 
TcR-a genes (15,17-20). 
In addition to the TcR-a and -.8 genes, a third rearranging T cell receptor like gene, TcR--y, 
has been described (21-28). Data from studies in the mouse indicate that TcR--y gene 
transcription takes place early in the T cell differentiation, most probably prior to TcR-.8 gene 
transcription (17,18). In mice and humans, the TcR-1 gene rearrangement and transcription 
seems to be T cell specific (17, 18,24-26). Although, the encoded protein has recently been 
identified, the precise function of the TcR--y-chain has still to be elucidated (29). The appearance 
of TcR--y-chain transcripts early in thymic development has led to the suggestion that the 
TcR--y-chain may combine with the TcR-.B-chain and in this way may play a role in T cell 
differentiation (17,18). 
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On the cell surface membrane the TcR is closely associated with the T cell antigen CD3 
(4,5,30,31), which in humans consists of at least three proteins (CD3-r, CD3-o, and CD3-<:) 
(32,33). In the murine system a CD3-Iike protein complex has recently been identified (34,35). 
Cell surface expression of the TcR-o:,B-CD3 complex seems to be dependent on the presence 
of the involved TcR protein chains (36,37). In this complex, the CD3 proteins may play a role 
in transduction of signals from TcR to cytoplasmic components (38,39). Recently the genes 
which code for the human CD3-o- and CD3-<:-chain as well as their murine homologues have 
been identified (40-42). Transcription of these genes appears to beT cell-specific (15,40,42). 
The precise order of gene rearrangement, transcription and expression of the TcR and CD3 
genes during the very immature differentiation stages of human T cell development is not yet 
known. Since leukemias and non-Hodgkin lymphomas can be regarded as the malignant 
counterparts of normal hematopoietic cells (43-45), we analyzed 22 T cell acute lymphoblas-
tic leukemias (T-ALL) to study the expression of the TcR-CD3 complex during early T cell 
differentiation. Ten of these T-ALL were arrested in very early stages of T cell differentiation, 
including three T-ALL which expressed the immunologic phenotype of the putative human 
prothymocyte (46). 
MATERIALS AND METHODS 
Cell samples 
Bone marrow samples (n=7), peripheral blood samples (n=14) and a pleural exudate sample (n=1) were 
obtained from 22 different T-ALL patients. Eleven of these patients were children (::; 16 y) and the other eleven 
were adults (> 16 y). Mononuclear cells (MNC) were isolated from bone marrow and peripheral blood by 
Ficoii-Paque (density: 1.077 gjml; Pharmacia, Uppsala, Sweden) density centrifugation. All washings were 
performed in phosphate-buffered saline (PBS) containing 0.5% bovine serum albumin (BSA), pH 7.8. 
Immunologic marker analysis 
The MNC were analyzed for the expression of terminal deoxynucleotidyl transferase (TdT), HLA-DR antigen, 
T cell markers CD7(Tp41), CD2(T11), CD5(T1), CD1 (T6), CD4(T4), CD8(T8) and CD3(T3), and CD10 (common ALL 
antigen)(47-62). The CD2(T11) antigen, which represents the sheep red blood cell receptor, was detected by use 
of monoclonal antibodies (McAb) or by use of the E rosette test (54,55,63). In addition, the majority of the cell 
samples was characterized by use of the following McAb: the anti-B cell antigen McAb BA-1 (CD24), BA-2(CD9) and 
B1 (CD20) and the anti-myelomonocytic antigen McAb My9(CD33), VIM-D5(CD15), and My4(CD14) (64-69). The 
general characteristics of the antibodies used for the immunologic characterization are summarized in Table 1. 
The reactivity of the antibodies was ·visualized by use of a fluorescein isothiocyanate-conjugated goat 
anti-rabbit-lg antiserum (Supertechs, Bethesda, MD) in the case of the rabbit anti-TdT antiserum and a fluorescein 
isothiocyanate-conjugated goat anti-mouse-lg antiserum (Central Laboratory of the Blood Transfusion Service, 
Amsterdam, The Netherlands) in the case of a mouse McAb. If more than 20% of MNC expressed a certain differen-
tiation antigen the T-ALL was considered to be positive for this antigen. 
Southern blot analysis 
DNA was prepared from frozen MNC of the bone marrow, peripheral blood and pleural exudate samples, as 
described (70). From all T-ALL cell samples with the exception of the T-ALL sample from patient 1 enough DNA 
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TABLE 1. Antibodies used for the immunologic marker analysis of T-ALL cells. 
Antibody Cluster of differentiationa 
Anti-TdTb 
Anti-HLA-DR0 or OKiad 
3A1e orWT1f CD7 
Leu-5° or OKT11 d CD2 
Leu-1° or OKT1d CDS 
Leu6° or OKT6d or CD1 
6611C7h 
Leu-3° or OKT 4d CD4 
Leu-2° or OKT8d CDS 
Leu-4° or OKT3d CD3 
VIL-A1i or J5d CD10 
BA-1i CD24 
BA-t CD9 
B1k CD20 
My91 CD33 
VIM-D5i CD15 
My41 CD14 
a. k; proposed by the Workshops on Human Leukocyte 
Differentiation Antigens (Paris, France, 1982; 
Boston, MA, 1984; Oxford, UK, 1986). 
b. Supertechs, Bethesda, MD. 
c. Becton Dickinson, Sunnyvale, CA. 
d. Ortho Diagnostic Systems, Raritan, NJ. 
e. American Type Culture Collection, Rockville, MD. 
f. Dr. W. Tax, Nijmegen, The Netherlands. 
Antigen recognized References 
TdT 47 
HLA-DR, non polymorphic antigen 48, 49 
(gp29/34) 
Tp41 antigen (gp41) 50-53 
T11 antigen (gp50), sheep red blood 50, 54, 55 
cell receptor9 
T1 antigen (gp67) 50, 56, 57 
T6 antigen (common thymocyte 50, 58 
antigen)(gp43, gp45, gp49) 
T4 antigen (gp60) 50, 59 
T8 antigen (gp32) 50, 59 
T3 antigen (gp16-25) 50, 60 
common ALL antigen (gp100) 61,62 
B cell antigen (gp42) 64 
B cell antigen (p24) 65 
B cell antigen (p35) 66 
myelo-monocytic antigen (gp67) 67 
myeloid antigen 68 
monocytic antigen (gp55) 69 
g.The sheep red blood cell receptor (CD2 (Ttl) antigen) 
can also be demonstrated by use of the E rosette test. 
h.Dr. J.M. van de Rijn, Amsterdam, The Netherlands. 
i. Dr. W. Knapp, Vienna, Austria. 
j. Hybritech, San Diego, CA. 
k. Coulter Clone, Hialeah, FL. 
1. Dr. J.D. Griffin, Boston, MA. 
was obtained to study the configuration of the TcR-,8 genes as well as the TcR-1 genes. In the case of the T-ALL 
from patient 1 only the TcR-1 gene configuration was investigated. DNA (15 f.Lg) was digested with EcoRI (New 
England Biolabs, Beverly, MA) and the fragments were separated by electrophoresis through a 0.7% agarose slab 
gel (Sigma Chemical Company, St. Louis, MO). DNA was transferred onto nitrocellulose as described (71). TcR-,8 
gene and TcR-1 gene rearrangements were detected by hybridization with 32P-Iabeled nick-translated probes. 
Rearrangement in the ,81 gene region was detected using the C,B probe, while rearrangement in the ,82 gene 
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Figure 1. Organization of the joining, diversity and constant regions of the human TcR-,8 chain gene and the 
joining and constant regions of the human TcR-)' chain gene. The location of the relevant £coRI (R) restriction 
enzyme sites are indicated. Solid bars, probes which were used for hybridization of the Southern blot filters. Upper, 
the J/32 probe consists of contiguous 1.9-kb Pvuli-Pvull and 1.5-kb Pvull-£coRVfragments containing J/32.3 through 
J/32.7; this probe does not hybridize to the J/31 gene segment and was used to detect rearrangement in the /32 
gene region. The C,B probe is a 1.1-kb Bg/11-Bglll fragment containing C,82 segments; this probe also hybridizes 
to the C/31 segment and was used to detect rearrangement in the /31 gene region. Lower, the J)' probe is an 1.0-
kb Psti-EcoRI fragment containing J)'2 segments; this probe hybridizes to both J)'1 and J)'2 gene segments and 
was used to detect rearrangements in these two gene regions. 
region was detected using the J,82 probe. The C,B probe is an 1.1-kb Bglli-Bglll fragment containing C,82 segments; 
it hybridizes to both C/31 and C/32 gene segments (Figure 1 )(72). The J/32 probe consists of contiguous 1.9-kb 
Pvuli-Pvull and 1.5-kb Pvuli-EcoRV fragments containing J/32.3 through J/32. 7; this probe does not hybridize to the 
J,81 gene segment. (Figure 1 )(72). 
Rearrangements in the J)'1 and J)'2 gene regions were detected by use of the J)' probe. The J)' probe is a 
1.0-kb Psti-EcoRI fragment containing J)'2 segments; it hybridizes to both J)'1, and J)'2 gene segments (Figure 
1}(26). The isolation of probes, hybridization, and washing conditions were as described (73). 
Northern blot analysis 
Total RNA was isolated using the LiCijurea method (71) from 12 of the 22 MNC samples (patients 1,3,7,10 
to 12,14 to 16,19,21 and 22). In the case of the other 10 T-ALL samples no sufficient cell material was available 
to isolate total RNA. Approximately 15 f.l,g of total RNA were size-fractionated on a 1.2% agarose gel in the 
presence of formaldehyde and blotted to Biodyne nylon membranes (Pall Ultrafine Filtration Corporation, Glen 
Core, NY). Specific RNA sequences were detected with 32P-Iabeled nick-translated CD3 eDNA probes 
(CD3-o:pPGBC9 (41); CD3-E:pDJ1 (42)) and TcR eDNA probes (TcR-a:pA65 (74), TcR-,B:pT10 (75); TcR-)':pT)'-1 
(26)). Hybridization and washing conditions were as described (73). 
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TABLE 2. Immunologic marker, Southern blot, and Northern blot analysis of the T-ALL cell samplesa. 0 
A (n=3) B (n=7) C (n=3) D (n=4) E (n=3) F (n=2) 
Analysis 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
(PB) (PB) (BM) (PB) (PB) (PB) (BM) (PB) (BM) (PB) (BM) (PE) (BM) (BM) (BM) (PB) (PB) (PB) (PB) (PB) (PB) (PB) 
Immunologic markerb 
TdT 90 84 92 90 90 100 96 87 84 96 74 97 92 92 81 99 95 81 95 47 0 0 
HLA-DR 97 87 74 0 55 0 0 4 0 0 4 1 1 1 2 0 1 0 3 4 0 7 
CD7 (Tp41) 92 96 85 95 98 100 99 85 99 99 97 98 96 94 95 99 90 89 95 90 100 75 
C02 (EjT11)c 98 91 87 36 98 57 83 40 9 80 96 95 78 95 94 79 99 96 99 92 99 88 
CD5 (T1) 2 8 1 76 82 100 99 93 98 76 99 99 93 97 90 87 86 82 97 88 100 80 
CD1 (T6) 0 0 0 0 0 0 0 1 9 4 93 98 92 25 52 45 23 0 1 1 0 0 
CD4 (T4) 1 1 2 5 0 3 0 3 2 87 14 41 87 36 65 66 42 48 4 70 99 1 
CDS (TB) 2 3 1 4 0 2 0 5 1 57 21 70 90 3 66 11 52 73 70 68 92 80 
CD3 (T3) 2 3 2 10 0 0 1 1 2 6 2 1 3 27 71 99 82 31 77 23 96 87 () 
Southern blottingd 
i; 
"tl 
TcR-,81 genes G G G G R D R D R R D D R R D R R R R R R ;;:j JJ TcR-,82 genes G G G R R R R R R R R R R R R R R R G R R 
"' TcR-'Y genes G G G G G R R R R R R R R R R R R R R R R R "' 
Northern blotting" 
CD3-o mRNA + + + + + + + + + + + + 
CD3-E mRNA + + + + + + + + + + + + 
TcR--a mRNA (1.7 kb) + + 
TcR-/l mRNA (1.0 kb) ± ± ± ± ± 
TcR-/l mRNA (1.1 kb) + + 
TcR-/l mRNA (1.3 kb) + + + + + + + 
TcR-'Y mRNA (1.6 kb) + ± + + ± ± 
a. Abbreviations used in this table: PB, peripheral blood; BM, bone marrow; PE, pleural exudate. 
b. The figures represent percentages of positive MNC. 
c. The CD2 (T11) antigen (sheep red blood cell receptor) can be detected by use of MoAb or by use of the E rosette test. In the case of patients 6 and 12 only the E rosette test was used. For the other 
patients the figures are given from the Immunofluorescence analysis. 
d. G, only germline bands were detected; R, at least one rearranged band was detected; D, neither rearranged bands nor the 10.5-kb germllne band could be detected (i.e., both C,B1 gene alleles were 
deleted). 
e. +,normal or strong band;±, weak band;-, no band detectable. 
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RESULTS 
Immunologic marker analysis 
The immunologic phenotypes of the 22 T-ALL (i.e. their expression of TdT, HLA-DR and the 
T cell markers CD7(Tp4i), CD2(Ti i), CDS(Ti), CDi (T6), CD4(T4), CD8(T8) and CD3(T3)) are 
summarized in Table 2. The T cell leukemias could be divided in three main groups, according 
to the expression of CDi and CD3 : "10 immature T-ALL (CDi-/CD3l, seven common 
thymocytic T-ALL (CDi + /CD3- or+), and five mature T-ALL (CDi-/CD3+ ). Each of the three 
main groups could be divided in two subgroups, based on the expression of TdT, CD?, CDS, 
CDi and CD3, resulting in six different groups of T-ALL: A: three prothymocytic T-ALL 
(TdT+ /CD?+ /CDS-/CDi-/CD3l; B: seven immature thymocytic T-ALL (TdT+ /CD?+ /CDS-
+ /CDi-/CD3l; C: three CD3- common thymocytic T-ALL (TdT+ /CD?+ /CDS+ /CDi + /CD3l; 
D: four CD3+ common thymocytic T-ALL (TdT+ /CD?+ /CDS+ /CDi + /CD3+); E: three TdT+ 
mature T-ALL (TdT+ /CD?+ /CDS+ jCDi-/CD3+); and F: twoTdlmatureT-ALL (Tdi/CD7+ j 
CDS+ /CDr /CD3+) (Table 2 and Figure 7). Four T-ALL expressed HLA-DR; all three 
prothymocytic T-ALL and one immature thymocytic T-ALL (patientS) (Table 2). All 22 T-ALL 
expressed the CD? antigen as well as the CD2 antigen, except one immature thymocytic T-ALL 
(patient 9), which did not express the CD2 antigen (Table 2). 
CDiO (common ALL) antigen was weakly expressed by 9 of the 22 T-ALL: patients 4, 6, 8, 
"10, "12, "13, "14, "16, and "18. Also the CD24(BA-1) antigen was weakly expressed by some T-ALL 
(patients 8, "16, and 2"1). Weak expression of B cell markers such as CDiO or CD24 is often 
seen in T-ALL (76). The B cell antigens CD9(BA-2) and CD20(Bi) and the myelomonocytic 
antigens CD33(My9), CDiS(VIM-DS), and CDi4(My4) were not expressed by the T-ALL tested 
(data not shown). 
Southern blot analysis 
To detect TcR-.8 gene rearrangements in the 2"1 T-ALL tested, the EcoRI digested DNAs 
were analyzed by use of the TcR-.8 probes C.B and J,82 (Figure "1). Hybridization with the C,B 
probe resulted in germline bands of about 3.8 kb (C,82 gene segment) and iO.S kb (C,Bi gene 
segment) in the two prothymocytic T-ALL tested (patients 2 and 3) as well as in two immature 
thymocytic T-ALL (patients 4 and S). In all other patients at least one rearranged band was 
detected or only the 3.8-kb germline band was detected; the latter indicates that the C,Bi gene 
segments on both chromosomes are deleted (Table 2 and Figure 2). Hybridization with the J,82 
probe resulted in the germline band of about 4. i kb in the two prothymocytic T-ALL tested 
(patients 2 and 3) and in one immature thymocytic T-ALL (patient 4), while in all other patients 
at least one rearranged band was detected, except in patient 20. (Table 2 and Figure 3). These 
data indicate that in patients 2, 3 and 4 the TcR-,8 genes were in germline configuration, while 
in all other patients the TcR-fi genes were rearranged. 
To detect TcR--y gene rearrangements in the 22 T-ALL cell samples, the Southern blot filters 
were hybridized with the J-y probe (Figure 1). In all three prothymocytic T-ALL (patients 1, 2 and 
3) as well as in two immature thymocytic T-ALL (patients 4 and S) only germline bands of "1.8 
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Figure 2. Southern blot analysis of £caRl-
digested DNA for the detection of rearrangement 
in the /31 gene region, by use of the C/3 probe. 
The two germline bands (G) of about 10.5 kb 
(C/31 gene segment) and 3.8 kb (C/32 gene 
segment) are indicated. The ALL cells from 
patients 2 and 3 had germline TcR-/31 genes, 
while in the ALL cells from patients 7, 17, 20 and 
22 the TcR-/31 genes appeared to be clonally 
rearranged or deleted. The weak 10.5-kb germ-
line band in the lanes from patients 17 and 22 
represents DNA from contaminating normal 
MNC. 
kb (J-y1 gene segment) and 3.3 kb (J-y2 gene segment) were present. In all other T-ALL at least 
one rearranged band was detected. In six T-ALL, especially mature T-ALL, one rearranged 
band was present, while in the remaining 11 T-ALL at least two rearranged bands were present 
(Table 2 and Figure 4). In addition to the six different types of rearrangements detected with 
the J-y probe, recently described in the classification of rearranged TcR--y genes (26), we did 
detect an additional type of TcR--y gene rearrangement, i.e. a non-germline band of 2.3 kb 
(Figure 4). The J-y probe detects rearrangement in the two highly homologous J-y1 and Jr2 
gene regions, initially described (26,27). Recent work indicates that additional diversity may be 
afforded to the TcR--y chain by additional joining regions in association with the two described 
TcR-CD3 complex during T cell differentiation 
Figure 3. Southern blot analysis of £coAl-
digested DNA for the detection of rearrange-
ment in the /32 gene region by use of the J/32 
probe. The 4.1-kb germline band (G) is indi-
cated on the right, while the size of the used 
molecular weight markers is indicated on the 
left. The T-ALL cells from patients 2, 3, and 4 
had germline TcR-/32 genes, while in the ALL 
cells from patients 8, 9, 12, and 13 one or two 
alleles of the TcR-/32 genes were clonally 
rearranged or deleted. 
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constant regions (77) (unpublished results). Rearrangements to these joining segments has not 
yet been characterized. It is possible that cells showing a germline configuration with the J-y 
probe may actually be rearranged to these other regions. At any rate, the J-y probe detects a 
difference between the prothymocytic leukemias and two immature thymocytic T-ALL (patients 
1 to 5) and the other T-ALL (patients 6 to 22). Either the prothymocytic leukemias and the two 
immature thymocytic T-ALL are truly unrearranged or are rearranged to joining regions not 
commonly utilized by more mature T cells. 
Northern blot analysis 
To analyze the expression of genes encoding for protein chains of the TcR-CD3 complex, 
we performed Northern blot analysis on RNA from 12 out of the 22 T-ALL by using the 
described TcR and CD3 eDNA probes. 
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Figure 4. Southern blot analysis of EcoRI-digested 
DNA for the detection of TcR--y gene rearrange-
ments using the J-y probe. The two germline bands 
(G) of about 1.8 kb (J-y1 gene segment) and 3.5 kb 
(J-y2 gene segment) are indicated. The weak 3.8-kb 
bands(*), present in all five Janes, are old hybridi-
zation signals from a previous hybridization. The 
T-ALL cells from patient 2 and 3 had germline J-y1 
and J-y2 gene regions, while in the ALL cells from 
patients 8, 9 and 13 the TcR-1 genes appeared to 
be clonally rearranged. In the lanes from patients 
8, 9 and 13 weak germline bands are also present. 
The non-germline bands are marked with Roman 
figures, according to the previously described 
classification of rearranged TcR--y genes (26) and 
their molecular weight is indicated on the left. The 
non-germline 2.3-kb band (VII) represents a new 
group of rearranged TcR--y genes. 
Hybridization with the COS-o and CDS-E probes revealed that normal size transcripts of the 
COS-o and CDS-E genes were present in all 12 T-ALL tested, including the two tested 
prothymocytic T-ALL and four additional cos- T-ALL (Table 2 and Figure 5). 
Hybridization with the TcR-a eDNA probe revealed that the two mature T-ALL tested 
expressed TcR-a transcripts, while in all other T-ALL tested no TcR-a transcripts could be 
detected, including the three CDS+ common thymocytic T-ALL tested (Table 2). 
The TcR-.8 eDNA probe detected a 1.S-kb mRNA as well as a 1.0-kb mRNA in several 
leukemias. The 1.S-kb mRNA, which represents a complete variable-diversity-joining constant 
transcript (78,79), was present in one immature thymocytic T-ALL (patient 10) and in all com-
mon thymocytic and mature T-ALL tested, except one (patient 14). The 1.0-kb mRNA, which 
may represent a diversity-joining-constant transcript (79), was present in the majority of T-ALL 
which contained 1.S-kb TcR-.8 mRNA. Patient 14 had a cos+ T-ALL, which only expressed 
TcR-CD3 complex during T cell differentiation 
Figure 5. Northern blot analysis for the detection 
of CD3-E transcripts. The size of the CD3-E tran-
script (1.4 kb) is indicated. The T-ALL cells from all 
patients appeared to contain CD3-E transcripts. 
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intermediate sized TcR-.B transcripts of about 1:1 kb. This 1.1-kb band was also present in a 
prothymocytic T-ALL (patient 3), which had germline TcR-.B chain genes (Table 2 and Figure 
6). 
Hybridization with the TcR--y eDNA probe revealed that distinct TcR--y mRNA was present 
in several immature and common thymocytic T-ALL, but was very weakly expressed by the 
mature T-ALL tested. The prothymocytic T-ALL tested did not contain TcR--y mRNA (Table 2). 
DISCUSSION 
The T cell leukemias studied here could be divided into six groups based on their 
immunologic phenotype. These six groups of T-ALL represent the various stages of T cell 
differentiation: A: prothymocytic T-ALL (TdT+ /CD?+ /CD5-/CD1-/CD3l; B: immature 
thymocytic T-ALL (TdT+ /CD?+ /CD5+ /CD1-/CD3l; C: CD3- common thymocytic T-ALL 
(TdT+ /CD?+ /CD5+ /CD1 + /CD3l; D: CD3+ common thymocytic T-ALL (TdT+ /CD?+ 1 
cos+ /CD1 + /CD3+); E: TdT+ mature T-ALL (TdT+ ;co?+ ;cos+ ;cor;co3+); and F: Tdl 
mature T-ALL (Tdi/CD7+ /CD5+ /CD1-/CD3+) (Table 2 and Figure 7). 
In the prothymocytic T-ALL the TcR-.B genes were in germline configuration, as were the J-y1 
and J-y2 segments of the TcR--y genes. Two immature thymocytic T-ALL also had germline 
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Figure 6. Northern blot analysis for the detection of TcR-,8 
transcripts. The sizes of the TcR-.8 transcripts (1.3 kb, 1.1 kb, and 
1.0 kb) are indicated. The presumptive functional 1.3-kb TcR-.8 
transcripts as well as weak bands of 1.0-kb transcripts were 
detected in patients 19 and 21. In patients 3 and 14, only 
intermediated sized 1.1-kb transcripts were detected, while in 
patient 7, no TcR-.8 transcripts could be detected. 
TcR--y genes. This is remarkable, since virtually all T-ALL reported until now had rearranged 
TcR--y genes (24-26). One of the two immature thymocytic T-ALL with the germline TcR--y genes 
(patient 4) appeared to have also germline TcR-.B genes. In the other one (patient 5) germline 
bands were detected by use of the C.B probe, while one non-germline band was detected by 
use of the J,B2 probe, suggesting a diversity-joining rearrangement in the ,82 region. It may be 
possible that in this leukemia the TcR--y genes are not germline, but rearranged to one of the 
recently described joining regions (77). In all other T-ALL (n=17) the TcR--y genes as well as 
the TcR-.8 genes were rearranged. These data indicate that rearrangement of TcR--y and TcR-,8 
genes takes place in early stages of thymocytic T cell differentiation, while prothymocytes still 
have germline TcR--y and TcR-.8 genes. 
The two tested prothymocytic T-ALL as well as all other T-ALL tested contained CD3-o and 
CD3-E transcripts. This finding supports the T cell origin of the prothymocytic T-ALL, since the 
presence of CD3 mRNA and CD3 proteins is T cell specific (41 ,42,60,80). On the other hand 
the presence of germ line TcR-.8 and TcR--y genes strongly supports the very immature character 
of the prothymocytic T-ALL, i.e. the expression ofTdT, HLA-DR, and the two pan-T cell antigens 
CD? and C02, but the absence of all other cell surface T cell markers tested. Although all 
HLA-DR+ ALL reported until now, appeared to have rearranged lg heavy chain genes (16,81-
83), the two prothymocytic T-ALL tested (patients 1 and 3) had germline lg heavy chain genes 
(data not shown). Previously we have described the immunologic phenotype of the normal 
counterpart of the prothymocytic T-ALL and reported that this cell is detectable in low frequen-
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Figure 7. Hypothetical differentiation scheme of the human T cell lineage. The immunologic phenotypes of the 
cells in the various T cell differentiation stages are indicated. A, B, C, D, E, and F, six groups of T-ALL used in this 
study. Dotted lines, the tissues where these cells are found; horizontal bars, the described data concerning the 
rearrangement of the TcR-r and TcR-,8 genes as well as the presence of transcripts for CD3-o, CD3-E, TcR-a, 
TcR-,8, and TcR-r genes. This differentiation scheme is hypothetical and does not pretend to be complete. In 
addition, future experiments have to elucidate whether CD3 + cells, which contain TcR-r transcripts but lack TcR-a 
transcripts, belong to a distinct differentiation lineage. 
cies in the bone marrow (0.02% to 0.05%) as well as the thymus (0.02%) (46). Occasionally this 
putative prothymocyte can be detected in the peripheral blood (46,84), suggesting migration 
from the bone marrow via the peripheral blood to the thymus. All these data may indicate that 
CD3 gene transcription is an early event in T cell differentiation, which most probably already 
takes place before entrance into the thymus, while TcR-,8 and TcR-r gene rearrangements may 
be thymus-restricted processes (Figure 7). 
It is remarkable that HLA-DR positivity was only found in immature T-ALL with germline 
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TcR-.8 genes and/or germline TcR-r genes: all prothymocytic T-ALL were HLA-DR+ and half 
of the leukemic cells of one of the immature thymocytic T-ALL (patient 5) were HLA-DR +. This 
is in line with the observation that most precursor cells in hematopoiesis express the HLA-DR 
antigen (85), and suggests that the expression of HLA-DR together with CD3 gene expression 
and the expression of the pan-T cell markers CD? and C02 may play a role in the initial phase 
of T cell development 
Data from the literature suggest that in mice, TcR-r genes are expressed prior to TcR-.8 
genes during ontogeny (17, 18). Our data indicate that in humans TcR-r and TcR-.8 genes 
rearrange in virtually the same early thymocytic differentiation stage. Nevertheless, TcR-r 
transcripts were detectable in an earlier stage than 1.3-kb TcR-.8 transcripts. Although ontogeny 
and differentiation are not completely comparable, these data suggest that T cell development 
in the murine and human species is rather similar. 
Preliminary data indicate that in humans as well as in mice the repertoire of the TcR-r genes 
is restricted as compared with the TcR-a and TcR-.8 gene repertoire (23,26,86). In addition to 
the recently described classification of TcR-r gene rearrangements, we here report an 
additional type of rearranged TcR-r genes, which results in a 2.3-kb band (Figure 4) (EcoRI 
digestion and hybridization with the Jr probe); we propose to use the Roman number VII 
(Figure 4), for this type of TcR-r gene rearrangement (26). Future experiments will elucidate the 
extent of the TcR-r gene repertoire and will demonstrate whether the recently discovered TcR-r 
joining regions are used in prothymocytic T-ALL 
In mice the presence of TcR-r transcripts is restricted to thymocytic cells (17). Our human 
data are similar, since distinct levels of TcR-r transcripts were only present in some thymocytic 
T-ALL, while the mature T-ALL were weakly positive. In the tested prothymocytic T-ALL (patient 
3) no TcR-r transcripts could be detected, which was in line with the presence of germline 
TcR-r genes, as analyzed by use of the described Jr probe. 
In many tested T-ALL two TcR-.8 transcripts of different sizes were detected (1.3 kb and 1.0 
kb). The presumptive functional1.3-kb TcR-.8 transcript, which represents a complete variable-
diversity-joining-constant transcript (78,79), was detected in almost all CD3- and CD3+ 
common thymocytic T-ALL as well as mature T-ALL tested. In most of these T-ALL 1.0-kb TcR-.8 
transcripts were also detected. Such transcripts most probably represent diver-
sity-joining-constant transcripts (79). One CD3+ common thymocytic T-ALL (patient 14) only 
expressed an intermediate-sized 1.1-kb TcR-.8 transcript and no detectable 1.3- or 1.0-kb 
transcripts. Since it has been suggested that expression of CD3 on the cell surface requires the 
presence of TcR chains (36,37), it is possible that an incomplete TcR-,8-chain may be present 
in the TcR-CD3 complex expressed by this T-ALL or that alternatively a non-a.B TcR is 
expressed (29). In the tested prothymocytic T-ALL (patient 3) also a weak intermediate-sized 
1.1-kb TcR-.8 transcript was detected, while all TcR-.8-chain genes in this leukemia were in 
germline configuration. This suggests that the 1.1-kb transcript may represent an aberrant 
joining-constant or constant transcript In one of the immature thymocytic T-ALL (patient 7) no 
TcR-.8 transcripts were detectable, although the TcR-.8 genes were rearranged. In the latter 
leukemia rearrangement of the TcR-.8 genes may have resulted in a transcriptional inactive 
gene, or alternatively this leukemia may represent a cell in an intermediate differentiation stage 
between rearrangement and- transcription of the TcR-.8 genes. 
The TcR-a transcripts were detected in mature T-ALL, but not in the CD3+ common 
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thymocytic T-ALL tested. Since it has been suggested that CD3 expression is dependent on 
the presence of TcR chains, this may indicate that the level of TcR-o: mRNA is below the 
detection limit, or that the TcR-o: chain is replaced by another chain, e.g. TcR-r (17). This pre-
sumption is supported by the presence of TcR-r transcripts in two of the three CD3 + common 
thymocytic T-ALL tested (Table 2). An alternate non-o:.B TcR has recently been described by 
Brenner et al. (29). Such non-o:.B TcR may be expressed by the T-ALL from patient 14, in which 
TcR-r mRNA was detected in absence of TcR-o: mRNA and i .3-kb TcR-.8 mRNA. 
Summarizing, we conclude that the presence of CD3 transcripts but absence of TcR gene 
rearrangements as well as lg gene rearrangements in TdT+ /HLA-DR+ /CD?+ /CD2+ ;cos-; 
CDi-/CDT T-ALL strongly supports our hypothesis that the normal counterparts of such 
leukemic cells in human bone marrow represent prothymocytes. On the other hand, this 
indicates that CD3 gene transcription is one of the earliest events in T cell differentiation, which 
already takes place in prothymocytes, most probably before entrance into the thymus. The 
TcR-r and TcR-.8 genes rearrange in a subsequent stage ofT cell differentiation (i.e. early in 
thymic T cell differentiation) and can consequently be transcribed. The TcR-r genes may only 
be transcribed transiently during thymic T cell differentiation, while the TcR-.8 transcription conti-
nues during further differentiation. Subsequently the TcR-o: genes are transcribed. The latter 
event may be the final step in the production of the complete set of TcR and CD3 proteins, 
resulting in the expression of the TcR-o:.B-CD3 complex at the cell surface of mature T cells 
(Figure 7). The consecutive processes described here are very analogous to those that 
precede the surface membrane lg expression during B cell differentiation. Recently Furley et 
al. have published similar data (87). However in their series of T-ALL no prothymocytic T-ALL 
were included and they did not analyze the configuration and expression of the TcR-r genes. 
Whether the CD3+ common thymocytic T-ALL, which lack TcR-o: transcripts, express an 
alternate receptor such as TcR-.Br or another TcR and whether the normal counterparts of 
these T-ALL may belong to a distinct differentiation lineage has to be further investigated. 
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SUMMARY 
We have cloned and sequenced two homologous J regions of the T cell 1 gene and 
localized one 5' of each constant region. They have been numbered J"{1.1 and J"{2.1; other 
J regions have been renamed in a similar manner. Southern blot analysis suggests that there 
is comparatively more rearrangement to these J regions in thymocytes than peripheral blood 
T cells. We propose that either there is 1-chain gene rearrangement first to J"{1.1 or 2.1 and 
then to J"{1.3 or 2.3, or there is selected cell death of thymic T cells bearing a J"[1.1 or 2.1 
rearrangement. 
INTRODUCTION 
The T cell "{-chain gene encodes one subunit of a cell surface receptor found on a small 
subset ofT cells (1 ,2). This receptor resembles the T cell antigen specific receptor found on 
most mature T cells (3). It is not necessary for cytotoxic or helper T cell function, and its precise 
role in the immune response remains obscure (4-7). To define the diversity and structure of the 
"{-chain, we and others have studied the 1 gene locus. The 1 gene undergoes somatic 
recombination in T cells and is structurally similar to the immunoglobulin and T cell receptor 
genes (3,8-11). There are only a few variable region genes encoded in the germline of mouse 
or man (9, 12-17). However, the overall diversity of "[-chains is expanded by the addition of 
template-independent sequence (N segments) at the variable joining (VJ)4 junction (5-
7,9, 12, 14, 17). Here we present evidence for greater germline J region diversity than previously 
suspected. We have determined the sequence and genomic location of two additional 1 gene 
joining regions. Surprisingly, the proportion of rearranged 1 genes that make use of these 
*Published in: J lmmunol1987; 138:2687-90. The V"[ gene nomenclature is adapted to the nomenclature according 
to M.-P. LeFranc and T.H. Rabbitts (Cell 1986;45:237-46; Trends Biochem Sci 1989;14:214-8). 
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joining regions is greater in thymocytes than in peripheral blood T cells. 
MATERIALS AND METHODS 
DNA preparation 
Adult thymic tissue and leukemic blood were collected in accordance with accepted guidelines regarding 
patients' rights and approval; normal peripheral blood was obtained from volunteers. Lymphocyte populations of 
leukemic and normal peripheral blood were separated by fractionation on a Ficoll gradient (Lymphoprep, 
Bionetics), and the mononuclear cell fraction was collected for analysis. In all cases DNA was prepared by 
digestion with proteinase Kin 0.5% sodium dodecyl sulfate (SDS), followed by extraction with phenol/chloroform 
and ethanol precipitation. 
Cloning of joining regions 
A rearranged fragment was cloned from DNA derived from a patient with T cell acute lymphoblastic leukemia 
(CD4-;cos+ jCD6l. EcoRI digested DNA was size fractionated on a preparative agarose gel and was ligated into 
.Agt 10. Recombinant phage were screened with a 32P nick-translated variable region (V-yll) probe derived from the 
previously described eDNA clone pT-y-10 (17). The 3' portion of the cloned fragment .ARBN was localized to the 
-y constant locus by hybridization to the previously described clone .A33, and comparison of restriction maps (13). 
A 250 basepair (bp) Accl fragment containing the VJ junction (see Figure 2) was isolated from .ARBN and was 
sequenced in both directions by using the dideoxy method of Sanger (18). This Accl fragment when used as a 
probe in a Southern blot of cloned -y constant region DNA hybridized to a 1 kilobase (kb) EcoRI fragment of the 
previously described clone p-yC1C2 (13). Nucleotide sequence analysis of this EcoRI fragment was carried out 
from an internal Hindlll site and the 3' EcoRI site. 
Southern blotting 
Genomic or cloned DNA was digested with EcoRI or Pvull, was size fractionated on a 0.9% agarose gel, and 
was transferred to nitrocellulose. Hybridization was carried out with 32P nick-translated probes as described (13). 
The J')'1.1 probe is a 250 bp Accl fragment that hybridizes to a 2.4-kb EcoRI genomic fragment containing J-y1.1 
and a 1-kb EcoRI genomic fragment containing J-y2.1, and to rearranged fragments that make use of Jr1.1 and 
Jr2.1. This probe contains 50 bp of variable region sequence and produces a faint 5-kb band representing the 
germline Vrii)(V/'9) fragment. Rearranged bands noted in thymus DNA are not due to hybridization to variable 
region sequence, because a corresponding full length variable region probe fails to produce these bands. Also this 
pattern has subsequently been reproduced with a germline Jr2.1 probe. The J-y1.2 probe is a 2-kb Hind ill fragment 
that hybridizes to a 6-kb germline Pvull fragment and rearrangements to this J region. The Jr1.3 probe is a 0.8-
kb Hindiii-EcoRI fragment that produces 1.2- and 3.5-kb EcoRI germline bands containing Jr1.3 and Jr2.3, 
respectively. Rearrangement patterns of leukemic T cells observed with this probe have been described (13). 
RESULTS AND DISCUSSION 
The human r gene is encoded by two highly homologous constant regions and 11 variable 
regions constituting four V region families (10, 11, 14, 17, 19). Previous studies have identified a 
single joining region associated with each constant region (Jr1 and Jr2) that differ by only a 
single bp (17, 19). Each of these J regions can be joined to one of the variable region genes. 
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;\RBN 
* * ** ** ****** Tyr Tyr Cys Ala Leu Trp Glu Val Arg Thr Thr Gly Trp Phe Lys lie Phe Ala Glu Gly Thr Lys Leu lie Val Thr Ser Pro
TACTACTGTGCCTTGTGGGAGGTGCGCACCACTGGTTGGTTCAAGATATTTGCTGAAGGGACTAAGCTCATAGTAACTTCACCTGGTAAGT 
Vyll (Vy9) N? Jy1.1 
___ Ser Ser Asp Trp lie Lys Thr Phe Ala Lys Gly Thr Arg Leu lie Val Thr Ser Pro , ..... 
GATTTTTGTAGAAGCTTAGACCAGTGTGATAGTAGTGATTGGATCAAGACGTTTGCAAAAGGGACTAGGCTCATAGTAACTTCGCCTGGTAAGT 
Jy2.1 
Figure 1. Nucleotide sequence of the productive rearrangement .\RBN and germline J"(2.1. Variable region and 
J"(1.1 sequences of .\RBN are underlined and labeled. Because of the loss of homology between .\RBN and J-y2.1 
at the VJ junction, it is postulated that an N segment has replaced the 5' J"(1.1 sequence. Because the sequence 
of V"(ll 0/"(9) is derived from a eDNA clone (17), it is also possible that these bases represent the 3' end of V"(ll 
0/"(9). The characteristic heptamer and nonamer recombination signals of J"(2.1 are overlined; RNA splicing 
signals are indicated by dots. Asterisks indicate conserved amino acids. 
Most T cell leukemias contain rearranged -y-chain genes on both chromosomes in which a 
variable region gene has joined to one of these J segments (13). A third J region (J-yP) was 
recently found in association with C-y1 and was noted to rearrange to a 1 V region (14). 
Screening of T cell leukemias with a V region probe (V-yll) has identified a rearranged 
fragment that does not hybridize to the known J regions. A 3.7-kb EcoRI fragment containing 
this rearrangement (.\RBN) was cloned from the lymphoblasts of a patient (BN) with T cell acute 
lymphoblastic leukemia. Nucleotide sequence analysis at the VJ junction (Figure 1) revealed 
the V-yii)(V-y9) variable region joined to 60 bp of sequence with 50% homology to previously 
described J regions and was flanked at the 3' end by GT MGT, the same splice signal found 
in previously described 1 J regions. This sequence thus represents a J segment located 5' of 
C-y1 (Figure 2). A region upstream of C-y2 contains a highly homologous J region with charac-
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Figure 2. Genomic organization of joining and constant regions of the human "(-chain gene. J regions are indicated 
by vertical lines. J regions described here are J"(1.1 and J"(2.1. Previously described J regions have been renamed; 
J"(1 was changed to J"(1.3, J"(2 was changed to J"(2.3, and J-yp was changed to J"(1.2. Constant region coding 
blocks are shown by hatching; genomic probes are stippled. Double cross-hatching of ARBN indicates variable 
region and 5' untranslated V region sequence that has rearranged to J"(1.1. The jagged line above J"(1.2 and 
flanking sequence indicates a region that has no correlate upstream of C-y2. Isolation and characterization of 
clones .\33 and p"(C1C2 has been described (13). Only relevant restriction sites are shown. Abbreviations: E, 
EcoRI; H, Hindlli; P, Pvuii; B, BamHI. 
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teristic heptamer and nonamer 5' sequences separated by 12 bp (Figure 1). The J segments 
described here are 70% homologous at the nucleotide level. Differences in the nucleotide 
sequence of these J regions at the 5' end are probably due to an N region in the rearranged 
gene. By nucleotide analysis, the cloned rearrangement appears to encode a functional 1 
protein. 
The genomic organization of the human 1 constant and joining locus is shown in Figure 2. 
Because the J regions described here are the furthest 5 ', they have been labeled J11.1 and 
J12.1; a tentative numbering scheme has been proposed for the other J regions. J11.2 appears 
not to have a correlate associated with C12. Probes derived from a 5-kb region flanking J11.2 
fail to hybridize to sequences between C11 and C12, indicating that this region of DNA was 
deleted at the time of duplication of the constant gene locus or was inserted after duplication. 
The organization of the human and mouse 1 genes now appear to be very different. The 
mouse gene has four constant regions, and each is associated with a single J region (7,9, 15). 
Rather than the constant regions being linked, recent evidence closely links two of the mouse 
constant regions to variable regions (7, 15). Other constant regions have a restricted pattern of 
rearrangement and may also be linked to variable regions. Although the organization of the 1 
locus was originally felt to be similar to the immunoglobulin >- locus, both the mouse and the 
human loci now appear to be quite different. The wide separation in the human of two or three 
J regions 5' of the constant region (J11.1 is 10 kb from C11) is unique to this locus. The a-
chain of the T cell receptor has J regions widely separated from the constant region, but 
appears to have a large total number of J regions (20). It is possible that other J regions may 
exist in the 1locus, but this could only be excluded by nucleotide sequence analysis of a large 
number of 1-chain eDNA. Additional J regions will be numbered in order of discovery by 
location and homology. 
We have studied the use of 1 J regions in different T cell populations by using J region 
probes in Southern blot analysis of adult thymocytes and peripheral blood T cells (Figure 1). 
Hybridization with the J11.2 probe to thymus and peripheral blood T cell DNA did not reveal 
rearrangement in these T cell populations. However, rearrangement was found with the other 
J region probes under similar conditions, suggesting that J11.2 is used less frequently in 
thymocytes and peripheral blood T cells than the other J regions. J11.2 is capable of 
rearrangement, because it was initially characterized by cloning a genomic rearranged fragment 
from leukemic cells (14). Although the heptamer and nonamer recognition sequences 
associated with J11.3 and J12.3 are extremely similar to those found in J12.1 (and presumably 
J1U), the heptamer and nonamer sequences of J11.2 are quite different. Lefranc et al. (14) 
have suggested that such differences might lead to infrequent use. 
J11.3 and 2.3 are much more extensively used than J11.2. Rearrangements to these J 
regions are easily visualized in both thymus and peripheral blood (Figure 3). This pattern is a 
composite of the rearrangements noted in a series ofT cell leukemias (13), although the 9.5-kb 
band is not seen here and a new 2.2-kb band is faintly seen. Bands in the peripheral blood 
and thymus lanes appear to be comparable except for the 0.9-kb rearrangement. Thus all of 
the rearrangements but one are equally represented in thymus and peripheral blood T cell 
populations. 
Probes containing J11.1 or J12.1 detect distinct rearranged bands when hybridized to 
thymus DNA, and there is diminution in intensity of the J11.1 germ line band (Figure 3). Although 
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Figure 3. Southern blots using genomic J region probes. Probes were isolated as shown in Figure 2 and were 
explained in text. Germline fragments are indicated by arrowheads on the left of each blot and rearranged 
fragments are indicated by arrows on the right. Blots probed with J"(1.3 and J-y1.1 are EcoRI digests, and J"(1.2 
blots represent Pvull digests. J-y1.3 rearrangements are 5.3, 4.2, 2.5, 2.2, 0.9, and 0.58 kb. J"(1.1 rearranged bands 
are 4.0, 3.3, 2.1, and 1.8 kb. 
faint rearranged bands could be detected in peripheral blood on the original autoradiograph, 
rearrangement in thymocytes is more prominent than in peripheral blood T cells. This is in 
sharp contrast to the findings with the J-y1.3 probe in which rearrangement is equally visible in 
both T cell populations. Thus the proportion of -y gene rearrangements that makes use of J-y1.1 
and J-y2.1 is greater in thymocytes than peripheral blood T cells. Ten peripheral blood T cell 
samples and two thymus samples of comparable age have been examined with these probes 
with similar results {data not shown). The observed difference in degree of rearrangement to 
these J regions could represent a developmental pattern characterized by rearrangement of 
J-y1.1 I J-y2.1 before rearrangement involving J-y1.3 and J-y2.3. Alternatively, T cells in which J-y1.1 
and J-y2.1 are rearranged may be selected for cell death or retention in the thymus. The greater 
frequency of the 0.9 kb rearrangement detected in the thymus with the J-y1.3 probe probably 
represents a similar phenomenon. Future studies should determine whether the r genes 
rearranged in thymus produce functional -y-chains. Such studies will help to distinguish between 
these two models. 
250 CHAPTER 4.4 
ACKNOWLEDGMENT. We thank Dr. Gaty Tanigawa for valuable discussion and expert secretarial assistance. 
This work was supported by National Institute for Health training (T. Quertermous, Grant T32-HL-07208; J.G. 
Seidman, Grant Al-19938 and Af-18436), the Netherlands Cancer Foundation (J.J.M. van Dongen) and the 
Mal/inkrodt Foundation (J.G. Seidman). 
REFERENCES 
1. Brenner MB, Mclean J, Dialynas DP, Strominger JL, Smith JA, Owen FL, Seidman JG, lp S, Rosen F, Krangel 
MS. Identification of a putative second T-cell receptor. Nature 1986;322:145-9. 
2. Bank I, DePinho RA, Brenner MB, Cassimeris J, Alt FW, Chess L A functional T3 molecule associated with 
a novel heterodimer on the surface of immature human thymocytes. Nature 1986;322: 179-81. 
3. Kronenberg M, Siu G, Hood LE, Shastri N. The molecular genetics of the T-cell antigen receptor and T-cell 
recognition. Annu Rev lmmunol1986;4:529-91. 
4. Heilig JS, Glimcher LH, Kranz DM, Clayton LK, Greenstein JL, Saito H, Maxam AM, Burakoff SJ, Eisen HN, 
Tonegawa S. Expression of the T-cell specific"( gene is unnecessary in T cells recognizing class II MHC 
determinants. Nature 1985;317:68-70. 
5. Rupp F, Frech G, Hengartner H, Zinkernagel RM, Joho R. No functional "(-chain transcripts detected in an 
alloreactive cytotoxic T-cell clone. Nature 1986;321 :876-8. 
6. Reilly EB, Kranz DM, Tonegawa S, Eisen HN. A functional"( gene formed from known"( gene segments is not 
neccessary for antigen-specific responses of murine cytotoxic T lymphocytes. Nature 1986;321 :878-80. 
7. Traunecker A, Oliveri F, Allen N, Karjalainen K. Normal T cell development is possible without "functional" "( 
chain genes. EMBO J 1986;5:1589-93. 
8. Saito H, Kranz DM, Takagaki Y, Hayday AC, Eisen HN, Tonegawa S. Complete primary structure of a 
heterodimeric T-cell receptor deduced from eDNA sequences. Nature 1984;309:757-62. 
9. Hayday AC, Saito H, Gillies SD, Kranz DM, Tanigawa G, Eisen HN, Tonegawa S. Structure, organization, and 
somatic rearrangement ofT cell gamma genes. Cell 1985;40:259-69. 
10. Murre C, Waldmann RA, Morton CC, Bongiovanni KF, Waldmann TA, Shows TB, Seidman JG. Human "(-chain 
genes are rearranged in leukaemic T-cells and map to the short arm of chromosome 7. Nature 1985;316:549-
52. 
11. Lefranc MP, Rabbitts TH. Two tandemly organized human genes encoding the T-cell "(constant-region 
sequences show multiple rearrangement in different T-cell types. Nature 1985;316:464-6. 
12. Kranz DM, Saito H, Heller M, Takagaki Y, Haas W, Eisen HN, Tonegawa S. Limited diversity of the rearranged 
T-cell-y gene. Nature 1985;313:752-5. 
13. Quertermous T, Murre C, Dialynas DP, Duby AD, Strominger JL, Waldmann TA, Seidman JG. Human T-cell 
"( chain genes: organization, diversity, and rearrangment. Science 1986;231 :252-5. 
14. Lefranc M-P, Forster A, Baer R, Stinson MA, Rabbitts TH. Diversity and rearrangement of the human T-cell 
rearranging"( genes: nine germ-line variable genes belonging to two subgroups. Cell 1986;45:237-46. 
15. Iwamoto A, Rupp F, Ohashi PS, Walker CL, Pircher H, Joho R, Hengartner H, Mak T. T cell-specific "( genes 
in C57BL/10 mice. J Exp Med 1986;163:1203-12. 
16. Garman RD, Doherty PJ, Raulet DH. Diversity rearrangement and expression of murine T cell gamma genes. 
Cell1986;45:733-42. 
17. Quertermous T, Strauss WM, Murre C, Dialynas DP, Strominger JL, Seidman JG. Human T-cell 1 genes 
contain N segments and have marked junctional variability. Nature 1986;322:184-7. 
18. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA 
1977;74:5463-7. 
19. Lefranc MP, Forster A, Rabbitts TH. Rearrangement of two distinct T-cell "(-chain variable-region genes in 
human DNA. Nature 1986;319:420-2. 
20. Yoshikai Y, Clark SP, TaylorS, Sohn U, Wilson Bl, Minden MD, Mak TW. Organization and sequences of the 
variable, joining and constant region genes of the human T-cell receptor a-chain. Nature 1985;3H5:837-40. 
251 
CHAPTER 4.5 
TWO TYPES OF GAMMA T CELL RECEPTORS EXPRESSED BY T CELL 
ACUTE LYMPHOBLASTIC LEUKEMIAS* 
Jacques J.M. van Dongen 1, Ingrid LM. Wolvers-Tettero 1, 
J.G. Seidman2, Siew-Lan AnJJ2, Rene J. van de Griend3, 
Evert F.R. de Vries and Jannie Borst4 
1. Department of Immunology, Erasmus University /University Hospital Dijkzigt, Rotterdam, The Netherlands; 
2. Department of Genetics, Harvard Medical School, Boston, MA 02115; 
3. Department of Immunology, Radiobiological Institute TNO, Rijswijk, The Netherlands; 
4. Department of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 
SUMMARY 
CD3 + cells, isolated from peripheral blood of two patients with T cell acute lymphoblastic 
leukemia (T-ALL) did not react with the monoclonal antibody WT31, which is thought to 
recognize a framework determinant on the conventional T cell receptor (TcR), consisting of 
disulfide-linked a and {3 chains. The T-ALL cells of neither patient synthesized TcR-a mRNA; the 
cells of patient DD contained only truncated (D-J) TcR-/3 mRNA, while the cells of patient HZ 
contained truncated as well as mature (V-D-J) TcR-/3 mRNA. The leukemic cells of both patients 
made TcR-r mRNA. At the cell surface, the T-ALL cells of patient DD expressed a COS-
associated disulfide-linked dimer, which contained the TcR-r protein. On the leukemic cells of 
patient HZ the TcR-r protein was present as a 41-44 kDa COS-associated subunit in a 
non-covalently linked form. The TcR-r genes in the T-ALL cells of patient DD were rearranged 
exclusively to the C-y1 locus, while in the T-ALL cells of patient HZ both Cr1 alleles were deleted 
and rearrangement to the Cr2 locus had occurred. The Oy1 gene segment, just like the TcR-a 
and TcR-/3 gene segments contains a cysteine codon in its second exon. This cysteine residue 
is involved in the formation of the interchain disulfide bond. The human Cr2 gene segment, 
however, does not contain a cysteine codon in its second exon. The absence of the cysteine 
residue in C-y2 encoded TcR-r chains explains the lack of an interchain disulfide bond in the 
TcR on the T-ALL cells of patient HZ. The TcR gene configuration as well as the expression of 
TcR mRNA and TcR protein as observed in these two leukemias, is consistent with a model for 
T cell differentiation in which the TcR-r gene rearranges first to the C-y1 locus prior to or 
coinciding with D-J joining of the TcR-/3 gene, followed by rearrangement to the Cr2 locus and 
V-D-J joining of the TcR-{3 gene. 
*Published in: Eur J lmmunol1987;17:1719-28. 
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INTRODUCTION 
Many studies have indicated that the receptor by which mature T cells recognize antigen 
in combination with molecules of the major histocompatibility complex (MHC) is a disulfide-
linked heterodimer, consisting of two structurally variable glycoproteins, the T cell receptor 
(TcR)-a and {3 chain (1 ,2). The TcR is closely associated with the CD3 antigen (3-7), which may 
play a role in signal transduction from the receptor to the cytoplasm (8-10). The TcR-a and 
TcR-/3 chains are encoded by variable, (diversity), joining and constant 0/, D, J and C) gene 
segments which join through rearrangement during T cell differentiation in the thymus (11-15). 
Functionally rearranged TcR genes give rise to the expression of the TcR-CD3 protein complex 
on the cell membrane of mature T cells. 
A third Tcell specific rearranging gene, termed TcR--y, has been identified (16-19). However, 
until recently the protein product of this gene remained elusive. The TcR--y gene is transcribed 
abundantly early in thymic ontogeny, prior to TcR-a gene transcription (20,21). During further 
development TcR--y gene transcription decreases, while TcR-a mRNA production increases 
(20,21). Mature T cells (T cell clones, blood T lymphocytes or mature T cell leukemias) may 
contain TcR--y mRNA (15,22-28) which, however, is non-functional in the great majority of cases 
(26-31). These data suggested a role for the TcR--y gene product during thymic differentiation 
(20,21). 
Recently, the TcR--y protein has been identified (32,33). In man, expression of the TcR--y 
chain in association with CD3 has been demonstrated on T cell clones derived from normal 
peripheral blood (PB) (34-36), cord blood (37), fetal PB (38,39) and PB from immunodeficient 
patients (32,34,35) as well as on a thymocyte-derived T cell clone (33). Indirect evidence 
suggests that the percentage of TeA--r-expressing CD3+ T lymphocytes in adult PB is about 
3%, while in the thymus this population is about 0.5% (40). In the mouse, it was shown that the 
TcR--y protein is expressed on the cell surface of CD3+ thymocytes at day 15 and 16 of fetal 
development (41 ,42) prior to expression of the TcR-a/3 (42). After birth the TcR--y chain is 
present on a small subset of murine thymocytes (42,43). The phenotype of TcR--y-expressing 
cells is predominantly CD3 + /CD4-;cos- (32-36,40). Cells expressing TcR--y protein may exert 
cytolytic activity (34,35,37). In this activity no involvement of MHC molecules as restriction 
elements has been demonstrated so far (34,35). 
T cell acute lymphoblastic leukemias (T-ALL) represent the malignant counterparts of cells 
in various stages of T cell differentiation (44,45). Therefore, we recently analyzed a series of 
T-ALL to determine the configuration of the T cell receptor genes and their transcription as well 
as the expression of the TcR-CD3 complex (15). Abundant TcR--y transcripts were detectable 
in the majority of thymocytic T-ALL, while the presumptive functional 1.3-kilobase (kb) TcR-/3 
transcripts were present in almost all thymocytic T-ALL as well as mature T-ALL TcR-a tran-
scripts were only detected in mature CD3+ T-ALL. However, in three CD3+ T-ALL no TcR-a 
mRNA could be detected, indicating that they did not express the TcR-a/3. We suggest that 
such leukemias express an alternate TcR (15), since the expression of the CD3 antigen has 
been demonstrated to be dependent on the presence of a TcR (46-48). Here we describe the 
TcR--y protein expression by two CD3 + /TcR-a mRNA -leukemias. Two different types of recep-
tors were found in association with CD3: one leukemia expressed a disulfide-linked dimer 
involving the TcR--y chain, while the other leukemia expressed a non-covalently linked TcR--y 
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chain. Analysis of the configuration and expression of the TcR-1 genes enabled us to explain 
the occurrence of these two types of TcR-1 receptors. 
MATERIALS AND METHODS 
Cell samples 
PB samples were derived from the T-ALL patient DD (11-year-old girl) and the T-ALL patient HZ (7-year-old 
girl). Mononuclear cells (MNC) were isolated from the PB samples by Ficoii-Paque (density: 1.077 gjmL; Phar-
macia, Uppsala, Sweden). The T cell lines HPB-ALL and Jurkat were used as control sources forT eR-a, TcR-,8 and 
TcR-1 mRNA. DNA from B chronic lymphocytic leukemia (B-CLL) cells and DNA from normal PB cells was used 
as germline control in Southern blot analysis of the TcR genes. In some of the immunoprecipitation experiments 
TcR-a,B expressing leukemic T cells were used as a reference. 
Immunologic marker analysis 
The MNC from patient DD and patient HZ were analyzed for nuclear expression of terminal deoxynucleotidyl 
transferase (TdT), for cell membrane expression of the T cell markers CD1, CD2, CD3, CD4, CDS, CD6, CD7 and 
CDS, the B cell markers CD10, CD19 and CD20, the myeloid-monocytic markers CD14, CD15 and CD33, the 
HLA-DR antigen, the transferrin receptor and the interleukin 2 (IL2) receptor (CD25) as well as for reactivity with 
the monoclonal antibody (McAb) WT31, which recognizes a non-polymorphic epitope on TcR-a,B (49). General 
information about the antibodies used for the immunologic marker analysis is summarized in Table 1 {45). The 
indirect immunofluorescence stainings forTdT and the cell membrane markers were performed as described (45). 
The fluorescence staining was evaluated by use of Zeiss fluorescence microscopes (Carl Zeiss, Oberkochen, FRG). 
Northern blot analysis 
Total RNA was isolated using the UCI/urea method (50) from frozen MNC of patient DD and patient HZ as 
well as from the T cell lines HPB-ALL and Jurkat. Approximately 15 p.g of total RNA was size-fractionated on a 1.2% 
agarose gel (Sigma Chemical Co, St. Louis, MO) containing formaldehyde and blotted to Biodyne nylon 
membranes (Pall Ultrafine Filtration Corporation, Glen Core, NY). Specific RNA sequences were detected with 
32P-nick-translated TcR-a, TcR-,8 and TcR-'Y eDNA probes (19,29,51,52). Hybridization and washing conditions 
were as described (50). 
Southern blot analysis 
DNA was prepared from frozen MNC of patient DD and patient HZ, as described (53). Fifteen p.g of DNA was 
digested with £coR I or BamHI (New England Biolabs, Beverly, MA) and the fragments were size fractionated by 
electrophoresis through a 0.7% agarose gel. DNA was transferred onto Gene Screen Plus nylon membranes (New 
England Nuclear, Boston, MA) as described (50). 
Rearrangements of the TcR-'Y genes were detected by use of 32P-nick-translated J11.3 and C-y probes (Figure 
1) (18,19,29,54-56). The J-y1.3 probe is a 0.8-kb £coRI-Hindlll fragment containing joining (J)11.3 segments; it 
hybridizes to both J-y1.3 and J-y2.3 gene segments (56). The C-y probe is a 0.4-kb BamHI-BamHI fragment 
containing a part of the first exon of the constant (C)'Y1 gene segments; it hybridizes to the first exon of C-y1 and 
C-y2 (18). 
The configuration of the TcR-,8 genes was analyzed by use of 32P-nick-translated C,B and J,82 probes. The C,B 
probe is a 0.7-kb Psti-Bg/11 fragment containing C,81 segments; it hybridizes to both C,81 and C,82 gene segments 
and allows detection of rearrangements in the TcR-,81 gene region in £coRI digests (57). The J,82 probe consists 
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Figure 1. Organization of the J and C regions of the human TcR-1' gene {c.f. 54,56). The locations of the relevant 
EcoRI (E) and BamHI (B) restriction enzyme sites are indicated. The solid bars represent the probes which were 
used for hybridization of the Southern blot filters. In the second exon of the C-y1 genes the codon TGT codes for 
the cysteine residue which is presumably involved in the interchain disulfide bond, while in the duplicated second 
exon of the C-y2 genes (exon 2R and exon 2) this codon has been changed into TAT or TGG {29,54,55). Although 
in the majority of the C-y2 gene-derived eDNA clones and genomic DNA clones a duplication of the second C-y2 
exon has been found, even a triplication of the second C-y2 exon has been described in two eDNA clones derived 
from the TcR-1' protein-expressing T cell line PEER {55). 
of contiguous 1.9-kb Pvull-Pvull and 1.5-kb Pvull-fcoRV fragments containing J/32.3 through J/32.7; this probe does 
not hybridize to J/31 gene segments and was used to detect rearrangements in the TcR-/32 region in EcoRI digests 
{58). The absence or presence of TcR-/3 gene rearrangements was confirmed by BamHI digests using the C/3 
probe. Hybridization and washing conditions were as described {50). 
Labeling 
For cell surface radioiodination, 50 x 106-100 x 106 cells were labeled with Na 1251 (Amersham Corp., Bucking-
hampshire, UK), using 1 ,3,4,6-tetrachloro-3-a, 6-a-diphenylglycoluril {lodogen, Pierce Chemical Co., Rockford, IL) 
as a catalyst. 
lmmunoprecipitation 
Digitonin-mediated lysis was performed in imrnunoprecipitation buffer {IPB) consisting of 0.01 M 
triethanolamine-HCI, pH 7.8, 0.15 M NaCI, 1 mM phenylmethylsulfonylfluoride (PMSF), and 0.02 mgjml ovomucoid 
trypsin inhibitor {Tl) supplemented with 1% digitonin (Sigma). Lysates were pretreated by centrifugation and 
preclearing as described {34). Specific immunoprecipitation was carried out with the anti-CD3 McAb Leu-4 that had 
been coupled covalently to Sepharose beads by means of dimethylpimelimidate-HCI (Pierce Chemical Co.). 
Subsequently, beads were subjected to five washes in IPB with 1% digitonin. 
To identify the TcR-1' protein the recently described rabbit antiserum was used, raised against a synthetic pep-
tide of amino acids 117-136 of the TcR C-y region {29,32). Prior to immunoprecipitation with this antiserum, lysates 
were denatured as described {32). lmmunoprecipitates were recovered from the lysates by incubation with protein 
A-Sepharose beads and subjected to five washes as above. Reprecipitation of CD3 precipitates with the anti-Cr 
serum was performed as described previously {34). 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Samples were analyzed on SDS-polyacrylamide {10-15%) gradient gels, using standard procedures, either 
under nonreducing conditions {1 mM iodoacetamide in SDS sample buffer), or under reducing conditions {5% 
(v jv) 2-mercaptoethanol in SDS sample buffer). 
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Two dimensional gel electrophoresis according to O'Farrell 
Two-dimensional gel electrophoresis according to O'Farrell was performed using ampholytes (LKB, Bromma, 
Sweden) of isoelectric point (pi) 3.5-10, 4-6, 5-8 and 9-11 as 10:1:1 :1 in the isoelectric focusing (IEF) dimension. 
The second dimension consisted of a 10-15% SDS-polyacrylamide gel. 
Sialidase treatment 
For sialidase treatment beads were resuspended in 50 JLL of 0.05 M sodium acetate, pH 5.5, 0.9% NaCI, 0.1% 
CaCI2, 1 mM PMSF, 0.02 mgjml Tl. Sialidase type VIII (Sigma) was added at 0.1 U /sample, and the mixture was 
incubated for 3 h at 37 • C, while shaking. 
RESULTS 
Immunologic marker analysis of the leukemia cells of patient DD and patient HZ. 
Immunologic marker analysis revealed that the majority of MNC isolated from PB of patients 
DD and HZ expressed the enzyme TdT and the transferrin receptor as well as the T cell 
markers CD2, CD3, CD5, CD6 and CD? (fable 1). The cells did not express the 8 cell markers 
CD19 and CD20 and they were negative for the myeloid markers CD14, CD15 and CD33 as 
well as for the HLA-DR antigen and the IL2 receptor (CD25). This indicated that both patients 
had a T-ALL Although both T-ALL were positive for CD3, they did not express the common 
determinant of the TcR-o:,B, recognized by the McAb WT31 (49). The T-ALL cells of patient DD 
and patient HZ differed in expression of the common thymocytic marker CD1, the accessory 
molecules CD4 and CDS, and the common ALL antigen (CD10). The T-ALL cells of patient DD 
were clearly CD1-/CD4-/ CD8-/CD10-, while the majority of the T-ALL cells of patient HZ 
expressed the CDI 0 antigen and a part of the cells weakly expressed CDI, CD4 and CDS 
(fable 1). These immunologic phenotypes would categorize the leukemia of patient DD as a 
"mature T-ALL" and the leukemia of patient HZ as a "CD3+ common thymocytic T-ALL" (15). 
TcR mRNA expression in the leukemic cells 
Since the T-ALL cells seemed to lack TcR-o:.B proteins at the cell surface while CD3 was 
expressed, it was analyzed which of the three known TcR genes were transcribed. Total RNA 
from the T cell lines HPB-ALL and Jurkat were used as controls (Figure 2). T-ALL cells of 
neither patient DD nor patient HZ synthesized TcR-o: mRNA, while in HPB-ALL and Jurkat 
mature 1.7-kb TcR-o: transcripts were present. In addition, immature 1.4-kb TcR-o: mRNA was 
detected in HPB-ALL. In T-ALL cells of patient DD only truncated 1.0-kb TcR-.8 transcripts were 
found, while in T-ALL cells of patient HZ 1.0-kb transcripts as well as 1.3-kb TcR-.8 transcripts 
were found. Jurkat synthesized both 1.0 and 1.3-kb TcR-.8 mRNA, while in HPB-ALL only 1.3-kb 
mRNA was present. TcR-.8 transcripts of 1.0 kb are probably derived from incompletely 
rearranged TcR-.8 genes with D-J joining, while complete V-D-J joining results in 1.3-kb 
transcripts (2,15). TcR-r mRNA was present in the cells of both patients as well as in the control 
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TABLE 1. Immunologic marker analysis of the T-ALL cells in the PB of patient DO and patient HZ. 
Antibody 
Anti-TdTb 
Leu-6° 
Leu-5° 
Leu-4° 
Leu-3c 
Leu-1c 
OKT1ye 
3A1f 
Leu-2c 
WT31g 
VIL-A1h 
B4i 
B1i 
My4i 
VIM-D5h 
My9i 
Anti-HLA-DRc 
661G1oi 
2A3° 
CD codea (antigen recognized) 
TdT 
CD1 (T6 antigen) 
C02 (T11 antigen) 
CD3 (T3 antigen) 
CD4 (T4 antigen) 
CD5 (T1 antigen) 
CD6 (Tp120 antigen) 
CD? (Tp41 antigen) 
CDS (T8 antigen) 
TcR-a,B 
CD10 (common ALL antigen) 
CD19 (pan B cell antigen) 
CD20 (B cell antigen) 
CD14 (monocytic antigen) 
CD15 (myeloid antigen) 
CD33 (pan-myeloid antigen) 
HLA-DR 
Transferrin receptor 
CD25 (IL2 receptor) 
% Positive MNC 
Patient 
DO 
78 
0 
95 
84 
88 
69d 
96 
0 
0 
0 
0 
2 
1 
18d 
70 
0 
a. Cluster of differentiation (CD) as proposed by the Workshops 
on Human Leukocyte Differentiation Antigens (Paris, France, 
1982; Boston, MA, 1984; Oxford, UK, 1986). 
e. Ortho Diagnostic Systems, Raritan, NY. 
f. American Type Culture Collection, Rockville, MD. 
g. Dr. W. Tax, Nijmegen, The Netherlands. 
b. Supertechs, Bethesda, MD. h. Dr. W. Knapp, Vienna, Austria. 
c. Becton Dickinson, Sunnyvale, CA. i. Coulter Clone, Hialeah, FL. 
HZ 
95 
40d 
98 
94 
59d 
95 
53d 
98 
14d 
2 
73 
1 
2 
3 
87 
0 
d. Weak expression. j. Dr. J.M. Van de Rijn, Amsterdam, The Netherlands. 
HPB-ALL cells. Interestingly, TcA--y transcripts in the T-ALL cells of patient DO were somewhat 
smaller (1.5-1.6 kb) than TcA--y transcripts in the T-ALL cells of patient HZ and those of 
HPB-ALL (Figure 2c). TcA--y mANA could not be detected in Jurkat. 
TcR--y protein expression 
Based on the lack of reactivity of the leukemic cells with the McAb WT31, the absence of 
T~R-o: mANA and the presence of TcA--y mRNA, it was anticipated that these cells might 
express the protein product of the TcA--y gene. The TcA-o:,B is expressed at the cell surface in 
obligatory association with the CD3 subunits (46-48). In analogy, it has been published that 
also the TcA--y protein occurs in association with CD3 (32-36). Therefore, the T-ALL cells of 
patient DO and patient HZ as well as TcA-o:,B+ T-ALL cells as a control were radiolabeled at 
the cell surface with 1251 and lysed with a buffer containing the mild detergent digitonin, which 
preserves the noncovalent associations between the subunits of the TcA-CD3 complex. 
Subsequently, immunoprecipitation with the CD3 McAb Leu-4 was performed. Precipitates were 
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Figure 2. Northern blot analysis for the detection of transcripts of the TcR genes of the T-ALL cells of patient DD 
and patient HZ as well as of the T cell lines HPB-ALL and Jurkat. A: TcR-a transcripts; B: TcR-,8 transcripts; C: 
TcR--y transcripts. 
analyzed by SDS-PAGE under reducing as well as under nonreducing conditions. 
In all precipitates both under reducing and nonreducing conditions the 19-29 kDa CD3 sub-
units could be detected. It was consistently observed that the CD3 components isolated from 
the T-ALL cells of patients DD and HZ displayed a lower molecular mass than the CD3 compo-
nents isolated from the TcR-a,B+ T-ALL cells. This difference appears to be due to differential 
glycosylation of the CD3 o subunit (unpublished results). On the T-ALL cells of patient DD the 
CD3 components were associated with a heterogeneous band of 38-41 kDa under reducing 
conditions, which occurred as a disulfide-linked dimer of 70-75 kDa under nonreducing condi-
tions (Figure 3a). For comparison, Figure 3b shows anti-CD3 precipitates from TcR-a,B+ T-ALL 
cells. The TcR-a and ,8 subunits of 44 and 37 kDa, respectively, were coprecipitated. These TcR 
chains formed an 80-kDa disulfide-linked dimer under nonreducing conditions (Figure 3b). On 
the T-ALL cells of patient HZ under both reducing and nonreducing conditions, CD3 was asso-
ciated with a 41-44-kDa band, indicating that this component was not disulfide-linked to any 
other molecule (Figure 3b). In the immunoprecipitate from patient HZ we observed a weak band 
migrating at approximately 69 kDa under reducing conditions and at 60 kDa under nonreducing 
conditions. This band seemed to be nonspecific, since it was also present in the immunopreci-
pitate from the TcR-a,B+ T-ALL cells under reducing conditions (Figure 3b). 
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Figure 3. SDS-PAGE of CD3-associated components isolated from 12~-labeled T-ALL cells of patient DD and 
patient HZ. A: Electrophoresis under nonreducing and reducing conditions of CD3 precipitates from T-ALL cells 
of patient DD. B: Electrophoresis under nonreducing and reducing conditions of CD3 precipitates from T-ALL cells 
of patient HZ compared with CD3 precipitates from TcR-a,s+ T-ALL cells. C: Comparison of CD3 precipitates from 
the cells of patient DD and patient HZ under reducing conditions. 
To determine whether the COS-associated components contained the TcR-r protein on the 
T-ALL cells of patients DD and HZ, a previously described rabbit anti-Cr antiserum was used, 
which was raised against a synthetic peptide and is reactive with products of both Cr1 and Cr2 
gene segments {29,32,34). The anti-Cr serum precipitated bands with a mol. mass of 38-41 
kDa and 41-44 kDa from lysates of the cells of patient DD and patient HZ, respectively, while 
no material was precipitated from the TcRa.B+ T-ALL cells (Figure 4). By reprecipitation of CD3 
precipitates with the anti-Cr antiserum it was proven that the 38-41-kDa and 41-44-kDa 
components previously found to be associated with CD3 were at least in part identical to the 
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Figure 4. SDS-PAGE of CD3 and anti-C-y immunoprecipitates from 1251-labeled cells. A: Comparison of CD3 
precipitates with anti-C"( precipitates from the cells of patient HZ and the TcR-ap+ T-ALL cells. B: Reprecipitation 
of a CD3 precipitate from the T-ALL cells of patient HZ with the anti-C"( antiserum, compared with a direct anti-
C-y precipitate. C: Reprecipitation of a CD3 precipitate from the T-ALL cells of patient DD with the anti-C-y 
antiserum, compared with a CD3 precipitate and a direct anti-C-y precipitate. 
TcR--y protein (Figure 4). 
It was consistently found that the mol. mass of the TcR--y protein expressed by the cells of 
patient DO was lower than that of the TcR--y protein expressed by the cells of patient HZ 
(Figure 3c). This may be related to the smaller size of the TcR--y transcripts in the cells from 
patient DO (Figure 2c), although such a discrepancy in mol. mass may also be caused by 
differential glycosylation. 
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Further characterization of the CD3-associated components 
The immunoprecipitation experiments proved that the TcR--y protein was expressed in 
noncovalent association with the CD3 subunits on the T-ALL cells of both patient DD and 
patient HZ. On the T-ALL cells of patient DD a disulfide-linked dimer was found, which could 
either be heterodimeric or homodimeric. This was not clear from SDS-PAGE, since the 
38-41-kDa band was very heterogeneous. On the T-ALL cells of patient HZ the TcR-r protein 
was not covalently associated. It was investigated by chemical cross-linking experiments, using 
three different reagents, whether the TcR--y protein on T-ALL cells of patient HZ interacted 
noncovalently with another protein (heterodimer) or possibly with another TcR-r subunit 
(homodimer). No evidence for such associations was found in repeated experiments, although 
cross-linking could be established between the CD3 components and the TcR chain (not 
shown). 
To obtain additional information about the composition of the 21-44-kDa components on 
the T-ALL cells of patient HZ tvto-dimensional gel electrophoresis according to O'Farrell (IEF 
followed by SDS-PAGE) of anti-CD3 immunoprecipitates from digitonin-solubilized cells was 
performed. To eliminate charge heterogeneity due to the presence of sialic acids, one sample 
was also subjected to sialidase treatment. At the position of the 41-44-kDa components about 
six spots slightly differing in charge (pi 4-5) were present, which were reduced to three more 
basic spots (pi 5-6) upon sialidase treatment (Figure 5). The remaining heterogeneity may be 
due to incomplete sialidase digestion, since some charge heterogeneity was also remaining in 
the CD3 components. We suspect that the three remaining spots are representative of one 
TcR-r chain, since no components with obviously different charge were detected. This suggests 
that the T-ALL cells of patient HZ express the TcR-r protein in a monomeric form, although the 
presence of a second chain cannot be excluded. 
Southern blot analysis 
General remarks. 
To investigate whether the absence or presence of interchain disulfide bonds in TcR-r 
receptors is related to the TcR-r gene configuration of the cells and whether the configuration 
of the TcR-,8 and TcR-r genes is related to the differentiation stage of the cells, we performed 
Southern blot analysis. 
Configuration of the TcR-r and TcR-,8 genes in the T-ALL cells of patient 00. 
To determine the configuration of the TcR-r genes, EcoRI-digested DNA and BamHI-
digested DNA was analyzed by using the J-y1.3 probe (see Figure 1 for the organization of 
the TcR-r genes). In the EcoRI digest the germline band of 1.8 kb (J-y1.3 gene segment) was 
absent, while the 3.3-kb germline band (J-y2.3 gene segment) was present. In addition two 
non-germline bands of 2.5 and 2.3 kb were detected, which represent rearrangement type IV 
and VII, respectively, according to the classification of rearranged TcR-r genes (15, 19) (Figure 
6a). These findings were confirmed in a BamHI digest using the J-y1.3 probe: the 23-kb 
germline band (Jr1 gene segments) was absent, while two non-germline bands were detected 
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Figure 5. Two-dimensional gel electrophoresis according to O'Farrell (IEF followed by SDS-PAGE) of CD3 
precipitates from 1251-labeled cells of patient HZ. A: No sialidase treatment. B: After sialidase treatment. 
in addition to the 12-kb germline band (J-y2 gene segments, Figure Be). In an EcoRI digest 
using the C-y probe it was demonstrated that both the C-yi and C-y2 gene segments were 
present (Figure 6b). These data indicate that both TcR--y1 alleles were rearranged, while both 
TcR--y2 alleles were in germline configuration. 
The configuration of the TcR-.B genes was determined by analysis of EcoRI-digested DNA 
by use of the C.B probe and J,B2 probe. In the EcoRI-digest using the C.B probe one 
non-germline band was detected in addition to the 1 0.5-kb and 3.8-kb germline bands, while 
in EcoRI digests using the J,B2 probe only the 4.1-kb germline band was detected. This 
indicates that one of the TcR-.Bi alleles was rearranged, while the other TcR-,81 allele as well 
as both TcR-,82 alleles were in germline configuration (Table 2). Analysis of BamHI digested 
DNA using the C.B probe confirmed that indeed only one TcR-.B allele was rearranged, while the 
other one was germline. 
Configuration of the TcR--y and TcR-.B genes in the T-ALL cells of patient HZ. 
Analysis of an EcoRI digest using the J-y1.3 probe revealed that both germline bands were 
absent, while two non-germline bands could be detected: a 5.3-kb band and a 0.9-kb band, 
which represent rearrangement type II and type V, respectively (15, i9) (Figure Sa). This was 
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Figure 6. Southern blot analysis to determine the TcR-r gene configuration of the T-ALL cells of patient DD and 
patient HZ. The size of the germline bands (G) is indicated. A: EcoRI-digested DNA from a control cell sample (B-
CLL) and from the cells of patient DD and patient HZ. The filter was hybridized with the J-y1.3 probe. The size of 
the non-germline bands type II, IV, V and VII (according to the classification of rearranged TcR-r genes) are 
indicated. B: EcoRI-digested DNA from a control cell sample (normal PB) and from the cells of patient DD and 
patient HZ. The filter was hybridized with the Cr probe. C: BamHI-digested DNA from a control cell sample (B-
CLL) and from the T-ALL cells of patient DD and patient HZ. The filter was hybridized with the J')'1.3 probe. 
confirmed in a BamHI digest using the Jr1.3 probe: both germline bands were absent, while 
two non-germline bands could be detected (Figure 6c). Analysis of an EcoRI digest using the 
Cr probe revealed that both C-y1 alleles were deleted, while Cr2 gene segments were still 
present (Figure 6b). These data indicate that both TcR-r1 alleles were deleted, while both 
TcR-r2 alleles were rearranged. 
Analysis of an EcoRI digest by use of the C/3 probe revealed that the 1 0.5-kb band was 
absent, while no non-germline bands could be detected. In an EcoRI digest using the J/32 
probe the 4.1-kb germline band was absent, while two non-germline bands were seen. These 
data indicate that both TcR-{31 alleles were deleted, while both TcR-/32 alleles were rearranged. 
Two types of TcR-r receptor 
TABLE 2. Southern blot analysis, Northern blot analysis and protein 
analysis of the T-All cells of patient DD and patient HZ. 
Southern blot analysis8 
T cR-.81 genes 
TcR-.82 genes 
TcR-r1 genes 
TcR-r2 genes 
Northern blot analysis 
TcR-a mRNA 
TcR-.8 mRNA 
TcR-r mRNA 
Protein analysis 
Mol. mass of TcR-r chain 
lnterchain disulfide bond 
DD 
R/G 
GjG 
R/R 
GjG 
1.0 kb 
1.5- 1.6 kb 
38-41 kDa 
+ 
Patient 
HZ 
D/D 
R/R 
D/D 
R/R 
1.0 and 1.3 kb 
1.6 kb 
41-44 kDa 
a. R, rearranged allele; D, deleted allele; G, allele in germline configuration. 
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Analysis of a BamHI digest using the C.B probe confirmed that both TcR-.8 alleles were 
rearranged (Table 2). 
DISCUSSION 
In a previous study we investigated TeA gene rearrangements and expression during T cell 
differentiation using T cell leukemias as a model system (15). In three out of twenty-two T-ALL 
the leukemic cells expressed CD3 on their cell surface without production of TcR-a mRNA, 
indicating that they lacked the TcR-a.B. We suggested that CD3 + /TcR-a mRNA- T cell leukemias 
may express an alternate TcR (15), since the cell surface expression of the CD3 antigen is 
dependent on the presence of a TcR (46-48). Therefore, we further analyzed two such 
leukemias, i.e. the T-ALL cells of patient DD and patient HZ. 
Although the two T-ALL lacked TcR-a mRNA, they transcribed the TcR-r genes as well as 
the TcR-.8 genes. Southern blot analysis of the TcR-r genes of the T-ALL cells of patient DD 
showed that both TcR-r1 alleles were rearranged, while both TcR-r2 alleles were in germline 
configuration. Thus, it was concluded that the TcR-r transcripts in these cells were derived from 
TcR-r1 genes. In the T-ALL cells of patient HZ both TcR-r1 alleles were deleted, while both 
TcR-r2 alleles were rearranged, indicating that the TcR-r transcripts in these cells were derived 
from TcR-r2 genes. The T-ALL cells of patient DD and patient HZ also differed with respect to 
the TcR-.8 genes. The presence of the truncated 1.0-kb TcR-.8 transcripts in the T-ALL cells of 
patient DD indicated that the rearrangement of the TcR-.81 allele involved a D-J joining, while 
the presence of the 1.0-kb and 1.3-kb TcR-.8 transcripts in the T-ALL cells of patient HZ suggest 
that one of the rearranged TcR-.82 alleles had a D-J joining, while the other rearranged TcR-.82 
1\) 
TABLE 3. Data from the literature about 18 human TcR-'Y chain expressing T cell populations. 0> ~ 
Code TcR-'Y+ T cells Origin TcR-,8 TcR-,8 TcR-'Y TcR-'Y Mol. mass lnterchain Organization Ref. 
genesa mRNAb genes mRNA TcR-'Y chain disulfide of the TcR 
(kb) (kb) (kDa) bond (mol. mass 
of TcR in kDa) 
A T cell clone AK119 Pleural effusion G 1,0? Ra 1.6 40 and 36 + (70) Homodimer 34 
B T cell clone AK615 Normal PB G c R 40 + (75) Heterodimer 34 
c T cell clone AK925 PB from SCID 
patientd G 1.0?b R 1.6 40 + (75) Heterodimer 34 
D-H Five CD3+ /COB-/ Normal PB from five 
CD4-T cell lines" different donors R 1.0 R 1.6 37 or 40 + (90) Heterodimer 36 
T cell clone Wi.1 CSF from SSPE 
patient1 Rg 1.0g Rg 1.6g 40 and 45 + (85) Homodimer? 61 
J T cell clone Mi.? CSF from SSPE 
patient1 Rg 1.0g Rg 1.6g 40 and 45 + (85) Homodimer? 61 () 
K T cell clone WM-14 Cord blood 1.0 1.6 43, 40, 38 + (78) Homodimer 37 ?; 
""o 
L T cell clone AK4 Normal PB R 1.0 R 1.6 40 + (75) Heterodimer 34 ~ 
M T cell clone PBL-C1 Normal PB R 1.0 R 1.6 40 and 36 + (70) Homodimer or 35 :n 
Heterodimer :1-01 
N T cell clone F6C7 Fetal blood 1.0 and 1.6 44 + (85) Homodimer 38,39 
1.3 
0 T cell leukemia PB from leukemia 
patient G Rh 1.6 43 Monomer? 60 
p T cell clone IDP2 PB from immune-
deficient patient R 1.0 R 1.6 55 and 40 Heterodimer 32,35 
Q T cell clone Cll Thymus 1.0 1.6 44 Heterodimer 33 
R T cell line PEER T cell leukemia 1.3 1.6 55 Monomer or 
Heterodimer 35,55,59 
a. G; both alleles in germline configuration; R; at least one allele rearranged. 
b. The TcR-fi transcripts in the T cell clones AK119 and AK925 are derived from germline TcR-P genes. Such transcripts have been reported to be 1.1 kb (c.f. 14,15). 
c. Blank space: not tested or not reported in the literature. 
d. SCID, severe combined immunodeficiency. 
e. Polyclonal T cell lines. 
f. CSF, cerebrospinal fluid; SSPE, subacute sclerosing panencephalites. 
g. Unpublished data (S.L. Ang). 
h. In this leukemia the TcR-71 genes were deleted, while both TcR-72 genes were rearranged. 
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allele had a V-D-J joining (both TcR-.81 alleles were deleted in the latter T-ALL). 
The T-ALL cells of patient DD as well as patient HZ expressed the TcR-r protein at the cell 
surface in association with CD3. However, the configuration of the TcR of these leukemias was 
different. The T-ALL cells of patient DD expressed a disulfide-linked heterodimer or homodimer, 
while the T-ALL cells of patient HZ bore the TcR-r protein in a non-disulfide-linked form. The 
DNA data revealed that the constant part of the TcR-r protein is encoded by Cr1 genes in the 
T-ALL cells of patient DD and by Cr2 genes in T-ALL cells of patient HZ. In the second exon 
of the Cr1 gene segment in human and mouse a cysteine residue is encoded (16,54,55). Such 
a cysteine codon is also found in the second exon of the C region gene segments of the TcR-a 
and .B chains and is most likely responsible for the formation of the interchain disulfide bond (2). 
Genomic DNA clones and eDNA clones derived from human Cr2-gene segments lack this 
cysteine codon (Figure 1) (29,54,55), which may well explain the absence of an interchain 
disulfide bond in the TcR-CD3 complex, expressed on the T-ALL cells of patient HZ. 
In contrast to the Cr1 genes, the second exon of the Cr2 genes is duplicated, which will 
result in 48 extra exon basepairs in case of TcR-r2 transcripts (29,54,55). This probably 
explains the slightly larger size of the TcR-r transcripts in the T-ALL cells of patient HZ and the 
T cell line HPB-ALL, which both have deleted their TcR-r1 gene alleles and use Cr2 gene 
segments (Figure 2c). This may also explain the lower mol. mass of the TcR-r1 chain (38-41 
kDa) on the T-ALL cells of patient DD (Figure 3c), although such mol. mass differences can 
also be due to differences in glycosylation. 
Disulfide-linked and non-disulfide-linked TcR-r chains have been described previously 
(32-37,39,59-61). Data from the literature are summarized in Table 3. Initially, a TcR-r+ cell line 
derived from PB of an immunodeficient patient was described, which expressed the TcR-r 
protein in non-covalent association with another protein, termed TcR-o (32). Disulfide-linked 
dimers were subsequently found on T cell clones derived from a small subset of PB 
lymphocytes (34-39). The majority of these disulfide-linked dimers are heterodimeric (34,36), 
although a few TcR-r homodimers have been described (34,37,39). While the T-ALL cells of 
patient DD express a disulfide-linked TcR-r receptor, it is not clear what the exact organization 
of the receptor on the T-ALL cells of patient HZ is. Our data suggest that the latter T-ALL cells 
express a TcR-r monomer, although it cannot be excluded that a partner of this chain, being 
either a TcR-r or a TcR-o chain, has remained undetected despite cross-linking experiments. 
The T-ALL cells of patient DD and patient HZ have a thymocytic phenotype, since they both 
express the enzyme TdT in addition toT cell markers such as CD3 and CD5. Several studies 
have indicated that CD3+ /TdT+ cells are not detectable outside the thymus (62,63). Based on 
the type of the expressed TcR-r chain, their immunologic phenotype and the configuration of 
the TcR-r and TcR-.8 genes, we tried to place the two T-ALL cells in a hypothetical 
differentiation scheme (Figure 7). This scheme is based on our own data and data from the 
literature (fables 2 and 3). Most likely TcR-r genes rearrange during differentiation in the 
thymus (15,20,21 ,64), although extrathymic TcR-r gene rearrangement cannot be excluded, 
since functional TcR-r transcripts have also been found in nude mice (65). In Figure 7 TcR-r1 
genes are depicted to rearrange prior to TcR-r2 genes. Functional rearrangement of TcR-r1 
genes results in TcR-r1 + T cells, which still may have germline TcR-.8 genes (e.g. T cell clones 
AK119, AK615 and AK925), or rearranged TcR-.8 genes with D-J joining (the majority ofTcR-r1 + 
T cells), or rearranged TcR-.8 genes with V-D-J joining (e.g. T cell clone F6C7) (c.f. Tables 2 en 
266 CHAPTER4.5 
3). If rearrangements of both TcR--y1 alleles are nonfunctional, TcR--y2 gene rearrangement 
occurs, deleting the TcR--y1 gene segments. This gives rise to TcR--y2+ T cells, of which the 
majority will have rearranged TcR-.8 genes (e.g. T cell clones 1 DP2 and Cll, the T cell line 
PEER, and the T cell leukemia of patient HZ; c. f. Tables 2 and 3). If TcR--y2 gene rearrange-
ments are nonfunctional as well, the TcR-/l and TcR-a gene rearrangements are completed, 
which may result in the different types of TcR-afl+ T lymphocytes (Figure 7). 
The hypothetical differentiation scheme presented here also explains why virtually all T-ALL 
have undergone rearrangement of the TcR-.8 genes as well as TcR--y genes (15,64,66,67). The 
majority of these leukemias probably belong to the TcR-afl branches of the T cell lineage, while 
a minority belongs to the TcR--y branches. The few CD3+ T-ALL with germline TcR-/l genes 
probably express TcR--y chains, which has recently been proven for one of them (60,68). The 
precise frequency of TcR--y+ /CD3+ T-ALL is still unknown. 
TcR--y + T cells which migrate to the periphery may well constitute a functionally relevant 
lineage. T cell clones expressing either disulfide-linked or non-disulfide-linked TcR--y receptors 
were found to exert broad cytolytic activity upon in vitro activation, in which involvement of MHC 
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.cVTcR·a genes rearrangedjl 
Figure 7. Hypothetical scheme of human T cell differentiation summarizing data about the TcR--y+ T cell leukemias 
presented here as well as data about TcR--y+ cells from the literature (2,15,32-39,42,59-61). The dotted lines 
represent the tissue compartments, where the cells in the various T cell differentiation stages are found. The 
horizontal bars summarize data concerning TcR gene rearrangement. Most likely TcR-'Y genes rearrange during 
differentiation in the thymus, although extrathymic TcR-'Y gene rearrangement cannot be excluded, since functional 
TcR-'Y transcripts have also been found in nude mice (65). The letter codes above the scheme represent the 
various TcR-'Y expressing T cell clones, T cell lines and T cell leukemias, which are located in this differentiation 
scheme according to their phenotypic and genotypic TcR characteristics (c.f. Tables 2 and 3). It is not yet clear 
whether TcR-'}'1 + cells and TcR-'}'2+ cells represent functionally different T cell subsets. 
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molecules as restriction elements on the target cells could not be detected (34-47). The T-ALL 
cells of the here presented patients, when tested within 24 h after thawing, did not exert MHC 
nonrestricted cytolysis (Dr. R.J. Van de Griend, unpublished results). It should be noted that 
such cells probably need to be activated or cloned to express this type of cytolytic activity, as 
was previously reported for CD3+ /CD4-/CD8- cells derived from normal individuals (34,69). 
It was not possible, however, to expand in vitro the TcR--y + leukemic cells of the two patients. 
Another explanation for the absence of lytic activity may be that these T-ALL cells were too 
immature to exhibit this function. 
Future studies will have to elucidate the exact specificity and in vivo function of the TcR--y + 
T cells. Furthermore, it is interesting that in PB of normal individuals only TcR--y1 + T cells have 
been found so far (34-39), while the reported TcR--y2+ cells are derived from thymus, thymic 
leukemias or PB of immunodeficient patients (32,33,59,60). Therefore, it should be studied 
whether TcR--y+ and TcR--y2+ cells represent functionally different T cell subsets. 
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SUMMARY 
A second type ofT cell receptor (feR) molecule has been identified on human and murine 
T lymphocytes, which involves the protein products of the 1 and S genes. T lymphocytes 
bearing this receptor may constitute a separate cell lineage with a distinct immune function. We 
have produced a monoclonal antibody (McAb), which specifically detects human T cell receptor 
(TcR)--yS in native as well as denatured states, this in contrast to previously used anti--y chain 
peptide sera, which only reacted with denatured protein. The receptor occurs in different 
molecular forms, with or without interchain disulfide bonds, in which a S chain may or may not 
be detected by cell surface iodination. The McAb is reactive with all these receptor forms. 
Therefore, this antibody could be used to determine the expression of TcR--yo on viable human 
T lymphocytes. In normal individuals, TcR--yo was found on a subset composing 2 to 7% of 
CD3 + lymphocytes in peripheral blood and 0.1 to 1.0% in thymus. The majority of these cells 
do not express the CD4 or CDS antigens, although a significant percentage of CDS+ cells was 
found. TcR--yo+ cells in peripheral blood are resting lymphocytes, as judged by ultrastructural 
analysis. T cell clones with different receptor types can display major histocompatibility complex 
(MHC)-nonrestricted cytolytic activity, which is shown to be induced by the culture conditions, 
most likely by growth factors such as interleukin 2. This strongly suggests that TcR--yo does not 
play a role in target cell recognition in MHC-nonrestricted cytotoxicity. The anti-TCR--y I S-1 McAb 
can specifically induce cytotoxic activity in clones expressing the receptor, but in addition inhibit 
growth factor induced cytotoxicity, which indicates a regulatory role of the TcR--yo /CD3 complex 
in MHC-nonrestricted cytotoxicity. 
*Published in: J Exp Med 1988;167:1625-44. 
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INTRODUCTION 
It is now clear that there are two types of T lymphocytes. Classical T cells recognize 
non-self antigens in the context of molecules of the major histocompatibility complex (MHC) by 
means of the T cell receptor (TcR), consisting of disulfide-linked a and fl chains (1-3). A recently 
defined type ofT cells, of which it is unclear what they recognize, uses a TcR encompassing 
the 1 chain (4,5). All three chains, a, fi, and 1, have a variable and a constant domain, encoded 
in different gene segments that join through rearrangement during T cell ontogeny (6-8). As 
compared with TcR-a and fi-genes, the germline diversity of the TcR-1 gene is more limited (9). 
The human genome contains 11 variable, 5 joining, and 2 constant (C) gene segments in 
tandem (10-12). The 1 gene is rearranged and expressed at an early stage in T cell 
development, coinciding with or preceding rearrangement and expression of respectively TcR-fl 
and TcR-a genes (13-15). The TcR-1 chain forms either disulfide-linked or non-disulfide-linked 
dimers with the so-called o protein, which is structurally distinct from 1 (16). The gene encoding 
this protein is positioned in the TcR-a locus (17) and thus organized in a similar fashion as a, 
fi, and 1 genes, but its exact ge:-~omic organization has not yet been unravelled. Before cell 
surface expression, either type of TcR associates with the CD3 protein complex, consisting of 
four invariant subunits (18, 19), which may play a role in signal transduction (20). 
Upon in vitro activation, TcR-1o-expressing cells can exert MHC-nonrestricted cytolytic 
activity towards allogeneic cells (21-23). In this and other functional aspects, TcR-1o+ cells 
share features with CD3- NK cells. On the other hand, they share features with CD3+ jTcR-afi+ 
MHC-restricted cells in the expression of CD3 and a potentially variable receptor. 
The existence of the TcR-1 protein has first been demonstrated biochemically using anti-
peptide sera, reactive with denatured protein. It was found in peripheral blood (PB) of normal 
individuals on cells derived from a small subset of CD3+ /CD4-/CD8- cells (4,21,24) and on 
CD3+ /CD4-/CD8- thymocytes in both mouse and man (5,25), which represent a small 
population in adults. Human TcR-1o has first been identified on CD3 + lymphocytes, which failed 
to react with the McAb WT31 (26), thought to recognize a common determinant on TcR-afi. 
Thus, TcR-1o+ cells may be identified using CD3 expression and lack of reactivity with WT31 
McAb as criteria. However, it was important to make antibodies that positively identify 
TcR-1o-expressing cells, particularly since we have recently found that TcR-1o+ cells may bind 
WT31 McAb under certain condition (27). We here report an McAb, which reacts with human 
TcR-1o in native as well as denatured states. This is in contrast to previously reported anti-
peptide sera, which exclusively detected TcR-1o after denaturation. With this reagent one can 
assess TcR-1o expression in lymphoid tissues and blood, isolate TcR-1o expressing cells, 
manipulate their function and use it for isolation of the protein: studies needed to elucidate the 
role TcR-1o+ cells play in the immune system. 
MATERIALS AND METHODS 
Cells 
PB samples were derived from healthy volunteers or from children hospitalized for afflictions other than 
infectious diseases or disorders ofthe immune system. Thymocyte samples were from children undergoing cardiac 
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surgery and from an 1S-wk-old human fetus (abortion on medical indication). These human samples were obtained 
with permission of the Committee of Medical Ethics of the University Hospital Dijkzigt/Erasmus University, 
Rotterdam, The Netherlands. Mononuclear cells (MNC) were isolated from PB by density separation using 
Ficoii-Hypaque. Cloned lymphocytes were generated from PB of normal individuals in the case of AK4, AK7S1 
(donor X; 22), 1012 (donor Y) and JS-93,-132,-22S (donorJS; 2S), from pleural exudate of a patient with a mamma 
carcinoma in the case of AK119, from PB of a patient with T--ylymphocytosis in the case of NK77 (29), and from 
PB of a patient with subacute sclerosing encephalitis in the case of Wi.K (30). Clones AK4, AK7S1 and AK119 
were derived from PB-MNC directly by limiting dilution, clone 1 012 was derived from CD4-;cos- sorted PB-MNC 
of donor Y, clone JS-22S was derived from WT31- sorted PB-MNC of donor JS. All clones were cultured in Yssel's 
medium (31), supplemented with 2% pooled human serum in round-bottom microwell plates (Greiner Labor 
Technik, Plidelsheim, FRG) in the presence of PHA, irradiated allogeneic PB-MNC and EBV-transformed B cells 
of the line JY (feeder cells), as described in detail elsewhere (32). The JY line (HLA-A2,2; B7,7; DR4,w6) was 
cultured in Yssel's medium supplemented with 2% pooled human serum. The human T leukemic cell line PEER 
(33), the Burkitt lymphoma cell line Daudi, the melanoma cell line MEWO, and the erythroid/myeloid cell line K562 
were cultured in lscove's medium containing 5% fetal calf serum under standard conditions. 
Antibodies 
The purified CD3 McAb WT32 (lgG2a) and McAb WT31 (lgG1) used for immunofluorescence, were kindly 
provided by Dr. W. Tax, Nijmegen, The Netherlands. Purified CD3, CD4, and CDS McAb Leu-4, Leu-3a, and Leu-2a, 
respectively, as well as phycoerythrin-conjugates of Leu-4, Leu-3a, and Leu-2a, and goat anti-mouse lg were from 
Becton Dickinson (San Jose, CA). For immunoprecipitation of CD3jTcR complexes the CD3 McAb 2G3 (lgG1) 
was used, which was a kind gift from Dr. Chang Geanwu, Dr. L. Willems lnstituut, Diepenbeek, Belgium. Anti-C-y 
antiserum was raised in rabbits against a synthetic peptide encompassing amino acids 137-157 of the human TcR--y 
protein (4) and was kindly provided by Dr. J.G. Seidman, Harvard Medical School, Boston, MA. 
Immunization protocol and generation of hybridomas 
For immunization, CD3 immunoprecipitates were prepared as described below from a digitonin-solubilized 
mixture of cloned cells expressing disulfide-linked TcR-ro. Antigen derived from 50 x 106 cells in the form of 
protein A-Sepharose/CD3 antigen complex was injected subcutaneously into BALB/c mice three times at 4-6-wk 
intervals. The fourth injection was done 7 wk after the third, directly into the spleen, using the same immunogen. 
The spleen was removed 4 days later. Spleen cells were fused to myeloma cells of the line SP2/0 at a ratio of 4:1 
using polyethylene glycol. Hybridomas were seeded into 96-well microtiter plates (Costar, Cambridge, MA) at 1 05 
spleen cell equivalents per well and grown and selected under standard conditions (hypoxanthin-aminopterin-
thymidine selection). 
Enzyme-linked immunosorbent assay (ELISA) 
ELISA was used for screening of reactivity of hybridoma supernatants with intact cells: cells were fixed in 
microwells using poly-L-Iysine and 0.025% glutaraldehyde. Specific binding of McAb to the cells was determined 
by incubation with biotinylated horse anti-mouse lg, followed by incubation with biotinyl-peroxidasejavidin complex 
(Vector Inc., Burlingame, CA) and addition of 5-aminosalicylic acid as a substrate and H20 2 as a catalyst. 
Immunofluorescence 
Hybridoma supernatants were screened by indirect immunofluorescence using fluorescein isothiocyanate 
(FITC)-conjugated goat anti-mouse F(ab)2 lg (Tago Inc., Burlingame, CA) for staining and a fluorescence 
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microscope for evaluation. For identification and phenotyping of TcR--ycS+ cells in PB and thymus of normal 
individuals described in Table 4, PB-MNC were first incubated with WT31 or anti-TCR--y 1 o-1 McAb followed by 
tetramethylrhodamine isothiocyanate (TRITC)-conjugated goat anti-mouse I g. Free binding sites of the second-step 
reagent were blocked with normal mouse serum and cells were incubated with FITC-conjugated McAb directed 
against CD3, CD4, or CDS (Becton Dickinson). Samples were analyzed by fluorescence microscopy. For 
determination of the percentages CD3 +, WT31 +, and anti-TCR-1' 1 o-1 + cells, 1,000 cells were inspected for each 
sample. For determination of the CD4/CD8 phenotype, 100 anti-TCR--y jo-1 + cells were inspected for each sample. 
As a control, normal mouse lg was used as the first-step reagent. Other analyses were performed as indicated in 
the legends of the appropriate figures. 
Cytotoxicity assays 
Assays were carried out in serum-free medium. Cytotoxicity was measured in triplicate as percentage of 
51 Cr-release in a 4-hour assay using round-bottom microtiter plates (Greiner Labor Technik). Effector cells were 
incubated with anti-TCR--y jo-1 McAb for 1 hour at 37•c before the assay at a dilution of ascitic fluid of 1:100 for 
induction or inhibition of cytotoxicity. The antibody remained present during the assay at a dilution of ascitic fluid 
of 1:200. 
Radiolabeling 
For cell surface radioiodination -20 x 1 o6 viable cells were washed with and resuspended in PBS, and labeled 
with 1-2 mCi Na 1251 (Amersham Co., Amersham, United Kingdom) using 1 ,3,4,6tetrachloro-3a,6a-diphenyl glycoluril 
(lodogen; Pierce Chemical Co., Rockford, IL) as a catalyst. 
lmmunoprecipitation 
Cells were lysed in immunoprecipitation buffer (IPB), consisting of 0.01 M triethanolamine-HCI, pH 7.8, 0.15 
M NaCI, 5 mM EDTA, 1 mM PMSF, 0.02 mgjml ovomucoid trypsin inhibitor, 1 mM TLCK, 1 mM TPCK, 0.02 mgjml 
leupeptin, supplemented with either 1% digitonin or 1% NP-40 as detergents. Nuclear debris was removed by 
centrifugation for 15 min at 13,000 g. Lysates were centrifuged for 30 min at 100,000 g and precleared by three 
subsequent incubations with 30 J.l.l of a 1 0% v jv suspension of protein A-CL4B Sepharose beads (Pharmacia, 
Uppsala, Sweden) coated with normal mouse I g. Specific immunoprecipitation was carried out for 2-4 hours with 
McAb, coupled covalently to protein A beads by means of dimethylpimelimidate-HCI (Pierce Chemical Co.). Beads 
were subsequently subjected to five washes in IPB with digitonin or NP-40 and samples were analyzed on 10-15% 
SDS-polyacrylamide gradient gels. Autoradiography was done using Kodak XAR-5 film in combination with 
intensifier screens (Cronex; Dupont Chemical Co., Newtown, CT). 
Electron microscopy 
PB-MNC were obtained from a normal donor. One-half of the cell sample was incubated with 0.01 mgjml 
purified WT31 McAb and one-half with a 1 :250 dilution of anti-TCR--y 1 o-1 ascitic fluid, followed by washing and 
incubation with purified rabbit anti-mouse lg. Next, cells were washed and labeled with protein A-colloidal gold 
probes (9 nm). Gold particles were prepared by the tannic acid/citrate reduction procedure (34) and complexed 
to protein A (Pharmacia). All incubations were performed for 30 min at 4 • C in the presence of sodium azide. 
Subsequently, cells were washed with ice-cold medium and fixed in a mixture of paraformaldehyde (2% w jv) and 
glutaraldehyde (2.5% v jv) in 0.1 M sodium cacodylate, pH 7.4, for 24 h at 4 • C. Cells were pelleted in 3% agar 
(Agar Noble, Difco Laboratories, Inc., Detroit, Ml) at so•c. After postfixation in Os04(1% wjv) in cacodylate buffer 
for 2 hours, slices of agar were rinsed, dehydrated in graded ethanol, and embedded in Epon 812 using a LKB 
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Ultra Processor (LKB Produkter, Bromma, Sweden). Ultrathin sections (70 nm) were cut with an LKB-Nova 
ultramicrotome, contrasted with uranyl magnesium acetate and lead citrate staining and examined in a JEOL-1200 
EX electron microscope (JEOL, Tokyo, Japan). 
RESULTS 
Generation of TcR--yo-specific McAb 
Human TcR--yo proteins can be isolated in two ways. The intact C03/TcR--yo complex can 
be recovered with C03 McAb from cells solubilized in the mild detergent digitonin (35), or from 
cells solubilized after chemical crosslinking afTeR and C03 components (36). In addition, rabbit 
antisera have been described raised against synthetic peptides encompassing TcR--y 
sequences (4,37). Such sera only detect TcR--y protein after denaturation. To prepare McAb, 
which would detect TcR--yo proteins in cell lysates as well as on intact, viable cells, we chose 
to immunize mice with C03/TcR--yo complexes isolated from digitonin-solubilized cells. A 
mixture of clones, expressing disulfide-linked dimers of TcR--y and o chains, was used. 
In the relevant fusion, lg was detected by ELISA in 344 hybridoma culture supernatants. 
These supernatants were assayed for reactivity in immunofluorescence with viable cells of clone 
1012, which expresses disulfide-linked TcR--yo. Only one supernatant contained reactivity with 
clone 1012, while no fluorescence was observed with the TcR-a.B+ clone JS-132 or the 
EBV-transformed B cell line JY. This supernatant also specifically reacted with glutaraldehyde-
fixed cells of clone 1012 in ELISA. This hybridoma was subcloned to give a stable clone, 
anti-TCR--y 1 o-1, which was used for further studies. The subclass of the McAb was lgG1. 
Reactivity of anti-TCR--y/o-1 McAb with viable clones of various phenotypes 
To assess the specificity of anti-TCR--yjo-1 McAb, first its reactivity was tested in 
immunofluorescence with PB-MNC of 1S normal donors. Positive PB-MNC ranged from 
undetectable to 5% as analyzed with a FAGS. Such percentages of reactivity would be expected 
for a TcR--yo-specific McAb, given previous results with WT31 McAb, and the suggestion that 
predominantly the small C03 + /C04-;cos-T cell subset would express TcR--ycS (3S). Next, we 
determined reactivity in immunofluorescence of anti-TCR--y/o-1 McAb on a number of cloned 
cells of different phenotypes, representing different lymphocyte subsets and cells with different 
configurations of TcR--yo: the NK clone NK77 (C03-/C04-/COSl, the non lytic clone AK7S1 
(C03+ /C04-/COS-/TcR-a.B+), the cytolytic clones JS-132 (C03+ /C04-/COS+ jTcR-a,B+, 
MHC-class-1 specific), and JS-93 (C03+ /C04 +;cos-/TcR-a.B+, MHC-class-11 specific), and the 
cytolytic clones Wi.K, JS-22S, AK119, and AK4 (C03+ /C04-;cos-, unknown specificity). It has 
been shown in immunoprecipitation experiments using anti-C-y peptide serum that the latter four 
clones express the TcR--y protein, be it in different configurations: non-disulfide-linked (Wi.K, 
JS-22S) or disulfide-linked (AK119, AK4), and without (Wi.K, AK 119) or with (JS-22S, AK4) 
direct evidence for participation of a o chain in the receptor (see below). Also tested was the 
T leukemic cell line PEER, which was previously shown to express a non-disulfide-linked TcR--y 
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Figure 1. Immunofluorescence stainings of various representative lymphocyte clones with anti-TCR-"( I o-1 McAb. 
Cells were incubated with O.D1 mgjml purified CD3 (WT32) or WT31 McAb, or with anti-TCR-"( jo-1 McAb at 1:500 
dilution of ascitic fluid, followed by incubation with FITC-conjugated goat anti-mouse F(ab)2 lg. Fluorescence 
analyses were performed using a FACS IV (Becton Dickinson , San Jose, CA). The characteristics of the cell 
samples used are indicated in the text. Fluorescence intensity is plotted on a logarithmic scale. For exact 
comparison, fluorescence indexes, defined as [(fluorescence intensity sample)-(fluorescence intensity negative con-
trol)]j(fluorescence intensity negative control), are tabulated above. 
chain of -55 kDa (24,39}, which is a different molecular (mol.) mass than found for the TcR--y 
chains on Wi.K or JS-228 (see below). 
As can be seen in Figure 1, neither the cos- NK clone, nor any of the TcR-ap+ clones 
reacted with anti-TCR--y I o-1 McAb. In contrast, all TcR--yo-expressing clones were positive. For 
comparison, fluorescence profiles obtained with CD3 and WT31 McAb are also shown. 
Fluorescence intensities are tabulated in the legend of Figure 1. Except NK77, all clones 
expressed CD3. TcR-ap+ clones reacted strongly with WT31 McAb, with intensities comparable 
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Figure 2. Characteristics of non-disulfide-linked TcR--y(o). Cells were labeled with 1251, CD3 (2G3) immune-
precipitates were made from digitonin lysates and analyzed by SDS-PAGE under nonreducing or reducing 
conditions. For reprecipitation of TcR--y chains, CD3 precipitates were incubated in IPB with 1% SDS and 2 mM 
DTT for 5 min at 68°C. The supernatant was diluted five times with IPB containing 1.5% NP-40, 20 mM 
iodoacetamide and 25 p.g myoglobin, precleared once with normal mouse lg-coated beads and subjected to 
immunoprecipitation with anti-C-y antiserum. Arrows indicate the positions of the o chain. A: CD3 precipitates 
(nonreducing and reducing conditions) and anti-C-y precipitate (reducing conditions) from cells of clone Wi.K. 8: 
CD3 precipitates (nonreducing and reducing conditions) and anti-C-y precipitate (reducing conditions) from cells 
of clone JS-228. C: CD3 precipitate (nonreducing and reducing conditions) and anti-C-y precipitate (reducing 
conditions) from cells of cell line PEER. 
to those obtained with CD3 McAb. TcR--yo+ clones also bound Wf31 McAb, but stained at low 
intensities, while on these clones fluorescence intensities with anti-TCR--yjo-1 McAb were more 
comparable to those obtained with CD3 McAb. These results clearly indicate that reactivity with 
anti-TcR--y j o-1 McAb, rather than lack of reactivity with Wf31 McAb is a proper criterion for the 
identification of TcR--yo-expressing cells. 
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Anti-TCR--yfo-1 McAb reacts with different molecular species of TcR--yo in immune-
precipitation 
In contrast to TcR-a.B, TcR--yo occurs in various molecular configurations. We have 
previously described (21) cytolytic clones such as AK4, expressing a TcR consisting of a 
40-kDa 1 chain disulfide linked to a 43-kDa o chain. Clone 1012 and eight other clones derived 
from the same culture express a similar receptor (not shown). Clone AK119 was an exception, 
in that it expressed a disulfide-linked receptor, including a differentially glycosylated 1 chain 
migrating at 36 and 40 kDa, while no o chain could be detected by cell surface iodination (21). 
Non-disulfide-linked TcR--yo have been demonstrated on a growth factor-dependent cell line 
derived from PB of an immunodeficiency patient (4), a leukemic T cell line (24,39), and PB-
MNC from a leukemic patient (40). We have derived several T cell clones expressing 
non-disulfide-linked TcR--yo from PB of a normal individual, one of which was used in these 
studies (JS-228). In addition, a clone expressing a non-disulfide-linked receptor has been 
isolated from PB of a patient with autoimmune disease (clone Wi.K). Figure 2 demonstrates the 
presence of the 'Y chain in the non-disulfide-linked COS-associated receptors found on clones 
Wi.K and JS-228, which was identified by immunoprecipitation with anti-C-y peptide serum. The 
mol. mass of the 1 chain was -41 kDa for clone Wi.K and -44 kDa for clone JS-228. This in 
contrast to the -55 kDa mol. mass of the 1 chain found on the cell line PEER (24,39). In clone 
JS-228 a o chain could be detected, migrating at 37 kDa under nonreducing and 40 kDa under 
reducing conditions. In clone Wi.K a o chain could not be demonstrated by cell surface 
iodination. Table 1 summarizes the different molecular forms of TcR--y(o). 
To prove that anti-TCR--yfo-1 McAb reacted with TcR--yo, we have carried out reprecipi-
tation experiments. CD3 immunoprecipitates were prepared from digitonin solubilized, 
1251-labeled TeA--yo-expressing clones. Next, TcR--yo was dissociated from CD3 by incubation 
of the immunoprecipitate in buffer with 1% NP-40 and 1% SDS, for 30 min at room temperature. 
The solubilized material was subjected to immunoprecipitation with anti-TCR--yfo-1 as detailed 
in the legend of Figure 3. In Figure 3 the CD3/TcR--y(o) complexes as isolated by CD3 McAb 
are shown, as well as TcR--y(o) reprecipitated with anti-TCR--yfo-1 McAb. The antibody could 
be used to reprecipitate both types of disulfide-linked receptors from TcR--y(o) + clones 1012 
TABLE 1. Molecular forms of TcR--y(o). 
Receptor lnterchain Mol. mass of Mol. mass of 
Clone type S-S bond 'Y chain in kDa o chain in kDa 
AK119 'Y (o) + -40+-36 NDa 
AK4 -yo + -40(+-36)b -43 
1012 -yo + -40(+-36) -43 
Wi.K 'Y (o) -41 NO 
JS-228 -yo -44 -40 (R),0 -37 (NR) 0 
PEER -yo -55 -40 (R), -37 (NR) 
a. ND, not detected. 
b. Occasionally detected. 
c. R, reducing conditions; NR, nonreducing conditions. 
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Figure 3. Biochemical proof that anti-TCR-"( jli-1 McAb detects TcR--y(li). CD3 precipitates were prepared as 
described for Figure 2. TcR--y(li) was dissociated from CD3 by incubation of one-half of the CD3 precipitates in 
IPB with 1% NP-40 and 1% SDS for 30 min at room temperature. The supernatant was diluted five times with IPB 
containing 1.5% NP-40 and 25 JI.g myoglobin, precleared once with normal mouse lg-coated beads, and subjected 
to immunoprecipitation with anti-TCR-"(/li-1 McAb and analyzed by SDS-PAGE under nonreducing or reducing 
conditions. A: CD3 and anti-TcR-"( jli-1 precipitates from cells of clone 1012, clone AK119 and clone Wi.K under 
reducing conditions. B: CD3 and anti-TcR-"( jli-1 precipitates from cells of clone AK119 under nonreducing 
conditions. 
(Figure 3A) and AK119 (Figure 3A and 38), as well as the non-disulfide-linked receptors from 
TcR--y(li) + clones Wi.K (Figure 3A) and JS-228 (not shown). 
Thus, anti-TCR--y 1 li-1 McAb reacts with all different types of TcR--y(li) described thus far, in 
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native state as present on intact viable cells, as well as in denatured state after detergent 
solubilization. 
Anti-TCR--yfo-1 McAb affects the function of cytolytic clones 
We have demonstrated previously (21 ,22) that TcA--y(cS)-expressing clones can exert 
cytolytic activity upon in vitro culture, without evidence for involvement of polymorphic domains 
of MHC molecules on the target cells. The activity could be regulated by McAb directed at CD3, 
which opened the possibility that the CD3-associated TeA--yo was involved in the recognition 
of these target cells. Another option would be that the cytotoxic spectrum of the clones did not 
reflect the specificity of the receptor and that the effect of CD3 McAb reflected the regulatory 
capacity of the TcA--ycSjCD3 complex. 
It had been observed that lymphokines, such as interleukin 2 (IL-2) and interferon f3 (IFN-/3) 
enhanced the cytotoxicity of TeA--yeS-expressing clones (22). Therefore, it was investigated in 
the first place, whether the lymphokines produced by the feeder cell mixture used to culture 
TeA--yo+ clones, affected the cytotoxic potential of the clones. For this purpose, two 
TeA--yeS-expressing clones, 1012 and Wi.K, were cultured for 5 days in the presence of irradiated 
feeder cells. Next, when feeder cells had disintegrated, clones were washed and cultured for 
an additional 72 hours in Yssel's medium with 2% pooled human serum, lacking lymphokines. 
To one part of the cells, deprived of feeder cell factors for 48 hours, recombinant IL-2 was 
added at 1 ,000 U jml for 24 hours. Control cells of the same batch were kept in culture for 8 
days without changing the medium. Then, cytotoxicity was tested towards four allogeneic tumor 
cell lines of different histologic origin. In Table 2 it can be seen that clone 1012, when harvested 
directly from the 8-day culture in the presence of feeder cells and their products (control), 
displayed significant MHC-nonrestricted cytotoxicity towards all target cells. The cytotoxicity of 
TABLE 2. Influence of feeder cell factors on the cytotoxicity of TcR--yo+ clones. 
Clone 
1012: Controf 
- factorsd 
+ IL-2e 
Wi.K: Control 
-factors 
+ IL-2 
a. Target cells used. 
b. Effector cell/target cell ratio. 
K562a 
10:1b 2:1 
52 32 
8 0 
66 46 
32 9 
7 0 
31 18 
c. Control: culture with feeder cells for 8 days. 
10:1 
35 
19 
55 
8 
11 
13 
Percent cytotoxicity 
JY Daudi 
2:1 10:1 2:1 
26 69 67 
10 73 37 
44 71 73 
3 4 2 
3 0 0 
14 0 0 
MEWO 
10:1 2:1 
39 22 
11 2 
53 31 
13 3 
1 0 
9 4 
d.- factors: culture as in "control", but harvested and washed on day five subsequently cultured in absence of lymphokines for 72 hours. 
e. + IL-2: culture as in"- factors", but cultured with 1,000 Ufml IL-2 during the last 24 hours. 
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factor-deprived cells of clone 1012 towards three of four target cells was drastically reduced, 
while it could be enhanced to a level comparable to or higher than that of control cells by the 
addition of IL-2. Clone Wi.K displayed significant cytotoxicity only towards K562 cells, where 
similar effects of factor depletion and IL-2 addition were observed as for clone 1012. IL-2 could 
not induce significant cytotoxicity of Wi.K towards the other three target cell lines. 
Secondly, it was determined whether anti-TCR-"f/o-1 McAb affected the function of the 
clones. Clones 1012, Wi.K, and as a control, the TcR-a,B+ cytotoxic clone JS-132, specific for 
a determinant on the HLA-A2 molecule, were used. To discriminate between factor-induced 
cytotoxicity and possible cytotoxicity reflecting the specificity of the TcR molecules, the assay 
was carried out with clones kept in culture with feeder cells for 8 days (control), as well as with 
clones harvested and washed on day six and cultured in the absence of lymphokines as 
described above, for 48 hours. The results of this experiment are shown in Table 3. Clone 
JS-132 displayed nonspecific cytotoxicity towards K562 and Daudi, which was strongly reduced 
in the absence of factors, while its specific activity towards JY and MEWO involving recognition 
of HLA-A2 by the TcR was retained. Again, the effect of factors produced by the feeder cell 
mixture on the cytotoxicity of clone 1012 was evident. In this experiment also the cytotoxicity 
of clone 1012 towards the cell line Daudi was reduced in the absence of factors, in contrast to 
the results shown in Table 2. Clone Wi.K did not display any cytotoxicity in this experiment. 
However, anti-TCR-'Y 1 o-1 McAb induced significant cytotoxicity of clone Wi.K towards K562 and 
Daudi, but not to JY or MEWO. The McAb had no effect on the cytotoxicity of clone 1012 to-
TABLE 3. Influence of anti-TCR-'Y/0-1 McAb on the cytotoxicity of TcR-"(o+ clones. 
Percent cytotoxicity 
Clone K562a JY Daudi MEWO 
10:1b 2:1 10:1 2:1 10:1 2:1 10:1 2:1 
1012: Controlc 37 11 23 10 55 21 42 17 
Control + McAb 28 18 7 4 13 5 7 2 
- factorsd 0 0 10 5 26 7 11 4 
- factors + McAb 10 6 3 2 
Wi.K: Control 3 0 0 0 2 0 3 1 
Control + McAb 57 46 4 2 63 33 13 6 
-factors 0 0 0 0 2 1 0 
- factors + McAb 30 25 0 0 28 13 2 
JS-132:Control 55 32 88 84 26 9 64 43 
Control + McAb 61 38 81 84 36 9 52 47 
-factors 15 6 90 86 2 1 54 43 
- factors + McAb 20 10 86 81 3 48 40 
a. Target cells used. 
b. Effector celljtarget cell ratio. 
c. Control: culture with feeder cells for 8 days. 
d. Factors: clones harvested and washed on day six and cultured in absence of lymphokines for 48 hours. 
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wards K562, but reduced its activity towards JY, Daudi, and MEWO. As expected, anti-
TCR--yjcS-1 had no effect on the activity of clone JS-132. 
It is concluded that the MHC-nonrestricted cytotoxicity of TcR--ycS+ clones 1012 and Wi.K 
is induced by the culture condition, most likely by growth factors such as IL-2 produced by the 
feeder cell mixture. Addition of McAb towards TcR--ycS can specifically induce cytotoxicity.The 
antibody can also specifically inhibit cytotoxicity, despite the fact that this activity must be 
categorized as factor induced. 
Distribution of TcR-')'(o)-bearing cells in normal PB-MNC and thymus. 
Since we had demonstrated the reactivity of anti-TCR--y jcS-1 McAb with all forms ofTcR--y(cS) 
described thus far, we felt confident to use this McAb to assess the occurrence of this second 
type of TcR in PB and thymus of normal individuals. In an initial experiment described above, 
using FAGS analysis of PB-MNC from 1S normal adult donors, variable percentages otTeR--yeS+ 
cells had been found, ranging from undetectable to 5%. In a few cases, including that of donor 
CM, a distinct subpopulation of TcR--ycS+ cells could be observed. PB-MNC from this donor 
were used to determine the percentage of CD3+ jTcR--ycS+ cells and the CD4/CDS phenotype 
of this population by double immunofluorescence stainings, followed by FAGS analysis. As can 
be seen in Figure 4, 6.7% of CD3+ cells in this individual expressed TcR--ycS (panel A). The 
majority of these cells were of the CD4-;cos- phenotype as previously described. No TcR-ro + 
cells expressing the CD4 marker were detectable (panel C). However, 21% of TcR--yo+ cells 
was cos+ (panel D). In Figure 4 it is also shown that freshly isolated TcR--yo+ cells stain very 
weakly or not with WT31 McAb (panel B). 
To determine the percentage of TcR--yo+ cells and their phenotype accurately, PB-MNC 
samples were labeled by double immunofluorescence stainings and analyzed by fluorescence 
microscopy. In these cases, PB-MNC were derived from donors ranging in age from 2 mo to 
16 yin order to investigate whether age affected the size of the TcR--yo+ population. In these 
samples, the percentages of CD3 +, WT31 +, and TcR--yo + cells were determined by 
examination of 1,000 cells for each marker. The CD4/CDS phenotypes of TcR--yo+ cells were 
determined by examination of 100 TcR--yo+ cells. The results from 10 donors are enumerated 
in Table 4. The percentages of TcR--yo+ cells ranged from 1.9 to 7.2% within the CD3+ cell 
population. The fluorescence of the TcR--yo+ population was virtually mutually exclusive with 
the fluorescence of the WT31 + population. In 4 of 10 donors CD4 + jTcR--yo + cells were 
detected, constituting up to 3.0% of TcR--yo+ cells. In all donors but one, cos+ jTcR--yo+ cells 
were found, ranging from 1.0 to 17% of TcR--ycS + cells. No obvious correlation between age of 
the donor and the size ofthe TcR--yo+ population could be found. In addition, Table 4 lists data 
obtained with thymocytes derived from three children. The relative size of the TcR--yo+ 
population in these thymuses was significantly smaller than in PB-MNC, ranging from 0.1 to 
1.0% of CD3+ cells. Also, mostTcR--yo+ thymocytes were of the CD4-/CDS- phenotype, while 
significantly more cos+ jTcR--yo+ than CD4 + jTcR--yo+ cells were found. The same analysis 
was done for thymocytes derived from an 1S-wk-old fetus. At this early stage in human 
development, the percentage of TcR--yo+ thymocytes was 0.7% of CD3+ cells. 
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Figure 4. Phenotypic analysis of TcR--y(o) + cells in PB of a healthy donor by double immunofluorescence 
stainings. PB-MNC were first incubated with anti-TCR--y 1 o-1 McAb, followed by goat anti-mouse lg-FITC conjugate 
(A, C, and D) or goat anti-mouse lg-phycoerythrin conjugate (B). Free binding sites of the second-step reagent 
were blocked with normal mouse serum and cells were incubated with phycoerythrin-conjugated McAb (A, C, and 
D) or FITC-conjugated WT31 (B). Fluorescence analysis was performed using a FACStar (Becton Dickinson). 
Fluorescence intensities for all panels are plotted identically on a 101og scale as indicated in A. A: CD3(Leu-4) 
phycoerythrin-labeled; anti-TCR--y IS -1 FITC-Iabeled. B: Anti-TCR--y I o-1 phycoerythrin-labeled; WT31 FITC-Iabeled. 
C: CD4(Leu-3a) phycoerythrin-labeled; anti-TCR--y lo-1 FITC-Iabeled. D: CD8(Leu-2a) phycoerythrin-labeled; 
anti-TCR-1' j 8-1 FITC-Iabeled. PE, phycoerythrin. 
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TABLE 4. Percentage and phenotype of anti-TCR-)'/o-1+ cells in PB of healthy donors and four thymus 
samples. 
Wf31+ Anti- CD4+ cos+ 
Donor Age CD3+ per TcR-'Y ;o-1 + per anti- per anti-
CD3+ per CD3+ TcR-'Y fo-1 + TcR-)'-o-1 + 
PB samples % % % % % 
HM 2 mo 47 98 1.9 0 10 
PvH 2.5 mo 62 98 1.9 3 12 
WB 3 mo 38 96 2.4 3 17 
KD 13 mo 44 94 5.6 0 9 
SB 27mo 38 95 4.7 0 
MH 6y 73 98 1.9 5 
MJ 7y 61 90 7.2 0 0 
SN sy 61 94 3.9 0 6 
AvdH 12 y 71 96 4.4 1 
EH 16 y 63 96 4.1 Nr 6 
Thymus sample 
A 3 wk 76 99.2 1.0 NT NT 
8 5y 63 99.5 0.2 0 8 
c 10 y 73 99.9 0.1 0 28 
Db 18wkb 78 99.0 0.7 NT NT 
a. NT, not tested. 
b. Fetal thymus. 
Ultrastructure of TcR-)'{o) + cells in PB. 
To study the morphological features ofTcR--y{o) +cells in PB, electron microscopy wasused. 
PB-MNC were derived from a healthy individual, who had previously 
been found by FACS analysis to contain a relatively high percentage of TcR--yo + cells. To 
identify these TcR--yo+ cells in electron microscopy, the total cell population was stained with 
anti-TCR--yjo-1 McAb, followed by rabbit anti-mouse lg and gold-conjugated protein A. For 
comparison, cells were labeled in the same fashion using WT31 McAb, which in a freshly 
isolated PB sample would allow predominantly the identification of TcR-afl+ cells. The gold 
labeling was specific as indicated by the fact that 40% of the cells were labeled using WT31 
McAb, while 4% of the cells were labeled using anti-TCR--yjo-1 McAb, figures corresponding 
to the results of immunofluorescence stainings. Figure 5 shows two cells, representative of the 
anti-TCR--yjo-1 +population or the WT31 +population. No significant overall differences in ultra-
structural morphology between these two populations were observed. Both cell types appeared 
to be medium-sized lymphocytes, -7-8 JLm in diameter. Moreover, like TcR-afl+ cells, TcR--yo+ 
cells were resting lymphocytes as determined by the following features: a high nucleusjcyto-
plasm ratio, a single "resting" nucleolus in a heterochromatin-rich nucleus, and a small amount 
of finely vesicular smooth-surfaced membranes; ribosomes existed as single units rather than 
as polysomal aggregates; rough endoplasmatic reticulum and Golgi system were almost 
completely absent and only some small mitochondria and a few lysosomes were observed. 
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Figure 5. Ultrastructure ofTcR--y(o) +cells in PB of a healthy donor. Cells were labeled with either anti-TCR-1 jo-1 
McAb (left) or WT31 McAb (right) and protein A-gold at 4 • C in the presence of sodium azide. Cells were 
subsequently fixed and embedded in Epon. The two insets show a higher magnification (x 16,000) to illustrate 
labeling of the antigens with gold particles. Bar, 1 j.Lm. 
There was no evidence for the presence of significant numbers of "granular structures" as can 
be identified in activated cytolytic T cells. 
DISCUSSION 
An McAb specific for human TcR--y(o) was generated, using as immunogen CD3/TcR 
complexes isolated from digitonin-solubilized clones. The major advantage of this McAb over 
the already available anti-TcR--y peptide sera is that it reacts with intact, viable cells. This allows 
positive identification of TcR--yo-expressing cells by immunofluorescence. Previously, human 
TcR--yo+ T cells have been identified using lack of reactivity with Wf31 McAb as an indication 
and immunoprecipitation with anti-C-y peptide serum as confirmation. This procedure is more 
time consuming than immunofluorescence, requires a relatively large number of cells, and is 
not fail-safe, since TcR--yo+ cells may react with Wf31 McAb (see above and reference 27). 
Reactivity of anti-TCR--yjo-1 McAb with viable cells also allows their selective isolation from 
heterogeneous cell populations and their subsequent use in functional or biochemical studies. 
Unlike TcR-cr,B, TcR--y(o) occurs in different molecular configurations. In the first place, 
TcR--y(o) can occur in either disulfide-linked or non-disulfide-linked forms. The molecular basis 
of this difference in organization has been unravelled (16,40,41). Of the two C gene segments 
in the 1 locus, C-y1 encodes a cysteine in its second exon, while C-y2 does not (11). This 
cysteine residue is thought to be responsible for the formation of an interchain-disulfide bond 
(6). Secondly, significant differences in size ofT cR--y chains are detected between non-disulfide-
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linked receptors on different cells. The leukemic line PEER (24,39) and the line IDP2 (4,24) 
express a 1 chain of -55 kDa, while on clones Wi.K and JS-228, as well as on PB-MNC from 
a leukemic patient (40), we have found a 1 chain of 40-44 kDa. In PEER, a triplication of the 
second exon of the C gene segment has occurred, rather than a duplication as in other cells 
using C-y2, which seems to be a polymorphic feature (41). However, since this exon contains 
only 48 bp, this is not sufficient to explain the size difference between the 55-kDa and the 
40-44-kDa 1 chains. Posttranslational modification of the 1 chain may play a role. A third aspect 
in which TcR--y(cS) shows organizational variation, is the appearance of the cS chain. In more than 
10 clones expressing disulfide-linked receptors analyzed thus far, we have clearly identified a 
-43-kDa cS chain (unpublished results). Clone AK119 is an exception in that no o chain can be 
detected after cell surface labeling with 1251. Moingeon et al. (23) have also reported 
disulfide-linked TcR--y in which no o chain could be detected. A similar problem is encountered 
in the analysis of non-disulfide-linked receptors. In PEER, Weiss et al. (39) observed only a 
55-kDa 1 chain, while Brenner et al. (24) in addition found a o chain that migrated at 40 kDa 
under reducing conditions and at a lower mol. mass under nonreducing conditions. Such a o 
chain was also found in the line IDP2 (4). Our results are consistent with those of Brenner et 
al. In PEER as well as in clone JS-228 derived from PB of a normal individual a o chain was 
expressed, which, however, did not label consistently well by cell surface iodination. In clone 
Wi.K as well as in TcR--y + leukemic T cells (40) no cS chain could be detected by cell surface 
labeling with 1251. Possibly, the o chain present in non-disulfidelinked receptors, as well as in 
the disulfide-linked receptor expressed on clone AK119, cannot be labeled efficiently by this 
technique. However, to account for such dramatic effect on 1251-labeling this chain must differ 
significantly in primary structure andjor conformation from the o chain found in the disulfide-
linked receptors. We are currently investigating the occurrence of the cS chain using metabolic 
labeling. Preliminary results indicate that all types of receptors contain a o chain. It should be 
remarked that it is not known, whether the o chain in disulfide-linked receptors and the o chain 
in non-disulfide-linked receptors are products of the same gene. 
Anti-TCR--y/o-1 McAb reacts with all types afTeR--yo. It is not clear on which chain ofTcR--yo 
the epitope recognized by anti-TCR--y/o-1 McAb is located. The McAb does not react in 
Western blotting, nor after separation of either disulfide-linked or non-disulfide-linked 1 and o 
chains by reductive alkylation and/or denaturation in SDS at high temperatures. Therefore, this 
point is difficult to resolve. 
TeA--yo-expressing cells can display MHC-nonrestricted cytotoxicity (21-24,37). As was 
shown earlier forT cells activated in mixed lymphocyte cultures ( 42) and cloned TcR-a.B + T cells 
(43), and as is shown here for TcR--yo+ T cell clones, such cytolytic activity is induced by the 
culture conditions. Cells are stimulated weekly with irradiated allogeneic PB-MNC and JY cells, 
and PHA. Growth factors are produced, such as IL-2, which previously has been shown to 
enhance cytolytic activity of TeA--yo-expressing clones (22). A TcR-a,B-expressing clone also 
displayed MHC-nonrestricted cytotoxicity, which was lost upon factor depletion. However, its 
specific activity dependent on expression of the HLA-A2 molecule on the target cells, was 
retained. Similarly, cytotoxicity of TcR--yo cells, reflecting the specificity of the receptor, would 
be expected to remain after factor depletion, particularly since expression of the receptor is not 
affected. Therefore, TcR--ycS most likely does not play a role in target cell recognition in the case 
of in vitro-induced MHC-nonrestricted activity, which has also been suggested by others (44). 
TcR-ro detected by a monoclonal antibody 287 
Recently, evidence has indeed been presented that MHC molecules may be the ligand of 
TCR-r I o (45). However, the receptor plays a role in the regulation ofT cell activity in the in vitro 
systems used. McAb directed at the receptor may induce nonspecific cytotoxicity (this paper 
and ref. 46), and proliferation (2S), as shown previously for TcR-a.Bexpressing cells, which is 
dependent on the presentation of the McAb via Fe receptors on the target cells (47,4S). Also, 
inhibition of nonspecific cytotoxicity was reproducible found. In one case, cytotoxicity of clone 
i 012 towards Daudi, which bears Fe receptors for lgGi, was inhibited, while cytotoxicity of 
clone Wi.K was induced. Perhaps the effect depends on the nature of the conformational 
change induced in the receptor by binding of the McAb. 
It is unknown what contribution TcR-ro+ cells make to the immune system. Therefore, it is 
of interest to determine in which tissues and in what relative numbers TcR-ro + lymphocytes are 
present in man, in health and disease. In this paper, we have reported the percentages of 
TcR-ro+ cells in PB and thymus of normal individuals. In 11 donors, TcR-ro+ cells constituted 
i .9 to 7.2% of CDS+ lymphocytes in PB. It has not yet been determined whether these 
percentages are constant with time in a given healthy donor. In thymus samples from three 
children, the percentage of TcR-ro + thymocytes ranged from 0. i to i .0% of CDS+ cells, which 
is significantly lower than in PB. These data are consistent with those reported for CDS+ /WTS r 
cells in PB-MNC and thymus (SS). WTSi expression is indeed very low or non-detectable on 
freshly isolated TcR-ro + cells. Thymocytes from an 1 8-wk-old human fetus were included in this 
study, since Pardoll et al. (49) had reported the expression of TcR-ro on all fetal thymocytes 
at day 15 of gestation in mouse. No higher percentage of TcR-ro+ cells were detected in 
human fetal thymus than in thymuses derived from children. It may be relevant to study earlier 
samples. 
The phenotype of the majority of TcR-ro+ cells in PB and thymus was CD4-/CDS-, in 
concordance with previously published data. However, in the total pool of TcR-ro + cells, as we 
have been able to study now, a significant proportion may bear the CDS antigen, ranging from 
0 to 28% between 1S donors, CDS+ /TcR-ro+ clones have indeed been reported (50). We have 
found that CD4 + /TcR-ro+ cells are much more infrequent, but do occur. TcR-ro+ cells of the 
CD4 + phenotype have not previously been reported. In double immunofluorescence stainings 
using FAGS analysis as well as fluorescence microscopy, we have observed some TcR-ro+ 
cells, which did not react with CDS McAb. Although it is an unlikely possibility, it will have to be 
investigated whether TcR-ro can be expressed at the cell surface in the absence of the CDS 
molecule. 
Electron microscopic analysis has pointed out that TcR-ro+ cells in PB are resting 
lymphocytes, like TcR-a.B+ cells and unlike NK cells. This is consistent with our previous 
observation that CDS+ /CD4-/CDS- cells derived from PB need in vitro activation in order to 
become functionally active (51). It will be investigated whether more subtle morphological 
features discern TcR-ro+ cells from TcR-a.B+ cells. For instance, CDS+ /CD4-/CDS- cells have 
previously been selectively isolated on continuous density gradients, which would imply certain 
differences in cellular structure (51). 
Further studies will involve the identification of human TcR-r& + cells in healthy and diseased 
states, their isolation and characterization, in which the developed McAb will be an important 
tool. 
288 CHAPTER4.6 
ACKNOWLEDGMENTS. We thank J. Sein, W.M. Comans-Bitter, and B. van Krimpen for technical assistance, M. 
Dessing for FACS analysis, P. Rothengatter for photography, Drs. G.D. Keizer, H. van der Donk, H. Geuze and 
J. W. Slot for advice and Drs. HL Ploegh and C.J.M. Melief for critically reading the manuscript. 
This work was supported by the Netherlands Cancer Foundation (J. Borst, E. de Vries and R.J. van de Griend, 
grants NKI83-18 and RRTI84-13) and the Sophia Foundation for Medical Research (J.J.M. van Dongen). 
REFERENCES 
1. Allison JP, Mcintyre BW, Bloch D. Tumor-specific antigen of murine T-lymphoma defined with monoclonal 
antibody. J lmmunol1982;129:2293-2300. 
2. Haskins K, Kubo R, White J, Pigeon M, Kappler J, Marrack P. The major histocompatibility complex-restricted 
antigen receptor on T cells. I. Isolation with a monoclonal antibody. J Exp Med 1983;157:1149-69. 
3. Meuer SC, Fitzgerald KA, Hussey RE, Hodgdon JC, Schlossman SF, Reinherz EL Clonotypic structures 
involved in antigen-specific human T cell function: relationship to the T3 molecular complex. J Exp Med 
1983;157:705-19. 
4. Brenner MB, McLean J, Dialynas DP, Strominger JL, Smith JA, Owen FL, Seidman JG, lp S, Rosen F, Krangel 
MS. Identification of a putative second T-cell receptor. Nature 1986;322:145-9. 
5. Lew AM, Pardoll DM, Maloy WL, Fowlkes BJ, Kruisbeek A, Cheng S-F, Germain RN, Bluestone JA, Schwartz 
RH, Coligan JE. Characterization ofT cell receptor gamma chain expression in a subset of murine thymocytes. 
Science 1986;234:1401-5. 
6. Kronenberg M, Siu G, Hood LE, Shastri N. The molecular genetics of the T-cell antigen receptor and T-cell 
antigen recognition. Ann Rev lmmunol 1986;4:529-91. 
7. Saito H, Kranz DM, Takagaki Y, Hayday AC, Eisen HN, Tonegawa S. Complete primary structure of a 
heterodimeric T-cell receptor deduced from eDNA sequences. Nature 1984;309:757-62. 
8. Murre C, Waldmann RA, Morton CC, Bongiovanni KF, Waldmann TA, Shows TB, Seidman JG. Human -y-chain 
genes are rearranged in leukaemic T cells and map to the short arm of chromosome 7. Nature 1985;316:549-
52. 
9. Kranz OM, Saito H, Heller M, Takagaki Y, Haas W, Eisen HN, Tonegawa S. Limited diversity of the rearranged 
T-cell -y gene. Nature 1985;313:752-5. 
10. LeFranc M-P, Forster A, Baer R, Stinson MA, Rabbitts TH. Diversity and rearrangement of the human T cell 
rearranging -y genes: nine germ-line variable genes belonging to two subgroups. Cell 1986;45:237-46. 
11. Strauss WM, Quertermous T, Seidman JG. Measuring the human T cell receptor -y-chain locus. Science 
1987;237:1217-9. 
12. Forster A, HuckS, Ghanem N, Lefranc M-P, Rabbitts TH. New subgroups in the human T cell rearranging V-y 
gene locus. EMBO J 1987;6:1945-50. 
13. Snodgrass HR, Dembic Z, Steinmetz M, Von Boehmer H. Expression ofT-cell antigen receptor genes during 
fetal development in the thymus. Nature 1985;315:232-3. 
14. Raulet DH, Garman RD, Saito H, Tonegawa S. Developmental regulation ofT-cell receptor gene expression. 
Nature 1985;314:103-7. 
15. Van Dongen JJM, Quertermous T, Bartram CR, Gold DP, Wolvers-Tettero ILM, Comans-Bitter WM, Hooijkaas 
H. Adriaansen HJ, De Klein A, Raghavachar A, Ganser A, Duby AD, Seidman JG, Van den Elsen P, Terhorst 
C. T cell receptor-CD3 complex during early T cell differentiation: analysis of immature T cell acute 
lymphoblastic leukemias (T-ALL) at DNA, RNA, and cell membrane level. J lmmunol 1987;138:1260-9. 
16. Krangel MS, Band H, Hata S, McLean J, Brenner MB. Structurally divergent human T cell receptor -y proteins 
encoded by distinct C-y genes. Science 1987;237:64-7. 
17. Chien Y-H, lwashima M, Kaplan KB, Elliott JF, Davis MM. A newT-cell receptor gene located within the alpha 
locus and expressed early in T-cell differentiation. Nature 1987;327:677-82. 
18. Borst J, Coligan JE, Oettgen H, Pessano S, Malin R, Terhorst C. The S-and €-chains of the human T3jT-cell 
receptor complex are distinct polypeptides. Nature 1984;312:455-8. 
19. Weissman AM, Samelson LE, Klausner RD. A new subunit of the human T-cell antigen receptor complex. 
TcR-"(8 detected by a monoclonal antibody 289 
Nature 1986;324:480-2. 
20. Weiss A, Imboden J, Hardy K, Manger B, Terhorst C, Stobo J. The role of the T3jantigen receptor complex 
in T-cell activation. Ann Rev lmmunol1986;4:593-619. 
21. Borst J, Van de Griend RJ, Van Oostveen JW, Ang S-L, Melief CJ, Seidman JG, Bolhuis RLH. AT-cell receptor 
1 jCD3 complex found on cloned functional lymphocyte. Nature 1987;325:683-8. 
22. Van de Griend RJ, TaxWJM, Van Krimpen BA, Vreugdenhil RJ, Ronteltap CPM, Bolhuis RLH. Analysis of tumor 
cells by CD3+ 4-8-16+ T cell receptor a.{r clones, regulated via CD3 and CD16 activation sites, recombinant 
interleukin 2, and interferon {3. J lmmunol1987;138:1627-33. 
23. Moingeon P, Jitsukawa S, Faure F, Troalen F, Triebel F, Graziani M, Forestier F, Bellet D, Bohuon C, Hercend 
T. A "(-chain complex forms a functional receptor on cloned human lymphocytes with natural killer-like activity. 
Nature 1987;325:723-6. 
24. Brenner MB, McLean J, Scheft H, Riberdy J, Ang S-L, Seidman JG, Devlin P, Krangel MS. Two forms of the 
T-cell receptor 1 protein found on peripheral blood cytotoxic T lymphocytes. Nature 1987;325:689-94. 
25. Bank I, DePinho RA, Brenner MB, Cassimeris J, Alt FW, Chess L. A functional T3 molecule associated with 
a novel heterodimer on the surface of immature human thymocytes. Nature 1986;322:179-81. 
26. Spits H, Borst J, Tax W, Capel PJA, Terhorst C, De Vries JE. Characteristics of a monoclonal antibody (WT-31) 
that recognizes a common epitope on the human T cell receptor for antigen. J lmmunol 1985;135:1922-8. 
27. Van de Griend RJ, Borst J,Tax WJM, Bolhuis RLH. Functional reactivtiy of WT31 monoclonal antibody with 
T cell receptor-"( expressing CD3+ 4-8- T cells. J lmmunol1988;140:1107-10. 
28. Borst J, Spits H, Voordouw A, De Vries E, Boylston A, De Vries JE. A family of T-cell receptor molecules 
expressed on T-cell clones with different specificities for allomajor histocompatibility antigens. Hum lmmunol 
1986;17:426-42. 
29. Van de Griend RJ, Bolhuis RLH. In vitro expansion and analysis of cloned cytotoxic T cells derived from 
patients with chronic T-ylymphoproliferative disorders. Blood 1985;65:1002-9. 
30. Ang S-L, Seidman JG, Peterman GM, Duby AD, Benjamin D, Lee SJ, Hafler DA. Functional"( chain-associated 
T cell receptors on cerebrospinal fluid.<:ferived natural killer-like T cell clones. J Exp Med 1987;165:1453-8. 
31. Yssel H, De VriesJE, Koken M, Van BlitterswijkW, Spits H. Serum-free medium for generation and propagation 
of functional human cytotoxic and helper T cell clones. J lmmunol Methods 1984;72:219-27. 
32. Van de Griend RJ, Bolhuis RLH. Rapid expansion of allospecific cytotoxic T cell clones using nonspecific 
feeder cell lines without further addition of exogenous IL-2. Transplantation 1984;38:401-6. 
33. Ravid Z, Goldblum N, Zaizov R, Schlesinger M, Kertes T, Minowada J, Verbi W, Greaves M. Establishment and 
characterization of a new leukaemic T-cell line (PEER) with an unusual phenotype. lnt J Cancer 
1980;25:705-1 0. 
34. Slot JW, Geuze HJ. A new method of preparing gold probes for multiple-labeling cytochemistry. Eur J Cell 
Bioi 1985;38:87-93. 
35. Oettgen HC, Pettey CL, Maloy WL, Terhorst C. A T3-like protein complex associated with the antigen receptor 
on murine T cells. Nature 1986;320:272-5. 
36. Brenner MB, Trowbridge IS, Strominger JL. Cross-linking of human T cell receptor proteins: association 
between the T cell idiotype f3 subunit and the T3 glycoprotein heavy subunit. Cell 1985;40:183-90. 
37. Lanier LL, Federspiel NA, Ruitenberg JJ, Phillips JH, Allison JP, Littman D, Weiss A. The T cell antigen receptor 
complex expressed on normal peripheral blood CD4-, cos-T lymphocytes: a CD3-associated disulfide-linked 
1 chain heterodimer. J Exp Med 1987;165:1076-94. 
38. Lanier LL, Weiss A. Presence of Ti (WT31) negative T lymphocytes in normal blood and thymus. Nature 
1986;324:268-70. 
39. Weiss A, Newton M, Crommie D. Expression of T3 in association with a molecule distinct from the T-cell 
antigen receptor heterodimer. Proc Natl Acad Sci USA 1986;83:6998-7002. 
40. Van Dongen JJM, Wolvers-Tettero ILM, Seidman JG, Ang S-L, Van de Griend RJ, De Vries EFR, Borst J. Two 
types of gamma T cell receptors expressed by T cell acute lymphoblastic leukemias. Eur J lmmunol 
1987;17:1719-28. 
41. Littman DR, Newton M, Crommie D, Ang S-L, Seidman JG, Gettner SN, Weiss A. Characterization of an 
expressed CD3-associated Ti "(-chain reveals C-y domain polymorphism. Nature 1987;326:85-8. 
42. Bolhuis RLH, Ronteltap CPM, De Rooy-Braam MAW, Van Krimpen BA, Schellekens H. Phytohaemag-
290 CHAPTER4.6 
glutinin-induced susceptibility to lysis by natural and activated killer cells of autologous, allogeneic and 
xenogeneic target cells. Mollmmunol 1982;19:1347-56. 
43. Van de Griend RJ, Giphart MJ, Van Krimpen BA, Bolhuis RLH. Human T cell clones exerting multiple cytolytic 
activities show heterogeneity in susceptibility to inhibition by monoclonal antibodies. J lmmunol 
1984;133:1222-29. 
44. Phillips JH, Weiss A, Gemlo BT, Rayner AA, Lanier LL. Evidence that the T cell antigen receptor may not be 
involved in cytotoxicity mediated by 'Y jo and a;.B thymic cell lines. J Exp Med 1987;166:1579-84. 
45. Matis LA, Cron R, Bluestone JA. Major histocompatibility complex-linked specificity of -yo receptor-bearing T 
lymphocytes. Nature 1987;330:262-4. 
46. Moingeon P, Ythier A, Goubin G, Faure F, Nowill A, Delmon L, Rainaud M, Forestier F, Daffos F, Bohuon C, 
Hercend T. A unique T-cell receptor complex expressed on human fetal lymphocytes displaying 
natural-killer-like activity. Nature 1986;323:638-40. 
47. Spits H, Yssel H, Leeuwenberg J, De Vries JE. Antigen-specific cytotoxic T cell and antigen-specific 
proliferating T cell clones can be induced to cytolytic activity by monoclonal antibodies against T3. Eur J 
lmmunol1985;15:88-91. 
48. Tax WJM, Hermes FFM, Willems RW, Capel PJA, Koene RAP. Fe receptors for mouse lgG1 on human 
monocytes: polymorphism and role in antibody-induced T cell proliferation. J lmmunol1984;133:1185-9. 
49. Pardoll DM, Fowlkes BJ, Bluestone JA, Kruisbeek A, Maloy WL, Coligan JE, Schwartz RH. Differential 
expression of two distinct T-cell receptors during thymocyte development. Nature 1987;326:79-81. 
50. Nowill A, Moingeon P, Ythier A, Graziani M, Faure F, Delmon L, Rainaut M, Forrestier F, Bohuon C, Hercend 
T. Natural killer clones derived from fetal {25 weak) blood: probing the human T cell receptor with WT31 
monoclonal antibody. J Exp Med 1986;163:1601-6. 
51. Van de Griend RJ, De Bruin HG, Riimke HC, Van Doorn R, Roos D, Astaldi A. Isolation and partial 
characterization of a novel subset of human T lymphocytes defined by monoclonal antibodies. lmmunol 
1982;47:313-20. 
CHAPTER 4.7 
REARRANGEMENT AND EXPRESSION OF 
T CELL RECEPTOR DELTA GENES IN 
T CELL ACUTE LYMPHOBLASTIC LEUKEMIAS* 
Jacques J.M. van Dongen 1, ln~rid L.M. Wolvers-Tettero 1, 
Fred Wassenaar2, Jannie Borst and Peter van den Elsen2 
1. Department of Immunology, Erasmus University/University Hospital Dijkzigt, Rotterdam; 
2. Department of Immunohematology and Blood Bank, University Hospital, Leiden; 
3. Department of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 
SUMMARY 
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We have analyzed T cell receptor o (fcR-o) gene rearrangement and transcription in 
appropriately phenotyped mononuclear cells derived from 12 patients with T cell acute 
lymphoblastic leukemia (f-ALL). The T-ALL cells were also analyzed for rearrangement and 
transcription of the TcR-,8 and -y genes as well as for the presence of TcR-o: gene transcripts. 
Four T-ALL expressed TcR--yo at the cell surface, while three expressed TcR-o:,B. The other five 
T-ALL did not express a TcR-CD3 complex on their cell membrane. The TcR--yo+ T-ALL had 
rearranged both TcR-o gene alleles and contained mature 2.2- and 1.5-kb TcR-o transcripts. 
In one case immature 1.9- and 1.2-kb TcR-o transcripts were also found. Furthermore, they 
contained mature TcR--y mRNA, mature or immature TcR-,8 mRNA, but no TcR-o: mRNA. The 
three TcR-o:,B+ T-ALL contained mature a and ,8 transcripts, but lacked TcR-o transcripts as a 
result of deletion of both TcR-o gene alleles. These data are in line with a mutually exclusive 
expression of TcR-a and -o genes, which may be important to ensure the presence of only one 
type of TcR per T cell. 
One out of five CD3- T-ALL had germline TcR-,8, --y and -o genes. The other four CD3-
T-ALL had rearranged their TcR-,8, --y and -o genes and contained immature 1.9- and 1.2-kb 
TcR-o gene transcripts. Remarkably, one of these T-ALL also contained TcR-a transcripts in 
addition to the immature TcR-o transcripts, which was in line with the deletion of one TcR-o 
gene allele and rearrangement of the other allele. This suggests that prevention of dual receptor 
expression may not only be regulated by the presence of germline TcR-o: genes in TcR--yo+ 
cells or by deletion of both TcR-o gene alleles in TcR-a,B+ cells, but also via other regulation 
mechanisms. 
*Published in: Blood 1989;74:334-42. 
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Finally our data indicated that the combinatorial repertoire of the TcR-o genes is limited, 
which has also been described for the TcR--y genes. 
INTRODUCTION 
The majority of mature T lymphocytes present in peripheral lymphoid organs, recognize 
antigens in the context of major histocompatibility (MHC) molecules by means of the classical 
T cell receptor (TcR), consisting of an a and a f3 chain (1 ,2). An alternative TcR, composed of 
'Y and o chains, has recently been defined in humans (3-5) and mice (6-8). Both receptors are 
expressed at the cell surface in association with the CD3-protein complex. In normal individuals, 
TcR--yo is found on 1 to 10% of mature CD3 + T cells and 0.1 to 1% of CD3 + thymocytes, which 
predominantly have the CD4-;cos- phenotype (4-12). It has been demonstrated that in vitro 
activated TcR--yo+ T cell clones can exhibit cytotoxic activity and/or secrete growth factors 
(4,5,9). However, the exact function and specificity of this type ofT cells remains to be defined. 
All four TcR chains are encoded by genes, which rearrange during differentiation to obtain 
receptor diversity (13-16). The genomic organization of the human TcR-a, TcR-/3 and TcR-'Y 
genes has for a large part been unraveled (17 -21) and during the last year also many data have 
become available about the recently discovered TcR-o genes (22-31). The TcR-o encoding 
genes are located within the TcR-a locus, approximately 85 kilobases (kb) 5' to theCa genes, 
in between the long stretch of Ja and the Va gene segments (14-16,24-30). In addition to three 
Do and three Jo gene segments, only one Co gene has been identified within the murine and 
human TcR-o gene complex (14, 15,22-31). The TcR-a and TcR-o gene segments have the 
same transcriptional orientation, which raises the possibility that a and o chains can potentially 
make use of the same V-region-gene pool (14, 15,24- 30). Some Vo genes in the mouse indeed 
show high homology with previously defined Va genes (14,15,32) and in humans, the 
nucleotide sequence of a Vo-cDNA clone appeared to be virtually identical to a Va gene of the 
Va6-gene family (33). 
TcR-0-gene rearrangements were first detected by use of pulsed-field-gel electrophoresis 
of large restriction fragments and hybridization with a Ca probe (16). During murine ontogeny, 
rearrangements in the TcR-o genes occur at least as early as day 14 in fetal thymocytes 
(14-16), i.e. at the same time or possibly before rearrangement and transcription of the TcR--y 
genes (15,34-36). TcR-/3 genes start to rearrange from day 14 on, resulting in fully rearranged 
genes and mature 1.3-kb transcripts two days later (34-38). Rearrangement and transcription 
of the TcR-a genes occurs from day 17 on (35,36). These data are in line with the finding that 
TcR--yo is already expressed by day-14-and day-15-fetal thymocytes, while the first TcR-a/3 
positive thymocytes can be detected two days later (7,8,39). 
Human T cell differentiation as studied by the analysis of TcR gene rearrangement and 
transcription in T cell acute lymphoblastic leukemias (T-ALL) seems to reflect T cell develop-
ment during murine ontogeny. This leukemia model system is based on the assumption that 
T-ALL represent the malignant counterparts ofT cells in the various stages of normal differen-
tiation (40,41). It was concluded that TcR--y genes rearrange and are transcribed before or si-
multaneously with the TcR-{3 genes, while TcR-a gene transcription occurs at a later stage 
during differentiation (42-45). 
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Here we have used the same model system to analyze TcR-o gene rearrangement and 
transcription during human T cell differentiation. Twelve T-ALL samples including four TcR-'Yo+ 
T-ALL were characterized by extensive immunologic marker analysis and by analysis of the 
configuration and transcription of the TcR genes. 
MATERIALS AND METHODS 
Cell samples 
Peripheral blood (PB) or bone marrow (BM) samples were obtained from T-ALL patients at initial diagnosis. 
The cell samples were obtained after informed consent of the patients, according to the guidelines of the Medical 
Ethics Committee of the University Hospital Dijkzigt/Erasmus University, Rotterdam, The Netherlands. Mononuclear 
cells (MNC) were obtained from these cell samples by Ficoii-Paque (density: 1.077 gjml; Pharmacia, Uppsala, 
Sweden) density centrifugation. These MNC samples were frozen and stored in liquid nitrogen. 
Immunologic marker analysis 
The MNC of the T-ALL patients were analyzed for the nuclear expression of terminal deoxynucleotidyl 
transferase (TdT), for cell membrane expression of the T cell markers CD1 (66IIC7), CD2(Leu-5b), CD3(Leu-4), CD4 
(Leu-3), CD5(Leu-1), CD7(3A1), and CD8(Leu-2), for the HLA-DR antigen as well as for reactivity with the 
monoclonal antibody (McAb) WT31, which recognizes a non-polymorphic epitope on TcR-a.B (46). CD3+ jWT31-
T -ALL were tested for reactivity with the recently developed anti-TcR-'Y 5 McAb (anti-TCR-'Y I 5-1, hybridoma 11 F2; 
c.f. reference 11), if sufficient cells were available. The rabbit anti-TdT antiserum was obtained from Supertechs 
(Bethesda, MD); the McAb Leu-1, Leu-2, Leu-3, Leu-4, Leu-5b and the anti-HLA-DR McAb were obtained from 
Becton Dickinson (Sunnyvale, CA); the 3A1 hybridoma was obtained from the American Type Culture Collection 
(Rockville, MD). The anti-CD1 antibody and WT31 were gifts from Dr. J.M. van de Rijn (Amsterdam, The 
Netherlands) and Dr. W. Tax (Nijmegen, The Netherlands), respectively. Indirect immunofluorescence stainings for 
TdT and the cell membrane markers were performed as described and evaluated with Zeiss fluorescence micro-
scopes (Carl Zeiss, Oberkochen, FRG) (47). 
Northern blot analysis 
Total RNA was isolated from frozen MNC by the LiCijurea method (48). Approximately 15 p,g of total RNA 
was size-fractionated on 1.0% agarose gels containing formaldehyde and blotted to Biodyne nylon membranes (Pall 
Ultrafine Filtration Corporation, Glen Core, NY). 32P-nick-translated eDNA probes were used to detect specific RNA 
sequences forT eR-a (pA65), TcR-.8 (pT10), TcR-'Y(PT'Y-1), and CD3-o (pPGBC9) (18,49-51). The TcR-5 transcripts 
were detected by use of a recently isolated eDNA probe, which contains exclusively human Co sequences (P. van 
den Elsen, unpublished results). 
Southern blot analysis 
DNA was isolated from frozen MNC as described (48). Fifteen p,g of DNA were digested with the appropriate 
restriction enzymes, obtained from Boehringer Mannheim (Mannheim, FRG) or from New England Biolabs (Beverly, 
MA). The restriction fragments were size-fractionated on 0.7% agarose gels and transferred to Gene Screen Plus 
nylon membranes (New England Nuclear, Boston, MA) or Nytran-13N nylon membranes (Schleicher and Schuell, 
Dassel, FRG) as described (48). 
TcR-'Y gene rearrangements were detected with 32P-nick-translated J')'1.3 and C'Y probes (21,52). The J')'1.3 
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Figure 1. Organization of the D, J and C regions of the human TeR-eS gene (c.f. references 24-31). The locations 
of the relevant Kpnl (K), EcoRI (E), Hindlll (H), BamHI (B), and Sacl (S) restriction enzyme sites are indicated. K* 
represents a polymorphic Kpnl restriction site. The solid boxes and the shaded box represent the coding exons 
and the 3' untranslated Co exon, respectively. The solid bars represent the three probes, which were used for 
hybridization of the Southern blot filters. 
probe is a 0.8-kb EcoRI-Hindlll fragment containing J11 .3 segments; it hybridizes to both J11 .3 and J12.3 gene 
segments and allows detection of rearrangements in these regions in EcoRI digests (21). In Kpnl digests the J11 .3 
probe detects each rearrangement in the J11 and J12 regions (53). The C1 probe is a 0.4-kb BamHI-BamHI 
fragment containing a part of the first exon of the C11 gene; it hybridizes to the first exon of C11 and C12 and 
allows detection of rearrangements to the 11 and 12 locus in BamHI digests (21). Deletion of C11 gene segments 
can be detected by this probe in EcoRI digests (21,52). All12 T-ALL DNA samples were analyzed with the J11.3 
probe (EcoRI and Kpnl digests) and the C1 probe (BamHI and EcoRI digests). 
The configuration of the TcR-,8 genes was analyzed with C,B and J,82 probes (54). The C,B probe is a 0.7-kb 
Pstl-Bg/11 fragment containing C,81 segments; it hybridizes to both C,81 and C,82 gene segments and allows 
detection of rearrangements to the ,81 locus in EcoRI digests (54). The J,82 probe consists of contiguous 1 .9-kb 
Pvuii-Pvull and 1 .5-kb Pvuii-EcoRV fragments containing J,82.3 to J,82.7; this probe does not hybridize to J,81 gene 
segments and was used to detect rearrangements to the ,82 locus in EcoRI digests (54). TcR-,8 gene 
rearrangements were confirmed using the C,B probe in BamHI digests. 
The configuration of the TeR-eS genes was analyzed by use of the Jo1 probe JoS16 (a 1.5-kb Sacl fragment) 
and the Jo2 probe R21XH (a 2.3-kb Hindiii-EcoRI fragment) (24,25) as well as by use of the above mentioned 
eDNA probe, which recognizes Co sequences only. All twelve DNA samples were analyzed by use of these probes 
in Kpnl, EcoRI, Bg/11, Hindlll, and BamHI digests as well as in Kpni/Hindlll, KpnljBamHI and BamHijSacl double 
digests. The three TeR-eS probes and the relevant Kpnl, BamHI, EcoRI, Hindlll and Sacl sites are indicated in Figure 
1. The location of the restriction sites in Figure 1 are derived from data in the literature (25-31) as well as from 
extensive Southern blot analysis of germline TeR-eS genes in normal individuals using the three TeR-eS probes. 
Recombinant plasmids were handled under PZEK1 containments according to the National Institutes of Health 
Guidelines for Research Involving Recombinant DNA molecules. 
RESULTS 
Phenotype of the ALL 
Of the 12 T-ALL analyzed, 7 expressed CD3 on the cell membrane, indicative of TcR 
surface expression (Table 1, patients 6 through 12). Of these, three were TcR-a,B positive 
(patients 10 through 12), as determined by immunofluorescence with the McAb WT31, while 
four were TcR-16 positive (patients 6 through 9), as determined by immunofluorescence with 
the McAb anti-TCR-1 /cS-1 (11) andjor previously reported immunoprecipitation studies (52). Two 
TcR-16 + T-ALL had the expected CD1-jCD4-;cos- phenotype, while two expressed CD1 and 
CD4. For further details on the marker analysis, we refer to Table 1. 
TcR-o genes in T-ALL 295 
TABLE 1. Immunologic marker analysis, Southern-blot analysis and Northern blot analysis of twelve T-ALL 
cell samples 
1 2 3 4 5 6 7 8 9 10 11 12 
Cell sample BM PB PB PB PB PB PB PB PB PB BM PB 
Immunologic markersa 
TdT + + + + + + + + + + + 
HLA-DR (L243) + 18% 
CD1 (6611C7) + 66% + 26% 40% 52% 
CD2 (Leu-Sb) + + 50% 37% + + + + + + + + 
CD3 (Leu-4) 52% +b +b +b 71% + + 
CD4 (Leu-3) + + 38% 59% 65% 48% + 
CDS (Leu-1) + + + + + + + + + + + 
CD? (3A1) + + + + + + + + + + + + 
CDS (Leu-2) 44% 67% + + 32% + 
TcR-a,B (WT31) -b b -b + + + 
TcR-1o (11 F2) NT" NT NT NT NT + +b +b NTb NT NT NT 
Southern blot analysisd 
TcR-.81 genes G/G R/R D/R D/R R/G R/G D/D R/G D/R D/R D/R D/R 
TcR-,82 genes G/G R/G R/R R/R R/G R/R R/R G/G R/G R/R R/G R/R 
TcR-11 genes G/Ge DjD DjD D/D DjD DjD D/D R/R D/D D/D D/D R/Gf 
TcR-12 genes G/G R/Rg R/R R/R R/R R/R R/R G/G R/R R/R R/Rg G/G 
TcR-o genesh G/G D/R R/R R/R R/R R/R R/R R/R R/R D/D D/D D/D 
Northern blot analysis; 
TcR-a (1.7 kb) ± + + + 
TcR-,8 (1.3 kb) + + + + + + + + 
TcR-,8 (1.1 kb) + + + 
TcR-,8 (1.0 kb) ± ± ± + + ± 
TcR-1 (1.6 kb) ± + + + + + + ± 
TcR-o (2.2 kb) + + + + 
TcR-o (1.9 kb) ± + + + + 
TcR-o (1.5 kb) + + + + 
TcR-o (1.2 kb) ± ± ± ± + 
CD3-o + + + + + + + + + + + + 
a. Immunologic marker analysis: +, more than 75% of the cells is positive; -, less than 15% of the cells is positive; percentages positivity 
between 15% and 75% are indicated. 
b. By immunoprecipitation it was proven that the CD3+ T-ALL cells of patients 7, 8 and 9 expressed TcR-18 (c.f. reference 52); the T-ALL 
cells of patient 8 expressed disulfide-linked TcR chains, whereas the T-ALL cells of patients 7 and 9 expressed a TcR without interchain 
disulfide bond. 
c. NT, not tested. 
d. Southern blot analysis: G, allele in germline configuration; R, rearranged allele; D, deletion of the involved gene complex. 
e. The T-ALL cells of patient 1 had germline TcR-1 genes; also no rearrangement to the J11.1 region could be detected. 
f. The TcR-1 genes of the T-ALL cells of patient 12 were rearranged to J11.1 on one allele, but the other allele was in germ line configuration. 
g. In the T-ALL cells of patients 2 and 11 one TcR-12 allele was rearranged to J12.3, while the other allele was probably rearranged to J12.1. 
h. Detailed information concerning the configu:ation of the TcR-o genes in the twelve T-ALL is summarized in Table 2. 
i. Northern blot analysis: +, transcripts present; ±, weak band visible; -, no transcripts could be detected. 
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TcR gene rearrangements in the T-ALL 
All T-ALL with the exception of the so-called prothymocytic T-ALL (patient 1; c.f. ref. 55) had 
rearranged TcR-.B genes. In the majority of cases this concerned rearrangement of both alleles 
and involvement of the ,82 locus. TcR--y gene rearrangements had also occurred in all but the 
prothymocytic T-ALL. In all these cases, except the TcR--y.S+ T-ALL of patient 8 and the 
TcR-a.B+ T-ALL of patient 12, both C-y1 alleles were deleted, while rearrangements had taken 
place to the -y2 locus on both alleles. Further details concerning the configuration of the TcR-.B 
and TcR--y genes are summarized in Table 1. 
Both TcR-.S gene alleles were deleted in the three TcR-a.B+ T-ALL, as would be expected 
to occur upon TcR-a gene rearrangement (14, 16,25,26). TcR-.S gene rearrangements were 
found in all four TcR--yo+ T-ALL as well as in four out of five cos- T-ALL Based on the 
extensive analyses of the TcR-o genes by use of eight different restriction enzyme digests and 
the three described TcR-.S probes, it appeared to be possible to determine the configuration 
of the TcR-.S genes in the eight T-ALL with rearranged c5 genes (Table 2). In the T-ALL of patient 
2, one TcR-o gene allele was deleted, while the other was rearranged. In most T-ALL the TcR-o 
gene alleles were rearranged to the J.S1 gene segment, but in two T-ALL, a rearrangement to 
the J.S2 gene segment was found. Rearrangements to the Jc51 gene segment could be identified 
in EcoRI and Bg/11 digests using the J.S1 probe (Figure 2A). These rearrangements were 
confirmed by use of several other digests, including Kpnl and BamHI. Rearrangements to the 
Jc52 gene segment could be detected in Hindi II and Bg/11 digests using the J.S2 probe and were 
confirmed in several other digests, including Kpnl and KpnljBamHI digests (Figure 28). It 
should be remarked that our analyses of the leukemic T cells and cells with germline TcR-o 
genes indicated that the Kpnl site at the 3' site of the C gene segments (located in the Vc52 
gene segment) is polymorphic. Therefore Kpnl digests will not always be informative and should 
be carefully interpreted. 
TABLE 2. Configuration of the TcR-o genes: summary of the results of the Southern blot analysis using 
eight different restriction enzyme digests and the three described TcR-o probes. 
Patients 2 3 4 5 6 7 8 9 10 11 12 
Jc51 gene segment G/Ga D/Ra R/R D/R R/R R/R D/R or R/Rc R/R R/R D/D D/D D/D 
Jc52 gene segment G/G D/G Rj?b R/G G/G G/G G/G G/G G/G D/D D/D D/D 
Jc53 gene segment G/G D/G G/G G/G G/G G/G G/G G/G G/G D/D D/D D/D 
Cogene segment G/G D/G G/G G/G G/G G/G G/G G/G G/G D/D D/D D/D 
V52 gene segment G/G D/R R/G G/G R/G G/G G/G G/G R/G D/D D/D D/D 
Combined results G/G D/R R/R R/R R/R R/R R/R R/R R/R D/D D/D D/D 
a. G, allele in germline configuration; R, rearranged allele; 0, deletion of the involved gene (segment). 
b. In some digests of the DNA from patient 3 hybridization of the Southern blot filters with the J82 probe showed two rearranged bands, while 
in other digests only one rearranged band was seen (c.f. Figure 28). 
c. In the T-ALL cells from patient 7 most probably the two rearranged TcR-8 gene alleles are rearranged identically as 
detected by the various TcR-8 probes. 
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In four T-ALL, including the TcR-ro+ T-ALL of patient 9, one of the TcR-o gene alleles 
appeared to be rearranged to the V02 gene segment, which is located within S kb at the S' side 
of the Co region (S1). Rearrangements to the Vo2 gene segment could be detected in Bg/11, 
BamHI and most Kpnl digests using the Co probe (Figure 2C). In case of rearrangements 
detected in Kpnl and BamHI digests, possible rearrangements to the Jo2 andjor JoS gene 
segments were studied by use of a BamHI/Sacl double digest and the Co probe and by use 
of a KpnljBamHI double digest and the Jo2 probe. Our Southern blot analyses indicate that 
rearrangements to the Vo2 gene segment can be detected in Bg/11 digests using the Co probe 
(Figure 2C). 
Transcription of the CD3 and TcR genes 
COS-o transcripts were present in all 12 T-ALL, supporting their T cell origin (42,4S,56). 
TcR-a transcripts were detected in the three TcR-a.B+ T-ALL A weak 1.7-kb TcR-a band was 
also found in one cos- T-ALL (patient 2), which may be due to the S% contaminating normal 
T cells in the sample (Table 1). However, it most probably concerns a transcripts of the 
leukemic cells, since in this T-ALL one TcR-o gene allele appeared to be rearranged, while the 
other was probably deleted, suggesting that a TcR-a gene rearrangement had occurred (Table 
2; Figure 2). 
Mature 1.S-kb TcR-.8 transcripts were detected in the three TcR-a,B+ T-ALL, in the COS-
T-ALL except for the prothymocytic T-ALL, and in one out of four TcR-ro + T-ALL Immature 1.0-
kb TcR-.8 transcripts, which are probably derived from genes with 0-J joining, were found in 
one TcR-a,B+ T-ALL, in three out of four TcR-ro+ T-ALL and in two COS- T-ALL Immature 1.1-
kb TcR-.8 transcripts, which may be derived from germline TcR-.8 genes (42,4S), were found 
in the prothymocytic T-ALL, in one other cos- T-ALL and in one TcR-ro+ T-ALL 
The TcR-r gene was expressed in all four TcR-ro+ T-ALL, in three out of five COS- T-ALL, 
and at a low level in one out of three TcR-a.B+ T-ALL One cos- T-ALL, in which extensive r 
gene rearrangement had occurred, did not express mature r mRNA (patient 5). 
Four different types of TcR-o gene transcripts have been described (FigureS). The 1.9- and 
1.2-kb transcripts do not contain V-region sequences and thus are probably derived from 
incomplete rearranged TcR-o genes, while the 2.2- and 1.5-kb transcripts do contain V regions 
(22,2S). The occurrence of two types of mature and immature o transcripts is probably caused 
by variability in the site of polyadenylation (22,2S). TcR-o mRNA of 2.2 and 1.5 kb was present 
in all four TcR-ro+ T-ALL, while no TcR-o transcripts were detected in the TcR-a.B+ T-ALL 
(FigureS). In all cos- T-ALL except of the prothymocytic leukemia only immature 1.9- and 1.2-
kb transcripts were found (FigureS), indicating that the transcribed TcR-o genes in these T-ALL 
are rearranged incompletely (patient 2, S, 4 and 5). Interestingly, in one of the TcR-ro + samples 
(patient 8) also both types of immature transcripts were detected in addition to the mature 
TcR-o transcripts, which denotes that one of the TcR-o gene alleles is rearranged incompletely 
(FigureS). 
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Figure 2. Southern blot analysis of the TcR-6 genes. DNA samples from the T-ALL and from a B cell leukemia as a control were digested with Bg/11 (A and C), 
Hindlll (B), KpnljBamHI (B) or Kpnl (C). The restriction fragments were size fractionated on agarose gels and transferred to nylon filters. The filters were hybridized 
with the 32P-Iabeled J61 probe (A), J62 probe (B), or C6 probe (C). The sizes (in kb) of the germline bands (G) and the majority of rearranged bands are indicated. ffi 
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Figure 3. TeR-eS gene transcripts. A: Northern blot analysis for the detection of TeR-eS gene transcripts. Total RNA 
from the :twelve T-ALL cell samples was size fractionated in agarose gels and blotted to nylon filters. The filters were 
hybridized to the 32P-Iabeled CcS eDNA probe. The sizes of the mature TeR-eS transcripts {2.2 kb and 1.5 kb) and 
the immature transcripts (1.9 kb and 1.2 kb) are indicated. The RNA from patient 8 was used in both Northern blots 
to indicate the precise position of the four types of transcripts. B: Schematic diagram of the four different types 
of TeR-eS transcripts. The mature 2.2-kb and 1.5-kb transcripts contain V regions {shaded area), which are lacking 
in the immature 1.9-kb and 1.2-kb transcripts {22,23). The occurrence of two types of mature and immature cS 
transcripts (1'700 base pairs difference; dotted area) is probably caused by variability in the site of polyadenylation 
in the 3' untranslated {3'UT) sequences {22,23). 
DISCUSSION 
We have analyzed 12 T-ALL samples for TcR gene rearrangement and expression, of which 
four expressed TcR--ycS at the cell surface and three TcR-a,B. The other five T-ALL did not 
express a TcR-CD3 complex. It should be mentioned that this series is not representative of all 
T-ALL, but has been selected in part for CD3 + jTcR-a,a- T-ALL. The real frequency of TcR--ycS + 
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T-ALL is probably much lower, which is in line with the low frequency afTeR--yo+ cells in normal 
PB and thymus (11,12). 
In the four TcR--yo+ T-ALL, both TcR-o gene alleles appeared to be rearranged. They all 
contained mature 2.2- and 1.5-kb TcR-o transcripts as well as TcR--y transcripts, but lacked 
TcR-a gene transcripts. One TcR--yo+ T-ALL contained immature 1.9- and 1.2-kb transcripts, 
indicating that the rearrangement of one TcR-o gene allele was incomplete, while the other was 
rearranged functionally. 
TcR-o gene rearrangements were not only found in the TcR--yo+ T-ALL, but also in four out 
of five CD3- T-ALL. The majority of the rearranged TcR-o genes appeared to be rearranged 
to the Jo1 gene segment. In two CD3- T-ALL a rearrangement to the Jo2 gene segment was 
found, while rearrangements to the Jo3 gene segment were not detected in this series of T-ALL. 
Rearrangements to the V 52 gene, which is located at the 3' side of the Co gene, were found 
on one allele in a TcR--yo+ T-ALL as well as in three CD3- T-ALL. Also, in adult murine 
thymocytes, rearrangement to the Vo gene at the 3' side of the Co region often occurs (57). 
These combined data suggest that the combinatorial diversity of the TcR-o genes is limited, 
which is illustrated by the restricted number of differently rearranged bands in Figure 2. This is 
in line with the fact that only six Vo, three Do, and three Jo gene segments have been reported 
so far (25,29,31 ,58,59). Such a limited combinatorial diversity has also been described for the 
TcR-r genes (21 ,60,61). On the other hand, an extensive junctional diversity has been found 
in both TcR--y and TcR-o genes (15,31 ,32,62,63), resulting in an enormous diversity afTeR--yo 
receptors (32). 
High levels of TcR-a mRNA were only found in the three TcR-a,B+ T-ALL. In these T-ALL, 
the TcR-o genes had been deleted, probably due to TcR-a gene rearrangement (14, 16,25,26). 
Consequently, they did not contain any TcR-o gene transcripts. TcR-a and TcR-o proteins have 
certain structural homologies, while also ,B and 'Y proteins have certain common properties, 
which are considered important for TcR-chain pairing (14). Therefore, most likely a and o chains 
will not pair with each other, nor will ,8 and 'Y chains. The latter has indeed be shown in the cell 
line PEER, where ,8 and 'Y proteins are expressed simultaneously; in this cell line a o protein is 
present, which exclusively pairs with the 1 chain (64). Apparently ,8, 'Y and o gene rearrange-
ment and expression can and do overlap without leading to aberrant TcR protein expression. 
There obviously exists an exclusion mechanism to avoid dual receptor expression. Deletion of 
TcR-o genes in TcR-a,B+ cells is in line with such an exclusion mechanism (14, 16,22,25,26). 
So far only limited data are available about the TcR-o genes in the postulated hierarchy of 
human TcR gene rearrangement. Recently two immature T-ALL with rearranged TcR-o genes, 
but germline ,B and 'Y genes have been reported, suggesting that TcR-o genes may rearrange 
early during T cell differentiation (65). This would be in line with the murine ontogenic data 
(14-16), which indicate that TcR--yo+ thymocytes develop first and that TcR-a,B+ thymocytes 
arise two days later (7,8,39). Several studies suggest that T cells which have non-functional 
TcR--y and/or TcR-o gene rearrangements can still rearrange their TcR-,8 and TcR-a genes and 
develop into TcR-a,B+ cells (7,52). The series ofT-ALL presented here fits within such a differen-
tiation model. However, this series does not add new information with respect to the hierarchy 
of TcR gene rearrangement, because four CD3- T-ALL had rearranged their TcR-,8, --y and -o 
genes, while these genes were in germline configuration in the fifth CD3- T-ALL. On the other 
hand, the CD3- leukemia of patient 2 is interesting, because this leukemia may represent a 
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transient cell between the TcR-ro lineage and the TcR-a.B lineage. The leukemic cells of this pa-
tient do not (yet) express a TcR-a.B on the membrane, but already contain mature TcR-.8 and 
low amounts otTeR-a transcripts, while also TcR--y and immature TeR-eS transcripts are present. 
This suggests that exclusion of dual receptor expression can not only be regulated by the 
presence of germline TcR-a genes in TcR-ro+ cells or deletion of both TeR-eS gene alleles in 
TcR-a.B+ cells, but that also other regulation mechanisms may be involved. Future studies have 
to elucidate whether prevention of co-expression of TcR-a.B and TcR-ro can also be regulated 
at the RNA or protein level. 
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ANALYSIS OF PATIENTS WITH DIGEORGE 
ANOMALY PROVIDES EVIDENCE FOR EXTRATHYMIC DEVELOPMENT 
OF TcR·yo+ LYMPHOCYTES IN MAN* 
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SUMMARY 
To investigate whether TcR--yo+ cells in man differentiate along a thymus-dependent 
pathway, we have analyzed the composition of T cells in peripheral blood of patients with 
DiGeorge Anomaly (DGA). DGA is an extremely rare, severe developmental field defect, that 
results in thymic hypoplasia or aplasia. The thymic defect is quantitative in that it solely involves 
a reduction of epithelial mass. The degree of T cell deficiency in DGA is related to the degree 
of thymus hypoplasia. In eight DGA patients, including one with a virtually complete absence 
ofT lymphocytes (complete DGA), absolute numbers TcR-a,B+ and TcR--yo+ cells in peripheral 
blood were determined. In some cases, a!so the repertoire ofTcR--yo+ cells and their CD4/CD8 
phenotype was analyzed with specific antibodies. Control values were collected by analyzing 
blood samples from a large number of healthy children in different age groups. Thymic 
hypoplasia or aplasia did not greatly affect the absolute numbers of TcR--yo + cells, nor their 
repertoire and CD4/CD8 phenotype. In contrast, the development ofTcR-a,B+ cells was affected 
to a variable but significant degree, which in the complete DGA patient resulted in a complete 
inversion of the TcR-a,B jTcR--yo ratio (85% of the few remaining T cells expressed TcR--yo). Also, 
thymic involution during maturation from infancy to adolescence coincided with a decrease in 
the absolute numbers of TcR-a.B+ cells, but not TcR--yo+ cells, supporting the relationship 
between thymic cortical mass and the numbers of TcR-a,B+ cells in blood. We conclude that 
TcR--yo+ cells in man can more effectively develop along an extrathymic differentiation pathway 
* Manuscript submitted. 
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than TcR-a,B+ cells and propose that human TcR--yo+ cells are subject to expansion and 
selection mechanisms in peripheral compartments. 
INTRODUCTION 
It has been accepted that mature TcR-a.B+ and TcR--yo+ lymphocytes constitute distinct 
functional subsets, buttheir exact lineage interrelationship remains to be elucidated. It is unclear 
to what extent TcR--yo + cells develop along the same thymus dependent differentiation pathway 
as TcR-a,B+ cells and whether they undergo repertoire selection during this process. Evidence 
for extrathymic development of TcR--yo+ cells originally came from the observation that TcR--y 
and TcR-o messenger RNA was expressed in peripheral lymphoid organs of athymic (nude) 
mice (1,2). Recent studies in normal mice indicate that the TcR--ys+ cells present in murine 
epidermis originate from an early wave of fetal TcR--yo+ thymocytes at around day 15 of 
embryonic life, while the TcR--yo+ cells found in epithelia of the reproductive organs have 
emerged from the thymus just around the time of birth (3-9). These murine TcR--yo+ fetal 
thymocytes and their descendants in skin and reproductive organs have a homogeneous 
combinatorial repertoire of V5J1 C-y1 /V1 D2J2Co and V6J1 C-y1 /V1 D2J2Co gene segments, 
respectively (4-9). They have junctional regions with negligible nucleotide (N) insertion (5,6,9), 
which is in line with the absence in fetal thymocytes of the nuclear enzyme terminal 
deoxynucleotidyl transferase (TdT), that is thought to be responsible for N region insertion 
(10, 11). These two thymus-dependent epithelial TcR--yo+ cell subsets with monomorphic 
receptors are indeed absent in nude mice (6, 12), while such mice do contain TcR--yo+ cells in 
spleen (1,2,13), lymph nodes (14) and the intestinal epithelium (6). Apparently, the various 
TcR--yo+ cell populations in mice have different environmental requirements for development. 
To study the thymus dependency of TcR--yo+ lymphocyte development in man, we have 
enumerated TcR-a,B+ and TcR--yo+ T cells in peripheral blood (PB) samples from eight infants 
with DiGeorge anomaly (DGA). DGA is characterized by facial, cardiac, parathyroid and thymic 
defects, due to malformations or disruptions of the third and fourth pharyngeal arches and 
pouches from which these organs develop (15-18). Furthermore, DGA is associated with 
chromosomal aberrations, particularly monosomy of chromosome 22 or deletion of 
chromosome band 22q11 (19). 
The degree of thymus hypoplasia in DGA is variable; this defect involves thymic epithelial 
mass and is not a dysplastic process, i.e. it is a quantitative rather than a qualitative defect 
(16, 18). It is generally assumed that the variable degree ofT cell immunodeficiency in DGA is 
directly related to the degree of thymus hypoplasia or aplasia (16, 18). DGA is an extremely rare 
and severe disorder. Complete DGA, characterized by total thymic aplasia and virtually 
complete absence of T cells, has according to a rough estimation an incidence of one in 106-
107 newborns (16). One patient with complete DGA and seven patients with variable degrees 
of DGA have been included in our study. 
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TABLE 1. Characteristics of eight DGA patients. 
Patients K.H. Y.G. C.S. B.D. v.c. M.V. T.S. A.L. 
Age 3 mo 6 mo 1 mo 2 mo 2 mo 1 mo 7 mo 2 mo 
DGA defects 
- facial dysmorphies + ± + + + + + + 
-cardiovascular abnormalities + + + + + + + + 
- hypocalcemia + ± ± + + + + + 
- absence of thymic shadow + + + + + + + + 
Cytogenetics 
- deletion of band 22q11 + NT + NT NT + NT + 
Lymphocyte proliferation 
- PHA, ConA and CD3 (OKT3) normal normal normal .j. .j. absent 
MATERIALS AND METHODS 
DGA patients 
PB samples of a total of eight DGA patients were collected at six different hospitals in Germany and The 
Netherlands, according to guidelines of the local Medical Ethics Committees. The DGA diagnosis of these patients 
was based on the presence of typical facial dysmorphies, cardio-vascular abnormalities, hypoparathyroidism with 
hypocalcemia, andjor the absence of a thymic shadow on thorax X-rays (16-18). At least three of these criteria 
had to be met for diagnosing DGA (Table 1). In addition, cytogenetic analysis of R-banded chromosome spreads 
from cultured PB cells was performed for four patients to evaluate the presence of constitutional aberrations of 
chromosome 22 (19). All four patients tested had a micro-deletion of band 22q11, supporting the DGA diagnosis. 
With respect to T cell immunodeficiency, the eight patients represented the broad spectrum from partial to 
complete DGA. As a hallmark of T cell immunodeficiency, the T cell proliferative response to mitogenic stimuli 
was measured. For this purpose, mononuclear cells (MNC) were incubated with phytohaemagglutinin (PHA), 
concanavalin A (Con A) and the CD3 antibody OKT3 (Table 1). 
Healthy controls 
To obtain normal values, PB samples were collected from ninety-two healthy children in different age-groups 
according to the guidelines of the Medical Ethics Committee of the Erasmus University /University Hospital Dijkzigt, 
Rotterdam. Upon routine physical examination no DGA defects were found. Serum calcium measurements and 
thorax X-rays were performed in only a minority of the children and found to be normal. 
Monoclonal antibodies (McAb) 
WT31 (20; Becton Dickinson, San Jose, CA) or BMA031 (21; Dr. R. Kurrle, Behringwerke AG, Marburg, FRG) 
were used to detect TcR-a,B, anti-TCR--yo-1 (hybridoma 11 F2, ref. 22, Dr. J. Borst, Amsterdam, The Netherlands) 
or TCRo1 (23; T Cell Sciences, Cambridge, MA) to detect TcR--yo and VIT-3 (Dr. W. Knapp, Vienna, Austria), Leu-
4 (Becton Dickinson) or OKT3 (Ortho Diagnostic Systems, Raritan, NJ) to detect the CD3 antigen. The TcR--yo 
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repertoire was analyzed with V')'9-specific McAb Ti-')'A (24; Dr. T. Hercend, Villejuif, France), Vo2-specific McAb BB3 
(25; Dr. L Maretta, Genova, Italy) and Vo1-Jo1 specific McAb oTCS1 (26; T Cell Sciences). B cells were defined 
with CD20 McAb B1 (Coulter Clone, Hialeah, FL), monocytes with CD14 McAb My4 (Coulter Clone). The CD4+ or 
cos+ phenotype of TcR--yo cells was determined with Leu-3 and Leu-2 McAb respectively (Becton Dickinson). 
Immunofluorescence (IF) procedures 
MNC were isolated from PB by ficoll density centrifugation (density 1.077 gjml). The composition of MNC 
from PB samples (Table 2) was determined by indirect IF staining, using unlabeled first McAb, followed by FITC-
conjugated goat anti-mouse lg (Nordic Immunological Laboratories, Tilburg, The Netherlands) as second step 
reagent Staining was evaluated by flowcytometry with a FACScan (Becton Dickinson). 
For double IF stainings presented in Figures 1 and 2, MNC were first incubated with one of the anti-TcR McAb 
(all of the murine lgG class) and with VIT-3 (lgM class), followed by incubation with FITC-conjugated goat anti-
mouse lgG and TRITC-conjugated goat anti-mouse lgM (Nordic) to detect the reactivity of the anti-TcR and the 
CD3 McAb, respectively. After labeling, cytocentrifuge preparations were made (Cytofuge, Nordic) and analyzed 
with a fluorescence microscope (Zeiss, Oberkochen, FRG) (27) (Figure 1). In each double IF staining, at least 500 
CD3+ cells were evaluated for TcR-a.B or TcR-')'o expression. In all MNC samples of Figure 2, the expression of 
TcR-a,B was determined with WT31 as well as BMA031 McAb, while the expression ofTcR-')'o was determined with 
anti-TCR-')'o-1 as well as TCRo1 McAb. In both cases, the numbers obtained with each McAb were virtually identical 
( <2% discrepancy). 
For double IF stainings presented in Table 2, MNC were first incubated with Ti-')'A, oTCS1, BB3, Leu-3 or Leu-
2 McAb, followed by TRITC-conjugated goat anti-mouse lg (Nordic Immunological Laboratories). Subsequently, 
free antigen binding sites of the second step reagent were blocked by incubation with normal mouse serum 
(dilution 1 :100), followed by biotinylated anti-TCR-')'o-1 and FITC-conjugated streptavidin (Boehringer Mannheim, 
Mannheim, FRG). Cytocentrifuge preparations were made and evaluated by fluorescence microscopy as outlined 
in Chapter 2.3. If available, at least 200 TcR--yo+ cells were evaluated for reactivity with Ti-')'A, oTCS1, BB3, Leu-
3 or Leu-2. 
RESULTS 
PB samples from eight DGA patients were collected over a period of two years and 
analyzed in this study in order to investigate the thymus dependency of TcR--yo+ cell 
differentiation in man. The patients varied in age from one to seven months. Their characteris-
tics, with respect to the various clinical manifestations of the disease, are given in Table 1. 
Patient A.L. was diagnosed as having complete DGA. 
It was determined to what extent the T lymphocyte population was decreased in the various 
DGA patients. T cells, B cells and monocytes were enumerated by IF staining, using CD3, 
CD20 and CD14 McAb, respectively (fable 2). We are aware that the cumulative percentages 
of B cells, T cells and monocytes do not add up to 100%. This is due to the presence of 
variable percentages of NK cells and immature granulocytes (rods), which can accumulate in 
PB of patients with recurrent infections. The absolute numbers of TcR-a.B+ and TcR--yo+ cells 
were determined in order to investigate the effect of the thymic defect on both T cell lineages. 
MNC were analyzed by double IF stainings with CD3 and anti-TcR McAb, in order to measure 
directly the relative distribution of TcR-a.B+ and TcR--yo+ cells within the CD3+ lymphocyte 
population. Stained cells were analyzed by fluorescence microscopy, rather than flowcytometry, 
because of its high accuracy, needed when very small cell populations ( < 1% of MNC) are 
studied. To obtain control values, the same analysis was performed on MNC from a large num-
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TABLE 2. Composition of MNC population in DGA patients and healthy age-matched controls. 
DGA patients Healthy children 
K.H. Y.G. c.s. B.D. v.c. M.V. T.S. A.L. (n=17) 
Age 3 mo 6mo 1 mo 2 mo 2 mo 1 mo 7 mo 2 mo 0-6 mo 
Total T cells(CD3+) 
%of MNC 44 36 42 22 24 25 8.0 1.1 59± 11b 
#X 109 /Ia 2.5 2.5 1.9 1.4 1.0 0.8 0.14 0.03 3.9 ± 1.4 
TcR-a.B+ cells 
%of MNC 41 36 39 20 22 25 7.0 0.04 55± 10 
#X 109/i 2.4 2.4 1.7 1.3 0.96 0.8 0.12 0.002 3.6 ± 1.3 
TcR--yo+ cells 
%of MNC 2.2 1.8 2.5 1.3 1.1 1.0 1.1 0.9 2.6 ± 1.5 
#X 109/1 0.12 0.10 0.11 0.08 0.05 0.02 0.02 0.03 0.16 ± 0.09 
B cells(CD20+) 
%of MNC 24 18 10 12 23 8 31 44 15 ± 8 
#X 109/i 1.4 1.3 0.5 0.8 1.0 0.3 0.6 1.3 1.0 ± 6 
Monocytes(CD14+) 
%of MNC 14 24 24 11 22 21 37 38 15 ± 9 
#X 109/i 0.8 1.7 1.1 0.7 1.0 0.7 0.7 1.1 1.0 ± 0.6 
a. Absolute numbers x 109 per liter blood. 
b. Mean ± standard deviation. 
ber of healthy children (n =92) in five different age groups, including seventeen children in the 
age group of 0-6 months, which represents the age-matched control group for the DGA 
patients. 
Table 2 illustrates that the absolute number ofT cells is normal or reduced to some degree 
in six DGA patients (K.H.-M.V.). In case of reduction, the absolute number of TcR-a.B+ cells is 
reduced relatively more than the absolute number of TcR--yo+ cells. But these differences are 
limited in patients K.H.-M.V. However, in patient T.S. and particularly in the complete DGA 
patient A.L., the absolute number of T cells has dropped dramatically. TcR--yo+ cells are 
affected in numbers to a factor of about three or four below normal age matched control 
values, but strikingly, TcR-a.B+ cells are affected to a factor of about 20 in patient T.S. and even 
a factor 1000 in patient A.L. 
A graphic representation of these data is given in Figure 2. Figure 2A shows the absolute 
numbers of total T cells, subdivided in TcR-a.B+ and TcR--yo+ populations for all DGA patients, 
and in addition, for healthy children of the five different age groups from 0-16 years old. As 
indicated in Table 2, the reference for DGA patients is the age group of 0-6 months. Figure 28 
gives the relative contribution of TcR-a.B+ and TcR--yo+ cells to the total cos+ population for 
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Figure 1. Analysis of MNC from PB of a healthy individual for coexpression of CD3 and TcR-')'o by fluorescence 
microscopy. A: Phase contrast morphology; B: CD3+ cells stained with VIT-3 and a TRITC-conjugated second step 
reagent; C: TcR-')'o+ cells stained with anti-TCR-')'o-1 and a FITC conjugated second step reagent. All three 
photographs represent the same microscopic field: three CD3+ cells are also positive for TcR-')'o. Methods are 
outlined in the Materials and Methods section. 
the DGA patients and the same groups of healthy children, as determined by double IF 
stainings with CD3 and anti-TcR McAb. This graph clearly illustrates how in the six patients 
K.H.-M.V., the percentage of TcR-')'o+ cells is normal or only slightly higher than in controls, 
while in patient T.S. and particularly in patient A.L the severe reduction in absolute numbers 
ofTcR-a,B+ cells relative to TcR-')'o+ cells has resulted in a significant increase in the percentage 
of TcR-')'o+ cells. In patient A.L., 85% of the few remaining CD3+ cells express TcR-')'o, while 
only 5% of the CD3+ cells reacted with anti-TcR-a,B McAb. 
It is remarkable that in healthy children the absolute numbers ofT cells gradually decrease 
from about 4 x 109 jl in early infancy to approximately 1.5 x 109 jl in adolescence (Figure 2A). 
This decrease only concerns TcR-a,B+ cells, since the absolute numbers of TcR-')'o+ cells 
remain stable (Figure 2A). This is also reflected in the increase of the percentage TcR-')'o + cells 
within the CD3+ population with age (Figure 28). 
Since no data are available on thymic repertoire selection of TcR-')'o+ cells in man, it was 
of interest to analyze the DGA patients in this respect. Three McAb are available, Ti-')'A, OTCS1 
and BB3, that detect epitopes encoded by V')'9, Vo1-Jo1 and Vo2 gene segments, respectively 
(24-26,28) and are therefore useful to analyze the TcR-')'o+ cell repertoire. It has previously 
been established that the combinatorial repertoire of TcR-')'o+ in PB of healthy adults is very 
limited, with the V1'9/Vo2 combination being expressed on >60% ofTcR-')'o+ cells in most indi-
viduals (24,28). The TcR-')'o+ cell populations in PB often healthy children, two incomplete DGA 
patients and the one patient with complete DGA were analyzed (Table 3). Despite some indi-
vidual variability, the relative distribution of V1 and Vo gene segment usage did not differ greatly 
between these samples. The majority ofTcR-')'o+ cells were positive for V')'9 (Ti-')'A) andjor Vo2 
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Figure 2. Expression of TcR-a,B and TcR-"(o by CD3+ lymphocytes in PB of DGA patients and healthy children of 
three different age-groups. A: Absolute numbers ofT cR-ap+ and TcR-"(o + T cells. 8: Relative distribution ofTcR-a,B 
and TcR-yo expression within the population of CD3+ T cells. Double IF was performed as indicated in the 
Materials and Methods section. In patient T.S. only single IF stainings were used; the percentages per CD3+ cells 
in this patient were calculated from the single IF stainings. For healthy children the mean± the standard deviation 
(vertical lines within the bars) is indicated. 
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(BB3), while a small proportion expressed Vo1-Jo1 (OTCS1). This was found in all patients, 
including complete DGA patient A.L., as well as in healthy controls. 
Since one could imagine that TcR--yo+ cells, like TcR-ap+ cells, would pass through a 
CD4 +/CDS+ double positive stage during thymic differentiation in order to acquire the single 
positive CD4 + or CDS+ phenotype (29), the expression of these accessory molecules was 
determined in selected patient materials and in healthy controls (Table 3). Although the majority 
afTeR--yo+ cells was found to have the CD4-/CDS- phenotype (in contrast to TcR-ap+ cells), 
a low, but detectable percentage of TcR--yo+ cells in healthy persons expressed CD4, while a 
significant proportion was CDS+, with great variation between individuals (see also refs. 22 and 
2S). It can be seen in Table 3, that in DGA patients the percentages of CD4 + and cos+ 
TcR--yo + cells did not differ significantly from those in healthy individuals. Strikingly, also in the 
complete DGA patient A.L. 13% afTeR--yo+ cells expressed CDS. Apparently, acquisition of this 
phenotype is not exclusively thymus dependent. 
DISCUSSION 
Our combined data indicate that in DGA patients, despite hypoplasia or aplasia of the 
thymus, the absolute numbers of TcR--yo+ cells as well as their combinatorial repertoire and 
CD4/CDS phenotype are virtually comparable to those in age-matched healthy children. In 
contrast, there is a severe effect on TcR-ap+ cell numbers. It is generally assumed that the 
thymic defect in DGA is a quantitative reduction in thymic epithelial mass (16, 1S). Therefore, we 
conclude that TcR-ap+ cell development in man is severely hampered by the decreased 
availability of thymic epithelial environment, while TcR--yo+ cell development is much less 
affected. This suggests that TcR--yo + cells can differentiate along an extrathymic pathway. 
These findings in man are comparable to those documented for the athymic (nude) mouse 
(1 ,2). Interestingly, we found that in healthy children the absolute number of TcR-ap+ cells 
gradually decreases approximately three-fold during maturation from infancy to adolescence, 
while the absolute number of TcR--yo + cells remains stable during this period. Simultaneously 
a prominent involution of the thymic cortex occurs (30). This coincidence of thymic involution 
and selective decrease of TcR-ap + cells is in line with the relationship between thymic mass and 
absolute numbers of TcR-ap+ cells as found in DGA patients. 
So far it is unclear to what extent the human thymus contributes to the maturation of 
TcR--yo+ cells. Unlike the situation in the mouse, TcR--yo+ cells in man do not predominate in 
the fetal thymus at any time-point (31). There seems to be no equivalent in man for the two 
thymus dependent TcR--yo+ cell populations found in epidermis and epithelia of reproductive 
organs of mice, since they are the far minority ofT cells at these sites (32-34). TcR--yo + cells 
are present in the human thymus (22), but as a very low percentage of CD3 + cells ( < 1%) 
(22,35) and occur in higher frequencies in the medulla than in the cortex (32,36). 
CD3-/CD4-/CDS- prothymocytes can gives rise to TcR--yo+ cells in vitro (37). However, 
because of obvious experimental constraints, no direct precursor -product relationships between 
prothymocytes and mature TcR--yo+ cells in PB have been determined in vivo. The here 
observed three to four fold reduction in absolute number of TcR--yo+ cells in DGA patients 
might suggest that the thymus does contribute to the development of TcR--yo+ cells, but less 
than for TcR-ap+ cells. 
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TABLE 3. TcR-ro repertoire and CD4/CD8 expression in PB of DGA patients and healthy children. 
Partial DGA patients 
B.D. v.c. 
Age 2 mo 2 mo 
vr 9(Ti-rA) + fTcR-ro+a 95 92 
vo1-Jo1 (oTCS1) + fTcR-ro+ 1 1 
Vo2(BB3) + fTcR-ro+ NT NT 
CD4(Leu-3)+ fTcR-ro+ 8 0 
CD8(Leu-2) + fT eR-r o + 45 13 
a. Percentage positivity within TcR·7S+ population. 
b. Mean ± standard deviation. 
c. Range. 
Complete DGA patient 
A.L. 
2 mo 
80 
79 
13 
Healthy children 
n=10 
2mo-2y 
72 ± 19b (32-91)c 
20 ± 14 (5-46) 
77 ± 18 (38-92) 
2 ± 1 (0-4) 
17 ± 5 (9-30) 
Our data derived from the complete DGA patient A.L. suggest that TcR-ro+ cells can 
expand extra-thymically into a population that is only three to four fold smaller in absolute 
numbers than in age-matched healthy children, while the TcR-a,B+ cell population remains 1000-
fold smaller than in healthy children. Also, as in many healthy individuals, the peripheral 
repertoire of the complete DGA patient A.L. is dominated by the Vr9+ /Vo2+ populations 
(24,28). Apparently, the combinatorial repertoire of human TcR-ro+ cells is regulated to a large 
extent by selection mechanisms in the periphery. We postulate that the Vr9+ jVo2+ subsets of 
TcR-ro+ cells is particularly prone to positive selection and expansion in the periphery. The 
activating and positively selecting element can either be a self MHC (-like?) molecule, or an 
ubiquitous antigen that would have to be categorized as a superantigen given its effect on such 
a large, but defined subset of TcR-ro+ cells. 
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INTRODUCTION: IMMUNOPHENOTYPING OF LEUKEMIAS 
AND NON-HODGKIN LYMPHOMAS* 
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INTRODUCTION 
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32"1 
The different types of hematologic malignancies can be regarded as malignant counter-
parts of cells in the various stages of hematopoiesis ("1 ,2). Differentiation schemes such as 
presented in Figures "1 and 2 are based on data concerning normal hematopoiesis as well as 
on data concerning leukemias and non-Hodgkin lymphomas (NHL) ("1 ,2). The lymphoid differen-
tiation consists of B cell and T cell lineages, while the myeloid differentiation consists of 
monocytic, granulocytic, erythroid and thrombocytic lineages. 
The majority of the cells in the various differentiation stages and their malignant 
counterparts can be recognized morphologically. However, immunologic marker analysis allows 
a further characterization of these cells. Immunologic markers are (glyco)proteins, which are 
located on the cell surface or intracellularly. These proteins are called immunologic markers, 
because they can be detected by means of immunologic techniques, in which the protein is 
generally recognized by use of a specific antibody. 
We will discuss several immunologic markers, the recently developed nomenclature for 
antibodies against immunologic markers and the expression of immunologic markers during 
hematopoietic differentiation. Subsequently we will indicate the possibilities of immunologic 
marker analysis for diagnosis and management of leukemias and NHL. 
IMMUNOLOGIC MARKERS AND THE CD NOMENCLATURE 
For the detection of immunologic markers predominantly monoclonal antibodies (McAb) are 
used. During the last "10 years many laboratories have produced McAb against the various 
immunologic markers. To create order and clearness within the large pool of these antibodies, 
a special nomenclature has been developed during four Leucocyte Typing Conferences (Paris 
1982; Boston 1984; Oxford 1986; Vienna 1989). According to this internationally accepted no-
*Published in: Neth J Med 1988;33:298-314. Updated for CD codes and several new immunologic markers. The 
updated Appendix of this manuscript is included in Chapter 2.2. 
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menclature many McAb against immunologic markers have received their own code: the CD 
(= cluster of differentiation/cluster designation) code (3-6). For example, the McAb against T 
cell markers T4 and T8 have received the codes CD4 and CDS, respectively, while antibodies 
against the common acute lymphoblastic leukemia antigen (CALlA) are grouped into the CD1 0 
cluster. 
Behind the CD code one can place within parentheses the name of the McAb, which is 
used to detect the marker concerned. In this way, code CD10 can be extended to CD10(J5), 
CD10(BA-3) or CD10(VIL-A1), depending on the antibody used. Such a supplementation can 
be important for optimal comparison of data from different laboratories, since some McAb that 
recognize the same marker may slightly differ in their reaction pattern. 
Information about all clustered immunologic markers and several relevant non-clustered 
markers is summarized in the Appendix of Chapter 2.2. 
EXPRESSION OF IMMUNOLOGIC MARKERS DURING HEMATOPOIESIS 
The majority ofthe immunologic markers represent differentiation antigens. Their expression 
is generally not restricted to a single differentiation stage, but occurs in several differentiation 
stages, sometimes even in several differentiation lineages. However, a combination of markers 
can be specific for one particular differentiation stage. In Figures 1 and 2 we have tried to 
indicate for each differentiation stage the expression of the most relevant immunologic markers. 
These markers, their CD codes and their alternative names are summarized in Table 1. 
Lymphoid markers 
The enzyme terminal deoxynucleotidyl transferase (TdT) is expressed on the nuclear 
membrane of immature lymphoid cells, but is absent in more mature lymphoid differentiation 
stages (7). This expression pattern is related to the important role of TdT in the rearrangement 
of immunoglobulin (lg) and T cell receptor (TcR) genes during the early stages of lympho-
poiesis (8,9). 
The B cell markers CD19 and CD22 are expressed at the cell surface in virtually all stages 
of B cell differentiation (10-12). Other B cell markers (such as CD10, CD20, CD21, CD37, FMC? 
and B-ly-7) as well as the various forms of lg expression can be used for further character-
ization of cells during B cell differentiation (10, 11, 13). The pre-8 cell stage, for example, is char-
Figure 1. Hypothetical scheme of lymphoid differentiation. The expression of relevant immunologic markers is 
indicated for each differentiation stage; markers in parentheses are not always expressed. The bars represent the 
various types of leukemias and NHL and indicate where these malignancies can be located according to their 
maturation arrest: ALL, acute lymphoblastic leukemia; ATLL, adult T cell leukemia lymphoma; AUL, acute 
undifferentiated leukemia; CB, centroblastic lymphoma; CB-CC, centroblastic-centrocytic lymphoma; CC, 
centrocytic lymphoma; CLL, chronic lymphocytic leukemia; CTLL, cutaneous T cell leukemia lymphoma (mycosis 
fungoidesjSezary syndrome); HCL, hairy cell leukemia; HTLV, human T cell leukemia virus; NHL, non-Hodgkin 
lymphoma; PLL, prolymphocytic leukemia. 
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acterized by the expression of the CD10 antigen and the weak cytoplasmic expression of the 
p. lg heavy chain (weak Cyp.) (7, 14). 
The T cell markers CD2 and CD? are expressed at the cell surface in virtually all stages of 
T cell differentiation (15). Furthermore, cytoplasmic expression of the CD3 antigen (CyCD3) 
occurs during the early stages of T cell differentiation, while mature T cells express the CD3 
antigen at their cell surface in close association with the TcR (TcR-CD3 complex) (15). The 
expression of the various other T cell markers (such as CD1, CD4, CD5 and CDS) is indicated 
in Figure 1 (15, 16). 
NK cells are negative for CyCD3 and the TcR-CD3 complex, but they are positive for the 
pan-T cell marker CD? and generally also for the C02 antigen. In addition, they express the 
CD16 antigen (low affinity receptor for lgG; Fc-yRIII) and the CD56 antigen (neural cell adhesion 
molecule; NCAM) (17, 1S). A subpopulation of the NK cells expresses the CDS antigen and the 
CD57 antigen (human NK cell antigen; HNK-1) (17). It should be noted that expression of 
CD16, CD56 and CD57 molecules is not NK-cell-specific, but that these molecules can also be 
found on T lymphocytes, especially cos+ T lymphocytes (Figure 1). 
Myeloid markers 
Analogous to lymphoid differentiation, also during myeloid differentiation certain markers 
become expressed, while others disappear. 
Almost all cells of the granulocytic and monocytic differentiation lineages express the pan-
myeloid markers CD13 and CD33 as well as myeloperoxidase (MPO) (19,20). In addition, the 
monocytic cells express the CD14 antigen, while cells of the granulocytic lineage express the 
CD15 antigen. Most macrophages are positive for CD6S and RFD9, and mature granulocytes 
express CD16 (Fc-yRIII) and the CD67 antigen (5,6) 
The H antigen (backbone of ABO blood group proteins) and glycophorin A (GpA) can be 
used as markers for cells of the erythroid lineage (21). The CD41 /CD61 and CD42 molecules 
represent platelet glycoproteins, which can be used as markers for the megakaryocytic-platelet 
lineage (22-24). 
Non-lineage-restricted markers 
Some immunologic markers are expressed in several differentiation lineages, such as in 
case of HLA-DR and the complement receptor type 3 (CR3), i.e. the CD11 b antigen. Further-
more, precursor cells of the lymphoid and myeloid lineages express the CD34 antigen (25). 
Several other non-lineage-restricted markers are given in Table 1 and Figures 1 and 2 (5,6). 
Figure 2. Hypothetical scheme of myeloid differentiation. The expression of relevant immunologic markers is 
indicated for each differentiation stage; markers in parentheses are not always expressed. The bars represent the 
various types of leukemias and NHL and indicate where these malignancies can be located according to their 
maturation arrest: AML, acute myeloid leukemia (the codes for the various types of AML are derived from the 
French-American-Britisch classification (26,27)): AUL, acute undifferentiated leukemia; CML, chronic myeloid 
leukemia; NHL, non-Hodgkin lymphoma. 
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TABLE 1. Immunologic markers (CD codes and alternative names) which can be used for immuno-
phenotyping of cells in the various stages of hematopoietic differentiation and their malignant 
counterparts. 
!~mature lymphoid marker 
TdT 
B cell markers 
CD10 
CD19 
CD20 
CD21 
CD22 
CD37 
FMC?* 
B-ly-7" 
weak CyJ.l. 
Smlg 
Cylg 
T cell markers 
CD1 
CD2 
CD3 
CyCD3 
CD4 
CD5 
CD? 
CDS 
TcR-CD3 
terminal deoxynucleotidyl trans-
ferase (expression on nuclear 
membrane) 
common ALL antigen (gp100) 
pan-B cell antigen (gp90) 
B cell antigen (p35) 
complement (C3d) receptor (CR2) 
(gp140) 
pan-B cell antigen (gp135) 
B cell antigen (gp40-52) 
B cell antigen (gp105) 
hairy cell marker (gp144) 
weak cytoplasmic expression of 
lg heavy chain J1. in pre-B cells 
surface membrane expression of 
lg (heavy and light chains) 
cytoplasmic expression of lg 
(heavy and light chains) 
T6 antigen (gp43, gp45, gp49) 
T11 antigen; leucocyte function 
antigen 2 (LFA-2) (gp50) 
T3 antigen (consists of at least 
five chains) (gp16-25) 
cytoplasmic expression of CD3 
protein chains 
T4 antigen (gp60) 
T1 antigen (gp67) 
Tp41 antigen (gp41) 
T8 antigen (gp32) 
expression of the T cell receptor-
CD3 complex on the cell surface 
NK cell markers 
CD56 neural cell adhesion molecule 
(NCAM) (gp220/135) 
CD57 human NK cell antigen (HNK-1) 
(gp110) 
* Non-clustered immunologic markers 
Pan-myeloid markers 
CD13 
CD33 
MPO 
pan-myeloid antigen (gp150) 
pan-myeloid antigen (gp67) 
myeloperoxidase (gp60/12) 
Myeloid-granulocytic markers 
CD15 X hapten 
CD67 granulocytic antigen (p1 00) 
Monocyte-macrophage markers 
CD14 
CD68 
RFD9" 
monocytic antigen (gp55) 
macrophage antigen (gp11 0) 
macrophage antigen (gp25) 
Erythroid markers 
H antigen 
GpA 
backbone of ABO blood group 
proteins 
glycophorin A (gp41) 
Megakaryocyte-platelet markers 
CD41 GPIIb-GPIIIa complex (Gianzmann 
antigen) (gp145/115) 
CD42 GPIX-GPib complex (Bernard-Soulier 
antigen) (gp143/22/20) 
CD61 GPIIIa (gp115); associated with 
Gpllb (see CD41) 
Non-lineage-restricted markers 
CD9 
CD11b 
CD11c 
CD16 
CD25 
CD34 
CD38 
HLA-DR 
p24 antigen 
complement (C3bi) receptor (CR3) 
adhesion molecule (p150,95) 
low affinity Fe receptor for lgG 
(FerRill) (gp50-65) 
interleukin-2 receptor (IL-2R) (gp55) 
precursor antigen (gp115) 
T1 0 antigen (gp45) 
MHC-class-11 antigen (gp29/34) 
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IMMUNOLOGIC PHENOTYPES OF LEUKEMIAS AND NHL 
Immunologic markers can not only be used for characterization of normal hematopoietic 
cells, but also for further characterization of their malignant counterparts, i.e. the various 
leukemias and NHL (1 ,2). 
The maturation arrest of the acute leukemias is located in the immature. differentiation 
stages, such as in case of the acute undifferentiated leukemias (AUL), acute lymphoblastic 
leukemias (ALL) and acute myeloid leukemias (AML) (26,27). In chronic leukemias the matur-
ation-arrest is located in more mature differentiation stages (chronic lymphocytic leukemia 
(CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HCL) and chronic myeloid leukemia 
(CML)) (1,28). NHL generally have a mature immunologic phenotype, such as in case of 
centroblastic (CB) lymphomas, centroblastic-centrocytic (CB-CC) lymphomas, centrocytic (CC) 
lymphomas, immunoblastic lymphomas and the true histiocytic lymphomas (29,30). Also the 
cutaneous T cell leukemia lymphoma (CTLL; mycosis fungoidesjSezary syndrome) and the 
adult T cell leukemia lymphoma (ATLL) have a mature immunologic phenotype (1,29-31). 
In Figures 1 and 2 we have tried to summarize where the various types of leukemias and NHL 
can be located according to their maturation-arrest. Their corresponding immunologic 
phenotypes can be read from these figures. It should be noticed that within a malignancy more 
than one differentiation stage can occur. This implies that not all cells of such a malignancy will 
express the same immunologic markers. It also indicates that malignant cells still have some 
capacity to mature and that a maturation arrest may involve more than one differentiation stage. 
Furthermore, loss of immunologic markers may occur in malignancies. These phenomena may 
explain discordances between immunologic and morphological classifications, which especially 
occur in AML and NHL (30,32). 
DIAGNOSTIC APPLICATIONS OF IMMUNOLOGIC MARKER ANALYSIS 
lmmunophenotyping of leukemias and NHL in addition to routine cytomorphology is 
important for a detailed and reproducible classification of these malignancies (1 ,2). In 15 to 30% 
of cases this will lead to a more appropriate or more accurate diagnosis than by use of 
cytomorphology alone. It is also important to search for correlations between morphological 
features, immunologic phenotypes and chromosomal aberrations, since this may give more 
insight into oncogenesis (33). Furthermore, this combined approach may allow the recognition 
of subgroups of leukemias and NHL, which differ in clinical behavior and response to therapy 
(34). Therefore, it is worthwhile to classify leukemias and NHL on the basis of morphological, 
immunologic and cytogenetic (MIG) criteria in order to adapt treatment protocols in the future 
(35). Immunologic marker analysis can also be used for the detection of two hematopoietic 
malignancies in one patient or for the detailed characterization of subpopulations within one 
malignancy (36). 
Finally, it should be remarked that immunologic markers can also be applicated for the 
detection of low numbers of malignant cells (37). During maintenance treatment and even after 
withdrawal of therapy it remains uncertain whether or not malignant cells are still present. The 
detection limit of conventional morphological techniques is not lower than 1 to 5% (1 to 5 malig-
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nant cells between 100 normal cells), since small numbers of malignant cells are difficult to 
discriminate from normal cells. Also the application of immunologic marker analysis for the 
detection of low numbers of malignant cells is hampered by the presence of normal counter-
parts, which express the same markers. However, in specific cases it is possible to detect 
minimal disease, based on the assumption that the presence of positive cells outside their 
normal homing areas is indicative of malignancy (37). In this way TdT can be used as marker 
for the detection of ALL cells in cerebrospinal fluid. This allows the early detection (or exclusion) 
of central nervous system leukemia, which is a severe complication in ALL (38). 
Another example is the detection of extremely low numbers of malignant cells in the bone 
marrow and blood of patients with a TdT positive T cell malignancy by use of a double labeling 
technique for a T cell marker and TdT. Due to its low detection limit (0.001-0.01%), this 
technique allows the recognition of a relapse 2 to 6 months earlier than by use of conventional 
cytomorphology (37). 
CONCLUSION 
Immunologic marker analysis of leukemias and NHL is an important supplementation in 
the diagnostics of these malignancies. It results in a precise and reproducible classification and 
also permits other applications, such as the detection of low numbers of malignant cells. These 
applications allow adjustment of diagnostic criteria as well as individualization of therapy, which 
is valuable for the prevention of undertreatment and overtreatment of patients. 
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SUMMARY 
The expression of cytoplasmic CD3 (CyCD3) was analyzed in 45 leukemias, five thymus cell 
samples, five peripheral blood (PB) samples, and ten cell lines. All T cell acute lymphoblastic 
leukemias (T-ALL) that did not express surface membrane CD3 (SmCD3) appeared to express 
CyCD3. Furthermore, the majority ofSmCD3+ T-ALL also expressed CyCD3. Analogous results 
were obtained with thymus cell samples in that about 95% of the thymocytes expressed CyCD3 
whereas 60 to 75% of the thymocytes also expressed SmCD3. In normal peripheral blood only 
prominent SmCD3 expression was found. These data indicate that immature T cells express 
CyCD3 only, that the combined expression of CyCD3 and SmCD3 is characteristic for 
intermediate differentiation stages and that mature T cells express prominent SmCD3. All 
(precursor) B cell leukemias, acute myeloid leukemias, and non-T cell lines tested did not 
express CyCD3. On the basis of these data, we conclude that CyCD3 expression is restricted 
to the T cell lineage and can be used as a diagnostic marker for immature SmCD3- T cell 
malignancies. Therefore, we evaluated which fixative is optimal for CyCD3 staining, and we 
determined by immunofluorescence staining and Western blotting which CD3 monoclonal 
antibody (McAb) can be used for the detection of CyCD3. In our opinion, acid ethanol was the 
best fixative for the cytocentrifuge preparations. Furthermore, we demonstrated that CyCD3 can 
be easily detected by use of McAb raised against denaturated CD3 chains such as those of 
the SP series (SP-6, SP-10, SP-64 and SP-78). In addition we tested 22 CD3 McAb of the 
Oxford CD3 panel that were raised against native SmCD3, and it appeared that only four 
(UCHT1, VIT-3b, G19-41 and SK7 /Leu-4) of them were able to detect CyCD3. In Western blot 
analysis all four McAb recognized the CD3-E chain only. 
*Published in: Blood 1988;71:603-12. 
332 CHAPTER5.2 
INTRODUCTION 
T cell differentiation and T cell ontogeny can be studied by analysis of thymus sub popula-
tions (1-4) or, alternatively, by analysis ofT cell leukemias because the latter can be regarded 
as the malignant counterparts of cells in the various T cell differentiation stages (5-8). Such 
studies revealed that the immunologic phenotype of T cells gradually changes during 
differentiation, finally resulting in mature T cells that express the CD3 antigen on their cell 
surface (1-10). 
The human CD3 antigen consists of at least three protein chains (CD3--y, CD3-o and CD3-<) 
(11-13), the encoding genes of which have been cloned recently (14-16). These CD3 chains 
are closely associated with the antigen-specific receptor ofT cells, the so-called T cell receptor 
(TcR) (13, 17, 18). To date, three different TcR chains have been described: TcR-o:, TcR-,8, and 
TcR--y (19). Like the immunoglobulin genes, the TcR genes rearrange during T cell differen-
tiation to enable receptor diversity (19). The majority of the mature T cells express a TcR that 
is composed of disulfide-linked TcR-o: and TcR-.8 chains (20,21). The TcR--y chain is expressed 
by a subpopulation of thymocytes and a small population of blood lymphocytes that can display 
non-major histocompatibility complex-restricted cytotoxicity (22-26). In the TcR-CD3 complex 
on the cell membrane of mature T cells the CD3 antigen probably plays a role in transduction 
of signals from the TcR to the cytoplasm (21 ,27,28). 
Link et al reported cytoplasmic expression of CD3 (CyCD3) by immature T cell leukemias 
as detected in frozen tissue sections and cytocentrifuge preparations, whereas no CD3 
expression could be detected on the cell surface of these immature T cells by immunofluores-
cence (IF) staining in suspensions (29). At that time they could not explain their findings; 
however, recent studies indicate that CD3 expression on the cell surface is dependent on the 
presence of the TcR (30-32) and that CD3 mRNA is already present in immature T cells (33,34). 
Therefore, CyCD3 can be expected in immature T cells that do not yet express the CD3 antigen 
on the cell surface membrane (SmCD3). Such CyCD3 expression has recently been reported 
by Furley et al (33) and Campana et al (35). 
In this study we evaluated the expression of CyCD3 during early T cell differentiation and 
proved its application as a diagnostic marker for immature T cell malignancies. Therefore, we 
determined by Western blotting and IF staining techniques which CD3 monoclonal antibodies 
(McAb) can be used for the detection of CyCD3. 
MATERIALS AND METHODS 
Cell samples 
Leukemic cell samples. 
Bone marrow (BM) and peripheral blood {PB) samples were obtained from 45 leukemia patients at diagnosis. 
These comprised 19 T cell acute lymphoblastic leukemias (f-ALL), one T cell chronic lymphocytic leukemia (f -CLL), 
12 precursor B-ALL (null ALL, common ALL or pre-B-ALL), seven B-CLL, and six acute myeloid leukemias (AML). 
Normal PB samples. 
Five PB samples were obtained from five healthy adult volunteers. 
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Thymus samples. 
Five thymus samples were obtained from five children ( < 2 y old) undergoing cardiac surgery. These samples 
were minced with scissors in RPMI1640 medium containing 1S% fetal calf serum (FCS) and were flushed through 
a nylon gauze filter with 100-JLm openings (Stokvis and Smits Textielmij, Haarlem, The Netherlands). 
All human cell samples were obtained with the approval of the Committee of Medical Ethics of the Academic 
Hospital, Rotterdam. 
Cell lines. 
For control experiments and for testing the various CD3 McAb, we used the T cell lines Molt4, H9, 81 02, 
CEM, and HSB; the precursor B cell lines BV173 and SMS-SB; and the Burkitt's lymphoma-derived cell line ROS-1, 
ROS-1S, and ROS-17. The cell lines were cultured in RPMI 1640 medium supplemented with 1S% FCS and 
antibiotics. 
Immunologic marker analysis 
Mononuclear cells (MNC) from BM and PB were isolated by Ficoii-Paque (density, 1.077 gjml; Pharmacia, 
Uppsala, Sweden) density centrifugation. All washings were performed in phosphate-buffered saline (PBS) 
containing O.S% bovine serum albumin (BSA), pH 7.8. 
Routine immunologic marker analysis. 
Routine immunologic marker analysis of the cell samples was performed by determining the nuclear membrane 
expression ofterminal deoxynucleotidyf transferase (TdT), surface membrane expression of lg (Smlg), and surface 
membrane expression of HLA-DR and various T cell markers, B cell markers, and myelomonocytic markers (8). 
Positivity for TdT was tested on cytocentrifuge preparations (Cytofuge, Nordic Immunological Laboratories, 
Til burg, The Netherlands) by using a rabbit anti-TdT antiserum and a fluorescein isothiocyanate (FITC)-conjugated, 
goat anti-rabbit lg, second-step antiserum (Supertechs, Bethesda, MD) (36). Expression of Smlg was tested by 
incubation of cells in suspension with FITC or tetramethylrhodamine isothiocyanate (TRITC)-conjugated goat 
antihuman lg antisera (anti-human " light chain, anti-human A light chain and anti-human JL heavy chain; Kallestad 
Laboratories, Austin, TX). Surface membrane expression of HLA-DR and the various T cell markers (CD1, CD2, 
CD3, CD4, CDS, CD7, CDS, and TcR-a,B), B cell markers (CD10, CD19, and CD20), and myelomonocytic markers 
(CD13, CD14, CD1S, and CD33) was tested by incubation of cells in suspension with the following McAb: L243 
(anti-HLA-DR, nonpolymorphicantigen), Leu-1 (CDS), Leu-2 (CDS), Leu-3 (CD4), Leu-4 (CD3), Leu-S (CD2), (Becton 
Dickinson, Sunnyvale, CA), 6611C7 (CD1; Dr. M. van de Rijn, Amsterdam), 3A1 (CD7; American Type Culture 
Collection, Rockville, MD), WT31 (recognizes a nonpolymorphic epitope on TcR-a,B; Dr. W. Tax, Nijmegen, The 
Netherlands), B1 (CD20), B4 (CD19), My4 (CD14), My7 (CD13), My9 (CD33) (Coulter Clone, Hialeah, FL), VIL-A1 
(CD10), and VIM-DS (CD1S), (Dr. W. Knapp, Vienna) (6,8,37). When McAb were used, an FITC-conjugated, goat 
anti-mouse lg antiserum (Central Laboratory of the Blood Transfusion Service (CLB), Amsterdam, The Netherlands) 
was used as a second-step reagent. 
Detection of CyCD3 protein chains. 
For the detection of CyCD3 protein chains, cytocentrifuge preparations were made, air-dried, fixed, and 
subsequently incubated with CD3-')', CD3-o, or CD3-E antibodies. Several fixatives for fixation of the cytocentrifuge 
preparations were tested: methanol, ethanol, acetone, acid ethanol (ethanol with S% (v jv) acetic acid), and formal 
acetone (acetone with 1% (vjv) formaldehyde). 
The following anti-CD3 protein chain antibodies were used: a rat CD3-')' polyclonal antiserum (16), the CD3-o 
McAb SP-64 and SP-78, and the CD3-E McAb SP-6 and SP-10 (38). A FITC-conjugated, goat anti-rat lg antiserum 
(Nordic) was used as a second-step reagent in the case of the rat antiserum and a FITC-conjugated, goat anti-
mouse lg antiserum in the case of the McAb. 
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Double IF staining for a surface membrane marker and an intracellular marker. 
Double IF stainings were performed for Smlg and CyCD3 as well as forT cell membrane markers and TdT. 
For SmlgjCyCD3 double IF stainings, the cells in suspension were incubated with a TRITC-conjugated, anti-human 
lg antiserum. Subsequently, cytocentrifuge preparation of these labeled cells were subjected to indirect IF staining 
with a CD3-o or CD3-€ McAb and a FITC-conjugated, goat anti-mouse lg antiserum as a second-step reagent. 
ForT cell markerjTdT double IF stainings, the cells in suspension were incubated with an anti-T cell marker McAb 
and an TRITC-conjugated, goat anti-mouse lg antiserum (CLB). Subsequently, cytocentrifuge preparations of these 
cells were subjected to indirect IF staining with the rabbit anti-TdT antiserum and the FITC-conjugated, goat anti-
rabbit antiserum. 
Microscopes. 
Zeiss (Carl Zeiss, Oberkochen, FRG) and Leitz (Ernst Leitz Wetzlar, Wetzlar, FRG) microscopes were used 
for the evaluation of the IF staining. The microscopes were equipped with HBO mercury lamps (Osram, Berlin, 
FRG), phase contrast facilities, and filter combinations for the selective visualization of FITC and TRITC. 
Western blotting 
lmmuno-affinity purified CD3 (0.1 nmol) from human tonsils (39) was loaded into a 10-cm well and 
electrophoresed in a 15% sodium dodecyl sulfate (SDS)-polyacrylamide gel (40). As was demonstrated previously, 
CD3-'Y, CD3-o, and CD3-€ chains can be separated from each other in SDS-polyacrylamide gel electrophoresis 
(41 ). The separated polypeptides were electrophoretically transferred at 4 o C to a nitrocellulose filter (Schleicher 
and Schuell, Dassel, FRG) at 300 V for two hours in a Tris-glycine-methanol buffer (16). The filter was blocked 
overnight at 4 o C with 2% (w jv) BSA, 5% (w jv) skim milk powder, 0.05% Tween 20, and 0.02% Na azide in PBS. 
Reactivity of the various CD3 McAb with the transferred CD3 polypeptides was studied by incubating strips of the 
nitrocellulose filter overnight at 4 o C with the McAb at a dilution of 1:50 in PBS containing 2% (w jv) BSA and 
0.02% Na azide. After washing three times in PBS and 0.05% Tween 20, the strips were incubated for 1.5 hours 
with a biotinylated rabbit anti-mouse lg antiserum (Vector Laboratories, Burlingame, CA) and washed as described 
earlier. The strips were finally incubated for one hour with horseradish peroxidase-conjugated avidin (Vector). After 
washing, bound antibody was visualized with diaminobenzidine (0.5 mgjml) and hydrogen peroxide (0.06%) in 10 
mmoljl Tris-HCI buffer, pH 7.4. 
CD3 McAb of the "Oxford CD3 panel" 
The CD3 McAb, which were tested for reactivity with CD3 protein chains in Western blotting and for reactivity 
with CyCD3 in IF staining techniques, were derived from the CD3 panel of the Third International Workshop and 
Conference on Human Leucocyte Differentiation Antigens (Oxford, UK, September 1986). McAb 471 through 492 
of the Oxford CD3 panel were tested: UCHT1 (471), X35-3 (472), XXIII.141 (473), XXIII.46 (474), XXIII.87 (475), 381 
(476), VIT-3 (477), VIT-3b (478), BMA031 (479), BMA032 (480), BW239/347 (481), BW264/56 (482), 12F6 (483), 
G19-4.1 (484), T3(2ADA) (485), T3/2T8-2F4 (486), T3jRW2-8C8 (487), TE/RW2-4B6 (488), CLB-T3/3 (489), CRIS-7 
(490), YTH12.5 (491) and SK7 /Leu-4 (492). 
RESULTS 
Detection of CyCD3 protein chains 
The McAb SP-6, SP-10, SP-64 and SP-78 (38) were used to determine which fixative should 
be used for the detection of CD3 protein chains in the cytoplasm of the T cell lines Molt4, H9, 
8102, CEM, and HSB. Fixation of the cytocentrifuge preparations with acid ethanol (ethanol with 
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Figure 1. Double IF staining for Smlg and CyCD3 (SP-64) on a mixture of the Burkitt's lymphoma-derived cell line 
ROS-1 and the T cell line Molt4. A: Phase contrast morphology. B: Smlg + cells (TRITC labeled). C: CyCD3 + cells 
(FITC labeled). The three micrographs represent the same field. All Smlg+ cells are negative for CyCD3. 
5% (vjv) acetic acid) for 15 minutes at -2o·G appeared to result in the most prominent 
GyGD3staining. It should be remarked that only cytocentrifuge preparations with a good cyto-
morphology as determined by phase contrast microscopy resulted in optimal GyGD3 staining. 
Therefore, all cytocentrifuge preparations were checked for their quality before they were 
subjected to the GyGD3 staining procedure. Each of the four McAb of the SP series was able 
to detect CyCD3 chains in the five T cell lines tested. Also, surface membrane-like CD3 staining 
was observed in the cytocentrifuge preparations of the T cell lines H9 and GEM (see the next 
section). 
To exclude nonspecific staining by the anti-GD3 chain McAb, an SmlgjGyGD3 double IF 
staining was performed on a 1:1 mixture of the T cell line Molt4 and the Burkitt's lymphoma-
derived cell line ROS-1. In these experiments it appeared that all Smlg + cells were negative 
for GyGD3 and vice versa, thereby indicating that GyGD3 staining can be easily used for 
evaluation at the single-cell level (Figure 1). 
CD3 staining patterns in cytocentrifuge preparations 
The typical GyGD3 staining is a nondiffuse, irregular, filamentous staining that is most 
prominent at the position of nuclear clefts. This often results in a dotlike staining when a large 
nuclear cleft is present (see Figures 1, 2 and 3). Such information can be obtained only if the 
fluorescence microscope is equipped with optimally adjusted phase contrast facilities and if 
the cells are studied at various focus levels. 
As was indicated earlier, the cells of the T cell lines H9 and GEM also expressed surface 
TABLE 1. Immunologic marker analysis (including the detection of CyCD3 chains) of 19 T-ALL cell samples8 • 
T-ALL cell samples 
Immunologic 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
marker (BM) (BM) (BM) (PB) (BM) (BM) (BM) (BM) (PB) (BM) (BM) (PB) (PB) (PB) (BM) (BM) (PB) (BM) (BM) 
CyCD3-cS (SP-64)b 71 83 99 100 85 86 99 70 98 77 63 73 96c 99 60c 98c od 97 94c 
CyCD3-€ (Sp-6)b 67 86 99 99 90 82 99 97 98 80 73 69 94c 98 59c 99C od 100 99C 
TdT 89 26 96 87 58 87 81 74 99 95 58 80 95 87 64 79 69 96 99 
HLA-DR 94 60 1 4 11 1 4 2 1 9 6 4 3 6 41 0 0 () 
CD7 (3A1) 95 89 (86) 99 99 96 (95) 92 99 97 96 98 71 (99) 84 98 85 91 93 78 97 99 ~ 
'11 
CD2 (Leu-5) 92 91 (68) 83 99 7 (0) 10 60 95 92 98 65 (96) 94 98 55 92 7 78 98 100 ;;j 
::0 
CD5 (Leu-1) 2 71 (61) 99 98 39 (48) 84 86 98 99 96 71 (89) 92 95 93 92 95 90 98 99 ?1 
CD1 (6611C7) 0 2 (0) 0 1 11 (18) 12 9 97 98 73 16 (22) 19 43 11 0 3 0 1 0 1\) 
CD4 (Leu-3) 0 7 (0) 0 0 31 (59) 45 77 14 93 91 10 (3) 59 59 3 2 29 2 88 48 
CDS (Leu-2) 8 (1) 0 38 3 (0) 17 61 51 93 93 59 (99) 72 14 5 36 4 0 4 32 
SmCD3 (Leu-4)e 4 3 (0) 0 2 (3) 1 2 11 2 12(6) 24 (13) 68 83 57 67 67 95 82 87 
TcR~f! (WT31) 2 2 (0) 0 3 (0) 0 12 2 15 (0) 24 (4) 69 2 2 12(0) 7(0) 23 68 
a. The figures represent percent positivity per MNC. The ligures in parentheses represent percent positivity per TdT+ cells as detected by double IF staining; such T cell markerfTdT double IF 
stainings were primarily performed If the percentage of TdT+ cells was lower than 60%. 
b. Cytoplasmic staining as determined in cytocentrifuge preparation. 
c. Both cytoplasmic and surface membrane-like staining were found. 
d. Only surface membrane-like staining was found. 
e. Surface membrane staining as determined by analysis of cells in suspension. 
CyCD3 as marker for immature T cells 337 
Figure 2. Staining for CD3 (SP-10) on a cytocentrifuge preparation of a thymus cell sample. A: Phase contrast 
morphology. 8: CD3-positive cells. This figure illustrates different CD3 staining patterns: the majority of the 
thymocytes express both CyCD3 and SmCD3, whereas one cell (arrow) mainly expresses SmCD3. 
membrane-like CD3 staining in addition to the typical CyCD3 staining. This was confirmed by 
CD3 staining of these cells in suspension. The SmCD3 staining pattern in cytocentrifuge 
preparations is dependent on the focus level and varies from ringlike (Figure 4), when the focus 
level is just above the object glass, to a more diffuse staining, when the focus level is somewhat 
higher (Figure 2). It should be remarked, however, that a weak CyCD3 staining may be 
undetectable in our assays when the SmCD3 staining is very bright. 
Expression of CyCD3 by human thymocytes 
Five thymocyte cell samples from children ( <2 years old) were evaluated for the expression 
of CyCD3 by using the McAb of the SP series (38) and the rat CD3-r antiserum. The majority 
(>95%) of the thymocytes were positive for the typical CyCD3 staining, and in addition, surface 
membrane-like staining was also seen on a major part of the thymocytes. The intensity of the 
CyCD3 and SmCD3 stainings varied from cell to cell. Three different types of CD3 staining 
patterns could be recognized in the thymus cell samples: about 20 to 30% of the thymocytes 
expressed only CyCD3, 60 to 75% expressed both CyCD3 and SmCD3, and about 5% of all 
thymocytes expressed prominent levels of SmCD3, whereas no typical CyCD3 staining was 
detectable in the latter cells (Figure 2). These findings indicate that the majority of SmCD3+ 
thymocytes also contain variable amounts of CD3 protein chains in the cytoplasm. 
Expression of CyCD3 by T-All cells 
Nineteen T-ALL cell samples were analyzed for the expression of CyCD3-o (SP-64 and 
SP-78) and CyCD3-E (SP-6 and SP-10) as well as the expression of TdT and the surface 
membrane expression of the T cell markers CD1, CD2, CD3, CD4, CD5, CD? and CDS; the 
B cell markers CD10, CD19, CD20; and the myeloid markers CD13, CD14, CD15 and CD33. 
The results of the immunologic marker analysis are summarized in Tables 1 and 2. All T-ALL 
(J.) 
(J.) 
TABLE 2. Immunologic marker analysis (including the detection of CyCD3 chains) of 45 leukemias, ten cell lines, and five normal samples. 00 
Immunologic markersa 
CD2 CyCD3-o CyCD3-€ SmCD3 CD5 CD7 CD10 CD13 CD14 CD15 CD19 CD20 CD33 
Cell samples TdT HLA-DR (Leu-5) (SP-64) (SP-6) (Leu-4) (Leu-1) (3A1) (VIL-A1) (My?) (My4) (VIM-05) (84) (81) (My9) 
SmCD3- T-ALL 
(n=11) 11/11 2/11 9/11 11/11b 11/11b 0/11 10/11 11/11 7/11 1/11c 0/10 0/11 1/11 0/10 1/11d 
SmCD3 + T-ALL 
(n = 8) 8/8 1/8 7/8 7/8b 7/8b 8/8 8/8 8/8 2/8 0/8 0/7 0/8 0/7 0/7 0/7 
T-CLL 
(n = 1) 0/1 0/1 1/1 0/1e 0/1e 1/1 1/1 1/1 0/1 0/1 0/1 0/1 0/1 0/1 0/1 
T cell lines 
(n = 5) 3/5 1/5 3/5 5/51 5/51 2/5 5/5 4/5 2/5 0/5 0/5 1/5 0/5 0/5 0/5 () 
Precursor B-ALL ~ 
(n = 12) 12/12 12/12 0/12 0/12 0/12 0/12 0/12 1/12 11/12 1/12 0/12 0/12 12/12 4/12 1/12 -o ill B-CLL ::0 
(n = 7) 0/4 7/7 0/7 0/7 0/7 0/7 7/7 0/7 0/7 0/6 0/7 0/7 5/5 6/7 0/1 ~ 
"' Precursor B cell lines 
(n = 5) 1/5 5/5 0/5 0/5 0/5 0/5 1/5 0/5 3/5 1/5 0/5 0/5 5/5 3/5 0/5 
AML 
(n = 6) 1/5 6/6 1/6 0/6 0/6 0/6 0/6 3/6 0/6 3/6 2/6 1/6 1/6 0/6 6/6 
Normal PB 
(n = 5) <0.1 26±9 67±9 56±10g 60±7g 58±8 56±7 54±11 <0.1 17±9 15±7 1±2 7±2 6±2 NTh 
a. The figures represent the number of positive leukemias or cell lines per total number of samples tested. A leukemia or cell line was considered to be positive if more than 25% of the MNC were 
positive. For the normal PB samples, percentages of positive cells ± SD are given. 
b. In the SmCD3- T-ALL mainly cytoplasmic staining tor CD3 chains was found, whereas in seven of the eight SmCD3+ T-ALL samples both cytoplasmic and surface membrane-like staining was 
observed. One SmCD3+ T-ALL sample did not express CyCD3 (see Table 1). 
c. The CD13+ T-ALL is the prothymocytic T-ALL of patient 1 (see Table 1 and Campana et al. (35) and Van Dongen et al. (42)). 
d. The CD33+ T-ALL is the immature thymocytic T-ALL of patient 2 (see Table 1). 
e. No CyCD3 staining was detected; only SmCD3 staining was found. 
f. In three of the five T cell lines, mainly cytoplasmic stainln~ for CD3 was found (see Table 3). 
g. These percentages represent surface membrane-like CD3 cells in the cytocentrifuge preparations; no typical cytoplasmic staining was detected. 
h. NT, not tested. 
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Figure 3. Expression of CyCD3 (SP-64) by an immature T-ALL (Table 1, patient 4). A: Phase contrast morphology. 
8: CD3-positive cells. All leukemic cells express CyCD3. 
samples expressed TdT. If the percentage of TdT+ cells was lower than 60%, double IF 
stainings for aT cell marker and TdT were performed to determine the immunologic phenotype 
of the TdT+ cells (fable 1). 
Eleven T-ALL samples did not express SmCD3 whereas eight T-ALL samples were positive 
for SmCD3. One SmCD3- T-ALL sample had the phenotype of the putative prothymocyte 
(fdT+ /HLA-DR+ /CD?+ /C02+ /COo /CD1-/CD3l, and six T-ALL samples appeared to be 
examples of immature thymocytic T-ALL (fdT+ /CD?+ ;co2+ ;cos+ /CD1-/CD3l (34). All 
eleven SmCDT T-ALL samples did express CyCD3, including the patient with prothymocytic 
T-ALL (Figure 3). Also seven out of eight T-ALL samples which expressed SmCD3, as 
determined by labeling of the cells in suspension, expressed CyCD3. These data probably 
indicate that all T-ALL samples, whether they are immature or mature, express either CyCD3, 
SmCD3, or both. 
In addition, it should be noted that in five of the nine SmCD3+ T-ALL samples almost no 
TcR-a.B (WT31) + cells were detected, and if they were detected, it was demonstrated by double 
IF staining that the TdT+ cells were negative for TcR-a.B (WT31). In a sixth SmCD3+ T-ALL a 
large discrepancy of about 60% was found between the percentages of SmCD3 positivity and 
TcR-a.B (WT31) positivity. This may indicate that the T-ALL cells in these cell samples express 
the TcR--y protein chain (22-26). 
Analysis of 45 leukemias and ten cell lines for CyCD3 expression 
The results of the immunologic marker analysis of the 45 leukemias and the ten cell lines 
are summarized in Table 2. All19 T-ALL samples were positive for TdT and the CD? antigen. 
In addition, they all expressed CyCD3 and/or SmCD3 as detected in cytocentrifuge 
preparations using CD3-o and CD3-E McAb (see the previous section and Tables 1 and 2). The 
T-CLL sample tested was negative for TdT but expressed the T cell markers C02, CD3, CD5 
and CD? on the cell surface. The SmCD3 expression was confirmed by the surface 
membrane-like CD3 staining in cytocentrifuge preparations (fable 2). Three out of five T cell 
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Figure 4. Staining for CD3 (SP-64) on a cytocentrifuge preparation of BM cells from a patient with a precursor B-
ALL at diagnosis. A: Phase contrast morphology. B: CD3-positive cells. The leukemic blasts are negative for 
CyCD3, whereas a few cells express SmCD3. The latter cells represent the normal T lymphocytes. This figure 
illustrates the surface membrane-like CD3 staining in cytocentrifuge preparations. 
lines were positive for TdT and mainly expressed CyCD3, whereas the other two T cell lines 
expressed both CyCD3 and SmCD3. 
All 12 precursor B-ALL samples were positive for TdT, HLA-DR, and the B cell antigen 
CD19. Eleven out of 12 precursor B-ALL samples also expressed the CD10 antigen (common 
ALL antigen). These precursor B-ALL samples did not express CyCD3 or SmCD3. This is 
illustrated in Figure 4, which shows CD3 staining on a cytocentrifuge preparation of BM cells 
from a patient with a precursor B-ALL: the leukemic blasts were negative for CD3, whereas a 
few normal T lymphocytes (about 3% of the total MNC population) expressed SmCD3. The 
B-CLL samples tested were positive for HLA-DR, the B cell antigen CD19, and the T cell antigen 
CD5, and in addition they weakly expressed Smlg. The B-CLL samples did not express CyCD3 
or SmCD3. The two precursor B cell lines and the three Burkitt's lymphoma-derived cell lines 
were positive for HLA-DR and the B cell antigen CD19, but they did not express CyCD3 or 
SmCD3. The six AML samples expressed HLA-DR and the myeloid antigen CD33. Three of 
these AML samples also expressed the myeloid antigen CD13, and three of them expressed 
the CD? antigen. None of the AML samples were positive for CyCD3 or SmCD3. 
These data indicate that the expression of CyCD3 andjor SmCD3 as detected in 
cytocentrifuge preparations by use of anti-CD3 chain McAb is restricted to cells of the T cell 
lineage. 
Expression of CyCD3 and SmCD3 by MNC from PB 
MNC from normal PB samples were analyzed for the expression of CyCD3 chains and 
SmCD3 as well as for several other T cell markers, B cell markers and myeloid markers (Table 
2). The percentages ofT lymphocytes varied from about 50 to 65%, whereas the percentage 
of B lymphocytes (CD19+ or CD20+) varied from about 5 to 10% and the monocytic cells 
(CD14+) from about 10 to 20%. 
The use of the anti-CD3 chain McAb in cytocentrifuge preparations of PB samples resulted 
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in surface membrane-like CD3 staining only. The typical CyCD3 staining could not be detected. 
The percentage of cells positive for SmCD3-c5 and SmCD3-E staining in the cytocentrifuge 
preparations were comparable with the percentages of SmCD3+ cells as found by staining of 
the PB cells in suspension (Table 2). 
Reactivity of the CD3 McAb of the Oxford panel in IF techniques and Western blotting 
In addition to the rat CD3--y antiserum (16), the CD3-c5 McAb SP-64 and SP-78, and the 
CD3-E McAb SP-6 and SP-10 (38), 22 CD3 McAb of the Oxford CD3 panel were evaluated for 
their capability to detect CyCD3 in cytocentrifuge preparations of the T cell lines Molt4, H9, and 
8102. In addition, these McAb were tested for their reactivity with CD3 chains in Western 
blotting. 
Detection of CyCD3 by the use of CD3 McAb of the Oxford panel. 
The rat CD3-'Y antiserum and the McAb of the SP series could detect CyCD3 chains in the 
three T cell lines (Table 3). 
The McAb of the Oxford panel were first optimally titrated by testing their reactivity with 
SmCD3 on normal PB lymphocytes in suspension. Subsequently the McAb were tested for 
their capacity to detect CyCD3 in the T cell lines Molt4, H9, and 8102. Two different titers were 
used for this purpose, i.e. the titer that was optimal for the detection of SmCD3 as well as a 
fourfold-lower titer. It appeared that four CD3 McAb (UCHT1, VIT-3b, G19-4.1, and SK7jLeu-4) 
were able to detect CyCD3 in all three T cell lines tested and that a fifth McAb, T3(2ADA), gave 
surface membrane-like CD3 staining in cytocentrifuge preparations of H9 and 8102. These five 
McAb did not show reactivity in cytocentrifuge preparations of B cell lines. The observation that 
Molt4 cells do not express SmCD3 may explain the absence of surface membrane-like staining 
in cytocentrifuge preparations stained with the McAb T3(2ADA); however, the surface 
membrane-like staining of the McAb T3(2ADA) in cytocentrifuge preparations of the SmCD3-
cellline 8102 remains unexplained. The McAb VIT-3 caused a weak CyCD3 staining in cyto-
centrifuge preparations of Molt4 but did not react with H9 and 8102. Lowering of the titer of this 
McAb did not result in a better staining. The McAb T3/2T8-2F4 gave a nonspecific filamentous 
staining in all three T cell lines. The same nonspecific staining was also found in PB monocytes, 
as determined by phase contrast facilities, as well as in B cell lines. This filamentous staining 
was also described by Lobach et al (4) and resembles the filamentous staining of the CD3 
McAb T10B9 as described by Campana et al (35). 
These results indicate that the McAb UCHT1, VIT-3b, G 19-4.1, and SK?/Leu-4 are able to 
detect CyCD3 in all three T cell lines tested and that the McAb T3(2ADA) only gives surface 
membrane-like CD3 staining in cytocentrifuge preparations. 
Reactivity of CD3 McAb of the Oxford panel with CD3 chains in Western blotting. 
Antibodies were screened in Western blots against an immune-affinity purified preparation 
of CD3 from human tonsils (39). An CD3--yc5E polyclonal antiserum was used to determine the 
location of the CD3--y, CD3-c5, and CD3-E chains in the filter strips. As could be expected, the 
rat CD3--y antiserum reacted with the CD3--y band, whereas McAb SP-64 and SP-78 reacted 
with the CD3-c5 band and McAb SP-6 and SP-1 0 with the CD3-E band. All anti-CD3 McAb of the 
TABLE 3. Reactivity of five anti-CD3 chain antibodies and 22 CD3 McAb from the Oxford CD3 panel as analyzed by the use of cytoplasmic IF staining and 
Western blotting. 
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Figure 5. Western blot analysis of the CD3 McAb of the Oxford CD3 panel. The reactivity of a polyclonal CD3-r 
S f antiserum, shown in the first filter strip, indicates the localization of the CD3-r, CD3-o, and CD3-f bands. Only 
the McAb UCHT1, VIT-3b, G19-4.1, T3(2ADA) and SK?jLeu-4 show reactivity in the Western blot filter strips. They 
all recognize the CD3-f band. The 18-kDa band migrating ahead of the CD3-f band (*) is a specific degradation 
product of the CD3-f polypeptide (39). 
Oxford panel were tested at a titer of 1 :50. Five McAb, (UCHT1, VIT-3b, G19-4.1, T3(2ADA) 
and SK7 jLeu-4) showed reactivity with the CD3-E band and an 18-kDa degradation product 
of this band (39), whereas all other McAb showed no reactivity (Figure 5). 
Comparison of the data of the IF staining with the data of the Western blotting indicates 
that the five CD3 McAb of the Oxford panel that are able to give CyCD3 andjor surface 
membrane-like CD3 staining in cytocentrifuge preparations are the same McAb that react with 
the CD3-E chains in Western blots (Table 3, Figure 5). 
DISCUSSION 
Expression of the CD3 antigen by a leukemia or non-Hodgkin's lymphoma proves the T cell 
origin of such a malignancy because the CD3 antigen is a T cell-specific marker (1, 7,9, 1 0). 
However, many T-ALL do not express the CD3 antigen on their surface membrane (9, 1 0,33,34). 
Link et al demonstrated CD3 expression in the cytoplasm of some immature T cell malignancies 
that did not express SmCD3(29). Such CyCD3 expression in immature T cells has recently also 
been described by Furley et al (33) and Campana et al (35). Cytoplasmic expression of 
antigens preceding the surface membrane expression has also been described for other 
proteins such as the B cell antigen CD22 (43). Another well-known example is the weak 
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cytoplasmic expression of p, heavy chains in pre-B cells that precedes the Smlg expression on 
B lymphocytes (44,45). 
Our study indicates that CyCD3 expression already occurs in immature stages of T cell 
differentiation because the majority of thymocytes and all immature T-ALL express CyCD3 
(Table 1, Figures 2 and 3). Even the most immature T-ALL, i.e. the prothymocytic T-ALL, 
weakly expressed CyCD3 (Table 1). Expression of the CD3 antigen in the cytoplasm of 
immature SmCD3- T cells is in line with the recent finding that CD3-o and CD3-E gene 
transcripts occur in all T-ALL (33,34). The expression of the CD3 antigen on the surface 
membrane is dependent on the presence of the TcR (30-32). The processes involved in the 
production of the TcR protein chains such as rearrangement and transcription of the TcR genes 
take place during thymic differentiation, finally resulting in the expression of the TcR-CD3 
complex at the cell surface (19,33,34). In our study, the majority of thymocytes and most 
SmCD3+ T-ALL appeared to express CyCD3 as well as SmCD3 (Figure 2 and Table 1). The 
mature T lymphocytes in PB and BM and a minor population of thymocytes (about 5%) 
expressed prominent levels of SmCD3, whereas the typical CyCD3 staining was not detectable 
in these cells (Table 2 and Figures 2 and 4). It should be remarked, however, that a weak 
CyCD3 staining may be undetectable in our assays when the SmCD3 staining is very bright. 
Thus, immature SmCD3- T cells express CyCD3 only, the combined expression of CyCD3 and 
SmCD3 is characteristic for intermediate differentiation stages, and SmCD3 + cells represent 
mature T cells. It might well be that the latter cells display a low CyCD3 expression because a 
continuous CD3 chain biosynthesis should compensate the SmCD3 turnover. 
Whether the precursor T cells in BM, i.e. the prothymocytes, also express CyCD3 has to 
be further investigated. On the basis of double and triple immunologic stainings we have 
previously postulated that a minor population of the TdT+ cells in BM represent prothymocytes 
thatexpresstheTdT+ /HLA-DR+ /CD?+ /C02+ ;cos-jCD1-/CD3-phenotype (42,46). Recently, 
Campana et al performed double IF stainings for CyCD3 and TdT but could not detect 
double-positive cells in BM (35). Although we did not perform such double IF stainings on BM 
samples, we demonstrated that the prothymocytic T-ALL sample tested weakly expressed 
CyCD3 and in addition, we recently showed that such leukemic cells contain CD3-o and CD3-E 
gene transcripts (34). 
The expression of the various T cell antigens, CyCD3 and the TcR-CD3 complex as well 
as the presence of CD3 transcripts during T cell differentiation are summarized in Figure 6. 
To exclude the possibility that non-T cells expressed CyCD3, we analyzed 12 precursor 
B-ALL samples, seven B-CLL samples, five (precursor) B cell lines and six AML samples in 
addition to 19 T-ALL samples, one T-CLL sample and five T cell lines. Only the T cell leukemias 
and T cell lines appeared to express CyCD3 andjor SmCD3. All other non-T cell leukemia 
samples and non-T cell lines were negative for the CD3 antigen. Also the CD?+ AML samples 
did not express CyCD3 (Table 2). These data and those of Campana et al (35) indicate that 
CyCD3 expression is restricted to the T cell lineage and can therefore be used as diagnostic 
marker for immature SmCD3- T cell malignancies. 
For the detection of CyCD3, Link et al used the McAb Leu-4 on acetone-fixed tissue 
sections or cytocentrifuge preparations (29), Furley et al used McAb of the SP series but did 
not mention their fixation method (33), and Campana et al used the McAb UCHT1 and OKT3 
on acetone-fixed cytocentrifuge preparations (35). Because the data discussed earlier indicated 
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Figure 6. Hypothetical differentiation scheme of the T cell lineage that summarizes the expression of CyCD3, the 
TcR-CD3 complex, and other T cell markers in the various differentiation stages. Immunologic markers in 
parentheses are not always expressed. The dotted lines represent the tissue compartments, and the horizontal 
bar indicates the presence of CD3 mRNA (see Furley et al. {33) and Van Dongen et al. {34)). 
that CyCD3 is an important diagnostic marker, we evaluated which fixation method is optimalfor 
the CyCD3 staining, and we determined which CD3 McAb can be used for the detection of 
CyCD3. 
In our hands acid ethanol appeared to be the best fixative to fixate the cytocentrifuge 
preparations and to denature the CD3 chains. Our data and those of Furley et al (33) clearly 
demonstrate that CyCD3 expression can readily be detected by McAb of the SP series (38); 
However, the McAb SP-6 and SP-10 (CD3-E) and the McAb SP-64 and SP-78 (CD3-o) do not 
recognize SmCD3 on cells in suspension (38), and in addition, they are not widely available. 
Therefore, we wished to analyze the reactivity of CD3 McAb that are raised against native 
SmCD3. For this purpose we were allowed to use 22 CD3 McAb of the Oxford CD3 panel, 
kindly provided by professor A.M. McMichaeL These McAb were tested for their capacity to 
detect CyCD3 in acid ethanol-fixed cytocentrifuge preparations of the T cell lines Molt4, H9 and 
8102 as well as for their reactivity with CD3 chains in Western blotting. 
Only five (UCHT1, VIT-3b, G19-4.1, T3(2ADA) and SK7 /Leu-4) of 22 CD3 McAb of the 
Oxford CD3 panel could detect CD3 chains in cytocentrifuge preparations. Western blotting 
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showed that the same five McAb recognize the CD3-E chain. All other CD3 McAb showed no 
reactivity with the CD3 chains in Western blotting. Four (UCHT1, VIT-3b, G19-4.1, and 
SK7 /Leu-4) out of five mentioned McAb recognized both CyCD3 and SmCD3 in cytocentrifuge 
preparations, whereas use of the fifth one, T3(2ADA), resulted in surface membrane-like CD3 
staining only (Table 3). In our opinion the McAb UCHT1 and SK7 /Leu-4 gave the best CyCD3 
staining. 
The lack of reactivity of the majority of the CD3 McAb with denatured CD3 chains in 
cytocentrifuge preparations and Western blots may be due to the possibility that they recognize 
epitopes on the CD3 antigen that are composed of two or more chains or epitopes that change 
during denaturation. In view of these speculations, it is interesting to find that all five CD3 McAb 
of the Oxford panel that do detect CD3 in cytocentrifuge preparations recognize the CD3-E 
chain. This may be connected with the fact that CD3-E chains, in contrast to CD3--y and CD3-o 
chains, are not glycosylated (11, 13). Another explanation may be that some epitopes on the 
CD3-E chains are less prone to denaturation-induced changes. 
Our results as a whole are consistent with CyCD3 being expressed by immature cells 
during T cell differentiation but not by precursor B cells and early myeloid cells. Thus CyCD3 
can be used as a diagnostic marker for SmCD3- T cell malignancies. Evaluation of different 
CD3 McAb to be used for the detection of CyCD3 in cytocentrifuge preparations demonstrated 
that CyCD3 can be detected not only by the use of McAb raised against denatured CD3 chains 
such as those of the SP series but also by a minority of CD3 McAb that are raised against 
SmCD3, eg, UCHT1, VIT-3b, G19-4.1 and SK?/Leu-4. 
Shortly before submission of this manuscript a report from Mirro et al. was published in 
which they described the detection of CyCD3 in five T-ALL cell samples by flowcytometry (47). 
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INTRODUCTION 
349 
The detection of small numbers of malignant cells is a major problem at diagnosis and 
during follow-up of malignancies (1). The possibilities and limitations of methods for the 
detection of minimal residual disease in general depend on their specificity (malignant cells 
have to be identified among many normal cells), sensitivity (detection limit of the method) and 
reproducibility. Although the method as such may have an excellent reproducibility, the cell 
sample may not always be representative for the whole cell population. 
In leukemias and non-Hodgkin lymphomas (NHL) the detection limit for the identification 
of small numbers of malignant cells by means of morphological techniques is not lower than 
1% (1 malignant cell among 100 normal cells). Therefore, many investigators have tried to use 
other techniques for the detection of small numbers of malignant cells, such as cytogenetics 
(2), cell culture systems (3), premature chromosome condensation (4) and recombinant DNA 
techniques (5-7). Most of these techniques, however, do not lower the 1% detection limit. 
Both the normal hematopoietic differentiation stages and their malignant counterparts (i.e. 
leukemias and NHL) can be characterized by immunologic marker analysis (8-11). Some 
immunologic markers have been introduced as tumor -specific (12), but it turned out that these 
so-called "tumor markers" as well as most other immunologic markers represent differentiation 
antigens, which are also expressed by normal cells (8). Nevertheless, it is possible to use 
immunologic marker analysis by means of microscopy or flow cytometry for the detection of 
small numbers of malignant cells (1). Its application for the detection of minimal residual acute 
lymphoblastic leukemia (ALL) will be discussed. 
* Published in: Hagenbeek A, Lowenberg B, eds. Minimal residual disease in acute leukemia 1986. Dordrecht: 
Martinus Nijhoff Publishers, 1986:113-33. Updated for CD codes. 
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Figure 1. Hypothetical scheme of lymphoid differentiation. The markers expressed by cells in the various lymphoid 
differentiation stages are indicated. Markers in parenthesis are not always expressed. The bars represent malignant 
counterparts, i.e. the various (sub)types of ALL 
IMMUNOLOGIC PHENOTYPES OF All 
All cells can be regarded as malignant counterparts of cells in immature lymphoid 
differentiation stages as indicated in Figure 1 (8,9). By use of immunologic marker analysis, 
at least five different immunologic phenotypes of ALL can be distinguished: null ALL, common 
ALL, pre-B-ALL, B-ALL and T-ALL (Table 1) (8,9, 13). The T-ALL can be divided into several 
subtypes based on their positivity for different T cell markers (Figure 1) (14-18). Detailed 
information about the various immunologic markers for the characterization of ALL is 
summarized in Table 2 (19-32). 
By use of recombinant DNA techniques it has been demonstrated that most null ALL, and 
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TABLE 1. Immunologic phenotypes of ALL. 
TdT HLA-DR CD19 CD10 weak CyJ.L Smlg T cell markers 
(CALLA) (CD2,CD7) 
null ALL + + (+)a 
common ALL + + + + 
pre-B-ALL + + + + + 
B-ALL + + (+)a + 
T-ALLb + _c +b 
a. Not always expressed. 
b. Several subtypes of T-ALL can be recognized, based on their positivity for the various T cell markers. 
c. A few T-ALL are HLA-DR positive. 
all common ALL and pre-B-ALL have rearranged immunoglobulin (lg) heavy chain genes or 
rearranged lg heavy and light chain genes (33-35), while most T-ALL have rearranged T cell 
receptor (TcR) f3 chain genes (7,35,36). However, some T-ALL appear to have rearranged lg 
heavy chain genes (37). Similarly, some non-T-ALL have rearranged TcR-/3 chain genes (35). 
Despite lineage infidelities, the lg gene and TcR gene rearrangement in general support the 
hypothesis that null ALL, common ALL and pre-B-ALL can be regarded as precursor B-ALL, 
as is indicated in Figure 1 (33-38). 
IMMUNOLOGIC MARKER ANALYSIS FOR THE DETECTION OF MINIMAL RESIDUAL 
All 
Although immunologic marker analysis can be used for a precise and reproducible 
immunologic classification of ALL (8,9), its application for the detection of small numbers of 
ALL cells is limited. This is mainly due to the presence of normal lymphoid cells which express 
the same immunologic markers (8,28,39,40). The frequencies of these normal cells influence 
the detectability of their malignant counterparts. Therefore, cells positive for certain markers 
or marker-combinations can only be regarded as malignant, if these positive cells are present 
in higher frequencies than normal or if they are detected outside their normal homing areas 
(Table 3). 
For the detection of small numbers of ALL cells the following immunologic markers or 
marker combinations may be used: kappa-lambda ratio, terminal deoxynucleotidyl transferase 
(TdT), common ALL antigen (CD1 0), CD1 antigen and double immunofluorescence (IF) staining 
for TdT and aT cell marker. 
Kappa-lambda ratio 
Since B cell malignancies are clonal expansions of one B cell they will express only one 
type of lg light chain: kappa or lambda (23,24). Therefore, lg light chain expression can be 
used as a marker of clonality and the kappa-lambda ratio can give an impression about the 
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TABLE 2. Immunologic markers for characterization of ALL 
Antibody/ Cluster of Antigen recognized Specificity References 
technique differentiation a 
anti-TdTb terminal deoxynucleo- immature lym- 19 
tidyl transferase (T dT) phoid cells 
B4c CD19 B cell antigen (p95) all (precursor) 20 
B cells 
Vll-A1d CD10 common All antigen pre-pre-B cells, 21 
(CALLA) (gp100) pre-B cells and sub-
population of B cells 
BA-1e CD24 B cell antigen (p45, most precursor B 21 
55,65) cells and all B cells 
weak Cyp.f weak expression of pre-B cells 22 
cytoplasmic p. heavy 
chain 
Smlgf surface membrane Smlg positive B cells 23,24 
{K:, .A, p., li, "(, a, E) immunoglobulin 
3A1g orWT1h CD7 Tp41 antigen (p41) all T cells 25,26 
E (rosette) "C02" sheep red blood cell all T cells 27 
(SRBC) receptor 
leu-5i or T11 c C02 T11 antigen; SRBC all T cells 28,29 
receptor (p50) 
Leu-1i orT1c CD5 T1 antigen (p67) thymocytes and 28,29 
mature T cells 
Leu-6i or T6c CD1 T6 antigen (common cortical thymocytes 28,29,30 
thymocyte antigen) and Langerhans cells 
(p45-12) in the epidermis 
Leu-3i or T4c CD4 T 4 antigen (p55) T helper cells 28,29 
Leu-2i or T8c CDS TS antigen (p32-33) T suppressorjcyto- 28,29 
toxic cells 
Leu-4i or T3c CD3 T3 antigen (p19-29) mature T cells 28,29 
anti-HLA-DRi HLA-DR, non poly- hematopoietic pre- 31,32 
morphic antigen (p19-34) cursor cells and B cells 
a. CD, cluster of differentiation as proposed by the "Leukocyte Typing Conference" (Boston, MA, 1984). 
b. Bethesda Research Laboratories, Gaithersburg, MD. 
c. Coulter Clone, Hialeah, FL. 
d. New England Nuclear, Boston, MA. 
e. Hybritech, San Diego, CA. 
f. Kallestad Laboratories, Austin, TX. 
g. American Type Culture Collection, Rockville, MD. 
h. Dr. W. Tax, Nijmegen, The Netherlands. 
i. Becton Dickinson, San Jose, CA. 
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TABLE 3. Detection of minimal residual ALL by immunologic marker analysis. 
Limitations: 
- some normal cells have the same immunologic phenotype as ALL cells 
-the frequency of normal positive cells influences the delectability of their malignant counterparts 
Possibilities: 
- detection of positive cells in higher frequencies than in normal cell samples 
- detection of positive cells outside their normal homing areas 
number of malignant B cells (23,24,41 ,42). Due to the presence of normal polyclonal B cells, 
the detection limit of the kappa-lambda ratio analysis is not lower than 1 to 10%, even when 
large numbers of cells are evaluated by use of a sensitive flow-cytometric method (43,44). 
This kappa-lambda ratio analysis may be useful for detection of B-ALL, but not for other ALL, 
since only B-ALL expresses surface membrane lg (Smlg). 
Terminal deoxynucleotidyl transferase (TdT) 
The enzyme TdT is present on the nuclear membrane of immature lymphoid cells of both 
B and T cell lineage as well as their malignant counterparts (precursor B-ALL and T-ALL) 
(8,45,46). TdT is a DNA polymerase lacking template requirements (45) and may play an 
important role in gene rearrangements (47), which are necessary for the transcription of lg 
genes and TcR genes. The lg gene rearrangements, occasionally found in acute myeloid 
leukemia (AML) (38), may therefore explain why some AML (5 to 10%) are TdT positive (48,49). 
The majority of the TdT positive cells in bone marrow (BM) represents precursor B cells 
(8,39,45), while the TdT positive cortical thymocytes represent the precursors of the T 
lymphocytes (28,40,45,46). TdT positive cells are not only detectable in BM and thymus, but 
also in lower frequencies at other sites, such as peripheral blood (PB) and lymph nodes (LN) 
(45,50,51). For the detection of small numbers of TdT positive cells , the TdT biochemical 
assay is rather insensitive, and therefore the TdT immunofluorescence (TdT-IF) assay is 
preferred (45,52-55). 
The frequencies of normal TdT positive cells in BM are age dependent and influenced by 
cytostatic therapy (45). Consequently, the percentages of TdT positive cells vary from about 
1 to 6% and may even in regenerating BM increase up to 11% (Table 4). In PB the percentages 
of TdT positive cells are significantly lower and vary from about 0.01 to 0.06% and may be as 
high as 0.38% in some ALL patients during maintenance therapy (Table 4). TdT positive cells 
are also detectable in LN in frequencies of about 0.025% (Table 4). In cerebrospinal fluid (CSF) 
of fifty patients who did not suffer from ALL, we could not detect TdT positive cells among 100 
to 1000 cells per sample evaluated. In some CSF samples from ALL patients in complete 
remission according to morphological criteria while receiving maintenance therapy, we detected 
TdT positive cells in low frequencies ( < 1 %) (56,57). Most probably, such TdT positive cells 
represent ALL cells, but induction and maintenance therapy may eliminate these ALL cells or 
suppress their further proliferation. 
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TABLE 4. Frequencies of normal TdT positive cells in BM, PB and LN. 
Children (2 to 16y) 
Adults 
Children under ALL 
maintenance therapy 
Children, 6 wk 
after withdrawal of 
maintenance therapy 
a. Mean± SD. 
b. Range of percentage of positive cells. 
c. Number of cell samples tested. 
d. NT, not tested. 
BM 
3.4 ± 2.5a 
(0.1-8.0)b 
(n=17)c 
1.1 ± 0.5 
(0.5-2.0) 
(n=8) 
2.0 ± 1.6 
(0.1-7.3) 
(n=174) 
6.0 ± 2.8 
(0.5-10.2) 
(n=8) 
Percentages of TdT positive cells 
PB 
0.036 ± 0.033 
(0.005-0.11) 
(n=14) 
0.018 ± 0.014 
(0-0.045) 
(n=8) 
0.063 ± 0.074 
{0-038) 
(n=221) 
0.027 ± 0.007 
(0.018-0.035) 
(n=3) 
NL 
0.025 ± 0.029 
(0-0.09) 
(n=15) 
NT 
NT 
The normal "background" of TdT positive cells in BM and to a lesser extent in PB and LN, 
limits the value of the TdT-IF assay for detection of minimal residual ALL cells (Tables 4 and 
5). However, Buchanan and colleagues (50,51) were able to detect elevated percentages of 
TdT positive cells in PB of ALL patients 3 to 5 wk prior to relapse. Their data indicate that the 
TdT-IF assay, performed on sequential PB samples, may be useful in detecting imminent 
relapse, if the PB is sampled at intervals of 2 to 4 wk. Barr et al. could not confirm these results 
(58). However, their PB sampling was performed less frequent and they evaluated lower 
numbers of cells. In addition they were hindered by the presence of non-specific fluorescent 
cells. This might have been due to their TdT-IF assay, since they did not fixate the cells and 
used anti-TdT antisera, which to our experience give high background staining (58,59). 
Based on our data the detection limit of the TdT-IF assay for the identification of ALL cells 
in PB is about 0.4% (Table 5). Whether this rather high detection limit is valuable for prediction 
of all TdT positive ALL relapses, has to be investigated. Additional analysis of the TdT positive 
cells by double IF staining such as CD10/TdTorTcell marker/TdT may be a more appropriate 
approach. 
Several studies indicate that the TdT-IF assay is valuable for improving the accuracy of the 
diagnosis of extramedullary ALL, e.g. by analysis of CSF and testis biopsies (56,57,60-62). 
This assay can be used for all TdT positive ALL, i.e. precursor B-ALL (null ALL, common ALL 
and pre-B-ALL) and T-ALL. 
Detection of minimal residual disease in ALL 355 
TABLE 5. Frequencies of normal positive cells as determined by immunologic marker analysis and their 
relevance for the detection limits of the various types of ALL cells. 
Immunologic Normal ratio or Detection limit of ALL type 
marker analysis frequency of positive cells minimal residual ALL 
Kappa-lambda ratio 0.8-2.0 1-10% B-ALL 
TdT staining BM: 1-6% BM: >11% TdT positive ALL 
(sometimes up to 11%) (null ALL, common 
PB: 0.01-0.06% PB: 0.4% ALL pre-B-ALL and 
(sometimes up to 0.38%) T-ALL) 
LN: 0.025% LN: 0.1% 
(sometimes up to 0.09%) 
CSF: no TdT positive CSF: ?a 
detectable in non-ALL 
patients a 
CD10 staining BM: 0.5-5%b BM: ?c CD1 0 positive ALL 
(in regenerating BM up to 50%)c (common ALL, pre-
PB: adults: <0.002%b PB: 0.03%b B-ALL and some 
children under maintenance 
therapy: 0.002-0.014% b 
B-ALL) 
(sometimes up to 0.025%) 
T cell marker fTdT 
double IF staining: 
- CD?jTdTand 
CD2/TdT staining BM: 0.002-0.05% BM: 0.04% prothymocytic ALL 
(sometimes up to 0.3%) (C02+ /CD?+ /HLA-
PB: 0.001-0.015% PB: 0.03% DR+ jTdT+) and 
(sometimes up to 0.02%) other TdT positive 
T cell malignancies 
- CDS /T dT and 
CD1jTdT staining BM: 0% BM: at least 0.01% most T-ALL and 
PB: 0% PB: at least 0.01% TdT positive T-NHL 
a. Most probably all TdT positive cells in CSF (whhout PB or BM contamination) represent ALL cells. • 
b. Percentages CD10 positive lymphoid precursor cells, as determined by CD10/TdT double IF stainings (see text). 
c. Due to high percentages CD10 positive cells in regenerating BM, no general detection limit for CD10 single IF staining can be 
determined. Only CD10/TdT double IF staining will be informative. 
Common All antigen (CD10 antigen) 
Initially, the CD10 antigen was regarded as leukemia specific (12). However, several 
investigators demonstrated CD10 positive cells in normal BM and fetal hematopoietic tissues 
(8,39,63,64). Especially in regenerating BM high percentages of CD10 positive cells are present 
(63). In the mononuclear cell (MNC) fraction of PB only extremely low numbers of CD10 
positive cells are found (63,65). The CD10 antigen is also weakly expressed by granulocytes 
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(66) and by a subpopulation of thymocytes (67) and their malignant counterparts (15, 18,68). 
According to our experience, especially CD1 positive T-ALL cells express the CD10 antigen. 
The use of the CD1 0 antigen as an immunologic marker for monitoring BM of ALL patients 
for early detection of relapse is hampered by the presence of normal CD1 0 positive cells in 
frequencies of 0.5 to 5% and sometimes even up to 50% in regenerating BM (63). Especially 
due to the high frequency of normal CD1 0 positive cells in regenerating BM of ALL patients 
after cessation of maintenance therapy, it was concluded that monitoring of CD1 0 positive cells 
in BM has no predictive value with respect to relapse (63). However, according to our 
experience, it is possible to discriminate between a relapse and regeneration, since in 
regenerating BM the percentages of CD1 0 positive cells markedly exceed the percentages of 
TdT positive cells, while at relapse of a CD10 positive ALL the percentages of CD10 positive 
cells are generally lower than, or equal to the percentages of TdT positive cells. 
CD10 positive lymphoid cells in PB are rare. It is difficult to detect these cells, since 
granulocytes are weakly positive for the CD1 0 antigen and CD1 0 monoclonal antibodies may 
nonspecifically bind to normal PB cells (63,66). Therefore, Ryan and colleagues tried to 
determine the frequency of normal CD10 positive lymphoid cells in PB by use of multiple 
flowcytometric parameters to exclude a variety of mature blood cells such as monocytes and 
granulocytes (65). By means of mixture experiments they demonstrated that it is possible to 
detect one CD10 positive lymphoid cell between 100,000 PB-MNC. The normal range of CD10 
positive cells in adult PB appeared to be less than 16 per million PB-MNC. Based on these data 
it was concluded that the low normal background of CD10 positive cells may permit early 
detection of ALL relapse by analysis of the PB cells (65). 
We have determined the background of normal CD1 0 positive cells in 90 PB samples from 
pediatric patients with ALL under maintenance therapy by double IF staining for the CD10 
antigen and TdT using fluorescence microscopy. The frequency of normal CD10+ /TdT+ cells 
in the PB of children under maintenance therapy appeared to be 0.002 to 0.014% (sometimes 
up to 0.025%). Based on the described data of Ryan and colleagues and our own data, we 
conclude that the detection of CD10 positive lymphoid cells by flowcytometry or CD10/TdT 
double IF staining in the PB of ALL patients in frequencies higher than 0.03%, may be indicative 
of an imminent relapse (fable 5). Further investigations have to substantiate the value of this 
PB monitoring. 
The CD10 antigen can also be used as immunologic marker for the detection of malignant 
cells in CSF. This application proved to be helpful for the diagnosis of meningeal involvement 
in ALL patients (69). 
Nevertheless it should be noted that the use of the CD10 antigen as immunologic marker 
for the detection of low numbers malignant cells in PB or CSF will only be valuable in CD1 0 
positive ALL if no phenotypic shift occurs. Loss or diminution of CD10 expression as well as 
acquisition of CD10 expression have been described (70). 
CD1 antigen 
The CD1 antigen is present on about 70% of the thymocytes but is also expressed by 
Langerhans cells in the epidermis and by cells in tonsils and lymph nodes (30,71,72). CD1 
positive cells in PB and regenerating BM have also been reported (73,74), but the precise 
Detection of minimal residual disease in ALL 3S7 
frequency and nature of these cells is still not known. By double IF staining it was demonstrated 
that the extrathymic CD1 positive cells are TdT negative (46,7S,76). 
It has been suggested that the CD1 antigen may be useful for the detection of minimal 
residual disease in patients with a CD1 positive T-ALL. However, it has to be remarked that the 
CD1 positive ALL represent only one third of T-ALL (17) and that phenotypic shift in CD1 
expression at relapse has been described [17). 
Double IF staining for a T cell marker and TdT is a better approach for detection of low 
numbers of T-ALL cells (7S,78). 
Double IF staining for a T cell marker and TdT 
Several studies indicate that cells positive for both a T cell marker and TdT are normally 
present in the thymus only and not in normal or regenerating BM and PB (8,39,46,S2,76,78). 
The T cell marker/TdT phenotype is also expressed by T-ALL (8,9, 14-18) and some Tcell NHL 
(T-NHL), especially lymphoblastic lymphomas (79-81). Therefore, it was concluded that the 
detection ofT cell marker+ /TdT+ cells in extrathymic locations is indicative of malignant T cells 
(8,S2, 78). Our experience with this assay will be discussed in the next section. 
T CELL MARKER/TdT DOUBLE IF STAINING FOR DETECTION OF MALIGNANT T CELLS 
To evaluate the possibilities and limitations of the double IF staining for the detection of 
malignant T cells we first determined the detection limit of this technique and investigated 
whether normal T cell marker+ /TdT+ cells indeed do not occur in BM and PB (7S,82). We use 
this double IF staining for detection of minimal disease at diagnosis and during follow-up. 
Detection limit of the double IF staining 
To determine the detection limit of the T cell marker /TdT double IF staining, we have 
performed several dilution experiments. Thymocytes or CD1 + /TdT+ T-NHL cells were diluted 
with a suspension of normal PB-MNC. A double IF staining for the CD1 antigen and TdT was 
performed. It proved to be possible to detect one CD1 + /TdT+ cell among 10,000 or even 
100,000 normal cells. The detection limit of the double IF staining method is therefore at least 
0.01% (7S). 
Normal T cell marker+ /TdT+ in BM and PB 
To investigate whether normal T cell marker+ /TdT+ cells occur in BM and PB, over fifty BM 
and PB samples from children as well as adults were analyzed by use of the double IF staining. 
CD?, C02, CDS and CD1 antigens (Figure 1 and Table 2) were used as T cell markers in the 
double IF staining. cos+ /TdT+ or CD1 + /TdT+ cells were not detected in any of the BM and 
PB samples analyzed. In contrast with data of other investigators (46,47), CD?+ /TdT+ and 
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C02+ /TdT+ cells were detected in normal childhood BM and in BM from children under 
maintenance therapy in low frequencies: 0.02 to O.OS% (sometimes up to 0.3%) (fableS). In 
adult BM and regenerating childhood BM, CD7+ /TdT+ and C02+ /TdT+ cells were not always 
detectable, and if detected, the frequency was about five to ten-fold lower. Occasionally, 
CD7+ /TdT+ cells could be detected in PB in a frequency of 0.001 to 0.01S% (sometimes up 
to 0.02%) (fable S). By use of triple immunologic staining for HLA-DR, the CD7 antigen and 
TdT (83), all CD7+ /TdT+ cells appeared to be positive for HLA-DR. Since most hematopoietic 
precursor cells are positive for HLA-DR (32) and since the CD7 and C02 antigens are pan-T 
cell markers (2S,26,28,29), the extrathymic CD7+ /HLA-DR+ /TdT+ cells and C02+ /TdT+ cells 
probably represent prothymocytes (82). 
The presence of a background of normal CD7+ /TdT+ and C02+ /TdT+ cells increases the 
detection limit of the T cell marker/TdT double IF staining when the CD7 and C02 antigens are 
used as T cell markers. Consequently, the detection limit for prothymocytic ALL 
(CD7+ /C02+ /HLA-DR+ /TdT+) is about 0.4% in BM and 0.03% in PB (fableS). Most T-ALL 
express additional T cell markers such as the CDS, CD1, CD4, COB and CD3 antigens (9, 14-
18), which are not expressed by normal extrathymic TdT positive cells (46, 7S,76,82). Therefore, 
the T cell marker /TdT double IF staining is very useful for the detection of minimal residual 
disease in patients with TdT positive T cell malignancies. 
Use of the T cell markerjTdT double IF staining for monitoring BM and PB of patients 
with TdT positive T cell malignancies 
The T cell marker /TdT double IF staining is routinely performed in our laboratory for the 
detection of low numbers of malignant cells in patients with T-ALL or TdT positive T-NHL at 
diagnosis as well as during follow-up (Figure 2). To prevent misdetection or underdetection of 
malignant cells due to phenotypic shift, we use two or three different T cell markers in parallel 
for the T cell marker /TdT double IF staining. The choice of these T cell markers is partly 
dependent on the immunologic phenotype of the malignancy at diagnosis. 
Until now (October 198S) we have monitored the BM and PB of twelve children with a TdT 
positive T cell malignancy: nine T-ALL patients and three T-NHL patients. Three T-ALL patients 
had one or two relapses. By use of the double IF staining, it was possible to detect these 
relapses 2 to 3 months earlier than by use of conventional cytomorphological techniques only. 
In the BM and PB of the other nine children no malignant cells could be detected during follow-
up; these patients are still in remission according to morphological as well as clinical criteria. 
The results of CDS/TdT double IF staining on the BM and PB cells of a T-ALL patient during 
follow-up are summarized in Figure 3. After 6 weeks of induction therapy this patient was in 
remission according to morphological criteria (less than S% blast cells in BM and no blast cells 
in PB). However, at that time still very low percentages of cos+ /TdT+ cells were detected in 
BM and PB. These percentages increased during follow-up, resulting in a morphological relapse 
about 3 months later. The patient received reinduction therapy and obtained remission 
according to morphological as well as immunologic criteria. After 10 weeks cos+ /TdT+ cells 
were again detected in PB. A second morphological relapse occurred two months later. This 
relapse proved to be therapy resistant. 
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Figure 2. CD4jTdT double staining on PB cells from a T-ALL patient. A: phase contrast morphology; B: CD4 
antigen positive cells (rhodamine labeled); C: TdT positive cell (fluorescein labeled). The TdT positive cell is also 
positive for the CD4 antigen and represents a T-ALL cell, while the other CD4 positive cells represent normal 
helper/inducer T lymphocytes. 
Based on our follow-up data the following conclusions can be drawn: 
Very low numbers of malignant cells (about 0.01%) give rise to a morphological relapse 2 
to 3 months later. This is in line with the results of animal experiments, in which injection 
of extremely low numbers of leukemic cells appeared to be able to cause a lethal leukemia 
(84,8S). 
The increase of percentages Cos+ /TdT+ cells in PB mimics the increase of Cos+ /TdT+ 
cells in BM (Rgure 3c), suggesting that the positive findings in PB reflect the process in BM. 
Therefore frequent PB sampling may be an useful alternative for frequent BM sampling 
during follow-up. 
The time interval between the detection of the immunologic relapse and the morphological 
relapse is shorter in the second relapse as compared to the first relapse. These data 
suggest that the proliferation capacity and/or therapy resistance of the T-ALL cells during 
the second relapse is higher than during the first relapse. This indicates that detection of 
low numbers of malignant cells can give information about both growth kinetics and the 
degree of therapy resistance. Furthermore, the double IF staining allows analysis of tumor 
regression during therapy, especially in the induction phase. Such analyses may turn out 
to be useful, if the kinetics of tumor regression has prognostic value. 
Applications of the T cell marker jTdT double IF staining 
Our results demonstrate that the T cell marker/TdT double IF staining can be used during 
follow-up of patients with a TdT positive T cell malignancy, to determine whether remission is 
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Figure 3. Follow-up of a T-ALL patient by morphological techniques and COSfTdT double IF staining. Solid 
squares: cos+ fTdT+ cells in PB; Open squares: blast cells in PB; Solid circles: COS+ fTdT+ cells in BM; Open 
circles: blast cells in BM; .!. • : induction therapy; .!. • : reinduction therapy. The three figures summarize data of A: 
cos+ fTdT+ cells and blast cells in PB; 8: cos+ fTdT+ cells and blast cells in BM; C: comparison between the 
percentages COS+ fTdT+ cells in BM and PB. 
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TABLE 6. Applications of the T cell markerjTdT double IF staining. 
1. During follow-up: 
- confirmation of remission after induction therapy 
- early detection of relapse 
- exclusion of relapse 
2. Staging of TdT positive T-NHL at diagnosis 
3. Autologous BM transplantation: 
- detection of residual malignant cells in the BM graft 
obtained during induction therapy, how fast this remission is obtained, and to detect a relapse 
at an early stage. In addition, it is possible to exclude an imminent relapse, when many suspect 
blast cells are detected by use of cytomorphological techniques, such as in regenerating BM 
(Table 6). 
The T cell marker /TdT double IF staining can also be used for staging of TdT positive T-
NHL at diagnosis (75,86). We analyzed BM and PB samples of three T-NHL patients at 
diagnosis, who had a stage I or stage II NHL according to morphological criteria. By use of 
double IF staining, malignant T cells were detected in low frequencies in all BM and PB 
samples. Therefore stage IV classification was more appropriate (Table 6). Our data underline 
the tendency of these T-NHL to disseminate and therefore explain why local treatment is 
insufficient in the majority of patients with mediastinal lymphoblastic lymphoma (87). 
Finally, the T cell marker /TdT double IF staining can be used for analysis of the BM graft 
from patients with a TdT positive T cell malignancy, who undergo autologous BM trans-
plantation. Since our data indicate that very low numbers of malignant cells can give rise to a 
relapse, it is important to exclude that malignant T cells are still present in the autologous BM 
graft (Table 6). 
CONCLUSION 
Detection of low numbers of ALL cells is possible by use of immunologic marker analysis. 
However, the detection limit is often not lower than the detection limit of cytomorphological 
techniques (1 to 10%) (Table 5). This is mainly due to a background of normal cells which 
express the same markers or marker-combination as the ALL cells. This normal background 
is age dependent and is influenced by cytostatic therapy. 
Especially the detection limit of precursor B-ALL and B-ALL cells is limited by the normal 
background, which is, however, low in PB. As a consequence, TdT and the CD10 antigen may 
be useful for monitoring PB in precursor B-ALL patients (Table 5). In addition, TdT can be used 
as a marker for the detection of meningeal involvement in patients with a TdT positive ALL 
The best results are obtained in case of TdT positive T cell malignancies by use of the T 
cell marker /TdT double IF staining. The detection limit of this technique is very low: at least 
0.01% for most T-ALL and TdT positive T-NHL (Table 5). Such low detection limits allow 
362 CHAPTER5.3 
adjustment of remission and staging criteria as well as individualization of therapy, which is 
valuable for the prevention of undertreatment as well as overtreatment of patients. 
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TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE (TdT)-POSITIVE 
CELLS IN CEREBROSPINAL FLUID AND THE DEVELOPMENT OF 
OVERT CNS LEUKEMIA: A 5-YEAR FOLLOW-UP STUDY IN 113 CHILDREN 
WITH A TdT POSITIVE LEUKEMIA OR NON-HODGKIN LYMPHOMA* 
Herbert Hooijkaas 1, Karel Hahlen2 , Henk J. Adriaansen 1, ina Dekke~, 
George E. van Zanen2, and Jacques J.M. van Dongen 1. 
1. Department of Immunology, Erasmus University, University HospitaljDijkzigt, Rotterdam; 
2. Department of Pediatrics, Subdivision Hematology-Oncology, Sophia Children's Hospital, Rotterdam, 
The Netherlands. 
SUMMARY 
We investigated whether an indirect nuclear terminal deoxynucleotidyl transferase (TdT) 
immunofluorescence (IF) assay on single cells present in the cerebrospinal fluid (CSF) is more 
effective than conventional cytomorphology for early detection or exclusion of (minimal) 
meningeal leukemic infiltration in patients with a TdT+ malignancy. During a 5-year follow-up 
study 1 ,661 consecutive CSF samples from 113 children with a TdT+ acute lymphoblastic 
leukemia (ALL) (n=100), a TdT+ acute non-lymphoblastic leukemia (ANLL) (n=8), or a TdT+ 
non-Hodgkin lymphoma (NHL) (n=5) were analyzed. In 1,511 (91.9%) out of 1,643 evaluative 
CSF samples, the positive and negative findings of both cytomorphology and the TdT-IF assay 
were concordant. In 47 (2.9%) samples out of 28 patients the cytomorphology was suspect 
while the TdT-IF assay was negative; follow-up as long as 58 months revealed no central 
nervous system (CNS) leukemia in any patient In 85 (5.2%) samples cytomorphology was 
negative (n = 70) or suspect (n = 15) but TdT+ cells were detected. Red blood cell (RBC) conta-
mination seriously hampered evaluation in 31 out of these 85 samples. From the remaining 54 
TdT+ samples out of 29 patients, 40 samples preceded overt CNS leukemia in 20 patients. Two 
consecutive findings of TdT+ cells in the CSF were always followed by overt CNS leukemia. At 
initial diagnosis, 11 children had TdT+ cells in their RBC-free CSF. In one of these children, 
morphology was suspect; a repeated lumbar puncture was positive on both assays. Thus, initial 
CNS leukemia was diagnosed. In the other 10 children, morphology was negative. In six of 
them, CNS leukemia was diagnosed 2 to 20 months later. In 32 other children examined at 
initial diagnosis, neither TdT+ cells nor blasts were observed in the CSF. In none of these 
*Published in: Blood 1989;74:416-22. 
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patients was a CNS leukemia diagnosed after a follow-up of 2.5 to 57 months (median 24 
months). In 207 control CSF samples from 58 children with Tdl oncologic, hematologic or 
infectious diseases, no TdT+ cells could be detected. The TdT-IF assay is easy to perform and 
is a more reliable diagnostic tool for the detection of CNS leukemia at an early stage than 
cytomorphology. At initial diagnosis, the finding of TdT+ cells in a RBC-free CSF sample with 
a negative cytomorphology is highly predictive for development of overt CNS leukemia. 
INTRODUCTION 
Extramedullary disease, in particular central nervous system (CNS) involvement, still 
represents a major concern in acute lymphoblastic leukemia (ALL) and T cell non-Hodgkin 
lymphoma (NHL) in childhood (1). As a result of improved systemic therapy, the growth of 
tumor cells in the CNS has become apparent (1 ,2). Prevention as well as treatment of early 
CNS involvement are important goals of therapy. In 2 to 15% of patients, relapses occur 
primarily in the CNS (2-16), notwithstanding CNS "prophylaxis". Early diagnosis of CNS 
leukemia implies unequivocal detection of a minimal number of leukemic blasts in the CSF. 
Such early detection of CNS leukemia has definite consequences for the choice of therapy, al-
though one should be aware that it represents a rather late stage of leukemic infiltration of the 
meninges (17). In many protocols for management of patients with leukemia or NHL, cell 
counting and cytomorphologic examination of the CSF at regular intervals have been integrated. 
Diagnostic problems arise when the CSF cell count is low and cytomorphology is suggestive 
but not conclusive for the presence of malignant cells (18-22). Viral infections or chemothe-
rapy can change normal mononuclear cells into atypical blastlike cells (22-24). Furthermore, 
malignant lymphoblasts may have the appearance of relatively well-differentiated lymphocytes 
(25). Therefore, the sensitivity and specificity of classic cytomorphologic techniques for 
detection of malignant lymphoid cells is insufficient and improvements can be expected, e.g. 
by use of immunologic marker analysis of CSF cells. Such analysis can be performed with 
monoclonal antibodies (McAb) or conventional antisera specific for cell surface antigens 
(18,20,26-32) or for the nuclear enzyme terminal deoxynucleotidyl transferase (TdT) (25,33-37). 
TdT is present on the nuclear membrane of immature lymphoid cells of both B cell and T cell 
lineages and of their malignant counterparts. All ALL (except the infrequently occurring mature 
B-ALL) and some T-NHL, especially lymphoblastic lymphomas, are TdT+ (38,39). TdT is also 
expressed in -20% of ANLL (40-42). Normally a substantial proportion of the mononuclear 
bone marrow (BM) cells (up to 11%) and thymocytes may be TdT+. Only low percentages of 
TdT+ cells ( <0.4%) have been detected at other sites, such as peripheral blood (PB) and 
lymph nodes (39,43,44). However, no TdT+ cells have been detected in the CSF from 
individuals not suffering from leukemia or NHL (25,39). Thus, the presence of TdT+ cells in the 
CSF indicates the presence of malignant cells. For the detection of small numbers of TdT+ 
cells, the biochemical TdT assay is insensitive as compared with the TdT immunofluorescence 
(TdT-IF) assay (45,46). In addition, the TdT-IF assay combined with phase contrast morpho-
logy is preferable to cell-surface antigen analysis with McAb for routine analysis of CSF for the 
presence of lymphoblasts, since no single specific cell-surface marker covers all subtypes of 
ALL and some subtypes of ANLL and NHL as efficiently as does TdT. 
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To determine whether the TdT-IF assay improves the detection or exclusion of (minimum) 
leukemic CNS infiltrates in patients with TdT+ malignancies, a longitudinal study was started 
in 1983. We report a 5-year follow-up study involving 1,661 CSF samples from 113 children with 
TdT+ ALL (n=100), TdT+ ANLL (n=S), or TdT+ NHL (n=5). 
MATERIALS AND METHODS 
Patients and evaluation of data 
From February 1, 1983 till February 1, 1988, all children with a newly diagnosed TdT+ leukemia (n=98) or 
TdT+ NHL (n=5) entered the study. In addition, all children with a cytomorphologically and clinically proven 
meningeal involvement diagnosed before February 1, 1983 (n=10) were included. A total number of 1,661 CSF 
samples from 113 patients was analyzed. As a control group, 207 CSF samples from 58 children with T dl 
leukemia, Tdl NHL, or other hematologic, oncologic, or infectious diseases were analyzed. 
The diagnosis of CNS leukemia was made on cytomorphologic criteria only, irrespective of the CSF cell count. 
Two successive CSF samples were examined for this purpose; the second sample was taken at the start of 
intrathecal therapy. A condusion was reached after blast cells had been judged by at least two independent 
observers. Since the TdT-IF assay was considered to be experimental, treatment for CNS involvement was never 
instituted on the basis of the presence of TdT+ cells in the CSF alone. The cytomorphologic investigations were 
performed in the diagnostic laboratory of the Subdivision Hematology/Oncology and the TdT-IF assay was 
performed in the diagnostic laboratory of the Department of Immunology. 
All children were treated according to current local protocols or to those of the Dutch Childhood Leukemia 
Study Group (DCLSG). Since 1984, a spinal tap was performed at initial diagnosis (without intrathecal therapy). 
According to protocol, every 3 months a bone marrow (BM) puncture and a spinal tap were performed, until 4 to 
5 years after initial diagnosis. 
For evaluation of the predictive value of the TdT-IF assay for development of CNS leukemia, only patients who 
did not relapse at other sites were considered. For calculation of the median follow-up, patients were censored 
at the moment of relapse at other sites. 
Treatment protocols 
Four treatment protocols were used related to clinical characteristics at diagnosis. The children without high-
risk characteristics O.e. WBC <50 x 109/1, no mediastinal enlargement, no initial CNS leukemia) were treated 
according to national DCLSG protocol V, in use until November 1983 (A) (47), or protocol VI, in use from November 
1983 to July 1988 (8)(48). Children with an initial WBC >50 x 109/1 were treated according to a local protocol, in 
use until December 1987 (C). Children with mediastinal involvement and with >25% blasts or without a leukemic 
BM were treated with a modified APO protocol (D). 
Induction treatment in protocols A, B and C consisted of vincristine (VCR), prednisone, and L-asparaginase. 
A randomization for addition of daunorubicin was made in protocol A. Maintenance treatment consisted of 7-wk 
cycles of 5 wk of daily oral 6-mercaptopurine (6-MP) and weekly methotrexate (MTX) alternating with 2 wk of 
prednisone and 2 weekly injections of VCR for 2 years (A,B) or 3 years (C). In protocol B, prednisone was 
substituted by dexamethasone from December 1984 on. In protocol C, cyclophosphamide, once every fortnight, 
was added in the 6-MP /MTX period during the first y of maintenance treatment. In protocol D, induction treatment 
consisted of VCR, prednisone, and doxorubicin, followed by L-asparaginase. Maintenance treatment in this protocol 
consisted of pulses of high-dose prednisone, high-dose 6-MP, VCR, and doxorubicin every 3 wk; five days of 
MTX was substituted for doxorubicin after the first 9 mo (49,50). 
CNS prophylaxis for protocols A and C consisted of 25 Gy craniocervical irradiation plus five intrathecal 
injections of MTX (delivered in 2,5 wk) as soon as remission-induction treatment ended. In protocol C, six 
intrathecal injections with MTX, with a 7-wk interval, were administered in addition during the first y of maintenance 
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treatment. 
In protocol B, CNS prophylaxis consisted of two intrathecal injections of MTX at wk 2 and 4 of remission-
induction treatment, followed by three 24-hour infusions of 2 g MTX plus an intrathecal injection of MTX, delivered 
weekly during the first 3 wk after the end of remission-induction treatment. During the first y of treatment, triple 
(MTX, cytarabine (ARA-C), and prednisone) therapy was administered intrathecally every 7 wk (eight times) (48). 
In protocol D, the originally described CNS prophylaxis (50) with cranial irradiation plus five intrathecal injections 
of MTX followed by a intrathecal injection of MTX once every 18 wk was changed as follows: CNS prophylaxis 
consisted of three intrathecal injections of MTX plus ARA-C at wk 3, 6, and 9 during remission-induction and 
consolidation treatment, followed by three 24-hour infusions, once every fortnight, of 2 g MTX plus intrathecal MTX 
and ARA-C followed by an intrathecal injection of MTX plus ARA-C every 6 wk during 1 y (eight times). 
Cell sampling and cytomorphology 
CSF was obtained by lumbar puncture and collected in two plastic tubes, 2 to 5 ml each. One tube was 
processed in the diagnostic laboratory of the Subdivision of Hematology /Oncology within 30 minutes after 
sampling for cell counting and cytomorphology; the other was sent to the diagnostic laboratory of the Department 
of Immunology and was subjected to the TdT-IF assay within three hours after sampling. Cells were counted in 
a Fuchs-Rosenthal chamber. At least two cytocentrifuge preparations were made (0.5 ml each) with a Shandon-
Elliott centrifuge (72 g, ten minutes) and stained with May-Grunwald-Giemsma or additional cytochemical stainings. 
Cytomorphology was considered positive when blasts were found that were unequivocally considered leukemic, 
irrespective of the CSF cell count. CSF samples that contained questionable blastlike cells or atypical (nonviral) 
lymphocytes were regarded as "suspect". 
TdT-IF assay 
For the TdT-IF assay, CSF samples (2 to 5 ml) were centrifuged (300 g, 5 minutes). The cell pellets were 
resuspended to 100 JLI and two cytocentrifuge preparations were made (200 g, 3 minutes, Cytofuge, Nordic 
Immunological Laboratories, Tilburg, The Netherlands). These were air-dried, fixed in methanol (30 minutes, 4 •q 
and washed in phosphate-buffered saline (PBS), pH 7.8, for 15 minutes. One preparation was incubated with 15 
JLI optimally titrated rabbit anti-TdT antiserum; the second preparation, as a control, was incubated with 15 JLI 
normal rabbit serum (moist chamber, 30 minutes, room temperature). After being washed in PBS, the preparations 
were incubated with 15 JLI fluorescein conjugated goat anti-rabbit immunoglobulin antiserum and washed again 
(51). The anti-TdT antiserum and the second-step antiserum were obtained from Bethesda Research Laboratories 
(Bethesda, MD) and from Supertechs (Bethesda, MD). The preparations were then mounted in glycerol PBS (9:1) 
containing p-phenylenediamine 1 mgjml (BDH Chemicals, Poole, UK) to prevent fading of fluorochrome, covered 
with a coverslip and sealed with paraffin wax with ceresin (BDH chemicals) (52). Cells expressing nuclear TdT were 
enumerated using Zeiss fluorescence microscopes (Carl Zeiss, Oberkochen, FRG) equipped with phase contrast 
facilities (52). A concentration effect (centrifugation of 2 to 5 ml CSF) might be the reason why we almost invariably 
detected cells on the TdT cytocentrifuge preparations, even when cell counts were low ( <5/JLI). If possible 100 to 
2,000 cells were screened. ·In 19% of cases, however, low cell count of the CSF allowed screening of 10 to 100 
cells only; 63% of the preparation contained 1 00 to 500 cells, whereas 18% contained < 1 0 cells. The percentage 
of TdT+ cells was calculated as the fraction of the number of nucleated cells, as determined by phase contrast 
morphology. If any TdT+ cells were found in an atraumatic (RBC-free) spinal tap, the result of the TdT-IF assay was 
considered positive, irrespective of the total number of cells in cytocentrifuge preparation or the CSF count. 
RESULTS 
Of i ,661 CSF samples available, i 8 samples were non- evaluative for comparison between 
cytomorphology and the TdT-IF assay since it proved impossible to perform both examinations. 
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In 1,643 samples from 113 children with a TdT+ acute leukemia or NHL the correlation be-
tween cytomorphology and the TdT-IF assay could be examined. Findings are summarized 
in Table 1. In 88.0% of the 1 ,643 evaluative samples, both cytomorphology and the TdT-IF 
assay were negative; in 3.9% of the 1 ,643 samples, the results were both positive. The 
cytomorphology was suspect in 62 samples (3.8%). In 47 out of these samples (2.9%) from 28 
patients no TdT+ cells were observed. No meningeal involvement has occurred in these pa-
tients during a median follow-up period of 26 months (range: 1 to 58 months). In the remaining 
15 (0.9%) cytomorphologically suspect samples TdT+ cells were observed. In 70 other samples 
(4.3%) in which no blasts were observed by cytomorphologic examination, TdT+ cells proved 
to be present (Table 1). 
The follow-up of the 49 ALL, one ANLL, and two NHL patients who contributed to the 85 
TdT+ but cytomorphologically suspect or negative CSF samples is summarized in Tables 2 and 
3. Table 2 shows data of children with TdT+ samples at initial diagnosis; Table 3 shows data 
of those with a first TdT+ sample during maintenance therapy or after cessation of treatment. 
Data are subdivided in CSF samples with or without RBC contamination (Tables 2 and 3). The 
31 RBC-contaminated CSF samples (18 at diagnosis and 13 during follow-up) were considered 
non-assessable. Out the 54 RBC-free TdT+ samples, 11 were obtained at initial diagnosis from 
nine ALL and two T-NHL patients (Table 2). The percentages of TdT+ cells ranged from 0.3 to 
70% (median 13%). In one child the CSF was cytomorphologically suspect, and a spinal tap 
repeated after 5 days contained both TdT+ cells and leukemic blasts according to cyto-
morphologic criteria. Thus, initial CNS leukemia was diagnosed. In the other ten patients a 
second CSF sample obtained 2 to 3 weeks later, during the systemic induction treatment, did 
not contain TdT+ cells anymore. However, six out of ten patients (five ALL and one T-NHL) 
developed a CNS leukemia as diagnosed by cytomorphology 2 to 20 months later. The other 
four patients did not develop a CNS leukemia during a median follow-up of 38 months (range 
31 to 55 months). In 32 patients without TdT+ cells in their RBC-free CSF samples at diagno-
sis, no CNS leukemia was diagnosed during a median follow-up of 24 months (range 2.5 to 57 
months). 
The other 43 RBC-free TdT+ CSF samples from 17 ALL, one ANLL and two T-NHL patients 
were obtained during follow-up on or off therapy (Table 3). Nine patients (ten samples) did not 
develop CNS leukemia; five out of them (six samples), however, relapsed in the BM and accor-
TABLE 1. Correlation between cytomorphology and TdT-IF assay in 1,643 CSF samples 
from 113 patients with a TdT+ ALL (n = 100), a TdT+ ANLL (n = 8), or a TdT+ 
NHL (n=5). 
TdT-IF assay 
Cytomorphology Negative Positive Total 
Negative 1,446 (88.0%) 70 (4.3%) 1,516 (92.3%) 
Suspect 47 (2.9%) 15 (0.9%) 62 (3.8%) 
Positive 0 (0%) 65 (3.9%) 65 (3.9%) 
Total 1,493 (90.9%) 150 (9.1 %) 1,643 (100.0%) 
(.,.) 
-...j 
1\) 
TABLE 2. Follow-up of 27 ALL and two NHL patients with TdT+ cells in CSF at initial diagnosis, but with negative or suspect CSF cytomorphology 
(n = 29 samples). 
CSF TdT-IF assay Clinical course 
WBCat PB BM 
Patient Age Diagnosis Blasts Blasts Immunologic Treatment TdT+ Inter- CNS Follow-up 
CSF sample No. Sex (y) (x109/l) (%) (%) Phenotype Protocol a Cells pretetion Leukemia (mo) 
No RBC, negative M 7 62.0 75 83 T-ALL D 0.3 + no 42+ 
cytomorphology 2 M 2 34.9 62 95 common ALL B 5.0 + yes 12 
3 M 3 10.3 37 98 common ALL B 11 + yes 2 
4 F 3 14.5 58 93 pre-BALL B 13 + no 31 + 
5 M 2 63.0 91 100 common ALL c 14 + no 34+ ~ 6 M 15 3.1 60 68 common ALL A 15 + yes 17 )::0 
7 F 5 266.0 73 92 T-ALL D 18 + yes 6 'U ;;:j 
8 F 4 1.5 27 85 pre-BALL B 70 + yes 20 JJ 
9 M 13 7.0 0 T-NHL D 2 + no 55+ f" 
-!>. 
10 F 8 9.9 0 3 T-NHL D 2 + yes 3 
No RBC, suspect 11 M 2 5.5 59 85 common ALL 55 + initial 
cytomorphology 
RBC contaminated, 12 M 12 124.4 90 97 T-ALL D 43 NAb yes 0.5 
negative or suspect 13-29 F:5 2-13 3.0-402.0 7-99 79-99 common ALL:9 B:12 0.2-67 NA no 5.5-37+ 
cytomorphology (n = 17) M:12 (m:5)0 (m:19.4) (m:59) (m:95) pre-B ALL:4 C:3 (m:20)d 
T-ALL:4 D:2 
a. Treatment protocols A, B, C, and D are described in the Materials and Methods section. 
b. NA, not assessable due to RBC contamination. 
c. m, median. 
d. Three patients developed a BM relapse. 
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TABLE 3. Evaluation of 29 patients with TdT+ cells in CSF during follow-up but with a negative or suspect 
CSF cytomorphology (n = 56 samples). 
TdT-IF assay Clinical course 
Number Number TdT+ cells Relapsed in Follow-up in mo 
RBC of of (%) Interpretation the CNS Median (range) 
in CSF patients a samples 
no 13 33 0.1-72 positive yes 2 (0.5-24) 
no 9 10 0.2-3.0 positive nob 4(1-48+) 
yes 12 13 0.01-1.4 not assessablec nod 7 (4-56+) 
a. Four patients are represented in more than one category. c. Three patients developed a BM relapse. 
b. Five patients developed a BM relapse. d. Not assessable due to RBC contamination. 
dingly received reinduction therapy, including CNS prophylaxis. Two samples from two patients 
were obtained in the last phase of successful CNS leukemia reinduction treatment and repre-
sented the last positive finding in a series of several TdT+ samples in which cytomorphology 
was already negative. One of the remaining two samples was positive during CNS prophylaxis, 
and the other was positive during maintenance therapy. These two patients did not develop 
CNS leukemia at 48 and 46 months of follow-up, respectively. In 13 patients (33 samples) 
findings of TdT+ cells in the CSF were followed by a diagnosis of overt CNS leukemia within 
a median follow-up of 1.5 months (range 0.5 to 24 months). In our series, two consecutive 
findings of TdT+ cells in the CSF were always followed by overt CNS leukemia. 
TdT+ cells were never detected in 207 RBC-free CSF samples from 58 patients with Tdl 
leukemia or NHL or with other hematologic, oncologic, or infectious diseases. Moreover, 
several patients in our leukemia and NHL follow-up study had episodes with bacterial or viral 
meningitis, sometimes paralleled with high CSF cell counts. However, neither were TdT+ cells 
noted in the CSF of patients with these infections. 
DISCUSSION 
The present study was undertaken to investigate (a) whether the presence of TdT+ cells in 
the CSF, as demonstrated by TdT-IF assay, would be helpful for early diagnosis of CNS 
leukemia and (b) whether the absence of TdT+ cells would strongly argue in favor of the 
absence of meningeal involvement. The result would have direct implications for treatment. 
Our data indicate that all CNS leukemias diagnosed on clinical and cytomorphologic criteria 
were always confirmed by TdT-IF assay, resulting in a 100% sensitivity. In addition, we were 
able to detect TdT+ cells before overt CNS leukemia according to cytomorphologic criteria 
could be diagnosed (Tables 2 and 3). We further investigated whether the presence of TdT+ 
cells (even in low numbers) is indicative for meningeal involvement. TdT+ cells do not belong 
to the normal CSF cell population and, as a consequence, every single TdT+ cell in the CSF 
should be considered malignant (25,35). Our experience concurs with these assumptions 
(36,39,45). The present study confirms the findings of other investigators (25) that TdT+ cells 
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do not occur in the CSF of non-leukemic patients. We further investigated the CSF of patients 
with a TdT+ malignancy who received systemic treatment or prophylactic CNS treatment which 
may prevent development of CNS leukemia. 
Each finding of TdT+ cells does not appear to be followed by overt CNS leukemia (fables 2 
and 3). This may be a consequence of treatment. During sampling the CSF may also become 
contaminated at times with leukemic or non-leukemic TdT+ cells from PB (23,53,54) or even 
BM (47,55-57). Such contamination may occur especially at diagnosis, when high numbers of 
TdT+ tumor cells can be present in PB and BM. Therefore, at diagnosis as well as during 
follow-up simultaneous analysis of both CSF .and PB for TdT+ cells is desirable. However, 
during traumatic lumbar puncture only -20% of the predicted numbers of WBC are found in 
the CSF, suggesting that a direct extrapolation of PB data to data of contaminated CSF is not 
accurate (8-60). We and other investigators believe that CSF samples with leukemic (or TdT+) 
cells derived from such contaminated punctures cannot be evaluated properly (22,23,53). In 
such cases the spinal tap should be repeated. For this reason, we have regarded results of 
TdT+ RBC-containing CSF samples as nonassessable (fables 2 and 3). 
Forty-three children had RBC-free CSF samples at initial diagnosis. In 32 of them no TdT+ 
cells were present in the CSF. In none of them was overt CNS leukemia diagnosed during a 
median follow-up of 24 months (range 2.5 to 57 months). Eleven of the 43 patients had TdT+ 
cells in their CSF. In one of them TdT+ cells were present while cytomorphology was suspect; 
initial CNS leukemia was unequivocally diagnosed at a repeated spinal tap five days later. In 
the other ten patients, no blasts were noted on cytomorphologic examination. Thus, based on 
the TdT-IF assay alone, the incidence of detectable CNS involvement at diagnosis was 25% (11 
out of 43), much higher than the commonly reported 5% based on cytomorphologic criteria 
(1, 14). Indeed, six out often children (60%) not diagnosed as having initial CNS leukemia, even-
tually developed overt CNS leukemia despite CNS prophylaxis. Why in the four patients with 
0.3 to 14% TdT+ cells in the CSF at diagnosis overt CNS leukemia was not diagnosed after a 
follow-up of 31 to 55 months is not clear. All ten children with TdT+ cells in the CSF at initial 
diagnosis received comparable CNS prophylaxis. At present, we must assume that the CNS 
prophylaxis was able to prevent or eliminate meningeal leukemia in these four patients. 
However, CNS leukemia can still occur many years after initial diagnosis (6); thus, the period 
of follow-up may still be too short. Nevertheless, our data indicate that a positive TdT-IF assay 
in the first RBC-free CSF sample of untreated patients selects for those at high risk of 
developing overt CNS leukemia according to standard criteria. Thus, we believe that the finding 
of TdT+ cells in a RBC-free CSF sample at diagnosis should be taken into account for a 
diagnosis of initial CNS leukemia and as a consequence should lead to a more intensive CNS 
treatment. 
Concerning the patients under maintenance treatment or treated for CNS leukemia, two 
consecutive findings of TdT+ cells in RBC-free CSF samples without cytomorphologically 
detectable leukemic blasts were always followed by a cytomorphologically confirmed CNS 
leukemia. Incidental findings of TdT+ cells in the CSF from such patients did not always result 
in overt CNS leukemia as a first event. Therapy, especially the therapy administered as a 
consequence of relapses at other sites than the CNS, might have prevented the development 
of overt meningeal leukemia in these patients. However, a first finding of TdT+ cells in the CSF 
from patients off therapy was always followed by a second finding. Subsequently, overt CNS 
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leukemia always resulted, indicating that a single finding of TdT+ cells in a CSF sample from 
patients after cessation of treatment might well be sufficient for the diagnosis of CNS leukemia 
relapse. 
In our experience and that of other researchers the TdT-IF assay can be performed easily, 
even when low numbers of cells are present in the CSF (25,35). The TdT-IF assay proved 
highly sensitive for evaluation of CSF samples from patients with TdT+ leukemia or NHL. This 
assay contributes to early detection as well as exclusion of CNS leukemia. In our opinion, it is 
the most reliable tool for diagnosing CNS leukemia in patients with TdT+ malignancies. 
Moreover, it also offers the possibility for selecting diagnosis of patients at high risk of 
developing overt CNS leukemia. Therefore, the diagnostic criteria for presence or absence of 
CNS leukemia should include the findings of the TdT-IF assay. 
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CHAPTER 6.1 
INTRODUCTION: IMMUNOGLOBULIN AND T CELL RECEPTOR GENES 
IN CLONAL EXPANSIONS OF LYMPHOCYTES 
J.J.M. van Dongen and I.L.M. Wolvers-Tettero 
Department of Immunology, Erasmus University/ 
University Hospital Dijkzigt, Rotterdam, The Netherlands. 
During the last decade the classification of lymphoproliferative diseases and related 
disorders has been improved by the application of immunologic marker analysis (1-7). Generally 
this is sufficient for identifying the 8 or T cell origin of a lymphoid malignancy and often allows 
a more detailed classification with the recognition of subgroups of the disease (1-7). The 
application of immunologic marker analysis for diagnostic purposes is discussed extensively 
in Chapter 5. 
It is also possible to prove the clonal origin of mature 8 cell malignancies which express 
immunoglobulin (I g) molecules, by demonstrating single lg light chain expression (1 0-14). Since 
clonality is equivalent to malignancy in the majority of cases, this test is useful for the distinction 
between malignant and reactive 8 cell populations (1,2,5,10-14). However, immature 8 cell 
malignancies, such as acute lymphoblastic leukemia (ALL) of the 8 cell type, and several 
mature 8 cell malignancies do not express lg molecules and in case of T cell malignancies 
there is no appropriate marker for clonality at the protein level (1 ,2,4-1 0). Many hematopoietic 
malignancies have chromosome aberrations (15-17) which can be used as markers for clonality 
and often also as tumor-specific markers (17, 18). However, optimal cytogenetic analysis can 
only be performed on freshly isolated cell samples or tissue biopsies and even then it may be 
difficult to obtain metaphases of the malignant cells (15,19). 
In some lymphoproliferative disorders the distinction between a malignant and a reactive 
process and the determination of the lineage association of the malignancy may be difficult or 
impossible on the basis of morphological studies and immunologic marker analysis. In these 
cases clonality and the origin of the involved lymphoid cell populations may be determined by 
studying the configuration of the genes which code for the antigen-specific receptors of lym-
phocytes: the lg genes and the T cell receptor (TcR) genes (20-25). This approach is based 
on the fact that 8 and T cells rearrange their lg and TcR genes, respectively, and that these 
gene rearrangements are different in each lymphocyte, but identical within a lymphocyte clone. 
This holds for both physiological and malignant clonal expansion. The configuration of germline 
and (clonally) rearranged lg and TcR genes can be studied by Southern blot analysis (see 
Chapter 3.3). 
In Chapter 6.2 we shall summarize the occurrence of lg and TcR gene rearrangements in 
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the various types of leukemias and non-Hodgkin lymphomas (NHL) to demonstrate that 
leukemias and NHL can at least partly be used as model system for studying the hierarchic 
order of lg and TcR gene rearrangements during normal lymphoid differentiation. In Chapter 
6.3 we shall critically discuss the possibilities and limitations of lg and TcR gene analysis for 
diagnosis and management of lymphoproliferative diseases and related disorders. This will be 
illustrated by a series of clinical cases. 
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CHAPTER 6.2 
REARRANGEMENT OF IMMUNOGlOBUliN AND T CEll RECEPTOR 
GENES IN LEUKEMIAS AND NON-HODGKIN lYMPHOMAS 
INTRODUCTION 
J.J.M. van Dongen and l.l.M. Wolvers-Tettero 
Department of Immunology, Erasmus University/ 
University Hospital Dijkzigt, Rotterdam, The Netherlands. 
* 
It has widely been accepted that each type of leukemia and non-Hodgkin lymphoma (NHL) 
has a normal cellular counterpart and that each of these counterparts can be fitted into a 
normal differentiation/maturation pathway (1-5). Several lymphoid malignancies indeed have 
obvious cellular counterparts with identical morphology and immunophenotype. However, this 
concept remains an "unproven hypothesis", since for several malignancies a normal counterpart 
has not (yet) been found (6-9). 
Some reports emphasize the diagnostic usefulness of immunophenotypic differences 
between lymphoid malignancies and their "normal counterparts" (7 ,9, 1 0). These differences 
include both acquisition and loss of immunologic markers (7,9, 10). Discrepancies between 
morphological and immunologic classifications of hematopoietic malignancies also occur, 
especially in acute myeloid leukemias (AML) and NHL (7-11). However, these discrepancies 
are at least partly due to the frequent occurrence of subpopulations, which may have different 
phenotypes (5). 
Despite the mentioned discrepancies, hypothetical differentiation schemes as presented in 
Chapters 2.3 and 5.1 form a useful conceptual framework for the relationship between the 
various lymphoid malignancies. It also allows the evaluation of the possible relationship between 
the differentiation stage of malignancies and the configuration of their Immunoglobulin (I g) and 
T cell receptor (TcR) genes. 
IMMUNOGlOBUliN GENE REARRANGEMENTS IN B CEll MALIGNANCIES 
The various types of precursor B cell acute lymphoblastic leukemia (precursor B-ALL; i.e. 
null ALL, common ALL and pre-B-ALL) and B-ALL can be regarded as malignant counterparts 
of immature B cells (1-5). The chronic B cell leukemias, such as B-CLL, B cell prolymphocytic 
leukemia (B-PLL) and hairy cell leukemia (HCL) as well as the various types of B-NHL can be 
*This manuscript wi!l be published as part of a review in Clin Chim Acta. 
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TABLE 1. lgH and lgL gene analysis of nineteen precursor B-ALL and seven chronic B cell leukemias. 
lgH genesb lg~ genesb lgA genesb 
Patient Type of JH probe c~ probe C). probe >.-IVS probe 
no. leukemiaa 
Bg/11 EcoRI Bam HI EcoRI EcoRI 
1. null ALL G/G GjG GjG GjG 8.3j8.3c 
2. null ALL R/R/Gw R/R/Gw GjG GjG 8.3/8.3 
3. null ALLd R/Rw/Rw/G e R/G GjG G/G 8.3/8.3 
4. null ALL R/R RjR GjG G/G 8.3/8.3 
5. null ALL R/R/Gw R/R/Gw GjG G/G 8.3/19.1 
6. common ALL R/Gw R/Gw GjG G/G 8.3/13.7 
7. common ALL R/Gw R/Gw GjG G/G 8.3/8.3 
8. common ALLd R/R/R/Gw e R/R/Gw GjG G/G 8.3/8.3 
9. common ALL R/R R/R GjG G/G 8.3/8.3 
10. common ALLd R/R/Rw e R/R/R R/G G/G 8.3/24.5 
11. common ALLd R/R/Rw/Rw/G R/R/R/Rw/G R/G G/G 8.3/8.3 
12. common ALLd R/R/R/Ge R/R/R/G R/G R/G 8.3/10g 
13. common ALL R/G RjG GjG R/R 8.3/-h 
14. pre-B-ALL R/G R/R GjG GjG 8.3/19.1 
15. pre-B-ALL d R/Rw/Rw/Rw e RjR GjG G/G 8.3/8.3 
16. pre-B-ALL R/R R/R/R GjG G/G 8.3/8.3 
17. pre-B-ALL d R/R/R/R/Rw/Rw R/R/R/R e GjG GjG 8.3/19.1 
18. Sm~+ B-ALL R/R R/R D/R GjG 8.3/8.3 
19. Sm>. +B-ALL R/R R/R DjD R/R -/-h 
20. Sm~+ B-CLL R/R R/R D/R GjG 8.3/8.3 
21. Sm~+ B-CLL R/G R/G D/R GjG 8.3/19.1 
22. Sm~+ B-CLL R/R/G RJR/G R/G GjG 8.3/8.3 
23. Sm>. + B-CLL R/G R/R DjD R/R 13.7/-h 
24. Sm). + B-CLL R/R R/Rw/Rw f DjD D/R _h/10g 
25. Sm>. + B-CLL R/Rw/Rw/G f R/R/G DjD R/R 8.3/5g 
26. Sm~+ B-PLL R/R R/R D/R GjG 8.3/8.3 
a. The different types of precursor B-ALL are defined as follows: null ALL: CD19+, CD10-, weak CyfJ--. Smlg-; common ALL: CD19+, CD10+, 
weak CyJ1--, Smlg-; pre-B-ALL: CD19+, CD10+, weak CyJl-+, Smlg-; B-ALL: CD19+, CD10 +or-. weak CyfJ--, Smlg +(see ref.5). 
b. G, germline band; Gw. weak germline band (Probably caused by contaminating non-B cells); R, rearranged band; Rw. weak rearranged 
band; D, deletion of the involved gene (segment). 
c. The numbers represent the sizes (in kb) of the bands detected with the ~-IVS probe in EcoRI digests. 
d.ln patients 3, 8, 10, 11, 12, 15 and 17 more than two rearranged bands were found in at least two different digests. 
e. These patterns of multiple rearranged bands were confirmed in BamHljHindlll digests. 
f. In patients 24 and 25 one strong rearranged band and two weak rearranged bands were detected in one digest. This was not confirmed 
in other digests. 
g. The 5 kb and 10 kb bands detected with the ~-IVS probe in EcoRI digests probably represent non-germ line bands due to rearrangements 
involving the C~2-C~3 gene segment. 
h. In some leukemias the C~2-C~3 gene segment is probably deleted on one or both alleles. 
regarded as the counterparts of B cells in mature stages of differentiation (2,3,5). Based on 
this concept the various B cell malignancies have repeatedly been used to study the lg heavy 
chain (lgH) and lg light chain (lgL) gene rearrangements during lymphoid differentiation (12-
28). As an example of this type of approach we have summarized the Southern blot data of 
twenty-five leukemias of B cell lineage in Table 1 and Figures 1-3. Data from several reports on 
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Figure 1. lgH gene analysis of precursor B-ALL, B-ALL and chronic B cell leukemias (see Table 1 ). DNA samples 
from control cells and from the leukemic cells were digested with Bg/11, size separated and blotted to a nylon 
membrane, which was hybridized with a 32P-Iabeled JH probe. A: precursor B-ALL; B: Smlg+ B cell leukemias. In 
most leukemias two rearranged bands were detected, but in some precursor B-ALL (e.g. patient 17) multiple 
rearranged bands were found. 
large series of leukemias are summarized in Table 2 (12-26). 
Except for a minority of precursor B-ALL (2%), especially null ALL, all leukemias of B cell 
origin have rearranged their lgH genes (Tables 1 and 2). In most of them rearrangement and/ 
or deletion has occurred on both lgH gene alleles: 80 to 85% of ALL and 75 to 80% of chronic 
B cell leukemias (13,17,18,20-24; Table 1). It has been suggested that monoallelic lgH gene 
rearrangements occur more frequently in Smx; + than in Sm>.. + malignancies (26). Rearrange-
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Figure 2. I gil: gene analysis of precursor B-ALL, B-ALL and chronic B cell leukemias (see Table 1 ). DNA samples 
from control cells and from the leukemic cells were digested with Bam HI, size separated and blotted to a nylon 
membrane, which was hybridized with a 32P-Iabeled C.~~: probe. A: precursor B-ALL; B: Smlg + B cell leukemias. 
In a few precursor B-ALL lg.K: gene rearrangements were detected. All Sm.~~:+ B cell leukemias had rearranged lg.K: 
genes, while the C.K: gene segment appeared to be deleted on both alleles in all Sm:>.. + B cell leukemias. 
ments and/or deletions in lg~~: and lg:>.. occur in 5 to 25% of precursor B-ALL. However, no clear 
hierarchic pattern of lgL gene rearrangements was found, since they appear to occur in all 
three types of precursor B-ALL in variable frequencies (Table 2). 
The pattern of lgL gene rearrangements is more clear in chronic B cell leukemias. All Sm.~~:+ 
leukemias had rearranged one or both lg~~: genes, while no lg:>.. gene rearrangements or biallelic 
lg~~: gene deletions were found (Tables 1 and 2). All lg:>.. + B cell leukemias had rearranged at 
least one lg:>.. gene allele and virtually all of them had deleted andjor rearranged their lg~~: genes. 
A _J _J _J _J 8 _J _J _J _J _J _J _J _J _J _J _J _J _J _J 
_J _J _J _J _J _J _J _J _J _J 
<( <( 
_J <( <( _J <( u u u u <( u u u u 
_J _J c c _J _J _J c c _J 00 00 00 00 00 00 00 00 00 00 
_J _J 0 0 <( _J _J 0 0 <( 
<( <( E E 00 <( <( E E cp + +, ~ + + + + ~ ~ ~ 
"' 
-< -< 
"' "' :; E E ~ :; E E ~ E E E E E E E E E E ::J 0 0 ::J 0 0 rJ) rJ) rJ) rJ) rJ) rJ) rJ) rJ) rJ) rJ) c c () () 0. c c () () 0. 
C\J '<!" C\J (') '<!" C\J '<!" C\J (') '<!" co 0 (') '<!" L!) co 0 (') '<!" L!) 
C\J N C\J N C\J C\J N N 
kb kb 
19.1 
-
_G 17.0_ 17.0= -G 
-G 14.0> 14.0- -G -G 13.7 .... 
12.0 10.0-
-* 1o.o-
-* 
8.3-
... ~- -G 8.3-
-
-G 
7.8..-
7.4~ -* 7.0-
7.2 
5.0- -t/IA 5.0- _!J;)\ 
4.7- -1/;A? 4.7- -tjJA.? 
4.4-
EcoRI, CA. probe EcoRI, >..-IVS probe EcoRI, CA. probe EcoRI, >..-IVS probe 
Figure 3. lgA gene analysis of precursor B-ALL, B-ALL and chronic B cell leukemias (see Table 1). DNA samples from control cells and from the leukemic cells were 
digested with EcoRI, size separated and blotted to a nylon membrane, which was hybridized with a 32P-Iabeled C.>- probe (A) and subsequently rehybridized with 
a 32P-Iabeled A-IVS probe (B). A few precursor B-ALL and all Sm.>-+ B cell leukemias had rearranged lgA genes. The 8.3 kb, 13.7 kb and 24.5 kb bands detected 
:X:, 
CD 
ru 
~ 
:::, 
<Q 
CD 
3 
CD 
~ 
0 
.... 
<Q 
ru 
:::, 
Q. 
()! 
:X:, 
<Q 
CD 
:::, 
~ 
s· 
m-
~ 
CD 
3 
n;· 
"' ru :::, 
Q. 
~ r-
with the .>--IVS probe represent germline bands of normal or amplified C.>-2-C.>-3 gene segments; the 5 kb and 10 kb bands represent non-germllne bands due to w 
rearrangements involving the CA2-CA3 gene segment. ~ 
390 CHAPTER6.2 
TABLE 2. lg gene rearrangements in leukemias of B cell lineage, as reported in the literature. 
Rearranged Rearranged Deleted Rearranged 
lgH genes lgK: genes lgK: genes lgA genes 
(R/G or R/R) (R/G, R/R or R/D) (D/D or D/G) (R/G or R/R) 
Acute lymphoblastic B cell leukemiasa 
null ALL (CD10-, CYiLl 95% (52/55) 13% (5/38) 8% (3/38) 9% (2/23)b 
common ALL (CD10+, Cyp.l 99% (119/120) 32% (22/69) 12% (8/69) 2% (1/52) 
pre-B-ALL (CD10+, Cyp.+) 100% (33/33) 8% (1/12) 8% (1/12) 20% (2/10) 
all CD10+ precursor B-ALL0 98% (193/196) 23% (28/121) 12% (14/121) 5% (5/92) 
all precursor B-ALL 98% (245/251) 21% (33/159) 11% (17/159) 6% (7 /115) 
B-ALL (Smlg +) 100% (3/3) 
Chronic B cell leukemiasd 
SmK:+ B-CLL 1 00% (27 /27) 100% (18/18) 0% (0/18) 0% (0/19) 
Sm~~:+ B-PLL 100% (8/8) 100% (6/6) 0% (0/6) 0% (0/4) 
SmK:+ HCL 100% (12/12) 100% (12/12) 0% (0/12) 0% (0/12) 
Sm.A + B-CLL 100% (18/18) 7% (1/14) 86% (12/14) 100% (11/11)b 
Sm.A + B-PLL 100% (7/7) 50% (3/6) 50% (3/6) 100% (5/5) 
Sm.A + HCL 100% (17/17) 12% (2/17) 83% (10/12)e 100% (16/16) 
a. The data concerning the ALL of B cell origin are derived from references 12-22. 
b. In one null ALL, a Sm>.+ B-CLL and a few Sm>.+ HCL rearranged lg.l. genes were found in the presence of germline lg/C genes (ret. 17,24 
and 25). 
c. The subgroup "CD10+ precursor B-ALL" include common ALL (CD10+, CYJ' land pre-B-ALL (CD10+, Cyt/) as well as the CD10+ precursor 
B-ALL (a total of 43 patients) from publications which did not report CyJJ. staining. 
d. The data concerning the chronic B cell leukemias are derived from refs. 23-26. 
e. In several cases of HCL the presence of non-leukemic cells hampered the detection of" deletions as determined by use of the CIC probe 
(23,25). These cases were excluded from the table. 
Only a few leukemias with rearranged lg). genes but germline lg~~: genes have been reported 
(17,24,25 and ALL patient 13 in Table 1). In 75 to 80% of leukemias with rearranged lg.\ genes, 
the C~~: gene segment appears to be deleted on both alleles (12, 17,18,21 ,23,24,26). 
Few studies on lgH and lgL gene analysis in B-NHL have been reported. It appears that 
in B-NHL the lgH and lgL gene rearrangements are comparable to those in chronic B cell 
malignancies (27,28). 
These data together indicate that a hierarchy in lg gene rearrangements exists, which 
nevertheless seems to be less obvious than predicted from the combined murine and human 
data OrJ normal B cell differentiation (c.f. Figure 11 in Chapter 3.2). This especially concerns 
the lgL gene rearrangements in precursor B-ALL, since lg~~: andjor lg.A gene rearrangements 
have been found in all three types of precursor B-ALL (Table 2). From the leukemia data it can 
be concluded that lgH genes rearrange earlier than lgL genes, that lg~~: genes generally 
rearrange prior to lg.A genes, and that in most cases with lg). gene rearrangement lg~~: gene 
segments have been deleted on both alleles (Figure 4). 
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Figure 4. Hypothetical scheme of human lymphoid differentiation, summarizing the available data about the 
ordered rearrangement of lg and TcR genes as determined by the analysis of leukemias and NHL (c.f. Figure 11 
in Chapter 3.2). 
T CELL RECEPTOR GENE REARRANGEMENTS IN T CELL MALIGNANCIES 
The T lymphoblastic malignancies such as T-ALL and lymphoblastic lymphomas ofT cell 
origin can be regarded as malignant counterparts of cells in immature T cell differentiation 
stages. About 65 to 70% of these immature T cell malignancies do not express a TcR-CD3 
complex on their cell membrane (CD3- T cell malignancies), while 30 to 35% are CD3+ (31), 
which implies that they express a TcR on the membrane (32,33). The mature T cell 
malignancies include the various types of peripheral T cell lymphomas, the T cell prolym-
phocytic leukemias (f-PLL) and the human T cell leukemia virus 1 (HTLV-1) positive adult T cell 
leukemia-lymphomas (ATLL) as well as the cutaneous T cell leukemia-lymphomas (CTLL) and 
related diseases such as Sezary syndrome (SS) (c. f. Figure 1 in Chapter 5.1). The far majority 
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of these mature T cell malignancies express CD3. The heterogeneous group of the more 
benign T cell proliferations such as T-CLL, T--y lymphocytosis and large granular lymphocyte 
(LGL) proliferations will be discussed in Chapter 6.3. 
In studies on the rearrangement and expression of TcR genes during human T cell 
differentiation, generally T-ALL have been used (19,21,22,34-60). In most studies only TcR-,8 
genes and/or TcR--y genes have been analyzed (19,21 ,22,34-52). Recently, also data about 
the TcR-o genes have been reported (54-60), while appropriate data about TcR-o: gene 
rearrangements are still scarce (53,61 ,62) due to the complexity of the TcR-o: gene locus with 
the long stretch of Jo: gene segments (61-65). Therefore, analysis of the TcR-o: gene locus 
needs multiple Jo: probes (53,61 ,62,66-68), which have to be distributed throughout the 
complete Jo: region in order to detect each TcR-o: gene rearrangement (53,61 ,62). Data from 
a large series of reports about TcR gene analysis ofT cell malignancies (34-60,69-75) are 
summarized in Table 3. Data about T cell lines are not included in this table (61 ,62,67). 
Approximately 85% of the CD3- lymphoblastic T cell malignancies have rearranged their 
TcR--y and TcR-fl genes (Figure 5 and Table 3). Several CD3- T-ALL (45,57,76,77) and CD3-
T-NHL (78,79) have rearranged TcR--y genes and germline TcR-fl genes, but also a few COT 
T cell leukemias with germline TcR--y genes and rearranged TcR-,8 genes have been reported 
(21 ,46). In some of the latter cases TcR--y gene rearrangements may have been missed, 
because only restricted TcR--y gene analyses were performed. 
In the far majority of CD3+ T cell malignancies both TcR-fl and TcR--y gene rearrangements 
have been found (Figure 5 and Table 3). Only four of the CD3+ T-ALL and three of the CD3+ 
T-NHL in Table 3 had germline TcR-fl genes (21 ,37,48,57). In three of the four T-ALL cases it 
was proven that the leukemic cells expressed TcR--yo (21 ,55,57). Probably also other reported 
CD3+ T cell malignancies with germline TcR-fl genes express TcR--yo (49,56,78,80-82). 
However, in most TcR--yo+ T-ALL the TcR-fl genes are rearranged (57,59). 
In most T cell malignancies (86 out of 98 tested; i.e. 88%) the TcR-fl gene rearrangements 
involved the ,82 locus on one or both alleles (21 ,34,38,40,41 ,46,47,49,50,82). This would imply 
that analysis of the fl2 locus detects the majority of TcR-fl gene rearrangements in T cell 
malignancies. The TcR--y gene rearrangements in T cell malignancies involve the -y2 locus on 
both alleles in 77% (66/86) of cases, while the remaining 23% have monoallelic or biallelic 
rearrangements within the -y1 locus (49,51 ,52,59,71 ,82). 
Recently, data about TcR-o genes in T cell malignancies have become available (54-60). 
These reports indicate that in virtually all CD3- and CD3+ T cell malignancies the TcR-o genes 
are rearranged and/or deleted (Figure 5 and Table 3). Even six immature T-ALL cases with 
germline TcR-,8 and TcR--y genes appeared to have rearranged TcR-o genes (55-57). Most 
TcR-o gene rearrangements appeared to involve the Jc51 gene segment (41 out of 47 
rearranged TcR-o gene alleles; i.e. 87%), while a few rearrangements to the Jc52 gene segment 
were found (13%) (54,56,59). Rearrangements in the TcR-o: genes are infrequent in CD3- T cell 
malignancies, but occur in high frequencies in CD3+ T cell malignancies (Table 3) (53,54). 
Rearrangement and/or transcription of the TcR-o: genes generally correspond with deletion of 
the TcR-o genes (54,55,57,59), which is in line with the fact that the TcR-o genes are located 
within the TcR-o: gene locus between the Vo: and Jo: gene segments (61 ,62,65). 
The majority ( -80%) of TcR-o:fl+ T cell malignancies have deleted both TcR-o gene alleles 
(31 ,54,55,57,59) but in some of them ( -20%) one germline or rearranged TcR-o gene allele is 
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TABLE 3. TeA gene rearrangements in various types ofT cell malignancies, as reported in the literaturea. 
Rearranged Rearranged Rearranged Rearranged Deleted 
TeA-a genesb TcR-.8 genes TcR-'Y genes TcR-o genes TcR-o genes 
(R/G or R/R) (R/G or R/R) (R/G or R/R) (R/G, R/R or R/D) (D/D or D/G) 
Lymphoblastic T cell malignanciesc 
CD3-T-ALL 14% (1/7)d 84% {144/172) 85% {106/124)e 76% {48/63) 16% (10/63) 
CD3+ T-ALL 67% (8/12) 96% {105/109)f 100% {85/85) 58% {31/53)g 42% (22/53) 
all T-ALL 89% {249/281) 91% (191/209) 68% (79/116) 28% (32/116) 
T-NHL 79% (11/14 100% (2/2) 
Mature T cell malignanciesh 
T-PLL 100% (22/22) 100% (7/7) 0% (0/9) 100% (9/9) 
ATLLi 100% (36/36) 95% (21/22)e 
peripheral T-NHL 93% (25/27)f 100% (12/12) 
Lennert lymphoma 100% (5/5) 100% (5/5) 
CTLL/MF 100% (27/27) 
ss 100% (22/22) 100% (2/2) 
a. Many reports on TcR gene rearrangements in a series ofT cell malignancies have been published (34-60,69-75). Several research groups 
have published more than once data on a series of T cell malignancies, which may therefore be (partly) identical. To avoid double 
counting, we have only included the most informative data of each research group by selecting the publications: refs. 53 and 54, leaving 
out refs. 35,40,51 and 68; combination of refs. 21 and 55; combination of refs. 49 and 56; ref. 74, leaving out refs. 73 and 75. 
b. Data on TcR-a gene rearrangements in T cell leukemias were only included if sufficient JCI probes were used. Therefore only refs. 53 and 
54 were used, while refs. 66 and 68 were excluded. 
c. The lymphoblastic T cell malignancies include T-ALL and lymphoblastic T-NHL. The data are derived from refs. 19,21,22,27,34,36-39,41-
44,46-50,53-60,7 4. 
d. In one CD3- T-ALL the TcR-a genes were proven to be rearranged on both alleles, while both TcR-6 gene alleles were deleted (53,54). 
e. In some studies the TcR-7 genes were only analyzed with the J71.3 probe in EcoRI digests. Therefore rearrangements to the J71.1, J71.2 
and J72.1 gene segments may have been missed (21 ,46,72). 
f. In seven CD3+ T cell malignancies no TcR-fl gene rearrangements were detected: four CD3+ T-ALL (21 ,48,57), one CD3+ lymphoblastic 
T-NHL (37) and two mature T-NHL (37). In three of the four T-ALL it was proven to concern a TcR-76+ leukemia (21 ,55,57). 
g. Nine CD3 T-ALL were proven to express TcR-76 and had TcR-6 gene rearrangements on both alleles (57,59). Another four CD3+ T-ALL 
had rearranged both TcR-o gene alleles with both TcR-a gene alleles in germline configuration, while three CD3+ T-ALL had TcR-o(D/R) 
and TcR-<l(R/G) (54). 
h. The data about the mature T cell malignancies (T-NHL, Tcell non-Hodgkin lymphoma; T-PLL, T cell prolymphocytic leukemia; ATLL, adult 
T cell leukemia-lymphoma; CTLL, cutaneous T cell leukemia-lymphoma; SS, sezary Syndrome) are derived from refs.: 27,35-39,41,49,69-
72. Chronic T cell proliferations such as T cell chronic lymphocytic leukemia (T-CLL), T-7 lymphocytosis and large granular lymphocyte 
(LGL) proliferations are not included, but will be discussed in Chapter 6.3. 
i. ATLL are positive for HTLV-1 and generally express CD3, CD4 and CD25 (IL-2 receptor), but are negative for CDS (72). 
still present (31 ,55,56). Most TcR--yo+ T cell leukemias have two rearranged TcR-o gene alleles, 
although one germline or deleted TcR-o gene allele may also occur (31 ,56). This implies that 
the detection of one rearranged TcR-o gene allele and deletion of the other TcR-o gene allele 
(with a possible rearrangement of the TcR-a genes on the same allele) does not allow 
discrimination between TcR-a.B+ or TcR--y.s+ T cell malignancies. 
All data together suggest that the TcR-o genes rearrange in the early stages ofT cell 
differentiation. Subsequently the TcR--y genes rearrange (-y1 probably before -y2), immediately 
followed by rearrangement of the TcR-.8 genes. In a part of the cells the TcR-a genes rearrange 
together with or after deletion of the TcR-o genes (Figure 4). This results in TcR--yo+ cells 
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(fcR--y: R/R or RjG; TeR-eS: R/G, R/R or RjD; TcR-,8: R or sometimes G/G) or in TcR-a.B+ cells 
(feR-a: R/R or RjG; TcR-,8: R/R or R/G; TcR--y: R/R or R/G; TcR-o: D/D or sometimes D/R). 
Based on our experience and data from the literature, we estimate that 60 to 75% of the 
CD3+ T cell malignancies express TcR-a,B, while 25 to 40% express TcR--yo. However, further 
studies with appropriate monoclonal antibodies (see Appendix of Chapter 2.2) (31) have to 
determine the precise frequencies of these phenotypes and have to reveal whether these 
frequencies are dependent on the type ofT cell malignancy. 
LINEAGE INFIDELITY OF lg AND TcR GENE REARRANGEMENTS 
Initially it was assumed that many immunologic, enzymatic and molecular characteristics 
of 8 and T cells were lineage specific or even specific for a particular differentiation stage. 
However, in recent years several forms of lineage infidelity have been described (83,84), 
including the unexpected rearrangements of lg and TcR genes (85,86). 
Early murine studies revealed that rearrangement and transcription of lg genes can occur 
in T cells (87-89). Also in human T cell malignancies lg gene rearrangements may occur 
(12, 15,21 ,22,24,27,37,39,40,42,44,45,51 ,56,58,68, 72-75,86,90-97), while TcR gene rearrange-
ments may occur in malignancies of B cell lineage (19-22,27,37,40,43,45,49,51 ,52,54,56,57,68, 
73-75,93,94,98-106). Rearranged lg and TcR genes have even been found in myeloid 
malignancies (19,107-117). 
The explanation of these cross-lineage rearrangements of lg and TcR genes probably lies 
in the control mechanisms for DNA recombination. There is evidence that a common 
recombinase is involved in the rearrangement of lg and TcR genes (118). The accessibility of 
the lg and TcR genes for this recombinase probably depends on the openess of the 
chromatine configuration around the genes (85). Progenitors of lymphoid cells or more primitive 
multipotential (myeloid/lymphoid) progenitors might rearrange their lg or TcR genes before 
lineage commitment. As soon as an irreversible commitment to T cell, 8 cell or myeloid lineage 
has occurred, the progenitor cell adapts its phenotype by down-regulating and up-regulating 
the expression of differentiation antigens, while the cross-lineage gene rearrangements remain 
as an "artefact". 
Therefore, lg and TcR gene rearrangements cannot be used as markers for 8 cell and T 
cell lineage, respectively. Nevertheless, the combined use of information about morphology, 
immunophenotype and the configuration of lg and TcR genes will generally provide sufficient 
information about the differentiation lineage of a hematopoietic malignancy. 
lg gene rearrangements in T cell malignancies 
lgH gene rearrangements occur in 10 to 15% of lymphoblastic T cell malignancies, while 
in the more mature T cell malignancies such as chronic T cell leukemias and peripheral T cell 
lymphomas this frequency is about 5% (Table 4). The lgH gene rearrangements in T cell 
malignancies involve only one allele in the majority of cases (12 out of 14 cases; i.e. 86%) 
(21 ,22,27,42,44,56,68, 72,92). 
lgl gene rearrangements appear to be rare in T cell malignancies. Rearranged lgx; genes 
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TABLE 4. lg gene rearrangements in T cell malignanciesa. 
Rearranged Rearranged Rearranged 
lgH genes lgl' genes lg). genes 
Lymphoblastic T cell malignancies 
CD3- T-ALL 16% {12/76} 0% {0/30} 0% {0/29} 
CD3+ T-ALL 6% {3/49} 0% {0/29} 0% {0/28} 
all T-ALL together 14% {26/180} 0% {0/62} 0% {0/59} 
T-NHL 10% {2/20} 33% {2/6}b 0% {0/1) 
Mature T cell malignancies 
T-CLL 3% {1/32} 0% {0/4} 0% {0/4} 
T-PLL 7% {1/14} 
ATLL 3% {1/30} 0% {0/3} 0% {0/3} 
peripheral T-NHL 4% {2/45} 12% (2/17}b 0% (0/2} 
Lennert lymfoom 0% {0/5} 0% (0/5} 
CTLL/MF 0% (0/14} 0% {0/1) 
ss 7% {1/15} 0% {0/5} 0% {0/5} 
a. The data about the frequency of lg gene rearrangements in T cell malignancies are derived from refs. 12,15,21 ,22,24,27,37,39,40,42,44, 
45,51 ,56,58,68,72-75,86,90-97. Several research groups have published more than one report on rearranged lg genes in T cell 
malignancies. To avoid double counting we have only included the most informative data of each research group: ref. 68, leaving out 
refs. 15,40,51,90 and 91; ref. 73, leaving out refs. 74 and 75; combination of refs. 93 and 94; ref. 96, leaving out ref. 95. For abbreviations: 
see Table 3, footnotes. 
b. lg/C gene rearrangements were found in only a few T cell malignancies, i.e. two lymphoblastic T-NHL (95-97) and two peripheral T-NHL 
(97). Remarkably one lymphoblastic T-NHL had rearranged lg/C genes but germline lgH genes (97). 
were found in only two lymphoblastic T-NHL and two peripheral T-NHL (95-97). Remarkably, 
one of the lymphoblastic T-NHL had rearranged lgl' genes, but germline lgH genes (97). Jg;. 
gene rearrangements have not been reported to occur in T cell malignancies (Table 4). 
TcR gene rearrangements in malignancies of B cell lineage 
TcR gene rearrangements occur in a relatively high frequency in precursor B-ALL, but their 
frequency is much lower or they are absent in B-ALL and mature B cell malignancies such as 
chronic B cell leukemias, B-NHL and multiple myeloma (Table 5). Within the group of precursor 
B-ALL the frequency of TcR--y gene rearrangements (-55%) is higher than the frequency of 
TcR-/3 gene rearrangements ( -33%). Rearrangements and/or deletions of the TcR-o genes 
occur even more frequently ( -80%) and also TcR-o: gene rearrangements are regularly found 
in precursor B-ALL ( -61%) (54,57, 105, 106). This implies that the cross-lineage rearrangements 
of TcR genes in precursor B-ALL is much more frequent than the cross-lineage rearrangements 
of lgH genes in T-ALL (- 14%) (Table 4). However, the frequency of TcR-/3 and TcR--y gene 
rearrangements in mature B cell malignancies (0 to 7%) is comparable to the frequency of lgH 
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TABLE s. TcR gene rearrangements in malignancies of 8 cell lineage. 
Rearranged Rearranged Rearranged Rearranged Deleted 
TcR-a genesa TcR-tl genes TcR-r genes TcR-o gene TcR-o genes 
lymphoblastic 8 cell malignancies 
null ALL (CD10-, CyJL}b 0% (0/2) 9% (3/33) 22% (7/32) 0% (0/6) 33% (2/6) 
common ALL (CD10+, CyJL) 0 41% (66/162) 66% (88/134) 54% (13/24) 25% (6/24) 
pre-B-ALL (CD10 +, CyJL +) c 23% (10/44) 44% (18/41) 20% (2/10) 0% (0/10) 
CD10+ precursor B-ALLb 63% (17/27) 35% (94/268) 59% (146/246) 52% (32/62) 27% (17/62) 
all precursor B-ALlb 61% (17 /29) 33% (105/318) 55% (160/289) 54% (52/97) 26% (25/97} 
B-ALL (Smlg+)b 0% (0/7) 0% (0/8) 
Mature B cell malignanciesd 
B-CLL 7% (11/165) 0% (0/116) 0% (0/15) 0% (0/15) 
B-PLL 0% (0/10) 0% (0/8) 0% (0/11) 0%(0/11) 
HCL 0% (0/9) 0% (0/9) 0% (0/7) 0% (0/7) 
B-NHL 6% (10/158) 6% (6/96) 
multiple myeloma 0% (0/5) 
a. The data about TcR-a gene rearrangements in precursor B-ALL are derived from ref. 105. 
b. The data about TcR gene rearrangements in null ALL, CD10+ precursor B-ALL, all precursor B·ALL and B-ALL are derived from refs. 19-
22,43,45,49,52,54,57,68,94,95,99,100,104,106,107. Several research groups have published more than once data on ToR gene 
rearrangements in precursor B-ALL. To avoid double counting, we have selected the most informative data from each research group: 
the data from refs. 54,68 and 105 were combined; the data from refs. 20 and 21 were combined; data from ref. 94 were used, while data 
from ref. 93 were excluded. 
c. The data about ToR gene rearrangements in common ALL (CD10+, CyJL} and pre-B-ALL (CD10+, CyJL +) are derived from refs. 
19,40,51,68,103 and 106. From ref. 51 we only used the TcR-1 data. 
d. The data about ToR gene rearrangements in mature B cell malignancies are derived from refs. 27,37,45,49,52,56,73-75,93,94,98, 100-102. 
Several research group have published more than one report about ToR gene rearrangements in mature B cell malignancies. To avoid 
double counting we have selected the most informative information from each research group: data from ref. 75 were used, while data 
from refs. 73 and 74 were excluded; data from refs. 49 and 56 were combined; only data from ref. 94 were used, while data from ref. 93 
were excluded. 
gene rearrangements in mature T cell malignancies (0 to 7%) (Tables 4 and 5) (27,37,45,49, 
52,56,73-75,93,94,98, 100-102). 
Assuming that the rate of lg and TcR gene rearrangements in leukemic cells reflects the 
rate in normal cells, it is intriguing to find less frequent cross-lineage gene rearrangements in 
mature malignancies than in immature lymphoid malignancies (Tables 4 and 5). This can be 
explained by assuming that the common recombinase is still active in ALL cells, especially 
precursor B-ALL cells, but that the activity of this enzyme is absent in mature lymphoid 
malignancies (98). Alternatively, it may be that the cross-lineage lg and TcR gene rearrange-
ments occur frequently in normal T and B cell progenitors (and their malignant counterparts), 
but that such cells are less able to differentiate and to expand than normal progenitors without 
cross-lineage gene rearrangements (98). This is in line with data that suggests that only a small 
part of the lymphoid precursor cells reach a mature stage of differentiation. Also non-functional 
intra-lineage lg and TcR gene rearrangements may cause the abortive events. 
398 CHAPTER6.2 
TABLE 6. Comparison of TcR gene rearrangements in precursor B-ALL and T-ALL. 
Rearranged TcR-.8 genes 
- monoallelic ,81 rearrangement 
- biallelic ,82 rearrangement 
Rearranged TcR-1 genes 
- monoallelic 11 rearrangement 
- biallelic 12 rearrangement 
Rearranged TcR-1 genes, but 
germline TcR-.8 genes 
Rearranged or deleted TcR-o genes, 
but germline TcR-.8 and TcR-1 genes 
a. Data derived from refs. 22.68.98 and 103. 
b. Data derived from refs. 21,34,40,41,46,47,49 and 59. 
c. Data derived from refs. 22,43,68,98 and 103. 
d. Data derived from refs. 43,49,51 and 59. 
precursor B-ALL 
0% (0/44)a 
43% (19/44)a 
51% (39/76)0 
9% (7/76)0 
28% (76/272)e 
16% (16/97)9 
e. Data derived from refs. 19,21,22,43,45,57,68,98,103 and 106. 
f. See Table 3. 
g. Data derived from refs. 54,57 and 106. 
T-ALL 
5% (4/80)b 
26% (21 /80)b 
3% (1/38)d 
82% (31/38)d 
rare (<5%)f 
rare (<5%)f 
The frequencies of cross-lineage TcR-.8 and TcR-1 gene rearrangements appear to be 
different for the various types of precursor B-ALL TcR-.B and TcR-1 gene rearrangements are 
infrequent in null ALL (CD10~ CyJLl, occur in higher frequencies in pre-B-ALL (CD10+,CyJL+), 
and are found most frequently in common ALL (CD10+ ,CyJLl (Table 5) (19,40,51 ,68, 103, 106). 
Several reports indicate that the frequency of TcR gene rearrangements in precursor B-ALL 
is also influenced by the age of the patient. TcR-.B and TcR-1 gene rearrangements occur in low 
frequencies in precursor B-ALL of young children ( <2 y), especially when it concerns CD10-
precursor B-ALL (20,21, 104). The frequency of the cross-lineage TcR gene rearrangements is 
higher in precursor B-ALL of older children (>2 y), while the highest frequencies are reported 
to occur in adult precursor B-ALL (1 03,1 04). 
The configurations of rearranged TcR-1 genes in precursor B-ALL are strikingly different 
from those in T-ALL (Table 6) (22,43,68,98, 1 03). In precursor B-ALL a large part of the TcR-1 
gene rearrangements (-51%) involve the 11 locus on one allele, while biallelic rearrangements 
to the 12 locus are infrequent ( -9%). This is in contrast to the high frequency of biallelic 12 
gene rearrangements and the low frequency of monoallelic 11 gene rearrangements in T-ALL 
(Table 6) (43,49,51,52,59). Such a large discrepancy is not found when the configurations of 
the rearranged TcR-.8 genes are compared (22,68,98, 1 03). 
In the reported series of T-ALL only a few T-ALL with rearranged TcR-1 genes but germline 
TcR-.8 genes occur and also T-ALL with rearranged TcR-o genes but germline TcR-.8 and TcR-r 
genes are rare (Table 3). However, about 28% of precursor B-ALL have rearranged TcR-1 
genes with germline TcR-.8 genes and about 16% of precursor B-ALL have rearranged or 
deleted TcR-o genes with germline TcR-.B and TcR-1 genes (Table 6)(19,21 ,22,43, 45,54,57,68, 
98,103,1 06). If one assumes that also the cross-lineage TcR gene rearrangements occur in a 
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hierarchic order, these findings support the T cell differentiation model in which TcR-o genes 
rearrange first, followed by TcR-r gene rearrangements (r1 rearrangements prior to r2 
rearrangements) and subsequently by TcR-.8 gene rearrangements (Figure 4). 
The position of the TcR-a genes in the hierarchic order of TcR gene rearrangements is 
difficult to determine, because too few data are available concerning TcR-a gene rear-
rangements in precursor B-ALL 
Most precursor B-ALL with rearranged TcR-a genes (11 out of 17) have rearranged or 
deleted TcR-8 genes as well as rearranged TcR-r genes andjor rearranged TcR-.8 genes. 
However, some of them have germline TcR-r and TcR-.B genes (105). This supports the 
hypothesis that rearrangement of TcR-8 genes and deletion of TcR-8 genes (followed by 
rearrangement of TcR-a genes) are early events in T cell differentiation, which probably play an 
important role in the bifurcation of TcR-ro and TcR-a.B pathways (see Chapters 3.2 and 4.1). 
lg and TcR gene rearrangements in acute myeloid leukemias 
lg and TcR gene rearrangements also occur in acute myeloid leukemias (AML) (19, 107-
117). Their frequencies are lower than the cross-lineage rearrangements of TcR gene 
rearrangements in precursor B-ALL, but comparable to the frequencies of lg gene rearrange-
TABLE 7. lg and TcR gene rearrangements in AML 
Rearranged 
lnvestigatorsa lgH genes lgK genes Ig). genes TcR-.8 genes TcR-r genes TcR-o genes Total 
Rovigatti et a1.(107) 2/14 2/14 
Ha et a1.(108) 1/19 0/19 0/19 1/19 
Cheng et a1.(109) 1/24b 0/24 3/24b 3/24 
Faa et a1.(110) 10/52c 3/40c 0/26 1;4r·d 4/51c,d 10/52 
Boehm et al.(111) 3/17e 0/17 0/17 3/17d 12/17d 13/17 
Chen et a1.(98) 0/9 0/9 0/9 
Serementis et al.(113) 5/38f 6/38f 10/38 
Goorha et al.(19) 2/12 0/12 0/12 2/12 
Wainscoat et a1.(119) 0/17 0/17 0/17 0/17 
Oster et al.(115) 10/69g 1/69g 3/69g 11/69 
Fontenay et al.(116) 11/57h 4/57h 3/57h 8/57h 13/57 
TOTAL 45/319 24/175 0/62 20/290 19/163 8/57 65/328 
percentage 14% 2% 0% 7% 12% 14% 20% 
a. Only reports which describe at least nine AML were used for this table. All AML were diagnosed according to the FAB criteria and the 
investigators did not mention selection criteria for inclusion in the study. Therefore we assume that the AML listed in this table are a 
representative sample. 
b. One AML had rearranged lgH and rearranged TcR-JJ genes (109). 
c. All AML with rearranged TcR-JJ, TcR-1 and/or lgJC genes had also rearranged lgH genes (110). 
d. All AML with rearranged TcR-JJ genes also had rearranged TcR-1 genes (110, 111). 
e. Two AML with rearranged lgH genes had rearranged TcR-1 genes and one out of them also had rearranged TcR-JJ genes (111). 
f. One AML had rearranged TcR-JJ genes as well as rearranged lgH senes (113). 
g. Two AML with rearranged lgH genes had rearranged TcR-JJ genes and one of them also had rearranged lgJC genes (115). 
h. Six AML with rearranged lgH genes, all four AML with rearranged TcR-JJ genes and all three AML with rearranged TcR-1 genes also had 
rearranged TcR-o genes (116). 
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TABLE 8. lg AND TcR GENE REARRANGEMENTS IN TdT+ AML AND Tdl AMLa. 
Rearranged 
lgH genes 
TdT+ AMLb 57% (24/42) 
TdT- AMLb 5% (7 /143) 
Rearranged 
lgit genes 
9%(1/11) 
0% (0/58) 
Rearranged 
TcR-,8 genes 
23% (9/40) 
1% (2/135) 
Rearranged 
TcR--y genes 
35% (6/17) 
2% (1/52) 
Total (rearranged lg 
andjor TcR genes) 
71% (30/42) 
6% (8/143) 
a. The data are derived from refs. 107,11 0,112·115. ~ should be remarked that in at least two of the four reports the investigators have 
selected for TdT+ AML (107,114). 
b. An AML was considered to be TdT+, when the percentage of TdT+ cells was > 25%. 
ments in T-ALL (Table 7) (19,98, 107-111,113,115,116, 119). Analogous to the latter, also in AML 
lgH gene rearrangements occur more frequently than lgL gene rearrangements and TcR-r 
gene rearrangements occur more frequently than TcR-.B gene rearrangements. Furthermore, 
all AML with rearranged lg~t genes also had rearranged lgH genes and virtually all AML with 
rearranged TcR-.B genes had rearranged TcR-r genes (110,111,115,116). Like in precursor 
B-ALL the TcR-r gene rearrangements in AML mainly represent monoallelic rearrangements to 
the r1 locus (110, 111). This cross-lineage hierarchic order of gene rearrangements in AML is 
in line with the normal hierarchic order of lg and TcR gene rearrangements during lymphoid dif-
ferentiation (Figure 4). 
Several reports suggest that lg and TcR gene rearrangements occur more frequently in 
TdT+ AML than in Tdl AML (Table 8) (107,110,112-115). Although TdT probably plays an 
important role during lg and TcR gene rearrangements by inserting nucleotides at junction 
sites (120-122), this enzyme has not been shown to be capable of initiating or mediating the 
process of gene rearrangement. Therefore it is not surprising that several recent studies on 
large series of AML do not find a significant relationship between TdT expression and lg or 
TcR gene rearrangements in AML (116, 117; H.J. Adriaansen, unpublished results). 
It has also been suggested that cross-lineage gene rearrangements are rare in adult AML 
of FAB type M4 and M5 (123). This is in contrast with other reports, which indicate that lg and 
TcR gene rearrangements can occur in any FAB group of AML (1 07-113, 115). 
lg and TcR gene rearrangements in acute undifferentiated leukemias and acute 
leukemias with ambiguous phenotype 
The frequent occurrence of cross-lineage lg and TcR gene rearrangements in ALL and AML 
(Table 4-8) hampers their use as markers for lineage in case of acute undifferentiated leukemias 
(AUL) and acute leukemias with ambiguous phenotype. Several reports describe that a large 
part of such leukemias have rearranged their lgH genes and that some of them have 
rearranged lgL genes or rearranged TcR-.B genes (16,113,124,125). This illustrates that the 
combined morphological, immunologic and molecular analyses do not always allow 
determination of lineage, although in the great majority of leukemias and NHL such analysis 
provide sufficient information for lineage assignment. 
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CONCLUSION 
The great majority of lymphoid malignancies of B and T cell origin have clonally rearranged 
lg and TcR genes, respectively. Analysis of these malignancies has given more insight in the 
hierarchic order lg and TcR gene rearrangements during lymphoid differentiation. 
Also cross-lineage lg and TcR gene rearrangements occur. This especially concerns TcR 
gene rearrangements in precursor B-ALL (30 to 80%, depending on the type of TcR gene), lgH 
gene rearrangements in T-ALL (5 to 15%) and lg andjor TcR gene rearrangements in AML 
(-20% of all AML). 
Both the appropriate and cross-lineage lg and TcR gene rearrangements in hematopoietic 
malignancies can be used for diagnostic purposes (see Chapter 6.3). 
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As indicated in Chapter 3.3, Southern blot analysis of immunoglobulin (lg) and T cell 
receptor (TcR) genes represents a powerful tool for the detection of clonal rearrangements of 
these genes. Since malignancies are clonal proliferations, lg and TcR gene analysis has several 
diagnostic applications: discrimination between polyclonal and monoclonallymphoproliferations; 
detection of two or more subclones within a malignancy at diagnosis; detection of clonal 
evolution at relapse; analysis of the clonal origin of two lymphoid malignancies in a single 
patient; and analysis of the differentiation lineage of a malignancy (Table I). These applications 
may be extremely useful in the diagnosis and follow-up of lymphoproliferative diseases, but it 
should be noticed that a clonal cell population does not always represent a malignancy. In this 
chapter we shall discuss the mentioned diagnostic applications of lg and TcR gene analysis 
and pay special attention to the pitfalls and limitations of such analyses. 
DISCRIMINATION BETWEEN POLYCLONAL AND MONOCLONAL LYMPHOPRO-
LIFERATIVE DISEASES 
Immunologic markers for clonality (e.g. Kj>-. ratio) and other cytologic markers are not 
always sufficiently informative in the evaluation of blood, tissue biopsies or other cell samples 
for malignancy. This particularly concerns B cell malignancies without lg light (lgl) chain 
expression, mature terminal deoxynucleotidyl transferase (TdT) negative T cell malignancies and 
cell samples in which a small number of malignant lymphoid cells is admixed with large 
numbers of non-neoplastic lymphoid cells. Analysis of lg and TcR genes then serves as a 
sensitive and specific procedure for identifying even minor populations (I to 5%) of clonal B or 
T cells. 
*This manuscript will be published as part of a review in Clin Chim Acta. 
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TABLE 1. Diagnostic applications of lg and TcR gene analysis. 
1. Discrimination between polyclonal and monoclonallymphoproliferative diseases. 
CAUTION: monoclonality does not necessarily imply malignancy (e.g. T-'Y lymphocytosis and 
monoclonal or oligoclonallymphoproliferations in immunodeficiency). 
2. Detection of two or more subclones within one malignancy. 
3. Analysis of lymphoid malignancies at diagnosis and subsequent relapses: 
-detection of identicallg and TcR gene rearrangements 
-detection of differences: clonal evolution at first relapse andjor subsequent relapses. 
4. Proof or exclusion of the common clonal origin of two malignant lymphoid cell populations. 
CAUTION: one should try to discriminate between two independent lymphoid malignancies and 
subclone formation within a malignancy. 
5. Assignment or exclusion of the differentiation lineage of a malignancy. 
6. Detection of low numbers of malignant cells. 
B cell non-Hodgkin lymphoma (B-NHL} without lgl chain expression andjor Joss of B 
cell antigens 
Like their putative normal counterparts, the majority of B-NHL cells express pan-B cell 
markers like CD19, CD20, CD22 and CD37 as well as surface membrane lg (Smlg). However, 
in 10 to 30% of cases the malignant B cells fail to express detectable lg on their cell membrane 
or in their cytoplasm (1-7). Lack of lg expression may be caused by aberrations at the DNA 
level (e.g. non-functionally rearranged lg genes), at the RNA level (truncated lg transcripts) or 
at the protein level (inappropriate protein processing) (1). In a recent report on Smlg- B-NHL 
the defective lg heavy (lgH) chain production could be explained (in 11 out of 19 cases) by 
inactivation of both lgH genes due to translocation of one allele in combination with deletion 
or defective rearrangement of the other allele (8). 
In 20 to 30% of B-NHL also loss of one or more pan-B cell antigens is found, which leads 
to abnormalities in marker expression (2,3,5). Although it has been suggested that such 
abnormalities can be used as diagnostic criterion for lymphoid malignancies (2,5), defining 
monoclonality may be of utmost importance for making a definite diagnosis in some cases of 
Smlg- B-NHL or "null cell" lymphoma (i.e. NHL without obvious B or T cell phenotype). 
Virtually all Smlg- B-NHL have clonal rearrangements of their lgH and/or lgl genes (1 ,4,6-
10). Also plasmacytomas without lgH chain expression ("lgL chain disease") appear to have at 
least one rearranged lgH gene allele in additi?n to the lglgene rearrangements (Figure 1). Also 
most "null cell" NHL appear to have rearranged lgH andjor lgl genes (without rearranged 
TcR-.8 genes), which indicates that they most probably belong to the B cell lineage (11). 
Therefore analysis of lgH genes (and lgl genes, if necessary) can give valuable diagnostic 
information concerning clonality and lineage of NHL. 
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Figure 1. Analysis of the lgH and lgK genes in BM samples from three patients with "lgL chain disease" 
(plasmacytoma without lgH chain expression). The malignant plasma cells expressed lgx: in all three patients. The 
percentages lgx:+ plasma cells were as follows: patient EB: 50%; patient JP: 30%; patient HM: 60%. The DNA 
samples were digested with Bglll or BamHI, size separated and blotted to nylon membrane filters, which were 
hybridized with a 32P-Iabeled JH probe (A) or a 32P-Iabeled ex: probe (B). In all three patients one clonally-
rearranged lgH gene band and one clonally-rearranged lgx: gene band were found. 
T-cell-rich B cell lymphoma: pseudo T cell lymphoma 
Occasionally lymphomas are encountered in which there is a predominance of T cells, 
suggesting that it concerns a T cell neoplasm on histomorphological and immunophenotypic 
grounds (12-15). Jaffe and colleagues cautioned for the occurrence of pseudo-peripheral T cell 
lymphomas and pointed to the fact that a small population of monoclonal B lymphocytes may 
be admixed with reactive T lymphocytes (13,14). These T lymphocytes may comprise up to 
75% or more of the total cell number. Especially in patients with follicular lymphomas this may 
lead to diagnostic problems (14). Southern blot analysis of lg and TcR genes will generally lead 
to the appropriate diagnosis (12-17). Figure 2 illustrates the detection of a small population of 
B-NHL cells in a lymph node with many normal (polyclonal) T and B lymphocytes. 
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Figure 2. Analysis of the lgH genes of lymph node 
cells from a patient who was suspected to have 
developed a NHL. The lymph node biopsy contained 
many T lymphocytes (60 to 70%) and -30% B 
lymphocytes, which were thought to represent the 
malignant lymphoma. Control DNA and DNA from the 
lymph node cells were digested with Bg/11 (A) or a 
combination of BamHI and Hindlll (B), size separated 
and blotted to nylon membrane filters which were 
hybridized to a 32P-Iabeled JH probe. In both digests 
two rearranged bands were detected; the density of 
these bands corresponds to the size of the B cell 
population in the lymph node, indicating that it 
concerned clonal B lymphocytes. 
Peripheral T cell lymphoma 
Immunologic markers for detection of clonality in T cell proliferations are not available. 
Nevertheless immature (TdT+) T cell malignancies such as T cell acute lymphoblastic leukemia 
(T-ALL) and lymphoblastic T-NHL can easily be detected by use ofT cell marker /TdT double 
immunofluorescence (IF) stainings (18, 19). This is based on the fact that TdT+ T cells normally 
only occur in the thymus and not in extrathymic locations such as bone marrow (BM), 
peripheral blood (PB) or lymph nodes (18,20). Even low numbers of malignant TdT+ T cells 
(0.01 to 0.001%) are easily detectable by use of the double IF staining technique (21 ,22; see 
Chapter 5.3). For mature (Tdl) T cell malignancies no such marker combination is available. 
Furthermore, disturbed expression ofT cell markers, especially the loss of one or more pan-T 
cell antigens, is frequently seen in peripheral T-NHL (2,5,23). Like in B-NHL, such marker 
abnormalities may be useful in the diagnosis of peripheral T-NHL (2,5,23). 
lg and TcR gene analysis for diagnostic purposes 413 
A 
kb 
10.5_ 
10.0-
7.9-
5.8-
e 
c 
0 
() 
3.8- ~ 
ro ro ro 
0... 0...(/) 0...(/) 
(ij ca= ca= 
EO E~ E~ 
>-Z o+ ot g2 cW cw 
EcoRI, Cf3 probe 
0:: 
0 
C::J' Q)_l 
:;::<( 
<ll' c.c 
-G 
-G 
B patient C.Y. 
kb 
6.0-
5.7-
e 
c 
0 
() 
4.1- ~ -G 
EcoRI, J{32 probe 
kb 
28.0-
22.5-
14.5-
e 
c 
0 
() 
-G 
BamHI, Cf3 probe 
Figure 3. Analysis of the TcR-,8 genes of normal PB cells, E rosette separated PB cell fractions, a T-ALL cell sample 
and a lymph node biopsy from a T-NHL patient. Control DNA and DNA from the mentioned cell samples were 
digested with EcoRI or BamHI, size separated in an 0.7% agarose gel and blotted to nylon membrane filters, which 
were hybridized to a 32P-Iabeled C,B probe or a 32P-Iabeled J,82 probe. A: EcoRI filter hybridized with a C,B probe. 
In theE rosette positive (E+) cell fraction (>95% T lymphocytes) the 10.8 kb band is of markedly reduced density 
as compared to the E rosette negative (El cell fraction ( <5% T lymphocytes). In the E+ lane no clonally-
rearranged bands are visible, but a vague background is present, which probably represents many differently-
rearranged bands derived from the polyclonal T lymphocytes. The 7.9 kb band (*) is due to partial digestion (see 
Chapter 3.3). Only in the lane of the T-ALL sample two clonally-rearranged bands are visible. 8: EcoRI and BamHI 
digested DNA from the lymph node biopsy of the T-NHL patient, analyzed with the C.B probe and J,82 probe. In 
both digests two rearranged bands are visible in addition to a strong germline band (G), indicating that a clonal 
T cell population is present between many lymph node cells with germline TcR-,8 genes. 
Still, in a part of peripheral T cell proliferations it is difficult to discriminate between a T-NHL 
and a reactive polyclonal T cell proliferation. In most of these cases analysis of the TcR-,8 genes 
will resolve this diagnostic problem (24-27). 
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Analysis of the TcR-,8 genes of non-T cells by use of EcoRI digests and the C,B probe 
reveals two germline bands of comparable intensity: 10.5 kb and S.8 kb (Figure SA). In 
polyclonal T cells the intensity of the 10.5 kb band is substantially reduced and no rearranged 
bands are detectable (also not by use of other digests and other TcR-,8 probes), indicating that 
polyclonal rearrangements have occurred on one or both TcR-,8 gene alleles. If the T cell 
proliferation concerns a T-NHL, generally one or two rearranged bands are detectable by 
appropriate analysis of the TcR-,8 genes (Figures SB and 4). Detailed information about TcR-
.B genes is given in Chapter S.S. 
In some cos- T-NHL as well as some cos+ T-NHL the TcR-,8 genes are in germline 
configuration (26). In such cases TcR-r and TcR-o genes should be analyzed. However, one 
should be aware that the combinatorial repertoire of both genes is limited, which results in a 
restricted number of rearranged bands (28-S5). Furthermore, recent studies indicate that TcR-ro 
cells exhibit a preferential use of the available V and J gene segments (S6-S8). Both the limited 
combinatorial diversity and the preferential V-J gene use hamper the interpretation of the TcR-r 
and TcR-o gene analyses. Especially in case ofT cell proliferations with polyclonally rearranged 
TcR-,8 genes but "monoclonal" TcR-r gene rearrangements (S9,40), one should consider the 
possibility that a part of the polyclonal T cells by chance have rearranged the same Vr and Jr 
gene segments, although they generally differ in their Vr-Jr junctional regions. 
In case of CDS+ T cell proliferations of unknown origin it is worthwhile to determine whether 
it concerns TcR-cr,B+ T cells or TcR-ro+ T cells, because the absence of clonally rearranged 
TcR-,8 genes in a TcR-cr,B+ T cell proliferation proves the polyclonality of the proliferation. 
Furthermore, most TcR-cr,B+ T cells have deleted both TcR-o gene alleles. Discrimination 
between polyclonality and monoclonality may be difficult in proliferations of TcR-ro + T cells with 
germline TcR-,8 genes. Strictly speaking, monoclonality in such cases can only be determined 
by proving that the Vr-Jr and Vo-Jo junctional regions of the involved T cells are identical. 
Although TcR gene rearrangements occur in the great majority ofT cell malignancies (see 
Chapter 6.2), the absence of TcR-,8 and TcR-r gene rearrangements in a subgroup of 
peripheral T-NHL has been described (41 ,42). Therefore in T-NHL TcR gene analysis may not 
always be helpful in determining clonality ( 41 ,42). 
Cutaneous lymphoma 
It is often difficult to distinguish cutaneous lymphomas from reactive lymphoproliferations 
on histologic grounds. For instance, early patch stages of mycosis fungoides (MF) can closely 
resemble some forms of chronic dermatitides (4S). Therefore it has been attempted to use 
additional techniques for evaluation of cutaneous lymphoid infiltrates. 
Immunohistology is generally able to distinguish primary or secondary cutaneous B cell 
lymphomas from benign cutaneous lymphoid hyperplasia (44). In the latter lesions usually 
normal follicular B and T cell compartmentalization is found (like in nodal hyperplasia) in 
addition to polyclonal expression of lgl chains, while in most cases of cutaneous B cell 
lymphoma lgl chain restriction can be used as diagnostic marker (44). if no lgH or lgl chain 
expression is demonstrable in a cutaneous B celllymphoproliferative disorder, analysis of lgH 
genes will be of major value in assessing the diagnostic problem (44). 
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Figure 4. Analysis of the TcR-,8 genes of skin biopsies from two patients with aT cell infiltrate of unknown origin. 
Control DNA and DNA from the two skin biopsies were digested with EcoRI, size separated and blotted to nylon 
membrane filters, which were hybridized with 32P-Iabeled C,B and J,82 probes. A: EcoRI filter hybridized with the 
J,82 probe. Two rearranged bands were visible in the skin biopsy of patient AM, indicating the presence of a clonal 
T cell population with rearrangements to the C,82 gene locus on both alleles. The 7.9 kb band (*) is due to partial 
digestion (see Chapter 3.3). B: EcoRI filter hybridized with the C,B probe and subsequently with the J,82 probe. One 
rearranged band was visible with the J,82 probe, while no rearrangements were detectable with the C,B probe. This 
indicates that a clonal T cell population with one rearranged TcR-.8 gene allele was present in the skin biopsy of 
patient GV. Both patient AM and patient GV were diagnosed to suffer from mycosis fungoides. 
The cutaneous T cell lymphomas in Western countries are mainly represented by MF and 
Sezary syndrome (SS), which are two closely related disorders (45). MF generally begins with 
chronic cutaneous patches evolving into plaques and tumor nodules, whereas erythroderma 
with extreme itching and rapid involvement of blood, lymph nodes and viscera are generally 
prominent in SS patients (45). Also in MF patients lymph nodes or viscera become often 
involved (45). Common features in MF and SS are the neoplastic Sezary cells with their cerebri-
form nuclei and T helper cell phenotype (C02 +, CD3 +, CD4 +, CD8l and strong tendency of 
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the neoplastic cells to migrate into the epidermis (44,45). It has now widely been accepted that 
SS is a leukemic variant of MF (45). Immunohistology does not represent an easy tool for a 
definitive diagnosis of MF ;ss as many immunophenotypic findings present in MF /SS can also 
be seen in benign inflammatory dermatoses (44). However, all studies on tumor lesions of MF 
patients and blood samples of SS patients revealed clonally rearranged TcR-.$ genes (24-
27,43,46) (Figure 4). In addition, in lymph nodes with histologically documented MF involvement 
as well as in most lymph nodes that histologically showed only dermatopathic lym-
phadenopathy clonal TcR-.$ gene rearrangements have been found (27,46,47). The latter is in 
line with the observation that palpable lymphadenopathy in a MF patient is a poor prognostic 
sign, regardless of whether the enlarged lymph node was infiltrated by morphologically 
abnormal cells or only showed dermatopathic changes (48,49). Therefore TcR gene analysis 
cannot only be used as an additional criterion for diagnosing MF /SS, but also for staging of 
the disease. 
Clonal TcR-.$ gene rearrangements have also been found in blood samples from several 
MF /SS patients without morphologically detectable Sezary cells, whereas in other patients 
clonal rearrangements were not detected in blood samples with small numbers of Sezary cells 
(50). The latter may be due to the detection limit of routinely performed Southern blotting (-5%) 
or to the aspecificity of the morphological techniques. These data suggest that both methods 
should be used next to each other for analysis of blood samples from M F /SS patients in order 
to obtain better prognostic information (50,51). 
Skin lesions of early MF stages (e.g. patch or plaque lesions) appear to have germline 
TcR-.$ genes (47). This may be explained by assuming that the infiltrating T cells in these skin 
lesions are polyclonal rather than monoclonal, i.e. that they are non-malignant. An alternative 
possibility is that the percentages of abnormal T cells are too low ( < 5%) to be detectable by 
routine Southern blot analysis. Whatever interpretation is correct, these findings may explain 
the indolent course and favorable prognosis seen in most patients with early MF stages (52). 
In Japan and the Caribbean, adult T cell leukemia-lymphoma (ATLL) represents a major 
cause of cutaneous nodular T cell lymphoma (53,54). ATLL cells are positive for human T cell 
leukemia virus I (HTLV-1) proviral DNA and generally express the C02, CD3, CD4 and CD25 
(IL-2 receptor) antigens (55). In a recent study on a series of 30 ATLL patients it was 
demonstrated that all ATLL had clonally rearranged TcR-.$ genes and that in all but one patient 
also the TcR--y genes were clonally rearranged (55). 
Clonality is equivalent to malignancy in most cutaneous T cell proliferations but several 
clinically-benign skin lesions can also contain clonal T cell populations: lymphomatoid papulosis 
(56,57), pityriasis lichenoides et varioliformis acuta (58), granulomatous slack skin (59) and 
pagetoid reticulosis (60)(see below). Although these skin disorders are not overtly lym-
phomatous at presentation, they have sometimes been associated with development of 
lymphoma. Therefore long-term follow-up of patients with a clinically-benign cutaneous T cell 
proliferation of clonal origin is advisable. 
CLONALITY DOES NOT ALWAYS IMPLY MALIGNANCY 
Although malignancies are clonal cell proliferations, conversely it is not correct to state that 
each clonal proliferation represents a malignancy. Benign monoclonal gammapathy and T--y 
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TABLE 2. Clinically-benign clonal lymphoproliferations which may evolve into a lymphoid malignancy. 
Disease state Possible evolution into References 
a lymphoid malignancya 
CLONAL B CELL PROLIFERATIONS 
Benign monoclonal gammapathies 
- in immunodeficient patients (0.1-1 0 gjl)b 
-/± 63 
- in immunocompetent individuals (3-30 gjl)b + (1 0-30%) 67,74 
EBV-associated lymphoproliferations 
- in primary immunodeficiencies + 75,76 
- in transplant patients + 77-83 
- in AIDS patients + 84,85,92 
Systemic Castleman's disease ? 96 
Extranodal lymphoid hyperplasias 
- ocular adnexa + 97,98 
- lung or gastrointestinal tract + 99-101,105 
- Sjogren's syndrome + 102,106-108 
- Hashimoto's thyroiditis ± (<1%) 103,104 
CLONAL T CELL PROLIFERATIONS 
CD8/T-"Y lymphocytosis ± 62,111-142 
Clinically-benign cutaneous T cell proliferations 
- lymphomatoid papulosis + (10-20%) 148 
- pityriasis lichenoides et varioliformis acuta + 58,149 
- granulomatous slack skin +? 59 
- pagetoid reticulosis +? 60 
T cell proliferations in immunodeficient patients ? 92,150,151 
Angioimmunoblastic lymphadenopathy with 
dysproteinemia + (20%) 152-156 
T cell proliferations in autoimmune diseases 171-173 
a. Used symbols: -, no evolution into malignancy; ±, rare evolution into malignancy; +, evolution into malignancy may occur in part of 
the patients; ?, unknown whether evolution into a malignancy may occur. 
b. Concentration of homogeneous lg component in serum. 
lymphocytosis are classical examples of clonal clinically-benign proliferations of B and T cells, 
respectively (61-63). Clonal proliferations of B or T cells have also been found in benign 
lymphoproliferative diseases with increased susceptibility to the development of a malignant 
lymphoma (56,57,64-66). Most of them are summarized in Table 2. Especially patients with a 
primary immunodeficiency or a secondary immunodeficiency (e.g. transplant patients) are prone 
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to the development of a clonal clinically-benign lymphoproliferative disease, which may 
transform into a malignancy in some of them. 
Benign monoclonal gammapathy 
Monoclonal gammapathies were initially only seen in serum of patients with multiple 
myeloma or other monoclonal B cell proliferative diseases (6"1 ,63,67). In these diseases the 
serum concentration of the monoclonallg component is generally higher than 30 gjl (67). With 
the introduction of more sensitive techniques, monoclonal gammapathies were also found in 
sera of patients with other clinical conditions i.e. without evidence of multiple myeloma, M. 
Waldenstrom, B-NHL or related disorders (6"1 ,63). These monoclonal gammapathies of 
undetermined significance are generally called benign monoclonal gammapathies (6"1 ,63,67). 
Benign monoclonal gammapathies occur in high frequencies (50 to "100%) in patients with 
a primary immunodeficiency with predominantly T cell-mediated deficiency as well as in patients 
with a secondary immunodeficiency such as due to a viral infection (63), bone marrow 
transplantation (63,68) or renal transplantation (69,70). Also in patients with a hematologic 
malignancy, autoimmune disease or severe aplastic anemia benign monoclonal gammapathy 
may occur (63). The benign monoclonal gammapathies in these disease states consist of single 
or multiple homogeneous lg components and generally have a serum concentration of 0. "1 to 
"10 gjl (63). Follow-up analyses revealed that most of these monoclonal gammapathies are 
transient (63,69). There is strong evidence that the development of these transient benign 
monoclonal gammapathies is due to a disturbance in regulatory T cell functions, especially in 
case of immunodeficient patients (6"1 ,63). This is supported by animal experiments (7"1, 72). 
However, also healthy individuals may develop benign monoclonal gammapathies (70). 
The incidence of benign monoclonal gammapathies in healthy individuals increases with 
aging and can be as high as "1 0% in elderly of > 80 y (73) or even over 70% in elderly of > 95 y 
(70), depending on the sensitivity of the technique. This suggests that the regulatory T cell 
functions become increasingly impaired during aging (6"1 ,69). 
A long-term follow-up study on benign monoclonal gammapathies (serum concentrations: 
3-32 gjl) in 24 "1 patients (96% older than 40 y; median age 64 y) revealed that multiple 
myeloma, M. Waldenstrom or another malignant lymphoproliferative process developed in 53 
patients (actuarial rate of "17% at ten years of follow-up and 33% at twenty years of follow-up) 
(67,74). So far, there is no reliable technique for absolute discrimination between a patient with 
benign monoclonal gammapathy and one who will subsequently develop multiple myeloma or 
another malignant B cell disease (67). The serum concentration of the homogeneous lg 
component at first recognition may be informative, since concentrations higher than 30 gjl are 
generally associated with an overt malignancy. However, the most reliable means of 
differentiating a benign from a malignant course is the serial measurement of the homogeneous 
lg component in the serum together with periodic reevaluation of clinical and laboratory features 
(67). 
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Epstein-Barr virus (EBV)-related lymphoproliferative disorders in patients with primary 
or secondary immunodeficiency 
EBV-related illness ranging from fulminant mononucleosis and polyclonal B cell hyperplasia 
to malignant B cell lymphoma is frequently seen in patients with primary immunodeficiency 
(75,76) as well as in patients with secondary immunodeficiency, resulting from immune 
suppressive therapy in allograft transplantation (77 -83) or from acquired immunodeficiency 
syndrome (AIDS) (84,85). EBV is a DNA virus of the herpes family and has a unique tropism 
forB lymphocytes and an inherent ability to transform and immortalize the host cell (64,65). 
The EBV-related B celllymphoproliferative disorders in immunodeficient patients frequently 
occur outside lymph nodes, e.g. in brain or soft tissues (64,65). They have a high tendency to 
progress and often have a fatal outcome (64,65). The incidence of B celllymphoproliferations 
in immunodeficient patients appears to depend on the type of immunodeficiency. They are 
relatively frequently seen in primary immunodeficiency syndromes such as ataxia telangiectasia 
and Wiskott-Aidrich syndrome (86,87). In transplant recipients the overall incidence is -0.6% 
for bone marrow transplant (BMT) patients (82), 1 to 2.5% for renal transplant patients 
(79,80,88), -2.3% for liver transplant patients (79), and 4.9 to 6.3% for heart transplant patients 
(79,80,89). The frequency of abnormal B cell proliferations in AIDS patients is estimated to be 
3 to 4% (65). In a large study on BMT patients it was found that T cell depletion of the donor 
marrow as well as administration of CD3 antibodies for treatment of graft-versus-host disease 
are high risk factors for developing EBV-related lymphoproliferations (82). These data together 
suggest that the incidence of the Jymphoproliferative diseases is related to the degree ofT cell 
deficiency. 
Despite the high mortality of the EBV-related B cell Jymphoproliferations, several 
investigators have reported that many of these B cell proliferations are polyclonal when tested 
with anti-lg~~; and anti-Jg>- antibodies (64,65,79,82,90). In some cases a monoclonal B cell 
population was identified, often not earlier than in the final stage of the disease (64,65,79,82,90, 
91). In other cases no lg expression could be demonstrated (65,79,89). Remarkably, in several 
of the immunophenotypic-"polyclonal" lesions of renal transplant patients clonal cytogenetic 
aberrations have been found (64), while in most immunophenotypic-"polyclonal" lesions of BMT 
patients clonallgH gene rearrangements were detected (82). Also in 18% of the enlarged lymph 
nodes from patients with AIDS-related lymphadenopathy syndrome (LAS) clonal lg gene 
rearrangements were found, although they are commonly considered to represent benign 
polyclonal lymphoid proliferations (85). 
Southern blot analysis of the lg genes of B-NHL in a series of transplant patients and a 
series of AIDS patients revealed the presence of clonal lgH and/or lgl gene rearrangements 
(82,83,85,89,92). In several cardiac transplant patients multiple lesions could be studied, which 
revealed that the lg gene rearrangements could differ between the lesions within a single 
patient (93). This led the investigators to suggest that lymphoproliferative disorders in transplant 
patients are multiclonal diseases (93). Interestingly, in some lesions of AIDS patients more 
than two rearranged lgH gene bands of different density were seen, indicating that more than 
one B cell clone occurred in these lesions (85,92). Furthermore, in the majority of B cell 
lymphomas from AIDS patients a rearrangement of the c-myc oncogene and/or a Burkitt 
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translocation was found, which indicates that it concerned malignant processes (85). In the 
clinically-benign LAS lesions of AIDS patients no such c-myc gene rearrangements were 
detectable, although in some of them clonally-rearranged lgH gene bands were found (85). 
All data together are in line with the hypothesis that EBV is an initiator of a multistep 
process that may ultimately lead to the development of a malignant B cell lymphoma (64,65,94). 
Especially patients with a severe suppression of T cell function seem to be at risk to develop 
such malignant lymphomas. EBV infection results in a polyclonal activation and proliferation of 
B lymphocytes. In the absence of sufficient T cell immunity an uncontrolled proliferation of 
"normal" B lymphocytes occurs, which may lead to oligoclonal or even monoclonal outgrowth 
of "normal" B cells due to growth advantage. During this uncontrolled proliferation malignant 
transformation may occur (e.g. a chromosomal aberration involving one or more oncogenes), 
leading to the development of a malignant B cell lymphoma (64,65,94), or multiple lymphomas 
(85,92,93). 
Oligoclonal or monoclonal B cell populations may remain undetectable by use of anti-lgl 
chain antibodies, because many polyclonal B cells may still be present andjor because the 
malignant cells may not express lg molecules due to damage of one of the lg genes (1 ,8). 
However, the occurrence of oligoclonal or monoclonal B cell populations in lymphoproliferative 
lesions of immunodeficient patients can easily be detected by use of Southern blot analysis of 
lg genes, if the clonal B cell population represents more than 5% of the cells (82,83,85,89,92, 
93). Whether the detected oligoclonal or monoclonal B cell populations are already malignantly-
transformed, can only be investigated by additional studies, such as cytogenetic analysis or 
Southern blot analysis of the relevant oncogenes (85). 
In transplant patients with predominantly regional lymphoproliferative disease, the lesions 
appear to regress upon reduction or discontinuation of immunosuppression, often without 
subsequent rejection of the graft (65,79). This suggests that the lymphoproliferative lesions in 
such patients were not yet malignantly-transformed, although oligoclonal or monoclonal B cell 
populations may already have been present. Systemic cytotoxic treatment of EBV-related 
lymphoproliferations in immunodeficient patients carries the potential for further immunosup-
pression and should be reserved for patients with a progressive disease, i.e. with malignantly-
transformed lesions (65). However, the results of conventional cytotoxic treatment are 
disappointing and mortality remains high (65). 
In conclusion, the EBV-related B cell lymphoproliferations can be regarded as basically 
benign proliferations, which have a high tendency to malignant transformation in immunodefi-
cient patients with suppressed T cell functions. An appropriate diagnosis and early withdrawal 
of immunosuppressive treatment in transplant patients before malignant transformation has 
occurred, will probably decrease the mortality rate. Southern blot analysis of the lg genes in the 
lymphoproliferative lesions may be helpful to discriminate between polyclonal lesions and 
lesions with oligoclonal or monoclonal B cell populations, which are difficult to detect with anti-
lgl chain antibodies. However, for discrimination between "normal" (oligo)clonal B cell 
populations and malignant B cell populations additional investigations are needed, such as 
cytogenetics and Southern blot analysis of the relevant oncogenes. 
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Castleman's disease 
Castleman's disease is an uncommon lymphoproliferative disorder, which is morphologically 
and clinically heterogeneous. Both a localized benign variant and a more aggressive form with 
systemic manifestations have been described (95). 
Two types of local variants are known: a hyaline vascular type and a plasma cell type with 
sheets of polyclonal plasma cells. These local variants of Castleman's disease are self-limiting 
processes, which are often localized in central lymph nodes, although also extranodallocations 
occur (95). Only mild systemic manifestations such as fever, anemia and hypergam-
maglobulinemia are seen in these patients. The disease is curable with local therapy (e.g. 
surgery), which generally also results in the disappearance of the systemic manifestations (95). 
The plasma cell type can also occur as a systemic multicentric variant of Castleman's 
disease. This variant is characterized by extensive peripheral lymphadenopathy, he-
patosplenomegaly, more severe clinical manifestations and an aggressive clinical course. The 
systemic variant is associated with infectious complications and an increased risk for developing 
neoplasias such as Kaposi's sarcoma and B cell malignancies (95,96). 
In a recent study clonal lgH gene rearrangements were found in the lymphoproliferative 
lesions of three of the four patients with systemic Castleman's disease, while in four patients 
with localized disease only germline bands were found (96). Interestingly, in two of the three 
patients with clonal lgH gene rearrangements copies of EBV genome were detected. 
These findings suggest that the lesions in systemic Castleman's disease resemble the 
EBV+ lymphoproliferations in immunodeficient patients (96). This is further supported by the 
fact that several features of systemic Castleman's disease are frequently seen in immuno-
deficient states, e.g. frequent infections, Kaposi's sarcoma and morphological similarities to 
lymph node lesions of AIDS patients (95,96). 
Extranodal noncutaneous lymphoid hyperplasia ("pseudolymphoma") 
About 10 to 25% of NHL are located outside the major lymphoid tissue-bearing sites. The 
most common extranodal sites are the gastrointestinal tract, skin and soft tissues, ocular 
adnexa, respiratory tract, and salivary glands, but extranodal NHL can arise in any conceivable 
anatomic site (97). A heterogeneous group of morphologically-benign lymphoid hyperplasias 
also occur in identical extranodal sites (97,98). They generally consist of small lymphocytic 
proliferations and are often designated "pseudolymphomas". These benign and malignant 
extranodallymphoproliferations represent a difficult diagnostic dilemma due to their overlapping 
clinical and histopathologic features (97,98). They even occur in association with each other, 
suggesting a pathogenetic relationship (97,98). This especially concerns patients with lymphoid 
hyperplasias in ocular adnexa, lung or gastrointestinal tract (97-101), patients with Sjogren's 
syndrome (1 02) or patients with Hashimoto's thyroiditis (1 03,1 04). 
Immunologic marker studies, especially determination of restricted lgl chain expression, 
demonstrated that a large part of the morphologically-benign pseudolymphomas on a solitary 
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noncutaneous extranodal site are in fact monoclonal B cell proliferations, which generally have 
a benign clinical course and long survival with only minimal therapeutic intervention (98, 1 05). 
Only a minority of patients with a morphologically-benign, immunophenotypic-monoclonallesion 
appeared to develop systemic malignant lymphoma within 2 to 5 years after initial presentation. 
However, this also occurred in patients with an immunologic-polyclonallesion (98, 106). 
Several recent studies have demonstrated that clonal rearrangements of lgH and/or lgl 
genes are present in the majority of the histopathologically-benign, immunophenotypic-
polyclonal lymphoid hyperplasias occurring in solitary extranodal sites. This concerned 
lymphoid lesions in ocular adnexa, diffuse lymphoid hyperplasias of the breast, benign 
lymphoepitheliallesions in salivary glands (often found in patients with Sjogren's syndrome) and 
the lymphocytic infiltration in the thyroid gland of a patient with Hashimoto's thyroiditis (97, 107-
11 0). The patterns of lg gene rearrangements varied from one or two distinct bands to multiple 
faint bands, which indicates the presence of monoclonal or oligoclonal B cell populations 
respectively (97, 107-110). In a particular patient with Sjogren's syndrome two distinct benign 
lymphoepitheliallesions were removed two years apart; the rearrangement patterns of the lgH 
as well as lgL genes in these two lesions were entirely different (108). So far, in the cases 
studied, no clonal TcR-.8 gene rearrangements were found (97, 11 0) and no EBV genomic 
sequences were detected (97). These reports indicate that the majority of morphologically-
benign and immunophenotypic-polyclonal extranodal noncutaneous lymphoid hyperplasias 
contain "occult" (oligo)clonal B cell populations. 
In three out of sixteen solitary lymphoid hyperplasias with clonally-rearranged lg genes also 
rearrangements in the bc/-1 or bc/-2 genes were found, which suggests that a malignant 
transformation had occurred in these patients. Nevertheless, after local treatment (irradiation) 
neither local recurrence nor systemic disease were seen in these patients during follow-up 
periods of 4, 29 and 30 months (97). However, two other patients with immunophenotypic-
polyclonal, but genotypic-monoclonal lymphoid hyperplasias developed overt malignant 
lymphoma, despite conservative surgical treatment (without irradiation) of the primary lesion 
(97). 
All data together suggest that the lymphoproliferative lesions in the various extranodal 
noncutaneous sites represent a continuous and progressive spectrum from true polyclonal B 
cell proliferations to malignant B cell lymphomas (97). Initially, small (oligo)clonal B cell 
populations may develop as a consequence of local or general defects in the mechanisms that 
normally regulate B cell proliferation. These clonal B cell expansions may become susceptible 
to genetic alterations (e.g. rearrangements of the bc/-1 or bc/-2 genes or other till now 
undetermined genes), which lead to malignant transformation (97). This is in line with the 
increased incidence of B-NHL in patients with lymphoid hyperplasia in ocular adnexa, lung or 
gastrointestinal tract, patients with Sjogren's syndrome and patients with Hashimoto's thyroiditis 
(97-104). 
It has been suggested that the best therapeutic approach for patients with a solitary 
extranodal lymphoid hyperplasia probably is irradiation of the local disease site, followed by a 
careful monitoring for lymphoid proliferations (97). lmmunophenotyping and analysis of lg 
genes are important to support the diagnosis. Detection of rearrangements in bc/-1 or bcl-2 
genes or other markers of malignant transformation, which may become available in the future, 
will probably allow us to distinguish between benign and malignant monoclonallymphoprolifera-
tions in extranodal sites (97). 
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Chronic T cell lymphocytosis: T cell chronic lymphocytic leukemia, T-r lymphocytosis, 
CDS lymphocytosis and granular lymphocyte proliferative disorder 
In the literature mature T cell proliferative disorders with a chronic clinical course have been 
described under a variety of names, such as chronic T cell lymphocytosis, T cell chronic 
lymphocytic leukemia (f-CLL), T-r lymphocytosis, CDS lymphocytosis, natural killer cell 
leukemia, large granular lymphocyte leukemia and granular lymphocyte proliferative disorders 
(62, 111-113). Most probably all these chronic T cell proliferative disorders form one disease 
entity, which predominantly occurs in males of older age (median age of 55-65 y) and is 
characterized by a moderate blood T lymphocytosis (ranging from 5,000/t£1 to 20,000/t£1) with 
T lymphocyte infiltration of the BM and often the spleen (62, 111-113). While in most patients 
chronic T cell lymphocytosis is not an aggressive disease, the patients are often neutropenic 
and have recurrent bacterial infections requiring antibiotic therapy. Some patients with a more 
aggressive disease may benefit from cytotoxic chemotherapy, but most patients do not require 
such treatment (62, 111-113). 
The T lymphocytes generally have a granular lymphocyte morphology, express the pan-T 
cell markers C02 and/or CD? and the majority of them are positive for the CDS molecule 
and/or the CD16 molecule. The latter represents the Fer receptor type Ill (FerRill) (62, 111-
113). 
One of the confusing topics concerning chronic T cell lymphocytoses has been the difficulty 
in determining whether it is a reactive polyclonal or a neoplastic monoclonal disorder (113). A 
large series of publications have described that most chronic T cell proliferative disorders have 
clonally rearranged TcR-.B andjor TcR-r genes (24,25,62, 114-142). The data become more 
clear when the T cell disorders are divided into CD3+ types ( -80%) and COT types ( -20%) 
(fable 3). 
As far as studied, the majority of the CD3+ chronic T cell lymphocytoses express TcR-a.B 
and only a minority express TcR-ro (62,130,141). Most CD3+ types are positive for the CDS 
molecule and the CD57 molecule (Leu-7 /HNK-1), about half of them express the CD16 
molecule and about one-fourth is positive for the CD56 molecule (neural cell adhesion 
molecule; NCAM) (fable 3). They generally exhibit antibody dependent cytotoxicity (ADCC) 
activity, but most of them lack NK activity (62, 111-113). The far majority of the CD3 + chronic 
T cell lymphocytoses have clonally rearranged TcR-.8 and/or TcR-r genes (fable 3 and Figure 
5). Some CD3+ lymphocytoses with germline TcR-.B genes appeared to have clonally 
rearranged TcR-r genes and therefore probably expressed TcR-ro (133, 141 ). It may well be 
that all CD3+ lymphocytoses with germline TcR-.8 genes are in fact clonal TcR-ro+ T cell 
lymphocytoses (fable 3). 
The CD3- chronic T cell lymphocytoses generally have the CD4-;cos- phenotype, 
although about one-fourth may express the CDS molecule; the majority express the CD16 
molecule as well as the CD56 molecule and half of them is positive for the CD57 molecule 
(fable 3). Most CD3-Iymphocytoses exhibit both ADCC and NK activity (62, 111-113). All CD3-
chronic T cell lymphocytoses appeared to have germline TcR-.8 and germline TcR-r genes 
(fable 3 and Figure 5). 
All data together indicate that the CD3 + lymphocytoses are clonal counterparts of normal 
cytotoxic T lymphocytes (62, 113), while the CD3- T cell lymphocytoses with germline TcR 
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TABLE 3. Summary of data from the literature concerning chronic T cell lymphocytoses, such as T-CLL, 
T--y lymphocytosis, CDS lymphocytosis and large granular lymphocyte proliferationsa. 
Relative frequency 
(within the total group) 
Neutropenia 
Cellular functionsb 
- AOCC activity 
- NK activity 
(non-MHC restricted cytotoxicity) 
lmmunophenotype 
TcR-a,B 
TcR--yS 
co4+ ;cos-
C04- ;cos+ 
co4+ ;cos+ 
co4- ;cos-
C016 (Fc-yRIII) + 
C056 (NCAM) + 
C057 (Leu-7/HNK-1)+ 
TcR gene rearrangements 
-clonal TcR-.8 genes 
- polyclonal TcR-.8 genes 
- germline TcR-.8 genes 
- clonal TcR--y genes 
CD3+ lymphocytosis 
-80% 
majority (90%) 
majority 
minority 
85-90% 
10-15% 
rare (3/67) 
majority {58/67} 
rare {4/67} 
rare {2/67)c 
-55% {27/49} 
-25% {6/23) 
-90% {52/58} 
84% {63/75} 
9% (7/75) 
7% {5/75)d 
97% {32/33)e 
CD3- lymphocytosis 
-20% 
about half of the patients 
majority 
majority 
(0/17) 
-25% {4/17} 
rare {1/17} 
majority {12/17} 
majority {11/13) 
majority {5/5} 
-50% {8/15} 
0% {0/19) 
0% (0/19) 
100% {19/19} 
0% (0/8) 
a. The immunophenotypic and TcR gene data are derived from publications which report the absence or presence of CD3 expression (refs. 
24,25,62,116,117,119-121,123-130,132,133,135,140,141). Several research groups have published more than one manuscript about 
chronic T cell lymphocytosis. To avoid duplications, we have only included the most informative data of each group by selecting the 
publications: combination of refs. 116 and 130, leaving out refs. 139 and 142; combination of refs. 121 and 132; ref. 133, leaving out ref. 
131; ref. 62, leaving out refs. 134 and 136; ref. 135, leaving out ref. 137. 
b. Data from refs. 62, 111-113. 
c. Only two out of sixty-seven CD3+ T cell lymphocytoses appeared to have the CD4-/CDS" phenotype. Both expressed TcR-76 (62, 141 ). 
d. In three out of five reported CD3+ T cell lymphocytoses with germline TcR-11 genes also the TcR-7 genes were analyzed. In all three 
cases the TcR-7 genes appeared to be clonally rearranged (133,141). 
e. In one out of thirty-three CD3+ T cell lymphocytoses the TcR-7 genes seemed to be in germline configuration. However, only the J71.3 
probe was used in this patient (123). 
genes are counterparts of normal NK cells, which also have germline TcR genes (62, 113,130, 
142-146). 
Like in other clonal clinically-benign lymphoproliferations, it may be important to monitor 
patients with a chronic T cell lymphocytosis in order to detect clinical evolution or remission 
of the disease. This monitoring can be supported by immunophenotyping or Southern blot 
analysis of TcR genes. The latter is important to determine whether a clinical remission of a 
CD3 + lymphocytosis actually results from or coincides with disappearance of the T cell clone 
(113). 
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Figure 5. Analysis of the TcR-.8 genes of PB cells from eight patients with a CDS/T-r lymphocytosis. Six patients 
had a TcR-a,B+ T lymphocytosis, while two patients had a NK cell (CD3l T lymphocytosis. Control DNA and DNA 
from PB cells of the eight patients were digested with £coR I (A) or Hind ill (B), size separated and blotted to nylon 
membrane filters, which were hybridized with a 32P-Iabeled C,B probe (not shown) and a J,82 probe. Clonally 
rearranged TcR-.8 genes were found in all patients with TcR-a,B+ T lymphocytosis, whereas in the patients with NK 
cell lymphocytosis only germline TcR-,8 genes were observed. 
In some patients with rheumatoid arthritis also T cell lymphocytosis, splenomegaly and 
neutropenia occur. This combination is termed Felty's syndrome (111, 125, 147). However, the 
T lymphocytes in blood of patients with Felty's syndrome appeared to be polyclonal instead of 
monoclonal (125). 
Clinically-benign cutaneous T cell proliferations 
Several clinically-benign skin lesions appear to contain clonal T cell populations: lym-
phomatoid papulosis (56,57), pityriasis lichenoides et varioliformis acuta (58), granulomatous 
slack skin (59) and pagetoid reticulosis (60). 
Lymphomatoid papulosis is characterized by the intermittent appearance of papular 
eruptions of the skin, which eventually ulcerate and later resolve as scars. The disease usually 
has a benign chronic course, although the histologic appearance of the skin lesions are 
consistent with that of a malignant neoplasm: the skin infiltrates contain a prominent population 
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of large atypical Reed-Sternberg-like cells or atypical cells with cerebriform nuclei. Evolution 
to malignant lymphoma may occur in 10 to 20% of the patients (148). Analysis of the TcR-.8 
genes revealed that in a large part of patients with lymphomatoid papulosis a clonal T cell 
population is present in their skin lesions (56,57). In one patient three separate skin biopsies 
were analyzed, which showed varying patterns of TcR-,8 gene rearrangements (56). This 
suggests that lymphomatoid papulosis may be multiclonal in origin. However, in another patient 
the same rearrangement pattern was found in two separate skin lesion biopsies taken eleven 
months apart (57), which illustrates the indolent course of the disease. Like in other clinically-
benign clonal cell proliferations, also lymphomatoid papulosis may develop from a polyclonal 
T cell proliferation via an oligoclonal stage into a monoclonal T cell lesion, which may transform 
into aT cell lymphoma in some patients. To prove such a multistep process, prospective 
studies are needed. 
Pityriasis lichenoides et varioliformis acuta (PLEVA) or Mucha-Habermann disease is 
characterized by extensive recurrent skin eruptions of papules that ulcerate and then heal over 
a period of weeks. It is believed to be an inflammatory disorder and not a lymphoproliferative 
process. Nevertheless, in a study on three patients with PLEVA all three patients appeared to 
have a clonal T cell population in their skin lesions (58). Clinically and histopathologically PLEVA 
shows several similarities to lymphomatoid pap ulosis (149), which is supported by the fact that 
both types of skin lesions can contain clonal T cell populations and that they may be 
associated with more aggressive neoplasms such as mycosis fungoides (58, 149). The principal 
difference between the two types of skin lesions is that lesions of lymphomatoid papulosis 
contain numerous large atypical lymphoid cells, which are lacking in PLEVA skin lesions 
(58, 149). 
Granulomatous slack skin is a rare disorder, characterized by the slow evolution of bulky 
erythematous skin folds that have a granulomatous histology and show destruction of dermal 
elastic tissue (59). The skin lesions contain a dense lymphohistiocytic infiltrate, in which the 
lymphocytes mainly exhibit the CD3+ /CD4 +;cos- immunophenotype. Analysis of the TcR-.8 
genes in the skin lesions of three patients demonstrated the presence of a major clonal T cell 
population in each case (59). Granulomatous slack skin has several features in common with 
mycosis fungoides, but granulomatous slack skin shows a marked tendency towards 
development of flexural lesions and the bulky lesions do not contain the atypical lymphoid cells 
which are seen in mycosis fungoides. Nevertheless, LeBoit and colleagues concluded that 
granulomatous slack skin is a slowly progressive lymphoma (59). 
Pagetoid reticulosis is a rare skin disorder consisting of solitary or localized, often hyper-
keratotic, cutaneous plaques. The involved skin areas show a prominent infiltrate of atypical T 
cells within a hyperplastic epidermis. Clinically these lesions are indolent (60). However, in a 
recent publication, it was demonstrated that a clonal T cell population was present in the skin 
lesions of a patient with localized pagetoid reticulosis (60). Because some patients with 
disseminated forms of pagetoid reticulosis have died from mycosis fungoides, it may be 
important to monitor patients with localized disease (60). 
Apparently, there exists a broad spectrum of cutaneous T celllymphoproliferative disorders 
with various types of clinically-benign disorders at one side and mycosis fungoides and other 
overt T cell lymphomas at the other side. All these cutaneous T cell disorders exhibit 
immunogenotypic evidence of oligoclonality or monoclonality and in several patients more than 
/g and TcR gene analysis for diagnostic purposes 427 
one of these diseases occur either concurrently or sequentially (60). The above described 
clinically-benign cutaneous T cell lymphoproliferative disorders are not overtly lymphomatous 
from their onset, but they have the potential to evolve into more aggressive forms of disease. 
Therefore, long-term follow-up is indicated in patients with lymphomatoid papulosis, PLEVA, 
granulomatous slack skin or pagetoid reticulosis. 
Monoclonal and oligoclonal T cell proliferations in immunodeficiency 
During the last four years we have detected oligoclonal autologous T cell proliferations in 
two patients (RR and GB) with severe combined immunodeficiency (SCID) as well as a 
monoclonal T cell proliferation in a kidney transplant patient (JB) during immunosuppression 
(Figure 6) (150). The T cell proliferation in these three patients concerned aT cell lymphocytosis 
with the CD3+ jTcR-a.B+ jCD4-/CDS+ immunophenotype. In SCID patient RR also T cell 
infiltrates in liver and lung were found. The infiltrate in the lung of this SCID patient consisted 
of only one of the three T cell clones which were present in PB (Figure 6). Despite the 
(oligo)clonality of the cos+ T cell proliferations no signs of malignancy were seen in the three 
immunodeficient patients during a follow-up period of 1 to 4 years. SCID patients RR and GB 
died from severe infections 21h y and 1 y after detection of the oligoclonal T cell proliferations, 
respectively. 
A few reports have described the occurrence of clonal T cell proliferations in immunodefi-
cient patients, i.e. some patients with AIDS (92) and a patient with a combined immunodeficien-
cy (CID)(151). In the AIDS patients it concerned monoclonal CD3+ jCD4-/CDS+ T lym-
phocytoses, which were interpreted as being chronic lymphocytic leukemias with an indolent 
course (92). In the CID patient it concerned an oligoclonal CD3+ jTcR-a.B+ jCD4-j cos-T 
lymphocytosis with massive lymphadenopathy and hepatosplenomegaly. Although the 
oligoclonal T cells in the CID patient had an autologous origin, the massive T cell infiltrates and 
histologic features of the skin were similar to those in graft-versus-host disease. Therefore 
cyclosporin therapy was initiated, resulting in a dramatic clinical improvement. Because of the 
unusual CD4-/CDS- phenotype of the majority of the oligoclonal T cells, the authors have 
suggested a relationship with autoimmune processes (151). 
The frequency of (oligo)clonal T cell proliferations in patients with primary or secondary 
immunodeficiency is probably higher than suggested by publication of only a few reports. This 
scarcity of reports on this subject may be related to the fact that T cell clonality can only be 
proven at the DNA level, since no protein markers are available for the detection of clonality in 
T cell proliferations. 
The precise nature of the clinically-benign clonal T cell proliferations in immunodeficiency 
patients is not yet clear. Do they represent antigen-triggered clonal expansions, are they virally-
induced proliferations or are they related to CDS/T-r lymphocytosis? Like in immunodeficient 
patients with benign monoclonal gammapathies or EBV-associated (oligo)clonal B cell 
proliferations (63,71 ,72,82), failing T cell control might allow inappropriate expansion of a few 
(generally cos+) T cell clones. Follow-up studies will elucidate whether these clinically-benign 
clonal T cell proliferations can transform into overt T cell malignancies. 
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Figure 6. Analysis of the TcR-,8 genes of cell samples from two SCID patients and a renal transplant patient. 
Control DNA and DNA from the patient samples were digested with EcoRI or Hind Ill, size separated and blotted 
to nylon membrane filters, which were hybridized with the C/3 probe (not shown) or the J/32 probe. A: EcoRI filter 
with DNA from two PB samples and a lung biopsy of SCID patient RR which was hybridized with the J/32 probe. 
Four distinct rearranged bands and two faint bands were present in the two PB samples. In the lung biopsy only 
two rearranged bands were detected, which have the same size as two of the distinct rearranged bands in the PB 
lanes. These data indicate that most probably three T cell clones were present in the PB of this SCID patient and 
that one of these T cell Clones had infiltrated the lung (ref. 150). 8: EcoRI and Hindlll filters with DNA from E rosette 
positive (E+) PB cells (>95% T lymphocytes) of SCID patient GB. The filters were hybridized with the J/32 probe. 
In the Hind Ill digest two strong and two weak rearranged bands were visible in addition to a faint germline band 
(G). In the EcoRI digest only one strong rearranged band and two faint rearranged bands were present. The band 
at the germline position probably represents also a rearranged band, which co-migrates with the germline band. 
The 7.9 kb band (*) in the EcoRI digest is due to incomplete digestion (see Chapter 3.3). These data indicate that 
two T cell clones of different size were present in the PB sample of patient GB. C: EcoRI filter with DNA from PB 
cells of kidney transplant patient JB. The filter was hybridized with the J/32 probe, which revealed the presence of 
two rearranged bands in addition to the germline band (G). This indicates that a clonal T cell population was 
present in the PB of this patient. 
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Angioimmunoblastic lymphadenopathy with dysproteinemia 
Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a systemic disease 
of unclear etiology, which generally develops at older age (>60 y) (66,"152-"156). AILD is 
characterized by generalized lymphadenopathy and in many patients by hepatosplenomegaly 
and skin rashes (66, "152-"156). Polyclonal hypergammaglobulinemia is often present and may 
be associated with a Coombs-positive hemolytic anemia (66, "152-"156). The clinical picture is 
consistent with a lymphoma-like syndrome, but histologically AILD resembles a benign 
lymphoproliferative disorder (66, "152-"156). 
Involved lymph nodes in AILD show an obliteration of the normal architecture by a 
polymorphic cellular infiltrate consisting of small lymphocytes, immunoblasts and plasma cells 
together with a proliferation of arborizing small blood vessels (66, "152-"155). lmmunophenotypic 
studies demonstrated that most lymphoid cells in AILD lymph nodes express T cell markers, 
but also polyclonal populations of small B lymphocytes and plasma cells may occur 
(66,"154,"157). 
Despite the "benign" histomorphology, in the majority of AILD patients the clinical course 
is aggressive with a median survival of less than two years (66, "152-"156). Most patients die from 
opportunistic infections (-50%), malignant lymphoma ( -20%), other malignancies or unrelated 
causes (66,"152-"156). On the other hand, about 25 to 30% of the AILD patients reach 
spontaneous remission (unrelated to treatment), which illustrates the unpredictable course in 
AILD ("152-"156). 
The lymphomas in AILD patients may be of B cell origin ("154,"158-"160), but probably most 
are ofT cell origin (66, "157, "16"1 ). To study whether the development of a lymphoma is related 
to the presence of clonal Tor B cell populations in the benign AILD infiltrates, lg and TcR gene 
analyses have been performed on biopsies from involved lymph nodes. These analyses 
revealed that in -70% of cases clonallg and/or TcR gene rearrangements were present ("16"1-
"166). In most of these cases (-85%) this concerned clonal TcR-.8 gene rearrangements, 
indicating the presence ofT cell clones ("16"1-"166). In some of them (5 to "10%) clonal lgH 
andjor lgl gene rearrangements were found, which is in line with the presence of B cell clones 
("162,"165). Finally, in some patients (5 to "10%) both clonallg and clonal TcR gene rearrange-
ments were observed, which suggests that two different clonal cell populations were present 
("164-"166). The rearranged bands are often faint or have a low density as compared to bands 
in control samples ("163,"165). This indicates that the 8 or T cell clones represent (small) 
subpopulations of the lymph node infiltrates. It should be noted that the lg or TcR gene 
rearrangement patterns can differ between separate lymph node biopsies from a single AILD 
patient. In addition, clonal lg and TcR gene rearrangements can emerge or disappear during 
the course of the disease ("165). 
Several investigators have suggested that AILD may be a disorder of immunoregulation 
in which lymphoid cells excessively proliferate, leading to clonal expansion(s) ofT lymphocytes 
and/or B lymphocytes ("162,"163,"165). This immune-dysregulation theory is supported by the 
observation that many AILD patients have hypergammaglobulinemia in association with 
autoimmune hemolytic anemia and that approximately half of the patients die from severe 
infections such as pneumonia and septicemia ("152-"156). 
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However, in AILD patients who die from a malignant Tor B cell lymphoma, the lymphoma 
may have been derived from one of the expanded T or B cell clones, due to a genetic error 
during the repeated cell divisions (165). Indeed clonal cytogenetic aberrations have been 
detected in AILD lymph nodes (167-170). These may represent secondary events, which 
account for malignant transformation and selective proliferation of the malignant clone. On the 
other hand, like in lg and TcR gene studies, also sequential cytogenetic studies indicate that 
some clones disappear, while other clones emerge (66, 169). 
Prospective studies are needed to unravel the role of clonal T and B cell populations in 
AILD patients. Do they represent pre-malignant proliferations in a multi-step process or 
(transient) clonal expansions as a consequence of disturbed immune functions? 
Clonal T cell populations in autoimmune disease 
In several autoimmune disorders T lymphocytes dominate in the local inflammatory 
infiltrates. TcR-.8 gene analysis of synovial fluid T lymphocytes from patients with rheumatoid 
arthritis (RA) showed a dominant rearranged band in three out of eleven RA patients tested 
(171). Also in two patients with chronic progressive multiple sclerosis (MS) evidence for 
oligoclonal T cells in cerebrospinal fluid (CSF) was found upon analysis of the TcR-.8 genes of 
independent CSF-derived T cell clones (172). In addition, in one of six cases with Hashimoto's 
thyroiditis a clonal TcR-.8 gene rearrangement was found upon analysis of thyroid tissue 
samples, which were proven to contain significant T lymphocyte infiltrates (173). 
Since RA, MS and Hashimoto's thyroiditis are not associated with the development ofT cell 
malignancies in the local inflammatory infiltrates, the above described data suggest that the T 
lymphocyte infiltrates in autoimmune diseases represent antigen-restricted T cell responses. 
These T cell responses are not only antigenic-specific, but probably clonally-restricted as well 
(173). 
DETECTION OF TWO OR MORE SUBCLONES WITHIN A MALIGNANCY 
Malignant lymphoid cells are generally regarded as a (mono)clonal expansion of a single 
malignantly-transformed cell. However, subclones can develop during this expansion. In several 
lymphoid malignancies of B cell origin subclones have been found at diagnosis by use of lg 
gene rearrangement studies and/or the application of anti-idiotype (ld) antibodies (Table 4). 
Multiple rearranged lgH gene bands have been found in precursor B-ALL (174-180), follicular 
lymphomas in immunocompetent individuals (181-187) and in immunodeficiency patients with 
EBV-associated lymphomas (85,92,93) (Table 4). 
Multiple lgH gene rearrangements in precursor B-cell acute lymphoblastic leukemias 
Several studies indicate that multiple rearranged lgH gene bands are detectable in 15 to 
30% of all precursor B cell acute lymphoblastic leukemias (precursor B-ALL), as detected by 
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TABLE 4. Occurrence of subclones in B cell malignancies as detected by lg gene analysis. 
Type of B cell Frequency of Possible causes of subclone References 
malignancy subclones formation 
Precursor B-ALL 15-30% - malignant transformation of an early pre- 173-180 
cursor (B) cell with germline lg genes, 
followed by lg gene rearrangements in 
descendents of the malignant progenitor cell 
- secondary rearrangements 
CAUTION: hyperdiploidy 14 and other chromosome 
14 aberrations should be excluded 
Germinal-center-cell- ++a - somatic mutations 181-187 
derived lymphomas (occurring in both exons and introns 
and immunocytomas of the expressed lg gene loci) 
- isotype switch 
EBV-associated lymphomas ++b multiple lymphomas, caused by the same 64,65,85, 
in immunodeficiency patients multistep oncogenic process 92,93 
a. The precise frequency of subclone formation in germinal-center-cell-derived lymphomas and immunocytomas has not yet been 
determined; probably more than half of them contain subc\ones with different idiotypes. 
b. The frequency of multiple lymphomas in immunodeficiency patients is not known. This frequency will probably appear to be higher than 
expected when multiple biopsies from one patient are analyzed. 
use of a JH probe in multiple restriction enzyme digests (174-180). The rearranged lgH gene 
bands in such ALL can vary in number from three to six or more and generally they differ in 
density (Figure 7). Glucose-6-phosphate dehydrogenase (G6PD) isotype analyses and 
cytogenetic analyses indicate that precursor B-ALL have a monoclonal origin (188-191). In only 
5 out of 463 ALL patients ( -1%) two cytogenetically independent cell populations have been 
observed (191). In only one out of these five cases more than two rearranged lgH bands were 
detected and additional studies on X-linked restriction fragment length polymorphism in three 
of these patients, suggested that the apparently-independent cell populations were derived from 
a common malignantly-transformed progenitor (191 ). Therefore, the presence of more than two 
rearranged lgH gene bands in multiple restriction enzyme digests can be attributed to the 
formation of subclones, based on the assumption that generally both lgH gene alleles are 
rearranged in precursor B-ALL cells (see Chapter 6.2). This is supported by the finding that the 
rearranged bands can often be paired according to their density (Figure 7). 
However, one should be aware that cytogenetic aberrations in ALL often concern numerical 
aberrations. Hyperdiploidy (>46 chromosomes per cell) is frequently seen in ALL and may 
involve chromosome 14 (192, 193), which contains the lgH gene locus (194, 195). Also other 
cytogenetic aberrations (translocations, inversions, etc.) may involve the lgH gene locus on 
chromosome 14q32 (189,190). Therefore, cytogenetic data are necessary for discrimination 
between multiple rearranged bands due to the presence of extra chromosomes 14 or 14q32 
aberrations on the one hand and multiple rearranged bands due to subclone formation on the 
other hand. This is illustrated by Figure 7, in which an ALL with three rearranged lgH gene 
bands was concluded to represent a monoclonal ALL rather than a biclonal ALL, because of 
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Figure 7. Analysis of the lgH genes in fifteen precursor B-ALL. Control DNA and DNA from precursor B-ALL cell 
samples were digested with Bg/11 (and several other restriction enzymes; not shown), size separated and blotted 
to nylon membrane filters which were hybridized with the 32P-Iabeled JH probe. In ten of the here presented precur-
sor B-ALL more than two rearranged lgH gene bands were detected. In six cases three or four bands occurred, 
while in four other cases more than four bands were observed. The multiple rearranged lgH gene bands differed 
in density in most cases. In two patients (2nd and 71h lane) trisomy 14 (+14) was the cause of one of the extra 
bands. Based on the combined lgH gene and cytogenetic data it was concluded that six of the fifteen presented 
precursor B-ALL were monoclonal, another six were biclonal and three were oligoclonal (more than two clones). 
the presence of three chromosomes 14 (trisomy 14; + 14). In the same way, another ALL with 
trisomy 14 was concluded to be a biclonal ALL instead of an oligoclonal ALL (three clones or 
more) (Figure 7). 
In one study a biclonal ALL (three rearranged lgH gene bands) and an oligoclonal ALL 
(seven rearranged lgH gene bands) were extensively analyzed by molecular cloning and 
lg and TcR gene analysis for diagnostic purposes 433 
sequencing of junctional regions (178). It was demonstrated that each band represented 
different V-D-J or D-J rearrangements. These findings explain why the multiple rearranged lgH 
gene bands are generally found in all restriction enzyme digests. The sequence data revealed 
that the junctional regions of the lgH gene alleles were different and that the complementarity 
determining regions (CDR1 and CDR2) did not contain a single somatic mutation (178). Based 
on these data, the subclone formation in precursor B-ALL can be explained in two ways: 
1. The oncogenic event occurs in a stem cell committed to the B cell lineage but lacking 
rearranged lg genes. Subsequently lgH gene rearrangements occur in descendents of this 
malignantly-transformed cell. If the growth rates of these descendents are comparable, 
multiple rearranged bands will be detectable at diagnosis. However, if one of the 
descendents obtains a growth advantage during expansion of the ALL, only one or two 
rearranged bands will be detectable at diagnosis. Nevertheless in the latter case small 
subclones may be present, but too small to be detectable by use of the Southern blot 
technique (detection limit: 1 to 5%). 
2. A second explanation for the subclone formation in precursor B-ALL is the occurrence of 
secondary rearrangements in cells of the malignantly-transformed precursor B cell clone. 
Secondary D to JH rearrangements can replace pre-existing D-JH rearrangements by joining 
an upstream D to a downstream JH gene segment (196). In addition, a novel VH gene 
segment can replace the VH segment of a pre-existing V-D-JH complex (197, 198). These 
secondary rearrangements have been reported to occur in immature B cells (1 96-1 98). Also 
in case of secondary rearrangements the growth rates of the different clones determine the 
lg gene rearrangement pattern at diagnosis. 
Future studies will elucidate which of the here proposed mechanisms represents the cause 
of subclone formation in precursor B-ALL. 
In their original report, Kitchingman and colleagues suggested that precursor B-ALL with 
multiple lgH gene rearrangements have a higher tendency to develop a relapse (175). This was 
not confirmed by other investigators (179, 180). Our own preliminary results on 58 precursor B-
ALL revealed a 46% higher relapse rate in the oligoclonal group (n = 7) and a 9% higher relapse 
rate in the biclonal group (n = 14) as compared to the monoclonal group (n =37), which had a 
relapse rate of 16% (median follow-up: 30 months) (Beishuizen et al., unpublished results). 
Therefore, our preliminary results suggest that the presence of subclones in precursor B-ALL 
represents a bad prognostic factor. 
The occurrence of multiple rearranged TcR gene bands is rare. To our knowledge only one 
report describes an ALL with three rearranged TcR-.8 gene bands of different density (191). In 
our laboratory multiple rearranged TcR-.8 gene bands have been found in only 1 out of 30 T-
ALL tested (Figure 8). Mechanisms for the development of subclones in T-ALL may be identical 
to those in precursor B-ALL, because secondary rearrangements have also been reported to 
occur in TcR genes (199,200). 
Multiple subclones in germinal-center-cell-derived lymphomas 
Using gene rearrangement studies and anti-ld antibodies it has been demonstrated that 
subclones can be present in some NHL at diagnosis (181, 185, 186). This especially concerns 
follicular lymphomas. First evidence for development of subclones in follicular lymphomas was 
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Figure 8. Analysis of the TcR-.8 genes in four T-ALL Control 
DNA and DNA from the four T-ALL cell samples were digested 
with EcoRI, size separated and blotted to a nylon membrane 
filter which was hybridized with the C,B probe. In patients DR, 
RH and DD one or two rearranged bands were observed, 
whereas in patient RS two strong and two weak rearranged 
bands were detectable. Cytogenetic analysis of the T-ALL cells 
from this patient did not reveal chromosome aberrations which 
could explain the presence of the two weak extra bands. 
Therefore, these findings indicate that the T-ALL of patient RS 
most probably consists of two subclones. 
found in patients who were treated with anti-ld antibodies (182, 183). In these patients tumor cell 
populations arose which were unreactive with the anti-ld antibodies, although lg expression 
was retained (182, 183). Cloning and sequence studies in one of these patients revealed that 
this was caused by subclone formation due to extensive somatic mutation in the functional VH 
gene region of the lymphoma cells (184). Additional sequence studies in a second patient 
revealed that numerous point mutations had occurred in the V region gene of the expressed 
lgH and lgl genes. The sequence data also indicated that the target for somatic mutation was 
much larger than the productive V gene region and extended into the J-C intron as well (186). 
It is obvious that this type of subclone formation proceeds with time and that tumor samples 
removed from the same follicular lymphoma patient, at different time points, will probably 
consist of different subclones (187). 
The extensive somatic mutations in both exons and introns of the expressed lg genes 
explain why this type of subclone formation is detectable by Southern blot analysis. The more 
extensive the somatic mutations, the more restriction sites will be affected. However, it is 
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unlikely that all restriction sites in and around the JH gene region are changed by somatic 
mutation. Therefore, extensive Southern blot analysis by use of multiple restriction enzyme 
digests will reveal that some restriction fragments differ between subclones, while others are 
identical (187). 
In normal B cell development somatic mutations occur after antigenic stimulation duringthe 
immune response. The mutation mechanisms are not continuously active during immune 
responses, but especially occur during the generation of memory B cells (201 ,202). Most 
memory B cells switch to the expression of another isotype than lgM, which has been 
suggested to terminate the somatic mutation process (202). The generation of memory B cells 
most probably occurs in germinal centers, which are well-defined accumulations of proliferating 
B cells, antigen presenting cells and T cells (203,204). Follicular lymphomas and several other 
related lymphomas are considered to be derived from germinal center cells (187). This can 
explain why these lymphomas exhibit somatic-mutation-induced subclone formation. The above 
data indicate that isotype switch can occur in addition to somatic mutation (202). lsotype switch 
can change the size of restriction fragments in the JH gene region, depending on the restriction 
enzymes used (e.g. BamHI and EcoRI). Detailed analysis of isotype switch can be performed 
by use of CH region probes (see Chapter 3.3). It should be noted that somatic mutations are 
probably restricted to the expressed lgH and lgl genes (202), while isotype switch frequently 
(-75% of cases) occurs on both the productive and non-productive alleles (205,206). This 
implies that changes in lgH gene rearrangement patterns can occur on both alleles. Therefore 
the use of multiple restriction enzyme digests is a prerequisite to prove the clonal origin of 
subclones in germinal-center-cell-derived lymphomas (187). 
Multiple lg gene rearrangements in EBV-associated lymphomas in immunodeficient 
patients 
As outlined in one of the previous sections of this Chapter, the EBV-associated B cell 
lymphomas in immunodeficient patients are probably caused by a multistep oncogenic process, 
which is initiated by a polyclonal activation and proliferation of B lymphocytes (64,65). Due to 
impaired T cell regulation an uncontrolled proliferation of the B lymphocytes occurs in these 
patients, which may lead to oligoclonal or monoclonal outgrowth of B cells (64,65). If malignant 
transformation occurs in more than one clone, multiple lymphomas will arise. This has been 
observed in transplant patients, who had multiple lymphoma lesions with different lg gene 
rearrangement patterns (93), as well as in AIDS patients, who had lesions with multiple 
rearranged lgH gene bands of different density (85,92). 
ANALYSIS Of LYMPHOID MALIGNANCIES AT DIAGNOSIS AND SUBSEQUENT 
RELAPSES 
Morphological techniques and immunologic marker analysis cannot give definite proof that 
the reoccurrence of a lymphoid malignancy indeed represents a relapse. A commen clonal 
origin can be proven by Southern blot analysis of lg and TcR genes. Such information may be 
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important to choose the optimal treatment protocol. For instance, if a leukemia patient receives 
a BMT and subsequently a leukemia develops again, it is important to know whether this 
concerns a post-BMT relapse of the initial leukemia or whether this leukemia represents a new 
malignancy (207). In case of a new leukemia, the patient may benefit from the standard therapy 
protocols. However, if it concerns a relapse, the leukemic cells may have become resistant to 
the standard therapeutic regimens. 
It is obvious that subclone formation as described in precursor B-ALL and follicular B cell 
lymphomas (175-187), will hamper the interpretation of the Southern blot data. This implies that 
(partly) identical lg and TcR gene rearrangement patterns prove the common clonal origin of 
the malignant cells at diagnosis and relapse. If the rearrangement patterns are different, they 
should be interpreted with caution. 
Proof that reoccurrence of a malignancy represents a relapse 
In case of T cell malignancies no protein markers for clonality are available yet. Therefore 
TcR gene analysis is at present the only available technique to prove or exclude that 
reoccurrence of a T-NHL is indeed a relapse. Generally TcR-.B gene analysis is sufficient for this 
purpose (Figure 9). 
In some patients with B cell lymphoma the histomorphological characteristics of the 
lymphoma cells change over time from small cell size with follicular histomorphology to large 
cell size with diffuse histomorphology (208). Such changes often coincide with evolution of the 
disease, therapy resistance and short survival (208). By use of lgH and lgL gene analysis it can 
be demonstrated whether the morphological changes only represent phenotypic changes, while 
the lg gene rearrangement pattern remains unchanged. Several examples of phenotypic shifts 
but genotypic identity in B-NHL have been published (187,208). On the other hand, changes 
in histomorphology may also be accompanied by changes in lgH and/or lgL gene rearrange-
ments (187,208) (see below). 
Also in precursor B-ALL and T-ALL as well as in acute myeloid leukemia (AML) with cross-
lineage rearrangement of lg or TcR genes, Southern blot analysis can be used for comparison 
of rearrangement patterns at diagnosis and relapse. Identical or partly identical patterns prove 
the clonal relationship between the leukemic cells. However, in case of different lg or TcR gene 
rearrangement patterns, a common clonal origin of the leukemic cells cannot be excluded, 
because clonal evolution at the lg or TcR gene level may have occurred (209-211). 
Clonal evolution at first andjor subsequent relapses in All 
From cytogenetic studies it is known that ALL cells at relapse often have additional 
chromosome aberrations as compared with the karyotype at initial diagnosis (212,213). Several 
reports indicate that also changes in lg and TcR gene rearrangement patterns can be found 
in relapsing ALL (209-211). 
In precursor B-ALL the changes often concern only one of the two rearranged lgH gene 
alleles (209-211) or additional rearrangements in the lgK: genes with identical lgH gene rear-
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Figure 9. Analysis of the TcR-,8 genes of a T-NHL at diagnosis and at relapse. Control DNA and DNA from lymph 
node biopsies at diagnosis and relapse were digested with EcoRI (A and B) or BamHI (C), size separated and 
blotted to nylon membrane filters, which were hybridized with the C,B probe (A and C) or the J,82 probe (B). The 
patterns of rearranged TcR-,8 gene bands at diagnosis and relapse were identical. 
rangements (210,211). To our experience these forms of clonal evolution at relapse occur in 
more than 50% of precursor B-ALL (Beishuizen et al., unpublished results). As can be 
anticipated, the changes in lgH gene rearrangement patterns are more extensive in oligoclonal 
precursor B-ALL, since in these leukemias a minor subclone may cause the relapse (Figure 1 0). 
Nevertheless, in most cases at least one rearranged lg gene allele remains unchanged. If the 
lgH gene rearrangement patterns at diagnosis and relapse are completely different (with 
germline lgL and TcR genes), only cytogenetic analysis can prove the common clonal origin 
of the ALL cells. 
Also in T-ALL changes in TcR gene rearrangements have been observed at relapse. Germ-
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Figure 10. Analysis of the lgH genes at diagnosis and relapse in two patients with precursor B-ALL. Control DNA 
and DNA from PB and BM samples at diagnosis and relapse were digested with Bg/11 or a combination of BamHI 
and Hindlll, size separated and blotted to nylon membrane filters which were hybridized with the 32P-labeled JH 
probe. A: In patient RBo three distinct and one weak rearranged band were seen at diagnosis in both digests, 
whereas only one distinct and one weak rearranged band were detected at relapse. The weak band at diagnosis 
was probably identical to the weak band at relapse, but all other bands differed in size in both digests, indicating 
that clonal evolution had occurred in this precursor B-ALL at relapse. B: In patient PV several rearranged bands 
were seen at diagnosis in both digests: one distinct band, one weaker band and several (>4) faint bands. At 
relapse two rearranged bands of comparable density were seen in both digests, which probably have the same 
size as two of the faint bands at diagnosis. This is vaguely visible in the Bg/11 filter. These data suggest that one 
of the small subclones present at diagnosis, has escaped from the cytotoxic treatment and caused the relapse. 
line TcR-,8 genes at diagnosis can appear to be rearranged at relapse and vice versa (210). In 
a series of five T-ALL we have found a deletion of a rearranged TcR-o gene in one T-ALL at 
relapse (Beishuizen et al., unpublished results). Our preliminary results suggest that the 
frequency of clonal evolution at the TcR gene level in T-ALL is lower than the frequency of 
clonal evolution at the lg gene level in precursor B-ALL. 
So far, no reports have been published about changes in cross-lineage TcR gene 
rearrangements in precursor B-ALL at relapse. Such information may be important, because 
TcR--y and TcR-o gene rearrangements occur in high frequency in precursor B-ALL (see 
Chapter 6.2) and therefore can serve as additional markers for clonality or common clonal 
origin. 
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Whether clonal evolution at the level of lg and TcR gene rearrangements is related to short 
suNival has not yet been investigated. Generally, subclone formation at relapse is related to 
therapy resistance and therefore is a poor prognostic factor. 
Clonal evolution in B cell lymphomas 
As described above, subclone formation due to somatic mutations occurs at high frequency 
in germinal-center-cell-derived lymphomas such as follicular lymphomas, but also in 
immunocytomas (181-187). In centrocytic lymphomas and CLL such somatic-mutation-induced 
subclone formation has not been obseNed (187). The somatic mutation process proceeds with 
time and may therefore result in multiple different subclones, of which at least a part will be 
detectable by use of Southern blot analysis of the lgH and lgl genes. The somatic mutations 
probably only occur on the expressed lg gene alleles (202). The unexpressed lgH gene allele 
in most follicular lymphomas is involved in a t(14;18)(q32;q21) (214-217), in which the bc/-2 
gene is juxtaposed to one of the JH gene segments (218-220). This bc/-2-JH rearrangement 
appears to be a stable marker, which is present in all subclones of a follicular lymphoma 
(186, 187,221). Therefore the common clonal origin of subclones in follicular lymphomas can 
generally be proven by use of an appropriate bc/-2 probe (221). 
PROOF OR EXCLUSION OF THE COMMON CLONAL ORIGIN OF TWO MALIGNANT 
LYMPHOID CELL POPULATIONS 
In some patients with a B cell malignancy a second B cell malignancy may develop or 
sometimes two B cell malignancies are simultaneously detected in one patient. Southern blot 
analysis of lgH and lgl genes can indicate whether such malignancies have a common clonal 
origin (185-187,209,221-226), or whether they represent two independent B cell malignancies 
(227-232). 
As indicated in the previous sections, the presence of two apparently-unrelated B cell 
malignancies should be discriminated from subclone formation due to somatic mutation (184-
187,221 ). Therefore extensive lgH gene analysis with multiple restriction enzyme digests should 
be performed to prove that the lgH gene alleles in the two malignant cell populations are all 
rearranged differently (187). In two patients a lymphoma with bitypic lgl chain expression has 
been found. The lg~~: + and lgA + subclones of these two lymphomas appeared to be derived 
from a common progenitor, because they had at least one identical lgH gene rearrangement 
as well as one identicallgl gene rearrangement (187). 
On the other hand, a patient has been described, in whom two lymph node biopsies, 
removed eighteen months apart, disclosed histologic and immunologic evidence for the 
presence of a B-NHL in the first lymph node and neoplastic lymphocytes of B and T cell origin 
in the second lymph node (233). Although the clonal B cell populations in both lymph nodes 
did not express lgH or lgl chains, the lgH, lg~~: and lgA gene rearrangements in the two lymph 
node biopsies were completely different. Therefore it was concluded that the patient had 
developed multiple lymphomas, of which the second B-NHL and the T-NHL may have been 
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induced by the cytostatic treatment of the first 8-NHL (233). 
Formally, lg and TcR gene analyses cannot completely exclude the possibility that two 
different lymphoid malignancies have a common clonal origin, because the oncogenic event 
may have affected an immature lymphoid precursor cell before lg or TcR gene rearrangement. 
Therefore, only cytogenetic analysis of both cell population can give definite proof concerning 
a possible common clonal origin. 
One of the most intriguing clinical problems concerning clonal origin is the relationship 
between the 8 cell malignancies in Richter's syndrome. 
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Figure 11. Analysis of the lgH, lg~~: and lgA genes of the B-CLL cells and B-NHL cells from patient LS with Richter's 
syndrome. Control DNA and DNA from PB cells (SmA + B-CLL cells) and ascites cells (Sm~~:+ B-NHL cells) were 
digested with Bg/11, Hindlll, BamHI or a combination of EcoRI and Hindlll. The filters were hybridized with the JH 
probe, the C~~: probe or the CA probe. A: Analysis of the lgH genes revealed that the distinct rearranged bands of 
the PB cells and the ascites cells differed in both digests. Interestingly in the PB lanes of both filters two faint bands 
were observed, which corresponded to the distinct rearranged bands in the ascites lanes. This indicates that low 
numbers of B-NHL cells were also present in PB, which was confirmed by the immunophenotypic data ( -5% of 
B-NHL cells in PB)(ref. 227). B: Analysis of the lgK: genes revealed that the CK: gene segments were deleted in the 
PB cells on both alleles, whereas one rearranged and one germline lg~~: gene band were found in the ascites cells. 
C: Analysis of the lgA genes demonstrated that only in the PB cells one rearranged band was present (arrow) in 
addition to the seven germline bands. The lgA genes of the ascites cells were in germline configuration. All data 
together indicate that the PB cells (SmA + B-CLL cells) had rearranged lgH genes, deleted C~~: gene segments and 
one rearranged lgA gene allele, whereas the ascites cells (Sm~~:+ B-NHL cells) had rearranged lgH genes, one 
rearranged lg~~: gene allele and germline lgA genes. The completely different rearrangement patterns of the B-CLL 
cells and the B-NHL cells indicate that they represent two independent B cell malignancies. 
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Richter's syndrome 
Richter's syndrome has been defined as the development of a large cell malignant 
lymphoma in a CLL patient, months to years after the initial diagnosis of the CLL (234,235). The 
relationship between both B cell malignancies in Richter's syndrome is difficult to establish on 
morphological criteria, because the NHL cells have an entirely different morphology then the 
CLL cells. In his original report Richter supposed the "reticular cell lymphoma" in a patient with 
CLL to be a second neoplasm (236). Based on the presence of identical lgH and lgl chain 
expression on the surface membrane of CLL and NHL cells in several patients with Richter's 
syndrome, it was concluded that Richter's syndrome in these cases represented a transforma-
tion or progression of a B-CLL clone to a B-NHL clone (237,238). However, the presence of 
identical lgH and lgl chains is not synonymous with clonality, since most B-CLL and B-NHL 
express the J.L heavy chain and the statistical likelihood of two independent B cell clones to 
express the same lgl chain is more than 50% (227). In some reports indeed it has been 
demonstrated that both the CLL cells and NHL cells in Richter's syndrome may express J.L 
heavy chains, but different lgl chains (227,228,239). 
Southern blot analysis of lgH and lgl genes is a more accurate method to study the clonal 
origin of the two B cell malignancies in Richter's syndrome. During the last years we were able 
to study three cases of Richter's syndrome by Southern blot analysis. 
In our first case of Richter's syndrome (patient LS) the CLL cells expressed lgJ.L,o,A, while 
the B-NHL cells were positive for lgJ.L,o,/1;. The difference in lgl chain expression already 
suggested that the CLL and NHL were independent malignancies. This was confirmed by 
extensive analysis of the lgH, lg/1; and lg.\ genes of both the PB cells (CLL cells) and the cells 
from the ascitic fluid (NHL cells): all lgH and lgl gene rearrangement patterns differed 
completely between the two cell populations (Figure 11). We therefore concluded that in this 
patient the B-NHL cannot be regarded as a progression of the B-CLL, but should be consid-
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Figure 12. Separation of the small lymphocytes and the large lymphoid blasts in PB of patient AZ with Richter's 
syndrome (Michiels et al., ref. 226). Left: The small lymphocytes ( -48% of the PB cells) and the large lymphoid 
blasts ( -37% of PB cells) were separated according to their cell volume by centrifugal elutriation. Immunologic 
marker analysis of the cell fractions revealed that fraction 1 contained -95% Sm/1;+ ;cos+ B-CLL cells, while 
fraction 7 consisted of -70% Sm/1;+ B-NHL cells and -25% CD14 + monocytes. Right: Electron microscopic picture 
of the PB cells, showing two small lymphocytes and one large lymphoid blast cell. 
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Figure 13. Analysis of the lgH genes of unfractionated PB cells, PB elutriation fraction 1 (Smx:+ B-CLL cells), PB 
elutriation fraction 7 (Smx:+ B-NHL cells) and lymph node cells (Smx:+ B-NHL cells) from patient AZ with Richter's 
syndrome (Michiels et al., ref. 226). Control DNA and DNA from unfractionated PB cells, PB fractions 1 and 7 (see 
Figure 12) and lymph node cells were digested with a combination of BamHI and Hindlll (A), Bg/11 (B) or EcoRI 
(C). The three filters were hybridized with the 32P-Iabeled JH probe. The rearranged bands in the PB cells and 
lymph node cells were identical in all digests. In the Bg/11 and EcoRI filters two rearranged bands occurred, while 
in the BamHI/Hindlll filter one rearranged band was observed which most probably consists of two co-migrating 
rearranged bands. The distinct germline bands in the unfractionated-PB-celllane and in the PB-fraction-71ane are 
probably due to the presence of non-malignant cells with germline lgH genes, such as T lymphocytes and for 
monocytes. The combined data indicate that the B-CLL cells and the B-NHL cells have a common clonal origin. 
ered as an independent B cell malignancy, which arose in a susceptible host (227). 
The second case of Richter's syndrome (patient AZ) concerned a CLL patient who 
developed a centroblastic B-NHL with massive lymphadenopathy and involvement of PB. The 
differential count was: 37% large lymphoid blasts (B-NHL cells), 48% small lymphocytes (B-
CLL cells), 9% granulocytes and 6% monocytes (Figure 12). The lymph node cells as well as 
both lymphoid cell populations in PB expressed lgJL,x:. For detailed analysis of the small 
lymphocytes and large lymphoid blasts in PB and optimal comparison with the lymph node 
cells, the PB cells were separated according to their cell volume by use of centrifugal elutriation 
(Figure 12). Fraction 1 contained the small PB cells (-95% cos+ jSmJL,x:+ B-CLL cells), while 
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Figure 14. Analysis of the lgH and lgK genes of PB cells, lymph node cells and BM cells from patient DJ with 
Richter's syndrome. Control DNA and DNA from PB cells ( -60% SmK+ B-CLL cells), lymph node cells (SmK+ B-
NHL cells) and BM cells (-10% CyK+ plasma cells) were digested with Bg/11 (A) or BamHI (Band C). The filters 
were hybridized with the JH probe (A and B) or the CK probe (C). A and 8: Analysis of the lgH genes revealed 
two germline bands in the PB lane, one rearranged band in the lymph node lane and one weak rearranged band 
in the BM lane. The rearranged bands in the lymphnode lane and the BM lane were identical in both digests, but 
differed from the rearranged bands in the PB lane. C: Analysis of the lgK genes demonstrated that the rearranged 
band in the lymph node lane was identical to the weak rearranged band in the BM lane. The rearranged band in 
the PB lane had a different size. These data indicate that the SmK+ B-CLL cells in PB on the one hand and the 
SmK+ B-NHL cells in the lymph node and CyK+ plasma cells in the BM on the other hand represent two indepen-
dent malignancies. The B-NHL cells and the CyK+ plasma cells in BM have a common clonal origin (see text). 
fraction 7 contained the large PB cells (-70% Smtt,K+ large B-NHL cells and -25% CD14+ 
monocytes). Extensive Southern blot analysis of the lgH genes of both PB cell fractions as 
well as lymph node cells and unfractionated PB cells revealed that the B-CLL and B-NHL cells 
had completely identicallgH gene rearrangement patterns (Figure 13). This indicates that the 
NHL in this patient represented a clonal progression of the CLL cells (226). 
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In our third case of Richter's syndrome (patient DJ) the 8-CLL was followed by an 
immunoblastic NHL and subsequent acute macroglobulinemia with hyper-viscosity syndrome. 
The 8-CLL cells in PB, the 8-NHL cells in the lymph nodes and the BM plasma cells expressed 
the same lgH and lgL chains: lgJL,K:. Southern blot analysis demonstrated that the lgH and lg~~: 
gene rearrangements of the 8-NHL cells and BM plasma cells were identical but differed from 
the 8-CLL cells in PB (Figure 14). This indicates that the 8-CLL and the immunoblastic NHL 
with subsequent evolution to acute macroglobulinemia represented two independent malignan-
cies. A comparable case has been published by Giardina and colleagues (228). However, in 
their case the diagnosis was facilitated by the fact that the 8-CLL cells on the one hand and 
the 8-NHL cells and plasma cells on the other hand produced different lgL chains (228). 
Our observations indicate that the immunologic and genotypic features of Richter's 
syndrome are more heterogeneous than assumed from the clinical picture. Apparently, the NHL 
may represent either a clonal progression of the CLL (222,226) or a second lymphoid 
malignancy (227,228,230,232). Prospective studies using the combined morphological, 
immunologic and Southern blot techniques should elucidate the clinical relevance of this 
heterogeneity in Richter's syndrome. 
DETERMINATION OF THE DIFFERENTIATION LINEAGE OF A MALIGNANCY 
In some cases it is not possible using immunologic marker analysis to determine whether 
the malignant cells belong to the 8 cell lineage or the T cell lineage, or whether it concerns a 
non-lymphoid malignancy. 
It is generally assumed that lg and TcR gene rearrangements are only functional in 8 and 
T cells, respectively. Nevertheless such rearrangements have been described to occur 
occasionally in cells from other lineages as well, such as lg rearrangements in T-ALL and AML 
and TcR gene rearrangements in precursor B-ALL and AML (240,241; see Chapter 6.2 for 
details). Due to such cross-lineage rearrangements, the detection of lg or TcR gene 
rearrangements in malignant cells does not provide definitive proof of the differentiation lineage 
to which the malignancy belongs. Despite this limitation in some lymphoproliferative diseases, 
Southern blot analysis of lg and TcR genes can be of great value for lineage assignment of the 
malignant cells. Also the absence of lg and TcR gene rearrangements can be informative. 
lennert's lymphoma 
Lennert's lymphoma is an unusual form of malignant lymphoma which is characterized by 
the presence of a large number of epithelioid cells (242). Initially it was thought to represent a 
variant of Hodgkin's disease, but later it was concluded that the proliferating (Ki-67+) CD4 + T 
lymphocytes in Lennert's lymphoma probably are the malignant cells (242,243). The clonal 
origin of these CD4 + T lymphocytes was proven by Southern blot analysis of the TcR genes. 
It appeared that in all studied cases of Lennert's lymphoma the TcR-.8 genes and TcR--y genes 
were cion ally rearranged and that in a part of them also clonally rearranged TcR-o genes were 
present (244-246). The lgH genes were in germline configuration in all studied cases (244-
246). 
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CD30+ lymphomas and T-cell-like lymphomas 
COSO (Ki-1) + NHL are anaplastic large cell lymphomas, characterized by the proliferation 
of large bizarre cells, which show early involvement of the area around B cell follicles and tend 
to disseminate into the marginal sinuses (247). The expression ofT cell andjor B cell markers 
in the absence of cytokeratin andjor macrophage markers suggests that the neoplastic cells 
are derived from activated (COSO+) lymphoid cells. Most commonly they are ofT cell origin and 
in some cases they represent cells of the B cell lineage (247,248). 
Southern blot analysis has supported this assumption, because in most cases indeed 
clonally rearranged TcR genes have been found in concordance with the T cell phenotype of 
the coso+ neoplastic cells (246,248). In some other cases lgH gene rearrangements have 
been observed, generally in association with the expression of B cell antigens by the COSO+ 
cells (246,248). In a few cases discordancies between marker expression and gene 
rearrangements have been found (248). This may be due to admixture of reactive cell 
populations, which is supported by the finding that the clonally rearranged TcR andjor lg gene 
bands often are of low density (248). Also COSO+ NHL with germline TcR and lg genes have 
been reported (248; see also patient SM in Table 5 and Figure 15). These data indicate that 
most coso+ NHL probably are ofT cell origin. However, Southern blot analysis cannot provide 
the desired information in each case. 
TABLE 5. Immunologic marker analysis and Southern blot analysis of TcR and lg genes in three malignant 
lymphomas with a few T cell characteristics. 
patient JW 
Cell sample peripheral blood 
lmmunophenotypea 
CD20 (81) 0% 
CD2 (Leu-5) 95% 
CD3 (Leu-4) 3% 
CD4 (Leu-3) 71% 
CD5 (Leu-1) 79% 
CD? (Leu-9) 3% 
CDS (Leu-3) 3% 
CD25 (IL-2R) 1% 
CD30 (Ki-1) NT 
Southern blot analysisb 
TcR-,8 R/R 
TcR--y R/R 
TcR-8 D/D 
lgH GjG 
patient SM 
lymph node 
± 
+ 
+ 
G/G 
GjG 
GjG 
GjG 
patient JS 
skin biopsy 
+ 
+ 
NT 
NT 
GjG 
GjG 
GjG 
GjG 
a. lmmunophenotypic data are derived from immunologic marker analysis of cells in suspension (positivity is given in percentages) or from 
immunologic marker analysis on frozen sections (expression indicated with symbols:-, only a few cells positive;±, weak expression; +, 
majority of cells positive). 
b. The Southern blot data are illustrated by Figure 5. The used letter codes indicate: G, germ line; R, rearranged; D, deleted. The configuration 
of both alleles is given. 
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Figure 15. Analysis of the TcR-,8, TcR-1' and TcR-o genes in three malignant lymphomas with a few T cell 
characteristics (see Table 5). Control DNA and DNA from the PB cells of patient JW (CD2+ ;cos+ T-NHL), two 
lymph node biopsies of patient SM (CD2± jCD30 + NHL) and a skin biopsy of patient JS (C02 + jCD7+ NHL) were 
digested with EcoRI, BamHI or Kpnl. The filters were hybridized with the C,B probe, J,82 probe, J-y1.3 probe or 
Jo1 probe (not all results are shown in the figure). A: Analysis of the TcR-,8 genes of the PB cells from patient JW 
revealed two rearranged bands in the BamHI digest after hybridization with the C,B probe, while no rearranged 
bands occurred in the EcoRI digest after hybridization with the J,B2 probe. This indicates that both TcR-,8 gene 
alleles of the T-NHL cells in PB are probably rearranged to the {31 locus. B: Analysis of the TcR--y and TcR-o genes 
of the cells in both lymph node biopsies from patient SM revealed only germline bands. The absence of the 3.3-kb 
germline band in the EcoRI filter hybridized with the J-y1.3 probe is due to a genetic polymorphism on both TcR-
1' gene alleles (see Chapter 3.3). C: Analysis of the TcR-1' and TcR-o genes of the cells in the skin biopsy of patient 
JS revealed only germline bands. Details concerning the malignant lymphomas of the three patients are 
summarized in Table 5. 
The limitations of Southern blot analysis for lineage assignment are also illustrated by the 
finding that some T cell lymphomas or "T-cell-like" lymphomas have germline TcR genes (41; 
patient JS in Table 5 and Figure 15). Such lymphomas may have been derived from immature 
T cells before TcR gene rearrangements or from immature lymphoid cells which aberrantly 
exhibit some T cell characteristics. 
Hodgkin's disease 
Reed-Sternberg (RS) cells are pathognomonic of Hodgkin's disease and are considered 
to be the neoplastic cell population in this disease. The precise identity and origin of RS cells 
is still unclear. A large series of studies have tried to unravel this problem by analyzing the lg 
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and TcR genes in biopsies from involved lymph nodes (245,246,249-259). Despite these efforts 
the data remained controversial. Some investigators have found rearranged lg and/orTcR gene 
bands (generally of low density) (245,246,253-255), while in other studies such rearrangements 
were only sporadically observed (249-25"1 ,256-258). Also no clear positive correlation has been 
found between the absence or presence of lg and/or TcR gene rearrangements on the one 
hand and percentages of RS cells on the other hand (250,252,258). 
Therefore, we conclude that the Southern blot analyses have not resolved the RS cell 
enigma. Since Hodgkin's disease is associated with decreased T cell function, it might be that 
the occurrence of (small) clonal B and T cell populations is due to dysregulation of the immune 
response (260). This is supported by the finding that EBV-DNA has been detected in Hodgkin's 
disease biopsies with clonal lg rearrangements (260). 
Absence of lg and TcR gene rearrangements 
Gene rearrangements studies for lineage assignment have generally been used to support 
the B or T cell origin of a lymphoproliferative disease ("1 0, "1 "1, "15-"17,4 "1 ,245,246,248). However, 
Figure 16. Analysis of the lgH genes of cells in an 
inguinal tumor mass which was thought to be an 
extramedullary plasmacytoma without lg ex-
pression. Control DNA from a T-ALL and a B-CLL 
as well as DNA from the inguinal tumor mass were 
digested with Bg/11 (A) or a combination of BamHI 
and Hindlll (B). Both filters were hybridized with 
the 32P-Iabeled JH probe. Only germline bands 
occurred in the DNA from the inguinal tumor mass. 
Since plasma cells have rearranged lgH genes, it 
was concluded that the inguinal tumor mass did 
not represent an extramedullary plasmacytoma. 
Additional immunophenotyping revealed that it 
concerned an anaplastic carcinoma. 
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the absence of lg and TcR gene rearrangements can be useful for lineage assignment in some 
cases, e.g. to support the myeloid origin of a malignancy (261). 
We performed Southern blot analysis of an inguinal tumor mass, which was diagnosed to 
be an extramedullary plasmacytoma without lg expression. Since all mature B cell malignancies 
have been reported to contain rearranged lg genes (see Chapter 6.2), we analyzed the 
configuration of the lgH genes, which were found to be germline in all restriction enzyme 
digests (Figure 16). Subsequent additional immunophenotypic studies revealed that it 
concerned an anaplastic carcinoma. 
DETECTION OF lOW NUMBERS OF MALIGNANT CEllS 
The detection limit of routinely performed Southern blot analysis for the detection of clonally 
rearranged lg and TcR genes is 1 to 5% (see Chapter 3.3). For many lymphoid malignancies 
such detection limits can also be reached by use of morphological techniques or immunologic 
marker analysis (19). Nevertheless, in some cases Southern blot analysis of lg or TcR genes 
may be valuable for the detection of minimal disease (180,209). 
After withdrawal of cytotoxic treatment in a patient with precursor B-ALL, the regenerating 
BM may be difficult to distinguish from a BM relapse, because many normal TdT+ /CD10+ 
precursor B cells (10 to 20% and sometimes up to 50%) are present in regenerating BM 
samples (19). Southern blot analysis of the lgH genes of such regenerating BM samples in 
combination with immunophenotypic data will generally provide sufficient information for the 
correct diagnosis. 
Some years ago a new molecular genetic technique, the so-called polymerase chain 
reaction (PCR), has been introduced (262-264). The PCR technique allows the selective 
amplification of a particular DNA fragment whill;l it is still incorporated in total genomic DNA 
(262-264). If the involved DNA fragment is tumor-specific, detection of low numbers of 
malignant cells is possible. 
The polymerase chain reaction and the detection of minimal residual disease 
The specificity of the DNA amplification in the PCR technique depends on the availability 
of the nucleotide sequences that flank the region of interest. Therefore two synthetic 
oligonucleotides are prepared, which can hybridize to the flanking regions of opposite strands. 
These two oligonucleotides serve as primers for extension by a DNA polymerase. The PCR 
procedure involves repeated cycles of heat denaturation of the genomic DNA (-95•C), 
annealing of the oligonucleotide primers to their co~plementary sequences (55 to 60.C), and 
extension of the annealed primers by use of DNA polymerase (70 to 75.C). The two primers 
are oriented with their 3' ends pointing towards each other, so that DNA synthesis by the 
polymerase proceeds across the region of interest, which is located between the primers. The 
extension products of one primer can serve as a template for the other primer. So each 
successive PCR cycle (denaturation, annealing and extension) essentially doubles the amount 
of DNA synthesized in the previous cycles. This results in an exponential amplification of the 
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DNA fragment of interest. The enzyme Taq polymerase is stable at the high denaturation 
temperature, which makes it unnecessary to add new polymerase after each cycle. This allows 
the PCR to continue for 20-30 cycles or more, theoretically resulting in 220 to 230 DNA 
fragments of interest (262-264), which can easily be detected in a dot blot or Southern blot by 
use of a 32P-Iabeled probe, which specifically hybridizes to the amplified DNA fragment. 
It is obvious that this PCR-mediated amplification of specific DNA fragments represents an 
excellent tool for the detection of low frequencies of tumor-specific DNA sequences (derived 
from low frequencies of tumor cells). Theoretically the detection limit is approximately 0.001 to 
0.0001% (one malignant cell between 105 to 106 normal cells), based on the fact that a PCR 
tube can maximally contain 1 to 10 J.Lg of DNA, while a human cell contains approximately 10 
pg of DNA. 
The PCR technique was first used for the detection of low numbers of malignant 
hematopoietic cells with a tumor-specific translocation, such as t(14;18)(q32;q21) or 
t(9;22)(q34;q1 1) (265-267). The two primers for these purposes were designed to recognize 
sequences at opposite sides of the breakpoint recombination area, so that the amplified DNA 
fragment represented the tumor-specific hybrid DNA segment. 
Recent reports indicate that PCR-mediated amplification of the junctional regions of 
rearranged lg and TcR genes can be used for the detection of minimal residual disease in 
lymphoid malignancies (268-270). This is based on the fact that the junctional region of 
rearranged lg and TcR genes can vary enormously due to the joining of V, (D) and J gene 
segments and the insertion of nucleotides at the joining sites (see Chapter 3.2). The junctional 
regions probably differ in each lymphocyte (clone) and therefore also in each leukemia or 
lymphoma. It has been suggested that the PCR-mediated amplification of leukemia/lymphoma-
specific junctional regions can be used in case of rearranged lgH genes (269), rearranged TcR-
'Y genes (268) and rearranged TcR-8 genes (270). However, it should be emphasized that 
oligoclonality at diagnosis and clonal evolution at relapse will severely hamper the application 
of this technique in precursor B-ALL and germinal-center-cell-derived lymphomas (see previous 
sections). This especially concerns subclone formation at the lgH gene level. Future studies 
will elucidate whether rearranged TcR--y and TcR-8 are less prone to the development of 
additional changes. If so, then PCR-mediated amplification of TcR--y and TcR-8 junctional 
regions will be an excellent procedure for the detection of minimal residual disease in precursor 
B-ALL with cross-lineage TcR gene rearrangements. 
CONCLUSION 
Southern blot analysis of lg and TcR genes is a powerful method for the detection of clonal 
B and T cell proliferations. Although in the majority of patients with a lymphoproliferative disease 
morphological techniques and immunologic marker analysis give sufficient information, in some 
patients gene rearrangement studies are necessary to make the correct diagnosis. The 
application should be restricted to selected diagnostic purposes (see Table 1), since Southern 
blotting is relatively expensive and time-consuming. In addition, much background information 
about lg and TcR gene analysis as well as broad experience are needed for correct 
interpretation of the Southern blot data. This is especially true for clinically-benign lym-
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phoproliferations, which are frequently seen in immunodeficiency patients. 
The application of Southern blot analysis of lg and TcR genes for the detection of minimal 
residual disease is hampered by the relatively high detection limit (1 to 5%). On the other hand, 
the recently developed PCR technique for the selective amplification of leukemia/lymphoma-
specific junctional regions seems to be promising for this purpose. 
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CHAPTER 7 
GENERAL DISCUSSION 
The extensive immunologic marker studies of normal immature and mature T cells as well 
as the studies on the rearrangement and expression of T cell receptor (feR) genes in T cell 
acute lymphoblastic leukemias (T-ALL) have given more insight into the various step-wise 
processes which occur during T cell differentiation. Especially, detailed information has been 
obtained about the expression of the TcR-CD3 complex during T cell development. In addition, 
analysis of TcR-a.B and TcR-ro expression by blood T lymphocytes in healthy children as well 
as infants with a hypoplastic or aplastic thymus (DiGeorge anomaly) has provided evidence for 
the existence of an extrathymic TcR-ro pathway, while the development of TcR-a.B+ cells is 
highly thymus-dependent. Detailed experimental data on human T cell differentiation and the 
interpretation of these data are described in Chapter 4. 
The experience and knowledge concerning immunologic marker analysis of normal and 
malignant T cells was extended to other hematopoietic cells and their malignant counterparts 
(Chapter 2). This allowed us to compose optimal panels of immunologic markers for 
immunophenotyping of the various types of leukemias and non-Hodgkin lymphomas (NHL), 
which is important for a detailed and reproducible classification of these malignancies (Chapters 
5.1 and 5.2). 
Similarly, the experience with the analysis of TcR genes was extended to the analysis of 
immunoglobulin (lg) genes (Chapter 3.3). The great majority of lymphoid malignancies of B 
and T cell origin have clonally rearranged lg and TcR genes, respectively. Also cross-lineage 
lg and TcR gene rearrangements occur. This especially concerns TcR gene rearrangements 
in precursor B cell acute lymphoblastic leukemias (precursor B-ALL), lg heavy chain (lgH) gene 
rearrangements in T-ALL and lg and/or TcR gene rearrangements in acute myeloid leukemias 
(AML) (Chapter 6.2). This information can be used for diagnostic purposes, because Southern 
blot analysis of lg and TcR genes is an excellent tool for the detection of clonality. The 
diagnostic applications are as follows: discrimination between polyclonal and monoclonal 
lymphoproliferations; detection of two or more subclones within a malignancy at diagnosis; 
detection of clonal evolution at relapse; analysis of the clonal origin of two lymphoid 
malignancies in a single patient; and analysis of the differentiation lineage of a malignancy. 
Although virtually all malignancies are clonal proliferations, it should be noticed that a clonal cell 
population does not always represent a malignancy (Chapter 6.3). In the majority of patients 
with a lymphoproliferative disease morphological techniques and immunologic marker analysis 
give sufficient information, but in 1 to 5% of cases gene rearrangement studies are necessary 
to make a correct diagnosis. The application of lg and TcR gene analysis for diagnostic 
purposes should be restricted to these cases, because the Southern blot technique is 
expensive and time-consuming. 
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Appropriate immunologic marker analysis and Southern blot analysis of lg and TcR genes 
can give important complementary information in addition to the information from routine 
cytomorphology. The combined morphological, immunophenotypic and genotypic information 
allows a more accurate diagnosis in patients with lymphoproliferative diseases or related 
disorders. This is not only important at initial diagnosis, but also during follow-up of these 
patients. However, the detection of low numbers of malignant cells is a major problem at 
diagnosis and during follow-up (1 ,2). During treatment and even after withdrawal of therapy it 
remains uncertain whether or not malignant cells are still present. This is especially true in 
childhood ALL, because these leukemias may relapse up to five years or more after initial 
diagnosis and subsequent treatment (1 ,2). Therefore, we have put much effort in designing 
techniques for detection of minimal (residual) disease in ALL 
DETECTION OF MINIMAL RESIDUAL DISEASE IN ALL 
The detection limit of conventional morphological techniques is not lower than 1 to 5% (i.e. 
1 to 5 malignant cells between 100 normal cells) since small numbers of malignant cells are 
difficult to discriminate from normal cells (1 ,2). Also the application of immunologic marker 
analysis for the detection of low numbers of malignant cells is hampered by the presence of 
normal counterparts which express the same markers. However, in specific cases it is possible 
to detect minimal disease, based on the assumption that the presence of positive cells outside 
their normal "homing areas" is indicative of malignancy (Chapter 5.3). In this way the enzyme 
terminal deoxynucleotidyl transferase (TdT) can be used as marker for the detection of ALL 
cells in cerebrospinal fluid (3-5). This allows the early detection (or exclusion) of central nervous 
system leukemia which is a severe complication in ALL patients (Chapter 5.4). Another example 
is the detection of extremely low numbers of malignant cells in bone marrow (BM) and 
peripheral blood (PB) of patients with a TdT+ T cell malignancy by use of a double 
immunofluorescence (IF) staining technique. This is based on the observation that certain T cell 
marker+ /TdT+ cells normally occur in the thymus only and not in extrathymic locations such 
as BM and PB (Chapter 5.3). 
Detection of minimal residual disease in TdT+ T cell malignancies 
Nearly all T-ALL and most T cell lymphoblastic lymphomas (T-LBL) express TdT as well as 
the pan-T cell markers C02, cytoplasmic CD3 (CyCD3), CD5 and CD?. Many of these also 
express additional T cell markers such as CD1, surface membrane CD3 (SmCD3), CD4 and/or 
CDS. Most cortical thymocytes express the T cell marker+ /TdT+ phenotype, but in extra-
thymic locations like BM and PB such cells are extremely rare. If they occur, they express the 
C02 andjor CD? antigens, but not CyCD3, CD5 or other T cell markers (Chapters 4.2 and 
5.3 and refs. 6-11 ). To determine the sensitivity of the double IF staining technique for aT cell 
marker and TdT, we have performed six dilution experiments, in which normal thymocytes 
(n=1), TdT+ T-LBL cells (n=2) or T-ALL cells (n=3) were mixed in various proportions with 
normal PB cells (8). These dilution experiments demonstrated that the double IF staining 
technique allows the detection of one T cell marker+ /TdT+ cell among 10,000 or even 100,000 
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Figure 1. Determination of the sensitivity of the T cell markerjTdT double IF staining technique. T-ALL cells were 
diluted with normal PB cells and subjected to a CDS/TdT double IF staining. The labeled cells in the cytocentrifuge 
preparations were evaluated by fluorescence microscopy. It appeared to be possible to detect one cos+ jTdT+ 
cell between 100,000 PB cells. 
normal cells (Figure 1). 
Based on these data it can be concluded that the T cell marker /TdT double IF staining 
technique is a valuable tool for the detection of low numbers of malignant cells in patients with 
a TdT+ T cell malignancy (Chapter 5.3 and refs. 11-13). In November 1982 we have started to 
use this double IF staining technique for monitoring of BM and PB samples of patients with a 
TdT+ T cell malignancy. The results of the first three years of this follow-up study are 
summarized in Chapter 5.3. Until now (May 1990) the double IF staining technique has been 
used to analyze BM and PB samples from 24 T-ALL patients and four T-LBL patients at 
diagnosis as well as during follow-up (generally at 4 to 8 week intervals). 
At diagnosis the four T-LBL patients had a stage I or stage II disease according to 
cytomorphological criteria. However, by use of the double IF staining technique CD5+ jTdT+ 
cells were detected in the BM and PB of each of the T-LBL patients, which indicated that they 
in fact had a stage IV disease. These findings confirm earlier data suggesting that T-LBL has 
a high tendency to disseminate and explain why local treatment is insufficient in most T-LBL 
patients (14). 
During follow-up of the 28 patients, nine T-ALL patients developed one or two BM relapses 
(total: n = 11 ). Except for one, all BM relapses were detected 5 to 21 weeks (median: 15 weeks) 
-earlier than by use of conventional morphology. The monitoring of the cos+ /TdT+ cells in PB 
of these patients is illustrated in Figure 2. The percentages of CD5 + jTdT+ cells in PB appeared 
to parallel those in BM, suggesting that T-ALL patients can be monitored by analysis of their 
PB only. One BM relapse was not predicted, probably because no BM or PB samples could 
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Figure 2. Follow-up of three T-ALL patients by analysis of PB samples using cytomorphology and the CD5jTdT 
double IF staining. Symbols: solid squares, cos+ jTdT+ cells; open squares, blast cells; t •. induction therapy; t •. 
reinduction therapy; t *, diagnosis of CNS leukemia and subsequent intrathecal therapy. In the three patients the 
relapses could be predicted 5 to 21 wk earlier than by use of conventional cytomorphology. 
be analyzed during the 15-week period before relapse. In the BM and PB of the other 15 T-
ALL patients and the four T-LBL patients no CD5+ /TdT+ cells were detected during a follow-
up period of 7 to 89 months (median: 52 months). These patients are still in remission 
according to cytomorphological and clinical criteria. 
Our data indicate that double IF staining for aT cell marker and TdT represents a sensitive 
and specific technique for the follow-up of patients with a TdT+ T cell malignancy and they 
suggest that monitoring of PB only is sufficient for early detection of relapse. The time periods 
between the first immunologic and first morphological detection of malignant cells indicate that 
the monitoring should be performed at 4 to 5 weeks intervals. 
Detection of minimal residual disease by use of the polymerase chain reaction 
Immunologic marker analysis cannot efficiently be used for the detection of minimal residual 
disease in patients with precursor B-ALL, because normal counterparts of such leukemic cells 
occur in relatively high frequencies in BM and PB, especially during the period of BM 
regeneration after withdrawal of cytotoxic treatment. However, recent reports indicate that the 
polymerase chain reaction (PCR) technique may be useful for the detection of minimal residual 
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disease via the amplification of the junctional regions of rearranged lg and TcR genes (15-17). 
This is based on the fact that the junctional regions of rearranged lg and TcR genes can vary 
enormously due to the differential ways of joining of V, (D) and J gene segments and the 
insertion of additional nucleotides at the joining sites (Chapter 3.2). The junctional regions 
probably differ in each lymphocyte (clone) and therefore also in each lymphoid leukemia. 
The specificity of the PCR-mediated amplification of junctional regions is based on the use 
of two synthetic oligonucleotides, which specifically recognize sequences on opposite strands 
that flank the DNA region of interest, i.e. the junctional region (18-21). These oligonucleotides 
function as primers for the DNA polymerase and are oriented with their 3' ends pointing 
towards each other. In this way the polymerase-mediated DNA synthesis proceeds across the 
junctional region. An example is given in Figure 3, where the Vo1 gene-segment is joined to the 
Jo1 gene segment via a junctional region which probably contains one or more Do gene 
segments as well as additional nucleotides at the joining sites of the gene segments. Two sets 
of primers are indicated in this figure: an outer set of a Vo1-5' oligo in combination with a Jo1-
3' oligo, and an inner set of a Vo1-3' oligo and a Jo1-5' oligo. These sets of primers can be 
used next to each other or sequentially. 
The PCR procedure involves repeated cycles of heat denaturation of the genomic DNA, 
annealing of the oligonucleotide primers to their complementary sequences, and extension of 
the annealed primers by use of the Taq polymerase (18-21). The extension product of one 
primer can serve as template for the other primer in the next PCR cycles, resulting in an 
exponential amplification of the junctional region (18-21). After this amplification, the PCR 
product can be detected in a dot blot or Southern blot by use of a leukemia-specific junctional 
region probe which has to be designed specifically for each patient (15-17). 
junctional 
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Figure 3. Schematic diagram of the Vo1 gene segment, joined to the Jo1 gene segment via a fictitious junctional 
region which may contain one or more Do gene segments as well as additional nucleotides at the joining sites. 
Four oligonucleotide primers for PCR-mediated amplification of the junctional region are indicated. Upper: The Vo 1-
5' and V o 1-3' oligonucleotides and the Jo 1-3' and Jo 1-5' oligonucleotides are indicated as dotted arrows, which 
point to the right and to the left, respectively. Lower: Nucleotide sequence of the rearranged Vo1-Jo1 gene 
segments. The Vo1-5' and Vo1-3' oligonucleotides are boxed, while the Jo1-3' and Jo1-5' oligonucleotides are 
indicated by bars, which are complementary to the opposite nucleotide sequences. The Sail restriction site at the 
5' ends of the Vo 1-5' and Jo 1-3' oligonucleotide primers can be used for cloning of the PCR product. 
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Figure 4. PCR analysis of the Vli1-Jii1 gene rearrangement in ten TcR-rli+ T-ALL. The cell line PEER was used as a positive control. PCR-mediated amplification of 
the junctional regions was performed by the use of the VIi 1-5' and the Jli 1-3' oligonucleotides as primers (see Figure 3 for oligonucleotides). The PCR products were 
separated in an ethidium bromide-stained agarose gel (A) and blotted to a nylon membrane which was hybridized with the 32P-Iabeled Vli1-3' oligonucleotide (B). The 
results indicate that the size of the PCR products vary from approximately 470 to 510 bases, which implies that the junctional regions can vary extensively ( -40 bases). 
The weak 1.0-kb band in the lane of patient HZ and the strong 1.0-kb band in the lane of patient MA represent doublets of PCR products. The origin of these doublets 
may be related to the fact that the leukemic cells of these two patients had Vli1-Jii1 gene rearrangements on both alleles. 
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PCR-mediated TcR--y and TcR-o gene analysis for detection of minimal residual disease 
in precursor B-All 
The frequency of intra-lineage and cross-lineage lg and TcR gene rearrangements in 
precursor B-ALL and T-ALL are summarized in Table 1 (see Chapter 6.2 for details). Based on 
these data the frequencies of lg and TcR gene rearrangements in the total group of ALL has 
been calculated, assuming that precursor B-ALL account for -80% of ALL, while T-ALL account 
for the remaining -20%. Table 1 indicates that lgH, TcR--y and TcR-o gene rearrangements 
occur in high frequency in precursor B-ALL as well as in the total group of ALL. Several recent 
publications suggest that the PCR-mediated amplification of leukemia-specific junctional regions 
can be used in case of rearranged lgH, TcR--y and TcR-o genes (15-17). It should be 
emphasized that oligoclonality at diagnosis (22-28) and clonal evolution at relapse (29-31) as 
detected by lgH gene rearrangement studies, will severely hamper the application of this 
technique in precursor B-ALL, because changes in lgH gene rearrangements and subclone 
formation will lead to false negative results (Chapter 6.3). However, cross-lineage TcR--y and 
TcR-o gene rearrangements occur in high frequency in precursor B-ALL (Table 1) and it might 
well be that subclone formation at the lgH gene level is not paralleled by changes in the cross-
lineage TcR gene rearrangement patterns. If so, the PCR-mediated amplification of TcR--y and 
TcR-o junctional regions will be an reliable procedure for the detection of minimal residual 
disease in precursor B-ALL with cross-lineage TcR gene rearrangements. 
An advantage in the PCR-mediated analysis of TcR--y and TcR-o genes is that the 
combinatorial repertoire of these genes is low (32-37), while the junctional repertoire is high 
(35,38-40). This implies that only limited numbers of oligonucleotide primers are necessary, 
while the leukemia-specific junctional region probes will differ extensively between the 
leukemias. The latter enhances the specificity of the technique. 
The extensive differences in the junctional regions of rearranged TcR-o genes is illustrated 
by the results of our studies on Vo and Jo gene usage in ten TcR--yo+ T-ALL (Figure 4) (Breit 
et al., unpublished results). It appeared that all ten leukemias had a Vo1-Jo1 gene rearrange-
TABLE 1. lg and TcR gene rearrangements in the total group of ALL. 
lgH lgx; lg>- TcR-.8 TcR-'Y TcR-o 
Ra R or Da R R R R D 
Precursor B-ALLb 98% 32% 6% 33% 55% 54% 26% 
(-80% of ALL) n=251 n=159 n=115 n=318 n=289 n=97 
T-ALLc 14% 0% 0% 89% 91% 68% 28% 
(-20% of ALL) n=180 n=62 n=59 n=281 n=209 n=116 
TOTALd 81% 26% 5% 44% 62% 57% 26% 
a. Symbols: R, one or both alleles rearranged; D, both alleles deleted. 
b. The data concerning lg and TcR gene rearrangements in precursor B-ALL are derived from Tables 2 and 5 in Chapter 6.2. 
c. The data concerning lg and TcR gene rearrangements in T-ALL are derived from Tables 3 and 4 in Chapter 6.2. 
d. Calculated percentages, based on the assumption that -80% of ALL represent precursor B-ALL, while -20% represent T-ALL. 
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ment on at least one allele and in two cases on both alleles (patients HZ and MA). PeR-
mediated amplification of the junctional regions was performed by use of the Vo1-5' and Jo1-
3' oligonucleotides as primers (see Figure 3 for oligonucleotides). The PCR products were 
separated in an agarose gel and blotted to a nylon membrane, which was hybridized with the 
32P-Iabeled Vo1-3' oligonucleotide. The results indicate that the size of the PCR products vary 
from approximately 470 to 510 bases, which indicates that the size of the junctional region can 
vary extensively (-40 bases). Recent publications (41 ,42) and our own experience (Breit et al., 
unpublished results) indicatethatVo1-Jo1 gene rearrangements occur frequently in T-ALL, while 
Vo2-Do3 and Do2-Do3 rearrangements are frequently observed in precursor B-ALL. 
Theoretically, the detection limit of the PCR technique is approximately 0.001 to 0.0001%, 
i.e. one malignant cell between 105 to 106 normal cells. This is based on the calculation that 
a PCR tube can maximally contain 1 to 10 J.Lg of genomic DNA, while one human cell contains 
approximately 10 pg of DNA. It should be noted that normal (polyclonal) T and B cells may 
have rearranged the same V to the same J gene segment as the leukemic cells. It is not known 
to what extent this normal background complicates the analysis of the PCR-mediated 
amplification of leukemia-specific junctional regions for the detection of minimal residual 
disease. For instance, normal TcR--yo+ T lymphocytes which use Vo1 in combination with Jo1, 
occur in PB in a frequency of 0.07-0.7% (Figure 5), but the junctional regions of these normal 
Vo1-Jo1 + T cells probably differ extensively from each other as well as from the junctional 
regions of the leukemic cells. This emphasizes the necessity to produce leukemia-specific 
junctional region probes. Future studies will establish the real detection limit of the proposed 
PCR analyses and will reveal whether the background of normal cells which use the same V 
and J gene segments as the leukemic cells, may cause false positive results. 
Of course not only precursor B-ALL patients, but also T-ALL patients may benefit from the 
PCR-mediated analysis of TcR--y andjor TcR-o genes for the detection of minimal residual 
disease. However, in case of T-ALL the above described T cell marker /TdT double IF staining 
is as yet a more established technique, about which already much information concerning 
sensitivity and specificity is available. 
Chromosome aberrations and the detection of minimal residual disease 
In the initial studies on the use of the PCR technique for the detection of minimal residual 
disease, chromosome aberrations such as t(14;18)(q32;q21) and t(9;22)(q34;q11) were used 
as tumor-specific markers (44-46). Oligonucleotide primers have been designed to recognize 
sequences at opposite sides of the breakpoint recombination area, so that the PCR product 
represents the tumor-specific hybrid DNA segment. However, only -10% of ALL have a 
detectable specific chromosome translocation such as t(4;11)(q21 ;q23), t(1 ;19)(q23;p13.3), 
t(8;14)(q24;q32), t(11 ;14)(p13;q11) or t(9;22)(q34;q11) (47-49). 
Another interesting approach for the detection of minimal disease in malignancies with a 
specific chromosome translocation, is the use of antibodies against the possible protein product 
of the fusion gene, i.e. the new hybrid gene which is caused by the translocation. For instance, 
the bcr-abl protein product, which can be produced in leukemias with t(9;22)(q34;q11) is a 
useful leukemia-specific marker (50). The sensitivity of such antibody techniques is probably 
comparable to that of the T cell marker /TdT double IF staining. 
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Figure 5. Detection limits of several techniques which can be used for the detection of minimal residual disease 
in ALL patients. Morphological techniques: -5%. Double IF staining techniques for aT cell marker and TdT: 0.01-
0.001%. PCR-mediated amplification of TcR-)' and TcR-o junctional regions: 0.01 to 0.0001% (it is not yet known 
to what extent this detection limit is influenced by the "background" of normal cells which use the same V and J 
gene segments as the leukemic cells). PCR-mediated amplification of translocation-associated breakpoint 
recombination areas: 0.0001%. The frequencies of ALL for which the mentioned techniques can be used, are 
indicated in parentheses. 
CONCLUSION 
To our experience, immunologic marker analysis and analysis of lg and TcR genes 
represent important tools in the diagnostics of leukemias and NHL The combined morphologi-
cal, immunophenotypic and genotypic information results in a more accurate diagnosis in 
patients with lymphoproliferative diseases or related disorders. This is important for the optimal 
choice of therapeutic regimens. 
Development and clinical evaluation of techniques for the detection of low numbers of 
malignant cells in ALL patients is another major effort of our laboratory. The above discussed 
data indicate that no uniform technique for the detection of minimal residual disease in ALL 
exists, but that the technique of choice is determined by the immunophenotype, lgjTcR 
genotype or the presence of a chromosome translocation, as indicated in Figure 5_ This figure 
also summarizes the detection limits of the various techniques. It is obvious that a diagnostic 
laboratory should possess both detailed background information and broad experience in 
several fields in order to be able to choose the appropriate technique for the detection of 
minimal residual disease in each ALL patient. This is the more true since the application of 
either of these techniques is relatively expensive. 
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Highly specific and sensitive techniques for the detection of minimal residual diseas13 enable 
adjustment of remission and relapse criteria as well as individualization of therapy, which allows 
prevention of undertreatment and overtreatment of the patients involved. Whether such 
adaptations of treatment protocols will result in lower relapse rates and higher survival rates 
should be evaluated in prospective studies. 
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SUMMARY 
T lymphocytes play a central role in the regulation of antigen-specific immune responses. 
The antigen-specificity of most T cell functions is achieved via the T cell receptor (feR), which 
represents the receptor for specific recognition of foreign antigens, a process which is 
dependent on antigen-presentation via major histocompatibility complex molecules. 
The TcR is closely associated with the CD3 protein chains which together form the 
TcR-CD3 complex on the cell surface of T lymphocytes. In this TcR-CD3 complex the CD3 
protein chains probably play a role in the signal transduction from the TcR to the cytoplasm. 
Two types of TcR have been identified: the classical TcR, which consists of a TcR-a and a 
TcR-.B chain, and the alternative TcR, consisting of a TcR-r and a TcR-o chain. The four TcR 
chains are encoded by genes which contain variable numbers of different V, (D) and J gene 
segments. During T cell differentiation these TcR genes have to rearrange before they can be 
transcribed and translated into functional protein products (Chapter 3.2). 
The aim of this thesis was to study the various aspects of human T cell differentiation, 
especially the mechanisms which determine the expression of the TcR-CD3 complex, and to 
study how this information about T cell differentiation can be used for the development of new 
diagnostic tools for hematopoietic malignancies and immunodeficiencies. In these studies we 
have used peripheral blood, bone marrow and thymus samples from individuals without 
hematologic, immunologic or infectious disease. In addition, we used cell samples from patients 
with DiGeorge anomaly (DGA), a primary T cell immunodeficiency and from patients with aT 
cell malignancy. Especially T cell acute lymphoblastic leukemias (T-ALL) have been used in our 
studies, because these malignancies are generally regarded as clonally-expanded malignant 
counterparts of cells in the various normal differentiation stages. 
Studying T cell differentiation by use of normal cell samples implies that the various cell 
types have to be studied at the single cell level, because normal cell samples are 
heterogeneous. For optimal immunophenotypic studies of such heterogeneous cell samples 
we developed several double and triple immunologic staining techniques, which allowed us to 
obtain detailed information about the expression of immunologic markers by small T cell 
populations. Detailed information about immunologic markers and the various techniques for 
marker analysis are described in Chapter 2. 
For genotypic studies, i.e. analysis of rearrangement and transcription of TcR genes, 
especially T-ALL have been used, because the clonal origin of the leukemic cells makes 
complex cell separations and purifications superfluous. For optimal analysis of the TcR genes 
in the various leukemic cell samples we collected the relevant TcR probes and firstly studied 
the germ line configuration of the TcR-,8, TcR-r and TcR-o genes. Detailed information about the 
techniques used, the various TcR probes and the germline configuration of the TcR genes is 
given in Chapter 3.2 as well as in Chapters 4.5 and 4.7. 
The results of our studies on T cell differentiation are extensively described in Chapter 4. 
They suggest that the precursors ofT cells in the bone marrow, the so-called prothymocytes, 
express the pan-T cell markers CD2 and CD? and that they are positive for HLA-DR and the 
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enzyme terminal deoxynucleotidyl transferase (TdT) (Chapter 4.2). TdT plays an important role 
in the generation of diversity in TcR molecules, based on its capability to insert nucleotides at 
the joining sites of V, D and J gene segments during rearrangement of the TcR genes. These 
TcR gene rearrangement processes probably start as soon as the immature T cells have 
arrived in the thymus and seem to occur in a hierarchic order. The results of the TcR gene 
studies in T-ALL suggest that the TeR-eS genes rearrange firstly, immediately followed by 
rearrangement of the TcR--y genes and in most cells also by rearrangement of the TcR-.8 genes. 
Probably the TcR--y gene rearrangements firstly involve the -y1 locus and if this rearrangement 
is non-functional, rearrangement to the -y2 locus occurs. Transcription of functional TcR--y and 
TeR-eS genes results in TcR--ycS+ T cells. If the TcR--y andjor TeR-eS gene rearrangements are not 
functional or incomplete, the involved T cells may be eliminated. Alternatively these T cells or 
other immature T cells may delete one or both TeR-eS genes and rearrange their TcR-.8 and 
TcR-a genes. In T cells with rearranged TcR-a genes the TeR-eS genes have been deleted, 
because the TeR-eS gene locus is located within the TcR-a gene locus, between the Va and Ja 
gene segments. The TeR-eS gene deletion and TcR-a gene rearrangement most probably 
represent two consecutive steps. Functional rearrangement of the TcR-a and TcR-.8 genes 
results in TcR-a.B+ T cells (Chapters 4.3, 4.4, 4.5 and 4.7). In immature T cells, which do not 
(yet) express the TcR-CD3 complex on their cell membrane, the CD3 genes are already 
transcribed and translated into CD3 protein chains, which accumulate in the cytoplasm, ready 
for assemblage into TcR-CD3 complexes as soon as the appropriate TcR chains are produced 
(Chapters 4.3 and 5.2). 
As indicated above, the T-ALL data suggest that TcR--ycS+ and TcR-a.B+ cells are derived 
from a linear differentiation pathway. However, recent data from studies in mice suggest that 
TcR-a.B+ and TcR--y.s+ cells develop along separate differentiation lineages and that several 
regulatory mechanisms involving the TcR-a/cS locus play a central role in the early divergence 
of the a.B and -yeS pathways (reviewed in Chapter 4.1). 
In man the frequency of TcR-a.B+ and TcR--ycS+ cells can be determined by use of 
monoclonal antibodies against non-polymorphic epitopes of the two types afTeR (Chapter 4.6). 
To study the thymus-dependency of TcR-a.B+ and TcR--ycS+ T lymphocytes, we have 
enumerated these cells in blood samples from healthy children as well as from eight infants with 
DGA. DGA is characterized by facial, cardiac, parathyroid and thymic defects. The degree of 
thymus hypoplasia or aplasia in DGA is assumed to determine the degree of T cell 
immunodeficiency (i.e. from partial to complete). In healthy children the majority of CD3+ 
lymphocytes express TcR-a.B, while only a minority express TcR--ycS. In seven infants with partial 
DGA the variable degrees of decrease in T lymphocytes mainly involved the TcR-a.B+ cells, 
whereas the absolute numbers of TcR--y.s+ cells were much less affected. In one patient with 
complete DGA the great majority of the few remaining T lymphocytes expressed TcR--ycS, but 
virtually no TcR-a.B+ T lymphocytes were found. These data indicate that the T cell deficiency 
in DGA patients is mainly restricted to TcR-a.B+ T lymphocytes, which implies that the 
development of TcR-a.B+ cells is severely hampered by the decrease in thymic mass in DGA, 
while the TcR--ycS lineage is less affected. This suggests that TcR--ycS + T lymphocytes in man can 
develop along an extrathymic differentiation pathway, which is supported by the observation 
thatTcR--ycS + cortical thymocytes and especially TcR--ycS + /TdT+ thymocytes are rare (Chapters 
4.1 and 4.8). 
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The various techniques and the obtained knowledge on human T lymphocyte differentiation 
appeared to be useful for diagnostic purposes. For instance, the cytoplasmic expression of 
CD3 (CyCD3) appeared to be an excellent marker for immature T cell malignancies, which do 
not express a TcR-CD3 complex on the cell surface (Chapter 5.2). In addition, the experience 
concerning immunologic marker analysis of normal and malignant T cells could easily be 
extended to immunologic marker analysis of other hematopoietic cells and their malignant 
counterparts (Chapter 2.3). This allowed us to compose optimal panels of immunologic markers 
for immunophenotyping of the various types of leukemias and non-Hodgkin lymphomas (NHL). 
lmmunophenotyping of leukemias and NHL in addition to routine cytomorphology is important 
for a detailed and reproducible classification of these malignancies. In -30% of cases this will 
lead to a more appropriate or more accurate diagnosis than by use of cytomorphology alone, 
which is important to institute the appropriate therapy (Chapter 5.1). 
The experience with the analysis of TcR genes was extended to the analysis of 
immunoglobulin (I g) genes (Chapter 3.3). The great majority of lymphoid malignancies of Band 
T cell origin have clonally rearranged lg and TcR genes, respectively. Also cross-lineage lg and 
TcR gene rearrangements occur. This especially concerns TcR gene rearrangements in 
precursor B-ALL (30 to 80%, depending on the type of TcR gene), lg heavy chain (lgH) gene 
rearrangements in T-ALL (5 to 15%) and lg and/or TcR gene rearrangements in acute myeloid 
leukemia (AML) (-20% of all AML). Detailed information about these lg and TcR gene 
rearrangements in hematopoietic malignancies is summarized in Chapter 6.2. This information 
can be used for diagnostic purposes, because Southern blot analysis of lg and TcR genes is 
an excellent tool for the detection of clonality. This allows the following diagnostic applications: 
discrimination between polyclonal and monoclonal lymphoproliferations; detection of two or 
more subclones within a malignancy at diagnosis; detection of clonal evolution at relapse; 
analysis of the clonal origin of two lymphoid malignancies in a single patient; and analysis of 
the differentiation lineage of a malignancy. Although virtually all malignancies are clonal 
proliferations, it should be noticed that a clonal cell population does not always represent a 
malignancy (Chapter 6.3). 
In the majority of patients with a lymphoproliferative disease morphological techniques and 
immunologic marker analysis give sufficient information, but in 1 to 5% of cases gene 
rearrangement studies are necessary to make a correct diagnosis. The application of lg and 
TcR gene analysis for diagnostic purposes should be restricted to these cases, because the 
Southern blot technique is expensive and time-consuming. Much background information 
concerning the technical possibilities and limitations of lg and TcR gene analysis as well as 
broad experience are needed for correct interpretation of the Southern blot data in conjunction 
with the results of immunologic marker analysis. This is especially true for clinically-benign 
lymphoproliferations, which are frequently seen in immunodeficiency patients (Chapter 6.3). 
The detection of small numbers of malignant cells is a major problem at diagnosis and 
during follow-up of malignancies. One of the most frightening vexations for patients and their 
doctors in attendance is the uncertainty whether or not all malignant cells have been eradicated 
by the treatment protocols. This is especially the case in childhood ALL, because these 
leukemias may relapse up to five years or more after initial diagnosis and subsequent 
treatment. Therefore, we have put a lot of effort in designing techniques for detection of minimal 
(residual) disease in ALL. The detection limit of conventional morphological techniques is not 
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lower than 1 to 5% (i.e. 1 to 5 malignant cells between 100 normal cells) since small numbers 
of malignant cells are difficult to discriminate from normal cells. Also the application of 
immunologic marker analysis for the detection of low numbers of malignant cells is hampered 
by the presence of normal counterparts which express the same markers. However, in specific 
cases it is possible to detect minimal disease based on the assumption that the presence of 
positive cells outside their normal "homing areas" is indicative for malignancy (Chapter 5.3). 
In this way TdT can be used as marker for the detection of ALL cells in cerebrospinal fluid. This 
allows the early detection (or exclusion) of central nervous system leukemia, which is a severe 
complication in ALL patients (Chapter 5.4). Another example is the detection of extremely low 
numbers of malignant cells in bone marrow and blood of patients with a TdT+ T cell malignancy 
by use of a double labeling technique for aT cell marker and TdT. This application is based on 
the observation that certain T cell marker+ /TdT+ cells normally occur in the thymus only and 
not in extrathymic locations such as bone marrow and blood. Due to the low detection limit of 
the double staining technique (0.01 to 0.001%), it is possible to diagnose a relapse of a TdT+ 
T cell malignancy 2 to 6 months earlier than by use of conventional cytomorphology (Chapter 
5.3). 
Immunologic marker analysis cannot efficiently be used for the detection of minimal residual 
disease in patients with precursor B-ALL, because normal counterparts of such leukemic cells 
occur in relatively high frequencies in bone marrow and blood, especially during the period of 
bone marrow regeneration after withdrawal of cytotoxic treatment. However, recent reports 
indicate that the polymerase chain reaction (PCR) technique may be useful for the detection 
of minimal residual disease via the amplification of the junctional regions of rearranged lg and 
TcR genes. This is based on the fact that the junctional regions of rearranged lg and TcR 
genes can vary enormously due to the differential ways of joining of V, (D) and J gene 
segments and the insertion of additional nucleotides at the joining sites (Chapter 3.2). The 
junctional regions probably differ in each lymphocyte (clone) and therefore also in each 
lymphoid leukemia. It has been suggested that the PCR-mediated amplification of leukemia-
specific junctional regions can be used in case of rearranged lgH, TcR--y and TcR-o genes. The 
theoretical detection limit of the PCR technique is 0.01 to 0.0001%. Future studies will establish 
the real detection limit of the proposed PCR analyses and reveal the frequency of false negative 
andjor false positive results. 
Highly specific and sensitive techniques for the detection of minimal residual disease allow 
adjustment of remission and relapse criteria as well as individualization of therapy, which is 
valuable for the prevention of undertreatment and overtreatment of patients. Whether such 
adaptations of treatment protocols will result in lower relapse rates and higher survival rates has 
to be evaluated in prospective studies. 
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T-lymfocyten spelen een centrale rol in de regulatie van antigeen-specifieke immuunreacties. 
De antigeen-specificiteit van de meeste T-cel functies wordt gerealiseerd via de T-cel-receptor 
(TcR). Deze TcR is betrokken bij de specifieke herkenning van vreemde antigenen, een proces 
dat afhankelijk is van antigeenpresentatie via moleculen van het "major histocompatibility 
complex". 
De TcR is nauw verbonden met de CD3 eiwitketens. Tezamen vormen zij het TcR-CD3 
complex op het celoppervlak van de T-lymfocyten. Binnen dit TcR-CD3 complex spelen de CD3 
eiwitketens waarschijnlijk een rol in de signaaloverdracht van de TcR naar het cytoplasma. Er 
bestaan twee soorten TcR: de "klassieke" TcR, die uit een TcR-a en een TcR-.8 keten bestaat, 
en de "alternatieve" TcR, welke gevormd wordt door een TcR-'Y en een TcR-o keten. De vier 
TcR ketens worden gecodeerd door genen die uit variabele aantallen verschillende V,(D) en 
J gensegmenten bestaan. Gedurende de differentiatie van T-cellen moeten deze TcR genen 
worden herschikt voordat door middel van transcriptie en translatie functionele eiwitproducten 
kunnen worden gevormd. 
Het doel van dit promotie-onderzoek was enerzijds de verschillende aspecten van de T-
ee! differentiatie bij de mens te bestuderen, in het bijzonder de mechanismen die de expressie 
van het TcR-CD3 complex bepalen, en anderzijds te onderzoeken hoe basale informatie 
betreffende de T-cel differentiatie kan worden gebruikt voor het ontwikkelen van nieuwe 
diagnostische methoden voor hematopoietische maligniteiten en immunodeficienties. In deze 
studies werden perifeer bloed-, beenmerg- en thymusmonsters van personen zonder 
hematologische, immunologische of infectieuze aandoeningen geanalyseerd. Bovendien werden 
celmonsters van zowel patienten met het DiGeorge syndroom (DGS), een primaire T-cel 
immunodeficientie, als van patienten met een T-cel maligniteit bestudeerd. Vooral T-cel acute 
lymfoblastaire leukemieen (T-ALL) werden in ons onderzoek gebruikt, aangezien deze 
maligniteiten gewoonlijk worden beschouwd als klonaal geexpandeerde maligne tegenpolen van 
cellen in de verschillende normale differentiatiestadia. 
Het gebruik van normale celmonsters bij het bestuderen van de T-cel differentiatie betekent 
dat de verschillende celtypen op "single cell" niveau moeten worden onderzocht, aangezien de 
celpopulaties van normale personen heterogeen van samenstelling zijn. Voor optimale 
immunofenotyperingstudies van dergelijke heterogene celmonsters ontwikkelden wij twee- en 
drievoudige immunologische kleuringstechnieken, waardoor het mogelijk was gedetailleerde 
informatie te verkrijgen over de expressie van immunologische markers door kleine populaties 
T-cellen. Gedetailleerde gegevens over immunologische markers en de verschillende 
technieken waarmee ze kunnen worden aangetoond staan beschreven in Hoofdstuk 2. Voor 
de analyse van de herschikking en transcriptie van de TcR genen werden vooral T-ALL cellen 
gebruikt, omdat de klonale oorsprong van de leukemiecellen complexe celscheidingen en 
celzuiveringen overbodig maakt. Om de TcR genen in de verschillende leukemische 
celmonsters optimaal te kunnen analyseren werden eerst de relevante TcR probes verzameld 
waarmee de kiemlijnconfiguratie van de TcR-.8, de TcR-1 en de TcR-o genen werd bestudeerd. 
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Gedetailleerde informatie over de gebruikte technieken, de verschillende gebruikte TcR probes 
en de kiemlijnconfiguratie van de TcR genen wordt gegeven in de Hoofdstukken 3.2, 4.5 en 4.7. 
De resultaten van de T-cel differentiatiestudies staan uitgebreid beschreven in Hoofdstuk 
4. Gevonden is, dat de voorloper T-cellen in het beenmerg, de zogenaamde prothymocyten, 
waarschijnlijk de pan-T-celmarkers C02 en CD? tot expressie brengen en dat zij positief zijn 
voor HlA-DR en het enzym terminaal deoxynucleotidyl transferase (TdT) (Hoofdstuk 4.2). Het 
enzym TdT speelt een belangrijke rol bij het ontstaan van de diversiteit in de TcR moleculen. 
Dit is gebaseerd op het feit dat TdT in staat is extra nucleotiden in te voegen op de zg. "joining 
sites" van V, D en J gensegmenten tijdens de herschikking van de TcR genen. Deze TcR 
genherschikkingsprocessen beginnen waarschijnlijk zodra de onrijpe T-cellen in de thymus zijn 
gearriveerd. Deze processen lijken in een hierarchisch bepaalde volgorde plaats te vinden. De 
resultaten die werden verkregen bij het bestuderen van de TcR genen in T-ALL doen 
vermoeden dat eerst de TcR-o genen herschikken, onmiddellijk gevolgd door de herschikking 
van de TcR--y genen, en in de meeste cellen tevens door die van de TcR-,8 genen. Waarschijnlijk 
is bij de TcR--y genherschikking eerst het -y1 locus betrokken en als deze -y1 herschikking niet-
functioneel is, vindt herschikking naar het -y2 locus plaats. Transcriptie van functionele TcR--y 
en TcR-o genen resulteert in TcR--yo + T-cellen. lndien de TcR--y enjof TcR-o genherschikkingen 
niet-functioneel of incompleet zijn, worden de betrokken T-cellen waarschijnlijk geelimineerd. 
Het is ook mogelijk dat deze T-cellen of andere onrijpe T-cellen een of beide TcR-o genen 
deleteren en hun TcR-.B en TcR-a genen gaan herschikken. T-cellen met herschikte TcR-a ge-
nen hebben hun TcR-o genen gedeleteerd, omdat het TcR-o genlocus midden in het TcR-a 
genlocus ligt en wei tussen de Va en Ja gensegmenten. De TcR-o gendeletie en de TcR-a 
genherschikking zijn zeer waarschijnlijk twee opeenvolgende stappen in het TcR genherschik-
kingsproces. Functionele herschikking van de TcR-a en de TcR-.B genen resulteert in TcR-a,B+ 
T-cellen (Hoofdstukken 4.3, 4.4, 4.5 en 4.7). In onrijpe T-cellen, die (nog) geen TcR-CD3 
complex op hun celmembraan tot expressie brengen, vindt al transcriptie en translatie van 
CD3 genen tot CD3 eiwitketens plaats. Deze ketens accumuleren in het cytoplasma, gereed 
voor assemblage tot TcR-CD3 complexen zodra de correcte TcR ketens worden geproduceerd 
(Hoofdstukken 4.3 en 5.2). 
Zoals hiervoor al is aangegeven, doen de gegevens verkregen uit de analyse van T-ALL 
vermoeden dat TcR--yo+ en TcR-a.B+ cellen uit een lineaire differentiatieroute afkomstig zijn. 
Recente gegevens afkomstig uit onderzoek bij de muis suggereren echter dat TcR-a,B+ en TcR-
-yo+ cellen zich langs gescheiden differentiatielijnen ontwikkelen en dat verschillende regulatie-
mechanismen in het TcR-a/o locus een centrale rol spelen in de vroege splitsing van de a,B en 
-yo differentiatieroutes (bediscussieerd in Hoofdstuk 4.1). 
Bij de mens kan de frequentie van TcR-a,B+ en TcR--yo+ cellen worden bepaald met behulp 
van monoklonale antistoffen tegen de niet-polymorfe epitopen van de twee typen TcR 
(Hoofdstuk 4.6). Om de thymus-afhankelijkheid van TcR-a,B+ en TcR--yo+ T-lymfocyten te 
bestuderen, hebben we hun frequentie bepaald in bloedmonsters afkomstig van normale 
kinderen en van acht kinderen met DGS. Het DGS wordt gekarakteriseerd door defekten aan 
gelaat, hart, bijschildklier en thymus. De mate van thymushypoplasie of thymusaplasie bepaalt 
waarschijnlijk de mate van T-cel immunodeficientie (d.w.z. van partieel tot volledig). Onze 
resultaten bij gezonde kinderen geven aan dat de meerderheid van de CD3 + lymfocyten de 
TcR-a,B tot expressie brengt en slechts een minderheid de TcR--yo. Bij zeven kinderen met een 
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partieel DGS werd een wisselende vermindering van het aantal T-lymfocyten waargenomen. Dit 
betrof voornamelijk TcR-a.B+ cellen, terwijl de absolute aantallen TcR--y.s+ cellen slechts in 
geringe mate waren afgenomen. In een patient met een compleet DGS bracht het merendeel 
van het geringe aantal resterende T-lymfocyten de TcR--yo tot expressie en werden er vrijwel 
geen TcR-a.B+ T-lymfocyten waargenomen. Dit betekent dat de T-cel deficientie in patienten met 
een DGS zich voornamelijk beperkt tot de TcR-a.B+ T-lymfocyten, hetgeen doet vermoeden dat 
de ontwikkeling van TcR-a.B+ cellen ernstig wordt belemmerd door de afname van de 
thymusmassa bij het DGS, terwijl de TcR--yo differentiatielijn minder is aangetast. Dit suggereert 
dat bij de mens de TcR--ycS+ T-lymfocyten zich langs een extrathymale differentiatieroute kunnen 
ontwikkelen. Dit wordt ondersteund door de bevinding dat TcR--ycS+ corticale thymocyten en 
met name TcR--ycS+ /TdT+ thymocyten zeldzaam zijn (Hoofdstukken 4.1 en 4.8). 
De verschillende gebruikte technieken en de opgedane kennis omtrent T-cel differentiatie 
bij de mens bleken bruikbaar te zijn voor diagnostische toepassingen. Zo bleek de cyto-
plasmatische expressie van CD3 (CyCD3) een uitstekende marker te zijn voor onrijpe T-cel 
maligniteiten die geen TcR-CD3 complex op het celoppeNiak tot expressie brengen (Hoofdstuk 
5.2). Bovendien kon de eNaring, opgedaan bij de immunologische markeranalyse van normale 
en maligne T-cellen, worden benut voor de immunologische markeranalyse van andere 
hematopoietische cellen en hun maligne tegenpolen (Hoofdstuk 2.3). Dit stelde ons in staat 
optimale panels van immunologische markers samen te stellen voor de immunofenotypering 
van de verschillende typen leukemieen en non-Hodgkin lymfomen (NHL). De immunofeno-
typering van leukemieen en NHL is, naast de routinematige cytomorfologische analyse, van 
belang voor een gedetailleerde en reproduceerbare klassificatie van deze maligniteiten. In 
-30% van de gevallen zal dit tot een meer correcte of meer nauwkeurige diagnose leiden dan 
wanneer aileen cytomorfologische technieken worden toegepast (Hoofdstuk 5.1). 
De eNaring die was opgedaan met het analyseren van TcR genen werd oak benut voor 
het analyseren van de immunoglobuline (lg) genen (Hoofdstuk 3.3). De grate meerderheid 
van lymfatische maligniteiten van 8- en T-cel oorsprong hebben klonaal herschikte lg genen, 
respectievelijk TcR genen. Oak kunnen "cross-lineage" lg en TcR genherschikkingen optreden. 
Dit betreft met name TcR genherschikkingen in voorloper B-ALL (30 tot 80%, afhankelijk van 
het type TcR gen), lg zware keten (lgH) genherschikkingen in T-ALL (5 tot 15%) en lg enjof 
TcR genherschikkingen in acute myelo"ide leukemieen (AML) (-20% van aile AML). 
Gedetailleerde informatie over deze lg en TcR genherschikkingen in hematopoietische 
maligniteiten is samengevat in Hoofdstuk 6.2. Deze informatie kan voor diagnostische 
doeleinden worden gebruikt, omdat Southern blot analyse van lg en TcR genen een 
uitstekende methode is om klonaliteit te detecteren. Dit maakt de volgende diagnostische 
toepassingen mogelijk: discriminatie tussen polyklonale en monoklonale lymfoproliferaties; 
detectie van twee of meer subklonen binnen een maligniteit; detectie van klonale evolutie bij een 
recidief; analyse van de klonale oorsprong van twee maligniteiten in een patient; en analyse van 
de differentiatielijn van een maligniteit. Alhoewel vrijwel aile maligniteiten klonale proliferaties 
zijn, moet opgemerkt worden dat een klonale celpopulatie niet altijd maligne is (Hoofdstuk 
6.3). 
In de meeste patienten met een klonale lymfoproliferatieve aandoening geven morfologische 
technieken en immunologische markeranalyse voldoende informatie. Echter in 1 tot 5% van 
de gevallen zijn genherschikkingstudies noodzakelijk om een correcte diagnose te stellen. De 
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toepassing van lg en TcR genanalyse voor diagnostische doeleinden dient beperkt te worden 
tot deze gevallen, omdat de "Southern blot" techniek kostbaar en tijdrovend is. Veel achter-
grondinformatie betreffende de technische mogelijkheden en beperkingen van de lg en TcR 
genanalyse en brede ervaring zijn nodig voor een correcte interpretatie van de "Southern blot" 
gegevens. Dit is met name het geval bij klinisch benigne lymfoproliferaties, die frequent worden 
gezien bij patienten met een immunodeficientie (Hoofdstuk 6.3). 
De detectie van kleine aantallen maligne cellen is een groot probleem bij de diagnose en 
follow-up van patienten met een maligniteit. Een van de grootste problemen voor patienten en 
hun behandelende artsen is de onzekerheid over het al dan niet geelimineerd zijn van aile 
maligne cellen door het gebruikte behandelingsprotocol. Dit is met name het geval in ALL bij 
kinderen, omdat deze leukemieen tot vijf jaar of Ianger na de initiele diagnose en de daarop 
volgende behandeling kunnen recidiveren. Om deze reden hebben wij veel energie gestoken 
in de ontwikkeling van technieken voor de detectie van kleine aantallen maligne cellen bij ALL. 
De detectiegrens van conventionele morfologische technieken is niet lager dan I tot 5% (I tot 
5 maligne cellen tussen 100 normale cellen), aangezien kleine aantallen maligne cellen moeilijk 
te onderscheiden zijn van normale cellen. Ook de toepassing van immunologische marker-
analyse voor de detectie van kleine aantallen maligne cellen wordt vaak beperkt door de 
aanwezigheid van normale tegenpolen, die dezelfde markers tot expressie brengen. Toch is het 
in sommige gevallen mogelijk om kleine aantallen maligne cellen te detecteren, gebaseerd op 
de aanname dat de aanwezigheid van positieve cellen buiten hun normale plaatsen van 
voorkomen op een maligniteit wijst (Hoofdstuk 5.3). Op deze manier kan TdT worden gebruikt 
als marker voor de detectie van ALL cell en in liquor cerebrospinalis. Dit maakt vroeg detecteren 
(of uitsluiten) van centraal zenuwstelsel leukemie, een ernstige complicatie bij patienten met 
ALL, mogelijk (Hoofdstuk 5.4). Een ander voorbeeld is de detectie van zeer kleine aantallen 
maligne cellen in beenmerg en bloed van patienten met een TdT+ T-cel maligniteit met behulp 
van een dubbellabelingstechniek voor een T-cel marker en TdT. Deze toepassing is gebaseerd 
op de waarneming dat bepaalde T-cel marker+ /TdT+ cellen normaal slechts voorkomen in de 
thymus en niet in extrathymale locaties zoals beenmerg en bloed. Dankzij de !age detectiegrens 
van de dubbellabelingstechniek (0,01 tot 0,001%) is het mogelijk om een recidiefvan een TdT+ 
T-cel maligniteit 2 tot 6 maanden eerder te diagnostiseren dan bij gebruik van conventionele 
cytomorfologie (Hoofdstuk 5.3). 
lmmunologische markeranalyse kan niet goed worden gebruikt voor de detectie van kleine 
aantallen maligne cellen bij patienten met een voorloper B-ALL, omdat de normale tegenpolen 
van zulke leukemische cell en in relatief hoge frequenties v66rkomen in beenmerg en bloed, met 
name tijdens de periode van beenmergregeneratie na het beeindigen van de cytostatische 
therapie. Recente bevindingen geven echter aan dat de polymerase ketting reactie (polymerase 
chain reaction; PCR) bruikbaar zou kunnen zijn voor de detectie van kleine aantallen maligne 
cellen door middel van amplificatie van de "junctional regions" van herschikte lg en TcR 
genen.Dit berust op het feit dat de "junctional regions" van herschikte lg en TcR genen sterk 
kunnen varieren als gevolg van het samenkomen van V, (D) en J gensegmenten en het 
toevoegen van extra nucleotiden op de verbindingsplaatsen van de gensegmenten (Hoofdstuk 
3.2). Deze "junctional regions" varieren waarschijnlijk per lymfocyt (kloon) en daarom ook per 
leukemie. Waarschijnlijk kan de PCR-gemedieerde amplificatie van de leukemie-specifieke 
"junctional regions" gebruikt worden voor het opsporen van kleine aantallen leukemie cellen in 
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geval van herschikte lgH, TcR-r enjofTcR-o genen. De theoretische detectiegrens van de PCR 
techniek is 0,01 tot 0,0001%. Toekomstig onderzoek zal inzicht moeten geven in de werkelijke 
detectiegrens van de voorgestelde PCR analyses, en duidelijk moeten maken hoe frequent vals 
negatieve enjof vals positieve resultaten worden verkregen. 
Uiterst specifieke en gevoelige technieken voor de detectie van kleine aantallen maligne 
cellen maken zowel aanpassing van remissie- en recidiefcriteria, als individualisering van de 
therapie mogelijk, hetgeen van belang is voor de preventie van onderbehandeling en 
overbehandeling van patienten. Prospectief onderzoek zal moeten uitwijzen of mogelijke 
aanpassingen van de behandelingsprotocollen zullen resulteren in kleinere recidiefkansen en 
grotere overlevingskansen. 
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ABBREVIATIONS 
3'UT : 3 ' untranslated Cylg : cytoplasmic lg 
5'-NT : 5 '-nucleotidase Cyfl. : cytoplasmic fl. lg heavy chain 
6-MP : 6-mercaptopurine D : diversity 
ADCC : antibody dependent cytotoxicity OAF : decay accelerating factor 
AET : 2-amino-ethylisothiouronium bromide DGA : DiGeorge anomaly 
AIDS : acquired immunodeficiency syndrome DNA : deoxyribonucleic acid 
AILD : angioimmunoblastic lymphadenopathy DPPIV : dipeptidylpeptidase IV 
with dysproteinemia OTT : dithiothreitol 
AIM : activation inducer molecule EBV : Epstein-Barr virus 
ALL : acute lymphoblastic leukemia FAB : French American British cytomor-
AML : acute myeloid leukemia phological classification of 
ANLL : acute non-lymphoblastic leukemia acute leukemias 
AP : alkaline phosphatase FAL : fucosyi-N-acetyllactosamine 
APC : allophycocyanin Fc-yR : Fe receptor for lgG 
ARA-C : cytosine arabinoside FcER : Fe receptor for lgE 
AT : ataxia telangiectasia Fcjl.R : Fe receptor for lgM 
ATG : anti-thymocyte globulin FCS : fetal calf serum 
ATLL : adult T cell leukemia lymphoma FITC : fluorescein isothiocyanate 
AUL : acute undifferentiated leukemia FLS : forward light scatter 
B-ALL : B cell ALL G6PD : glucose-6-phosphate 
B-CLL : B cell CLL dehydrogenase 
B-NHL : B cell NHL GMP : granule membrane protein 
B-PLL : B cell PLL GP or gp : glycoprotein 
BAL : bronchoalveolar lavage GpA : glycophorin A 
BC : blast crisis h :hinge 
BM : bone marrow HCL : hairy cell leukemia 
BMT : bone marrow transplantation HEV : high endothelial venules 
bp : base pairs HIV : human immunodeficiency virus 
BrdU : 5 '-bromo-2 '-deoxyuridine HNK : human natural killer cell 
BSA : bovine serum albumin HTLV-1 : human T cell leukemia virus I 
c : constant HVP : hypervariable (or length) 
CALLA : common ALL antigen polymorphism 
CB : centroblastic lymphoma I CAM : intercellular adhesion molecule 
CB-CC : centroblastic-centrocytic lymphoma ld : idiotype 
cc : centrocytic lymphoma IEF : isoelectric focussing 
CD : cluster of differentiation/cluster IF : immunofluorescence 
of designation IFN : interferon 
CDR : complementarity determining region lg : immunoglobulin 
COw : CD ''workshop" (preliminary clustering) lgH : lg heavy chain 
CID : combined immunodeficiency lgL : lg light chain 
CLL : chronic lymphocytic leukemia IGSS : immunogold silver staining 
CML : chronic myeloid leukemia IL-2 : interleukin 2 
CNS : central nervous system IPB : immunoprecipitation buffer 
ConA : concanavalin A J :joining 
CR : complement receptor kb : kilobase 
CSF : cerebrospinal fluid kDa : kilo Dalton 
CTLL : cutaneous T cell leukemia lymphoma Kde : kappa deleting element 
CyCD3 : cytoplasmic expression of CD3 antigen LAD : leukocyte adhesion deficiency 
CyCD22 : cytoplasmic expression of CD22 antigen LAS : lymphadenopathy syndrome 
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LBL : lymphoblastic lymphoma s :switch 
LCA : leukocyte common antigen SCID : severe combined 
LeuCAM : leukocyte adhesion molecule immunodeficiency 
LFA : leukocyte function antigen SDS : sodium dodecyl sulfate 
LGL : large granular lymphocyte SDS-PAGE : sodium dodecyl sulfate polyacryl-
LN :lymph node amide gel electrophorese 
McAb : monoclonal antibody ;antibodies SITS : acetamide isothiocyanate stilbene 
MCP : membrane cofactor protein disulphonic acid 
MF : mycosis fungoides SmCD3 : surface membrane CD3 antigen 
MHC : major histocompatibility complex Smlg : surface membrane lg 
MIG : morphologic, immunologic and cyto- SRBC : sheep red blood cells 
genetic classification ss : Sezary syndrome 
MNC : mononuclear cells SSPE : subacute sclerosing 
mo : month(s) pan encephalitis 
mol. mass : molecular mass T-ALL : T cell ALL 
MPO : myeloperoxidase T-CLL : T cell CLL 
MRBC : mouse red blood cells T-LBL : T cell LBL 
MS : multiple sclerosis T-NHL : T cell NHL 
MTX : methotrexate TAE : Tris-acetate/EDTA electrophoresis 
N : nucleotide buffer 
NCAM : neural cell adhesion molecule TcR : T cell receptor 
NHL : non-Hodgkin lymphoma TcR-0:,8 : T cell receptor a,B (classical TcR) 
NK cell : natural killer cell TcR--yo : T cell receptor 1 o (alternative TcR) 
NP-40 : Nonidet P40 (detergent) TcR-CD3 : complex of TcR and CD3 chains 
OLB : oligonucleotide labeling buffer TdT : terminal deoxynucleotidyl 
p : protein transferase 
PB : peripheral blood TE : Tris-EDTA buffer 
PBL : peripheral blood lymphocytes TEA : T early alpha 
PBS : phosphate buffered saline TES : Tris-EDTA-SDS buffer 
PCR : polymerase chain reaction Tl : trypsin inhibitor 
PE : pleural exudate TLCK : tosyllysine chloromethyl ketone 
PHA : phytohaemagglutinin (protease inhibitor) 
PI : phosphatidyl-inositol glycan TNE : Tris-NaCI-EDTA buffer 
pi : isoelectric point TPCK : tosylphenylalanine chloromethyl 
PLEVA : pityriasis lichenoides et varioliformis ketone (protease inhibitor) 
acuta TRITC : tetramethylrhodamine 
PLL : prolymphocytic leukemia isothiocyanate 
PLS : perpendicular light scatter TX :Texas red 
PMSF : phenylmethylsulfonyl fluoride (protease v :volume 
inhibitor) v : variable 
PNH : paroxysmal nocturnal hemoglobinuria VCR : vincristine 
PO : peroxidase VLA antigen : very late activation antigen 
R : receptor VNR : vitronectin receptor 
RA : rheumatoid arthritis w :weight 
RBC : red blood cells WBC : white blood cells 
RFLP : restriction fragment length poly- weak Gyp. : weak cytoplasmic expression of p. 
morphism lg heavy chain 
RNA : ribonucleic acid wk : week(s) 
RS cell : Reed-Sternberg cell y : year(s) 
RT : room temperature 
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DANKWOORD 
Dit proefschrift is tot stand gekomen dankzij de medewerking van velen, zowel voor als 
achter de schermen. lk wil hen allen dan oak op deze plaats hartelijk danken voor hun inzet 
en steun. Daarbij wil ik diverse personen met name in dit dankwoord betrekken. 
Allereerst gaat mijn dank uit naar mijn promotor Professor Dr. R. Benner. Beste Rob, jij 
hebt de basis gecreeerd van waaruit dit onderzoek heeft kunnen plaatsvinden. Door het 
vertrouwen en de vrijheid die je me gaf, was het mogelijk een nieuwe researchlijn op te 
bouwen. Jouw houding heeft me gestimuleerd om de mogelijkheden zo goed mogelijk te 
benutten. Daarbij wist ik me altijd door jou gesteund. Niet aileen in voorspoedige tijden was je 
er, maar vooral oak in moeilijke tijden was je bereikbaar en bereid om mee te denken. Dit 
gevoel van steun en vriendschap hoop ik te blijven ervaren in onze samenwerking. 
Professor Dr. A. Hagemeijer, beste Anne, dankzij de goede samenwerking met jou en de 
verschillende medewerkers van jouw groep is het mogelijk geweest het eerste gezamenlijke 
KWF-project uit te voeren, dat de aanzet heeft gegeven voor het humane immunologische 
onderzoek op onze afdeling. lk ben dan ook zeer verheugd, dat je bereid was om mede mijn 
promotor te zijn. 
Professor Dr. 0. Vas dank ik voor zijn samenbindende en stimulerende rol binnen onze 
afdeling, als vaak stille, maar altijd krachtige steun op de achtergrond. 
Professor Dr. J.J. van Rood en Professor Dr. B. Lowenberg wil ik danken dat zij zitting 
hebben willen nemen in de "kleine" promotiecommissie. lk ben hen zeer erkentelijk voor hun 
bereidwilligheid om binnen een zeer kart tijdsbestek de manuscripten voor dit proefschrift te 
beoordelen. 
Dankzij Ingrid Wolvers-Tettero en Marieke Comans-Bitter heb ik steeds vier extra 
rechterhanden gehad. Hun enorme inzet en enthousiasme, gecombineerd met gouden handen 
en ogen plus een grate bereidwilligheid om altijd en overal (in de trein, in de volkstuin of in het 
weekend) met het werk bezig te zijn, maakt dat ze niet aileen tijdens mijn promotie, maar oak 
in het Ieven van alledag mijn paranimfen zijn. Beste Ingrid en Marieke, jullie steun en hulp is 
onmisbaar! Verder is oak een woord van dank aan hun thuisfront op zijn plaats. Hans en Rob, 
bedankt voor jullie begrip en bereidheid om oak jullie steentje bij te dragen. 
Mijn collega's Herbert Hooijkaas en Henk Adriaansen wil ik danken voor hun steun en 
collegialiteit. Beste Herbert, al in een vroeg stadium heb je meegeholpen het humane 
immunologisch onderzoek en de immunodiagnostiek op te bouwen. Met plezier denk ik terug 
aan de beginperiode, toen we samen "een hok" deelden. Het gezamenlijk werken aan de op-
en uitbouw van het immunodiagnostisch laboratorium was een bijzondere ervaring. lk ben 
dan oak blij dat je op de dag van mijn promotie als ceremonie-meester opnieuw de zaken 
regelt. In een wat later stadium kwam Henk ons team versterken. Beste Henk, oak jouw 
bereidwilligheid, inzet en steun waren onmisbaar voor de immunodiagnostiekgroep. In de loop 
der tijd heeft ieder zijn eigen taken en verantwoordelijkheden gekregen, maar de nauwe 
samenwerking en collegialiteit is binnen ons trio altijd blijven bestaan. 
Dr. G.E. van Zanen en Dr. K. Hahlen, beste George en Karel, de samenwerking tussen de 
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subafdeling Hematologie/Oncologie van de afdeling Kindergeneeskunde van het Sophia 
Kinderziekenhuis en onze afdeling heeft een belangrijke bijdrage geleverd aan de ontwikkeling 
van de immunodiagnostiek van leukemieen en maligne lymfomen. De prettige en vruchtbare 
samenwerking met jullie groep is in de loop der jaren steeds verder uitgegroeid en zal zeker 
gecontinueerd worden. 
Dr. J. Borst, beste Jannie, ik heb je leren kennen en waarderen als een prettige en integere 
collega. Het is stimulerend om met je te "brainstormen" over de vele facetten van de 
immunologie. lk hoop dan ook dat onze samenwerking van lange duur zal zijn. 
Professor Dr. H.J. Neijens en Dr. R. de Groot, beste Herman en Ronald, sinds enkele jaren 
bestaat er een vruchtbare samenwerking op het gebied van immunodeficienties bij kinderen. 
lmmunopediatrie heeft mij altijd geboeid. lk hoop dan ook dat ons gezamenlijk onderzoek meer 
inzicht zal geven in de achtergronden van primaire immunodeficienties en dat de betreffende 
patientjes baat zullen hebben bij de resultaten. 
Dr. G. Grosveld en Dr. A. de Klein, beste Gerard en Annelies, jullie wil ik bedanken voor 
het advies en de hulp die ik gekregen heb bij mijn eerste schreden op het "DNA-pad". 
Prof. Dr. C. Terhorst en Dr. P. van den Elsen, beste Cox en Peter, jullie wil ik bedanken 
voor de mogelijkheid om in Boston onderzoekervaring op te doen. In aile opzichten was het 
een leerzame en boeiende periode. 
Dr. E. van Wering en Dr. A. van der Does, beste Elisabeth en Anna, ik wil jullie en de 
Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK) waarvan jullie dee! uitmaken, 
danken voor de waardevolle samenwerking van de afgelopen jaren. Dit is een geweldige 
stimulans geweest voor het immunologische onderzoek bij kinderen met leukemie. Ook onze 
nieuwe gezamenlijke onderzoekplannen betreffende het opsporen van "minimal residual 
disease" lijken veelbelovend. lk hoop dan oak dat onze gezamenlijke inspanningen mogen 
leiden tot een beter inzicht in de diagnostiek en behandeling van kinderen met leukemie. 
Tar van Os en Cor van Dijk zijn op velerlei wijze betrokken geweest bij de visuele 
verslaglegging van de onderzoekresultaten en ideeen. Vaak was het veel en vaak was er 
haast, maar aan de kwaliteit van de figuren en dia's was dat nooit te merken. Hartelijk dank 
voor jullie zorg en inzet. 
Tom Vermetten, Rein Smit, Piet Hartwijk, Mevrouw Godijn, Jopie Bolman, Elly Hoffman en 
Joke Bolman, zonder jullie steun achter de schermen is het goed functioneren van een afdeling 
als de onze onmogelijk. Daarom wil ik jullie op deze plaats bedanken voor jullie continue en 
betrouwbare ondersteuning. 
Geertje de Korte, Jacqueline de Goey-van Dooren, Elly Schenkel en de laatste maanden 
vooral Rieke de Jager, jullie wil ik danken voor de uitstekende secretariele ondersteuning en 
vooral ook voor jullie inzet bij het verwerken van de teksten en de opmaak van de hoofdstuk-
ken van dit proefschrift. 
In de afgelopen jaren hebben velen bijgedragen aan de opbouw en het optimaal 
functioneren van het immunodiagnostisch laboratorium. Dit laboratorium neemt een centrale 
plaats in binnen onze afdeling en is onontbeerlijk voor de medisch-immunologische research. 
Daarom dank ik Rene van den Beemd, Carla Borg, Annemiek Broos, Marieke Comans-Bitter, 
Ellen Cristen, Rian Deijkers-van Strien, Diana van den Goorbergh, Jacqueline de Groot-
Pijnenburg, Sinka 't Hooft-Benne, Carin Kappetijn-van Til borg, Manfred van Kerckhoven, Rianne 
van der Linde-Preesman, Jeroen te Marvelde, Hidde Osinga, Felix Rodriguez, Petra Soeting, 
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An net Wierenga-Wolf, Anita Wijdenes-de Bresser, Annemarie Wijkhuijs en Ingrid Waivers-Tettero 
voor hun inzet en enthousiasme ten behoeve van het immunodiagnostische werk. 
Mijn directe medewerkers, Auke Beishuizen, Timo Breit, Marieke Comans-Bitter, Ellen Mol, 
Marie-Anne Verhoeven en Ingrid Wolvers-Tettero wil ik danken voor hun inzet en enthousiasme, 
waarmee ze hebben meegeholpen aan het afronden van dit proefschrift. Dat jullie bereid waren 
taken op je te nemen om mij te ontlasten, en bij te springen waar dat nodig was, maakte het 
voor mij mogelijk om dit proefschrift te voltooien. De steer waarin dit gebeurde, houdt een 
belofte in voor de toekomst. 
Mijn dierbare ouders, "ons ma en ons pa", ben ik dankbaar voor hetgeen ik van ze heb 
meegekregen en geleerd. Mijn moeder was het voorbeeld in doorzettingsvermogen en inzet. 
In het tegemoet treden van moeilijke situaties was mijn vader het voorbeeld. Van hen beiden 
heb ik veel warme belangstelling voor mijn werk en steun in velerlei vorm mogen ondervinden. 
Vaak was ma nag enthousiaster over mijn onderzoekresultaten dan ikzelf en pa genoot in stilte 
mee. Aan een goed gesprek heeft het nooit ontbroken. Pa en ma, jullie positieve en reele 
levensvisie zal mij blijvend be"invloeden. 
En tenslotte, lieve Jeanette, niet aileen ik, maar ieder die jou van nabij kent, weet dat zonder 
jouw warmte, spontaniteit en wonderbaarlijke verdraagzaamheid dit proefschrift in deze vorm 
nooit tot stand was gekomen. De stelling "Belofte maakt schuld, oak voor een promovendus" 
is voor jou en voor ons samen bedoeld. 
Nieuwerkerk aan den IJssel, 
juni 1990 
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